0000790526-20-000003.txt : 20200316 0000790526-20-000003.hdr.sgml : 20200316 20200316164530 ACCESSION NUMBER: 0000790526-20-000003 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 93 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200316 DATE AS OF CHANGE: 20200316 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RadNet, Inc. CENTRAL INDEX KEY: 0000790526 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 133326724 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33307 FILM NUMBER: 20717796 BUSINESS ADDRESS: STREET 1: 1510 COTNER AVE CITY: LOS ANGELES STATE: CA ZIP: 90025 BUSINESS PHONE: 3104787808 MAIL ADDRESS: STREET 1: 1510 COTNER AVE CITY: LOS ANGELES STATE: CA ZIP: 90025 FORMER COMPANY: FORMER CONFORMED NAME: PRIMEDEX HEALTH SYSTEMS INC DATE OF NAME CHANGE: 19930518 FORMER COMPANY: FORMER CONFORMED NAME: CCC FRANCHISING CORP DATE OF NAME CHANGE: 19920703 10-K 1 radnet10k2019document.htm 10-K Document
false--12-31FY201900007905262.503.002.001.502.002.503.001.50P5Y10000P0Y0.00010.0001200000000200000000489774855031432848977485503143280.01000.02000.01250.02250.01750.02750.00750.01750.00500.01500.0930.0560.0370.0440.0152022-12-312020-12-312019-12-31P1YP10YP5Y00.02000.02250.02750.01750.01500.00350.00400.00450.00300.00302037-12-312039-12-31P3YP3YP3YP3YP5YP5Y 0000790526 2019-01-01 2019-12-31 0000790526 2020-03-09 0000790526 2019-06-30 0000790526 2018-12-31 0000790526 2019-12-31 0000790526 2018-01-01 2018-12-31 0000790526 2017-01-01 2017-12-31 0000790526 us-gaap:HealthCarePatientServiceMember 2017-01-01 2017-12-31 0000790526 rdnt:CapitationArrangementsMember 2019-01-01 2019-12-31 0000790526 rdnt:CapitationArrangementsMember 2017-01-01 2017-12-31 0000790526 rdnt:CapitationArrangementsMember 2018-01-01 2018-12-31 0000790526 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000790526 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-12-31 0000790526 rdnt:StockholdersEquityDeficitMember 2018-01-01 2018-12-31 0000790526 rdnt:StockholdersEquityDeficitMember 2017-01-01 2017-12-31 0000790526 2016-12-31 0000790526 rdnt:StockholdersEquityDeficitMember 2019-01-01 2019-12-31 0000790526 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-12-31 0000790526 us-gaap:NoncontrollingInterestMember 2017-01-01 2017-12-31 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000790526 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0000790526 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0000790526 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000790526 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0000790526 us-gaap:NoncontrollingInterestMember 2019-12-31 0000790526 rdnt:StockholdersEquityDeficitMember 2018-12-31 0000790526 us-gaap:NoncontrollingInterestMember 2018-12-31 0000790526 us-gaap:RetainedEarningsMember 2018-12-31 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000790526 rdnt:StockholdersEquityDeficitMember 2017-12-31 0000790526 us-gaap:CommonStockMember 2019-12-31 0000790526 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0000790526 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0000790526 us-gaap:CommonStockMember 2017-12-31 0000790526 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000790526 us-gaap:NoncontrollingInterestMember 2017-12-31 0000790526 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0000790526 rdnt:StockholdersEquityDeficitMember 2016-12-31 0000790526 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000790526 2017-12-31 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000790526 us-gaap:CommonStockMember 2016-12-31 0000790526 us-gaap:CommonStockMember 2018-12-31 0000790526 us-gaap:RetainedEarningsMember 2019-12-31 0000790526 rdnt:StockholdersEquityDeficitMember 2019-12-31 0000790526 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000790526 us-gaap:RetainedEarningsMember 2016-12-31 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000790526 us-gaap:RetainedEarningsMember 2017-12-31 0000790526 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000790526 us-gaap:NoncontrollingInterestMember 2016-12-31 0000790526 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000790526 rdnt:GardenStateRadiologyNetworkLLCMember 2019-08-01 2019-08-01 0000790526 rdnt:NulogixMember 2019-08-01 0000790526 rdnt:HudsonValleyRadiologyAssociatesMember us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2019-02-27 0000790526 rdnt:MedicalArtsRadiologyMember 2018-10-01 2018-10-01 0000790526 rdnt:NulogixMember 2018-04-12 0000790526 2017-04-01 2017-04-30 0000790526 2017-08-07 2017-08-07 0000790526 rdnt:NulogixMember 2019-08-01 2019-08-01 0000790526 2018-01-01 0000790526 2017-07-01 2017-07-31 0000790526 rdnt:NewJerseyImagingNetworkLLCMember 2018-10-01 2018-10-01 0000790526 rdnt:GardenStateRadiologyNetworkLLCMember 2019-08-01 0000790526 rdnt:MedicalArtsRadiologyMember 2019-12-31 0000790526 rdnt:MedicalArtsRadiologyMember 2018-10-01 0000790526 rdnt:NewJerseyImagingNetworkLLCMember 2018-10-01 0000790526 2017-10-05 2017-10-05 0000790526 rdnt:VenturaCountyImagingGroupLLCMember 2019-03-01 0000790526 rdnt:HudsonValleyRadiologyAssociatesMember 2019-02-28 2019-02-28 0000790526 rdnt:HudsonValleyRadiologyAssociatesMember us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2019-02-27 2019-02-27 0000790526 rdnt:MedicalArtsRadiologyMember 2018-01-01 2018-12-31 0000790526 rdnt:ScriptSenderMember 2019-12-31 0000790526 rdnt:BeverlyRadiologyMedicalGroupIIIMember rdnt:BoardMemberMember 2019-12-31 0000790526 rdnt:BeverlyRadiologyMedicalGroupIIIMember srt:ChiefExecutiveOfficerMember 2019-12-31 0000790526 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000790526 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000790526 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000790526 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000790526 us-gaap:InterestRateSwapMember 2019-01-01 2019-12-31 0000790526 rdnt:Medicare1Member 2018-01-01 2018-12-31 0000790526 us-gaap:HealthCarePatientServiceMember 2018-01-01 2018-12-31 0000790526 rdnt:PatientServicesNetMember 2017-01-01 2017-12-31 0000790526 us-gaap:HealthCareOtherMember 2018-01-01 2018-12-31 0000790526 rdnt:CommercialInsurance1Member 2018-01-01 2018-12-31 0000790526 rdnt:Medicaid1Member 2017-01-01 2017-12-31 0000790526 rdnt:HealthCareManagementServiceMember 2018-01-01 2018-12-31 0000790526 rdnt:HealthCareManagementServiceMember 2019-01-01 2019-12-31 0000790526 rdnt:CommercialInsurance1Member 2017-01-01 2017-12-31 0000790526 us-gaap:HealthCarePatientServiceMember 2019-01-01 2019-12-31 0000790526 rdnt:WorkersCompensationPersonalInjury1Member 2019-01-01 2019-12-31 0000790526 rdnt:CommercialInsurance1Member 2019-01-01 2019-12-31 0000790526 rdnt:ImagingOnCallMember 2017-01-01 2017-12-31 0000790526 rdnt:WorkersCompensationPersonalInjury1Member 2017-01-01 2017-12-31 0000790526 rdnt:HealthCareManagementServiceMember 2017-01-01 2017-12-31 0000790526 us-gaap:HealthCareOtherMember 2019-01-01 2019-12-31 0000790526 rdnt:ImagingOnCallMember 2019-01-01 2019-12-31 0000790526 rdnt:PatientServicesNetMember 2018-01-01 2018-12-31 0000790526 rdnt:Medicare1Member 2019-01-01 2019-12-31 0000790526 rdnt:ImagingOnCallMember 2018-01-01 2018-12-31 0000790526 rdnt:HealthCarePatientServiceOtherMember 2019-01-01 2019-12-31 0000790526 rdnt:Medicaid1Member 2019-01-01 2019-12-31 0000790526 rdnt:PatientServicesNetMember 2019-01-01 2019-12-31 0000790526 rdnt:WorkersCompensationPersonalInjury1Member 2018-01-01 2018-12-31 0000790526 rdnt:HealthCarePatientServiceOtherMember 2017-01-01 2017-12-31 0000790526 rdnt:HealthCarePatientServiceOtherMember 2018-01-01 2018-12-31 0000790526 rdnt:Medicare1Member 2017-01-01 2017-12-31 0000790526 us-gaap:HealthCareOtherMember 2017-01-01 2017-12-31 0000790526 rdnt:Medicaid1Member 2018-01-01 2018-12-31 0000790526 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000790526 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000790526 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000790526 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000790526 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000790526 us-gaap:InterestRateCapMember 2019-12-31 0000790526 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000790526 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000790526 us-gaap:InterestRateSwapMember 2019-12-31 0000790526 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000790526 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000790526 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000790526 us-gaap:InterestRateCapMember 2017-01-01 2017-12-31 0000790526 us-gaap:InterestRateCapMember 2018-01-01 2018-12-31 0000790526 us-gaap:InterestRateCapMember 2019-01-01 2019-12-31 0000790526 rdnt:RadNetMember rdnt:SantaMonicaImagingMember 2017-04-01 0000790526 us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0000790526 rdnt:GlendaleAdvancedImagingMember rdnt:DignityHealthMember srt:MinimumMember rdnt:JointVentureMember 2019-01-01 2019-12-31 0000790526 rdnt:CedarsSinaiMedicalCenterMember rdnt:SantaMonicaImagingMember 2019-01-01 0000790526 srt:MaximumMember 2019-01-01 2019-12-31 0000790526 rdnt:September2020CapMember 2019-12-31 0000790526 us-gaap:InterestRateSwapMember rdnt:A2019SWAPS1Member 2019-06-30 0000790526 rdnt:TurnerImagingSystemsMember 2018-02-01 2018-02-01 0000790526 us-gaap:InvestmentAdvisoryManagementAndAdministrativeServiceMember 2018-01-01 2018-12-31 0000790526 srt:MaximumMember rdnt:PropertyAndEquipmentMember 2019-01-01 2019-12-31 0000790526 rdnt:USAttorneysOfficeForTheWesternDistrictofNewYorkMember 2019-06-30 0000790526 us-gaap:InvestmentAdvisoryManagementAndAdministrativeServiceMember 2019-01-01 2019-12-31 0000790526 us-gaap:InterestRateSwapMember rdnt:A2019SWAPSMember 2019-06-30 0000790526 rdnt:TurnerImagingMember 2019-10-11 0000790526 us-gaap:InvestmentAdvisoryManagementAndAdministrativeServiceMember srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2019-01-01 2019-09-30 0000790526 rdnt:TurnerImagingMember us-gaap:CommercialPaperMember 2019-01-01 0000790526 rdnt:BlueShieldMember srt:MinimumMember 2019-12-31 0000790526 rdnt:RestatedPlanMember 2019-12-31 0000790526 rdnt:MedicVisionMember 2018-03-01 2018-03-01 0000790526 rdnt:ImagingOnCallMember 2018-01-01 2018-12-31 0000790526 rdnt:HealthInsuranceMember 2019-12-31 0000790526 rdnt:PrimedexHealthSystemsInc.andRadiologixMember rdnt:HudsonValleyRadiologyAssociatesMember 2019-02-28 0000790526 rdnt:WhiteRabbit.aiInc.Member 2019-11-05 2019-11-05 0000790526 rdnt:PatientServicesNetMember rdnt:ERADMember 2017-01-01 2017-12-31 0000790526 rdnt:MedicVisionMember 2017-03-24 0000790526 us-gaap:InvestmentAdvisoryManagementAndAdministrativeServiceMember 2017-01-01 2017-12-31 0000790526 rdnt:HealthInsuranceMember 2018-12-31 0000790526 us-gaap:InterestRateSwapMember rdnt:A2019SWAPS1Member us-gaap:LondonInterbankOfferedRateLIBORMember 2019-06-30 0000790526 rdnt:October2020CapMember 2019-12-31 0000790526 rdnt:Caps2016Member 2019-12-31 0000790526 rdnt:RadNetMember rdnt:SantaMonicaImagingMember 2019-01-01 0000790526 rdnt:MedicVisionMember 2017-03-24 2017-03-24 0000790526 rdnt:BarclaysMember 2019-12-31 0000790526 rdnt:SunTrustMember 2019-12-31 0000790526 rdnt:A2019SWAPSMember 2019-06-30 0000790526 rdnt:MedicVisionMember 2019-12-31 0000790526 rdnt:BarclaysMember 2018-12-31 0000790526 rdnt:USAttorneysOfficeForTheWesternDistrictofNewYorkMember us-gaap:SettledLitigationMember 2019-09-01 2019-09-30 0000790526 rdnt:PatientServicesNetMember rdnt:ERADMember 2018-01-01 2018-12-31 0000790526 rdnt:Caps2016Member us-gaap:LondonInterbankOfferedRateLIBORMember 2019-12-31 0000790526 rdnt:PatientServicesNetMember rdnt:ERADMember 2019-01-01 2019-12-31 0000790526 rdnt:October2025Member rdnt:A2019SWAPSMember 2019-06-30 0000790526 rdnt:NulogixMember 2018-04-12 2018-04-12 0000790526 rdnt:RadiologixMember 2006-11-30 0000790526 us-gaap:InterestRateSwapMember rdnt:A2019SWAPSMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-06-30 0000790526 rdnt:GlendaleAdvancedImagingMember rdnt:DignityHealthMember srt:MaximumMember rdnt:JointVentureMember 2019-01-01 2019-12-31 0000790526 rdnt:October2023Member rdnt:A2019SWAPSMember 2019-06-30 0000790526 rdnt:CedarsSinaiMedicalCenterMember rdnt:SantaMonicaImagingMember 2017-04-01 0000790526 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2019-01-01 2019-12-31 0000790526 us-gaap:InvestmentAdvisoryManagementAndAdministrativeServiceMember srt:MinimumMember rdnt:PropertyAndEquipmentMember 2019-01-01 2019-09-30 0000790526 rdnt:GardenStateRadiologyNetworkLLCMember 2014-10-06 2014-11-06 0000790526 rdnt:RadNetMember rdnt:SantaMonicaImagingMember 2019-01-01 2019-01-01 0000790526 rdnt:BlueShieldMember srt:MaximumMember 2019-12-31 0000790526 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000790526 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0000790526 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000790526 us-gaap:InterestRateCapMember 2018-12-31 0000790526 srt:MinimumMember rdnt:PropertyAndEquipmentMember 2019-01-01 2019-12-31 0000790526 srt:MinimumMember 2019-01-01 2019-12-31 0000790526 rdnt:SunTrustMember 2018-12-31 0000790526 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2019-01-01 2019-12-31 0000790526 rdnt:ValleyMetabolicImagingMember 2018-04-01 2018-04-01 0000790526 rdnt:RadNetMember rdnt:AdvancedImagingAtTimoniumMember 2017-07-01 0000790526 rdnt:OrangeCountyDiagnosticsImagingCenterMember us-gaap:NoncompeteAgreementsMember 2018-12-03 0000790526 rdnt:ZilkhaRadiologyMember 2019-04-01 0000790526 rdnt:MedicalArtsRadiologyMember us-gaap:NoncompeteAgreementsMember 2018-10-01 0000790526 rdnt:HudsonValleyRadiologyAssociatesMember 2019-02-28 0000790526 rdnt:NewJerseyImagingNetworkLLCMember 2018-10-01 0000790526 rdnt:KernRadiologyImagingSystemsInc.Member 2019-04-01 0000790526 rdnt:BreastlinkMedicalMember 2017-09-01 2017-09-01 0000790526 rdnt:WestValleyImagingGroupLLCMember 2019-02-01 2019-02-01 0000790526 rdnt:JeffersonHealthMember 2019-08-01 0000790526 rdnt:WashingtonHeightsMedicalManagementLLCMember 2018-09-01 0000790526 rdnt:ValleyMetabolicImagingMember 2018-04-01 0000790526 rdnt:ArcadiaRadiologyImagingMember us-gaap:NoncompeteAgreementsMember 2018-11-05 0000790526 rdnt:WestValleyImagingGroupLLCMember rdnt:WestValleyImagingGroupLLCMember 2019-02-01 0000790526 rdnt:DignityHealth.Member rdnt:VenturaCountyImagingGroupLLC.Member 2019-03-01 2019-03-01 0000790526 rdnt:NulogixInc.Member 2019-08-01 0000790526 rdnt:SouthernCaliforniaDiagnosticImagingIncMember 2018-11-01 0000790526 rdnt:AdvancedImagingAtTimoniumMember 2017-07-01 2017-07-01 0000790526 rdnt:SouthernCaliforniaDiagnosticImagingIncMember us-gaap:NoncompeteAgreementsMember 2018-11-01 0000790526 rdnt:ImagingServicesCompanyofNewYorkMember us-gaap:NoncompeteAgreementsMember 2018-02-22 0000790526 rdnt:WestValleyImagingGroupLLCMember 2019-02-01 0000790526 rdnt:RhodeIslandMedicalImagingIncMember 2017-04-28 2017-04-28 0000790526 rdnt:NewJerseyImagingNetworkLLCMember us-gaap:TradeNamesMember 2018-10-01 0000790526 rdnt:DignityHealth.Member rdnt:VenturaCountyImagingGroupLLC.Member 2019-03-01 0000790526 rdnt:WestValleyImagingGroupLLCMember 2017-04-01 2017-04-01 0000790526 rdnt:MedicalArtsRadiologyMember us-gaap:CommonStockMember 2018-10-01 0000790526 rdnt:SouthernCaliforniaDiagnosticImagingIncMember us-gaap:LeaseholdImprovementsMember 2018-11-01 0000790526 rdnt:SouthernCaliforniaDiagnosticImagingIncMember 2018-11-01 2018-11-01 0000790526 rdnt:MedicalArtsRadiologyMember us-gaap:TradeNamesMember 2018-10-01 0000790526 rdnt:SierraImagingAssociatesMember 2018-04-01 0000790526 rdnt:ImagingServicesCompanyofNewYorkMember 2018-02-22 0000790526 rdnt:ArcadiaRadiologyImagingMember 2018-11-05 0000790526 rdnt:KernRadiologyImagingSystemsInc.Member 2019-04-01 2019-04-01 0000790526 rdnt:MemorialCareMedicalFoundationMember rdnt:BeachImagingGroupLLCMember 2018-01-01 0000790526 rdnt:MemorialCareMedicalFoundationMember rdnt:BeachImagingGroupLLCMember 2018-01-01 2018-01-01 0000790526 rdnt:OrangeCountyDiagnosticsImagingCenterMember 2018-12-03 0000790526 rdnt:NewJerseyImagingNetworkLLCMember 2019-08-01 0000790526 rdnt:OncologyPracticesMember 2017-04-01 2017-04-01 0000790526 rdnt:WestValleyImagingGroupLLCMember rdnt:WestValleyImagingGroupLLCMember 2019-02-01 2019-02-01 0000790526 rdnt:HudsonValleyRadiologyAssociatesMember us-gaap:TradeNamesMember 2019-02-28 0000790526 rdnt:ZilkhaRadiologyMember 2019-04-01 2019-04-01 0000790526 rdnt:ValleyMetabolicImagingMember us-gaap:NoncompeteAgreementsMember 2018-04-01 0000790526 rdnt:WomensImagingSpecialistsinHealthcareMember us-gaap:NoncompeteAgreementsMember 2018-04-01 0000790526 rdnt:SierraImagingAssociatesMember us-gaap:NoncompeteAgreementsMember 2018-04-01 0000790526 rdnt:WomensImagingSpecialistsinHealthcareMember 2018-04-01 0000790526 rdnt:RadNetMember rdnt:WestValleyImagingGroupLLCMember 2017-04-01 0000790526 rdnt:VenturaCountyImagingGroupLLC.Member 2019-03-01 2019-03-01 0000790526 rdnt:NewJerseyImagingNetworkLLCMember 2018-10-01 2018-10-01 0000790526 rdnt:VenturaCountyImagingGroupLLC.Member 2019-03-01 0000790526 rdnt:RadNetMember rdnt:SantaMonicaImagingMember 2017-08-01 0000790526 rdnt:MedicalArtsRadiologyMember us-gaap:CommonStockMember 2018-10-01 2018-10-01 0000790526 rdnt:WashingtonHeightsMedicalManagementLLCMember us-gaap:NoncompeteAgreementsMember 2018-09-01 0000790526 rdnt:OrangeCountyDiagnosticsImagingCenterMember 2018-12-03 2018-12-03 0000790526 rdnt:CedarsSinaiMedicalCenterMember rdnt:SantaMonicaImagingMember 2017-08-01 0000790526 rdnt:MemorialCareMedicalFoundationMember rdnt:BeachImagingGroupLLCMember 2018-01-01 0000790526 rdnt:ArcadiaRadiologyImagingMember us-gaap:LeaseholdImprovementsMember 2018-11-05 0000790526 rdnt:ArcadiaRadiologyImagingMember 2018-11-05 2018-11-05 0000790526 rdnt:HudsonValleyRadiologyAssociatesMember us-gaap:NoncompeteAgreementsMember 2019-02-28 0000790526 rdnt:WomensImagingSpecialistsinHealthcareMember us-gaap:TradeNamesMember 2018-04-01 0000790526 rdnt:RadNetMember rdnt:BeachImagingGroupLLCMember 2018-01-01 0000790526 rdnt:WomensImagingSpecialistsinHealthcareMember 2018-04-01 2018-04-01 0000790526 rdnt:SierraImagingAssociatesMember 2018-04-01 2018-04-01 0000790526 rdnt:WashingtonHeightsMedicalManagementLLCMember 2018-09-01 2018-09-01 0000790526 rdnt:ImagingServicesCompanyofNewYorkMember 2018-02-22 2018-02-22 0000790526 rdnt:PropertyAndEquipmentMember 2019-12-31 0000790526 us-gaap:GoodwillMember 2019-12-31 0000790526 rdnt:DevelopedtechnologyMember 2019-01-01 2019-12-31 0000790526 rdnt:TradeNamesAmortizedMember 2019-12-31 0000790526 rdnt:CovenantNotToCompeteMember 2019-12-31 0000790526 rdnt:ManagementServiceContractsMember 2019-12-31 0000790526 us-gaap:SoftwareDevelopmentMember 2019-12-31 0000790526 rdnt:TradeNamesIndefiniteLifeMember 2019-12-31 0000790526 rdnt:DevelopedtechnologyMember 2019-12-31 0000790526 rdnt:CovenantNotToCompeteMember 2019-01-01 2019-12-31 0000790526 rdnt:ManagementServiceContractsMember 2019-01-01 2019-12-31 0000790526 rdnt:TradeNamesAmortizedMember 2019-01-01 2019-12-31 0000790526 rdnt:ValleyMetabolicImagingMember 2018-01-01 2018-12-31 0000790526 rdnt:WashingtonHeightsMedicalManagementMember 2018-01-01 2018-12-31 0000790526 rdnt:NulogixMember 2019-01-01 2019-12-31 0000790526 rdnt:RamicMahwahLLCMember 2019-01-01 2019-12-31 0000790526 rdnt:WomensImagingSpecialistsyMember 2018-01-01 2018-12-31 0000790526 rdnt:DignityHealthMember 2019-01-01 2019-12-31 0000790526 rdnt:MedicalArtsRadiologicalGroupPCMember 2018-01-01 2018-12-31 0000790526 rdnt:HudsonValleyRadiologyAssociatesMember 2019-01-01 2019-12-31 0000790526 rdnt:ImagingServicesCompanyofNewYorkMember 2018-01-01 2018-12-31 0000790526 rdnt:NewJerseyImagingNetworkLLCMember 2018-01-01 2018-12-31 0000790526 rdnt:WestValleyImagingGroupLLCMember 2019-01-01 2019-12-31 0000790526 rdnt:MedicalArtsRadiologicalGroupPCMember 2019-01-01 2019-12-31 0000790526 rdnt:OrangeCountyDiagnosticsImagingCenterMember 2018-01-01 2018-12-31 0000790526 rdnt:ZilkhaRadiologyMember 2019-01-01 2019-12-31 0000790526 rdnt:MemorialCareMedicalFoundationMember 2018-01-01 2018-12-31 0000790526 rdnt:GardenStateRadiologyNetworkLLCMember 2019-01-01 2019-12-31 0000790526 rdnt:KernRadiologyImagingSystemsInc.Member 2019-01-01 2019-12-31 0000790526 rdnt:SierraImagingAssociatesMember 2018-01-01 2018-12-31 0000790526 rdnt:SouthernCaliforniaDiagnosticImagingIncMember 2018-01-01 2018-12-31 0000790526 rdnt:ArcadiaRadiologyImagingMember 2018-01-01 2018-12-31 0000790526 us-gaap:SoftwareDevelopmentMember 2019-01-01 2019-12-31 0000790526 us-gaap:LeaseholdImprovementsMember 2019-12-31 0000790526 us-gaap:ConstructionInProgressMember 2019-12-31 0000790526 rdnt:MedicalEquipmentMember 2019-12-31 0000790526 rdnt:ComputerandOfficeEquipmentMember 2019-12-31 0000790526 us-gaap:EquipmentMember 2018-12-31 0000790526 us-gaap:SoftwareDevelopmentMember 2018-12-31 0000790526 us-gaap:LeaseholdImprovementsMember 2018-12-31 0000790526 us-gaap:FurnitureAndFixturesMember 2019-12-31 0000790526 us-gaap:EquipmentMember 2019-12-31 0000790526 us-gaap:FurnitureAndFixturesMember 2018-12-31 0000790526 us-gaap:AssetsHeldUnderCapitalLeasesMember 2018-12-31 0000790526 us-gaap:LandMember 2019-12-31 0000790526 us-gaap:LandMember 2018-12-31 0000790526 us-gaap:SoftwareDevelopmentMember 2019-12-31 0000790526 us-gaap:AssetsHeldUnderCapitalLeasesMember 2019-12-31 0000790526 rdnt:LeverageRatioOneMember us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:EurodollarMember 2016-07-01 2016-07-01 0000790526 rdnt:LeverageRatioTwoMember us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2016-07-01 2016-07-01 0000790526 rdnt:LeverageRatioFourMember us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2016-07-01 2016-07-01 0000790526 rdnt:LeverageRatioThreeMember us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2016-07-01 2016-07-01 0000790526 rdnt:LeverageRatioFourMember us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:EurodollarMember 2016-07-01 2016-07-01 0000790526 rdnt:LeverageRatioThreeMember us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:EurodollarMember 2016-07-01 2016-07-01 0000790526 rdnt:LeverageRatioOneMember us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2016-07-01 2016-07-01 0000790526 rdnt:LeverageRatioTwoMember us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:EurodollarMember 2016-07-01 2016-07-01 0000790526 us-gaap:CommercialPaperMember 2019-12-31 0000790526 rdnt:FirstLienTermLoanMember rdnt:TermLoanMember 2018-12-31 0000790526 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2018-12-31 0000790526 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-12-31 0000790526 rdnt:RestatedAgreementMember rdnt:TermLoanMember 2018-12-31 0000790526 rdnt:FirstLienTermLoanMember rdnt:TermLoanMember 2019-12-31 0000790526 us-gaap:CommercialPaperMember 2018-12-31 0000790526 rdnt:RestatedAgreementMember rdnt:TermLoanMember 2019-12-31 0000790526 rdnt:TermLoanMember 2019-12-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementSixthAmendmentMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2019-12-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember rdnt:BarclaysMember us-gaap:LineOfCreditMember 2019-12-31 0000790526 rdnt:SunTrustMember rdnt:TermLoanMember 2018-12-31 0000790526 rdnt:FirstLienCreditAgreementSeventhAmendmentMember 2019-04-18 0000790526 rdnt:SunTrustMember rdnt:TermLoanMember 2018-01-01 2018-12-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:BarclaysMember us-gaap:LetterOfCreditMember 2019-01-01 2019-12-31 0000790526 rdnt:RestatedAgreementMember rdnt:TermLoanMember 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:SunTrustMember us-gaap:LineOfCreditMember 2019-12-31 0000790526 rdnt:FirstLienCreditAgreementSeventhAmendmentMember 2019-04-18 2019-04-18 0000790526 rdnt:LeverageRatioThreeMember us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementSixthAmendmentMember us-gaap:LineOfCreditMember us-gaap:EurodollarMember 2019-01-01 2019-12-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:BarclaysMember 2019-12-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementSixthAmendmentMember us-gaap:LineOfCreditMember 2019-04-18 0000790526 us-gaap:RevolvingCreditFacilityMember 2019-12-31 0000790526 rdnt:FirstLienCreditAgreementSixthAmendmentMember us-gaap:MediumTermNotesMember 2017-08-22 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember rdnt:SunTrustMember us-gaap:LineOfCreditMember 2018-08-31 0000790526 srt:MaximumMember rdnt:FirstLienTermLoanMember rdnt:TermLoanMember 2019-12-31 0000790526 rdnt:FirstLienTermLoanMember rdnt:BarclaysMember rdnt:TermLoanMember 2019-01-01 2019-12-31 0000790526 rdnt:RestatedAgreementMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementSixthAmendmentMember us-gaap:LineOfCreditMember us-gaap:EurodollarMember 2019-12-31 0000790526 rdnt:BarclaysMember 2019-12-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember rdnt:SunTrustMember us-gaap:LineOfCreditMember 2019-12-31 0000790526 rdnt:LeverageRatioThreeMember us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementSixthAmendmentMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2019-01-01 2019-12-31 0000790526 us-gaap:NotesPayableOtherPayablesMember 2019-01-01 2019-12-31 0000790526 srt:MinimumMember us-gaap:CapitalLeaseObligationsMember 2019-12-31 0000790526 srt:MaximumMember us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000790526 srt:MaximumMember us-gaap:CapitalLeaseObligationsMember 2019-12-31 0000790526 us-gaap:CommercialPaperMember 2019-01-01 2019-12-31 0000790526 srt:MinimumMember us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000790526 us-gaap:CapitalLeaseObligationsMember 2019-01-01 2019-12-31 0000790526 rdnt:PricingLevelIVMember us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember 2018-08-31 2018-08-31 0000790526 rdnt:PricingLevelIVMember us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:EurodollarMember 2018-08-31 2018-08-31 0000790526 rdnt:PricingLevelIIIMember us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember 2018-08-31 2018-08-31 0000790526 rdnt:PricingLevelIIMember rdnt:RestatedAgreementMember 2018-08-31 0000790526 rdnt:PricingLevelIIIMember rdnt:RestatedAgreementMember 2018-08-31 0000790526 rdnt:PricingLevelVMember rdnt:RestatedAgreementMember 2018-08-31 0000790526 rdnt:PricingLevelIIMember us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:EurodollarMember 2018-08-31 2018-08-31 0000790526 rdnt:PricingLevelIIMember us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:BaseRateMember 2018-08-31 2018-08-31 0000790526 rdnt:PricingLevelVMember us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember 2018-08-31 2018-08-31 0000790526 rdnt:PricingLevelIIIMember us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:EurodollarMember 2018-08-31 2018-08-31 0000790526 rdnt:PricingLevelIVMember rdnt:RestatedAgreementMember 2018-08-31 0000790526 rdnt:PricingLevelIVMember us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:BaseRateMember 2018-08-31 2018-08-31 0000790526 rdnt:PricingLevelIMember us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember 2018-08-31 2018-08-31 0000790526 rdnt:PricingLevelIIMember us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember 2018-08-31 2018-08-31 0000790526 rdnt:PricingLevelIMember us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:BaseRateMember 2018-08-31 2018-08-31 0000790526 rdnt:PricingLevelVMember us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:BaseRateMember 2018-08-31 2018-08-31 0000790526 rdnt:PricingLevelVMember us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:EurodollarMember 2018-08-31 2018-08-31 0000790526 rdnt:PricingLevelIMember us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:EurodollarMember 2018-08-31 2018-08-31 0000790526 rdnt:PricingLevelIMember rdnt:RestatedAgreementMember 2018-08-31 0000790526 rdnt:PricingLevelIIIMember us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:BaseRateMember 2018-08-31 2018-08-31 0000790526 srt:MaximumMember 2019-12-31 0000790526 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000790526 rdnt:FacilitiesMember 2019-12-31 0000790526 srt:MinimumMember 2019-12-31 0000790526 us-gaap:DomesticCountryMember 2019-12-31 0000790526 us-gaap:DomesticCountryMember us-gaap:TaxYear2018Member 2019-12-31 0000790526 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0000790526 rdnt:RavenHoldingsMember us-gaap:DomesticCountryMember 2019-12-31 0000790526 us-gaap:DomesticCountryMember 2019-01-01 2019-12-31 0000790526 us-gaap:StateAndLocalJurisdictionMember 2019-01-01 2019-12-31 0000790526 rdnt:FutureServiceMember 2019-01-01 2019-12-31 0000790526 us-gaap:StockOptionMember 2019-12-31 0000790526 rdnt:RestatedPlanMember 2019-01-01 2019-12-31 0000790526 srt:MaximumMember rdnt:RestatedPlanMember 2019-01-01 2019-12-31 0000790526 rdnt:RestatedPlanMember 2017-01-01 2018-12-31 0000790526 us-gaap:RestrictedStockMember 2019-12-31 0000790526 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0000790526 us-gaap:RestrictedStockMember 2018-12-31 0000790526 us-gaap:StockOptionMember 2019-01-01 2019-12-31 0000790526 us-gaap:StockOptionMember 2018-12-31 0000790526 srt:MinimumMember rdnt:RestatedPlanMember 2019-01-01 2019-12-31 0000790526 2019-01-01 2019-03-31 0000790526 2019-04-01 2019-06-30 0000790526 2018-01-01 2018-03-31 0000790526 2019-10-01 2019-12-31 0000790526 2018-10-01 2018-12-31 0000790526 2018-07-01 2018-09-30 0000790526 2019-07-01 2019-09-30 0000790526 2018-04-01 2018-06-30 0000790526 rdnt:WhiteRabbit.aiInc.Member 2019-12-31 2019-12-31 0000790526 rdnt:DeepHealthInc.Member us-gaap:SubsequentEventMember 2020-04-01 2020-04-01 0000790526 us-gaap:AllowanceForNotesReceivableMember 2017-01-01 2017-12-31 0000790526 us-gaap:AllowanceForNotesReceivableMember 2016-12-31 0000790526 us-gaap:AllowanceForNotesReceivableMember 2017-12-31 xbrli:shares iso4217:USD xbrli:shares rdnt:joint_venture iso4217:USD xbrli:pure rdnt:Center


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
 
FORM 10-K
 
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the fiscal year ended December 31, 2019

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
 
Commission File Number 001-33307
 
RadNet, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
13-3326724
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
 
 
 
1510 Cotner Avenue
 
Los Angeles,
California
90025
(Address of principal executive offices)
(Zip Code)
 
Registrant’s telephone number, including area code: (310) 478-7808
Securities registered pursuant to Section 12(b) of the Act:
 
Title of Each Class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.0001 par value
RDNT
NASDAQ Global Market
 
Securities registered pursuant to Section 12(g) of the Act: None
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes    No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
Emerging growth company
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act) Yes No
The aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was approximately $576.6 million on June 30, 2019 (the last business day of the registrant’s most recently completed second quarter) based on the closing price for the common stock on the NASDAQ Global Market on June 30, 2019.
The number of shares of the registrant’s common stock outstanding on March 9, 2020, was 50,694,375.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive proxy statement for the 2020 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this annual report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the close of the registrant’s fiscal year.
 



1



RADNET, INC.
TABLE OF CONTENTS
 
FORM 10-K ITEM
PAGE
 
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
 
 
 
Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
 
 
 
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
 
 
 
Item 15.
Item 16.
 
 


i



Cautionary Note Regarding Forward-Looking Statements
 
This annual report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements reflect current views about future events and are based on our currently available financial, economic and competitive data and on current business plans. Actual events or results may differ materially depending on risks and uncertainties that may affect our operations, markets, services, prices and other factors.
 
Statements in this annual report concerning our ability to successfully acquire and integrate new operations, to grow our contract management business, our financial guidance, our future cost saving efforts, our increased business from new equipment or operations, inclusive of their anticipated benefits, and our ability to finance our operations are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “assumption” or the negative of these terms or other comparable terminology.
 
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These risks include those factors listed in Item 1 — “Business,” Item 1A— “Risk Factors,” Item 3— “Legal Proceedings,” Item 7 — “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this annual report and in other reports that we file with the Securities and Exchange Commission.
 
We do not undertake any responsibility to release publicly any revisions to these forward-looking statements to take into account events or circumstances that occur after the date of this annual report or any unanticipated events which may cause actual results to differ from those expressed or implied by the forward-looking statements contained in this annual report, except to the extent required by law.


ii



PART I
 
Item 1.
Business
 
Business Overview
 
We are a leading national provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States based on number of locations and annual imaging revenue. We have been in business since 1985 and incorporated in Delaware in 2008. At December 31, 2019, we operated directly or indirectly through joint ventures with hospitals, 335 centers located in California, Delaware, Florida, Maryland, New Jersey, and New York. Our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, often reducing the cost and amount of care for patients. Our services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. The vast majority of our centers offer multi-modality imaging services, a key point of differentiation from our competitors. Our multi-modality strategy diversifies revenue streams, reduces exposure to reimbursement changes and provides patients and referring physicians one location to serve the needs of multiple procedures.
 
We seek to develop leading positions in regional markets in order to leverage operational efficiencies. We develop our medical imaging business through a combination of organic growth and acquisitions. Our scale and density within selected geographies provide close, long-term relationships with key payors, radiology groups and referring physicians. Each of our center-level and regional operations teams is responsible for managing relationships with local physicians and payors, meeting our standards of patient service, and maintaining profitability. We provide training programs, standardized policies and procedures, and sharing of best practices among the physicians in our regional networks.
 
In addition to our imaging services, we own and operate a number of technology businesses that are complementary to our imaging business. Our subsidiary eRAD, Inc., develops and sells computerized systems for the diagnostic imaging industry, which provide the technology to distribute, display, store and retrieve digital images. Our subsidiary Imaging On Call LLC, currently provides teleradiology services for remote interpretation of images on behalf of hospitals and hospital-based radiology groups. In 2019, we increased our efforts in Artificial Intelligence (AI) by acquiring the remaining 75% that we did not already own in Nulogix, Inc. and made an investment in Whiterabbit.ai to use AI and other technologies to create new solutions for breast cancer imaging.
 
Available Information
 
All reports we file with the Securities and Exchange Commission are available free of charge via EDGAR through the SEC website at www.sec.gov. We also maintain a website at www.radnet.com where we make available, free of charge, our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and all amendments to those reports as soon as is reasonably practicable after the material is electronically filed with the Securities and Exchange Commission. References to our website in this report are provided as a convenience and the information contained on, or otherwise accessible through, the website is not incorporated by reference into, nor does it form a part of this annual report on Form 10-K or any other document that we file with the Securities and Exchange Commission.
 
Industry Overview
 
Diagnostic imaging involves the use of non-invasive procedures to generate representations of internal anatomy and function that can be recorded on film or digitized for display on a video monitor. Diagnostic imaging procedures facilitate the early diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, often minimizing the cost and amount of care for patients. Diagnostic imaging procedures include MRI, CT, PET, nuclear medicine, ultrasound, mammography, X-ray and fluoroscopy.
 
While X-ray remains the most commonly performed diagnostic imaging procedure, the fastest growing and higher margin procedures are MRI, CT and PET. The rapid growth in PET scans is attributable to the increasing recognition of the efficacy of PET scans in the diagnosis and monitoring of cancer. The number of MRI and CT scans performed annually in the United States continues to grow due to their wider acceptance by physicians and payors, an increasing number of applications for their use and a general increase in demand due to the aging population.

Although currently small in scope, Artificial Intelligence (AI) methods are now being employed to aid radiologists in scan interpretation by quickly allowing comparison to large imaging databases to enable pinpoint diagnosis in shorter time frames.


1



In addition, AI methods can keep track of individuals needing procedures on a regular basis (i.e. mammograms, follow ups, etc.) and alert our staff to contact the patient and schedule appointments.
 
Diagnostic Imaging Settings
 
Diagnostic imaging services are typically provided in one of the following settings:
 
Fixed-site, freestanding outpatient diagnostic facilities
 
These facilities range from single-modality to multi-modality facilities and are generally not owned by hospitals or clinics. These facilities depend upon physician referrals for their patients and generally do not maintain dedicated, contractual relationships with hospitals or clinics. In fact, these facilities may compete with hospitals or clinics that have their own imaging systems to provide services to these patients. These facilities bill third-party payors, such as managed care organizations, insurance companies, Medicare or Medicaid. All of our wholly owned facilities are in this category.
 
Hospitals
 
Many hospitals provide both inpatient and outpatient diagnostic imaging services, typically on site. These inpatient and outpatient centers are owned and operated by the hospital or clinic, or jointly by both, and are primarily used by patients of the hospital or clinic. The hospital or clinic bills third-party payors, such as managed care organizations, insurance companies, Medicare or Medicaid. We have entered into joint ventures with certain hospitals to provide diagnostic imaging services at those hospitals.
 
Mobile Imaging
 
While many hospitals own or lease their own equipment, certain hospitals provide diagnostic imaging services by contracting with providers of mobile imaging services. Using specially designed trailers, mobile imaging service providers transport imaging equipment and provide services to hospitals and clinics on a part-time or full-time basis, thus allowing small to mid-size hospitals and clinics that do not have the patient demand to justify fixed on-site access to advanced diagnostic imaging technology. Diagnostic imaging providers contract directly with the hospital or clinic and are typically reimbursed directly by them. We do not provide mobile imaging services.

Diagnostic Imaging Modalities
 
The principal diagnostic imaging modalities we use at our facilities are:

MRI
 
MRI has become widely accepted as the standard diagnostic tool for a wide and fast-growing variety of clinical applications for soft tissue anatomy, such as those found in the brain, spinal cord, abdomen, heart and interior ligaments of body joints such as the knee. MRI uses a strong magnetic field in conjunction with low energy electromagnetic waves that are processed by a computer to produce high-resolution, three-dimensional, cross-sectional images of body tissue. A typical MRI examination takes from 20 to 45 minutes. MRI systems are designed as either open or closed and have magnetic field strength of 0.2 Tesla to 3.0 Tesla.
 
CT
 
CT provides higher resolution images than conventional X-rays, but generally not as well defined as those produced by MRI. CT uses a computer to direct the movement of an X-ray tube to produce multiple cross-sectional images of a particular organ or area of the body. CT is used to detect tumors and other conditions affecting bones and internal organs. It is also used to detect the occurrence of strokes, hemorrhages and infections. A typical CT examination takes from 15 to 45 minutes.
 
PET
 
PET scanning involves the administration of a radiopharmaceutical agent with a positron-emitting isotope and the measurement of the distribution of that isotope to create images for diagnostic purposes. PET scans provide the capability to determine how metabolic activity impacts other aspects of physiology in the disease process by correlating the reading for the PET with other tools such as CT or MRI. PET technology has been found highly effective and appropriate in certain clinical circumstances for the detection and assessment of tumors throughout the body, the evaluation of some cardiac conditions and the assessment of epilepsy seizure sites. The information provided by PET technology often obviates the need to perform further


2



highly invasive or diagnostic surgical procedures. In addition, we employ combined PET/CT systems that blend the PET and CT imaging modalities into one scanner.
 
Nuclear Medicine
 
Nuclear medicine uses short-lived radioactive isotopes that release small amounts of radiation that can be recorded by a gamma camera and processed by a computer to produce an image of various anatomical structures or to assess the function of various organs such as the heart, kidneys, thyroid and bones. Nuclear medicine is used primarily to study anatomic and metabolic functions.
 
X-ray
 
X-rays use roentgen rays to penetrate the body and record images of organs and structures on film. Digital X-ray systems add computer image processing capability to traditional X-ray images, which provides faster transmission of images with a higher resolution and the capability to store images more cost-effectively.
 
Ultrasound
 
Ultrasound imaging uses sound waves and their echoes to visualize and locate internal organs. It is particularly useful in viewing soft tissues that do not X-ray well. Ultrasound is used in pregnancy to avoid X-ray exposure as well as in gynecological, urologic, vascular, cardiac and breast applications.
 
Mammography
 
Mammography is a specialized form of radiology using low dosage X-rays to visualize breast tissue and is the primary screening tool for breast cancer. Mammography procedures and related services assist in the diagnosis of and treatment planning for breast cancer.
 
Fluoroscopy
 
Fluoroscopy uses ionizing radiation combined with a video viewing system for real time monitoring of organs.
 
Industry Trends
 
We believe the diagnostic imaging services industry will continue to grow as a result of a number of factors, including the following:
 
Escalating Demand for Healthcare Services from an Aging Population
 
According to the United States Census Bureau estimates released in June 2017, the number of US residents age 65 or over increased from 35.0 million in 2000 to an estimated 56.1 million in 2020, and the median age for the United States is also expected to continue to increase. Because diagnostic imaging use tends to increase as a person ages, we believe the aging population will generate more demand for diagnostic imaging procedures.

Greater Consumer Awareness of and Demand for Preventive Diagnostic Screening
 
Diagnostic imaging, such as elective full-body scans, is increasingly being used as a screening tool for preventive care procedures. Consumer awareness of diagnostic imaging as a less invasive and preventive screening method has added to the growth in diagnostic imaging procedures. We believe that further technological advancements allowing for early diagnosis of diseases and disorders using less invasive procedures will create additional demand for diagnostic imaging.
 
New Effective Applications for Diagnostic Imaging Technology
 
New technological developments are expected to extend the clinical uses of diagnostic imaging technology and increase the number of scans performed. Recent technological advancements include:
 
MRI spectroscopy, which can differentiate malignant from benign lesions;

MRI angiography, which can produce three-dimensional images of body parts and assess the status of blood vessels;


3




enhancements in teleradiology systems, which permit the digital transmission of radiological images from one location to another for interpretation by radiologists at remote locations,

the development of combined PET/CT and PET/MRI scanners, which combine technologies to create a powerful diagnostic imaging system; and

use of augmented reality technologies make it possible to create three dimensional images that physicians can examine through virtual reality headsets or print using a three dimensional printer.

Additional improvements in imaging technologies, contrast agents and scan capabilities are leading to new non-invasive diagnostic imaging application, including methods of diagnosing blockages in the heart’s vital coronary arteries, liver metastases, pelvic diseases and vascular abnormalities without exploratory surgery. We believe that the use of the diagnostic capabilities of MRI and other imaging services will continue to increase because they are cost-effective, time-efficient and non-invasive, as compared to alternative procedures, including surgery, and that newer technologies and future technological advancements will further increase the use of imaging services. At the same time, the industry has increasingly used upgrades to existing equipment to expand applications, extend the useful life of existing equipment, improve image quality, reduce image acquisition time and increase the volume of scans that can be performed. We believe the use of equipment upgrades rather than equipment replacements will continue, as we do not foresee new imaging technologies on the near-term horizon that will displace MRI, CT or PET as the principal advanced diagnostic imaging modalities. 

Utilization of Artificial Intelligence
 
AI has the potential to significantly change the medical imaging industry. Current AI applications are focused on comparing images against large databases and flagging areas of concern for the radiologist. This is expected to result in improved quality, particularly with diseases, injuries, or conditions that are difficult to detect without supplemental technology. AI can also improve business processes to better effectively serve customers and improve reimbursement and collections accuracy.
 
Our Competitive Strengths
 
Our Scale and Position as the Largest Provider of Freestanding, Fixed-site Outpatient Diagnostic Imaging Services in the United States, Based on Number of Centers and Revenue
 
As of December 31, 2019, we operated 335 centers in California, Delaware, Florida, Maryland, New Jersey, and New York. Our size and scale allow us to achieve operating, sourcing and administrative efficiencies, including equipment and medical supply sourcing savings and favorable maintenance contracts from equipment manufacturers and other suppliers. Our specific knowledge of our geographic markets drives strong relationships with key payors, radiology groups and referring physicians within our markets. 

Our Comprehensive "Multi-Modality" Diagnostic Imaging Offering
 
The vast majority of our centers offer multiple types of imaging procedures, driving strong relationships with referring physicians and payors in our markets and a diversified revenue base. At each of our multi-modality facilities, we offer patients and referring physicians one location to serve their needs for multiple procedures. This prevents multiple patient visits or unnecessary travel between facilities, thereby increasing patient throughput and decreasing costs and time delays. Our revenue is generated by a broad mix of modalities. We believe our multi-modality strategy lessens our exposure to reimbursement changes in any specific modality.
 
Our Competitive Pricing
 
Our business focus, scale, resources and access to technology afford us with certain operating efficiencies. As such, we believe our fees are generally lower than hospital fees for the services we provide.
 
Our Facility Density in Many Highly Populated Areas of the United States
 
The strategic organization of our diagnostic imaging facilities into regional networks concentrated in major population centers in six states offers unique benefits to our patients, our referring physicians, our payors and us. We are able to increase the convenience of our services to patients by implementing scheduling systems within geographic regions, where practical. For example, many of our diagnostic imaging facilities within a particular region can access the patient appointment calendars of other


4



facilities within the same regional network to efficiently allocate time available and to meet a patient's appointment, date, time, or location preferences. The grouping of our facilities within regional networks enables us to easily move technologists and other personnel, as well as equipment, from over-utilized to under-utilized facilities on an as-needed basis, and drive referrals. Our organization of referral networks results in increased patient throughput, greater operating efficiencies, better equipment utilization rates and improved response time for our patients. We believe our networks of facilities and tailored service offerings for geographic areas drives local physician referrals, makes us an attractive candidate for selection as a preferred provider by third-party payors and creates economies of scale.

Our Strong Relationships with Payors and Diversified Payor Mix
 
Our revenue is derived from a diverse mix of payors, including private payors, managed care capitated payors and government payors, which should mitigate our exposure to possible unfavorable reimbursement trends within any one payor class. In addition, our experience with capitation arrangements has provided us with the expertise to manage utilization and pricing effectively, resulting in a predictable and recurring stream of revenue. We believe that third-party payors representing large groups of patients often prefer to enter into managed care contracts with providers that offer a broad array of diagnostic imaging services at convenient locations throughout a geographic area. In 2019, we received approximately 56% of our net service revenue from commercial insurance payors, 11% from managed care capitated payors, 21% from Medicare and 2% from Medicaid.
 
Our Strong Relationships with Experienced and Highly Regarded Radiologists
 
Our contracted radiologists have outstanding credentials, strong relationships with referring physicians, and a broad mix of sub-specialties. The collective experience and expertise of these radiologists translates into more accurate and efficient service to patients. Our close relationship with Howard G. Berger, M.D., our President and Chief Executive Officer, and Beverly Radiology Medical Group (“BRMG”) in California and our long-term arrangements with radiologists outside of California enable us to better ensure that medical service provided at our facilities is consistent with the needs and expectations of our referring physicians, patients and payors.
 
Our Experienced and Committed Management Team
 
Our senior management group has more than 100 years of combined healthcare management experience. Our executive management team has created our differentiated approach based on their comprehensive understanding of the diagnostic imaging industry and the dynamics of our regional markets. We have a track record of successful acquisitions and integration of acquired businesses into RadNet, and have managed the business through a variety of economic and reimbursement cycles.
 
Our Technologically Advanced Operations
 
Our eRad subsidiary develops and sells computerized imaging systems for the industry and our Imaging On Call subsidiary provides teleradiology services for interpretation of images for radiology groups, hospitals and other medical groups. We have assembled an industry leading team of software developers to create radiology workflow solutions and have increased our efforts in AI by acquiring Nulogix, Inc. and making an investment in Whiterabbit.ai as noted above.
 
Business Strategy
 
Maximize Performance at Our Existing Facilities
 
We intend to enhance our operations and increase scan volume and revenue at our existing facilities by expanding physician relationships and increasing the procedure offerings.
 
Expansion Into Related Businesses
 
With our acquisition of eRad we entered the business of the development and sale of software systems essential to the imaging industry. Similarly, with our acquisition of Imaging On Call, we entered the teleradiology business. Our investment in WhiteRabbit.ai Inc. is expanding our use of AI in diagnostic imaging services. We intend to regularly evaluate potential acquisitions of other businesses to the extent they complement our imaging business.
 
Focus on Profitable Contracting
 
We regularly evaluate our contracts with third-party payors, industry vendors and radiology groups, as well as our equipment and real property leases, to determine how we may improve the terms to increase our revenues and reduce our expenses.


5



Because many of our contracts with third party payors are short-term in nature, we can regularly renegotiate these contracts, if necessary. We believe our position as a leading provider of diagnostic imaging services and our long-term relationships with physician groups in our markets enable us to obtain more favorable contract terms than would be available to smaller or less experienced imaging services providers.

Optimize Operating Efficiencies
 
We try to maximize our equipment utilization by adding, upgrading and re-deploying equipment where we experience excess demand. We will continue to trim excess operating and general and administrative costs where it is feasible to do so. We may also continue to use, where appropriate, highly trained radiology physician assistants to perform, under appropriate supervision of radiologists, basic services traditionally performed by radiologists. We will continue to upgrade our advanced information technology system to create cost reductions for our facilities in areas such as image storage, support personnel and financial management.
 
Expand Our Networks
 
We intend to continue to expand the number of our facilities both organically and through targeted acquisitions, using a disciplined approach for evaluating and entering new areas, including consideration of whether we have adequate financial resources to expand. Our current plans are to strengthen our market presence in geographic areas where we currently have existing operations and to expand into neighboring and other areas where we believe we can compete effectively. We perform extensive due diligence before developing a new facility or acquiring an existing facility or entering into a joint venture with a hospital to manage a facility, including surveying local referral sources and radiologists, as well as examining the demographics, reimbursement environment, competitive landscape and intrinsic demand of the geographic market. We generally will only enter new markets where:
 
there is sufficient patient demand for outpatient diagnostic imaging services;

we believe we can gain significant market share;

we can build key referral relationships or we have already established such relationships; and

payors are receptive to our entry into the market.

Expand Our Joint Ventures
 
As part of our growth strategy we have entered into joint ventures with hospitals, health systems or radiology practices that were formed for the purpose of owning and operating diagnostic imaging centers. We have created a number of joint ventures in key markets with well-established hospital systems to manage additional facilities. We intend to continue to expand in established markets through additional joint ventures, particularly with hospital systems. We believe that such joint ventures strengthen and expand our strength in markets where we are already established.
 
Our Services
 
We offer a comprehensive set of imaging services including MRI, CT, PET, nuclear medicine, X-ray, ultrasound, mammography, fluoroscopy and other related procedures. We focus on providing standardized high quality imaging services, regardless of location, to ensure patients, physicians and payors consistency in service and quality. To ensure the high quality of our services, we monitor patient satisfaction, timeliness of services to patients and reports to physicians.
 
The key features of our services include:
 
patient-friendly, non-clinical environments;

a 24-hour turnaround on routine examinations;

interpretations within one to two hours, if needed;

flexible patient scheduling, including same-day appointments;

extended operating hours, including weekends;



6



reports delivered by courier, facsimile or email;

availability of second opinions and consultations;

availability of sub-specialty interpretations at no additional charge; and

standardized fee schedules by region.

Radiology Professionals
 
In the states in which we provide services (except Florida), a lay person or any entity other than a professional corporation or similar professional organization is not allowed to practice medicine, including by employing professional persons or by having any ownership interest or profit participation in or control over any medical professional practice. This doctrine is commonly referred to as the prohibition on the “corporate practice” of medicine. In order to comply with this prohibition, we contract with radiologists to provide professional medical services in our facilities, including the supervision and interpretation of diagnostic imaging procedures. The radiology practice maintains full control over the physicians it employs. Pursuant to each management contract, we make available the imaging facility and all of the furniture and medical equipment at the facility for use by the radiology practice, and the practice is responsible for staffing the facility with qualified professional medical personnel. In addition, we provide management services and administration of the non-medical functions relating to the professional medical practice at the facility, including among other functions, provision of clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities. As compensation for the services furnished under contracts with radiologists, we generally receive an agreed percentage of the medical practice billings for, or collections from, services provided at the facility, typically 79% of global net service fee revenue or collections after deduction of the professional component of the medical practice billings.
 
Many states have also enacted laws prohibiting a licensed professional from splitting fees derived from the practice of medicine with an unlicensed person or business entity. We do not believe that the management, administrative, technical and other non-medical services we provide to each of our contracted radiology groups violate the corporate practice of medicine prohibition or that the fees we charge for such services violate the fee splitting prohibition. However, the enforcement and interpretation of these laws by regulatory authorities and state courts vary from state to state. If our arrangements with our independent contractor radiology groups are found to violate state laws prohibiting the practice of medicine by general business corporations or fee splitting, our business, financial condition and ability to operate in those states could be adversely affected.
 
The Consolidated Medical Group
 
The consolidated medical group ("the Group") consist of professional corporations owned or controlled by individuals within our senior management, namely Howard G. Berger, M.D., our President and Chief Executive Officer, and John V. Crues, III, M.D., RadNet's Medical Director, both of whom are members of our Board of Directors. The Group provides professional medical services in California, Delaware, Maryland, New Jersey and New York, and includes the Beverly Radiology Medical Group (BRMG). BRMG is responsible for the professional medical services at nearly all of our facilities located in California.

We believe that physicians are drawn to the Group, and the other external radiologist groups with whom we contract by the opportunity to work with the state-of-the-art equipment we make available to them, as well as the opportunity to receive specialized training through our fellowship programs, and engage in clinical research programs, which generally are available only in university settings and major hospitals.

Under our management agreement with BRMG, we are paid a percentage of the amounts collected for the professional services BRMG physicians render as compensation for our services and for the use of our facilities and equipment. For the year ended December 31, 2019, this percentage was 79%. The percentage may be adjusted, if necessary, to ensure that the parties receive the fair value for the services they render. The following are the other principal terms of our management agreement with BRMG:
 
The agreement expires on January 1, 2024. The agreement automatically renews for consecutive 10-year periods, unless either party delivers a notice of non-renewal to the other party no later than six months prior to the scheduled expiration date. Either party may terminate the agreement if the other party defaults under its obligations, after notice and an opportunity to cure. We may terminate the agreement if Dr. Berger no longer owns at least 60% of the equity of BRMG; as of December 31, 2019, he owned indirectly 99% of the equity interests of BRMG.



7



At its expense, BRMG employs or contracts with an adequate number of physicians necessary to provide all professional medical services at almost all of our California facilities.

At our expense, we provide all furniture, furnishings and medical equipment located at the facilities and we manage and administer all non-medical functions at, and provide all nurses and other non-physician personnel required for the operation of, the facilities.

If BRMG wants to open a new facility, we have the right of first refusal to provide the space and services for the facility under the same terms and conditions set forth in the management agreement.

If we want to open a new facility in California, BRMG must use its best efforts to provide medical personnel under the same terms and conditions set forth in the management agreement. If BRMG cannot provide such personnel, we have the right to contract with other physicians to provide services at the facility.

BRMG must maintain medical malpractice insurance for each of its physicians with coverage limits not less than $1 million per incident and $3 million in the aggregate per year. BRMG also has agreed to indemnify us for any losses we suffer that arise out of the acts or omissions of BRMG and its employees, contractors and agents.

The management contracts with the remaining professional medical corporations within the Group are on a basis similar to our contract with BRMG.
 
Other Professional Radiology Groups
 
At locations where the Group does not provide professional medical services, we have entered into long-term contracts with prominent third-party radiology groups in the area to provide physician services at those facilities.
 
These third-party radiology practice groups provide professional services, including supervision and interpretation of diagnostic imaging procedures, in our diagnostic imaging centers. The radiology practices maintain full control over the provision of professional services. The contracted radiology practices have outstanding physician and practice credentials and reputations; strong competitive market positions; a broad sub-specialty mix of physicians; a history of growth and potential for continued growth. In these facilities we have entered into long-term agreements (typically 10-40 years in length) under which, in addition to obtaining technical fees for the use of our diagnostic imaging equipment and the provision of technical services, we provide management services and receive a fee based on the practice group’s professional revenue. We typically receive 100% of the technical reimbursements associated with imaging procedures plus certain fees paid to us for providing additional management services. The radiology practice groups retain the professional reimbursements associated with imaging procedures after deducting management service fees paid to us.

Additionally, we perform certain management services for a portion of the professional groups with whom we contract who provide professional radiology services at local hospitals. For performing these management services, which include billing, collecting, transcription and medical coding, we receive management fees.
 
Payors
The fees charged for diagnostic imaging services performed at our facilities are paid by a diverse mix of payors, as illustrated for the following periods presented in the table below:
 
 
% of Net Service Fee Revenue
 
Year Ended
December 31,
2019
 
Year Ended
December 31,
2018
 
Year Ended
December 31,
2017
Commercial Insurance (1)
56
%
 
56
%
 
58
%
Managed Care Capitated Payors
11
%
 
11
%
 
12
%
Medicare
21
%
 
20
%
 
19
%
Medicaid
2
%
 
3
%
 
3
%
 
(1) Includes co-payments, direct patient payments and payments through contracts with physician groups and other non-insurance company payors.
 


8



We have described below the types of reimbursement arrangements we have with third-party payors.
 
Commercial Insurance
 
Generally, insurance companies reimburse us, directly or indirectly, including through the consolidated medical group or through the contracted radiology groups elsewhere, on the basis of agreed upon rates. These rates are negotiated and may differ materially with rates set forth in the Medicare Physician Fee Schedule for the particular service. The patients may be responsible for certain co-payments or deductibles.
 
Managed Care Capitation Agreements
 
Under these agreements, which are generally between BRMG in California and outside of California between the contracted radiology group (typically an independent physician group or other medical group) and the payor (which in most cases are large medical groups or Independent Practice Associations), the payor pays a pre-determined amount per-member per-month in exchange for the radiology group providing all necessary covered services to the managed care members included in the agreement. These contracts pass much of the financial risk of providing outpatient diagnostic imaging services, including the risk of over-use, from the payor to the radiology group and, as a result of our management agreement with the radiology group, to us.
 
We believe that through our comprehensive utilization management, or UM, program we have become highly skilled at assessing and moderating the risks associated with the capitation agreements, so that these agreements are profitable for us. Our UM program is managed by our UM department, which consists of administrative and nursing staff as well as BRMG medical staff who are actively involved with the referring physicians and payor management in both prospective and retrospective review programs. Our UM program includes features such as physician education combined with peer review procedures which are designed to manage our costs while ensuring that patients receive appropriate care.
 
Medicare/Medicaid
 
Medicare is the federal health insurance program for people age 65 or older and people under age 65 with certain disabilities. Medicaid, funded by both the federal government and states, is a state-administered health insurance program for qualifying low-income and medically needy persons. For services for which we bill Medicare directly or indirectly, including through contracted radiologists, we are paid under the Medicare Physician Fee Schedule. Under the Protecting Access to Medicare Act of 2014, Congress introduced a new quality incentive program that, effective January 1, 2016, reduces Medicare payments for certain CT services reimbursed through the Medicare Physician Fee Schedule that are furnished using equipment that does not meet certain dose optimization and management standards. Medicare patients usually pay a 20% co-payment unless they have secondary insurance. Medicaid rates are set by the individual states for each state program and Medicaid patients may be responsible for a modest co-payment.
 
Contracts with Physician Groups and Other Non-Insurance Company Payors
 
For some of our contracts with physician groups and other providers, we do not bill payors, but instead accept agreed upon rates for our radiology services. These rates are typically at or below the rates set forth in the current Medicare Fee Schedule for the particular service. However, we often agree to a specified rate for MRI and CT procedures that is not tied to the Medicare Fee Schedule.
 
Facilities
 
Our facilities are primarily located in geographic networks that we refer to as regions. The majority of our facilities are multi-modality sites, offering various combinations of MRI, CT, PET, nuclear medicine, ultrasound, X-ray, fluoroscopy services and other related procedures. A portion of our facilities are single-modality sites, offering either X-ray or MRI services. Consistent with our regional network strategy, we locate our single-modality facilities near multi-modality facilities, to help accommodate overflow in targeted demographic areas.
 
The following table sets forth the number of our facilities operated directly or managed through joint ventures for each year during the five-year period ended December 31, 2019:



9



 
Years Ended
December 31,
 
2015
 
2016
 
2017
 
2018
 
2019
Total facilities owned or managed (at beginning of the year)
259

 
300

 
305

 
297

 
344

Facilities added by:
 
 
 
 
 
 
 
 
 
Acquisition
43

 
10

 
8

 
55

 
9

Internal development
1

 
8

 
4

 
5

 
4

Facilities closed or sold
(3
)
 
(13
)
 
(20
)
 
(13
)
 
(22
)
Total facilities owned or managed (at year end)
300

 
305

 
297

 
344

 
335


Diagnostic Imaging Equipment
 
The following table indicates, as of December 31, 2019, the quantity of principal diagnostic equipment available at our facilities operated directly or through joint venture investments:

Equipment Count
Years Ended December 31,
 
2017
 
2018
 
2019
MRI
257

 
273

 
288

CT
152

 
162

 
168

PET/CT
49

 
59

 
62

Mammography
261

 
289

 
303

Ultrasound
614

 
632

 
662

X-ray
285

 
308

 
343

Nuclear Medicine
52

 
53

 
50

Fluoroscopy
102

 
117

 
120

Total equipment
1,772

 
1,893

 
1,996


The average age of our MRI and CT units is less than five years, and the average age of our PET units is less than four years. The useful life of our MRI, CT and PET units is typically ten years.
 
Facility Acquisitions
 
Information regarding our facility acquisitions can be found within Item 7 - “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, as well as Note 4 to our consolidated financial statements included in this annual report on Form 10-K.
 
Information Technology
 
Our corporate headquarters and many of our facilities are interconnected through a state-of-the-art information technology system. This system, which is compliant with the Health Insurance Portability and Accountability Act of 1996, is comprised of a number of integrated applications and provides a single operating platform for billing and collections, electronic medical records, practice management and image management.
 
This technology has created cost reductions for our facilities in areas such as image storage, support personnel and financial management and has further allowed us to optimize the productivity of all aspects of our business by enabling us to:
 
capture patient demographic, history and billing information at point-of-service;

automatically generate bills and electronically file claims with third-party payors;

record and store diagnostic report images in digital format;



10



digitally transmit in real-time diagnostic images from one location to another, thus enabling networked radiologists to cover larger geographic markets by using the specialized training of other networked radiologists;

perform claims, rejection and collection analysis; and

perform sophisticated financial analysis, such as analyzing cost and profitability, volume, charges, current activity and patient case mix, with respect to each of our managed care contracts.
 
We have developed our own Radiology Information System through our team of software development engineers, which is used as our front desk patient tracing system, and began running this internally developed system in the first quarter of 2015.
 
Personnel
 
At December 31, 2019, we had a total of 6,165 full-time, 616 part-time and 1,717 per diem employees, including those employed by the consolidated medical group. These numbers include 144 full-time and 40 part-time physicians and 2,033 full-time, 412 part-time and 1,129 per-diem technologists. In addition to our company personnel, we contract 96 full-time physicians through a relationship with Envision Healthcare.

We employ site managers who are responsible for overseeing day-to-day and routine operations at each of our facilities, including staffing, modality and schedule coordination, referring physician and patient relations and purchasing of materials. These site managers report to regional managers and directors, who are responsible for oversight of the operations of all facilities within their region, including sales, marketing and contracting. The regional managers and directors, along with our directors of contracting, marketing, facilities, management/purchasing and human resources all report to our chief operating officers. These officers, our chief financial officer, our director of information services and our medical director report to our chief executive officer.
 
None of our employees is subject to a collective bargaining agreement nor have we experienced any work stoppages. We believe our relationship with our employees is good.
 
Sales and Marketing
 
Our sales and marketing team employs a multi-pronged approach to marketing, including physician, payor and sports marketing programs, each of which are described below:
 
Physician Marketing
 
Each customer service representative on our physician marketing team is responsible for marketing activity on behalf of one or more facilities. The representatives act as a liaison between the facility and referring physicians, holding meetings periodically and on an as-needed basis with them and their staff to present educational programs on new applications and uses of our systems and to address particular patient service issues that have arisen. In our experience, consistent hands-on contact with a referring physician and his or her staff generates goodwill and increases referrals to our facilities. The representatives also continually seek to establish referral relationships with new physicians and physician groups. In addition to a base salary, each representative receives a bonus based upon success.
 
Payor Marketing
 
Our marketing team regularly meets with managed care organizations and insurance companies to solicit contracts and meet with existing contracting payors to solidify those relationships. The comprehensiveness of our services, the geographic location of our facilities and the reputation of the physicians with whom we contract all serve as tools for obtaining new or repeat business from payors.
 
Sports Marketing Program
 
Our west coast operations provide diagnostic digital X-ray services for the Los Angeles Lakers, Clippers, Kings and Sparks at the Staples Center and at the Coliseum for the University of Southern California Trojans football team. In exchange for these services the teams provide us with season tickets and parking. Contract lengths vary from yearly up to five years. We also provide radiology services at many of our imaging centers for the Los Angeles Angels, Anaheim Ducks, and the Oakland Athletics organizations.
 


11



Through our east coast operations, we have entered into sponsorship agreements with the Baltimore Ravens of the National Football League and the Baltimore Orioles of Major League Baseball which permits us to state we are the imaging partner to each organization. The sponsorship agreement with the Ravens lasts through 2022 and the Orioles through 2020.

Suppliers
 
We acquire our major diagnostic imaging equipment directly from original equipment manufacturers or through third party financing companies and purchase medical supplies from various national vendors. We have excellent working relationships with our providers who are of comparable stature in the event one becomes unavailable.

Our diagnostic imaging equipment represents a cornerstone investment of the company as it provides our customers the latest in imaging technology. We employ direct purchase or finance arrangements to accomplish our needs with such firms as GE, Hologic, Key Equipment, Philips, Siemens and Spectrum. At December 31, 2019, our liabilities for financing arrangements for radiology equipment, inclusive of operating and finance leases, amounted to approximately $60.6 million. If we open or acquire additional imaging facilities, we may incur material lease obligations. See Note 9, Leases, to our consolidated financial statements included in this annual report from on Form 10-K for further information.

Timely and effective maintenance is essential for achieving high utilization rates of our imaging equipment. In order to ensure operational efficiency, we have maintenance arrangements with the various service arms of the original equipment manufacturers.
 
Competition
 
Our competitors include independent imaging operators and smaller regional operators, as well as hospitals and hospital groups that operate their own imaging services. In addition, some physician practices have established their own diagnostic imaging facilities within their group practices. We experience additional competition as a result of those activities.
 
We compete principally on the basis of our reputation, our ability to provide multiple modalities at many of our facilities, the location of our facilities, the quality of our diagnostic imaging services and technologists and our ability to establish and maintain relationships with healthcare providers and referring physicians. See “Competitive Strengths” above. Some of our competitors may now or in the future have access to greater financial resources than we do, which could allow them to establish more facilities and provide access to newer, more advanced equipment.
 
Each of the third party contracted radiology practices has entered into agreements with its physician shareholders and full-time employed radiologists that generally prohibit those shareholders and radiologists from competing for a period of two to five years within defined geographic regions after they cease to be owners or employees, as applicable. In certain states, like California, a covenant not to compete is enforced in limited circumstances involving the sale of a business. In other states, a covenant not to compete will be enforced only:
 
to the extent it is necessary to protect a legitimate business interest of the party seeking enforcement;

if it does not unreasonably restrain the party against whom enforcement is sought; and

if it is not contrary to public interest.
Enforceability of a non-compete covenant is determined by a court based on all of the facts and circumstances of the specific case at the time enforcement is sought. For this reason, it is not possible to predict whether or to what extent a court will enforce the contracted radiology practices’ covenants. The inability of the contracted radiology practices or us to enforce radiologist’s non-compete covenants could result in increased competition from individuals who are knowledgeable about our business strategies and operations.
 
Liability Insurance
 
We maintain insurance policies with coverage we believe is appropriate in light of the risks attendant to our business and consistent with industry practice. We maintain general liability insurance and professional liability insurance in commercially reasonable amounts. Additionally, we maintain workers’ compensation insurance on all of our employees. Coverage is placed on a statutory basis and corresponds to individual state’s requirements. However, adequate liability insurance may not be available to us in the future at acceptable costs or at all. In addition, insurers from which we purchase such insurance may experience financial hardship which would impact their ability to pay covered policyholder claims.


12



 
Pursuant to our agreements with physician groups with whom we contract, including the consolidated medical group, each must maintain medical malpractice insurance for each physician in the group, having coverage limits of not less than $1.0 million per incident and $3.0 million in the aggregate per year.
 
California’s medical malpractice cap further reduces our exposure. California places a $250,000 limit on non-economic damages for medical malpractice cases. Non-economic damages are defined as compensation for pain, suffering, inconvenience, physical impairment, disfigurement and other non-pecuniary injury. The cap applies whether the case is for injury or death, and it allows only one $250,000 recovery in a wrongful death case. No cap applies to economic damages. Other states in which we now operate do not have similar limitations and in those states we believe our insurance coverage to be sufficient.
 
Regulation
 
General
 
The healthcare industry is highly regulated, and changes in the regulatory environment could significantly affect our operations in the future. Our ability to operate profitably will depend in part upon us, and the contracted radiology practices and their affiliated physicians, obtaining and maintaining all necessary licenses and other approvals, and operating in compliance with applicable healthcare regulations. We believe that healthcare regulations will continue to change. Therefore, we monitor developments in healthcare law and modify our operations from time to time as the business and regulatory environment changes.
 
Licensing and Certification Laws
 
Ownership, construction, operation, expansion and acquisition of diagnostic imaging facilities are subject to various federal and state laws, regulations and approvals concerning licensing of facilities and personnel. In addition, free-standing diagnostic imaging facilities that provide services not performed as part of a physician office must meet Medicare requirements to be certified as an independent diagnostic testing facility before it can be authorized to bill the Medicare program.
 
Corporate Practice of Medicine
 
In the states in which we operate, other than Florida, a lay person or any entity other than a professional corporation or other similar professional organization is not allowed to practice medicine, including by employing professional persons or by having any ownership interest or profit participation in or control over any medical professional practice. The laws of such states also prohibit a lay person or a non-professional entity from exercising control over the medical judgments or decisions of physicians and from engaging in certain financial arrangements, such as splitting professional fees with physicians. We structure our relationships with the radiology practices, including the purchase of diagnostic imaging facilities, in a manner that we believe keeps us from engaging in the practice of medicine, exercising control over the medical judgments or decisions of the radiology practices or their physicians, or violating the prohibitions against fee-splitting.
 
Medicare and Medicaid Fraud and Abuse – Federal Anti-kickback Statute
 
During the year ended December 31, 2019, approximately 21% of our net service revenue generated at our diagnostic imaging centers was derived from federal government sponsored healthcare programs (Medicare) and 2% from state sponsored programs (Medicaid).
 
Federal law known as the Anti-kickback Statute prohibits the knowing and willful offer, payment, solicitation or receipt of any form of remuneration in return for, or to induce, (i) the referral of a person, (ii) the furnishing or arranging for the furnishing of items or services reimbursable under the Medicare, Medicaid or other governmental programs or (iii) the purchase, lease or order or arranging or recommending purchasing, leasing or ordering of any item or service reimbursable under the Medicare, Medicaid or other governmental programs. Noncompliance with the federal Anti-kickback Statute can result in exclusion from the Medicare, Medicaid or other governmental programs and civil and criminal penalties.
 
The Anti-kickback Statute is broad, and it prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. To create better clarity, the Office of the Inspector General of the U.S. Department of Health and Human Services has issued regulations as "safe harbor" guidelines which if met in form and substance, will assure healthcare providers that they will not be prosecuted for violation of the Anti–kickback Statute. Although full compliance with these provisions ensures against prosecution under the federal Anti-kickback Statute, the failure of a transaction or arrangement to fit within a specific safe harbor does not necessarily mean that the transaction or arrangement is illegal or that prosecution under the federal Anti-kickback Statute will be pursued.


13




Although some of our arrangements may not fall within a safe harbor, we believe that such business arrangements do not violate the Anti-kickback Statute because we are careful to structure them to reflect fair value and ensure that the reasons underlying our decision to enter into a business arrangement comport with reasonable interpretations of the Anti-kickback Statute. However, even though we continuously strive to comply with the requirements of the Anti-kickback Statute, liability under the Anti-kickback Statute may still arise because of the intentions or actions of the parties with whom we do business. While we are not aware of any such intentions or actions, we have only limited knowledge regarding the intentions or actions underlying those arrangements. Conduct and business arrangements that do not fully satisfy one of these safe harbor provisions may result in increased scrutiny by government enforcement authorities such as the Office of the Inspector General.
 
Medicare and Medicaid Fraud and Abuse – Stark Law
 
The Ethics in Patient Referral Act of 1989, commonly known as the Stark Law prohibits a physician from referring Medicare patients to an entity providing designated health services in which the physician (or immediate family member) has an ownership or investment interest or with which the physician (or immediate family member) has entered into a compensation arrangement. The Stark Law also prohibits the entity from billing for any such prohibited referral. The penalties for violating the Stark Law include a prohibition on payment by these governmental programs and civil penalties of as much as $15,000 for each violation referral and $100,000 for participation in a circumvention scheme. We believe that, although we receive fees under our service agreements for management and administrative services, we are not in a position to make or influence referrals of patients.
 
Under the Stark Law, radiology and certain other imaging services and radiation therapy services and supplies are services included in the designated health services subject to the self-referral prohibition. Such services include the professional and technical components of any diagnostic test or procedure using X-rays, ultrasound or other imaging services, CT, MRI, radiation therapy and diagnostic mammography services (but not screening mammography services). PET and nuclear medicine procedures are also included as designated health services under the Stark Law. The Stark Law, however, excludes from designated health services: (i) X-ray, fluoroscopy or ultrasound procedures that require the insertion of a needle, catheter, tube or probe through the skin or into a body orifice; (ii) radiology procedures that are integral to the performance of, and performed during, non-radiological medical procedures; and (iii) invasive or interventional radiology, because the radiology services in these procedures are merely incidental or secondary to another procedure that the physician has ordered.
 
The Stark Law provides that a request by a radiologist for diagnostic radiology services or a request by a radiation oncologist for radiation therapy, if such services are furnished by or under the supervision of such radiologist or radiation oncologist pursuant to a consultation requested by another physician, does not constitute a referral by a referring physician. If such requirements are met, the Stark Law self-referral prohibition would not apply to such services. The effect of the Stark Law on the radiology practices, therefore, will depend on the precise scope of services furnished by each such practice’s radiologists and whether such services derive from consultations or are self-generated.
 
We believe that, other than self-referred patients, all of the services covered by the Stark Law provided by the contracted radiology practices derive from requests for consultation by non-affiliated physicians. Therefore, we believe that the Stark Law is not implicated by the financial relationships between our operations and the contracted radiology practices. In addition, we believe that we have structured our acquisitions of the assets of existing practices, and we intend to structure any future acquisitions, so as not to violate the Anti-kickback Statute and Stark Law and regulations. Specifically, we believe the consideration paid by us to physicians to acquire the tangible and intangible assets associated with their practices is consistent with fair value in arms’ length transactions and is not intended to induce the referral of patients or other business generated by such physicians. Should any such practice be deemed to constitute an arrangement designed to induce the referral of Medicare or Medicaid patients, then our acquisitions could be viewed as possibly violating anti-kickback and anti-referral laws and regulations. A determination of liability under any such laws could have a material adverse effect on our business, financial condition and results of operations.
 
Medicare and Medicaid Fraud and Abuse – General
 
The federal government embarked on an initiative to audit all Medicare carriers, which are the companies that adjudicate and pay Medicare claims. These audits are expected to intensify governmental scrutiny of individual providers. An unsatisfactory audit of any of our diagnostic imaging facilities or contracted radiology practices could result in any or all of the following: significant repayment obligations, exclusion from the Medicare, Medicaid or other governmental programs, and civil and criminal penalties.
 
Federal regulatory and law enforcement authorities have increased enforcement activities with respect to Medicare, Medicaid fraud and abuse regulations and other reimbursement laws and rules, including laws and regulations that govern our activities and the activities of the radiology practices. The federal government also has increased funding to fight healthcare fraud


14



and is coordinating its enforcement efforts among various agencies, such as the U.S. Department of Justice, the U.S. Department of Health and Human Services Office of Inspector General, and state Medicaid fraud control units. The government may investigate our or the radiology practices’ activities, claims may be made against us or the radiology practices and these increased enforcement activities may directly or indirectly have an adverse effect on our business, financial condition and results of operations.
 
State Anti-kickback and Physician Self-referral Laws
 
Many states have adopted laws similar to the federal Anti-kickback Statute. Some of these state prohibitions apply to referral of patients for healthcare services reimbursed by any source, not only the Medicare and Medicaid programs. Although we believe that we comply with both federal and state Anti-kickback laws, any finding of a violation of these laws could subject us to criminal and civil penalties or possible exclusion from federal or state healthcare programs. Such penalties would adversely affect our financial performance and our ability to operate our business.
 
Federal False Claims Act
 
The federal False Claims Act provides, in part, that the federal government may bring a lawsuit against any person who it believes has knowingly presented, or caused to be presented, a false or fraudulent request for payment from the federal government, or who has made a false statement or used a false record to get a claim approved. The federal False Claims Act further provides that a lawsuit thereunder may be initiated in the name of the United States by an individual, a “whistleblower,” who is an original source of the allegations. The government has taken the position that claims presented in violation of the federal anti-kickback law or Stark Law may be considered a violation of the federal False Claims Act. Penalties include civil penalties of not less than $5,500 and not more than $11,000 for each false claim, plus three times the amount of damages that the federal government sustained because of the act of that person.
 
Further, states are being encouraged to adopt false claims acts similar to the federal False Claims Act, which establish liability for submission of fraudulent claims to the State Medicaid program and contain whistleblower provisions. Even in instances when a whistleblower action is dismissed with no judgment or settlement, we may incur substantial legal fees and other costs relating to an investigation. Future actions under the False Claims Act may result in significant fines and legal fees, which would adversely affect our financial performance and our ability to operate our business.
 
We believe that we are in compliance with the rules and regulations that apply to the federal False Claims Act as well as its state counterparts.
 
Healthcare Reform Legislation
 
Healthcare reform legislation enacted in the first quarter of 2010 by the Patient Protection and Affordable Care Act or PPACA, specifically requires the U.S. Department of Health and Human Services, in computing physician practice expense relative value units, to increase the equipment utilization factor for advanced diagnostic imaging services (such as MRI, CT and PET) from a presumed utilization rate of 50% to 65% for 2010 through 2012, 70% in 2013, and 75% thereafter. Excluded from the adjustment is low-technology imaging modalities such as ultrasound, X-ray and fluoroscopy. The Health Care and Education Reconciliation Act of 2010 (H.R. 4872) or Reconciliation Act, which was passed by the Senate and approved by the President on March 30, 2010, amends the provision for higher presumed utilization of advanced diagnostic imaging services to a presumed rate of 75%. The higher utilization rate was fully implemented in the beginning of 2011 and replaced the phase-in approach provided in the PPACA. This utilization rate was further increased to 90% by the American Taxpayer Relief Act of 2012 (“ATRA”), effective as of January 1, 2014.
 
The aim of increased utilization of diagnostic imaging services is to spread the cost of the equipment and services over a greater number of scans, resulting in a lower cost per scan. These changes have precipitated reductions in federal reimbursement for medical imaging and result in decreased revenue for the scans we perform for Medicare beneficiaries. Other changes in reimbursement for services rendered by Medicare Advantage plans may also reduce the revenues we receive for services rendered to Medicare Advantage enrollees.
 
On November 8, 2016, Donald Trump was elected President of the United States. President Trump has repeatedly signaled his intent to repeal and replace the PPACA and members of the Republican Party in Congress have also advocated the repeal or modification of the PPACA. On January 20, 2017, President Trump signed an “Executive Order Minimizing the Economic Burden of the Patient Protection and Affordable Care Act Pending Repeal.” (the “PPACA Executive Order”). Under the PPACA Executive Order it is the policy of the Trump Administration to seek prompt repeal of the PPACA.
 


15



On December 22, 2017, President Trump signed into law the Tax Cuts and Jobs Act (the “TCJA”)). Among numerous changes to the tax code, the TCJA repealed the individual mandate tax penalty (the “Individual Mandate”), a PPACA provision that required individuals to pay additional taxes if he or she was uninsured during the year.
 
Repeal of the Individual Mandate may lead to more people being uninsured, and could raise premium rates for insured persons. Such a development, as well as other changes to (or the full repeal of) the PPACA (whether through legislation or judicial action), could affect reimbursement, coverage, and utilization of diagnostic imaging services in ways that are currently unpredictable.
 
Health Insurance Portability and Accountability Act of 1996
 
Congress enacted the Health Insurance Portability and Accountability Act of 1996, or HIPAA, in part, to combat healthcare fraud and to protect the privacy and security of patients’ individually identifiable healthcare information.  HIPAA, among other things, amends existing crimes and criminal penalties for Medicare fraud and enacts new federal healthcare fraud crimes, including actions affecting non-government healthcare benefit programs. Under HIPAA, a healthcare benefit program includes any private plan or contract affecting interstate commerce under which any medical benefit, item or service is provided. A person or entity that knowingly and willfully obtains the money or property of any healthcare benefit program by means of false or fraudulent representations in connection with the delivery of healthcare services is subject to a fine or imprisonment, or potentially both. In addition, HIPAA authorizes the imposition of civil money penalties against entities that employ or enter into contracts with excluded Medicare or Medicaid program participants if such entities provide services to federal health program beneficiaries. A finding of liability under HIPAA could have a material adverse effect on our business, financial condition and results of operations.
 
Further, HIPAA requires healthcare providers and their business associates to maintain the privacy and security of individually identifiable protected health information (“PHI”). HIPAA imposes federal standards for electronic transactions, for the security of electronic health information and for protecting the privacy of PHI. The Health Information Technology for Economic and Clinical Health Act of 2009 (“HITECH”), signed into law on February 17, 2009, dramatically expanded, among other things, (1) the scope of HIPAA to now apply directly to “business associates,” or independent contractors who receive or obtain PHI in connection with providing a service to a covered entity, (2) substantive security and privacy obligations, including new federal security breach notification requirements to affected individuals, DHHS and prominent media outlets, of certain breaches of unsecured PHI, (3) restrictions on marketing communications and a prohibition on covered entities or business associates from receiving remuneration in exchange for PHI, and (4) the civil and criminal penalties that may be imposed for HIPAA violations, increasing the annual cap in penalties from $25,000 to $1.5 million per year.
 
In addition, many states have enacted comparable privacy and security statutes or regulations that, in some cases, are more stringent than HIPAA requirements. In those cases it may be necessary to modify our operations and procedures to comply with the more stringent state laws, which may entail significant and costly changes for us. We believe that we are in compliance with such state laws and regulations. However, if we fail to comply with applicable state laws and regulations, we could be subject to additional sanctions.
 
We believe that we are in compliance with the current HIPAA requirements, as amended by HITECH, and comparable state laws, but we anticipate that we may encounter certain costs associated with future compliance. Moreover, we cannot guarantee that enforcement agencies or courts will not make interpretations of the HIPAA standards that are inconsistent with ours, or the interpretations of our contracted radiology practices or their affiliated physicians. A finding of liability under the HIPAA standards may result in significant criminal and civil penalties. Noncompliance also may result in exclusion from participation in government programs, including Medicare and Medicaid. These actions could have a material adverse effect on our business, financial condition, and results of operations.
 
U.S. Food and Drug Administration or FDA
 
The FDA has issued the requisite pre-market approval for all of the MRI and CT systems we use.

Our mammography systems are regulated by the FDA pursuant to the Mammography Quality Standards Act of 1992, as amended by the Mammography Quality Standards Reauthorization Acts of 1998 and 2004 (collectively, the “MQSA”). All mammography facilities are required to meet the applicable MQSA requirements, including quality standards, be accredited by an approved accreditation body or state agency and certified by the FDA or an FDA-approved certifying state agency. Pursuant to the accreditation process, each facility providing mammography services must comply with certain standards that include, among other things, annual inspection of the facility's equipment, personnel (interpreting physicians, technologists and medical physicists) and practices.
 


16



Compliance with these MQSA requirements and standards is required to obtain Medicare payment for services provided to beneficiaries and to avoid various sanctions, including monetary penalties, or suspension of certification. Although the Mammography Accreditation Program of the American College of Radiology is an approved accreditation body and currently accredits all of our facilities which provide mammography services, and although we anticipate continuing to meet the requirements for accreditation, if we lose such accreditation, the FDA could revoke our certification. Congress has extended Medicare benefits to include coverage of screening mammography but coverage is subject to the facility performing the mammography meeting prescribed quality standards described above. The Medicare requirements to meet the standards apply to diagnostic mammography and image quality examination as well as screening mammography.
 
Radiologist Licensing
 
The radiologists providing professional medical services at our facilities are subject to licensing and related regulations by the states in which they provide services. As a result, we require the radiology groups with which we contract to require those radiologists to have and maintain appropriate licensure. We do not believe that such laws and regulations will either prohibit or require licensure approval of our business operations, although no assurances can be made that such laws and regulations will not be interpreted to extend such prohibitions or requirements to our operations.
 
Insurance Laws and Regulation
 
States in which we operate have adopted certain laws and regulations affecting risk assumption in the healthcare industry, including those that subject any physician or physician network engaged in risk-based managed care to applicable insurance laws and regulations. These laws and regulations may require physicians and physician networks to meet minimum capital requirements and other safety and soundness requirements. Implementing additional regulations or compliance requirements could result in substantial costs to the contracted radiology practices, limiting their ability to enter into capitated or other risk-sharing managed care arrangements and indirectly affecting our revenue from the contracted practices.
 
U.S. Federal Budget
 
We derive a substantial portion of our revenue from direct billings to governmental healthcare programs, such as Medicare and Medicaid, and private health insurance companies and/or health plans, including but not limited to those participating in the Medicare Advantage program. As a result, any negative changes in governmental capitation or fee-for-service rates or methods of reimbursement for the services we provide could have a significant adverse impact on our revenue and financial results.
 
Because governmental healthcare programs generally reimburse on a fee schedule basis rather than on a charge-related basis, we generally cannot increase our revenues from these programs by increasing the amount of charges for services. Moreover, if our costs increase, we may not be able to recover our increased costs from these programs. Government and private payors have taken and may continue to take steps to control the cost, eligibility for, use, and delivery of healthcare services as a result of budgetary constraints, cost containment pressures and other reasons. We believe that these trends in cost containment will continue. These cost containment measures, and other market changes in non-governmental insurance plans have generally restricted our ability to recover, or shift to non-governmental payors, any increased costs that we experience. Our integrated care business and financial operations may be materially affected by these developments.
 
Environmental Matters
 
The facilities we operate or manage generate hazardous and medical waste subject to federal and state requirements regarding handling and disposal. We believe that the facilities that we operate and manage are currently in compliance in all material respects with applicable federal, state and local statutes and ordinances regulating the handling and disposal of such materials. We do not believe that we will be required to expend any material additional amounts in order to remain in compliance with these laws and regulations or that compliance will materially affect our capital expenditures, earnings or competitive position.
 
Compliance Program
 
We maintain a program to monitor compliance with federal and state laws and regulations applicable to healthcare entities. We have a compliance officer who is charged with implementing and supervising our compliance program, which includes the adoption of (i) Standards of Conduct for our employees and affiliates and (ii) a process that specifies how employees, affiliates and others may report regulatory or ethical concerns to our compliance officer. We believe that our compliance program meets the relevant standards provided by the Office of Inspector General of the Department of Health and Human Services.
 


17



An important part of our compliance program consists of conducting periodic audits of various aspects of our operations and that of the contracted radiology practices. We also conduct mandatory educational programs designed to familiarize our employees with the regulatory requirements and specific elements of our compliance program.
 
Item 1A.
Risk Factors
 
If our contracted radiology practices terminate their agreements with us, our business could substantially diminish.
 
Our relationship with professional corporations contracted to provide medical services is an integral part of our business. These professional corporations must use their best efforts to provide medical services at any new facilities that we open or acquire in their areas of operation. In addition, these professional corporation's strong relationships with referring physicians are largely responsible for the revenue generated at the facilities they service. Although our management agreements are for multiple years, the radiology groups have the right to terminate the agreements if we default on our obligations and fail to cure the default. Also, the various radiology groups’ ability to continue performing under the management agreements may be curtailed or eliminated due to the groups’ financial difficulties, loss of physicians or other circumstances. If the radiology groups cannot perform their obligations to us, we would need to contract with one or more other radiology groups to provide the professional medical services at the facilities serviced by the group. We may not be able to locate radiology groups willing to provide those services on terms acceptable to us, if at all. Even if we were able to do so, any replacement radiology group’s relationships with referring physicians may not be as extensive as those of the terminated group. In any such event, our business could be seriously harmed. In addition, the radiology groups are party to substantially all of the managed care contracts from which we derive revenue. If we were unable to readily replace these contracts, our revenue would be negatively affected.
 
Our ability to generate revenue depends in large part on referrals from physicians.
 
We derive substantially all of our net revenue, directly or indirectly, from fees charged for the diagnostic imaging services performed at our facilities. We depend on referrals of patients from unaffiliated physicians and other third parties who have no contractual obligations to refer patients to us for a substantial portion of the services we perform. If a sufficiently large number of these physicians and other third parties were to discontinue referring patients to us, our scan volume could decrease, which would reduce our net revenue and operating margins. Further, commercial third-party payors have implemented programs that could limit the ability of physicians to refer patients to us. For example, prepaid healthcare plans, such as health maintenance organizations, sometimes contract directly with providers and require their enrollees to obtain these services exclusively from those providers. Some insurance companies and self-insured employers also limit these services to contracted providers. These “closed panel” systems are now common in the managed care environment. Other systems create an economic disincentive for referrals to providers outside the system’s designated panel of providers. If we are unable to compete successfully for these managed care contracts, our results and prospects for growth could be adversely affected.

If our contracted radiology practices, including the consolidated medical group, lose a significant number of their radiologists, our financial results could be adversely affected.
 
At times, there has been a shortage of qualified radiologists in some of the regional markets we serve. In addition, competition in recruiting radiologists may make it difficult for our contracted radiology practices to maintain adequate levels of radiologists. If a significant number of radiologists terminate their relationships with our contracted radiology practices and those radiology practices cannot recruit sufficient qualified radiologists to fulfill their obligations under our agreements with them, our ability to maximize the use of our diagnostic imaging facilities and our financial results could be adversely affected. Increased expenses for the Group will impact our financial results because the management fee we receive from them, which is based on a percentage of their collections, is adjusted annually to take into account their expenses as applicable. Neither we, nor our contracted radiology practices, maintain insurance on the lives of any affiliated physicians.
 
We may become subject to professional malpractice liability, which could be costly and negatively impact our business.
 
The physicians employed by our contracted radiology practices are from time to time subject to malpractice claims. We structure our relationships with the practices under our management agreements in a manner that we believe does not constitute the practice of medicine by us or subject us to professional malpractice claims for acts or omissions of physicians employed by the contracted radiology practices. Nevertheless, claims, suits or complaints relating to services provided by the contracted radiology practices have been asserted against us in the past and may be asserted against us in the future. In addition, we may be subject to professional liability claims, including, without limitation, for improper use or malfunction of our diagnostic imaging equipment or for accidental contamination or injury from exposure to radiation. We may not be able to maintain adequate liability insurance to protect us against those claims at acceptable costs or at all.


18



 
Historically, we have sought to manage this risk of loss by, among other things, purchasing professional liability insurance. However, the insurer from which we purchased such insurance for the period ending July 15, 2017, Fairway Physicians Insurance Company, A Risk Retention Group (“Fairway”), experienced financial hardship.  As a result, on August 29, 2017, the District of Columbia Department of Insurance, Securities and Banking (“DISB”) found that Fairway was statutorily insolvent and that its continued operation would be hazardous to its policyholders, creditors and the general public.  On October 25, 2017, the Superior Court for the District of Columbia issued an order authorizing the DISB Commissioner to liquidate Fairway.  Fairway’s liquidation is currently pending, and it is presently unknown whether the Fairway liquidation estate will be able to pay covered policyholder claims, including claims asserted against us.
 
Any claim made against us that is not fully covered by insurance could be costly to defend, result in a substantial damage award against us and divert the attention of our management from our operations, all of which could have an adverse effect on our financial performance. In addition, successful claims against us may adversely affect our business or reputation. Although California places a $250,000 limit on non-economic damages for medical malpractice cases, no limit applies to economic damages and no such limits exist in the other states in which we provide services.
 
We may not receive payment from some of our healthcare provider customers because of their financial circumstances.
 
Some of our healthcare provider customers do not have significant financial resources, liquidity or access to capital. If these customers experience financial difficulties they may be unable to pay us for the equipment and services that we provide. A significant deterioration in general or local economic conditions could have a material adverse effect on the financial health of certain of our healthcare provider customers. As a result, we may have to increase the amounts of accounts receivables that we write-off, which would adversely affect our financial condition and results of operations.

Capitation fee arrangements could reduce our operating margins.
 
For the year ended December 31, 2019, we derived approximately 11% of our total net revenue from capitation arrangements, and we intend to increase the revenue we derive from capitation arrangements in the future. Under capitation arrangements, the payor pays a pre-determined amount per-patient per-month in exchange for us providing all necessary covered services to the patients covered under the arrangement. These contracts pass much of the financial risk of providing diagnostic imaging services, including the risk of over-use, from the payor to the provider. Our success depends in part on our ability to negotiate effectively, on behalf of the contracted radiology practices and our diagnostic imaging facilities, contracts with health maintenance organizations, employer groups and other third-party payors for services to be provided on a capitated basis and to efficiently manage the utilization of those services. If we are not successful in managing the utilization of services under these capitation arrangements or if patients or enrollees covered by these contracts require more frequent or extensive care than anticipated, we would incur unanticipated costs not offset by additional revenue, which would reduce operating margins.

Changes in the method or rates of third-party reimbursement could have a negative impact on our results
 
From time to time, changes designed to contain healthcare costs have been implemented, some of which have resulted in decreased reimbursement rates for diagnostic imaging services that impact our business.

On April 16, 2015, President Obama signed into law the Medicare Access and CHIP Reauthorization Act (H.R. 2), which provides for sweeping changes to how Medicare pays physicians. H.R. 2, among other things, repealed the Sustainable Growth Rate (SGR) formula. The SGR formula was enacted in 1997 and was linked to the growth in the U.S. gross domestic product, which led Congress to repeatedly intervene to mitigate the negative reimbursement impact associated with it. H.R. 2 provides that for services paid under the physician fee schedule and furnished during calendar years 2016 through 2019, Medicare’s payment rates will increase by 0.5% per year over calendar year 2015. Fees will remain at the 2019 level through 2025, but providers have the ability to participate in the Quality Payment Program (“QPP”) and have the opportunity for additional payments. Under one track, incentive payments will be based upon participating in an innovative payment model (e.g., participating in the Medicare Shared Savings Program), and under the other track, incentive payments will be based upon quality, resource use, clinical practice improvement activities and meaningful use of electronic health record technology. Given that the QPP remains under CMS’ continued development, we cannot determine the impact of such payments models on our business at this time. However, in general, shifting to value-based care may decrease our revenue and require us to invest heavily in new IT infrastructure and analytic tools.
 
In 2013, Congress adjusted Medicare payment rates for physician imaging services in an attempt to better reflect actual usage, by revising upward the assumed usage rate for diagnostic imaging equipment costing more than $1 million to 90% effective January, 1, 2014. Additionally, under the Protecting Access to Medicare Act of 2014 (“PAMA”), Congress introduced a new quality


19



incentive program that, effective January 1, 2016, reduced Medicare payment for certain CT services reimbursed through the Medicare Physician Fee Schedule that are furnished using equipment that does not meet certain dose optimization and management standards. Other changes in reimbursement for services rendered by Medicare Advantage plans may reduce the revenues we receive for services rendered to Medicare Advantage enrollees.
 
Pressure to control healthcare costs could have a negative impact on our results.
 
One of the principal objectives of health maintenance organizations and preferred provider organizations is to control the cost of healthcare services. Healthcare providers participating in managed care plans may be required to refer diagnostic imaging tests to certain providers depending on the plan in which a covered patient is enrolled. In addition, managed care contracting has become very competitive, and reimbursement schedules are at or below Medicare reimbursement levels. The expansion of health maintenance organizations, preferred provider organizations and other managed care organizations within the geographic areas covered by our network could have a negative impact on the utilization and pricing of our services, because these organizations will exert greater control over patients’ access to diagnostic imaging services, the selections of the provider of such services and reimbursement rates for those services.
 
We experience competition from other diagnostic imaging companies and hospitals, and this competition could adversely affect our revenue and business.
 
The market for diagnostic imaging services is highly competitive. We compete for patients principally on the basis of our reputation, our ability to provide multiple modalities at many of our facilities, the location of our facilities and the quality of our diagnostic imaging services. We compete locally with groups of radiologists, established hospitals, clinics and other independent organizations that own and operate imaging equipment. Our competitors include independent imaging operators, such as Alliance Healthcare and smaller regional operators, as well as hospitals and hospital groups that operate their own imaging services. Some of our competitors may now or in the future have access to greater financial resources than we do and may have access to newer, more advanced equipment. In addition, some physician practices have established their own diagnostic imaging facilities within their group practices and compete with us. We are experiencing increased competition as a result of such activities, and if we are unable to successfully compete, our business and financial condition would be adversely affected.

Our success depends in part on our key personnel and loss of key executives could adversely affect our operations. In addition, former employees and radiology practices we have previously contracted with could use the experience and relationships developed while employed or under contract with us to compete with us.
 
Our success depends in part on our ability to attract and retain qualified senior and executive management, and managerial and technical personnel. Competition in recruiting these personnel may make it difficult for us to continue our growth and success. The loss of their services or our inability in the future to attract and retain management and other key personnel could hinder the implementation of our business strategy. The loss of the services of Dr. Howard G. Berger, our President and Chief Executive Officer, and Norman R. Hames or Stephen M. Forthuber, our Chief Operating Officers, West Coast and East Coast, respectively, could have a significant negative impact on our operations. We believe that they could not easily be replaced with executives of equal experience and capabilities. Additionally, if we lose the services of Dr. Berger, our relationship with BRMG could deteriorate, which would materially adversely affect our business.
 
Many of the states in which we operate do not enforce agreements that prohibit a former employee from competing with a former employer. As a result, many of our employees whose employment is terminated are free to compete with us, subject to prohibitions on the use of trade secret information and, depending on the terms of the employee’s employment agreement, on solicitation of existing employees and customers (if enforceable). A former executive, manager or other key employee who joins one of our competitors could use the relationships he or she established with third party payors, radiologists or referring physicians while our employee and the industry knowledge he or she acquired during that tenure to enhance the new employer’s ability to compete with us.
 
The agreements with most of our radiology practices contain non-compete provisions; however the enforceability of these provisions is determined by a court based on all the facts and circumstances of the specific case at the time enforcement is sought. Our inability to enforce radiologists’ non-compete provisions could result in increased competition from individuals who are knowledgeable about our business strategies and operations.
 
Our failure to successfully, and in a timely manner, integrate similar businesses and/or new lines of businesses we acquire could reduce our profitability.
 


20



We may never realize expected synergies, business opportunities and growth prospects in connection with our acquisitions and joint ventures. We may not be able to capitalize on expected business opportunities, assumptions underlying estimates of expected cost savings may be inaccurate, or general industry and business conditions may deteriorate. In addition, integrating operations will require significant efforts and expenses on our part. Personnel may leave or be terminated because of an acquisition. Our management may have its attention diverted while trying to integrate an acquisition. If these factors limit our ability to integrate the operations of an acquisition successfully or on a timely basis, our expectations of future results of operations, including certain cost savings and synergies as a result of the acquisition, may not be met.
 
In the past we have acquired, and may again in the future acquire, companies that create a new line of business. The process of integrating the acquired business, technology, service and research and development component into our business and operations and entry into a new line of business in which we are inexperienced may result in unforeseen operating difficulties and expenditures. In developing a new line of business, we may invest significant time and resources that take away the attention of management that would otherwise be available for ongoing development of our business, which may affect our results of operations and we may not be able to take full advantage of the business opportunities available to us as we expand new lines of business. In addition, there can be no assurance that our new lines of business will ultimately be successful. The failure to successfully manage these risks in the development and implementation of new lines of business could have a material, adverse effect on the Company’s business, financial condition, and results of operations.
 
We may not be able to successfully grow our business, which would adversely affect our financial condition and results of operations.
 
Historically, we have experienced substantial growth through acquisitions that have increased our size, scope and geographic distribution. During the past two fiscal years, we have completed 16 acquisitions. These acquisitions have added 64 centers to our fixed-site outpatient diagnostic imaging services. Our ability to successfully expand through acquiring facilities, developing new facilities, adding equipment at existing facilities, and directly or indirectly entering into contractual relationships with high-quality radiology practices depends upon many factors, including our ability to:
 
identify attractive and willing candidates for acquisitions;

identify locations in existing or new markets for development of new facilities;

comply with legal requirements affecting our arrangements with contracted radiology practices, including state prohibitions on fee-splitting, corporate practice of medicine and self-referrals;

obtain regulatory approvals where necessary and comply with licensing and certification requirements applicable to our diagnostic imaging facilities, the contracted radiology practices and the physicians associated with the contracted radiology practices;

recruit a sufficient number of qualified radiology technologists and other non-medical personnel;

expand our infrastructure and management; and

compete for opportunities.
We may not be able to compete effectively for the acquisition of diagnostic imaging facilities. Our competitors may have more established operating histories and greater resources than we do. Competition may also make any acquisitions more expensive.
 
Managing our recent acquisitions, as well as any other future acquisitions, will entail numerous operational and financial risks, including:
 
inability to obtain adequate financing;

failure to achieve our targeted operating results;

diversion of management’s attention and resources;

failure to retain key personnel;

difficulties in integrating new operations into our existing infrastructure; and


21




amortization or write-offs of acquired intangible assets, including goodwill.
If we are unable to successfully grow our business through acquisitions it could have an adverse effect on our financial condition and results of operations. Further we cannot ensure we will be able to receive the required regulatory approvals for any future acquisitions, expansions or replacements, and the failure to obtain these approvals could limit the market for our services and have an adverse effect on our financial condition and results of operations.

We are subject to tax audits, challenges to our tax positions, or adverse changes or interpretations of tax laws.
 
We are subject to federal and applicable state income tax laws and regulations. Income tax laws and regulations are often complex and require significant judgment in determining our effective tax rate and in evaluating our tax positions. Our determination of our tax liability is subject to review by applicable tax authorities. Any audits or challenges of such determinations may adversely affect our effective tax rate, tax payments or financial condition. Recently enacted U.S. tax legislation, most significant of which is the Tax Cuts and Jobs Act of 2017 (the "Tax Act"), made significant changes to federal tax law, including the taxation of corporations, by, among other things, reducing the corporate income tax rate, disallowing certain deductions that had previously been allowed, and altering the expensing of capital expenditures. The implementation and evaluation of these changes is ongoing and additional administrative guidance is necessary to fully evaluate the effects of many provisions.

The ultimate impact of the Tax Act may differ from our estimates due to changes in interpretations and assumptions made by us as well as potential amendments, technical corrections, and additional regulatory guidance that may be issued, and any such changes could have an adverse effect on our business, results of operations, financial condition and cash flow. Furthermore, future related changes may occur at the state level that could result in unfavorable adjustments to our tax liability.

We may be required to recognize an impairment of our goodwill or other indefinite-lived intangible assets, which could have an adverse effect on our financial position and results of operations.

We recognized an impairment of goodwill and trade name in our Imaging On Call reporting unit in the amount of $3.9 million for the year ended December 31, 2018. We are required to perform impairment tests for goodwill and other indefinite-lived intangible assets annually and whenever events or circumstances indicate that it is more likely than not that impairment exists or that the carrying amounts of the assets may not be recoverable, we recognize an impairment. A decline in the Company's operating results, future estimated cash flows and other assumptions could impact our estimated fair values, potentially leading to a material impairment of goodwill or other indefinite-lived assets, which could adversely affect our financial position and results of operations.

Our substantial debt could adversely affect our financial condition and prevent us from fulfilling our obligations under our outstanding indebtedness.
 
Our current substantial indebtedness and any future indebtedness we incur could adversely affect our financial condition. We are highly leveraged. As of December 31, 2019, our total combined indebtedness of term loans, capital leases and notes payable, excluding discount on term loan debt, was $706.0 million. Term loan indebtedness, excluding related discount, was $705.7 million of which $649.8 million constituted Barclays first lien term loans and the SunTrust term loan of $55.9 million. Our substantial indebtedness could also:
 
make it difficult for us to satisfy our payment obligations with respect to our outstanding indebtedness;

require us to dedicate a substantial portion of our cash flow from operations to payments on our debt, reducing the availability of our cash flow to fund working capital, capital expenditures, acquisitions and other general corporate purposes;

expose us to the risk of interest rate increases on our variable rate borrowings, including borrowings under our new senior secured credit facilities;

increase our vulnerability to adverse general economic and industry conditions;

limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate;

place us at a competitive disadvantage compared to our competitors that have less debt; and



22



limit our ability to borrow additional funds on terms that are satisfactory to us or at all.
 

Increases in interest rates could increase the amount of our debt payments and reduce our operating cash flows.
 
We have incurred significant indebtedness that accrues interest at variable rate borrowing and we may incur additional debt in the future. Increases in interest rates on our current outstanding debt or any other debt we may incur will reduce our operating cash flows and if we need to repay any of our variable rate borrowing during period of high interest rates, we could be required to forgo other opportunities in order to repay the debt which may not permit us to realize future earnings of those forgone opportunities. To mitigate this risk, we have entered into an interest rate cap contract on our term loan debt facilities. See Note 8 in the notes to our consolidated financial statements included in this annual report on Form 10-K.

We may not be able to finance future needs or adapt our business plan to changes because of restrictions placed on us by our credit facilities and instruments governing our other indebtedness.
 
Our credit facilities contain affirmative and negative covenants which restrict, among other things, our ability to:
 
pay dividends or make certain other restricted payments or investments;

incur additional indebtedness and certain disqualified equity interests;

create liens (other than permitted liens) securing indebtedness or trade payables;

sell certain assets or merge with or into other companies or otherwise dispose of all or substantially all of our assets;

enter into certain transactions with affiliates;

create restrictions on dividends or other payments by our restricted subsidiaries; and

create guarantees of indebtedness by restricted subsidiaries.

All of these restrictions could affect our ability to operate our business and may limit our ability to take advantage of potential business opportunities as they arise. A failure to comply with these covenants and restrictions would permit the relevant creditors to declare all amounts borrowed under the applicable agreement governing such indebtedness, together with accrued interest and fees, to be immediately due and payable. If the indebtedness under our credit facilities is accelerated, we may not have sufficient assets to repay amounts due under the credit facilities or on other indebtedness then outstanding.
 
A restriction in our ability to make capital expenditures would restrict our growth and could adversely affect our business.
 
We operate in a capital intensive, high fixed-cost industry that requires significant amounts of capital to fund operations, particularly the initial start-up and development expenses of new diagnostic imaging facilities and the acquisition of additional facilities and new diagnostic imaging equipment. We incur capital expenditures to, among other things, upgrade and replace equipment for existing facilities and expand within our existing markets and enter new markets. If we open or acquire additional imaging facilities, we may have to incur material capital lease obligations. To the extent we are unable to generate sufficient cash from our operations, funds are not available from our lenders or we are unable to structure or obtain financing through operating leases, finance leases or long-term installment notes, we may be unable to meet our capital expenditure requirements to support the maintenance and continued growth of our operations.
 
We may be impacted by eligibility changes to government and private insurance programs.
 
Due to potential decreased availability of healthcare through private employers, the number of patients who are uninsured or participate in governmental programs may increase. Healthcare reform legislation will increase the participation of individuals in the Medicaid program in states that elect to participate in the expanded Medicaid coverage. A shift in payor mix from managed care and other private payors to government payors as well as an increase in the number of uninsured patients may result in a reduction in the rates of reimbursement or an increase in uncollectible receivables or uncompensated care, with a corresponding decrease in net revenue. Changes in the eligibility requirements for governmental programs such as the Medicaid program and state decisions on whether to participate in the expansion of such programs also could increase the number of patients who participate in such programs and the number of uninsured patients. Even for those patients who remain in private insurance plans, changes to those plans could increase patient financial responsibility, resulting in a greater risk of uncollectible receivables.


23



Furthermore, additional changes to, or repeal of, the PPACA, whether through legislation or judicial action, may also affect reimbursement and coverage in ways that are currently unpredictable. These factors and events could have a material adverse effect on our business, financial condition, and results of operations.
 
Our business could be adversely impacted if there are deficiencies in our disclosure controls and procedures or internal control over financial reporting.
 
The design and effectiveness of our disclosure controls and procedures and internal control over financial reporting may not prevent all errors, misstatements or misrepresentations. While our management regularly reviews the effectiveness of our disclosure controls and procedures and internal control over financial reporting, there can be no guarantee that our disclosure controls and procedures or our internal control over financial reporting will be effective in accomplishing all control objectives all of the time. Deficiencies, including any material weakness, in our internal control over financial reporting that may occur in the future could result in misstatements of our results of operations, restatements of our financial statements, or otherwise adversely impact our financial condition, results of operations, cash flows, and our ability to satisfy our debt service obligations.

The regulatory framework in which we operate is uncertain and evolving.
 
Although we believe that we are operating in compliance with applicable federal and state laws, neither our current or anticipated business operations nor the operations of the contracted radiology practices have been the subject of judicial or regulatory interpretation. We cannot assure you that a review of our business by courts or regulatory authorities will not result in a determination that could adversely affect our operations or that the healthcare regulatory environment will not change in a way that restricts our operations. In addition, healthcare laws and regulations may change significantly in the future. We continuously monitor these developments and modify our operations from time to time as the regulatory environment changes. We cannot assure you however, that we will be able to adapt our operations to address new regulations or that new regulations will not adversely affect our business.
 
Certain states have enacted statutes or adopted regulations affecting risk assumption in the healthcare industry, including statutes and regulations that subject any physician or physician network engaged in risk-based managed care contracting to applicable insurance laws and regulations. These laws and regulations, if adopted in the states in which we operate, may require physicians and physician networks to meet minimum capital requirements and other safety and soundness requirements. Implementing additional regulations or compliance requirements could result in substantial costs to us and the contracted radiology practices and limit our ability to enter into capitation or other risk-sharing managed care arrangements.
 
State and federal anti-kickback and anti-self-referral laws may adversely affect income.
 
Various federal and state laws govern financial arrangements among healthcare providers. The federal Anti-Kickback Law prohibits the knowing and willful offer, payment, solicitation or receipt of any form of remuneration in return for, or to induce, the referral of Medicare, Medicaid, or other federal healthcare program patients, or in return for, or to induce, the purchase, lease or order of items or services that are covered by Medicare, Medicaid, or other federal healthcare programs. Similarly, many state laws prohibit the solicitation, payment or receipt of remuneration in return for, or to induce the referral of patients in private as well as government programs. Violation of these Anti-Kickback Laws may result in substantial civil or criminal penalties for individuals or entities and/or exclusion from federal or state healthcare programs. We believe we are operating in compliance with applicable law and believe that our arrangements with providers would not be found to violate the Anti-Kickback Laws. However, these laws could be interpreted in a manner inconsistent with our operations.
 
Federal law prohibiting physician self-referrals, known as the Stark Law, prohibits a physician from referring Medicare or Medicaid patients to an entity for certain “designated health services” if the physician has a prohibited financial relationship with that entity, unless an exception applies. Certain radiology services are considered “designated health services” under the Stark Law. Although we believe our operations do not violate the Stark Law, our activities may be challenged. If a challenge to our activities is successful, it could have an adverse effect on our operations. In addition, legislation may be enacted in the future that further addresses Medicare and Medicaid fraud and abuse or that imposes additional requirements or burdens on us.
 
In addition, under the DRA, states enacting false claims statutes similar to the federal False Claims Act, which establish liability for submission of fraudulent claims to the State Medicaid program and contain qui tam or whistleblower provisions, receive an increased percentage of any recovery from a State Medicaid judgment or settlement. Adoption of new false claims statutes in states where we operate may impose additional requirements or burdens on us.
 
Federal and state privacy and information security laws are complex, and if we fail to comply with applicable laws, regulations and standards, or if we fail to properly maintain the integrity of our data, protect our proprietary rights to our systems, or


24



defend against cybersecurity attacks, we may be subject to government or private actions due to privacy and security breaches, and our business, reputation, results of operations, financial position and cash flows could be materially and adversely affected.
 
Our operations rely on the secure processing, transmission and storage of confidential, proprietary and other information in our computer systems and networks. We must comply with numerous federal and state laws and regulations governing the collection, dissemination, access, use, security and privacy of PHI, including HIPAA and its implementing privacy and security regulations, as amended by the federal HITECH Act and collectively referred to as HIPAA. Information security risks have significantly increased in recent years in part because of the proliferation of new technologies, the use of the internet and telecommunications technologies to conduct our operations, and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including foreign state agents. If we fail to comply with applicable privacy and security laws, regulations and standards, properly maintain the integrity of our data, protect our proprietary rights to our systems, or defend against cybersecurity attacks, our business, reputation, results of operations, financial position and cash flows could be materially and adversely affected.
 
We are continuously implementing multiple layers of security measures through technology, processes, and our people; utilize current security technologies; and our defenses are monitored and routinely tested internally and by external parties. Despite these efforts, our facilities and systems may be vulnerable to privacy and security incidents; security attacks and breaches; acts of vandalism or theft; computer viruses; coordinated attacks by activist entities; emerging cybersecurity risks; misplaced or lost data; programming and/or human errors; or other similar events. Emerging and advanced security threats, including coordinated attacks, require additional layers of security which may disrupt or impact efficiency of operations.
 
Any security breach involving the misappropriation, loss or other unauthorized disclosure or use of confidential information, including protected health information, financial data, competitively sensitive information, or other proprietary data, whether by us or a third party, could have a material adverse effect on our business, reputation, financial condition, cash flows, or results of operations. The occurrence of any of these events could result in interruptions, delays, the loss or corruption of data, cessations in the availability of systems or liability under privacy and security laws, all of which could have a material adverse effect on our financial position and results of operations and harm our business reputation. If we are unable to protect the physical and electronic security and privacy of our databases and transactions, we could be subject to potential liability and regulatory action, our reputation and relationships with our patients and vendors would be harmed, and our business, operations, and financial results may be materially adversely affected. Failure to adequately protect and maintain the integrity of our information systems (including our networks) and data, or to defend against cybersecurity attacks, could subject us to monetary fines, civil suits, civil penalties or criminal sanctions and requirements to disclose the breach publicly, and may further result in a material adverse effect on our results of operations, financial position, and cash flows.
 
Complying with federal and state regulations is an expensive and time-consuming process, and any failure to comply could result in substantial penalties.
 
We are directly or indirectly, through the radiology practices with which we contract, subject to extensive regulation by both the federal government and the state governments in which we provide services, including:
 
the federal False Claims Act;

the federal Medicare and Medicaid Anti-Kickback Laws, and state anti-kickback prohibitions;

federal and state billing and claims submission laws and regulations;

the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and comparable state laws;

the federal physician self-referral prohibition commonly known as the Stark Law and the state equivalent of the Stark Law;

state laws that prohibit the practice of medicine by non-physicians and prohibit fee-splitting arrangements involving physicians;

federal and state laws governing the diagnostic imaging and therapeutic equipment we use in our business concerning patient safety, equipment operating specifications and radiation exposure levels; and



25



state laws governing reimbursement for diagnostic services related to services compensable under workers compensation rules.
If our operations are found to be in violation of any of the laws and regulations to which we or the radiology practices with which we contract are subject, we may be subject to the applicable penalty associated with the violation, including civil and criminal penalties, damages, fines and the curtailment of our operations. Any penalties, damages, fines or curtailment of our operations, individually or in the aggregate, could adversely affect our ability to operate our business and our financial results. The risks of our being found in violation of these laws and regulations is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action brought against us for violation of these laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business.
 
If we fail to comply with various licensure, certification and accreditation standards, we may be subject to loss of licensure, certification or accreditation, which would adversely affect our operations.
 
Ownership, construction, operation, expansion and acquisition of our diagnostic imaging facilities are subject to various federal and state laws, regulations and approvals concerning licensing of personnel, other required certificates for certain types of healthcare facilities and certain medical equipment. In addition, freestanding diagnostic imaging facilities that provide services independent of a physician’s office must be enrolled by Medicare as an independent diagnostic treatment facility, or IDTF, to bill the Medicare program. Medicare carriers have discretion in applying the IDTF requirements and therefore the application of these requirements may vary from jurisdiction to jurisdiction. In addition, federal legislation requires all suppliers that provide the technical component of diagnostic MRI, PET/CT, CT, and nuclear medicine to be accredited by an accreditation organization designated by CMS (which currently include the American College of Radiology (ACR), the Intersocietal Accreditation Commission (IAC) and the Joint Commission). Our MRI, CT, nuclear medicine, ultrasound and mammography facilities are currently accredited by the American College of Radiology. We may not be able to receive the required regulatory approvals or accreditation for any future acquisitions, expansions or replacements, and the failure to obtain these approvals could limit the opportunity to expand our services.
 
Our facilities are subject to periodic inspection by governmental and other authorities to assure continued compliance with the various standards necessary for licensure and certification. If any facility loses its certification under the Medicare program, then the facility will be ineligible to receive reimbursement from the Medicare and Medicaid programs. For the year ended December 31, 2019, approximately 21% and 2% of our net service fee revenue came from Medicare and various state Medicaid programs, respectively. A change in the applicable certification status of one of our facilities could adversely affect our other facilities and in turn us as a whole. Credentialing of physicians is required by our payors prior to commencing payment. We have experienced a slowdown in the credentialing of our physicians over the last several years which has lengthened our billing and collection cycle, and could negatively impact our ability to collect revenue from patients covered by Medicare.
 
Our agreements with the contracted radiology practices must be structured to avoid the corporate practice of medicine and fee-splitting.
 
State law prohibits us from exercising control over the medical judgments or decisions of physicians and from engaging in certain financial arrangements, such as splitting professional fees with physicians. These laws are enforced by state courts and regulatory authorities, each with broad discretion. A component of our business has been to enter into management agreements with radiology practices. We provide management, administrative, technical and other non-medical services to the radiology practices in exchange for a service fee typically based on a percentage of the practice’s revenue. We structure our relationships with the radiology practices, including the purchase of diagnostic imaging facilities, in a manner that we believe keeps us from engaging in the practice of medicine or exercising control over the medical judgments or decisions of the radiology practices or their physicians, or violating the prohibitions against fee-splitting. There can be no assurance that our present arrangements with BRMG or the physicians providing medical services and medical supervision at our imaging facilities will not be challenged, and, if challenged, that they will not be found to violate the corporate practice of medicine or fee splitting prohibitions, thus subjecting us to potential damages, injunction and/or civil and criminal penalties or require us to restructure our arrangements in a way that would affect the control or quality of our services and/or change the amounts we receive under our management agreements. Any of these results could jeopardize our business.
 
Some of our imaging modalities use radioactive materials, which generate regulated waste and could subject us to liabilities for injuries or violations of environmental and health and safety laws.
 
Some of our imaging procedures use radioactive materials, which generate medical and other regulated wastes. For example, patients are injected with a radioactive substance before undergoing a PET scan. Storage, use and disposal of these


26



materials and waste products present the risk of accidental environmental contamination and physical injury. We are subject to federal, state and local regulations governing storage, handling and disposal of these materials. We could incur significant costs and the diversion of our management’s attention in order to comply with current or future environmental and health and safety laws and regulations. Also, we cannot completely eliminate the risk of accidental contamination or injury from these hazardous materials. Although we maintain professional liability insurance coverage in amounts we believe is consistent with industry practice in the event of an accident, we could be held liable for any resulting damages, and any liability could exceed the limits of or fall outside the coverage of our professional liability insurance.
 
Technological change in our industry could reduce the demand for our services and require us to incur significant costs to upgrade our equipment.
 
The development of new technologies or refinements of existing modalities may require us to upgrade and enhance our existing equipment before we may otherwise intend. Many companies currently manufacture diagnostic imaging equipment. Competition among manufacturers for a greater share of the diagnostic imaging equipment market may result in technological advances in the speed and imaging capacity of new equipment. This may accelerate the obsolescence of our equipment, and we may not have the financial ability to acquire the new or improved equipment and may not be able to maintain a competitive equipment base. In addition, advances in technology may enable physicians and others to perform diagnostic imaging procedures without us. If we are unable to deliver our services in the efficient and effective manner that payors, physicians and patients expect our revenue could substantially decrease.
 
Because we have high fixed costs, lower scan volumes per system could adversely affect our business.
 
The principal components of our expenses, excluding depreciation, consist of debt service, capital lease payments, compensation paid to technologists, salaries, real estate lease expenses and equipment maintenance costs. Because a majority of these expenses are fixed, a relatively small change in our revenue could have a disproportionate effect on our operating and financial results depending on the source of our revenue. Thus, decreased revenue as a result of lower scan volumes per system could result in lower margins, which could materially adversely affect our business.
 
We may be unable to effectively maintain our equipment or generate revenue when our equipment is not operational.
 
Timely, effective service is essential to maintaining our reputation and high use rates on our imaging equipment. Although we have a agreements with original equipment manufacturers pursuant to which they maintain and repair the majority of our imaging equipment, those agreements do not compensate us for loss of revenue when our systems are not fully operational and our business interruption insurance may not provide sufficient coverage for the loss of revenue. Also, service representatives may not be able to perform repairs or supply needed parts in a timely manner, which could result in a loss of revenue. Therefore, if we experience more equipment malfunctions than anticipated or if we are unable to promptly obtain the service necessary to keep our equipment functioning effectively, our ability to provide services would be adversely affected and our revenue could decline.
 
Disruption or malfunction in our information systems could adversely affect our business.
 
We rely on information technology systems to process, transmit and store electronic information. A significant portion of the communication between personnel, customers, business partners, and suppliers depends on information technology. We rely on our information systems to perform functions critical to our ability to operate, including patient scheduling, billing, collections, image storage and image transmission. We also use information technology systems and networks in our operations and supporting departments such as marketing, accounting, finance, and human resources. The future success and growth of our business depends on streamlined processes made available through information systems, global communications, internet activity and other network processes.
 
Despite our current security measures, our information technology systems, and those of our third-party service providers, may be vulnerable to information security breaches, acts of vandalism, computer viruses and interruption or loss of valuable business data. Our information technology system is vulnerable to damage or interruption from:
 
earthquakes, fires, floods and other natural disasters;

power losses, computer systems failures, internet and telecommunications or data network failures, operator negligence, improper operation by or supervision of employees, physical and electronic losses of data and similar events; and



27



computer viruses, penetration by hackers seeking to disrupt operations or misappropriate information and other breaches of security.
We have technology security initiatives and disaster recovery plans in place to mitigate our risk to these vulnerabilities, but these measures may not be adequate or implemented properly to ensure that our operations are not disrupted or that data security breaches do not occur.
 
We could face attempts by others to gain unauthorized access through the Internet or to introduce malicious software to our information technology systems. If a malicious hacker gained unauthorized access to our systems and network, it could have a material adverse impact on our business or operations. Such incidents, whether or not successful, could result in our incurring significant costs related to, for example, rebuilding internal systems, defending against litigation, responding to regulatory inquiries or actions, paying damages, or taking other remedial steps with respect to third parties. In addition, these threats are constantly changing, thereby increasing the difficulty of successfully defending against them or implementing adequate preventive measures. Accordingly, an extended interruption in our information technology system’s function could significantly curtail, directly and indirectly, our ability to conduct our business and generate revenue.
 
If our network was compromised, it could give rise to unwanted media attention, materially damage our payor and physician relationships, harm our business, reputation, results of operations, cash flows and financial condition, result in fines or lawsuits, and may increase the costs we incur to protect against such information security breaches, such as increased investment in technology, the costs of compliance with consumer protection laws and costs resulting from consumer fraud. While we maintain cyber liability insurance, our insurance may not be sufficient to protect against all losses we may incur if we suffer significant or multiple attacks.
 
Adverse changes in general domestic and worldwide economic conditions and instability and disruption of credit markets could adversely affect our operating results, financial condition, or liquidity.
 
We are subject to risk arising from adverse changes in general domestic and global economic conditions, including recession or economic slowdown and disruption of credit markets. Continued concerns about the systemic impact of potential long-term and wide-spread recession, inflation, energy costs, geopolitical issues, the availability and cost of credit have contributed to increased market volatility and diminished expectations for the United States economy. The United States and other western countries have responded to this economic situation by exercising monetary policy to keep interest rates low. Any significant change in economic conditions or change in fiscal monetary policy could result in material changes in interest rates.
 
Continued turbulence in domestic and international markets and economies may adversely affect our liquidity and financial condition, and the liquidity and financial condition of our patients. If these market conditions continue, they may increase expenses associated with borrowing, limit our ability and the ability of our patients, to timely replace maturing liabilities, and access the capital markets to meet liquidity needs, resulting in adverse effects on our financial condition and results of operations.

Business disruptions and interruptions due to external events beyond our control can adversely affect our business, financial condition or results of operations.

Our operations can be subject to external events beyond our control, such as the effects of earthquakes, fires, floods, severe weather, public health issues, power failures, telecommunication loss, and other natural and man-made events, some of which may be intensified by the effects of climate change and changing weather patterns. Our corporate headquarters and over 100 of our radiology centers are located in California, which is subject to wildfires, blackouts, and potentially damaging earthquakes. In addition, several of our facilities located in parts of the east coast have suffered from weather events that caused us to temporarily close facilities. More recently, the novel coronavirus outbreak has impacted other countries. This or such other events could cause disruption or interruption to our operations and significantly impact our employees.
 
Possible volatility in our stock price could negatively affect us and our stockholders.
 
The trading price of our common stock on the NASDAQ Global Market has fluctuated significantly in the past. During the period from January 1, 2018 through December 31, 2019, the trading price of our common stock fluctuated from a high of $20.45 per share to a low of $9.65 per share. In the past, we have experienced a drop in stock price following an announcement of disappointing earnings or earnings guidance. Any such announcement in the future could lead to a similar drop in stock price. The price of our common stock could also be subject to wide fluctuations in the future as a result of a number of other factors, including the following:
 
changes in expectations as to future financial performance or buy/sell recommendations of securities analysts;


28




our, or a competitor’s, announcement of new services, or significant acquisitions, strategic partnerships, joint ventures or capital commitments; and

the operating and stock price performance of other comparable companies.

In addition, the U.S. securities markets have experienced significant price and volume fluctuations. These fluctuations often have been unrelated to the operating performance of companies in these markets. Broad market and industry factors may lead to volatility in the price of our common stock, regardless of our operating performance. Moreover, our stock has limited trading volume, and this illiquidity may increase the volatility of our stock price.
 
In the past, following periods of volatility in the market price of an individual company’s securities, securities class action litigation often has been instituted against that company. The institution of similar litigation against us could result in substantial costs and a diversion of management’s attention and resources, which could negatively affect our business, results of operations or financial condition.
 
Provisions of the Delaware General Corporation Law and our organizational documents may discourage an acquisition of us.
 
In the future, we could become the subject of an unsolicited attempted takeover of our company. Although an unsolicited takeover could be in the best interests of our stockholders, our organizational documents and the General Corporation Law of the State of Delaware both contain provisions that will impede the removal of directors and may discourage a third-party from making a proposal to acquire us. For example, the provisions:
 
permit the board of directors to increase its own size, within the maximum limitations set forth in the bylaws, and fill the resulting vacancies;

authorize the issuance of shares of preferred stock in one or more series without a stockholder vote;

establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to the board of directors; and

prohibit transfers and/or acquisitions of stock (without consent of the Board of Directors ) that would result in any stockholder owning greater than 5% of the currently outstanding stock resulting in a limitation on net operating loss carryovers, capital loss carryovers, general business credit carryovers, alternative minimum tax credit carryovers and foreign tax credit carryovers, as well as any loss or deduction attributable to a “net unrealized built-in loss” within the meaning of Section 382 of the internal revenue code of 1986, as amended.

We are subject to Section 203 of the Delaware General Corporation Law, which could have the effect of delaying or preventing a change in control.
 
Item 1B.
Unresolved Staff Comments
 
None.
 
Item 2.
Properties

Our corporate headquarters is located in adjoining premises at 1508, 1510 and 1516 Cotner Avenue, Los Angeles, California 90025, and approximately 21,500 square feet is occupied under these leases, which including options, expire June 30, 2027. We also have a regional office of approximately 39,000 square feet in Baltimore, Maryland under a lease, which including options, expires September 30, 2028. In addition, we lease approximately 52,000 square feet of warehouse space under leases nationwide, which expire at various dates, including options, through December 31, 2028. As of December 31, 2019, total square footage operated directly or indirectly under lease, including medical office, administrative and warehouse locations, was approximately 2.6 million square feet.

At December 31, 2019, we operated directly or indirectly through joint ventures with hospitals, 335 centers located in California, Delaware, Florida, Maryland, New Jersey, and New York. We lease the premises at which these facilities are located and do not have options to purchase the facilities we rent. Our most common initial term varies in length from 5 to 15


29



years. Including renewal options negotiated with the landlord, we can have a total span of 10 to 35 years at the facilities we lease. We also lease smaller satellite X-Ray locations on mutually renewable terms, usually lasting one year. Rental increases can range from 1% to 10% on an annual basis, depending on the location and market conditions where we do business.
 
Item 3.
Legal Proceedings
 
We are engaged from time to time in the defense of lawsuits arising out of the ordinary course and conduct of our business. We believe that the outcome of our current litigation will not have a material adverse impact on our business, financial condition and results of operations. However, we could be subsequently named as a defendant in other lawsuits that could adversely affect us.
 
Item 4.
Mine Safety Disclosures
 
Not applicable.
 


30



PART II
 
Item 5.
Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
 
Principal Trading Market

Our common stock is quoted on the NASDAQ Global Market under the symbol “RDNT”.
 
Dividends
 
We have never declared or paid cash dividends on our capital stock and we do not expect to pay any dividends in the foreseeable future. We currently intend to retain future earnings, if any, to finance the growth and development of our business. Our current credit facilities place restrictions on our ability to issue dividends. See discussion under “Liquidity and Capital Resources” regarding our current credit facilities. Payment of future dividends, if any, will be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements and such other factors as the board of directors deems relevant.
 
Equity Compensation Plans Information
 
The information required by this item will be contained in our definitive proxy statement, to be filed with the SEC in connection with our 2020 annual meeting of stockholders, which is expected to be filed not later than 120 days after the end of our fiscal year ended December 31, 2019, and is incorporated in this report by reference.
 
Stock Performance Graph
 
The following graph compares the yearly percentage change in cumulative total stockholder return of our common stock during the period from 2014 to 2019 with (i) the cumulative total return of the S&P 500 index and (ii) the cumulative total return of the S&P 500 – Healthcare Sector index. The comparison assumes $100 was invested on December 31, 2014 in our common stock and in each of the foregoing indices and the reinvestment of dividends through December 31, 2019. The stock price performance on the following graph is not necessarily indicative of future stock price performance.
 
This graph shall not be deemed incorporated by reference by any general statement incorporating by reference this Form 10-K into any filing under the Securities Act or under the Exchange Act, except to the extent that RadNet specifically incorporates this information by reference, and shall not otherwise be deemed filed under the Securities Act or the Exchange Act.
 


31



chart-c596de076de05269b73.jpg

 
 
ANNUAL RETURN PERCENTAGE
Years Ending
Company / Index
 
12/31/15
 
12/31/16
 
12/30/17
 
12/29/18
 
12/31/19
RadNet, Inc.
 
(27.63)
 
4.37
 
56.59
 
0.69
 
99.61
S&P 500 Index
 
1.38
 
11.96
 
21.83
 
(4.38)
 
31.49
S&P Health Care Sector
 
6.89
 
(2.69)
 
22.08
 
6.47
 
20.82
 
 
 
Base
 
INDEXED RETURNS
Years Ending
 
 
Period
 
 
 
 
 
 
 
 
 
 
Company / Index
 
12/31/14
 
12/31/15
 
12/31/16
 
12/30/17
 
12/29/18
 
12/31/19
RadNet, Inc.
 
100

 
72.37
 
75.53
 
118.27
 
119.09
 
237.7
S&P 500 Index
 
100

 
101.38
 
113.51
 
138.29
 
132.23
 
173.86
S&P Health Care Sector
 
100

 
106.89
 
104.01
 
126.98
 
135.19
 
163.34
 
Recent Sales of Unregistered Securities
 
None


32



Item 6.
Selected Consolidated Financial Data
 
The following table sets forth our selected historical consolidated financial data. The selected consolidated statements of operations data set forth below for the years ended December 31, 2019, 2018 and 2017, and the consolidated balance sheet data as of December 31, 2019 and 2018, are derived from our audited consolidated financial statements and notes thereto included in this annual report on Form 10-K. The selected historical consolidated statements of operations data set forth below for the years ended December 31, 2016 and 2015, and the consolidated balance sheet data set forth below as of December 31, 2017, 2016 and 2015, are derived from our audited consolidated financial statements not included herein. This data should be read in conjunction with and is qualified in its entirety by reference to the audited consolidated financial statements and the related notes included elsewhere in this annual report and Item 7 - “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

The financial data set forth below and discussed in this annual report are derived from the consolidated financial statements of RadNet, its subsidiaries and certain affiliates. As a result of the contractual and operational relationship among Dr. Berger, Dr. Crues and the Company, we are considered to have a controlling financial interest in the consolidated medical group ("the Group") pursuant to applicable accounting guidance. Due to the deemed controlling financial interest, we are required to include the Group as consolidated entities in our consolidated financial statements. This means, for example, that revenue generated by the Group from the provision of professional medical services to our patients, as well as the Group's costs of providing those services, are included as net revenue and cost of operations in our consolidated statement of operations, whereas the management fee that the Group pays to us under our management agreement with the Group is eliminated as a result of the consolidation of our results. Also, because the Group is consolidated in our financial statements, any borrowings or advances we have received from or made to the Group has been eliminated in our consolidated balance sheet. If the Group was not treated as consolidated entities in our consolidated financial statements, the presentation of certain items in our income statement, such as net service fee revenue and costs and expenses, would change but our net income would not, because in operation and historically, the annual revenue of the Group from all sources closely approximates its expenses, including Dr. Berger’s and Dr. Crues’ compensation, fees payable to us and amounts payable to third parties.



33



 
Years Ended December 31,
 
2019
 
2018
 
2017
 
2016
 
2015
 
(in thousands, except per share data)
Statement of Operations Data:
 
 
 
 
 
 
 
 
 
Net revenue
$
1,154,179

 
$
975,146

 
$
922,186

 
$
884,535

 
$
809,628

Operating expenses:
 
 
 
 
 
 
 
 
 
Cost of operations, excluding depreciation and amortization
999,692

 
867,547

 
802,377

 
775,801
 
708,289
Depreciation and amortization
80,607

 
72,899

 
66,796

 
66,610
 
60,611
(Gain) loss on sale and disposal of equipment, net
2,383

 
(2,054
)
 
1,142

 
767
 
866
Gain on sale of imaging center and medical practice

 

 
(3,146
)
 

 
(5.434
)
Gain on re-measurement of pre-existing interest
(768
)
 
(39,539
)
 

 

 

Gain on return of common stock

 

 

 
(5,032
)
 

Meaningful use incentive

 

 
(250
)
 
(2,808)
 
(3,270)
Loss on extinguishment of debt

 

 

 

 
0
Loss on impairment

 
3,937

 

 

 

Net income attributable to RadNet common stockholders
14,756

 
32,243

 
53

 
7,230
 
7,709
 
 
 
 
 
 
 
 
 
 
Basic income per share attributable to RadNet common stockholders
0.30

 
0.67

 

 
0.18
 
0.03
 
 
 
 
 
 
 
 
 
 
Diluted income per share attributable to RadNet common stockholders
0.29

 
0.66

 

 
0.17
 
0.03
 
 
 
 
 
 
 
 
 
 
Balance Sheet Data:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and cash equivalents
$
40,165

 
$
10,389

 
$
51,322

 
$
20,638

 
$
446

Total assets
1,646,986

 
1,109,330

 
868,979

 
849,476
 
836,427
Total long-term liabilities
1,086,419

 
669,560

 
607,448

 
642,082
 
643,007
Total liabilities
1,413,847

 
909,077

 
799,054

 
797,423
 
799,966
Working capital (exclusive of current operating lease liability)
(23,007
)
 
(30,827
)
 
43,745

 
62,573
 
72,410
Equity
233,139

 
200,253

 
69,925

 
52,053
 
36,461



34



Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to help the reader understand the results of operations and financial condition of RadNet Inc. MD&A is provided as a supplement to, and should be read in conjunction with, our consolidated financial statements and the accompanying notes included in this annual report on Form 10-K.
 
Overview
 
We are a leading national provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States based on number of locations and annual imaging revenue. Our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, often reducing the cost and amount of care for patients. We have developed our medical imaging business through a combination of organic growth, acquisitions and joint venture formations, and derive substantially all of our revenue from fees charged for the diagnostic imaging services performed at our facilities.

In 2019, we expanded our presence in the Kern County, California area with the acquisition of Kern Radiology in Bakersfield. Combined with our already established presence, we are now a leading imaging operator in the greater Bakersfield, California area. We made additional acquisitions and formed partnerships to strengthen our positions in California, New York and New Jersey. Turning our focus to our imaging technology and work-flow processes, we have increased our efforts in Artificial Intelligence (AI) by acquiring the remaining 75% that we did not already own in Nulogix, Inc. and formed a partnership with Whiterabbit.ai to use AI and other technologies to create new solutions for breast cancer imaging.

The following table shows our facilities in operation at year end and revenues for the years ended December 31, 2019, 2018 and 2017:
 
 
Years Ended December 31,
 
2019
 
2018
 
2017
Facilities in operation
335

 
344

 
297

Total revenue (millions)
$
1,154.2

 
$
975.1

 
$
922.2


Our revenue is derived from a diverse mix of payors, including private payors, managed care capitated payors and government payors. We believe our payor diversity mitigates our exposure to possible unfavorable reimbursement trends within any one payor class. In addition, our experience with capitation arrangements over the last several years has provided us with the expertise to manage utilization and pricing effectively, resulting in a predictable stream of revenue. Our service fee revenue, net of contractual allowances and discounts, the provision for bad debts, and revenue under capitation arrangements for the years ended December 31, are summarized in the following table (in thousands):
 


35



 
Years Ended December 31,
 
2019
 
2018
 
2017
Commercial insurance
$
642,341

 
$
542,011

 
$
534,224

Medicare
237,427

 
192,881

 
179,678

Medicaid
28,283

 
25,615

 
24,133

Workers' compensation/personal injury
42,792

 
34,193

 
32,969

Other patient revenue
23,862

 
25,117

 
29,882

Management fee revenue
11,659

 
13,882

 
13,127

Imaging on call and software
17,317

 
16,261

 
18,116

Other
24,555

 
18,781

 
25,049

Service fee revenue, net of contractual allowances and discounts
1,028,236

 
868,741

 
857,178

Provision for bad debts

 

 
(46,555
)
Net service fee revenue
1,028,236

 
868,741

 
810,623

Revenue under capitation arrangements
125,943

 
106,405

 
111,563

Total net revenue
$
1,154,179

 
$
975,146

 
$
922,186

 
We typically experience some seasonality to our business. During the first quarter of each year we generally experience the lowest volumes of procedures and the lowest level of revenue for any quarter during the year. This is primarily the result of two factors. First, our volumes and revenue are typically impacted by winter weather conditions in our northeastern operations. It is common for snowstorms and other inclement weather to result in patient appointment cancellations and, in some cases, imaging center closures. Second, in recent years, we have observed greater participation in high deductible health plans by patients. As these high deductibles reset in January for most of these patients, we have observed that patients utilize medical services less during the first quarter, when securing medical care will result in significant out-of-pocket expenditures.

Our services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. The following table shows the number of systems that we had in operation as of the years ended December 31, 2019, 2018 and 2017:
 
 
Years Ended December 31,
 
2017
 
2018
 
2019
MRI
257

 
273

 
288

CT
152

 
162

 
168

PET/CT
49

 
59

 
62

Mammography
261

 
289

 
303

Ultrasound
614

 
632

 
662

X-ray
285

 
308

 
343

Nuclear Medicine
52

 
53

 
50

Fluoroscopy
102

 
117

 
120

Total equipment
1,772

 
1,893

 
1,996

 
Facility Acquisitions, Equity Investments and Formation of Joint Ventures
 
The following discussion summarizes certain details concerning our acquisition or disposition of facilities, our equity investment and our joint venture transaction. See Note 4, Facility Acquisitions and Dispositions to our consolidated financial statements included in this annual report on Form 10-K for further information.

Facility acquisitions
 
On August 1, 2019 we completed a step-up acquisition upon the dissolution of our former 49% owned joint venture, Garden State Radiology LLC ("GSRN"). GSRN consisted of two multi-modality centers operating in New Jersey. GSRN became our wholly owned subsidiary with the withdrawal of the 51% majority partner for the full ownership of one center with no other consideration. We made a fair value determination of our original 49% interest which resulted in a step-up gain of  approximately


36



$1.3 million. We determined a fair value of the remaining acquired imaging center of $3.1 million in assets and $426,000 in liabilities were recognized. We recorded $1,000 in other assets, $679,000 in fixed assets, $426,000 in right-of-use assets, $426,000 in operating lease liabilities, and $2.0 million in goodwill.

On August 1, 2019 we completed a step-up acquisition of our former 25% owned joint venture, Nulogix, via a stock issuance of RadNet common shares valued at $1.5 million to obtain the remaining 75% outstanding Nulogix shares. We made a fair value determination of the acquired assets and approximately $189,000 in fixed assets, $732,000 in intangible assets, $278,000 in deferred tax liability and goodwill of $1.3 million were recorded. We also made a fair value determination of our 25% pre-existing interest in the business and recognized a loss of $504,000 which is included in operating expenses within the consolidated statements of operations.
On April 1, 2019 we completed our acquisition of certain assets of Kern Radiology Imaging Systems Inc., consisting of four multi-modality imaging centers located in Bakersfield, California for purchase consideration of $19.3 million. We made a fair value determination of the acquired assets and assumed liabilities and approximately $10.1 million in property and equipment, $9.7 million in right-of-use assets, $36,000 in other assets, $3.4 million in intangible assets, $14.5 million in operating lease liabilities, and $10.5 million in goodwill were recorded.
On April 1, 2019 we completed our acquisition of certain assets of Zilkha Radiology Inc. consisting of two multi-modality centers located in Islip, New York for purchase consideration of $4.5 million. We made a fair value determination of the acquired assets and assumed liabilities and approximately $2.2 million in property and equipment, $5.1 million in right-of-use assets, $100,000 in intangible assets, $5.1 million in operating lease liabilities, $332,000 in finance lease liabilities and $2.6 million in goodwill were recorded.
On February 28, 2019, one of our Variable Interest Entities (VIEs), Lenox Hill Radiology and Medical Imaging Associates, P.C. ("LHR"), purchased the membership interest of Hudson Valley Radiology Associates, P.L.L.C. ("HVRA") for $6.0 million of RadNet common stock and contingent consideration valued at $680,000 to guarantee the share value issued for a period of six months post acquisition date. LHR has performed a fair value purchase price allocation and recorded equipment of $10,000, a covenant not to compete of $50,000, trade name of $380,000, other intangible assets of $340,000 and goodwill of $3.1 million from the transaction. In connection with the acquisition, RadNet also settled against the purchase consideration, $2.8 million, net of taxes, of an unfavorable vendor contract with HVRA stemming from the previous acquisition of Radiologix, Inc. in November 2006.
On February 1, 2019, our majority owned subsidiary, West Valley Imaging Group, LLC ("WVIG") completed its acquisition of certain assets of West Valley Imaging Center, LLC ("West Valley"), consisting of a single multi-modality imaging center located in West Hills, CA for purchase consideration of $3.0 million all of which was initially funded by the Company. We have made a fair value determination of the acquired assets and approximately $300,000 in equipment and fixed assets, $7,000 in other assets, $200,000 in intangible assets and $2.5 million in goodwill were recorded. Subsequent to the transaction, our partner in WVIG, Cedars Sinai Medical Center, contributed $750,000 in cash to maintain its 25% economic interest in the venture.

On December 3, 2018 we completed our acquisition of certain assets of Orange County Diagnostics Imaging Center consisting of five multi-modality imaging centers located in Orange County, California for purchase consideration of $6.6 million. We have made a fair valuation determination of the acquired assets and approximately $23,000 of current assets, $69,000 of other assets, $2.8 million of leaseholds and equipment, a $50,000 of covenant not to compete, and $3.6 million of goodwill were recorded.

On November 5, 2018 we completed our acquisition of certain assets of Arcadia Radiology Imaging consisting of one multi-modality imaging center and one women’s center located in Arcadia, California for purchase consideration of $3.8 million. We have made a fair value determination of the acquired assets and approximately $20,000 of other assets, $819,000 of leaseholds, $80,000 equipment, $300,000 in covenants not to compete, and $2.6 million of goodwill were recorded.

On November 1, 2018 we completed our acquisition of certain assets of Southern California Diagnostic Imaging consisting of a multi-modality imaging center located in Santa Ana, California for purchase consideration of $1.4 million. We have made a fair value determination of the acquired assets and approximately $18,000 of other assets, $1.2 million of leasehold improvements, $110,000 of equipment, $50,000 of covenants not to compete, and $41,000 of goodwill were recorded.

On October 1, 2018 we obtained control over the operations of New Jersey Imaging Network (NJIN), formerly a joint venture, consisting of eighteen multi-modality imaging centers located throughout the state of New Jersey for no consideration through an agreement with the other equity interest holder. The change in control was effective upon the execution of an Irrevocable Proxy Agreement with the joint venture partner and third amendment of the operating agreement, which provided RadNet with the ability to make unilateral operating decisions. We have made a fair value determination of the acquired net assets and


37



approximately $11.6 million of net working capital, $235,000 of other assets, $34.4 million of property and equipment, $582,000 of trade name. $106.1 million of goodwill, $1.0 million in net unfavorable lease contracts, $5.2 million of assumed equipment debt, and $60.0 million of assumed bank debt were recorded. We also made a fair value determination of our 49% pre existing interest in the business of approximately $42.5 million and we recognized fair value of non controlling interest of $44.3 million on the date of the transaction. The re-measurement in valuation from an existing equity investment in joint venture resulted in a gain of $39.5 million which is included in Other Income within the consolidated statements of operations.

On October 1, 2018 we acquired certain assets of Medical Arts Radiology consisting of a 10 multi-modality imaging centers located in Long Island, New York. Total purchase consideration of $59.6 million consisted of cash in the amount of $50.9 million, issuance of 531,560 RadNet common shares valued at $8.0 million on the acquisition date and contingent consideration valued at $739,000 to guarantee the share value issued for a period of twelve months post acquisition date. We also assumed $2.7 million in equipment debt. We have made a value determination of the acquired assets and approximately $2.7 million of net working capital, $224,000 of other assets,$16.0 million of property and equipment, $24,000 in a covenant not to compete, $1.4 million for its trade name, unfavorable lease contracts of $130,000 and $40.7 million of goodwill were recorded.

On September 1, 2018 we completed our acquisition of certain assets of Washington Heights Medical Management, LLC, consisting of a multi-modality imaging center located in New York, New York, for $3.3 million in cash. We have made a fair value determination of the acquired assets and approximately $43,000 other assets, $904,000 of leaseholds and equipment, $50,000 in a covenant not to compete, and $2.3 million of goodwill were recorded.

On April 1, 2018 we completed our acquisition of certain assets of Women’s Imaging Specialists in Healthcare, consisting of a single multi-modality center located in the city of Fresno California, for purchase consideration of $5.1 million in cash. We have made a fair value determination of the acquired assets and approximately $636,000 of fixed assets and equipment, $143,000 in intangible covenants not to compete, $53,000 in intangible trade name, and $4.3 million in goodwill were recorded.

On April 1, 2018 we completed our acquisition of certain assets of Valley Metabolic Imaging LLC, consisting of a single multi-modality center located in Fresno, California, for purchase consideration of $1.7 million in cash. We have made a fair value determination of the acquired assets and approximately $22,000 of fixed assets and equipment, $183,000 in intangible covenants not to compete, and $1.5 million in goodwill were recorded.

On April 1, 2018 we completed our acquisition of certain assets of Sierra Imaging Associates LLC, consisting of a single multi-modality center located in Clovis, California, for purchase consideration of $1.5 million in cash. We have made a fair value determination of the acquired assets and approximately $270,000 of fixed assets and equipment, $83,000 in intangible covenants not to compete, and $1.1 million in goodwill were recorded.

On February 22, 2018 we completed our acquisition of certain assets of Imaging Services Company of New York, LLC, consisting of a single multi-modality center located in New York, New York, for purchase consideration of $5.8 million. We have made a fair value determination of the acquired assets and approximately $3.0 million in fixed asset and equipment, a $100,000 covenant not to compete, and $2.7 million in goodwill were recorded.

On January 1, 2018 we formed Beach Imaging Group, LLC (“Beach Imaging”) and contributed the operations of 24 imaging facilities spread across southern Los Angeles and Orange Counties. On the same day, MemorialCare Medical Foundation contributed $22.3 million in cash, $7.6 million in fixed assets, $7.4 million in equipment, and $545,000 in goodwill. As part of the formation, the Beach Imaging assumed $4.0 million in capital lease debt. As a result of the transaction, the Company will retain a 60% controlling interest in Beach Imaging and MemorialCare Medical Foundation will retain a 40% noncontrolling interest in Beach Imaging.

Equity Investments

Turner Imaging Systems, based in Utah, develops and markets portable X-ray imaging systems that provide a user the ability to acquire X-ray images wherever and whenever they are needed. On February 1, 2018, we purchased 2.1 million preferred shares in Turner Imaging Systems for $2.0 million. On January 1, 2019 we funded a convertible promissory note in the amount of $143,000 that converted to an additional 80,000 preferred shares on October 11, 2019. No impairment in our investment was noted for the year ended December 31, 2019.
WhiteRabbit.ai Inc., based in California, is currently developing an artificial intelligence suite which aims to improve the speed and accuracy of cancer detection in radiology and improve patient care. On November 5, 2019 we acquired an equity interest in the company for $1.0 million and also loaned the company $2.5 million in support of its operations. No impairment in our investment was noted for the year ended December 31, 2019.


38




Formation of new joint ventures
On February 13, 2019 we formed a wholly owned subsidiary, Ventura County Imaging Group, LLC ("VCIG"). On March 1, 2019, Dignity Health joined as a venture partner. Total agreed contribution of both parties was $10.4 million of cash and assets with RadNet contributing net assets with a book value of $4.3 million for a 60% economic interest and Dignity Health contributing $6.1 million in cash and assets for a 40% economic interest. For its contribution, RadNet transferred net assets of three wholly owned multi-modality imaging centers. Dignity Health contributed approximately $800,000 in assets to acquire 5% economic interest and paid RadNet $5.3 million for an additional 35% economic interest. We maintain controlling economic interest in VCIG and fully consolidate the results into our financial statements.
Sale of joint venture interest:
On April 1, 2017, we formed in conjunction with Cedars Sinai Medical Center (“CSMC”) the Santa Monica Imaging Group, LLC (“SMIG”), consisting of two multi-modality imaging centers located in Santa Monica, CA. Upon formation, RadNet held a 40% economic interest and CSMC held a 60% economic interest. RadNet accounts for our share of the venture under the equity method. On January 1, 2019, CSMC purchased from us an additional five percent economic interest in SMIG valued at $134,000. As a result of the transaction, our economic interest in SMIG has been reduced to 35%. We recorded a loss of $2,000 on the transaction.

Change in control of existing joint ventures

On October 6, 2014, we acquired a 49% equity interest in Garden State Radiology Network, LLC ("GSRN") for cash consideration of $2.2 million. The venture consisted of two imaging centers located in New Jersey. On August 1, 2019, the entity was dissolved by transferring ownership of the assets of the centers to the partners for no consideration, with each partner receiving full ownership of one center.

On April 12, 2018 we acquired 25% share capital in Nulogix, Inc. for cash consideration of $2.0 million. On August 1, 2019 we completed via the issuance of RadNet common stock valued at $1.5 million, the acquisition of the remaining 75% economic interest and we now consolidate the financial statements of Nulogix.

On October 1, 2018, we obtained control over the operations of NJIN through an agreement with the other equity interest holder for no cash consideration. As such, we consolidated the financial statements of NJIN effective that date. The economic interest of each party remained the same after consolidation.

Results of Operations
 
The following table sets forth, for the periods indicated, the percentage that certain items in the statements of operations bears to net revenue for the years 2019 and 2018 and net revenue before provision for bad debts for the year 2017.


39



 
Years Ended December 31,
 
2019
 
2018
 
2017
NET REVENUE
 

 
 

 
 

Service fee revenue, net of contractual allowances and discounts
 
 
 
 
88.5
 %
Provision for bad debts
 
 
 
 
(4.8
)%
Net service fee revenue
89.1
 %
 
89.1
 %
 
83.7
 %
Revenue under capitation arrangements
10.9
 %
 
10.9
 %
 
11.5
 %
Total net revenue
100.0
 %
 
100.0
 %
 
95.2
 %
OPERATING EXPENSES
 

 
 

 
 

Cost of operations, excluding depreciation and amortization
86.6
 %
 
89.0
 %
 
82.8
 %
Depreciation and amortization
7.0
 %
 
7.5
 %
 
6.9
 %
(Gain) loss on sale and disposal of equipment
0.2
 %
 
(0.2
)%
 
0.1
 %
Loss on impairment
 %
 
0.4
 %
 
 %
Severance costs
0.1
 %
 
0.2
 %
 
0.2
 %
Total operating expenses
93.9
 %
 
96.8
 %
 
90.0
 %
INCOME FROM OPERATIONS
6.1
 %
 
3.2
 %
 
5.2
 %
 
 
 
 
 
 
OTHER INCOME AND EXPENSES
 

 
 

 
 

Interest expense
4.2
 %
 
4.5
 %
 
4.2
 %
Meaningful use incentive
 %
 
 %
 
 %
Equity in earnings of joint ventures
(0.7
)%
 
(1.2
)%
 
(1.4
)%
Gain on re-measurement of pre-existing interest
(0.1
)%
 
(4.1
)%
 
 %
Gain on sale of imaging centers and medical practice
 %
 
 %
 
(0.3
)%
Gain on return of common stock
 %
 
 %
 
 %
Other expenses
0.1
 %
 
 %
 
 %
Total other expenses
3.5
 %
 
(0.8
)%
 
2.4
 %
INCOME BEFORE INCOME TAXES
2.6
 %
 
4.0
 %
 
2.7
 %
Provision for income taxes
(0.5
)%
 
 %
 
(2.5
)%
NET INCOME
2.0
 %
 
3.9
 %
 
0.2
 %
Net income attributable to noncontrolling interests
0.8
 %
 
0.6
 %
 
0.2
 %
NET INCOME ATTRIBUTABLE TO RADNET, INC.
 

 
 

 
 

COMMON STOCKHOLDERS
1.3
 %
 
3.3
 %
 
 %

Year Ended December 31, 2019 Compared to the Year Ended December 31, 2018

We grow through a combination of organic growth as well as acquisitions and joint ventures. We have segregated some of our information to demonstrate which is attributable to centers that were in operation throughout the entirety of the comparison period, and which is attributable to centers that were acquired or disposed of during the period. For the discussion below, same centers are those that were in continuous operation from January 1, 2018 through December 31, 2019.

Total Net Revenue
 
In Thousands
Year Ended December 31,
Revenue
2019
2018
$ Increase/(Decrease)
% Change
Total Revenue
$1,154,179
$975,145
$179,034
18.4%
Same Center Revenue
$971,610
$915,644
$55,966
6.1%
 


40



Higher same center revenue experienced for the period resulted from increased volume of advanced radiology modalities, with MRI, CT and PET procedures rising at 4.7%, 6.2% and 7.8% respectively over the same period last year. This comparison excludes revenue contributions from centers that were acquired or divested subsequent to January 1, 2018. For the twelve months ended December 31, 2019, net service fee revenue from centers that were acquired or divested subsequent to January 1, 2018 and excluded from the above comparison was $182.6 million. For the twelve months ended December 31, 2018, net service fee revenue from centers that were acquired or divested subsequent to January 1, 2018 and excluded from the above comparison was $59.5 million.
  
Operating Expenses
 
Cost of operations for the twelve months ended December 31, 2019 increased approximately $139.3 million, or 14.7%, from $944.3 million for the twelve months ended December 31, 2018 to $1.1 billion for the twelve months ended December 31, 2019. As a percentage of net revenue, operating expenses declined from 89% for the twelve months ended December 31, 2018 to approximately 87% for the twelve months ended December 31, 2019. The following table sets forth our cost of operations and total operating expenses for the twelve months ended December 31, 2019 and 2018 (in thousands):
 
 
Years Ended December 31,
 
2019
 
2018
 
 
 
 
Salaries and professional reading fees, excluding stock-based compensation
$
634,209

 
$
549,693

Stock-based compensation
8,731

 
7,662

Building and equipment rental
106,495

 
89,852

Medical supplies
45,955

 
38,775

Other operating expenses  *
204,302

 
181,565

Cost of operations
999,692

 
867,547

 
 
 
 
Depreciation and amortization
80,607

 
72,899

(Gain) loss on sale and disposal of equipment
1,615

 
(2,054
)
Loss on impairment

 
3,937

Severance costs
1,619

 
1,931

Total operating expenses
$
1,083,533

 
$
944,260

 
* Includes billing fees, office supplies, repairs and maintenance, insurance, business tax and license, outside services, telecommunications, utilities, marketing, travel and other expenses.
  
Salaries and professional reading fees, excluding stock-based compensation and severance
In Thousands
Year Ended December 31,
Salaries and Professional Fees
2019
2018
$ Increase/(Decrease)
% Change
Total
$634,209
$549,693
$84,516
15.4%
Same Center
$551,165
$521,684
$29,481
5.7%
 
The rise in same center salaries and professional fees was precipitated by increased physician cost due to greater procedure volume and added personnel and existing employee wage and benefit increases in support of operations. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2018. For the twelve months ended December 31, 2019, salaries and professional reading fees from centers that were acquired or divested subsequent to January 1, 2018 and excluded from the above comparison was $83.0 million. For the twelve months ended December 31, 2018, salaries and professional reading fees from centers that were acquired or divested subsequent to January 1, 2018 and excluded from the above comparison was approximately $28.0 million.
Stock-based compensation


41




Stock-based compensation increased $1.1 million, or 14.0%, to approximately $8.7 million for the twelve months ended December 31, 2019 compared to $7.7 million for the twelve months ended December 31, 2018. This increase was driven by the higher fair value of RSA’s awarded and vested in the year ended December 31, 2019 as compared to RSA’s awarded and vested in the same period in 2018. 
Building and equipment rental
In Thousands
Year Ended December 31,
Building & Equipment Rental
2019
2018
$ Increase/(Decrease)
% Change
Total
$106,495
$89,852
$16,644
18.5%
Same Center
$88,125
$82,784
$5,341
6.5%
 
The increase in same center building and equipment rental expenses relates to new imaging centers, lease extensions at current centers, and radiology equipment leases to support increased scan volumes and expanded service offerings. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2018. For the twelve months ended December 31, 2019, building and equipment rental expenses from centers that were acquired or divested subsequent to January 1, 2018 and excluded from the above comparison was $18.4 million. For the twelve months ended December 31, 2018, building and equipment rental expenses from centers that were acquired or divested subsequent to January 1, 2018 and excluded from the above comparison was also $7.1 million.
Medical supplies
In Thousands
Year Ended December 31,
Medical Supplies Expense
2019
2018
$ Increase/(Decrease)
% Change
Total
$45,955
$38,775
$7,181
18.5%
Same Center
$37,613
$35,759
$1,855
5.2%
 
Same center medical supplies increase was attributable to higher procedure volumes of advanced radiology modalities. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2018. For the twelve months ended December 31, 2019, medical supplies expenses from centers that were acquired or divested subsequent to January 1, 2018 and excluded from the above comparison was $8.3 million. For the twelve months ended December 31, 2018, medical supplies expense from centers that were acquired or divested subsequent to January 1, 2018 and excluded from the above comparison was $3.0 million.
Other operating expenses
In Thousands
Year Ended December 31,
Other Operating Expenses
2019
2018
$ Increase/(Decrease)
% Change
Total
$204,302
$181,565
$22,738
12.5%
Same Center
$167,883
$169,895
$(2,012)
(1.2)%
 
This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2018. For the twelve months ended December 31, 2019, other operating expense from centers that were acquired or divested subsequent to January 1, 2018 and excluded from the above comparison was $36.4 million. For the twelve months ended December 31, 2018, other operating expense from centers that were acquired or divested subsequent to January 1, 2018 was $11.7 million.
Depreciation and amortization
In Thousands
Year Ended December 31,
Depreciation & Amortization
2019
2018
$ Increase/(Decrease)
% Change
Total
$80,607
$72,899
$7,708
10.6%
Same Center
$63,413
$67,843
$(4,430)
(6.5)%


42



  
The decrease in same center depreciation and amortization is primarily due to several of our assets completing their depreciation schedules subsequent to the end of our fourth quarter of 2018. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2018. For the twelve months ended December 31, 2019, depreciation expense from centers that were acquired or divested subsequent to January 1, 2018 and excluded from the above comparison was $17.2 million. For the twelve months ended December 31, 2018, depreciation and amortization from centers that were acquired or divested subsequent to January 1, 2018 and excluded from the above comparison was $5.1 million.
 
Loss on sale and disposal of equipment

We recorded a loss on the sale of equipment of approximately $2.4 million for the twelve months ended December 31, 2019 and a gain on disposal of equipment of approximately $2.1 million for the twelve months ended December 31, 2018.

Severance Costs
 
We incurred severance expenses of $1.6 million for the twelve months ended December 31, 2019 and $1.9 million for the twelve months ended December 31, 2018.

Impairment Charges

We recorded impairment charges to our Imaging On Call reporting unit of $3.9 million for the twelve months ended December 31, 2018, with goodwill representing $3.8 million of the total and the remainder being a write off the Imaging On Call trade name of approximately $100,000. We did not record any impairment charges for the twelve months ended December 31, 2019.
  
Interest expense
In Thousands
Year Ended December 31,
Interest Expense
2019
2018
$ Increase/(Decrease)
% Change
Total Interest Expense
$48,044
$43,456
$4,588
10.6%
Interest related to amortization*
$4,184
$3,933
$251
6.4%
Adjusted Interest Expense
$43,860
$39,523
$4,337
11.0%
*Includes combined non cash amortization of deferred loan costs and discount on issuance of debt.

Excluding interest related to amortization, interest expense the twelve months ended December 31, 2019 compared to the twelve months ended December 31, 2018 increased $4.3 million or 11.0%. The main drivers behind the increase were the interest payments on assumed debt of the New Jersey Imaging Network and the additional term loan debt stemming from the Sixth Amendment to the First Lien Term Loan. See “Liquidity and Capital Resources” below for more details on our credit facilities.

To mitigate our future interest expense exposure the Company has entered into two forward interest rate cap agreements. See Derivative Instruments section of Note 2 to the consolidated financial statements included in this annual report on Form 10-K and ITEM 7a, Quantitative and Qualitative Disclosure About Market Risk below for more details on our derivative transactions.

Equity in earnings from unconsolidated joint ventures
 
For the twelve months ended December 31, 2019 we recognized equity in earnings from unconsolidated joint ventures of $8.3 million versus $11.4 million for the twelve months ended December 31, 2018, a decrease of $3.0 million or 26.6%. The decrease was related to the assumption of operational control of the New Jersey Imaging Network which became a consolidated subsidiary on October 1, 2018.

Gain on re-measurement valuation of pre-existing interest

On August 1, 2019 we completed a step-up acquisition upon the dissolution of our former 49% owned joint venture, Garden State Radiology LLC ("GSRN"). Also on August 1, 2019, in a separate transaction, we issued RadNet common stock in the amount of $1.5 million to acquire a 75% controlling interest in our formerly 25% owned joint venture Nulogix. In both


43



instances, we made a fair value determination of our original interests, and recorded a step-up gain of  approximately $1.3 million for the GSRN and recognized a a loss of $504,000 on our 25% pre-existing interest in Nulogix. In sum we recorded a net gain on re-measurement of approximately $800,000 for the year ended December 31, 2019 on these transactions.

On October 1, 2018 we completed an step-up acquisition of New Jersey Imaging Network, formerly a joint venture. The change in control was effective upon the execution of an agreement which provided RadNet with the ability to make unanimous operating decisions. Upon a fair value determination of our 49% interest in the business of approximately $42.5 million, the step-up in valuation from an existing investment caused us to recognize a gain of $39.5 million for the year ended December 31, 2018.

Other expenses / income
 
For the year ended ended December 31, 2019 we recorded approximately $1.3 million of other expenses and for the year ended December 31, 2018 we recorded approximately $181,000 of other income, respectively.

Provision for income taxes
 
We had a tax provision for the twelve months ended December 31, 2019 of $6.2 million or 21.0% of income before income taxes, compared to a tax provision for the twelve months ended December 31, 2018 of $394,000 or 1.0% of income before income taxes. Income tax provision increased in 2019 primarily due to non-recognition of gain on re-measurement of pre-existing interest in the prior year. The income tax rates for the twelve months ended December 31, 2019 diverge from the federal statutory rate due to noncontrolling interests of the controlled partnerships and the prior year adjustments partially offset by effects of state income taxes.

Year Ended December 31, 2018 Compared to the Year Ended December 31, 2017

For the comparison of results of operations for the year ended December 31, 2018 to the year ended December 31, 2017, please see Item 7, Management's Discussion and Analysis of Financial Condition and Operations in our Form 10-K for the year ended December 31, 2018, filed with the SEC on March 18, 2019.
 
Non-GAAP Financial Measures
 
We use both GAAP and non-GAAP metrics to measure our financial results. We believe that, in addition to GAAP metrics, non-GAAP metrics such as Adjusted EBITDA and Free Cash Flow assist us in measuring our cash generated from operations and ability to service our debt obligations.
 
Adjusted EBITDA
 
Our Adjusted EBITDA metric removes non-cash and non-recurring charges that occur in the affected period and provides a basis for measuring the Company’s core financial performance against other periods.
 
We define Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, as adjusted to exclude losses or gains on the disposal of equipment, other income or loss, loss on debt extinguishment, bargain purchase gains, loss on de-consolidation of joint ventures and non-cash equity compensation.  Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries, and is adjusted for non-cash or one-time events that take place during the period.
 
Adjusted EBITDA is a non-GAAP financial measure used as an analytical indicator by us and the healthcare industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.
 
The following is a reconciliation of the nearest comparable GAAP financial measure, net income, to Adjusted EBITDA for the years ended December 31, 2019, 2018, and 2017, respectively (in thousands):



44



 
Years Ended December 31,
 
2019
 
2018
 
2017
Net income attributable to RadNet, Inc. common stockholders
$
14,756

 
$
32,243

 
$
53

Plus provision for income taxes
6,229

 
394

 
24,310

Plus interest expense
48,044

 
43,456

 
40,623

Plus severance costs
1,619

 
1,931

 
1,821

Plus depreciation and amortization
80,607

 
72,899

 
66,796

Plus non-cash employee stock-based compensation
8,730

 
7,662

 
6,787

Plus loss on sale and disposal of equipment
2,383

 

 
1,142

Plus other expenses
1,283

 

 

Plus legal settlement and related expenses
1,248

 

 
723

Plus refinancing fees

 

 
235

Plus expenses of divested/closed operations

 

 
3,186

Plus gain on sale of equipment attributable to noncontroling interest

 
440

 

Plus transaction costs EmblemHealth/ACP

 
681

 

Plus one time legal settlement

 
786

 

Plus changes in the organization of east coast and international operations

 
19,101

 

Plus loss on impairment

 
3,937

 

Less gain on sale of imaging center and medical practice

 

 
(3,146
)
Less gain on sale and disposal of equipment

 
(2,054
)
 

Less other income

 
(181
)
 
(8
)
Less gain on re-measurement of pre-existing interest
(768
)
 
(39,539
)
 

Adjusted EBITDA
$164,131
 
$141,756
 
$142,522
 
Free Cash Flow
 
Another non-GAAP measure that we use is “Free Cash Flow”. We use free cash flow as an additional way of viewing our liquidity that, when viewed with our GAAP results, provides a more complete understanding of factors and trends affecting our cash flows, and consequently our ability to service debt and make capital expenditures. Free cash flow is used in addition to and in conjunction with results presented in accordance with GAAP and free cash flow should not be relied upon to the exclusion of GAAP financial measures.
 
We define free cash flow as Adjusted EBITDA, less capital expenditures, and less the cash portion of our interest expense. We reconcile free cash flow to “net cash flows provided by operating activities”. We use free cash flow to conduct and evaluate our business because, although it is similar to cash flow from operations, we believe it is a more conservative measure of cash flows since purchases of fixed assets and the cash portion of our interest expense are a necessary component of our ongoing operations. In limited circumstances in which proceeds from sales of fixed assets exceed purchases, free cash flow could exceed cash flow from operations. However, since we do not anticipate being a net seller of fixed assets, we expect free cash flow to be less than operating cash flows.
 
Free cash flow has limitations due to the fact that it does not represent the residual cash flow available for discretionary expenditures. For example, free cash flow does not incorporate payments made on capital lease obligations or cash payments for business acquisitions. Therefore, we believe it is important to view Free Cash Flow as a complement to our entire consolidated statements of cash flows.
 
The following table provides a reconciliation of free cash flow to “net cash flows from operations” the most directly comparable amounts reported in accordance with GAAP for the years ended December 31, 2019, 2018 and 2017:



45



 
Years Ended December 31,
 
2019
 
2018
 
2017
Adjusted EBITDA
$
164,131

 
$
141,756

 
$
142,522

Less cash paid for interest
(46,254
)
 
(37,016
)
 
(34,197
)
Less cash capital purchases (1)
(71,540
)
 
(72,180
)
 
(61,336
)
Less new finance/capital lease debt
(51
)
 

 
(5,500
)
Plus proceeds from sale of equipment
1,160

 
2,575

 
852

Plus proceeds from sale of imaging and medical practice assets

 

 
8,429

Free cash flow
$
47,446

 
$
35,135

 
$
50,770

Free cash flow as a percent of
 
 
 
 
 
cash flow from operations
45.5
%
 
30.1
%
 
35.7
%
 

(1)Purchase of Property Plant & Equipment is adjusted for capital purchases of NJIN, which is excluded from our debt covenant calculation.

Liquidity and Capital Resources
 
The following table is a summary of key balance sheet data as of December 31, 2019 and December 31, 2018 and income statement data for the twelve months ended December 31, 2019, 2018 and 2017 (in thousands):

Balance Sheet Data for the period ended December 31,
2019
 
2018
 
2017
Cash and cash equivalents
$
40,165

 
$
10,389

 
 
Accounts receivable
154,763

 
148,919

 
 
Working capital (exclusive of current operating lease liability)
(23,007
)
 
(30,827
)
 
 
Stockholders' equity
233,139

 
200,253

 
 
 
 
 
 
 
 
Income Statement data for the twelve months ended December 31,
 
 
 
 
 
Total revenue
$
1,154,179

 
$
975,146

 
$
922,186

Net income attributable to RadNet common stockholders
14,756

 
32,243

 
53


We operate in a capital intensive, high fixed-cost industry that requires significant amounts of capital to fund operations. In addition to operations, we require a significant amount of capital for the initial start-up and development of new diagnostic imaging facilities, the acquisition of additional facilities and new diagnostic imaging equipment. Because our cash flows from operations have been insufficient to fund all of these capital requirements, we have depended on the availability of financing under credit arrangements with third parties.
 
Based on our current level of operations, we believe that cash flow from operations and over the next twelve months available cash, together with available borrowings from our senior secured credit facilities, will be adequate to meet our short-term liquidity needs. Our future liquidity requirements will be for working capital, capital expenditures, debt service and general corporate purposes. Our ability to meet our working capital and debt service requirements, however, is subject to future economic conditions and to financial, business and other factors, many of which are beyond our control. If we are not able to meet such requirements, we may be required to seek additional financing. There can be no assurance that we will be able to obtain financing from other sources on the terms acceptable to us, if at all.
 
On a continuing basis, we also consider various transactions to increase stockholder value and enhance our business results, including acquisitions, divestitures and joint ventures. These types of transactions may result in future cash proceeds or payments but the general timing, size or success of any acquisition, divestiture or joint venture effort and the related potential capital commitments cannot be predicted. We expect to fund any future acquisitions primarily with cash flow from operations and borrowings, including borrowing from amounts available under our senior secured credit facilities or through new equity or debt issuances.
 


46



We and our subsidiaries or affiliates may from time to time, in our or their sole discretion, continue to purchase, repay, redeem or retire any of our outstanding debt or equity securities in privately negotiated or open market transactions, by tender offer or otherwise. However, we have no formal plan of doing so at this time. We have invested over $100 million in each of the past two years in expanding our operations through the acquisition of new facilities and equipment. We expect to continue to make similar investments for the foreseeable future. While we don't anticipate one at this time, a significant decrease in our liquidity would limit our ability to make these investments and consequently limit our growth.
 
Sources and Uses of Cash
The following table summarizes key components of our sources and uses of cash for the twelve months ended December 31, 2019 and 2018:
Cash Flow Data
December 31, 2019
 
December 31, 2018
     Cash provided by operating activities
$
104,322

 
$
116,754

     Cash used in investing activities
(99,465
)
 
(146,749
)
     Cash provided by (used in) financing activities
24,951

 
(10,869
)
  
For cash used in investing activities for the twelve months ended December 31, 2019, we purchased property and equipment for approximately $74.2 million, acquired imaging facilities for $27.2 million, made equity investments at fair value of $143,000 and an equity contribution to an existing joint venture of $103,000. We received proceeds from the sale of equipment of $1,160,000.
 
The cash provided by financing activities for the twelve months ended December 31, 2019 was mainly due to our additional term loan debt issuance of April 18, 2019, offset by payments on our term loans and revolving credit facility borrowings.
 
We have entered into factoring agreements with various institutions and sold certain accounts receivable under non-recourse agreements. These transactions are accounted for as a reduction in accounts receivable as the agreements transfer effective control over and risk related to the receivables to the buyers. The aggregate gross amount factored under these facilities  for the year ended December 31, 2019 was approximately $9.0 million, inclusive of discount recorded to reflect the difference between market interest rates and the stated interest rate of the receivable. At December 31, 2019 we have $24.2 million, net of discount, remaining to be collected on these agreements. We do not utilize factoring arrangements as an integral part of our financing for working capital.

Senior Credit Facilities:

At December 31, 2019, our Barclays credit facilities were comprised of one tranche of term loans (“First Lien Term Loans”) and a revolving credit facility of $137.5 million (the “Barclays Revolving Credit Facility”), both of which are provided pursuant to the Amended and Restated First Lien Credit and Guaranty Agreement dated July 1, 2016 (as amended, the "First Lien Credit Agreement").

At December 31, 2019, our SunTrust credit facilities, which relate to our consolidated subsidiary NJIN, were comprised of one term loan (the "SunTrust Term Loan") and a revolving credit facility of $30.0 million (the "SunTrust Revolving Credit Facility") both of which are provided pursuant to the SunTrust Restated Credit Agreement.

As of December 31, 2019, we were in compliance with all covenants under our credit facilities.

Deferred financing costs at December 31, 2019, net of accumulated amortization, was $1.6 million and is specifically related to our Barclays Revolving Credit Facility.
 
Included in our consolidated balance sheets at December 31, 2019 are $636.2 million of First Lien Term Loans and $55.9 million of SunTrust Term Loan Agreement debt for a combined total of $692.1 million (net of unamortized discounts of $13.6 million) in thousands:



47



 
Face Value
 
Discount
 
Total Carrying
Value
Barclays First Lien Term Loans
$
649,824

 
$
(13,579
)
 
$
636,245

SunTrust Term Loan Agreement
55,875

 

 
55,875

Total Term Loans
$
705,699

 
$
(13,579
)
 
$
692,120


We had no outstanding balance under our $137.5 million Barclays Revolving Credit Facility at December 31, 2019 and had reserved an additional $5.9 million for certain letters of credit. The remaining $131.7 million of our Barclays Revolving Credit Facility was available to draw upon as of December 31, 2019. We also had no balance under our $30.0 million SunTrust Revolving Credit Facility at December 31, 2019.

The following relates to our Barclays financing activities:

2019 Amendments to the First Lien Credit Agreement:

On April 18, 2019 we entered into the following two new amendments to the First Lien Credit Agreement: (i) Amendment No. 6, Consent and Incremental Joinder Agreement to Credit and Guaranty Agreement dated as of April 18, 2019 (the “Sixth Amendment”); and (ii) Amendment No. 7 to Credit and Guaranty Agreement dated as of April 18, 2019 (the “Seventh Amendment”). The Sixth Amendment amended the First Lien Credit Agreement to issue $100.0 million in incremental First Lien Term Loans and to add an additional $20.0 million of revolving commitments to the Barclay's Revolving Credit Facility. The Seventh Amendment amends the First Lien Credit Agreement to extend the maturity date of the Barclays Revolving Credit Facility by an additional two years to July 1, 2023, unless sooner terminated in accordance with the terms of the First Lien Credit Agreement. Total issue costs added in relation to the amendments in 2019 amounted to approximately $4.4 million. Of this amount, $2.1 million was identified and capitalized as discount on debt, $683,000 was capitalized as deferred financing costs, and $1.6 million was expensed. Amounts capitalized will be amortized over the remaining term of the agreement.

Terms of Barclays Credit Facilites:

First Lien Term Loans:
  
Interest: First Lien Term Loans bear interest at either an Adjusted Eurodollar Rate or a Base Rate plus an applicable margin. Rates of the applicable margin for borrowing under the First Lien Credit Agreement will alter depending on our leverage ratio, according to the following schedule:
First Lien Leverage Ratio
Eurodollar Rate Spread
Base Rate Spread
> 5.50x
4.50%
3.50%
> 4.00x but ≤ 5.50x
3.75%
2.75%
>3.50x but ≤ 4.00x
3.50%
2.50%
≤ 3.50x
3.25%
2.25%

At December 31, 2019 the effective Adjusted Eurodollar Rate and the Base Rate for the First Lien Term Loans was 2.01% and 4.75%, respectively and the applicable margin for Adjusted Eurodollar Rate and Base Rate borrowings was 3.50% and 2.50%, respectively.

Payments. The First Lien Credit Agreement provides for quarterly payments of principal under the First Lien Term Loans in the amount of approximately $9.7 million.

Maturity Date. The maturity date for the First Lien Term Loans shall be on the earliest to occur of (i) July 1, 2023, and (ii) the date on which all First Lien Term Loans shall become due and payable in full under the First Lien Credit Agreement, whether by acceleration or otherwise.

Additional Borrowing. Under the First Lien Credit Agreement, we can elect to request (i) an increase to the existing Barclays Revolving Credit Facility and/or (ii) issue additional First Lien Term Loans, provided that the aggregate amount of such increases and additions does not exceed (a) $100.0 million and (b) as long as the First Lien Leverage Ratio (as defined in the First Lien Credit Agreement) would not exceed 4.00:1.00 after giving effect to such incremental facilities, an uncapped amount of incremental facilities, in each case subject to the conditions and limitations set forth in the First Lien Credit Agreement. Each


48



lender approached to provide all or a portion of any incremental facility may elect or decline, in its sole discretion, to provide an incremental commitment or loan.
Barclays Revolving Credit Facility:

Interest: Revolving loans borrowed under the Revolving Credit Facility bear interest at either an Adjusted Eurodollar Rate or a Base Rate plus an applicable margin. Rates of the applicable margin for borrowing under the Revolving Credit Facility also change depending on our leverage ratio and are the same rates as noted in the schedule above for First Lien Term Loans. As of December 31, 2019, the effective interest rate payable on revolving loans was 7.25%.
 
Letters of Credit: For letters of credit issued under the Revolving Credit Facility, letter of credit fees accrue at the applicable margin of Adjusted Eurodollar Rate, currently 3.50%, and fronting fees accrue at 0.25% per annum, in each case on the average aggregate daily maximum amount available to be drawn under all letters of credit issued under the First Lien Credit Agreement. In addition a commitment fee of 0.50% per annum accrues on the unused revolver commitments under the Revolving Credit Facility.
 
Maturity Date: The Revolving Credit Facility will terminate on the earliest to occur of (i) July 1, 2023, (ii) the date we voluntarily agree to permanently reduce the Revolving Credit Facility to zero pursuant to section 2.13(b) of the First Lien Credit Agreement, and (iii) the date the Revolving Credit Facility is terminated due to specific events of default pursuant to section 8.01 of the First Lien Credit Agreement.

The following relates to our SunTrust financing activities:

Amended and Restated Revolving Credit and Term Loan Agreement

On August 31, 2018, our subsidiary, NJIN, entered into the Amended and Restated Revolving Credit and Term Loan Agreement (as amended, the "SunTrust Restated Credit Agreement") as borrower with SunTrust Bank and other financial institutions as lenders and to provide NJIN aggregate credit facilities of $90.0 million as categorized below:

SunTrust Term Loan: Pursuant to the SunTrust Restated Credit Agreement, the lenders thereunder made a term loan to NJIN in the amount of $60.0 million. The SunTrust Term Loan is repayable in scheduled quarterly amounts (as described below) and has a maturity date of the earlier of (i) August 31, 2023 and (ii) the date on which the principal amount of the SunTrust Term Loan has been declared or automatically has become due and payable (whether by acceleration or otherwise).

SunTrust Revolving Credit Facility: The SunTrust Restated Credit Agreement establishes a $30.0 million revolving credit facility available to NJIN for funding requirements. The SunTrust Revolving Credit Facility terminates on the earliest of (i) August 31, 2023, (ii) the voluntary termination thereof by NJIN pursuant to Section 2.8 of the SunTrust Restated Credit Agreement, or (iii) the date on which all amounts outstanding under the SunTrust Restated Credit Agreement have been declared or have automatically become due and payable (whether by acceleration or otherwise). NJIN has not borrowed against the revolving credit line.

Interest: Interest rates and fees of the applicable margin for borrowing under the SunTrust Restated Credit Agreement adjust depending on our leverage ratio, according to the following table:



49



Pricing Level
Leverage Ratio
Applicable Margin for Eurodollar Loans
Applicable Margin for Base Rate Loans
Applicable Margin for Letter of Credit Fees
Applicable Percentage for Commitment Fee
I
Greater than or equal to 3.00:1.00
2.75%
per annum
1.75%
per annum
2.75%
per annum
0.45%
per annum
II
Less than 3.00:1.00 but greater than or equal to 2.50:1.00
2.25%
per annum
1.25%
per annum
2.25%
per annum
0.40%
per annum
III
Less than 2.50:1.00 but greater than or equal to
2.00:1.00
2.00%
per annum
1.00%
per annum
2.00%
per annum
0.35%
per annum
IV
Less than 2.00:1.00 but greater than or equal to 1.50:1.00
1.75%
per annum
0.75%
per annum
1.75%
per annum
0.30%
per annum
V
Less than 1.50:1.00
1.50%
per annum
0.50%
per annum
1.50%
per annum
0.30%
per annum


The loans and other obligations outstanding under the SunTrust Restated Credit Agreement currently bear applicable margin and fees based on Pricing Level III described above. The loans outstanding under the SunTrust Restated Credit Agreement currently bear interest based on a three month Eurodollar election, plus the applicable margin.

Payments: The scheduled amortization of the SunTrust Term Loan began December 31, 2018 with quarterly payments of $750,000, representing annual amortization equal to 5.0% of the original principal amount of the SunTrust Term Loan. At scheduled intervals, the quarterly amortization increases by $375,000, with the remaining balance to be paid at maturity.

Contractual Commitments
 
Our future obligations for notes payable, equipment under finance leases, lines of credit, equipment and building operating leases and other contractual obligations for the next five years and thereafter include (dollars in thousands):

 
2020
 
2021
 
2022
 
2023
 
2024
 
Thereafter
 
Total
Notes payable (1)
$
43,571

 
$
43,670

 
$
44,795

 
$
573,938

 
$

 
$

 
$
705,974

Finance leases (2)
3,492

 
2,624

 
702

 
11

 
10

 

 
6,839

Operating leases (3)
89,881

 
88,848

 
80,932

 
69,916

 
54,517

 
262,027

 
646,121

Total
$
136,944

 
$
135,142

 
$
126,429

 
$
643,865

 
$
54,527

 
$
262,027

 
$
1,358,934

 
(1)
Includes variable rate debt for which the contractual obligation was estimated using the applicable rate at December 31, 2019.

(2)
Includes interest component of finance lease obligations.

(3)
Includes interest component of operating lease obligations.

We have service agreements with various vendors under which they have agreed to be responsible for the maintenance and repair of a majority of our equipment for a fee that is based on the type and age of the equipment. Under these agreements, we are committed to minimum payments of approximately $30.0 million in 2020.
 
Critical Accounting Policies
The Securities and Exchange Commission defines critical accounting estimates as those that are both most important to the portrayal of a company’s financial condition and results of operations and require management’s most difficult, subjective or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. In Note 2 to our consolidated financial statements in this annual report on Form 10-K we


50



discuss our significant accounting policies, including those that do not require management to make difficult, subjective or complex judgments or estimates. The most significant areas involving management’s judgments and estimates are described below.

USE OF ESTIMATES - The financial statements were prepared in accordance with U.S. generally accepted accounting principles (GAAP), which requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect various matters, including our reported amounts of assets and liabilities in our consolidated balance sheets at the dates of the financial statements; our disclosure of contingent assets and liabilities at the dates of the financial statements; and our reported amounts of revenues and expenses in our consolidated statements of operations during the reporting periods. These estimates involve judgments with respect to numerous factors that are difficult to predict and are beyond management’s control. As a result, actual amounts could materially differ from these estimates.
 
REVENUES – Our revenues generally relate to net patient fees received from various payors and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.
 
As it relates to the consolidated medical group, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by them as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to others centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.
 
Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of conractrual allowances under managed care and commercial insurance plans are based upon historical collection experience of the payments received from such payors in accordance with the underlying contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have price concessions applied. We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect.

Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.

On January 1, 2018, we adopted the new revenue recognition accounting standard issued by the Financial Accounting Standards Board (“FASB”) and codified in the ASC as topic 606 (“ASC 606”). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding our revenue recognition policies and significant judgments employed in the determination of revenue.

We applied the modified retrospective approach to all contracts when adopting ASC 606. As a result, at the adoption of ASC 606 the majority of what was previously classified as the provision for bad debts in the statement of operations are now reflected as implicit price concessions and therefore included as a reduction to net operating revenues in 2018 and later. For changes in credit issues not assessed at the date of service, we will prospectively recognize those amounts in other operating expenses on the statement of operations. For periods prior to the adoption of ASC 606, the provision for bad debts has been presented consistent with the previous revenue recognition standards that required it to be presented separately as a component of net operating revenues. As part of the adoption of ASC 606 allowance for doubtful accounts was reclassified to be a component of net patient accounts receivable. Other than these changes in presentation on the consolidated statement of operations and consolidated balance sheet, the adoption of ASC 606 did not have a material impact on the consolidated financial statements. As part of the adoption of ASC 606, we elected two of the available practical expedients provided for in the standard. First, we did not adjust the transaction price


51



for any financing components as those were deemed to be insignificant. Additionally, we expensed all incremental customer contract acquisition costs as incurred as such costs are not material and would be amortized over a period less than one year.
ACCOUNTS RECEIVABLE - Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. Receivables generally are collected within industry norms for third-party payors. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience.
INCOME TAXES - Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income, including tax planning strategies, in determining whether our net deferred tax assets are more likely than not to be realized.

INVENTORIES – Inventories, consisting mainly of medical supplies, are stated at the lower of cost or net realizable value with cost determined by the first-in, first-out method.
DEFERRED FINANCING COSTS - Costs of financing are deferred and amortized using the effective interest rate method. Deferred financing costs, net of accumulated amortization, were $1.6 million and $1.4 million, as of December 31, 2019 and December 31, 2018, respectively and related to our line of credit.

PROPERTY AND EQUIPMENT – Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are provided using the straight-line method over the estimated useful lives, which range from 3 to 15 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 3 to 15 years. Maintenance and repairs are charged to expense as incurred.

BUSINESS COMBINATION – In January 2017, the FASB issued ASU No. 2017-01 (“ASU 2017-01”), Clarifying the Definition of a Business. The update provides a framework for evaluating whether a transaction should be accounted for as an acquisition and/or disposal of a business versus assets. In order for a purchase to be considered an acquisition of a business, and receive business combination accounting treatment, the set of transferred assets and activities must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. If substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets, then the set of transferred assets and activities is not a business. We first evaluate all purchases under this framework.

Once the purchase has been determined to be the acquisition of a business, we are required to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.

GOODWILL AND INDEFINITE LIVED INTANGIBLES – Goodwill totaled $441.0 million and $418.1 million at December 31, 2019 and December 31, 2018, respectively. Indefinite lived intangible assets at December 31, 2019 were $11.3 million and $9.8 million at December 31, 2018 and are associated with the value of certain trade name intangibles. Goodwill and trade name intangibles are recorded as a result of business combinations. When we determine the carrying value of goodwill exceeds its fair value, an impairment charge would be recognized which should not exceed the total amount of goodwill allocated to that reporting unit. We determined fair values for each of the reporting units using the market approach, when available and appropriate, or the income approach, or a combination of both. We assess the valuation methodology based upon the relevance and availability of the data at the time we perform the valuation. If multiple valuation methodologies are used, the results are weighted appropriately. We tested both goodwill and trade name intangibles for impairment on October 1, 2019, noting no impairment, and have not identified any indicators of impairment through December 31, 2019.


52



LONG-LIVED ASSETS - We evaluate our long-lived assets (property and equipment) and intangibles, other than goodwill and indefinite lived intangibles, for impairment whenever indicators of impairment exist. To evaluate the long-lived assets our management estimates the undiscounted future cash flows expected to be derived from the asset. The accounting standards require that if the sum of the undiscounted expected future cash flows from a long-lived asset or definite-lived intangible is less than the carrying value of that asset, an asset impairment charge must be recognized. The amount of the impairment charge is calculated as the excess of the asset’s carrying value over its fair value, which generally represents the discounted future cash flows from that asset or in the case of assets we expect to sell, at fair value less costs to sell. No indicators of impairment were identified with respect to our long-lived assets as of December 31, 2019.
LEASES - We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and long term operating lease liability in our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liability, and long-term finance lease liability in our consolidated balance sheets.  ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. We use the implicit rate when readily determinable. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We include options to extend a lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For a contract in which we are a lessee that contains fixed payments for both lease and non-lease components, we have elected to account for the components as a single lease component, as permitted. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term.

EQUITY BASED COMPENSATION – We have one long-term incentive plan that we adopted in 2006 and which we first amended and restated as of April 20, 2015, and again on March 9, 2017 (the “Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. We have reserved for issuance under the Restated Plan 14,000,000 shares of common stock. We can issue options, stock awards, stock appreciation rights, stock units and cash awards under the Restated Plan. Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options and warrants generally vest over three to five years and expire five to ten years from date of grant. The compensation expense associated with option grants is calculated based on a valuation model, typically the Black–Scholes model, which requires certain management assumptions with respect to volatility. The compensation expense recognized for all equity-based awards is recognized over the awards’ service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees.

COMMITTMENTS AND CONTINGENCIES - We are party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business. With respect to these matters, we evaluate the developments on a regular basis and accrue a liability when we believe a loss is probable and the amount can be reasonably estimated. We believe that the amount or any estimable range of reasonably possible or probable loss will not, either individually or in the aggregate, have a material adverse effect on our business and consolidated financial statements. However, the outcome of these matters is inherently uncertain. Therefore, if one or more of these matters were resolved against us for amounts in excess of management's expectations, our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable, could be materially adversely affected.
 
Recent Accounting Standards
 
Accounting standards adopted

In February 2016, the FASB issued Accounting Standard Update ("ASU") No. 2016-02, Leases (Topic 842) (ASU 2016-02), which amends the existing accounting standards for leases. In September 2017, the FASB issued ASU No. 2017-13 which provides additional clarification and implementation guidance on the previously issued ASU No. 2016-02. Subsequently, in July 2018, the FASB issued ASU No 2018-10, Codification Improvements to Topic 842, Leases, and ASU No. 2018-11, Targeted Improvement, to clarify and amend the guidance in ASU No. 2016-02. The amendments in this update were effective for fiscal years (and interim reporting periods within fiscal years) beginning after December 15, 2018, with early adoption permitted for all entities. Under the new guidance, a lessee is required to recognize a lease liability and right-of-use asset for all leases with terms in excess of twelve months. The new guidance also requires additional disclosures to enable users of financial statements to understand the amount, timing, and potential uncertainty of cash flows arising from leases. Consistent with current guidance, a lessee’s recognition, measurement, and presentation of expenses and cash flows arising from a lease will continue to depend primarily on its classification. We have elected the optional transition method to apply the standard as of the effective date and


53



therefore, we will not apply the standard to the comparative periods presented in the consolidated financial statements. We elected the transition package of three practical expedients permitted within the standard, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs. See Note 9, Leases, to the consolidated financial statement included in this annual report on Form 10-K for more information.
In February 2018, the FASB issued ASU No. 2018-02 (“ASU 2018-02”), Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. ASU 2018-02 allows for the reclassification of certain income tax effects related to the Tax Cuts and Jobs Act between “Accumulated other comprehensive income” and “Retained earnings.” This ASU relates to the requirement that adjustments to deferred tax liabilities and assets related to a change in tax laws or rates to be included in “Income from continuing operations”, even in situations where the related items were originally recognized in “Other comprehensive income” (rather than in “Income from continuing operations”). Subsequently, in March 2018, the FASB issued ASU No. 2018-05, Income Taxes, to clarify and amend guidance in ASU 2018-02. ASU 2018-02 and ASU 2018-05 are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. Adoption of this ASU is to be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the tax laws or rates were recognized. The adoption had no significant impact on the our results of operations, financial position and cash flows.

In April 2019, the FASB issued ASU 2019-04, ("ASU 2019-04"), Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, which, among other things, clarifies certain hedge accounting guidance. For the year ended 2017, we elected to early adopt ASU 2017-12, Targeted Improvements to Accounting for Hedging Activities, (Topic 815), for which this current ASU 2019-04 amends. For those entities that have already adopted ASU 2017-12, the hedging amendments in ASU 2019-04 are effective as of the beginning of the first annual reporting period beginning after 25 April 2019 and early adoption is permitted. We elected early adoption of ASU 2019-04 and the adoption had no effect on our financial statements.

Accounting standards not yet adopted
 
Stated below are accounting policies which are under evaluation for their potential impact on our statement of operations and cash flows.

In June 2016, the FASB issued ASU No. 2016-13 ("ASU 2016-13), Financial Instruments - Credit Losses. ASU 2016-13 replaces the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The standard will be effective for us beginning after December 15, 2019, with early adoption permitted. We are currently evaluating the impact of this standard on our consolidated financial statements, including accounting policies, processes, and systems.

In August 2018, the FASB issued ASU No. 2018-15 (“ASU 2018-15”), Intangibles-Goodwill and Other-Internal-Use Software. ASU 2018-15 aligns the requirements for deferring implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This ASU is effective in the first quarter of 2020 with early adoption permitted and can be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We are currently assessing the impact of the adoption of this ASU on our results of operations, financial position and cash flows.

Subsequent Events

On March 11, 2020, we announced a definitive agreement to acquire DeepHealth, Inc. ("DeepHealth"). DeepHealth is developing solutions in machine learning and artificial intelligence to assist radiologists in interpreting images and improving patient care. The close is planned for April 1, 2020 and we will issue approximately 1.0 million RadNet common stock shares to complete the acquisition.
 
Additional Information
 
Additional information concerning RadNet, Inc., including our consolidated subsidiaries, for each of the years ended December 31, 2019, 2018 and 2017 is included in the consolidated financial statements and notes thereto in this annual report.
 
Item 7A.
Quantitative and Qualitative Disclosures About Market Risk
 


54



Foreign Currency Exchange Risk. We receive payment for our services exclusively in United States dollars. As a result, our financial results are unlikely to be affected by factors such as changes in foreign currency, exchange rates or weak economic conditions in foreign markets.
  
We maintain research and development facilities in Prince Edward Island, Canada and Budapest, Hungary for which expenses are paid in the local currency. Accordingly, we do have currency risk resulting from fluctuations between such local currency and the United States Dollar. At the present time, we do not have any foreign currency exchange contracts to mitigate this risk. At December 31, 2019, a hypothetical 1% decline in the currency exchange rates between the U.S. dollar against the Canadian dollar and the Hungarian Forint would have resulted in an annual increase of approximately $30,000 in operating expenses. 
Interest Rate Sensitivity: We pay interest on various types of debt instruments to our suppliers and lending institutions. The agreements entail either fixed or variable interest rates.  Instruments which have fixed rates are mainly leases on radiology equipment. Variable rate interest obligations relate primarily to amounts borrowed under our outstanding credit facilities. Accordingly, our interest expense and consequently, our earnings, are affected by changes in short term interest rates. However due to our purchase of caps, described below, the effects of interest rate changes are limited.

Interest Rate Sensitivity Barclays First Lien Term Loans
 
At December 31, 2019, we had $650 million outstanding subject to an adjusted Eurodollar election on First Lien Term Loans. We can elect Eurodollar or Base Rate (Prime) interest rate options on amounts outstanding under the First Lien Term Loans.
 
To mitigate interest rate risk sensitivity, in the fourth quarter of 2016 we entered into two forward interest rate cap agreements (the “2016 Caps”) which were designated at inception as cash flow hedges of future cash interest payments. The 2016 Caps are designed to provide a hedge against interest rate increases. Under these arrangements, we purchased a cap on 3 month LIBOR at 2.0%. At December 31, 2019, our effective 3 month LIBOR was 2.01%. The 2016 Caps have a notional amount of $150,000,000 and $350,000,000 and will mature in September and October 2020. We are liable for a $5.3 million premium to enter into the caps which is being accrued and paid over the life of the 2016 Caps. See Note 2 to the consolidated financial statements included in this annual report on Form 10-K.
  
A hypothetical 1% increase in the adjusted Eurodollar rates under the First Lien Credit Agreement over the rates experienced in 2019 would, after considering the effects of the 2016 Caps, result in an increase of $1.5 million in annual interest expense and a corresponding decrease in income before taxes.  At December 31, 2019, we had an additional $9.7 million in debt instruments tied to the prime rate. A hypothetical 1% increase in the prime rate would result in an annual increase in interest expense of approximately $97,000 and a corresponding decrease in income before taxes. These amounts are determined by considering the impact of the hypothetical interest rates on the borrowing costs and cap agreements.

Interest Rate Sensitivity SunTrust Term Loan

At December 31, 2019, we had $55.9 million outstanding subject to an adjusted Eurodollar election on the Amended and Restated Revolving Credit and Term Loan Agreement (the "SunTrust Restated Credit Agreement"). We can elect Eurodollar or Base Rate (Prime) interest rate options on amounts outstanding under the Restated Agreement.

At December 31, 2019, our effective 3 month LIBOR was 4.10%. A hypothetical 1% increase in the adjusted Eurodollar rates under the SunTrust Restated Agreement over the rates experienced in 2019 would result in an increase of approximately $559,000 in annual interest expense and a corresponding decrease in income before taxes. No amounts are tied to the prime rate under the SunTrust Restated Agreement.


55



Item 8.
Financial Statements and Supplementary Data
 
 
 
 
 
 
 
 
 
 



56



Report of Independent Registered Public Accounting Firm
 
 
To the Stockholders and the Board of Directors of RadNet, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of RadNet, Inc. and subsidiaries (the Company) as of December 31, 2019 and 2018, the related consolidated statements of operations, comprehensive income (loss), equity and cash flows for each of the three years in the period ended December 31, 2019, and the related notes and the financial statement schedule listed in the Index at Item 15(a)(2) (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated March 16, 2020 expressed an unqualified opinion thereon.
Adoption of ASU No. 2016-02
As discussed in Note 3 to the consolidated financial statements, the Company changed its method for accounting for leases in 2019 due to the adoption of Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842), and the related amendments.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
                                                                                                                         
/s/ Ernst & Young LLP

We have served as the Company’s auditor since 2007.
Los Angeles, California
March 16, 2020


  
 
 


57



RADNET, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)
 
As of December 31,
 
2019
 
2018
ASSETS
 
 
 
CURRENT ASSETS
 

 
 

Cash and cash equivalents
$
40,165

 
$
10,389

Accounts receivable
154,763

 
148,919

Due from affiliates
1,242

 
595

Prepaid expenses and other current assets
45,004

 
46,288

Assets held for sale
2,041

 
2,499

Total current assets
243,215

 
208,690

PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS
 
 
 
Property and equipment, net
366,746

 
345,729

Operating lease right-of-use-assets
445,477

 

Total property, equipment and right-of-use-assets
812,223

 
345,729

OTHER ASSETS
 
 
 
Goodwill
440,981

 
418,093

Other intangible assets
42,994

 
40,593

Deferred financing costs
1,559

 
1,354

Investment in joint ventures
34,470

 
37,973

Deferred tax assets
34,548

 
31,506

Deposits and other
36,996

 
25,392

Total assets
$
1,646,986

 
$
1,109,330

LIABILITIES AND EQUITY
 
 
 
CURRENT LIABILITIES
 
 
 
Accounts payable, accrued expenses and other
$
207,585

 
$
181,028

Due to affiliates
14,347

 
13,089

Deferred revenue related to software sales
1,316

 
2,398

Current portion of deferred rent

 
3,735

Current portion of finance lease liability
3,283

 

Current portion of operating lease liability
61,206

 

Current portion of notes payable
39,691

 
33,653

Current portion of obligations under capital leases

 
5,614

Total current liabilities
327,428

 
239,517

LONG-TERM LIABILITIES
 
 
 
Deferred rent, net of current portion

 
31,542

Long-term finance lease liability
3,264

 

Long-term operating lease liability
420,922

 

Notes payable, net of current portion
652,704

 
626,507

Obligations under capital lease, net of current portion

 
6,505

Other non-current liabilities
9,529

 
5,006

Total liabilities
1,413,847

 
909,077

EQUITY
 
 
 
RadNet, Inc. stockholders' equity:
 
 
 
Common stock - $.0001 par value, 200,000,000 shares authorized; 50,314,328 and 48,977,485 shares issued and outstanding at December 31, 2019 and 2018 respectively
5

 
5

Additional paid-in-capital
262,865

 
242,835

Accumulated other comprehensive (loss) income
(8,026
)
 
2,259

Accumulated deficit
(103,159
)
 
(117,915
)
Total RadNet, Inc.'s stockholders' equity
151,685

 
127,184

Noncontrolling interests
81,454

 
73,069

Total equity
233,139

 
200,253

Total liabilities and equity
$
1,646,986

 
$
1,109,330


The accompanying notes are an integral part of these financial statements.


58



RADNET, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)
 
 
Years Ended December 31,
 
2019
 
2018
 
2017
REVENUE
 

 
 

 
 

Service fee revenue, net of contractual allowances and discounts


 


 
$
857,178

Provision for bad debts


 


 
(46,555
)
Service fee revenue
$
1,028,236

 
$
868,741

 
810,623

Revenue under capitation arrangements
125,943

 
106,405

 
111,563

Total revenue
1,154,179

 
975,146

 
922,186

OPERATING EXPENSES
 
 
 
 
 
Cost of operations, excluding depreciation and amortization
999,692

 
867,547

 
802,377

Depreciation and amortization
80,607

 
72,899

 
66,796

Loss (gain) on sale and disposal of equipment and other
2,383

 
(2,054
)
 
1,142

Loss on impairment

 
3,937

 

Severance costs
1,619

 
1,931

 
1,821

Total operating expenses
1,084,301

 
944,260

 
872,136

INCOME FROM OPERATIONS
69,878

 
30,886

 
50,050

 
 
 
 
 
 
OTHER INCOME AND EXPENSES
 
 
 
 
 
Interest expense
48,044

 
43,456

 
40,623

Equity in earnings of joint ventures
(8,350
)
 
(11,377
)
 
(13,554
)
Gain on re-measurement of pre-existing interest
(768
)
 
(39,539
)
 

Gain on sale of imaging centers and medical practice

 

 
(3,146
)
Other expenses (income)
1,283

 
(181
)
 
(258
)
Total other expenses (income)
40,209

 
(7,641
)
 
23,665

INCOME BEFORE INCOME TAXES
29,669

 
38,527

 
26,385

Provision for income taxes
(6,229
)
 
(394
)
 
(24,310
)
NET INCOME
23,440

 
38,133

 
2,075

Net income attributable to noncontrolling interests
8,684

 
5,890

 
2,022

 
 
 
 
 
 
NET INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
$
14,756

 
$
32,243

 
$
53

 
 
 
 
 
 
BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
$
0.30

 
$
0.67

 
$

 
 
 
 
 
 
DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
$
0.29

 
$
0.66

 
$

 
 
 
 
 
 
WEIGHTED AVERAGE SHARES OUTSTANDING
 
 
 
 
 
Basic
49,674,858

 
48,114,275

 
46,880,775

Diluted
50,244,006

 
48,678,999

 
47,401,921

 
The accompanying notes are an integral part of these financial statements.


59



RADNET, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(IN THOUSANDS)
 
 
Years Ended December 31,
 
2019
 
2018
 
2017
NET INCOME
$
23,440

 
$
38,133

 
$
2,075

Foreign currency translation adjustments
(32
)
 
(69
)
 
26

Change in fair value of cash flow hedge, net of taxes
(10,253
)
 
2,876

 
(880
)
COMPREHENSIVE INCOME
13,155

 
40,940

 
1,221

Less comprehensive income attributable to noncontrolling interests
8,684

 
5,890

 
2,022

 
 
 
 
 
 
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
$
4,471

 
$
35,050

 
$
(801
)

The accompanying notes are an integral part of these financial statements.
 
 
 
 
 


60



RADNET, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF EQUITY
(IN THOUSANDS EXCEPT SHARE DATA)
 
 
 
 
 
 
Additional
 
Accumulated Other
 
 
 
Radnet, Inc.
 
 
 
 
 
Common Stock
 
Paid-in
 
Comprehensive
 
Accumulated
 
Stockholders'
 
Noncontrolling
 
Total
 
Shares
 
Amount
 
Capital
 
(Loss) Income
 
Deficit
 
Equity
 
Interests
 
Equity
BALANCE - JANUARY 1, 2017
46,574,904

 
$
4

 
$
198,387

 
$
306

 
$
(150,211
)
 
$
48,486

 
$
3,567

 
$
52,053

Stock-based compensation
867,248

 
1

 
7,833

 

 

 
7,834

 

 
7,834

Issuance of stock for acquisitions
281,763

 

 
2,500

 

 

 
2,500

 

 
2,500

Sale to noncontrolling interests, net of taxes

 

 
3,541

 

 

 
3,541

 

 
3,541

Contributions from noncontrolling interests

 

 

 

 

 

 
4,304

 
4,304

Distributions paid to noncontrolling interests

 

 

 

 

 

 
(1,528
)
 
(1,528
)
Change in cumulative foreign currency translation adjustment

 

 

 
26

 

 
26

 

 
26

Change in fair value cash flow hedge, net of taxes

 

 

 
(880
)
 

 
(880
)
 

 
(880
)
Net income

 

 

 

 
53

 
53

 
2,022

 
2,075

BALANCE - DECEMBER 31, 2017
47,723,915

 
$
5

 
$
212,261

 
$
(548
)
 
$
(150,158
)
 
$
61,560

 
$
8,365

 
$
69,925

Issuance of stock upon exercise of options
10,000

 

 
20

 

 

 
20

 

 
20

Stock-based compensation
713,160

 

 
7,719

 

 

 
7,719

 

 
7,719

Forfeiture of restricted stock
(1,150
)
 

 
(7
)
 

 

 
(7
)
 

 
(7
)
Issuance of stock for acquisitions
531,560

 

 
8,000

 

 

 
8,000

 

 
8,000

Sale to noncontrolling interests, net of taxes

 

 
11,991

 

 

 
11,991

 
22,666

 
34,657

Special distribution from noncontrolling interest

 

 
2,894

 

 

 
2,894

 
(9,175
)
 
(6,281
)
Purchase of noncontrolling interests

 

 
(43
)
 

 

 
(43
)
 
(157
)
 
(200
)
Contributions from noncontrolling interests

 

 

 

 

 

 
2,640

 
2,640

Distributions paid to noncontrolling interests

 

 

 

 

 

 
(1,427
)
 
(1,427
)
Re-measurement of noncontrolling interest upon change in control

 

 

 

 

 

 
44,267

 
44,267

Change in cumulative foreign currency translation adjustment

 

 

 
(69
)
 

 
(69
)
 

 
(69
)
Change in fair value cash flow hedge, net of taxes

 

 

 
2,876

 

 
2,876

 

 
2,876

Net income

 

 

 

 
32,243

 
32,243

 
5,890

 
38,133

BALANCE - DECEMBER 31, 2018
48,977,485

 
$
5

 
$
242,835

 
$
2,259

 
$
(117,915
)
 
$
127,184

 
$
73,069

 
$
200,253

Issuance of stock upon exercise of options
12,500

 

 
75

 

 

 
75

 

 
75

Stock-based compensation
771,042

 

 
8,735

 

 

 
8,735

 

 
8,735

Forfeiture of restricted stock
(1,500
)
 
 
 
(5
)
 
 
 
 
 
(5
)
 
 
 
(5
)
Non-cash severance
12,692

 

 
188

 

 

 
188

 

 
188

Issuance of stock for acquisitions
542,109

 

 
7,500

 

 

 
7,500

 

 
7,500

Sale to noncontrolling interests, net of taxes

 

 
3,537

 

 

 
3,537

 
2,008

 
5,545

Contributions from noncontrolling interests

 

 

 

 

 

 
750

 
750

Distributions paid to noncontrolling interests

 

 

 

 

 

 
(3,057
)
 
(3,057
)
Change in cumulative foreign currency translation adjustment

 

 

 
(32
)
 

 
(32
)
 

 
(32
)
Change in fair value cash flow hedge, net of taxes

 

 

 
(10,253
)
 

 
(10,253
)
 

 
(10,253
)
Net income

 

 

 

 
14,756

 
14,756

 
8,684

 
23,440

BALANCE - DECEMBER 31, 2019
50,314,328

 
$
5

 
$
262,865

 
$
(8,026
)
 
$
(103,159
)
 
$
151,685

 
$
81,454

 
$
233,139



61



 
The accompanying notes are an integral part of these financial statements.
 
 


62



RADNET, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
 
 
Years Ended December 31,
 
2019
 
2018
 
2017
CASH FLOWS FROM OPERATING ACTIVITIES
 

 
 

 
 

Net income
$
23,440

 
$
38,133

 
$
2,075

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
 
 
Depreciation and amortization
80,607

 
72,899

 
66,796

Amortization of operating lease right-of-use assets
66,842

 

 

Provision for bad debts

 

 
46,555

Equity in earnings of joint ventures, net of dividends
248

 
13,469

 
(4,864
)
Amortization and write off of deferred financing costs and loan discount
4,184

 
3,898

 
3,483

Loss (gain) on sale and disposal of equipment and other
2,383

 
(2,054
)
 
1,142

Gain on sale of imaging centers

 

 
(3,146
)
Gain on re-measurement of pre-existing interest
(768
)
 
(39,539
)
 

Loss on impairment

 
3,937

 

Stock-based compensation
8,730

 
7,662

 
6,787

Other non cash item in other expenses
(559
)
 

 

Non cash severance
188

 

 
1,047

Change in value of contingent consideration
(3,123
)
 
1,749

 

Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:
 
 
 
 
 
Accounts receivable
(17,482
)
 
2,145

 
(37,164
)
Other current assets
(3,557
)
 
(9,248
)
 
1,461

Other assets
(2,326
)
 
(1,687
)
 
(801
)
Deferred taxes
(3,888
)
 
(6,935
)
 
19,504

Operating lease liability
(66,831
)
 

 

Deferred rent

 
6,312

 
2,135

Deferred revenue
(1,082
)
 
(208
)
 
1,034

Accounts payable, accrued expenses and other
17,316

 
26,221

 
36,181

Net cash provided by operating activities
104,322

 
116,754

 
142,225

CASH FLOWS FROM INVESTING ACTIVITIES
 
 
 
 
 
Purchase of imaging facilities
(27,150
)
 
(73,192
)
 
(27,612
)
Investment at cost
(143
)
 
(2,200
)
 
(500
)
Purchase of property and equipment
(74,153
)
 
(72,180
)
 
(61,336
)
Proceeds from sale of equipment
1,160

 
2,575

 
852

Proceeds from the sale of equity interests in a joint venture
132

 

 

Proceeds from sale of imaging and medical practice assets

 

 
8,429

Proceeds from sale of internal use software

 
248

 
492

Nulogix return of capital
792

 

 

Cash contribution from partner in JV formation

 

 
1,473

Equity contributions in existing and purchase of interest in joint ventures
(103
)
 
(2,000
)
 
(1,118
)
Net cash used in investing activities
(99,465
)
 
(146,749
)
 
(79,320
)
CASH FLOWS FROM FINANCING ACTIVITIES
 
 
 
 
 
Principal payments on notes and leases payable
(6,494
)
 
(6,072
)
 
(6,836
)
Payments on term loan debt
(40,742
)
 
(33,830
)
 
(196,666
)
Proceeds from debt issuance, net of issuance costs
97,144

 

 
164,938

Distributions paid to noncontrolling interests
(3,057
)
 
(1,427
)
 
(1,528
)
Proceeds from sale of noncontrolling interest
5,275

 

 
7,720

Contributions from noncontrolling partners
750

 
2,640

 
125

Proceeds from revolving credit facility
261,200

 
204,300

 
200,800

Payments on revolving credit facility
(289,200
)
 
(176,300
)
 
(200,800
)
Purchase of noncontrolling interests

 
(200
)
 

Proceeds from issuance of common stock upon exercise of options
75

 
20

 

Net cash provided by (used in) financing activities
24,951

 
(10,869
)
 
(32,247
)
EFFECT OF EXCHANGE RATE CHANGES ON CASH
(32
)
 
(69
)
 
26

NET INCREASE (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS
29,776

 
(40,933
)
 
30,684

CASH AND CASH EQUIVALENTS, beginning of period
10,389

 
51,322

 
20,638

CASH AND CASH EQUIVALENTS, end of period
$
40,165

 
$
10,389

 
$
51,322

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
 
 
 
 
 
Cash paid during the period for interest
$
46,254

 
$
37,016

 
$
34,197

Cash paid during the period for income taxes
$
5,884

 
$
4,933

 
$
4,939

 
 
The accompanying notes are an integral part of these financial statements.
 
 
RADNET, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
 
 
Supplemental Schedule of Non-Cash Investing and Financing Activities
 
We acquired equipment and certain leasehold improvements for approximately $51.7 million, $47.8 million, and $18.5 million during the years ended December 31, 2019, 2018 and 2017, respectively, that we had not paid for as of December 31, 2019, 2018 and 2017, respectively. The offsetting amount due was recorded in our consolidated balance sheets under “accounts payable, accrued expenses and other.”
 
We executed inclusive of all acquisitions, finance lease liability/capital lease debt of approximately $51,000, $6.7 million, and $5.5 million during the twelve months ended December 31, 2019, 2018, and 2017.
We transferred approximately $4.3 million in net assets to our new joint venture, Ventura County Imaging Group. LLC in March 2019. See Note 4, Facility Acquisitions and Dispositions, for further information.
On February 27, 2019, we issued 440,207 shares of our common stock to the sellers of Hudson Valley Radiology Associates, P.L.L.C. ("HVRA") which permitted our variable interest entity, Lenox Hill Radiology and Medical Imaging Associates, P.C., to complete its purchase of the membership interest of HVRA. The shares were ascribed a value of $6.0 million. We also recorded contingent consideration valued at $680,000 to guarantee the share value issued for a period of six months post acquisition date, which was taken to income upon the completion of the time period.

On August 1, 2019 we completed a step-up acquisition upon the dissolution of our former 49% owned joint venture, Garden State Radiology LLC ("GSRN"). We made a fair value determination of our original 49% interest which resulted in a step-up gain of  approximately $1.3 million. See Note 4, Facility Acquisitions and Dispositions, for further information.

On August 1, 2019 we issued RadNet common stock in the amount of $1.5 million to acquire a 75% controlling interest in our formerly 25% owned joint venture Nulogix. We also made a fair value determination of our 25% pre-existing interest in the business and recognized a loss of $504,000 which is included in operating expenses within the consolidated statements of operations. See Note 2, Significant Accounting Policies, for further information.

On October 1, 2018, we obtained control over the operations of New Jersey Imaging Network (NJIN) through an agreement with the other equity interest holder for no cash consideration. As such, we consolidated the financial statements of NJIN effective that date and recognized fair value of non controlling interest of $44.3 million on the date of the transaction. We remeasured NJIN's pre-existing 49% equity interest in NJIN upon consolidation and recognized a non cash gain of $39.5 million. We also obtained control of $5.4 million cash in NJIN as a result of such consolidation. The economic interest of each party remained the same after consolidation. See Note 4, Facility Acquisitions and Dispositions, to the consolidated financial statements contain herein for further information.

On October 1, 2018 we acquired Medical Arts Radiology for cash consideration of $50.9 million, the assumption of $2.7 million in equipment debt, and $8.0 million in RadNet common stock. As part of the transaction, we recorded a contingent liability of approximately $700,000 to guarantee the sellers stock price stability for a period of one year from the date of acquisition. For the year ended December 31, 2018 we recorded a $1.7 million charge to record the contingent liability at fair market value. For the year ended December 31, 2019, we recorded $2.4 million to income to resolve the fair market value charge recorded at December 31, 2018 and the original contingent liability at purchase. See Note 4, Facility Acquisitions and Dispositions, to the consolidated financial statements contain herein for further information.

The Company received a one-time special distribution from a controlled subsidiary which resulted in a $9.2 million adjustment to noncontrolling interest and $3.0 million, net of taxes, to the Company’s additional paid in capital account in September 2018.

The Company received $15.0 million in fixed assets and assumed $4.0 million in capital lease debt in January 2018 from the Company’s partner in Beach Imaging LLC. See Note 4, Facility Acquisitions and Assets Held for Sale contained herein for further information.
 
We transferred approximately $2.5 million in net assets in April 2017 to our new joint venture, Santa Monica Imaging Group LLC.
 
We transferred approximately $4.6 million in net assets in July 2017 to a new majority owned subsidiary, Advanced Imaging at Timonium Crossing, LLC.
 
On August 7, 2017 we acquired Diagnostic Imaging Associates for $13.0 million in cash and $1.5 million in RadNet common stock.
 
On October 5, 2017 we completed our acquisition of all of the outstanding equity interests in RadSite, LLC, for $1.0 million in common stock and $856,000 in cash.
 



63



RADNET, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
NOTE 1 – NATURE OF BUSINESS
 
We are a national provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. At December 31, 2019, we operated directly or indirectly through joint ventures with hospitals, 335 centers located in California, Delaware, Florida, Maryland, New Jersey, and New York. Our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Our services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. The vast majority of our centers offer multi-modality imaging services. Our multi-modality strategy diversifies revenue streams, reduces exposure to reimbursement changes and provides patients and referring physicians one location to serve the needs of multiple procedures. In addition to our imaging services, we have certain other software subsidiaries which design and sell computerized systems for the imaging industry and internally develop Artificial Intelligence, and Imaging On Call LLC, which provides teleradiology services. Our operations comprise a single segment for financial reporting purposes.
 
The consolidated financial statements include the accounts of RadNet, Inc as well as its subsidiaries in which RadNet has a controlling financial interest. The consolidated financial statements also include certain variable interest entities in which we are the primary beneficiary (as described in more detail below). All material intercompany transactions and balances have been eliminated upon consolidation. . All of these affiliated entities are referred to collectively as “RadNet”, “we”, “us”, “our” or the “Company” in this report
Accounting regulations stipulate that generally any entity with a) insufficient equity to finance its activities without additional subordinated financial support provided by any parties, or b) equity holders that, as a group, lack the characteristics which evidence a controlling financial interest, is considered a Variable Interest Entity (“VIE”). We consolidate all VIEs in which we are the primary beneficiary. We determine whether we are the primary beneficiary of a VIE through a qualitative analysis that identifies which variable interest holder has the controlling financial interest in the VIE. The variable interest holder who has both of the following has the controlling financial interest and is the primary beneficiary: (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. In performing our analysis, we consider all relevant facts and circumstances, including: the design and activities of the VIE, the terms of the contracts the VIE has entered into, the nature of the VIE’s variable interests issued and how they were negotiated with or marketed to potential investors, and which parties participated significantly in the design or redesign of the entity.

VIEs that we consolidate as the primary beneficiary consist of professional corporations which are owned or controlled by individuals within our senior management, namely Howard G. Berger, M.D., our President and Chief Executive Officer, and John V. Crues, III, M.D., RadNet's Medical Director; both of whom are members of our Board of Directors. Dr. Berger owns, indirectly, 99% of the equity interests in Beverly Radiology Medical Group III (BRMG) and a controlling interest in two professional corporations in New York City. BRMG is responsible for the professional medical services at nearly all of our facilities located in California. Dr. Crues owns six professional corporations which provide medical services in Delaware, Maryland, New Jersey and New York. Additionally, Dr. Crues is a 1% owner of BRMG. These VIEs are collectively referred to as the consolidated medical group ("the Group").
RadNet provides non-medical, technical and administrative services to the Group for which it receives a management fee, pursuant to the related management agreements. Through the management agreements we have exclusive authority over all non-medical decision making related to the ongoing business operations and we determine the annual budget. The Group has insignificant operating assets and liabilities, and de minimis equity. Through management agreements with us, substantially all cash flows of the Group after expenses, including professional salaries, are transferred to us. We consolidate the revenue and expenses, assets and liabilities of the Group.

The Group on a combined basis recognized $157.4 million, $132.9 million, and $134.6 million of revenue, net of management services fees to RadNet, for the years ended December 31, 2019, 2018, and 2017, respectively and $157.4 million, $132.9 million, and $134.6 million of operating expenses for the years ended December 31, 2019, 2018, and 2017, respectively. RadNet, Inc. recognized $618.9 million, $505.2 million, and $435.5 million of total billed net service fee revenue for the years ended December 31, 2019, 2018, and 2017, respectively, for management services provided to them relating primarily to the technical portion of billed revenue.
 


64



The cash flows of the Group are included in the accompanying consolidated statements of cash flows. All intercompany balances and transactions have been eliminated in consolidation. In our consolidated balance sheets at December 31, 2019 and December 31, 2018, we have included approximately $100.3 million and $88.9 million, respectively, of accounts receivable and approximately $7.0 million and $5.6 million of accounts payable and accrued liabilities related to the Group, respectively.
 
The creditors of the Group do not have recourse to our general credit and there are no other arrangements that could expose us to losses on behalf of them. However, RadNet may be required to provide financial support to cover any operating expenses in excess of operating revenues.

We also own a 49% economic interest in ScriptSender, LLC, which provides secure data transmission services of medical information. Through a management agreement, RadNet provides management and accounting services and receives an agreed upon fee. ScriptSender LLC is dependent on the Company to finance its own activities, and as such we determined that it is a VIE but we are not a primary beneficiary since we do not have the power to direct the activities of the entity that most significantly impact the entity’s economic performance.

At all of our centers not serviced by the Group we have entered into long-term contracts (typically 40 years) with independent radiology groups to provide physician services at those centers. These radiology practices provide professional services, including supervision and interpretation of diagnostic imaging procedures, in our diagnostic imaging centers. The radiology practices maintain full control over the provision of professional services. Under these arrangements, in addition to obtaining technical fees for the use of our diagnostic imaging equipment and the provision of technical services, we provide management services and receive a fee based on the value of the services we provide. We own the diagnostic imaging equipment and, therefore, receive 100% of the technical reimbursements associated with imaging procedures. The radiology practice groups retain the professional reimbursements associated with imaging procedures after deducting management service fees paid to us and we have no economic controlling interest in these radiology practices as such, the financial results of these practices are not consolidated in our financial statements.

 
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
PRINCIPLES OF CONSOLIDATION – The operating activities of subsidiaries are included in the accompanying consolidated financial statements (“financial statements”) from the date of acquisition. Investments in companies in which we have the ability to exercise significant influence, but not control, are accounted for by the equity method. All intercompany transactions and balances, with our consolidated entities and the unsettled amount of intercompany transactions with our equity method investees, have been eliminated in consolidation. As stated in Note 1 above, the Group consists of VIEs and we consolidate the operating activities and balance sheets of each. Additionally, we determined that our unconsolidated joint venture, ScriptSender, LLC, is also a VIE as it is dependent on our operational funding but we are not a primary beneficiary since RadNet does not have the power to direct the activities of the entity that most significantly impact the entity’s economic performance.

USE OF ESTIMATES - The financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP), which requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect various matters, including our reported amounts of assets and liabilities in our consolidated balance sheets at the dates of the financial statements; our disclosure of contingent assets and liabilities at the dates of the financial statements; and our reported amounts of revenues and expenses in our consolidated statements of operations during the reporting periods. These estimates involve judgments with respect to numerous factors that are difficult to predict and are beyond management’s control. As a result, actual amounts could materially differ from these estimates.
 
RECLASSIFICATION – For the year 2017, we have reclassified certain amounts within other income and expenses on the consolidated statement of operations and proceeds from issuance of debt on the consolidated statement of cash flows to conform to our 2018 and 2019 presentation. For the year 2018, we have reclassified certain amounts within other expenses on the consolidated statement of cash flows to conform to our 2019 presentation. For the years 2018 and 2017, we have reclassified certain amounts within our reconciliation of the statutory U.S. federal rate and effective rates to conform to our 2019 presentation.
 
REVENUES – Our revenues generally relate to net patient fees received from various payors and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided


65



by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.
 
As it relates to the consolidated medical group, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by them as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to others centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.
 
Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual allowances under managed care and commercial insurance plans are based upon historical collection experience from such payors in accordance with the underlying contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have price concessions applied. We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect.

Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.

On January 1, 2018, we adopted the new revenue recognition accounting standard issued by the Financial Accounting Standards Board (“FASB”) and codified in the ASC as topic 606 (“ASC 606”). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding our revenue recognition policies and significant judgments employed in the determination of revenue.

We applied the modified retrospective approach to all contracts when adopting ASC 606. As a result, at the adoption of ASC 606 the majority of what was previously classified as the provision for bad debts in the statement of operations are now reflected as implicit price concessions and therefore included as a reduction to net operating revenues in 2018 and later. For changes in credit issues not assessed at the date of service, we will prospectively recognize those amounts in other operating expenses on the statement of operations. For periods prior to the adoption of ASC 606, the provision for bad debts has been presented consistent with the previous revenue recognition standards that required it to be presented separately as a component of net operating revenues. As part of the adoption of ASC 606 allowance for doubtful accounts was reclassified to be a component of net patient accounts receivable. Other than these changes in presentation on the consolidated statement of operations and consolidated balance sheet, the adoption of ASC 606 did not have a material impact on the consolidated financial statements. As part of the adoption of ASC 606, we elected two of the available practical expedients provided for in the standard. First, we did not adjust the transaction price for any financing components as those were deemed to be insignificant. Additionally, we expensed all incremental customer contract acquisition costs as incurred as such costs are not material and would be amortized over a period less than one year.

Our total net revenues for the years ended December 31, 2019, 2018, and 2017 are presented in the table below (in thousands):
 


66



 
2019
 
2018
 
2017
Commercial insurance
$
642,341

 
$
542,011

 
$
534,224

Medicare
237,427

 
192,881

 
179,678

Medicaid
28,283

 
25,615

 
24,133

Workers' compensation/personal injury
42,792

 
34,193

 
32,969

Other patient revenue
23,862

 
25,117

 
29,882

Management fee revenue
11,659

 
13,882

 
13,127

Imaging on call and software
17,317

 
16,261

 
18,116

Other
24,555

 
18,781

 
25,049

Service fee revenue, net of contractual allowances and discounts
1,028,236

 
868,741

 
857,178

Provision for bad debts

 

 
(46,555
)
Net service fee revenue
1,028,236

 
868,741

 
810,623

Revenue under capitation arrangements
125,943

 
106,405

 
111,563

Total net revenue
$
1,154,179

 
$
975,146

 
$
922,186


 
ACCOUNTS RECEIVABLE – Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. We continuously monitor collections from our payors and record an estimated price concession based upon specific payor collection issues that we have identified and our historical experience.

In 2019 and 2018 we entered into factoring agreements with various institutions and sold certain accounts receivable under non-recourse agreements. These transactions are accounted for as a reduction in accounts receivable as the agreements transfer effective control over and risk related to the receivables to the buyers. The aggregate amounts factored under these facilities, net of discounts recorded to reflect market interest rates, was $9.0 million during the year ended December 31, 2019 and $20.5 million during the year ended December 31, 2018.

Proceeds on notes receivable are reflected as operating activities on our statement of cash flows and on our balance sheet as prepaid expenses and other current assets for the current portion and deposits and other for the long term portion. At December 31, 2019 we have $24.2 million remaining to be collected on these agreements. We do not utilize factoring arrangements as an integral part of our financing for working capital.
 
MEANINGFUL USE INCENTIVE – Under the American Recovery and Reinvestment Act of 2009, a program was enacted that provides financial incentives for providers that successfully implement and utilize electronic health record technology to improve patient care. Our software development team in Canada developed a Radiology Information System (RIS) software platform that has been awarded meaningful use certification. We recorded the meaningful use incentive within non-operating income. The program ended in 2017 and we recorded approximately $250,000 to other income during the twelve months ended December 31, 2017 relating to this incentive. 
 
SOFTWARE REVENUE RECOGNITION – Our subsidiary, eRAD, Inc., sells Picture Archiving Communications Systems (“PACS”) and related services, primarily in the United States. The PACS systems sold by eRAD are primarily composed of certain elements: hardware, software, installation and training, and support. Sales are made primarily through eRAD’s sales force and generally include hardware, software, installation, training and first-year warranty support. Hardware, which is not unique or special purpose, is purchased from a third-party and resold to eRAD’s customers with a small mark-up.
 
We have determined that our core software products, such as PACS, are essential to most of our arrangements as hardware, software and related services are sold as an integrated package. Revenue is recognized when a performance obligation is satisfied by transferring a promised good or service to a customer.
  
For the years ended December 31, 2019, 2018 and 2017, we recorded approximately $10.1 million, $6.8 million, and $6.1 million, respectively, in revenue related to our eRAD business which is included in net service fee revenue in our consolidated statement of operations. At December 31, 2019 we had a deferred revenue liability of approximately $1.3 million associated with eRAD sales which we expect to recognize into revenue over the next 12 months.
 
SOFTWARE DEVELOPMENT COSTS – When we develop our own software solutions through our eRad subsidiary, we capitalize and amortize those costs over their useful life. Costs related to the research and development of new software products


67



and enhancements to existing software products all for resale to our customers are expensed as incurred. If we enter into agreements where we license our software to outside customers, we have recorded the receipt of these funds against the capitalized software costs.

Our most major software development to date was the Radiology Information System, a front desk patient tracking software, which had total capitalized costs of approximately $6.4 million and was fully amortized as of December 31, 2018.

CONCENTRATION OF CREDIT RISKS – Financial instruments that potentially subject us to credit risk are primarily cash equivalents and accounts receivable. We have placed our cash and cash equivalents with one major financial institution. At times, the cash in the financial institution is temporarily in excess of the amount insured by the Federal Deposit Insurance Corporation, or FDIC. Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. We continuously monitor collections and maintain an allowance for bad debts based upon our historical collection experience. In addition, we have notes receivable stemming from our factoring of accounts receivable as stated above. Companies with which we factor our receivables are well known established buyers of such instruments, have agreed to assume the full risk of their collection, and to date have made all payments due to us in a timely manner.
 
CASH AND CASH EQUIVALENTS – We consider all highly liquid investments that mature in three months or less when purchased to be cash equivalents. The carrying amount of cash and cash equivalents approximates the fair market value.
 
DEFERRED FINANCING COSTS – Costs of financing are deferred and amortized using the effective interest rate method. Deferred financing costs are solely related to our Barclays Revolving Credit Facilities. Deferred financing costs, net of accumulated amortization, were $1.6 million and $1.4 million for the twelve months ended December 31, 2019 and 2018, respectively. See Note 8, Revolving Credit Facility, Notes Payable, and Capital Leases for more information on our revolving lines of credit.
 
INVENTORIES – Inventories, consisting mainly of medical supplies, are stated at the lower of cost or net realizable value with cost determined by the first-in, first-out method.
 
PROPERTY AND EQUIPMENT – Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are provided using the straight-line method over the estimated useful lives, which range from 3 to 15 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 3 to 15 years. Maintenance and repairs are charged to expense as incurred.
 
BUSINESS COMBINATION – When the qualifications for business combination accounting treatment are met, it requires us to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.
 
GOODWILL AND INDEFINITE LIVED INTANGIBLES – Goodwill totaled $441.0 million and $418.1 million at December 31, 2019 and December 31, 2018, respectively. Indefinite lived intangible assets at December 31, 2019 were $11.3 million and $9.8 million at December 31, 2018 and are associated with the value of certain trade name intangibles. Goodwill and trade name intangibles are recorded as a result of business combinations. When we determine the carrying value of goodwill exceeds its fair value, an impairment charge would be recognized which should not exceed the total amount of goodwill allocated to that reporting unit. We determined fair values for each of the reporting units using the market approach, when available and appropriate, or the income approach, or a combination of both. We assess the valuation methodology based upon the relevance and availability of the data at the time we perform the valuation. If multiple valuation methodologies are used, the results are weighted appropriately. We tested both goodwill and trade name intangibles for impairment on October 1, 2019, noting no impairment, and have not identified any indicators of impairment through December 31, 2019.

During the testing of goodwill and trade name intangibles at October 1, 2018, our Teleradiology reporting unit, Imaging On Call, (IOC), experienced a reduction of professional medical group clients and a loss of a contract with a major local health provider during 2018. This affected its estimated fair value and resulted in impairment charges to our reporting unit of $3.9 million for the twelve months ended December 31, 2018, with goodwill representing $3.8 million of the total and the remainder being its


68



trade name of approximately $100,000. The estimated fair value of IOC reporting unit was determined by using the discounted cash flow method.

LONG-LIVED ASSETS – We evaluate our long-lived assets (property and equipment) and intangibles, other than goodwill, for impairment when events or changes indicate the carrying amount of an asset may not be recoverable. Accounting standards requires that if the sum of the undiscounted expected future cash flows from a long-lived asset or definite-lived intangible is less than the carrying value of that asset, an asset impairment charge must be recognized. The amount of the impairment charge is calculated as the excess of the asset’s carrying value over its fair value, which generally represents the discounted future cash flows from that asset or in the case of assets we expect to sell, at fair value less costs to sell. We determined that there were no events or changes in circumstances that indicated our long-lived assets were impaired during any periods presented.
 
INCOME TAXES – Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income in determining whether our net deferred tax assets are more likely than not to be realized. Income taxes are further explained in Note 10, Income Taxes. 
LEASES - We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liability, and long term operating lease liability in our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liability, and long-term finance lease liability in our consolidated balance sheets.  ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. We use the implicit rate when readily determinable. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We include options to extend a lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For a contract in which we are a lessee that contains fixed payments for both lease and non-lease components, we have elected to account for the components as a single lease component, as permitted. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. See Note 9, Leases, for more information.

UNINSURED RISKS – On November 1, 2008 we obtained a fully funded and insured workers’ compensation policy, thereby eliminating any uninsured risks for employee injuries occurring on or after that date. This fully funded policy remained in effect through November 1, 2013 and continues to cover any claims incurred through this date.
 
On November 1, 2013 we entered into a high-deductible workers’ compensation insurance policy. We have recorded liabilities of $3.8 million and $2.8 million for each of the years ending December 31, 2019 and December 31, 2018, respectively, for the estimated future cash obligations associated with the unpaid portion of the workers compensation claims incurred.
 
We and our affiliated physicians carry an annual medical malpractice insurance policy that protects us for claims that are filed during the policy year and that fall within policy limits. The policy has a deductible for which is $10,000 per incidence for the years ending December 31, 2019 and December 31, 2018, respectively.
 
In December 2008, in order to eliminate the exposure for claims not reported during the regular malpractice policy period, we purchased a medical malpractice claims made tail policy, which provides coverage for any claims reported in the event that our medical malpractice policy expires. As of December 31, 2019, this policy remains in effect.
 
We have entered into an arrangement with Blue Shield to administer and process claims under a self-insured plan that provides health insurance coverage for our employees and dependents. We have recorded liabilities as of December 31, 2019 and 2018 of $4.9 million and $4.8 million, respectively, for the estimated future cash obligations associated with the unpaid portion of the medical and dental claims incurred by our participants. Additionally, we entered into an agreement with Blue Shield for a stop loss policy that provides coverage for any claims that exceed $250,000 up to a maximum of $1.0 million in order for us to limit our exposure for unusual or catastrophic claims. 

EMPLOYEE BENEFIT PLAN – We adopted a profit-sharing/savings plan pursuant to Section 401(k) of the Internal Revenue Code that covers substantially all non-professional employees. Eligible employees may contribute on a tax-deferred basis a percentage of compensation, up to the maximum allowable under tax law. Employee contributions vest immediately. As of


69



January 1, 2017, RadNet provides a matching contribution in the amount to a maximum of 1.0% per 4.0% of employee contribution. RadNet contributed $2.6 million for the year ended December 31, 2018 and is expected to contribute approximately $3.0 million for the plan year ended December 31, 2019.
 
LOSS AND OTHER UNFAVORABLE CONTRACTS – We assess the profitability of our contracts to provide management services to our contracted physician groups and identify those contracts where current operating results or forecasts indicate probable future losses. Anticipated future revenue is compared to anticipated costs and if the anticipated future cost exceeds the revenue, a loss contract accrual is recorded. In connection with the acquisition of Radiologix in November 2006, we acquired certain management service agreements which met this criterion and recorded to other non-current liabilities an $8.9 million loss contract accrual. Of the $4.6 million ending balance at December 31, 2018, approximately $4.0 million, ($2.8 million net of taxes), was settled against the purchase consideration of Hudson Valley Radiology Associates, P.L.L.C. (HVRA) by our VIE entity Lenox Hill Radiology and Medical Associates, P.C. and the remaining balance of approximately $558,000 was written off upon ending a contract with a physician group. See Note 4, Facility Acquisitions, Assets Held for Sale and Dispositions for further information on the purchase of HVRA.
 
Related to acquisition activity, we entered into certain operating lease commitments for facilities where the fair market rent differs from the lease contract rate. We recorded an unfavorable contract liability representing the difference between the total value of the fair market rent and the contract rent over the current term of the lease applicable from the date of acquisition. As of December 31, 2018, the unfavorable contract liability on these leases was $2.2 million. This balance was transferred to operating lease right-of-use assets in conjunction with adoption of Accounting Standard Update No. 2016-02, Leases, which amended the accounting standards for leases. See Note 9, Leases, for further information.
 
EQUITY BASED COMPENSATION – We have one long-term incentive plan that we adopted in 2006 and which we first amended and restated as of April 20, 2015, and again on March 9, 2017 (the “Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. We have reserved for issuance under the Restated Plan 14,000,000 shares of common stock. We can issue options, stock awards, stock appreciation rights, stock units and cash awards under the Restated Plan. Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options and warrants generally vest over three to five years and expire five to ten years from date of grant. The compensation expense associated with option grants is calculated based on a valuation model, typically the Black–Scholes model, which requires certain management assumptions with respect to volatility. The compensation expense recognized for all equity-based awards is recognized over the awards’ service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees. See Note 11 Stock-Based Compensation for more information.
 
FOREIGN CURRENCY TRANSLATION – The functional currency of our foreign subsidiaries is the local currency. In accordance with ASC 830, Foreign Currency Matters, assets and liabilities denominated in foreign currencies are translated using the exchange rate at the balance sheet dates. Revenues and expenses are translated using average exchange rates prevailing during the reporting period. Any translation adjustments resulting from this process are shown separately as a component of accumulated other comprehensive income (loss). Foreign currency transaction gains and losses are included in the determination of net income.
 
COMPREHENSIVE INCOME (LOSS) – Accounting guidance establishes rules for reporting and displaying comprehensive income (loss) and its components. Our unrealized gains or losses on foreign currency translation adjustments and our interest rate cap and swap agreements are included in comprehensive income (loss). The components of comprehensive income (loss) for the three years in the period ended December 31, 2019 are included in the consolidated statements of comprehensive income (loss).
CONTINGENCIES - We are party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business. With respect to these matters, we evaluate the developments on a regular basis and accrue a liability when we believe a loss is probable and the amount can be reasonably estimated. We believe that the amount or any estimable range of reasonably possible or probable loss will not, either individually or in the aggregate, have a material adverse effect on our business and consolidated financial statements. However, the outcome of these matters is inherently uncertain. Therefore, if one or more of these matters were resolved against us for amounts in excess of management's expectations, our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable, could be materially adversely affected.
In the second quarter of 2019, we accrued a liability of $2.3 million related to allegations by the US Attorney's Office for the Western District of New York that RadNet submitted certain claims which incorrectly identified the physician who furnished the radiology services.  The final settlement, which admits no wrong-doing on behalf of RadNet, was $2.2 million and paid in September 2019.


70




DERIVATIVE INSTRUMENTS

2016 CAPS

In the fourth quarter of 2016, we entered into two forward interest rate cap agreements ("2016 Caps"). The 2016 Caps will mature in September and October 2020. The 2016 Caps had notional amounts of $150,000,000 and $350,000,000, respectively, which were designated at inception as cash flow hedges of future cash interest payments associated with portions of our variable rate bank debt. Under these arrangements, we purchased a cap on 3 month LIBOR at 2.0%. We are liable for a $5.3 million premium to enter into the caps which is being accrued to current liabilities on our balance sheet and paid over the life of the 2016 Caps.
 
At inception, we designated our 2016 Caps as cash flow hedges of floating-rate borrowings. In accordance with ASC Topic 815, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss of the hedge (i.e. change in fair value) is reported as a component of accumulated other comprehensive income in the consolidated statement of equity. See Fair Value Measurements section below for the fair value of the 2016 Caps at December 31, 2019.
 
A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive income (loss), net of taxes is as follows (amounts in thousands):

 
Interest Rate Contracts
 
 
 
 
For the twelve months ended
Amount of (Loss) Gain Recognized on Derivative, net of taxes
Location of Loss Recognized
in Income on Derivative
December 31, 2019
$(4,383)
Other Comprehensive Loss
December 31, 2018
2,876
Other Comprehensive Income
December 31, 2017
(880)
Other Comprehensive Loss
 
2019 SWAPS
In the second quarter of 2019, we entered into four forward interest rate agreements ("2019 swaps"). The 2019 swaps have total notional amounts of $500,000,000, consisting of two agreements of $50,000,000 each and two agreements of $200,000,000 each. The 2019 swaps will secure a constant interest rate associated with portions of our variable rate bank debt and have an effective date of October 13, 2020. They will mature in October 2023 for the two smaller notional and October 2025 for the two larger notional. Under these arrangements, we arranged the 2019 swaps with locked in 1 month LIBOR rates at 1.96% for the two $50,000,000 notional and at 2.05% for the two $200,000,000 notional.
At inception, we designated our 2019 swaps as cash flow hedges of floating-rate borrowings. In accordance with ASC Topic 815, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss of the hedge (i.e. change in fair value) is reported as a component of comprehensive loss in the consolidated statement of equity.  See Fair Value Measurements section below for the fair value of the 2019 swaps at December 31, 2019.

For the twelve months ended December 31, 2019
 
 
 
Effective Interest Rate Swap
Amount of Loss Recognized on Derivative, net of taxes
Location of Loss Recognized
in Income on Derivative
Interest rate contracts
$(5,870)
Other Comprehensive Loss



FAIR VALUE MEASUREMENTS – Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement:
 


71



Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
 
Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.
 
Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.

Derivatives:

The table below summarizes the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets in our consolidated balance sheets, as follows (in thousands):

 
As of December 31, 2019
 
Level 1
 
Level 2
 
Level 3
 
Total
Current and long term liabilities
 

 
 

 
 

 
 

2016 CAPS - Interest Rate Contracts
$

 
$
1,081

 
$

 
$
1,081

2019 SWAPS - Interest Rate Contracts
$

 
$
9,477

 
$

 
$
9,477

 
 
As of December 31, 2018
 
Level 1
 
Level 2
 
Level 3
 
Total
Current assets
 

 
 

 
 

 
 

2016 CAPS - Interest Rate Contracts
$

 
$
3,316

 
$

 
$
3,316



The estimated fair value of these contracts was determined using Level 2 inputs. More specifically, the fair value was determined by calculating the value of the difference between the fixed interest rate of the interest rate swaps and the counterparty’s forward LIBOR curve. The forward LIBOR curve is readily available in the public markets or can be derived from information available in the public markets.
 
Long Term Debt

The table below summarizes the estimated fair value and carrying amount of our SunTrust (Term Loan Agreement) and Barclays (First Lien Term Loans) long-term debt as follows (in thousands):
 
 
As of December 31, 2019
 
Level 1
 
Level 2
 
Level 3
 
Total Fair Value
 
Total Face Value
Term Loan Agreement and First Lien Term Loans
$

 
$
708,948

 
$

 
$
708,948

 
$
705,699

 
 
As of December 31, 2018
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Total Face Value
Term Loan Agreement and First Lien Term Loans
$

 
$
633,229

 
$

 
$
633,229

 
$
646,441


 
Our Barclays revolving credit facility had no aggregate principal amount outstanding as of December 31, 2019 and a $28.0 million principal amount outstanding as of December 31, 2018. Our SunTrust revolving credit facility had no aggregate principal amount outstanding for the periods ending December 31, 2019 and December 31, 2018, respectively.


72



 
The estimated fair values of our long-term debt, which is discussed in Note 8, was determined using Level 2 inputs for the Barclays and SunTrust term loans. Level 2 inputs primarily related to comparable market prices.
 
We consider the carrying amounts of cash and cash equivalents, receivables, other current assets, current liabilities and other notes payables to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment. Additionally, we consider the carrying amount of our capital lease obligations to approximate their fair value because the weighted average interest rate used to formulate the carrying amounts approximates current market rates.
 
EARNINGS PER SHARE - Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):
 
 
Years Ended December 31,
 
2019
 
2018
 
2017
Net income attributable to RadNet, Inc. common stockholders
$
14,756

 
$
32,243

 
$
53

 
 
 
 
 
 
BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
 
 
 
 
 
Weighted average number of common shares outstanding during the period
49,674,858

 
48,114,275

 
46,880,775

Basic net income per share attributable to RadNet, Inc. common stockholders
$
0.30

 
$
0.67

 
$

DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
 
 
 
 
 
Weighted average number of common shares outstanding during the period
49,674,858

 
48,114,275

 
46,880,775

Add nonvested restricted stock subject only to service vesting
208,963

 
180,631

 
274,940

Add additional shares issuable upon exercise of stock options and warrants
360,185

 
384,093

 
246,206

Weighted average number of common shares used in calculating diluted net income per share
50,244,006

 
48,678,999

 
47,401,921

Diluted net income per share attributable to RadNet, Inc. common stockholders
$
0.29

 
$
0.66

 
$

 
 
 
 
 
 
Stock options excluded from the computation of diluted per share amounts:
 
 
 
 
 
Weighted average shares for which the exercise price exceeds average market price of common stock

 
6,250

 
175,037



EQUITY INVESTMENTS AT FAIR VALUE- As of December 31, 2019, we have three equity investments for which a fair value is not readily determinable and we do not have significant influence and therefore the total amounts invested are recognized at cost. In accordance with accounting guidance, if there is no readily determinable fair value, the guidance allows entities the ability to measure investments at cost less impairment, whereby impairment is based on a qualitative assessment.
 
Medic Vision:
 
Medic Vision, based in Israel, specializes in software packages that provide compliant radiation dose structured reporting and enhanced images from reduced dose CT scans.
 
On March 24, 2017, we acquired an initial 12.50% equity interest in Medic Vision - Imaging Solutions Ltd for $1.0 million. We also received an option to exercise warrants to acquire up to an additional 12.50% equity interest for $1.4 million within one year from the initial share purchase date, if exercised in full. On March 1, 2018 we exercised our warrant in part and acquired an additional 1.96% for $200,000. Our initial equity interest has been diluted to 12.25% and our total equity investment stands at 14.21%.
 
In accordance with accounting guidance, as we exercise no significant influence over Medic Vision’s operations, the investment is recorded at its cost of $1.2 million, given that the fair value is not readily determinable. No impairment in our investment was noted as of the year ended December 31, 2019.
 


73



Turner Imaging:
 
Turner Imaging Systems, based in Utah, develops and markets portable X-ray imaging systems that provide a user the ability to acquire X-ray images wherever and whenever they are needed. On February 1, 2018, we purchased 2.1 million preferred shares in Turner Imaging Systems for $2.0 million. On January 1, 2019 we funded a convertible promissory note in the amount of $143,000 that converted to an additional 80,000 preferred shares on October 11, 2019. No impairment in our investment was noted for the year ended December 31, 2019.

WhiteRabbit.ai Inc:
WhiteRabbit.ai Inc., based in California, is currently developing an artificial intelligence suite which aims to improve the speed and accuracy of cancer detection in radiology and improve patient care. On November 5, 2019 we acquired an equity interest in the company for $1.0 million and also loaned the company $2.5 million in support of its operations. No impairment in our investment was noted for the year ended December 31, 2019.
 
INVESTMENT IN JOINT VENTURES – We have 12 unconsolidated joint ventures with ownership interests ranging from 35% to 55%. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers.  Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture.  Our investment in these joint ventures is accounted for under the equity method, as we do not have a controlling financial interest in such ventures. We evaluate our investment in joint ventures, including cost in excess of book value (equity method goodwill) for impairment whenever indicators of impairment exist. No indicators of impairment existed as of December 31, 2019.
 
Sale of joint venture interest:
On April 1, 2017, we formed in conjuncture with Cedars Sinai Medical Center (“CSMC”) the Santa Monica Imaging Group, LLC (“SMIG”), consisting of two multi-modality imaging centers located in Santa Monica, CA with RadNet holding a 40% economic interest and CSMC holding a 60% economic interest. RadNet accounts for our share of the venture under the equity method. On January 1, 2019, CSMC purchased from the us an additional five percent economic interest in SMIG valued at $134,000. As a result of the transaction, our economic interest in SMIG has been reduced to 35%. We recorded a loss of $2,000 on the transaction.

Change in control of existing joint ventures

On October 6, 2014, we acquired a 49% equity interest in Garden State Radiology Network, LLC ("GSRN") for cash consideration of $2.2 million. The venture consisted of two imaging centers located in New Jersey. On August 1, 2019, the entity was dissolved by transferring ownership of the assets of the centers with each partner receiving full ownership of one center. See Note 4, Facility Acquisitions and Dispositions, for further information.

On April 12, 2018 we acquired 25% share capital in Nulogix, Inc. for cash consideration of $2.0 million. On August 1, 2019 we completed via the issuance of RadNet common stock valued at $1.5 million, the acquisition of the remaining 75% economic interest and we now consolidate the financial statements of Nulogix.  See Note 4, Facility Acquisitions and Dispositions, for further information.

On October 1, 2018, we obtained control over the operations of NJIN through an agreement with the other equity interest holder for no cash consideration. As such, we consolidated the financial statements of NJIN effective that date. The economic interest of each party remained the same after consolidation. See Note 4, Facility Acquisitions and Dispositions, to the consolidated financial statements contain herein for further information.

Joint venture investment and financial information
 
The following table is a summary of our investment in joint ventures during the years ended December 31, 2019 and December 31, 2018 (in thousands):
 


74



Balance as of December 31, 2017
$
52,435

Equity contributions in existing and purchase of interest in joint ventures
2,000

Equity in earnings in these joint ventures
11,377

Disposition of equity method interest upon acquisition of control in NJIN
(2,993
)
Distribution of earnings
(24,846
)
Balance as of December 31, 2018
$
37,973

Equity contributions in existing and purchase of interest in joint ventures
103

Equity in earnings in these joint ventures
8,350

Sale of ownership interest
(134
)
Dissolution of GSRN
(1,428
)
Nulogix return of capital
(792
)
Nulogix change in control
(1,004
)
Distribution of earnings
(8,598
)
Balance as of December 31, 2019
$
34,470



We charged management service fees from the centers underlying these joint ventures of approximately $11.4 million, $13.8 million and $13.1 million for the years ended December 31, 2019, 2018 and 2017, respectively . We eliminate any unrealized portion of our management service fees with our equity in earnings of joint ventures.
 
The following table is a summary of key unaudited financial data for these joint ventures as of December 31, 2019 and 2018, respectively, and for the years ended December 31, 2019, 2018 and 2017, respectively, (in thousands):

 
December 31,
Balance Sheet Data:
2019
 
2018
Current assets
$
27,427

 
$
28,317

Noncurrent assets
61,037

 
45,912

Current liabilities
(9,217
)
 
(4,300
)
Noncurrent liabilities
(18,872
)
 
(4,898
)
Total net assets
$
60,375

 
$
65,031

Book value of RadNet joint venture interests
$
28,001

 
$
30,030

Cost in excess of book value of acquired joint venture interests accounted for as equity method goodwill
6,469

 
7,943

Total value of RadNet joint venture interests
$
34,470

 
$
37,973

Total book value of other joint venture partner interests
$
32,374

 
$
35,001

  
 
2019
 
2018
 
2017
Net revenue
$
108,051

 
$
155,820

 
$
188,849

Net income
$
18,624

 
$
24,596

 
$
28,644



NOTE 3 – RECENT ACCOUNTING STANDARDS
 
Accounting standards adopted

In February 2016, the FASB issued Accounting Standard Update ("ASU") No. 2016-02, Leases (Topic 842) (ASU 2016-02), which amends the existing accounting standards for leases. In September 2017, the FASB issued ASU No. 2017-13 which provides additional clarification and implementation guidance on the previously issued ASU No. 2016-02. Subsequently, in July 2018, the FASB issued ASU No 2018-10, Codification Improvements to Topic 842, Leases, and ASU No. 2018-11, Targeted Improvement, to clarify and amend the guidance in ASU No. 2016-02. The amendments in this update were effective for fiscal years (and interim reporting periods within fiscal years) beginning after December 15, 2018, with early adoption permitted for all entities. Under the new guidance, a lessee is required to recognize a lease liability and right-of-use asset for all leases with terms in excess of twelve months. The new guidance also requires additional disclosures to enable users of financial statements to understand the amount, timing, and potential uncertainty of cash flows arising from leases. Consistent with current guidance, a


75



lessee’s recognition, measurement, and presentation of expenses and cash flows arising from a lease will continue to depend primarily on its classification. We have elected the optional transition method to apply the standard as of the effective date and therefore, we will not apply the standard to the comparative periods presented in the consolidated financial statements. We elected the transition package of three practical expedients permitted within the standard, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs. See Note 9, Leases, for more information.
In February 2018, the FASB issued ASU No. 2018-02 (“ASU 2018-02”), Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. ASU 2018-02 allows for the reclassification of certain income tax effects related to the Tax Cuts and Jobs Act between “Accumulated other comprehensive income” and “Retained earnings.” This ASU relates to the requirement that adjustments to deferred tax liabilities and assets related to a change in tax laws or rates to be included in “Income from continuing operations”, even in situations where the related items were originally recognized in “Other comprehensive income” (rather than in “Income from continuing operations”). Subsequently, in March 2018, the FASB issued ASU No. 2018-05, Income Taxes, to clarify and amend guidance in ASU 2018-02. ASU 2018-02 and ASU 2018-05 are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. Adoption of this ASU is to be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the tax laws or rates were recognized. The adoption had no significant impact on the our results of operations, financial position and cash flows.

In April 2019, the FASB issued ASU 2019-04, ("ASU 2019-04"), Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, which, among other things, clarifies certain hedge accounting guidance. For the year ended 2017, we elected to early adopt ASU 2017-12, Targeted Improvements to Accounting for Hedging Activities, (Topic 815), for which this current ASU 2019-04 amends. For those entities that have already adopted ASU 2017-12, the hedging amendments in ASU 2019-04 are effective as of the beginning of the first annual reporting period beginning after 25 April 2019 and early adoption is permitted. We elected early adoption of ASU 2019-04 and the adoption had no effect on our financial statements.

Accounting standards not yet adopted
 
In June 2016, the FASB issued ASU No. 2016-13 ("ASU 2016-13), Financial Instruments - Credit Losses. ASU 2016-13 replaces the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The standard will be effective for us beginning after December 15, 2019, with early adoption permitted. We are currently evaluating the impact of this standard on our consolidated financial statements, including accounting policies, processes, and systems.

In August 2018, the FASB issued ASU No. 2018-15 (“ASU 2018-15”), Intangibles-Goodwill and Other-Internal-Use Software. ASU 2018-15 aligns the requirements for deferring implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This ASU is effective in the first quarter of 2020 with early adoption permitted and can be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We are currently assessing the impact of the adoption of this ASU on our results of operations, financial position and cash flows.

In December 2019, the FASB issued ASU 2019-12 ("ASU 2019-12"), Income Taxes (Topic 740). ASU 2019-12 removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other areas of the standard. ASU 2019-12 will be effective beginning in the first quarter of 2021. Early adoption is permitted. Certain amendments in this update must be applied on a prospective basis, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings/(deficit) in the period of adoption. We are currently evaluating the impact this ASU will have on our financial statements and related disclosures as well as the timing of adoption.

In January 2020, the FASB issued ASU 2020-01 ("ASU 2020-01"), Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815), clarifying the interaction between accounting standards related to equity securities, equity method investments, and certain derivatives. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020. We do not expect the adoption of this guidance will have a material impact on its consolidated financial statements.



  


76



 

 
NOTE 4 – FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS
 
Acquisitions
 
On August 1, 2019 we completed a step-up acquisition upon the dissolution of our former 49% owned joint venture, Garden State Radiology LLC ("GSRN"). GSRN consisted of two multi-modality centers operating in New Jersey. GSRN became our wholly owned subsidiary with the withdrawal of the 51% majority partner for the full ownership of one center with no other consideration. We made a fair value determination of our original 49% interest which resulted in a step-up gain of  approximately $1.3 million. We determined a fair value of the remaining acquired imaging center of $3.1 million in assets and $426,000 in liabilities were recognized. We recorded $1,000 in other assets, $679,000 in fixed assets, $426,000 in right-of-use assets, $426,000 in operating lease liabilities, and $2.0 million in goodwill.

On August 1, 2019 we completed a step-up acquisition of our former 25% owned joint venture, Nulogix, via a stock issuance of RadNet common shares valued at $1.5 million to obtain the remaining 75% outstanding Nulogix shares. We made a fair value determination of the acquired assets and approximately $189,000 in fixed assets, $732,000 in intangible assets, $278,000 in deferred tax liability and goodwill of $1.3 million were recorded. We also made a fair value determination of our 25% pre-existing interest in the business and recognized a loss of $504,000 which is included in operating expenses within the consolidated statements of operations.
On April 1, 2019 we completed our acquisition of certain assets of Kern Radiology Imaging Systems Inc., consisting of four multi-modality imaging centers located in Bakersfield, California for purchase consideration of $19.3 million. We made a fair value determination of the acquired assets and assumed liabilities and approximately $10.1 million in property and equipment, $9.7 million in right-of-use assets, $36,000 in other assets, $3.4 million in intangible assets, $14.5 million in operating lease liabilities, and $10.5 million in goodwill were recorded.
On April 1, 2019 we completed our acquisition of certain assets of Zilkha Radiology Inc. consisting of two multi-modality centers located in Islip, New York for purchase consideration of $4.5 million. We made a fair value determination of the acquired assets and assumed liabilities and approximately $2.2 million in property and equipment, $5.1 million in right-of-use assets, $100,000 in intangible assets, $5.1 million in operating lease liabilities, $332,000 in finance lease liabilities and $2.6 million in goodwill were recorded.
On February 28, 2019, one of VIE entities, Lenox Hill Radiology and Medical Imaging Associates, P.C. ("LHR"), purchased the membership interest of Hudson Valley Radiology Associates, P.L.L.C. ("HVRA") for $6.0 million of RadNet common stock and contingent consideration valued at $680,000 to guarantee the share value issued for a period of six months post acquisition date. LHR has performed a fair value purchase price allocation and recorded equipment of $10,000, a covenant not to compete of $50,000, trade name of $380,000, other intangible assets of $340,000 and goodwill of $3.1 million from the transaction. In connection with the acquisition, RadNet also settled against the purchase consideration, $2.8 million, net of taxes, of an unfavorable vendor contract with HVRA stemming from the previous acquisition of Radiologix, Inc. in November 2006.
On February 1, 2019 our majority owned subsidiary, West Valley Imaging Group, LLC ("WVIG") completed its acquisition of certain assets of West Valley Imaging Center, LLC ("West Valley"), consisting of a single multi-modality imaging center located in West Hills, CA for purchase consideration of $3.0 million all of which was initially funded by the Company. We have made a fair value determination of the acquired assets and approximately $300,000 in equipment and fixed assets, $7,000 in other assets, $200,000 in intangible assets and $2.5 million in goodwill were recorded. Subsequent to the transaction, our partner in WVIG, Cedars Sinai Medical Center, contributed $750,000 in cash to maintain its 25% economic interest in the venture.

On December 3, 2018 we completed our acquisition of certain assets of Orange County Diagnostics Imaging Center consisting of five multi-modality imaging centers located in Orange County, California for purchase consideration of $6.6 million. We have made a fair valuation determination of the acquired assets and approximately $23,000 of current assets, $69,000 of other assets, $2.8 million of leaseholds and equipment, a $50,000 of covenant not to compete, and $3.6 million of goodwill were recorded.

On November 5, 2018 we completed our acquisition of certain assets of Arcadia Radiology Imaging consisting of one multi-modality imaging center and one women’s center located in Arcadia, California for purchase consideration of $3.8 million. We have made a fair value determination of the acquired assets and approximately $20,000 of other assets, $819,000 of leaseholds, $80,000 equipment, $300,000 in covenants not to compete, and $2.6 million of goodwill were recorded.



77



On November 1, 2018 we completed our acquisition of certain assets of Southern California Diagnostic Imaging consisting of a multi-modality imaging center located in Santa Ana, California for purchase consideration of $1.4 million. We have made a fair value determination of the acquired assets and approximately $18,000 of other assets, $1.2 million of leasehold improvements, $110,000 of equipment, $50,000 of covenants not to compete, and $41,000 of goodwill were recorded.

On October 1, 2018 we obtained control over the operations of New Jersey Imaging Network (NJIN), formerly a joint venture, consisting of eighteen multi-modality imaging centers located throughout the state of New Jersey for no consideration through an agreement with the other equity interest holder. The change in control was effective upon the execution of an Irrevocable Proxy Agreement with the joint venture partner and third amendment of the operating agreement, which provided RadNet with the ability to make unilateral operating decisions. We have made a fair value determination of the acquired net assets and approximately $11.6 million of net working capital, $235,000 of other assets, $34.4 million of property and equipment, $582,000 of trade name. $106.1 million of goodwill, $1.0 million in net unfavorable lease contracts, $5.2 million of assumed equipment debt, and $60.0 million of assumed bank debt were recorded. We also made a fair value determination of our 49% pre existing interest in the business of approximately $42.5 million and we recognized fair value of non controlling interest of $44.3 million on the date of the transaction. The re-measurement in valuation from an existing equity investment in joint venture resulted in a gain of $39.5 million which is included in Other Income within the consolidated statements of operations.

On October 1, 2018 we acquired certain assets of Medical Arts Radiology consisting of a 10 multi-modality imaging centers located in Long Island, New York. Total purchase consideration of $59.6 million consisted of cash in the amount of $50.9 million, issuance of 531,560 RadNet common shares valued at $8.0 million on the acquisition date and contingent consideration valued at $739,000 to guarantee the share value issued for a period of twelve months post acquisition date. We also assumed $2.7 million in equipment debt. We have made a value determination of the acquired assets and approximately $2.7 million of net working capital, $224,000 of other assets,$16.0 million of property and equipment, $24,000 in a covenant not to compete, $1.4 million for its trade name, unfavorable lease contracts of $130,000 and $40.7 million of goodwill were recorded.

On September 1, 2018 we completed our acquisition of certain assets of Washington Heights Medical Management, LLC, consisting of a multi-modality imaging center located in New York, New York, for $3.3 million in cash. We have made a fair value determination of the acquired assets and approximately $43,000 other assets, $904,000 of leaseholds and equipment, $50,000 in a covenant not to compete, and $2.3 million of goodwill were recorded.

On April 1, 2018 we completed our acquisition of certain assets of Women’s Imaging Specialists in Healthcare, consisting of a single multi-modality center located in the city of Fresno California, for purchase consideration of $5.1 million in cash. We have made a fair value determination of the acquired assets and approximately $636,000 of fixed assets and equipment, $143,000 in intangible covenants not to compete, $53,000 in intangible trade name, and $4.3 million in goodwill were recorded.

On April 1, 2018 we completed our acquisition of certain assets of Valley Metabolic Imaging LLC, consisting of a single multi-modality center located in Fresno, California, for purchase consideration of $1.7 million in cash. We have made a fair value determination of the acquired assets and approximately $22,000 of fixed assets and equipment, $183,000 in intangible covenants not to compete, and $1.5 million in goodwill were recorded.

On April 1, 2018 we completed our acquisition of certain assets of Sierra Imaging Associates LLC, consisting of a single multi-modality center located in Clovis, California, for purchase consideration of $1.5 million in cash. We have made a fair value determination of the acquired assets and approximately $270,000 of fixed assets and equipment, $83,000 in intangible covenants not to compete, and $1.1 million in goodwill were recorded.

On February 22, 2018 we completed our acquisition of certain assets of Imaging Services Company of New York, LLC, consisting of a single multi-modality center located in New York, New York, for purchase consideration of $5.8 million. We have made a fair value determination of the acquired assets and approximately $3.0 million in fixed asset and equipment, a $100,000 covenant not to compete, and $2.7 million in goodwill were recorded.

On January 1, 2018 we formed Beach Imaging Group, LLC (“Beach Imaging”) and contributed the operations of 24 imaging facilities spread across southern Los Angeles and Orange Counties. On the same day, MemorialCare Medical Foundation contributed $22.3 million in cash, $7.6 million in fixed assets, $7.4 million in equipment, and $545,000 in goodwill. As part of the formation, the Beach Imaging assumed $4.0 million in capital lease debt. As a result of the transaction, the Company will retain a 60% controlling interest in Beach Imaging and MemorialCare Medical Foundation will retain a 40% noncontrolling interest in Beach Imaging.

Joint venture formations


78



On February 13, 2019 we formed a wholly owned subsidiary, Ventura County Imaging Group, LLC ("VCIG"). On March 1, 2019, Dignity Health joined as a venture partner. Total agreed contribution of both parties was $10.4 million of cash and assets with RadNet contributing net assets with a book value of $4.3 million for a 60% economic interest and Dignity Health contributing $6.1 million in cash and assets for a 40% economic interest. For its contribution, RadNet transferred net assets of three wholly owned multi-modality imaging centers. Dignity Health contributed approximately $800,000 in assets to acquire 5% economic interest and paid RadNet $5.3 million for an additional 35% economic interest. We maintain controlling economic interest in VCIG and fully consolidate the results into our financial statements.

Assets held for sale
Effective January 1, 2018 we agreed to sell certain assets of four women’s imaging centers to MemorialCare Medical Foundation. The sale was initially anticipated within 12 months of the effective date. We are currently in discussions with the buyer and expect to complete the sale in 2020. The following table summarizes the major categories of assets which remain classified as held for sale in the accompanying consolidated balance sheets at December 31, 2019 (in thousands):
Property and equipment, net
$1,049
Goodwill
992

Total assets held for sale
$2,041


Dispositions
On April 1, 2017, we formed in conjunction with Cedars Sinai Medical Center (“CSMC”) the Santa Monica Imaging Group, LLC (“SMIG”), consisting of two multi-modality imaging centers located in Santa Monica, CA. Upon formation, RadNet held a 40% economic interest and CSMC held a 60% economic interest. RadNet accounts for our share of the venture under the equity method. On January 1, 2019, CSMC purchased from us an additional five percent economic interest in SMIG valued at $134,000. As a result of the transaction, our economic interest in SMIG has been reduced to 35%. We recorded a loss of $2,000 on the transaction.

On September 1, 2017 we completed the equity sale of a wholly owned breast oncology practice, Breastlink Medical Group, Inc., to Verity Medical Foundation for approximately $2.8 million. We recorded a gain of approximately $845,000 and incurred severance expense of approximately $1.2 million on this transaction.
 
On July 1, 2017 we formed a majority owned subsidiary, Advanced Imaging at Timonium Crossing, LLC, in conjunction with the University of Maryland St. Joseph Medical Center. As part of that transaction, we sold a 25% noncontrolling interest in an imaging center of our wholly owned subsidiary, Advanced Imaging Partners, Inc., to the University of Maryland St. Joseph Medical Center for $3.9 million. On the date of sale, the net book value of the 25% interest was $1.1 million and the proceeds in excess of net book value amounting to $2.8 million were recorded to equity.
 
On April 28, 2017 we completed the sale of five imaging centers operating in Rhode Island to Rhode Island Medical Imaging, Inc. for approximately $4.5 million. We recorded a gain of approximately $1.9 million in the second quarter with regard to this transaction and have no remaining imaging centers in the state.
 
On April 1, 2017 we received from Cedars Sinai Medical Center $5.9 million in exchange for a 25% noncontrolling interest in the West Valley Imaging Group, LLC (“WVI”). The determined net book value of the 25% interest was approximately $3.0 million. The proceeds in excess of the net book value, amounting to $1.8 million net of taxes, were recorded to equity.
 
On April 1, 2017 we completed the sale of 2 wholly owned oncology practices to Cedars Sinai Medical Center in connection with the sale of non-controlling interest of the WVI subsidiary described above for approximately $1.2 million. We recorded a gain of approximately $361,000 on this transaction.
 
NOTE 5 – GOODWILL AND OTHER INTANGIBLE ASSETS
 
Goodwill is recorded as a result of business combinations. Activity in goodwill for the years ended December 31, 2018 and 2019 is provided below (in thousands):


79



Balance as of December 31, 2017
$256,776
 Goodwill acquired through the acquisition of Imaging Services Company of New York, LLC
2,692

 Goodwill acquired through the acquisition of certain assets of MemorialCare Medical Foundation
545

 Goodwill transferred to assets held for sale
(1,059
)
 Goodwill acquired through the acquisition of Women's Imaging Specialists in Healthcare
4268

 Goodwill acquired through the acquisition of Valley Metabolic Imaging
1,469

 Goodwill acquired through the acquisition of Sierra Imaging Associates
1,147

 Goodwill disposed through the sale of plastic surgery unit
(80
)
 Goodwill acquired through the acquisition of Washington Heights Medical Management
2,303

 Goodwill acquired through the acquisition of Medical Arts Radiological Group, P.C.
41,469

 Goodwill acquired through the acquisition of Arcadia Radiology Imaging Services, LLC
2,582

 Goodwill acquired through the acquisition of Southern California Diagnostic Imaging, Inc.
41

 Goodwill acquired through the acquisition of Orange County Diagnostics Imaging Center, Inc.
3,618

 Goodwill acquired through assuming operational control of New Jersey Imaging Network, LLC
106,122

 Goodwill impaired in the Imaging On Call reporting unit
(3,800
)
Balance as of December 31, 2018
418,093

Adjustments to our preliminary allocation of the purchase price of Medical Arts Radiological Group, P.C.
722

Goodwill acquired through the acquisition of certain assets of Dignity Health
1

Goodwill acquired through the acquisition of certain assets of West Valley Imaging Center, LLC
2,490

Goodwill disposed through sale of assets
(123
)
Goodwill acquired by Lenox Hill Radiology through the membership purchase of HVRA
3,125

Goodwill acquired through the acquisition of certain assets of Kern Radiology, Inc.
10,507

Goodwill acquired through the acquisition of certain assets of Zilkha Radiology, Inc.
2,577

Goodwill acquired through the acquisition of certain assets of Ramic Mahwah, LLC
231

Goodwill acquired through the acquisition of GSRN
2,021

Goodwill acquired through the acquisition of Nulogix
1,337

Balance as of December 31, 2019
$440,981

 
The amount of goodwill from these acquisitions that is deductible for tax purposes as of December 31, 2019 is $160.5 million.
 
Other intangible assets are primarily related to our business combinations and software development. They include the estimated fair values of such items as service agreements, customer lists, covenants not to compete, acquired technologies, and trade names.
 
Total amortization expense was $3.1 million, $2.7 million, and $2.6 million for the years ended December 31, 2019, 2018 and 2017, respectively. Intangible assets are amortized using the straight-line method over their useful life determined at acquisition. Management service agreements are amortized over 25 years using the straight line method. Software development is capitalized and amortized over the useful life of the software when placed into service. Trade names are reviewed annually for impairment.

The following table shows annual amortization expense, by asset classes that will be recorded over the next five years (in thousands): 


80



 
2020
 
2021
 
2022
 
2023
 
2024
 
Thereafter
 
Total
 
Weighted average amortization period remaining in years
Management Service Contracts
$
2,287

 
$
2,287

 
$
2,287

 
$
2,287

 
$
2,287

 
$
15,820

 
$
27,255

 
11.9

Covenant not to compete and other contracts
759

 
699

 
650

 
537

 
129

 
142

 
2,916

 
4.4

Developed Technology
244

 
244

 
142

 

 

 

 
630

 
2.6

Trade Names amortized
142

 
69

 
69

 
61

 
58

 
219

 
618

 
8.4

Trade Names indefinite life

 

 

 

 

 
11,270

 
11,270

 

Software in development

 

 

 

 

 
305

 
305

 

Total Annual Amortization
$
3,432

 
$
3,299

 
$
3,148

 
$
2,885

 
$
2,474

 
$
27,756

 
$
42,994

 
 

 
 
NOTE 6 - PROPERTY AND EQUIPMENT
 
Property and equipment and accumulated depreciation and amortization are as follows (in thousands):
 
 
 
December 31,
 
2019
 
2018
Land
$
250

 
$
250

Medical equipment
425,892

 
449,776

Computer and office equipment, furniture and fixtures
120,490

 
102,798

Software development costs

 
6,391

Leasehold improvements
377,417

 
337,878

Equipment under financing/capital lease
14,105

 
12,119

Total property and equipment cost
938,154

 
909,212

Accumulated depreciation
(571,408
)
 
(563,483
)
Total property and equipment
$
366,746

 
$
345,729


 
Included in our property and equipment at December 31, 2019 is approximately $42.4 million total of construction in process amounts consisting of $15.9 million in medical equipment, $2.3 million in computer and office equipment, and $24.2 million in leasehold improvements.

Depreciation and amortization expense of property and equipment, including amortization of equipment under finance/capital leases, for the years ended December 31, 2019, 2018 and 2017 was $77.5 million, $70.2 million, and $64.2 million, respectively.
 
NOTE 7 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES
 
Accounts payable and accrued expenses were comprised of the following (in thousands):
 
 
December 31,
 
2019
 
2018
Accounts payable
$
64,300

 
$
68,040

Accrued expenses
83,853

 
60,958

Accrued salary and benefits
42,003

 
37,167

Accrued professional fees
17,429

 
14,863

Total
$
207,585

 
$
181,028


 
NOTE 8 - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES
  
Revolving credit facility, notes payable, and capital lease obligations:


81



 
 
December 31, 2019
 
December 31, 2018
First Lien Term Loans collateralized by RadNet's tangible and intangible assets
$
649,824

 
$
587,191

Discount on First Lien Term Loans
(13,579
)
 
(15,112
)
Term Loan Agreement collateralized by NJIN's tangible and intangible assets
55,875

 
59,250

Revolving Credit Facility

 
28,000

Promissory note payable to the former owner of a practice acquired at an interest rate of 1.5% due through 2019

 
199

Equipment notes payable at interest rates ranging from 4.4% to 5.6%, due through 2020, collateralized by medical equipment
275

 
632

Obligations under capital leases at interest rates ranging from 3.7% to 9.3%, due through 2022, collateralized by medical and office equipment (1)

 
12,119

Total debt obligations
692,395

 
672,279

Less current portion
(39,691
)
 
(39,267
)
Long-term portion debt obligations
$
652,704

 
$
633,012


(1)Obligations under capital leases were transferred to Finance Lease Liability at January 1, 2019 in accordance with the adoption of Accounting Standards Update No 2016-02, Leases (Topic 842). See Note 9, Leases, for more information.

The following is a listing of annual principal maturities of notes payable exclusive of all related discounts and repayments on our revolving credit facilities for years ending December 31 (in thousands):

2020
$
43,571

2021
43,670

2022
44,795

2023
573,938

Total notes payable obligations
$
705,974




Senior Credit Facilities:

At December 31, 2019, our Barclays credit facilities were comprised of one tranche of term loans (“First Lien Term Loans”) and a revolving credit facility of $137.5 million (the “Barclays Revolving Credit Facility”), both of which are provided pursuant to the Amended and Restated First Lien Credit and Guaranty Agreement dated July 1, 2016 (as amended, the "First Lien Credit Agreement").

At December 31, 2019, our SunTrust credit facilities, which relate to our consolidated subsidiary NJIN, were comprised of one term loan (the "SunTrust Term Loan") and a revolving credit facility of $30.0 million (the "SunTrust Revolving Credit Facility") both of which are provided pursuant to the SunTrust Restated Credit Agreement.

As of December 31, 2019, we were in compliance with all covenants under our credit facilities.

Deferred financing costs at December 31, 2019, net of accumulated amortization, was $1.6 million and is specifically related to our Barclays Revolving Credit Facility.
 
Included in our consolidated balance sheets at December 31, 2019 are $636.2 million of First Lien Term Loans and $55.9 million of SunTrust Term Loan debt for a combined total of $692.1 million (net of unamortized discounts of $13.6 million) in thousands:



82



 
Face Value
 
Discount
 
Total Carrying
Value
First Lien Term Loans
$
649,824

 
$
(13,579
)
 
$
636,245

Term Loan Agreement
55,875

 

 
55,875

Total Term Loans
$
705,699

 
$
(13,579
)
 
$
692,120



We had no outstanding balance under our $137.5 million Barclays Revolving Credit Facility at December 31, 2019 and had reserved an additional $5.9 million for certain letters of credit. The remaining $131.7 million of our Barclays Revolving Credit Facility was available to draw upon as of December 31, 2019. We also had no balance under our $30.0 million SunTrust Revolving Credit Facility related to our consolidated subsidiary NJIN at December 31, 2019.

The following relates to our Barclays financing activities:

2019 Amendments to the First Lien Credit Agreement:

On April 18, 2019 we entered into the following two new amendments to the First Lien Credit Agreement: (i) Amendment No. 6, Consent and Incremental Joinder Agreement to Credit and Guaranty Agreement dated as of April 18, 2019 (the “Sixth Amendment”); and (ii) Amendment No. 7 to Credit and Guaranty Agreement dated as of April 18, 2019 (the “Seventh Amendment”). The Sixth Amendment amended the First Lien Credit Agreement to issue $100.0 million in incremental First Lien Term Loans and to add an additional $20.0 million of revolving commitments to the Barclay's Revolving Credit Facility. The Seventh Amendment amends the First Lien Credit Agreement to extend the maturity date of the Barclays Revolving Credit Facility by an additional two years to July 1, 2023, unless sooner terminated in accordance with the terms of the First Lien Credit Agreement. Total issue costs added in relation to the amendments in 2019 amounted to approximately $4.4 million. Of this amount, $2.1 million was identified and capitalized as discount on debt, $683,000 was capitalized as deferred financing costs, and $1.6 million was expensed. Amounts capitalized will be amortized over the remaining term of the agreement.

Terms of Barclays Credit Facilites:

First Lien Term Loans:
  
Interest: First Lien Term Loans bear interest at either an Adjusted Eurodollar Rate or a Base Rate plus an applicable margin. Rates of the applicable margin for borrowing under the First Lien Credit Agreement will alter depending on our leverage ratio, according to the following schedule:
First Lien Leverage Ratio
Eurodollar Rate Spread
Base Rate Spread
> 5.50x
4.50%
3.50%
> 4.00x but ≤ 5.50x
3.75%
2.75%
>3.50x but ≤ 4.00x
3.50%
2.50%
≤ 3.50x
3.25%
2.25%


At December 31, 2019 the effective Adjusted Eurodollar Rate and the Base Rate for the First Lien Term Loans was 2.01% and 4.75%, respectively and the applicable margin for Adjusted Eurodollar Rate and Base Rate borrowings was 3.50% and 2.50%, respectively.

Payments. The First Lien Credit Agreement provides for quarterly payments of principal under the First Lien Term Loans in the amount of approximately $9.7 million.

Maturity Date. The maturity date for the First Lien Term Loans shall be on the earliest to occur of (i) July 1, 2023, and (ii) the date on which all First Lien Term Loans shall become due and payable in full under the First Lien Credit Agreement, whether by acceleration or otherwise.

Additional Borrowing. Under the First Lien Credit Agreement, we can elect to request (i) an increase to the existing Barclays Revolving Credit Facility and/or (ii) issue additional First Lien Term Loans, provided that the aggregate amount of such increases and additions does not exceed (a) $100.0 million and (b) as long as the First Lien Leverage Ratio (as defined in the First Lien Credit Agreement) would not exceed 4.00:1.00 after giving effect to such incremental facilities, an uncapped amount of incremental facilities, in each case subject to the conditions and limitations set forth in the First Lien Credit Agreement. Each


83



lender approached to provide all or a portion of any incremental facility may elect or decline, in its sole discretion, to provide an incremental commitment or loan.
Barclays Revolving Credit Facility:

Interest: Revolving loans borrowed under the Revolving Credit Facility bear interest at either an Adjusted Eurodollar Rate or a Base Rate plus an applicable margin. Rates of the applicable margin for borrowing under the Revolving Credit Facility also change depending on our leverage ratio and are the same rates as noted in the schedule above for First Lien Term Loans. As of December 31, 2019, the effective interest rate payable on revolving loans was 7.25%.
 
Letters of Credit: For letters of credit issued under the Revolving Credit Facility, letter of credit fees accrue at the applicable margin of Adjusted Eurodollar Rate, currently 3.50% , and fronting fees accrue at 0.25% per annum, in each case on the average aggregate daily maximum amount available to be drawn under all letters of credit issued under the First Lien Credit Agreement. In addition a commitment fee of 0.50% per annum accrues on the unused revolver commitments under the Revolving Credit Facility.
 
Maturity Date: The Revolving Credit Facility will terminate on the earliest to occur of (i) July 1, 2023, (ii) the date we voluntarily agree to permanently reduce the Revolving Credit Facility to zero pursuant to section 2.13(b) of the First Lien Credit Agreement, and (iii) the date the Revolving Credit Facility is terminated due to specific events of default pursuant to section 8.01 of the First Lien Credit Agreement.

 
The following relates to our SunTrust financing activities:

Amended and Restated Revolving Credit and Term Loan Agreement

On August 31, 2018, our subsidiary, NJIN, entered into the Amended and Restated Revolving Credit and Term Loan Agreement (as amended, the "SunTrust Restated Credit Agreement") as borrower with SunTrust Bank and other financial institutions as lenders and to provide NJIN aggregate credit facilities of $90.0 million as categorized below:

SunTrust Term Loan: Pursuant to the SunTrust Restated Credit Agreement, the lenders thereunder made a term loan to NJIN in the amount of $60.0 million. The SunTrust Term Loan is repayable in scheduled quarterly amounts (as described below) and has a maturity date of the earlier of (i) August 31, 2023 and (ii) the date on which the principal amount of the SunTrust Term Loan has been declared or automatically has become due and payable (whether by acceleration or otherwise).

SunTrust Revolving Credit Facility: The SunTrust Restated Credit Agreement establishes a $30.0 million revolving credit facility available to NJIN for funding requirements. The SunTrust Revolving Credit Facility terminates on the earliest of (i) August 31, 2023, (ii) the voluntary termination thereof by NJIN pursuant to Section 2.8 of the SunTrust Restated Credit Agreement, or (iii) the date on which all amounts outstanding under the SunTrust Restated Credit Agreement have been declared or have automatically become due and payable (whether by acceleration or otherwise). NJIN has not borrowed against the revolving credit line.

Interest: Interest rates and fees of the applicable margin for borrowing under the SunTrust Restated Credit Agreement adjust depending on our leverage ratio, according to the following table:



84



Pricing Level
Leverage Ratio
Applicable Margin for Eurodollar Loans
Applicable Margin for Base Rate Loans
Applicable Margin for Letter of Credit Fees
Applicable Percentage for Commitment Fee
I
Greater than or equal to 3.00:1.00
2.75%
per annum
1.75%
per annum
2.75%
per annum
0.45%
per annum
II
Less than 3.00:1.00 but greater than or equal to 2.50:1.00
2.25%
per annum
1.25%
per annum
2.25%
per annum
0.40%
per annum
III
Less than 2.50:1.00 but greater than or equal to
2.00:1.00
2.00%
per annum
1.00%
per annum
2.00%
per annum
0.35%
per annum
IV
Less than 2.00:1.00 but greater than or equal to 1.50:1.00
1.75%
per annum
0.75%
per annum
1.75%
per annum
0.30%
per annum
V
Less than 1.50:1.00
1.50%
per annum
0.50%
per annum
1.50%
per annum
0.30%
per annum



The loans and other obligations outstanding under the SunTrust Restated Credit Agreement currently bear applicable margin and fees based on Pricing Level III described above.The loans outstanding under the SunTrust Restated Credit Agreement currently bear interest based on a three month Eurodollar election, plus the applicable margin.

Payments: The scheduled amortization of the SunTrust Term Loan began December 31, 2018 with quarterly payments of $750,000, representing annual amortization equal to 5.0% of the original principal amount of the SunTrust Term Loan. At scheduled intervals, the quarterly amortization increases by $375,000, with the remaining balance to be paid at maturity.

NOTE 9 – LEASES
Adoption of Standard

In February 2016, the FASB issued a new standard related to leases to increase transparency and comparability among organizations by requiring the recognition of right-of-use (“ROU”) assets and lease liabilities on the balance sheet for all leases with terms in excess of twelve months. Sufficient disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The standard was effective for us beginning January 1, 2019. We have elected the optional transition method to apply the standard as of the effective date and therefore, we will not apply the standard to the comparative periods presented in the consolidated financial statements. We also elected the transition package of three practical expedients permitted within the standard, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs.

The adoption of the standard had a material impact on our condensed consolidated balance sheets, but did not have material impact on our condensed consolidated income statements or cash flows. Adoption of the standard resulted in the recognition of an operating lease liability of $455.5 million. Operating lease ROU assets were recorded in the amount of $419.0 million. Inclusive in the adoption was the transfer of $35.3 million in deferred rent liability and $792,000 in unfavorable rental contract liabilities to operating lease ROU assets. For finance leases, the effect of the adoption amounted to a finance lease liability of $12.1 million, which was transfered from capital lease debt and a finance right of use assets in the amount of $14.1 million which remained in property, plant and equipment.
Lease Liability

We have operating leases for medical facilities, administrative offices, warehouse space and major medical equipment. We lease the premises at which these facilities are located and do not have options to purchase the facilities we rent. Our most common initial term varies in length from 5 to 15 years. Including renewal options negotiated with the landlord, we can have a total span of 10 to 35 years at the facilities we lease. We also lease smaller satellite X-Ray locations on mutually renewable terms, usually lasting one year. Additionally, we have operating and finance leases for certain medical and office equipment, with lease terms generally lasting from 5 to 8 years. Our Incremental Borrowing Rate ("IBR") used to discount the stream of lease payments


85



is closely related to the interest rates charged on our collateralized debt obligations and our IBR is adjusted when those rates experience a substantial change.

The components of lease expense were as follows:
 
 
 
Twelve months ended

(In thousands)
December 31, 2019

 
 
Operating lease cost
$
95,348

 
 
Finance lease cost:
 
     Depreciation of leased equipment
$
3,135

     Interest on lease liabilities
395

Total finance lease cost
$
3,530


Supplemental cash flow information related to leases was as follows:
 
Twelve months ended

(In thousands)
December 31, 2019

 
 
Cash paid for amounts included in the measurement of lease liabilities:
 
     Operating cash flows from operating leases
$
95,922

     Operating cash flows from financing leases
395

     Financing cash flows from financing leases
5,939

Right-of-use & Equipment assets obtained in exchange for lease obligations:
 
     Operating leases(1) 
482,399

     Financing leases
14,105


(1) Amounts for the twelve months ended December 31, 2019 include the transition adjustment for the adoption of Topic 842 discussed in Note 3, Recent Account Standards, for further information.

Supplemental balance sheet information related to leases was as follows:


86



(In thousands, except lease term and discount rates)
 
 
December 31, 2019

 
 
Operating Leases
 
Operating lease right-of-use assets
$
445,477

Current portion of operating lease liability
61,206

Operating lease liabilities
420,922

     Total operating lease liabilities
$
482,128

 
 
Finance Leases
 
Equipment at cost
$
14,105

Accumulated depreciation
(3,135
)
Equipment, net
$
10,970

Current portion of finance lease
$
3,283

Finance lease liabilities
3,264

Total finance lease liabilities
$
6,547

 
 
Weighted Average Remaining Lease Term
 
Operating leases - years
8.8

Finance leases - years
3.3

 
 
Weighted Average Discount Rate
 
Operating leases
6.4
%
Finance leases
4.4
%




Maturities of lease liabilities were as follows:
(In thousands)
 
 
 
Operating

Financing

Year Ending December 31,
Leases

Leases

2020
$
89,881

$
3,492

2021
88,848

2,624

2022
80,932

702

2023
69,916

11

2024
54,517

10

Thereafter
262,027


Total Lease Payments
646,121

6,839

Less imputed interest
(163,993
)
(292
)
Total
$
482,128

$
6,547



As of December 31, 2019, we have additional operating leases for facilities and medical equipment that have not yet commenced of approximately $16.4 million. These operating leases will commence in 2020 with lease terms of 1 to 16 years.


As previously disclosed in our 2018 Annual Report on Form 10-K and under the previous lease accounting, maturities of operating lease liabilities were as follows as of December 31, 2018 (in thousands):


87



 
Facilities
 
Equipment
 
Total
2019
$
75,588

 
$
14,924

 
$
90,512

2020
66,116

 
14,385

 
80,501

2021
57,826

 
12,966

 
70,792

2022
48,542

 
10,264

 
58,806

2023
38,800

 
7,095

 
45,895

Thereafter
160,327

 
5,144

 
165,471

 
$
447,199

 
$
64,778

 
$
511,977



 
NOTE 10 – INCOME TAXES
  
For the years ended December 31, 2019, 2018 and 2017, we recognized income tax expense comprised of the following (in thousands):
 
 
December 31,
 
2019
 
2018
 
2017
Federal current tax
$
(161
)
 
$
(765
)
 
$
871

State current tax
7,715

 
7,263

 
4,906

Other current tax
22

 
20

 
23

Federal deferred tax
3,396

 
(2,020
)
 
21,389

State deferred tax
(4,743
)
 
(4,104
)
 
(2,879
)
 
 
 
 
 
 
Income tax expense
$
6,229

 
$
394

 
$
24,310


 
A reconciliation of the statutory U.S. federal rate and effective rates is as follows:
 
Years Ended December 31,
 
2019
 
2018
 
2017
Federal tax
$
6,231

 
21.00
 %
 
$
8,256

 
21.00
 %
 
$
8,971

 
34.00
 %
State franchise tax, net of federal benefit
3,891

 
13.12
 %
 
1,332

 
3.39
 %
 
1,799

 
6.82
 %
Other Non deductible expenses
674

 
2.27
 %
 
471

 
1.20
 %
 
91

 
0.35
 %
Noncontrolling interests in partnerships
(1,824
)
 
(6.15
)%
 
(1,237
)
 
(3.15
)%
 
(687
)
 
(2.61
)%
Changes in valuation allowance
(462
)
 
(1.56
)%
 
1,760

 
4.48
 %
 
(1,045
)
 
(3.96
)%
Tax Cuts and Jobs Act

 
 %
 

 
 %
 
13,527

 
51.27
 %
Gain on change in control

 
 %
 
(8,303
)
 
(21.12
)%
 

 
 %
Deferred true-ups and other
(761
)
 
(2.56
)%
 
(4,254
)
 
(10.82
)%
 
(194
)
 
(0.74
)%
Other reconciling items
(1,520
)
 
(5.12
)%
 
2,369

 
6.02
 %
 
1,848

 
7.00
 %
 
 
 
 
 
 
 
 
 
 
 
 
Income tax expense
$
6,229

 
21.00
 %
 
$
394

 
1.00
 %
 
$
24,310

 
92.13
 %

 
Pursuant to the federal tax legislation that was enacted on December 22, 2017 ("Tax Act"), the Company re-measured its existing deferred tax assets and liabilities based on 21%, the current rate at which they are expected to reverse in the future. In 2017, the Company recorded provisional amounts for certain enactment-date efforts of the Act by applying the guidance in SAB 118 because it had not yet completed our enactment-date effects of the Act. The Company has completed analysis of Tax Act's income tax effects. In total, the Company recorded a non-cash charge of 13.6 million, which is included as a component of income tax expense from continuing operations in 2017. Upon further analysis of certain aspects of the Tax Act and refinement of the calculations during the 12 months ended December 31, 2018, the Company found an immaterial adjustment was necessary.

Deferred income taxes reflect the net tax effects of temporary differences between carrying amounts of assets and liabilities for financial and income tax reporting purposes and operating loss carryforwards.
 
Our deferred tax assets and liabilities comprise the following (in thousands):


88



 
December 31,
Deferred tax assets:
2019
 
2018
Net operating losses
$
34,490

 
$
46,875

Accrued expenses
4,280

 
3,421

Operating lease liability
126,546

 

Straight-Line rent adjustment

 
9,811

Unfavorable contract liability

 
1,354

Equity compensation
1,374

 
1,065

Allowance for doubtful accounts
27,220

 
14,850

Other
4,616

 
2,815

Valuation allowance
(5,348
)
 
(5,810
)
Total Deferred Tax Assets
$
193,178

 
$
74,381

Deferred tax liabilities:
 
 
 
Property and equipment
(6,450
)
 
(6,194
)
Goodwill
(24,637
)
 
(19,780
)
Intangibles
(6,669
)
 
(8,110
)
Operating lease right-of-use asset
(115,364
)
 

Non accrual experience method reserve

 
(1,446
)
Other
(5,510
)
 
(7,345
)
Total Deferred Tax Liabilities
$
(158,630
)
 
$
(42,875
)
 
 
 
 
Net Deferred Tax Asset
$
34,548

 
$
31,506



 
As of December 31, 2019, the Company had federal net operating loss carryforwards of approximately $136.2 million, which comprise of definite and indefinite net operating losses. We had federal net operating loss carryforwards of approximately $124.7 million, which expire at various intervals from the years 2023 to 2037, and had carryforwards of $11.5 million of net operating losses generated in 2018, which do not expire. Federal net operating losses generated following December 31, 2017 carryover indefinitely and may generally be used to offset up to 80% of future taxable net income. The Company also had state net operating loss carryforwards of approximately $98.6 million, which expire at various intervals from the years 2020 through 2039. As of December 31, 2019, $24.6 million of our federal net operating loss carryforwards acquired in connection with the 2011 acquisition of Raven Holdings U.S., Inc. and the 2019 acquisition of Nulogix Health, Inc. are subject to limitations related to their utilization under Section 382 of the Internal Revenue Code. Future ownership changes as determined under Section 382 of the Internal Revenue Code could further limit the utilization of net operating loss carryforwards.
   
We considered all evidence available when determining whether deferred tax assets are more likely-than-not to be realized, including projected future taxable income, scheduled reversals of deferred tax liabilities, prudent tax planning strategies, and recent financial operations. The evaluation of this evidence requires significant judgment about the forecasts of future taxable income, based on the plans and estimates we are using to manage the underlying businesses. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income. As of December 31, 2019, we have determined that deferred tax assets of $193.2 million are more likely-than-not to be realized. We have also taken into consideration deferred tax liabilities of $24.6 million are related to book basis in goodwill that has an indefinite life.
 
We file consolidated income tax returns in the U.S. federal jurisdiction and various states and foreign jurisdictions. We continue to reinvest earnings of the non-US entities for the foreseeable future and therefore have not recognized any U.S. tax expense on these earnings. With limited exceptions, we are no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for years before 2015. We do not anticipate the results of any open examinations would result in a material change to its financial position.
 
At December 31, 2019, the Company has unrecognized tax benefits of $4.3 million of which $3.5 million will affect the effective tax rate if recognized.
 
A reconciliation of the total gross amounts of unrecognized tax benefits for the years ended are as follows (in thousands):


89



 
December 31,
 
2019
 
2018
 
2017
Balance at beginning of year
$
4,629

 
$
3,615

 
$
3,861

Increases related to prior year tax positions
(34
)
 
896

 
1

Increases related to current year tax positions
119

 
111

 

Expiration of the statute of limitations for the assessment of taxes
(393
)
 

 

Increase (decrease) related to change in rate
(1
)
 
7

 
(247
)
Balance at end of year
$
4,320

 
$
4,629

 
$
3,615



We believe it is reasonably possible it will not materially reduce its unrecognized tax benefits within the next twelve months.
 
The Company recognizes accrued interest and penalties related to unrecognized tax benefits in income tax expense. During the year ended December 31, 2019 the Company accrued approximately $30,000 of interest and penalties. As of December 31, 2019, accrued interest and penalties amounted to approximately $300,000.

 
NOTE 11 – STOCK-BASED COMPENSATION
 
Stock Incentive Plans
 
Options
 
We have one long-term equity incentive plan which we refer to as the 2006 Equity Incentive Plan, which we first amended and restated as of April 20, 2015 and again on March 9, 2017 (“the Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. We have reserved for issuance under the 2017 Restated Plan 14,000,000 shares of common stock. We can issue options, stock awards, stock appreciation rights, stock units and cash awards under the 2017 Restated Plan. Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options generally vest over three to five years and expire five to ten years from the date of grant.
  
As of December 31, 2019, we had outstanding options to acquire 478,951 shares of our common stock, of which options to acquire 148,456 shares were exercisable. The following summarizes all of our option transactions for the twelve months ended December 31, 2019:
Outstanding Options
Under the 2006 Plan
 
Shares
 
Weighted Average
Exercise price
Per Common Share
 
Weighted Average
Remaining
Contractual
Life(in years)
 
Aggregate
Intrinsic
Value
Balance, December 31, 2018
 
513,282

 
$
7.44

 
 
 
 
Granted
 
89,200

 
10.93

 
 
 
 
Exercised
 
(12,500
)
 
6.00

 
 
 
 
Canceled, forfeited or expired
 
(111,031
)
 
0.79

 
 
 
 
Balance, December 31, 2019
 
478,951

 
8.21

 
7.33
 
$
5,790,763

Exercisable at December 31, 2019
 
148,456

 
7.29

 
6.42
 
1,931,633


 
Aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between our closing stock price on December 31, 2019 and the exercise price, multiplied by the number of in-the-money options as applicable) that would have been received by the holder had all holders exercised their options on December 31, 2019. As of December 31, 2019, total unrecognized stock-based compensation expense related to non-vested employee awards was $710,861 which is expected to be recognized over a weighted average period of approximately 1.8 years.
  
Restricted Stock Awards (“RSA’s”)
 


90



The Restated Plan permits the award of restricted stock awards (“RSA’s”). As of December 31, 2019, we have issued a total of 6,118,276 RSA’s of which 387,934 were unvested at December 31, 2019 . The following summarizes all unvested RSA’s activities during the twelve months ended December 31, 2019:
 
 
RSA's
 
Weighted-Average
Remaining
Contractual
Term (Years)
 
Weighted-Average
Fair Value
RSA's unvested at December 31, 2018
277,504

 
 
 
$
9.77

Changes during the period
 
 
 
 
 
Granted
636,656

 
 
 
$
11.78

Vested
(524,726
)
 
 
 
$
11.03

Forfeited
(1,500
)
 
 
 
$
12.76

RSA's unvested at December 31, 2019
387,934

 
1.13
 
$
11.61


 
We determine the fair value of all RSA’s based of the closing price of our common stock on award date.
   
Other stock bonus awards
 
The Restated Plan also permits the award of stock bonuses not subject to any future service period. These awards are valued and expensed based on the closing price of our common stock on the date of award. During the twelve months ended December 31, 2019 we issued 66,600 shares relating to these awards, amounting to $1.0 million of compensation expense.
 
Plan summary
 
In summary, of the 14,000,000 shares of common stock reserved for issuance under the Restated Plan, at December 31, 2019, we had issued 14,875,694 total shares between options, RSA’s and other stock awards. With options cancelled and RSA’s forfeited amounting to 3,281,040 and 61,703 shares, respectively, there remain 2,467,049 shares available under the Restated Plan for future issuance.
 
NOTE 12 – QUARTERLY RESULTS OF OPERATIONS (unaudited)
 
The following table sets forth a summary of our unaudited quarterly operating results for each of the last eight quarters in the years ended December 31, 2019 and 2018. This quarterly data has been derived from our unaudited consolidated interim financial statements which, in our opinion, have been prepared on substantially the same basis as the audited financial statements contained elsewhere in this report and include all normal recurring adjustments necessary for a fair presentation of the financial information for the periods presented. These unaudited quarterly results should be read in conjunction with our financial statements and notes thereto, included elsewhere in this report. The operating results in any quarter are not necessarily indicative of the results that may be expected for any future period (in thousands except per share data).
 


91



 
2019 Quarter Ended
 
2018 Quarter Ended
 
Mar 31
 
June 30
 
Sept 30
 
Dec 31
 
Mar 31
 
June 30
 
Sept 30
 
Dec 31
Statement of Operations Data:
 

 
 

 
 

 
 

 
 

 
 

 
 

 
 

Net  revenue
$
271,549

 
$
289,097

 
$
292,692

 
$
300,840

 
$
231,392

 
$
244,395

 
$
242,148

 
$
257,211

Total operating expenses
264,279

 
267,113

 
275,842

 
277,571

 
232,280

 
228,525

 
225,700

 
257,755

Total other expenses
12,295

 
13,668

 
11,897

 
10,194

 
10,040

 
10,646

 
10,670

 
(27,620
)
Equity in earnings of joint ventures
(1,873
)
 
(2,244
)
 
(1,955
)
 
(2,278
)
 
(2,977
)
 
(3,748
)
 
(2,822
)
 
(1,830
)
Benefit from (provision for) income taxes
1,230

 
(2,969
)
 
(1,816
)
 
(2,673
)
 
2,497

 
(2,505
)
 
(2,827
)
 
2,441

Net (loss) income
(1,922
)
 
7,591

 
5,092

 
12,680

 
(5,454
)
 
6,467

 
5,773

 
31,347

Net income (loss) attributable to noncontrolling interests
1,811

 
2,692

 
1,897

 
2,283

 
1,884

 
1,061

 
734

 
2,211

Net (loss) income attributable to Radnet, Inc. common stockholders
$
(3,733
)
 
$
4,899

 
$
3,195

 
$
10,397

 
$
(7,338
)
 
$
5,406

 
$
5,039

 
$
29,136

Basic net (loss) income attributable to Radnet, Inc. common stockholders (loss) earnings per share:
$
(0.08
)
 
$
0.10

 
$
0.06

 
$
0.21

 
$
(0.15
)
 
$
0.11

 
$
0.10

 
$
0.60

Diluted net (loss) income attributable to Radnet, Inc. common stockholders (loss) earnings per share:
$
(0.08
)
 
$
0.10

 
$
0.06

 
$
0.21

 
$
(0.15
)
 
$
0.11

 
$
0.10

 
$
0.59

Weighted average shares outstanding
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic
49,554

 
49,703

 
49,807

 
49,905

 
47,823

 
47,969

 
48,011

 
48,633

   Diluted
49,554

 
50,145

 
50,360

 
50,634

 
47,823

 
48,526

 
48,615

 
49,259



 
NOTE 13 – RELATED PARTY TRANSACTIONS
As stated in Note 2, Summary of Significant Accounting Policies, we have an equity investment in WhiteRabbit.ai Inc.. In addition to our equity investment, we have a loan of $2.5 million to the company outstanding at December 31, 2019.


NOTE 14 – SUBSEQUENT EVENTS
 
On March 11, 2020, we announced a definitive agreement to acquire DeepHealth, Inc. ("DeepHealth"). DeepHealth is developing solutions in machine learning and artificial intelligence to assist radiologists in interpreting images and improving patient care. The close is planned for April 1, 2020 and we will issue approximately 1.0 million RadNet common stock shares to complete the acquisition.




92



Item 9. 
Changes In and Disagreements with Accountants on Accounting and Financial Disclosure
 
None.

Item 9A
Controls and Procedures
 

Evaluation of Disclosure Controls and Procedures
 
Under the supervision of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, as of December 31, 2019. Based on this evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2019.

Limitations on Effectiveness of Controls and Procedures
 
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with existing policies or procedures may deteriorate.

Management's Report on Internal Control over Financial Reporting
 
Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles (“GAAP”). Internal control over financial reporting includes policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the Company are transacted in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.
Our management, under the supervision of our Principal Executive Officer and Principal Financial Officer, conducted an assessment of the effectiveness of its internal control over financial reporting as of December 31, 2019 based on the criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on this assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2019.
Ernst & Young LLP, the Company’s independent registered public accounting firm, has audited the Company’s internal control over financial reporting as of December 31, 2019, as stated in their report, which is included below in this Annual Report on Form 10-K.

Changes in Internal Control over Financial Reporting

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarter ended December 31, 2019, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.



93



Report of Independent Registered Public Accounting Firm
 
To the Stockholders and the Board of Directors of RadNet, Inc.
Opinion on Internal Control Over Financial Reporting
We have audited RadNet, Inc. and subsidiaries’ internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, RadNet, Inc. and subsidiaries’ (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2019 and 2018, the related consolidated statements of operations, comprehensive income (loss), equity and cash flows for each of the three years in the period ended December 31, 2019, and the related notes and the financial statement schedule listed in the Index at Item 15(a)(2) and our report dated March 16, 2020 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ Ernst & Young LLP

Los Angeles, California
March 16, 2020

 



94



-
Item 9B. 
Other Information.
 
None
 
PART III
 
Item 10.
Directors, Executive Officers and Corporate Governance
 
The information required by this Item 10 will be included under the captions “Election of Directors,” “Executive Officers,” “Board of Directors and Corporate Governance,” and “Section 16(a) Beneficial Ownership Reporting Compliance” in our definitive Proxy Statement for the 2020 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of our fiscal year (the “Proxy Statement”) and is incorporated herein by reference.
 
We have adopted a code of financial ethics applicable to our directors, officers and employees which is designed to deter wrongdoing and to promote:
 
honest and ethical conduct;

full, fair, accurate, timely and understandable disclosure in reports and documents that we file with the SEC and in our other public communications;

compliance with applicable laws, rules and regulations, including insider trading compliance; and

accountability for adherence to the code and prompt internal reporting of violations of the code, including illegal or unethical behavior regarding accounting or auditing practices.

You may obtain a copy of our Code of Financial Ethics on our website at www.radnet.com under Investor Relations — Corporate Governance. The Audit Committee is responsible for reviewing the Code of Financial Ethics and amending as necessary. Any amendments will be disclosed on our website.
 
Item 11.
Executive Compensation
 
The information required by this Item 11 will be included under the captions “Compensation of Directors,” “Compensation of Executive Officers,” “Compensation Discussion and Analysis,” “Compensation Committee Interlocks and Insider Participation,” and “Compensation Committee Report “in the Proxy Statement and is incorporated herein by reference.
 
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
 
The information required by this Item 12 will be included under the captions “Security Ownership of Certain Beneficial Owners and Management” and “Equity Compensation Plan Information” in the Proxy Statement and is incorporated herein by reference.
 
Item 13.
Certain Relationships and Related Transactions, and Director Independence
 
The information required by this Item 13 will be included under the captions “Certain Relationships and Related Party Transactions” and “Board of Directors and Corporate Governance” in the Proxy Statement and is incorporated herein by reference.
 
Item 14.
Principal Accountant Fees and Services
 
The information required by this Item 14 will be included under the caption “Independent Registered Public Accounting Firm Fees” in the Proxy Statement and is incorporated herein by reference.
 


95



 


96



PART IV

Item 15.   Exhibits and Financial Statements Schedule

(a) Documents filed as part of this annual report on Form 10-K
 

(2) Financial Statement Schedules
  
SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS
RADNET, INC. AND SUBSIDIARIES
 
Balance at Beginning of Year
 
Additional Charges Against Income
 
Deductions from Reserve
 
Balance at End of Year
 
 
 
 
 
 
 
 
Year Ended December 31, 2017
 
 
 
 
 
 
 
     Accounts Receivable-Allowance for Bad Debts
$
20,674

 
$
46,555

 
$
(32,585
)
 
$
34,644


All other schedules are omitted because they are not applicable or the required information is shown in the consolidated financial statements or notes thereto.
 


97



The following exhibits are filed herewith or incorporated by reference herein:
 
Exhibit No.
 
Description of Exhibit
3.1
 
 
 
 
3.2
 
 
 
 
3.3
 
 
 
 
4.1
 
 
 
 
10.1
 
 
 
 
10.2
 
 
 
 
10.3
 
 
 
 
10.4
 
 
 
 
10.5
 
 
 
 
10.6
 
 
 
 
10.7
 
 
 
 
10.8
 
 
 
 


98



10.9
 
 
 
 
10.10
 
 
 
 
10.11
 
 
 
 
10.12
 
 
 
 
10.13
 
 
 
 
10.14
 
 
 
 
10.15
 
 
 
 
10.16
 
 
 
 
10.17
 
 
 
 
10.18
 
Employment Agreement dated as of June 12, 1992 with Howard G. Berger, M.D. (incorporated by reference to exhibit filed with an amendment to Form 8-K report for June 12, 1992).*
 
 
 
10.19
 
 
 
 
10.20
 
 
 
 
10.21
 
 
 
 
10.22
 
 
 
 
10.23
 
 
 
 
10.24
 
 
 
 


99



10.25
 
 
 
 
10.26
 
 
 
 
10.27
 
 
 
 
10.28
 
 
 
 
10.29
 
 
 
 
10.30
 
 
 
 
10.31
 
 
 
 
10.32
 
 
 
 
21.1
 
 
 
 
23.1
 
 
 
 
24.1
 
 
 
 
31.1
 
 
 
 
31.2
 
 
 
 
32.1
 
 
 
 
32.2
 
 
 
 
101.INS
 
XBRL Instance Document
 
 
 
101.SCH
 
XBRL Schema Document
 
 
 
101.CAL
 
XBRL Calculation Linkbase Document
 
 
 
101.LAB
 
XBRL Label Linkbase Document
 
 
 


100



101.PRE
 
XBRL Presentation Linkbase Document
 
 
 
101.DEF
 
XBRL Definition Linkbase Document
 
 
 
 
* Indicates management contract or compensatory plan.
 
 
 


101



Item 16.  10-K Summary

None
SIGNATURES
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
RADNET, INC.
 
 
 
 
Date: March 16, 2020
/s/ HOWARD  G. BERGER, M.D .
 
 
 
Howard G. Berger, M.D., President,
 
 
 
Chief Executive Officer and Director
 
 
POWER OF ATTORNEY
 
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby severally constitutes and appoints Howard G. Berger, M.D. and Mark D. Stolper, and each of them, his true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution for him and in his name, place and stead, in any and all capacities to sign any and all amendments to this report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that each said attorneys-in-fact and agents or any of them or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
 
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of registrant in the capacities and on the dates indicated.
 
By
/s/ HOWARD G. BERGER, M.D.
Howard G. Berger, M.D., Director, Chief Executive Officer and President
 
 
Date: March 16, 2020
 
 
By
/s/ MARVIN S. CADWELL
Marvin S. Cadwell, Director
 
Date: March 16, 2020
 
 
By
/s/ JOHN V. CRUES, III, M.D.
John V. Crues, III, M.D., Director
 
Date: March 16, 2020
 
 
By
/s/ RUTH VILLIGER-WILSON
Ruth Villiger-Wilson, Director
 
Date: March 16, 2020
 
 
By
/s/ DAVID L. SWARTZ
David L. Swartz, Director
 


102



Date: March 16, 2020
 
 
By
/s/ LAWRENCE L. LEVITT
Lawrence L. Levitt, Director
 
 
Date: March 16, 2020
 
 
By
/s/ MICHAEL L. SHERMAN, M.D.
Michael L. Sherman, M.D., Director
 
Date: March 16, 2020
 
 
By
/s/ MARK D. STOLPER
Mark D. Stolper,Chief Financial Officer (Principal Accounting Officer)
 
Date: March 16, 2020
 
 
 
 


103
EX-21 2 a10k2019exhibit211.htm EXHIBIT 21 Exhibit


EXHIBIT 21.1
 
SUBSIDIARIES
 
Name of Subsidiary
 
 
Jurisdiction of Organization
 
 
 
 
Radnet Managed Imaging Services, Inc.
 
 
California
Radnet Management I, Inc.
 
 
California
Radnet Management II, Inc.
 
 
California
Radnet Sub, Inc.
 
 
California
Beach Imaging Group, LLC
 
 
California
Diagnostic Village, LLC
 
 
California
FRI II, Inc.
 
 
California
FRI, Inc.
 
 
California
Glendale Advanced Imaging Center LLC
 
 
California
Orange County Radiation Oncology, LLC
 
 
California
Pacific Imaging Partners, Inc.
 
 
California
Rolling Oaks Imaging Corporation
 
 
California
Rolling Oaks Radiology, Inc.
 
 
California
Santa Monica Imaging Group, LLC
 
 
California
SoCal MR Site Management, Inc.
 
 
California
Valley Imaging Partners Inc.
 
 
California
Ventura County Imaging Group, LLC
 
 
California
West Valley Imaging Group, LLC
 
 
California
RMIS Imaging Services, Inc.
 
 
Canada
Advanced Imaging Partners, Inc.
 
 
Delaware
Advanced NA, LLC
 
 
Delaware
American Radiology Services of Delaware, Inc.
 
 
Delaware
American Radiology Services LLC
 
 
Delaware
Community Imaging Partners, Inc.
 
 
Delaware
Delaware Imaging Partners, Inc.
 
 
Delaware
Diagnostic Imaging Services, Inc.
 
 
Delaware
Healthcare Rhode Island LLC
 
 
Delaware
Ide Imaging Partners, Inc.
 
 
Delaware
Image Medical Corporation
 
 
Delaware
Mid Rockland Imaging Partners, Inc.
 
 
Delaware
Nulogix Health, Inc.
 
 
Delaware
Orange County Radiation Oncology, LLC
 
 
Delaware
PantheonXT Partners, LLC
 
 
Delaware
Radiologix, Inc.
 
 
Delaware
Radiology and Nuclear Medicine Imaging Partners, Inc.
 
 
Delaware
Radnet Management I, LLC
 
 
Delaware
Radnet Venture Investment Fund I, L.P.
 
 
Delaware
Radsite LLC
 
 
Delaware
Raven Holdings U.S., Inc.
 
 
Delaware
Treasure Coast Imaging Partners, Inc.
 
 
Delaware
Turner Imaging Systems, Inc.
 
 
Delaware
Questar Imaging, Inc.
 
 
Florida
Questar Victorville, Inc.
 
 
Florida
Scriptsender, LLC
 
 
Florida





Kepdoktor Kft
 
 
Hungary
Medic Vision Imaging Solutions Ltd
 
 
Israel
Advanced PET Imaging of Maryland, L.P.
 
 
Maryland
Advanced Radiology, LLC
 
 
Maryland
Advanced /Upper Chesapeake Health Center, LLC
 
 
Maryland
Baltimore County Radiology, LLC
 
 
Maryland
Baltimore Washington Imaging Center, LLC
 
 
Maryland
Calvert Imaging Center
 
 
Maryland
Carroll County Radiology, LLC
 
 
Maryland
Franklin Imaging, LLC
 
 
Maryland
Greater Baltimore Diagnostic Imaging Partnership
 
 
Maryland
Montgomery Community Magnetic Imaging Center Limited Partnership
 
 
Maryland
Mount Airy Imaging Center, LLC
 
 
Maryland
MRI at St. Joseph Medical Center, LLC
 
 
Maryland
Radiology Alliance Delivery System, LLC
 
 
Maryland
Radar Medical Systems, LLC
 
 
Michigan
Imaging On Call, LLC
 
 
New York
Park West Circle Realty, LLC
 
 
New York
Garden State Radiology Network, LLC
 
 
New Jersey
Health Diagnostics of New Jersey, LLC
 
 
New Jersey
Integrated Health Network Inc.
 
 
New Jersey
New Jersey Imaging Network, LLC
 
 
New Jersey
New Jersey Imaging Partners, Inc.
 
 
New Jersey
eRad, Inc.
 
 
Pennsylvania
Roentgen Reinsurance Company, Ltd
 
 
Turks and Caicos



EX-23 3 a10k2019exhibit231.htm EXHIBIT 23 Exhibit


Exhibit 23.1
 
 
Consent of Independent Registered Public Accounting Firm
 
We consent to the incorporation by reference in the following Registration Statements:

(1)
Registration Statement on Form S-3ASR (No. 333-235711) pertaining to an automatic shelf registration statement; and
(2)
Registration Statements on Form S-8 (Nos. 333-143462, 333-143652, 333-153228, 333-160100, 333-176324, 333-206311, and 333-219824) pertaining to the 2006 Equity Incentive Plan.

of our reports dated March 16, 2020, with respect to the consolidated financial statements and schedule of RadNet, Inc. and subsidiaries, and the effectiveness of internal control over financial reporting of RadNet, Inc. and subsidiaries, included in this Annual Report (Form 10-K) for the year ended December 31, 2019.
 

/s/ Ernst & Young LLP
 
Los Angeles, California
March 16, 2020




EX-31.1 4 q42019exhibit311.htm EXHIBIT 31.1 Exhibit


EXHIBIT 31.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 
I, Howard G. Berger, M.D., certify that:
 
1.       I have reviewed this report on Form 10-K of RadNet, Inc.;
 
2.       Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.       Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.       The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a.
 
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b.
 
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c.
 
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d.
 
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.       The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
a.
 
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
b.
 
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Dated: March 16, 2020
 





 
/s/    Howard G. Berger, M.D.
 
Howard G. Berger, M.D.
 
President, Chief Executive Officer and Chairman of the Board of Directors


EX-31.2 5 q42019exhibit312.htm EXHIBIT 31.2 Exhibit


EXHIBIT 31.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 
I, Mark D. Stolper, certify that:
 
1.       I have reviewed this report on Form 10-K of RadNet, Inc.;
 
2.       Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.       Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.       The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:
 
a.
 
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b.
 
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c.
 
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d.
 
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.       The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
a.
 
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
b.
 
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 





Dated: March 16, 2020
  
 
/s/   Mark D. Stolper
 
Mark D. Stolper
 
Executive Vice President
 
and Chief Financial Officer


EX-32.1 6 q42019exhibit321.htm EXHIBIT 32.1 Exhibit


EXHIBIT 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Annual Report of RadNet, Inc. (the “Company”) on Form 10-K for the twelve month period ended December 31, 2019, as filed with the Securities and Exchange Commission on March 16, 2020 (the “Report”), I, Howard G. Berger, M.D., Chairman and Chief Executive Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
 
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
 
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for the periods presented in the Report.
 
 
/s/    Howard G. Berger, M.D.
 
Howard G. Berger, M.D.
 
Chairman, President and Chief Executive Officer
 
(Principal Executive Officer)
 
March 16, 2020
 
A signed original of this written statement required by Section 906 has been provided to the Company and will be furnished to the Securities and Exchange Commission or its staff upon request.


EX-32.2 7 q42019exhibit322.htm EXHIBIT 32.2 Exhibit


EXHIBIT 32.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Annual Report of RadNet, Inc. (the “Company”) on Form 10-K for the twelve month period ended December 31, 2019, as filed with the Securities and Exchange Commission on March 16, 2020 (the “Report”), I, Mark D. Stolper, Chief Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
 
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
 
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for the periods presented in the Report.
 
 
/s/    Mark D. Stolper
 
Mark D. Stolper
 
Chief Financial Officer
 
(Principal Financial Officer)
 
March 16, 2020
 
A signed original of this written statement required by Section 906 has been provided to the Company and will be furnished to the Securities and Exchange Commission or its staff upon request.


EX-101.SCH 8 rdnt-20191231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2109100 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONSOLIDATED STATEMENT OF EQUITY link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - FACILITY ACQUISITIONS AND DISPOSITIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS (Details - Assets held for sale) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS (Details - Narrative) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Details - Annual Amortization Schedule) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Details - Narrative) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Details - Schedule of Goodwill) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - INCOME TAXES (Details - Income tax expense) link:presentationLink link:calculationLink link:definitionLink 2413404 - Disclosure - INCOME TAXES (Details - Narrative) link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - INCOME TAXES (Details - Reconciliation of the statutory U.S. federal rate and effective rates) link:presentationLink link:calculationLink link:definitionLink 2413406 - Disclosure - INCOME TAXES (Details - Unrecognized tax benefit) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - LEASES (Details - Additional Information) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - LEASES (Details - Lease Cost) link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - LEASES (Details - Maturities of Operating and Finance Lease) link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - LEASES (Details - Maturities of Operating and Finance Lease) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - LEASES (Details - Supplemental Balance Sheet) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - LEASES (Details - Supplemental Cash Flows) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - LEASES (Notes) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - NATURE OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - NATURE OF BUSINESS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - NCOME TAXES (Details - Deferred tax assets and liabilities) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Annual Note Payable Maturities) link:presentationLink link:calculationLink link:definitionLink 2410406 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Margin Spread Based on Leverage Ratio) link:presentationLink link:calculationLink link:definitionLink 2410407 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Margin Spread Based on Leverage Ratio, Debt Instrument) (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Narrative) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Schedule of Debt) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Schedule of Debt) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Term Loans) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - PROPERTY AND EQUIPMENT (Details - Narrative) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - QUARTERLY RESULTS OF OPERATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - QUARTERLY RESULTS OF OPERATIONS (unaudited) link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - QUARTERLY RESULTS OF OPERATIONS (unaudited) (Details - Statements of Operations) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - RECENT ACCOUNTING STANDARDS link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 2417401 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS link:presentationLink link:calculationLink link:definitionLink 2419401 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - STOCK-BASED COMPENSATION (Details - Narrative) link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - STOCK-BASED COMPENSATION (Details-Outstanding options and warrants) link:presentationLink link:calculationLink link:definitionLink 2414404 - Disclosure - STOCK-BASED COMPENSATION (Details - RSU's) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 2418401 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Derivatives) link:presentationLink link:calculationLink link:definitionLink 2402407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Earnings Per Share) link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Fair Value Measurements) link:presentationLink link:calculationLink link:definitionLink 2402408 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Investment in Joint Ventures) link:presentationLink link:calculationLink link:definitionLink 2402409 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Key Financial Data on Joint Ventures) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Narrative) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Summary of net revenue) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 rdnt-20191231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 rdnt-20191231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 rdnt-20191231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Imaging Services Company of New York Imaging Services Company of New York [Member] Imaging Services Company of New York [Member] MemorialCare Medical Foundation MemorialCare Medical Foundation [Member] Womens Imaging Specialists Womens Imaging Specialists [Member] Valley Metabolic Imaging Valley Metabolic Imaging LLC [Member] Sierra Imaging Associates Sierra Imaging Associates LLC [Member] Washington Heights Medical Management Washington Heights Medical Management [Member] Medical Arts Radiological Group, PC Medical Arts Radiological Group, PC [Member] Medical Arts Radiological Group, PC [Member] Arcadia Radiology Imaging Arcadia Radiology Imaging [Member] Arcadia Radiology Imaging [Member] Southern California Diagnostic Imaging, Inc Southern California Diagnostic Imaging, Inc [Member] Southern California Diagnostic Imaging, Inc [Member] Orange County Diagnostics Imaging Center Orange County Diagnostics Imaging Center [Member] Orange County Diagnostics Imaging Center [Member] New Jersey Imaging Network, LLC New Jersey Imaging Network, LLC [Member] New Jersey Imaging Network, LLC [Member] Dignity Health Dignity Health [Member] West Valley Imaging Group, LLC West Valley Imaging Group, LLC [Member] West Valley Imaging Group, LLC [Member] Hudson Valley Radiology Associates Hudson Valley Radiology Associates [Member] Hudson Valley Radiology Associates [Member] Kern Radiology Imaging Systems Inc. Kern Radiology Imaging Systems Inc. [Member] Kern Radiology Imaging Systems Inc. [Member] Zilkha Radiology Zilkha Radiology [Member] Zilkha Radiology [Member] Ramic Mahwah LLC Ramic Mahwah LLC [Member] Ramic Mahwah LLC [Member] Garden State Radiology Network LLC Garden State Radiology Network LLC [Member] Garden State Radiology Network LLC [Member] Nulogix, Inc. Nulogix, Inc. [Member] Goodwill [Line Items] Goodwill [Line Items] Goodwill [Roll Forward] Goodwill [Roll Forward] Goodwill, beginning balance Goodwill Goodwill acquired through acquisitions Goodwill, Acquired During Period Goodwill transferred to other assets Goodwill, Transfers Goodwill disposed of through sale or transfer Goodwill, Written off Related to Sale of Business Unit Goodwill, impairment loss Goodwill, Impairment Loss Goodwill, ending balance Accounting Policies [Abstract] Schedule of service fee revenue Schedule of Principal Transactions Revenue [Table Text Block] Schedule of effect of derivative instruments on comprehensive income Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block] Schedule of fair value of assets and liabilities Fair Value, by Balance Sheet Grouping [Table Text Block] Schedule of earnings per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of investment in joint ventures Equity Method Investments [Table Text Block] Joint venture investment and financial information Joint venture investment and financial information Joint venture investment and financial information [Table Text Block] Business Combinations [Abstract] FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS Mergers, Acquisitions and Dispositions Disclosures [Text Block] Payables and Accruals [Abstract] Schedule of accounts payable and accrued expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Statement of Financial Position [Abstract] Common stock - par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock - authorized (in shares) Common Stock, Shares Authorized Common stock - issued (in shares) Common Stock, Shares, Issued Common stock - outstanding (in shares) Common Stock, Shares, Outstanding Share-based Payment Arrangement [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Equity Option Equity Option [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Begining Balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Canceled, forfeited or expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Ending Balance (in shares) Exercisable at the end (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Begining Balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Canceled, forfeited or expired (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Ending Balance (in dollars per share) Exercisable at the end (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Remaining Contractual Life Weighted Average Remaining Contractual Life Weighted Average Remaining Contractual Life abstract Ending Balance Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term Exercisable at the end Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Aggregate Intrinsic Value Aggregate Intrinsic Value Aggregate value outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate value exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Debt Disclosure [Abstract] NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES Debt and Capital Leases Disclosures [Text Block] Income Tax Disclosure [Abstract] INCOME TAXES Income Tax Disclosure [Text Block] New Accounting Pronouncements and Changes in Accounting Principles [Abstract] RECENT ACCOUNTING STANDARDS New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Federal tax Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount State franchise tax, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Other Non deductible expenses Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount Noncontrolling interests in partnerships Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount Changes in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Tax Cuts and Jobs Act Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Gain on change in control Effective Income Tax Rate Reconciliation, Gain on Change in Control, Amount Effective Income Tax Rate Reconciliation, Gain on Change in Control, Amount Deferred true-ups and other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Other reconciling items Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount Income tax expense Income Tax Expense (Benefit) Federal tax, percent Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent State franchise tax, net of federal benefit, percent Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Other Non deductible expenses, percent Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent Noncontrolling interests in partnerships, percent Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent Changes in valuation allowance, percent Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Tax Cuts and Jobs Act, percent Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Gain on change in control, percent Effective Income Tax Rate Reconciliation, Gain on Change in Control, Percent Effective Income Tax Rate Reconciliation, Gain on Change in Control, Percent Deferred true-ups and other, percent Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Other reconciling items, percent Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent Income tax expense (benefit), percent Income tax expense (benefit) Income tax expense (benefit) Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 Fair Value, Inputs, Level 3 [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Interest Rate Cap Interest Rate Cap [Member] Interest Rate Swap Interest Rate Swap [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] 2016 CAPS - Interest Rate Contracts Accrued Liabilities, Fair Value Disclosure 2016 CAPS - Interest Rate Contracts Financial and Nonfinancial Liabilities, Fair Value Disclosure First Lien Term Loans Debt Instrument, Fair Value Disclosure Maturities of Notes Payables [Abstract] Maturities of Long-term Debt and Capital Lease Obligations [Abstract] 2020 Long-term Debt and Capital Lease Obligations, Repayments of Principal in Next Twelve Months 2021 Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Two 2022 Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Three 2023 Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Four Total notes payable obligations Long-term Debt and Lease Obligation Net income attributable to RadNet, Inc. common stockholders Net Income (Loss) Attributable to Parent BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS Earnings Per Share, Basic [Abstract] Weighted average number of common shares outstanding during the period (in shares) Weighted Average Number of Shares Outstanding, Basic Basic net income per share attributable to RadNet, inc. common stockholders (in dollars per share) Earnings Per Share, Basic DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS Earnings Per Share, Diluted [Abstract] Add nonvested restricted stock subject only to service vesting (in shares) Weighted Average Number of Shares, Restricted Stock Add additional shares issuable upon exercise of stock options and warrants (in shares) Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Weighted average number of common shares used in calculating diluted net income per share (in shares) Weighted Average Number of Shares Outstanding, Diluted Diluted net income per share attributable to RadNet, Inc. common stockholders (in dollars per share) Earnings Per Share, Diluted Stock options excluded from the computation of diluted per share amounts: Earnings Per Share, Diluted, Other Disclosures [Abstract] Weighted average shares for which the exercise price exceeds average market price of common stock (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Line of Credit Facility [Table] Line of Credit Facility [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Line of Credit Line of Credit [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Eurodollar Eurodollar [Member] Base Rate Base Rate [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] First Lien Credit Agreement First Lien Credit Agreement [Member] Leverage Ratio [Axis] Leverage Ratio [Axis] Leverage Ratio [Axis] Leverage Ratio [Domain] Leverage Ratio [Domain] [Domain] for Leverage Ratio [Axis] 5.50x Leverage Ratio One [Member] Leverage Ratio One [Member] 4.00x but ≤ 5.50x Leverage Ratio Two [Member] Leverage Ratio Two [Member] 3.50x but ≤ 4.00x Leverage Ratio Three [Member] Leverage Ratio Three [Member] ≤ 3.50x Leverage Ratio Four [Member] Leverage Ratio Four [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Schedule of options activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Schedule of RSA activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Quarterly Financial Information Disclosure [Abstract] Schedule of quarterly financial information Quarterly Financial Information [Table Text Block] STOCK-BASED COMPENSATION Share-based Payment Arrangement [Text Block] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Construction in Progress Construction in Progress [Member] Medical Equipment Medical Equipment [Member] Medical Equipment [Member] Computer and Office Equipment Computer and Office Equipment [Member] Computer and Office Equipment [Member] Leasehold improvements Leasehold Improvements [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property and equipment, gross Property, Plant and Equipment, Gross Construction in progress, gross Construction in Progress, Gross Depreciation and amortization expense Depreciation, Depletion and Amortization, Nonproduction Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Raven Holdings Raven Holdings [Member] Raven Holdings [Member] Tax Period [Axis] Tax Period [Axis] Tax Period [Domain] Tax Period [Domain] Tax Year 2018 Tax Year 2018 [Member] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Domestic Tax Authority Domestic Tax Authority [Member] State and Local Jurisdiction State and Local Jurisdiction [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Tax cuts and jobs act, change in tax rate, income tax expense (benefit) Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit) Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit) Net operating loss carryforward Operating Loss Carryforwards Operating loss carryforwards, subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Operating loss ending expiration date Operating Loss Carryforwards, Expiration Date Deferred tax assets, tax benefit may not be realized Deferred Tax Assets, Tax Benefit May Not Be Realized Deferred Tax Assets, Tax Benefit May Not Be Realized Deferred tax liabilities goodwill Deferred Tax Liabilities, Goodwill Unrecognized tax benefits Unrecognized Tax Benefits Unrecognized tax benefits, tax impact if recognized Unrecognized Tax Benefits, Tax Impact If Recognized Unrecognized Tax Benefits, Tax Impact If Recognized Unrecognized tax benefits, income tax penalties and interest accrued during period Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued During Period Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued During Period Unrecognized tax benefits, income tax penalties and interest accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Leases [Abstract] Operating lease cost Operating Lease, Cost Depreciation of leased equipment Finance Lease, Right-of-Use Asset, Amortization Interest on lease liabilities Finance Lease, Interest Expense Total finance lease cost Finance Lease Cost Finance Lease Cost Cover page. Document Type Document Type Document Annual Report Document Annual Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity a Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity a Voluntary Filer Entity Voluntary Filers Entity's Reporting Status Current Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Public Float Entity Public Float Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] PROPERTY AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Health Care, Patient Service Health Care, Patient Service [Member] Commercial insurance Commercial Insurance1 [Member] Commercial Insurance1 [Member] Medicare Medicare1 [Member] Medicare1 [Member] Medicaid Medicaid1 [Member] Medicaid1 [Member] Workers' compensation/personal injury Workers' Compensation/Personal Injury1 [Member] Workers' Compensation/Personal Injury1 [Member] Other patient revenue Health Care, Patient Service Other [Member] Health Care, Patient Service Other [Member] Management fee revenue Health Care, Management Service [Member] Health Care, Management Service [Member] Imaging on call and software Imaging On Call [Member] Imaging On Call [Member] Other Health Care, Other [Member] Net service fee revenue Patient Services, Net [Member] Patient Services, Net [Member] Revenue under capitation arrangements Capitation Arrangements [Member] Capitation Arrangements [Member] Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Service fee revenue, net of contractual allowances and discounts Revenue from Contract with Customer, Excluding Assessed Tax Provision for bad debts Health Care Organization, Patient Service Revenue Provision for Bad Debts Total revenue Revenues Finance Lease Assets And Liabilities Lessee [Abstract] Finance Lease Assets And Liabilities Lessee [Abstract] Finance Lease Assets And Liabilities Lessee [Abstract] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Current portion of operating lease liability Operating Lease, Liability, Current Operating lease liabilities Operating Lease, Liability, Noncurrent Total operating lease liabilities Operating Lease, Liability Operating Lease Assets And Liabilities Lessee [Abstract] Operating Lease Assets And Liabilities Lessee [Abstract] Operating Lease Assets And Liabilities Lessee [Abstract] Equipment at cost Finance Lease Right Of Use Asset Gross Finance Lease Right Of Use Asset Gross Accumulated depreciation Finance Lease Right Of Use Asset Accumulated Depreciation Finance Lease Right Of Use Asset Accumulated Depreciation Equipment, net Finance Lease, Right-of-Use Asset Current portion of finance lease Finance Lease, Liability, Current Finance lease liabilities Finance Lease, Liability, Noncurrent Total finance lease liabilities Finance Lease, Liability Weighted Average Remaining Lease Term [Abstract] Weighted Average Remaining Lease Term [Abstract] Weighted Average Remaining Lease Term [Abstract] Operating leases - years Operating Lease, Weighted Average Remaining Lease Term Finance leases - years Finance Lease, Weighted Average Remaining Lease Term Leases Weighted Average Discount Rate [Abstract] Leases Weighted Average Discount Rate [Abstract] Leases Weighted Average Discount Rate [Abstract] Operating leases Operating Lease, Weighted Average Discount Rate, Percent Finance leases Finance Lease, Weighted Average Discount Rate, Percent Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Amortization of operating lease right-of-use assets Operating Lease Right of Use Asset Amortization Operating Lease Right of Use Asset Amortization Provision for bad debts Accounts Receivable, Credit Loss Expense (Reversal) Equity in earnings of joint ventures, net of dividends Income (Loss) from Equity Method Investments, Net of Dividends or Distributions Amortization and write off of deferred financing costs and loan discount Amortization of Debt Issuance Costs Loss (gain) on sale and disposal of equipment and other Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Gain on sale of imaging centers Gain (Loss) on Disposition of Assets Gain on re-measurement of pre-existing interest Gain (Loss) on Step Up Valuation Gain (Loss) on Step Up Valuation Loss on impairment Goodwill and Intangible Asset Impairment Stock-based compensation Share-based Payment Arrangement, Noncash Expense Other non cash item in other expenses Increase Decrease In Other Noncash Item Increase Decrease In Other Noncash Item Non cash severance Non cash severance Non cash severance. Change in value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions: Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Other current assets Increase (Decrease) in Other Current Assets Other assets Increase (Decrease) in Other Operating Assets Deferred taxes Increase (Decrease) in Deferred Income Taxes Operating lease liability Increase Decrease in Operating Lease Liability Increase Decrease in Operating Lease Liability Deferred rent Deferred rent The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting rent yet to be earned for which cash or other forms of consideration was received or recorded as a receivable. Deferred revenue Increase (Decrease) in Deferred Revenue Accounts payable, accrued expenses and other Increase (Decrease) in Accounts Payable and Accrued Liabilities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Purchase of imaging facilities Payments to Acquire Productive Assets Investment at cost Payments to Acquire Investments Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Proceeds from sale of equipment Proceeds from Sale of Property, Plant, and Equipment Proceeds from the sale of equity interests in a joint venture Proceeds from Divestiture of Interest in Joint Venture Proceeds from sale of imaging and medical practice assets Proceeds from Sale of Machinery and Equipment Proceeds from sale of internal use software Proceeds from Sale of Intangible Assets Nulogix return of capital Proceeds from Equity Method Investment, Distribution, Return of Capital Cash contribution from partner in JV formation Proceeds from Contributions from Affiliates Equity contributions in existing and purchase of interest in joint ventures Payments to Acquire Interest in Joint Venture Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Principal payments on notes and leases payable Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security Payments on term loan debt Repayments of Debt Proceeds from debt issuance, net of issuance costs Proceeds from Short-term Debt Distributions paid to noncontrolling interests Payments to Noncontrolling Interests Proceeds from sale of noncontrolling interest Proceeds from Sales of Business, Affiliate and Productive Assets Contributions from noncontrolling partners Proceeds from Contributed Capital Proceeds from revolving credit facility Proceeds from Lines of Credit Payments on revolving credit facility Repayments of Lines of Credit Purchase of noncontrolling interests Payments to Acquire Additional Interest in Subsidiaries Proceeds from issuance of common stock upon exercise of options Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities EFFECT OF EXCHANGE RATE CHANGES ON CASH Effect of Exchange Rate on Cash and Cash Equivalents NET INCREASE (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) CASH AND CASH EQUIVALENTS, beginning of period Cash and Cash Equivalents, at Carrying Value CASH AND CASH EQUIVALENTS, end of period SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Supplemental Cash Flow Information [Abstract] Cash paid during the period for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid during the period for income taxes Income Taxes Paid, Net Statement [Table] Statement [Table] Variable Interest Entities [Axis] Variable Interest Entities [Axis] Variable Interest Entity, Classification [Domain] Variable Interest Entity, Classification [Domain] Variable Interest Entity, Not Primary Beneficiary Variable Interest Entity, Not Primary Beneficiary [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Noncontrolling Interest Noncontrolling Interest [Member] Radnet, Inc. Stockholders' Equity Total Radnet, Inc.'s Equity [Member] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] Ventura County Imaging Group, LLC Ventura County Imaging Group, LLC [Member] Ventura County Imaging Group, LLC [Member] Medical Arts Radiology Medical Arts Radiology [Member] Medical Arts Radiology [Member] Statement [Line Items] Statement [Line Items] Equipment acquired and leasehold improvements Equipment acquired and leasehold improvements Capital lease debt Capital lease debt Fixed assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Shares issues (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Equity interest issued, value assigned Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Consideration transferred Business Combination, Consideration Transferred Equity interest percentage Equity Method Investment, Ownership Percentage Gain (loss) on equity method investment Equity Method Investment, Realized Gain (Loss) on Disposal Payments to acquire equity method investments Payments to Acquire Equity Method Investments Adjustment of New Jersey Imaging Network investment balance Business Combination, Step Acquisition, Adjustment Of Investment Balance Business Combination, Step Acquisition, Adjustment Of Investment Balance Disposition of equity method interest upon acquisition of control in NJIN Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain Step acquisition, cash acquired Business Combination, Step Acquisition, Cash Acquired Business Combination, Step Acquisition, Cash Acquired Consideration transfered Payments to Acquire Businesses, Gross Assumption of debt as consideration Business Combination, Consideration Transferred, Liabilities Incurred Common stock issued as consideration Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Contingent consideration liability Business Combination, Liabilities Arising from Contingencies, Amount Recognized Contingent consideration liability adjustment Business consideration liability adjustment recorded amount Business Combination, Liabilities Arising from Contingencies, Amount Recognized, Other than at Fair Value Special distribution from noncontrolling interest Noncontrolling Interest, Special Distribution Noncontrolling Interest, Special Distribution Capital lease assumed Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation Assets transferred to Santa Monica Imaging Group LLC Assets transferred to Santa Monica Imaging Group LLC Assets transferred to Advanced Imaging at Timonium Crossing, LLC Assets transferred to Advanced Imaging at Timonium Crossing, LLC Acquisition of Diagnostic Imaging Associates, cash Acquisition of Diagnostic Imaging Associates, cash Acquisition of Diagnostic Imaging Associates, for RadNet common stock Acquisition of Diagnostic Imaging Associates, for RadNet common stock Acquisition of RadSite, LLC, for common stock Acquisition of RadSite, LLC, for common stock Acquisition of RadSite, LLC, cash Acquisition of RadSite, LLC, cash Schedule of goodwill and other intangible assets Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of annual amortization expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Federal current tax Current Federal Tax Expense (Benefit) State current tax State and Local Income Tax Expense (Benefit), Continuing Operations Other current tax Other Tax Expense (Benefit) Federal deferred tax Deferred Federal Income Tax Expense (Benefit) State deferred tax Deferred State and Local Income Tax Expense (Benefit) Deferred tax assets: Components of Deferred Tax Assets [Abstract] Net operating losses Deferred Tax Assets, Operating Loss Carryforwards Accrued expenses Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Operating lease liability Deferred Tax Assets, Operating Lease Liabilities Deferred Tax Assets, Operating Lease Liabilities Straight-Line rent adjustment Deferred Tax Assets, Tax Deferred Expense, Straight-Line rent adjustment Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals. Unfavorable contract liability Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities Equity compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits Allowance for doubtful accounts Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts Other Deferred Tax Assets, Other Valuation allowance Deferred Tax Assets, Valuation Allowance Total Deferred Tax Assets Deferred Tax Assets, Gross Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Property and equipment Deferred Tax Liabilities, Property, Plant and Equipment Goodwill Intangibles Deferred Tax Liabilities, Goodwill and Intangible Assets Operating lease right-of-use asset Deferred Tax Liabilities, Operating Right-Of-Use Assets Deferred Tax Liabilities, Operating Right-Of-Use Assets Non accrual experience method reserve Deferred Tax Liabilities, Deferred Expense, Other Capitalized Costs Other Deferred Tax Liabilities, Other Total Deferred Tax Liabilities Deferred Tax Liabilities, Net Net Deferred Tax Asset Deferred Tax Assets, Net Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Unrecognized tax benefit, Balance at beginning of year Decrease related to prior year tax positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Increases related to prior year tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Increases related to current year tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Expiration of the statute of limitations for the assessment of taxes Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Increase (decrease) related to change in rate Unrecognized Tax Benefits, Increase (Decrease) Change in Enacted Tax Rate Unrecognized Tax Benefits, Increase (Decrease) Change in Enacted Tax Rate Unrecognized tax benefit, Balance at end of year Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Offsetting Assets [Table] Offsetting Assets [Table] Offsetting Assets [Line Items] Offsetting Assets [Line Items] Change in fair value of cash flow hedge, net of taxes Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Change in fair value of cash flow hedge, net of taxes Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Goodwill deductible for tax purposes Goodwill deductible for tax purposes Goodwill deductible for tax purposes Amortization expense Amortization Amortization period Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Property Subject to or Available for Operating Lease [Axis] Property Subject to or Available for Operating Lease [Axis] Property Subject to or Available for Operating Lease [Domain] Property Subject to or Available for Operating Lease [Domain] Facilities Facilities [Member] Equipment Equipment [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Lessee, Operating Lease, Liability, Payment, Due [Abstract] Lessee, Operating Lease, Liability, Payment, Due [Abstract] 2020 Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three 2023 Lessee, Operating Lease, Liability, Payments, Due Year Four 2024 Lessee, Operating Lease, Liability, Payments, Due Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total Lease Payments Lessee, Operating Lease, Liability, Payments, Due Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total Finance Lease, Liability, Payment, Due [Abstract] Finance Lease, Liability, Payment, Due [Abstract] 2020 Finance Lease, Liability, Payments, Due Next Twelve Months 2021 Finance Lease, Liability, Payments, Due Year Two 2022 Finance Lease, Liability, Payments, Due Year Three 2023 Finance Lease, Liability, Payments, Due Year Four 2024 Finance Lease, Liability, Payments, Due Year Five Thereafter Finance Lease, Liability, Payments, Due after Year Five Total Lease Payments Finance Lease, Liability, Payment, Due Less imputed interest Finance Lease, Liability, Undiscounted Excess Amount Total 2019 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2020 Operating Leases, Future Minimum Payments, Due in Two Years 2021 Operating Leases, Future Minimum Payments, Due in Three Years 2022 Operating Leases, Future Minimum Payments, Due in Four Years 2023 Operating Leases, Future Minimum Payments, Due in Five Years Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Total operating lease payments Operating Leases, Future Minimum Payments Due Organization, Consolidation and Presentation of Financial Statements [Abstract] Number of centers Number Of Centers Number Of Centers Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Beverly Radiology Medical Group III Beverly Radiology Medical Group III [Member] Beverly Radiology Medical Group III [Member] ScriptSender LLC ScriptSender LLC [Member] Title of Individual [Axis] Title of Individual [Axis] Title of Individual [Domain] Title of Individual [Domain] Chief Executive Officer Chief Executive Officer [Member] Board Member Board Member [Member] Board Member [Member] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] BRMG and NY Groups revenues Variable Interest Entity, Measure of Activity, Revenues BRMG and NY Groups operating expenses Variable Interest Entity, Measure of Activity, Expense Management services provided to BRMG and NY Groups Variable Interest Entity, Measure of Activity, Income or Loss before Tax BRMG and NY Groups accounts receivable Variable Interest Entity, Consolidated, Carrying Amount, Assets BRMG and NY Groups accounts payable Variable Interest Entity, Consolidated, Carrying Amount, Liabilities Balance Sheet Data: Key financial data for joint ventures Key financial data for joint ventures Current assets Equity Method Investment, Summarized Financial Information, Current Assets Noncurrent assets Equity Method Investment, Summarized Financial Information, Assets Current liabilities Equity Method Investment, Summarized Financial Information, Current Liabilities Noncurrent liabilities Equity Method Investment, Summarized Financial Information, Liabilities Total net assets Equity Method Investment, Aggregate Cost Book value of RadNet joint venture interests Equity Method Investments Cost in excess of book value of acquired joint venture interests accounted for as equity method goodwill Equity Method Investment, Underlying Equity in Net Assets Total value of RadNet joint venture interests Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Total book value of other joint venture partner interests Total book value of other joint venture partner interests Total book value of other joint venture partner interests Net revenue Net revenue Net revenue from joint ventures Net Income From Joint Ventures Net Income From Joint Ventures Net Income From Joint Ventures SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Accounts Receivable-Allowance for Bad Debts SEC Schedule, 12-09, Allowance, Notes Receivable [Member] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Balance at Beginning of Year SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Additional Charges Against Income SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Deductions from Reserve SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Balance at End of Year Cash paid for amounts included in the measurement of lease liabilities: Cash Flow Lessee [Abstract] Cash Flow Lessee [Abstract] Operating cash flows from operating leases Operating Lease, Payments Operating cash flows from financing leases Finance Lease, Interest Payment on Liability Financing cash flows from financing leases Finance Lease, Principal Payments Right-of-use & Equipment assets obtained in exchange for lease obligations: Right Of Use Asset Obtained In Exchange For Lease Liability [Abstract] Right Of Use Asset Obtained In Exchange For Lease Liability [Abstract] Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Financing leases Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Schedule of Long Lived Assets Held-for-sale [Table] Schedule of Long Lived Assets Held-for-sale [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Property and equipment, net Propery and equipment, net [Member] Goodwill Goodwill [Member] Long Lived Assets Held-for-sale [Line Items] Long Lived Assets Held-for-sale [Line Items] Total assets held for sale Assets Held-for-sale, Not Part of Disposal Group Lease, cost Lease, Cost [Table Text Block] Assets and liabilities lessee Assets And Liabilities Lessee [Table Text Block] [Table Text Block] for Assets And Liabilities Lessee [Table] Maturities of finance lease liability Finance Lease, Liability, Maturity [Table Text Block] Maturities of operating lease liability Lessee, Operating Lease, Liability, Maturity [Table Text Block] Land Land [Member] Medical equipment Computer and office equipment, furniture and fixtures Furniture and Fixtures [Member] Software development costs Software Development [Member] Equipment under financing/capital lease Assets Held under Capital Leases [Member] Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Total property and equipment Property, Plant and Equipment, Net Restricted Stock Restricted Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] RSA's outstanding, beginning balance Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number RSA's granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period RSA's vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period RSA's forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period RSA's outstanding, ending balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted-average fair value, beginning balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted-average fair value, granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average fair value, vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted-average fair value, ending balance Weighted-Average Remaining Contractual Term (Years) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Schedule of revolving credit facility, notes payable, and capital lease obligations Schedule of Debt [Table Text Block] Schedule of annual principal maturities of notes payable Schedule of Maturities of Long-term Debt [Table Text Block] Schedule of term loans and financing activity Schedule of Long-term Debt Instruments [Table Text Block] Schedule of leverage ratio Schedule Of Leverage Ratio [Table Text Block] Schedule Of Leverage Ratio [Table Text Block] PRINCIPLES OF CONSOLIDATION Consolidation, Policy [Policy Text Block] USE OF ESTIMATES Use of Estimates, Policy [Policy Text Block] RECLASSIFICATION Reclassification, Policy [Policy Text Block] REVENUES Revenue [Policy Text Block] ACCOUNTS RECEIVABLE Receivable [Policy Text Block] MEANINGFUL USE INCENTIVE Internal Use Software, Policy [Policy Text Block] SOFTWARE REVENUE RECOGNITION Revenue from Contract with Customer [Policy Text Block] SOFTWARE DEVELOPMENT COSTS Research, Development, and Computer Software, Policy [Policy Text Block] CONCENTRATION OF CREDIT RISKS Concentration Risk, Credit Risk, Policy [Policy Text Block] CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Policy [Policy Text Block] DEFERRED FINANCING COSTS Deferred Charges, Policy [Policy Text Block] INVENTORIES Inventory, Policy [Policy Text Block] PROPERTY AND EQUIPMENT Property, Plant and Equipment, Policy [Policy Text Block] BUSINESS COMBINATION Business Combinations Policy [Policy Text Block] GOODWILL AND INDEFINITE LIVED INTANGIBLES Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block] LONG-LIVED ASSETS Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] INCOME TAXES Income Tax, Policy [Policy Text Block] LEASES Lessee, Leases [Policy Text Block] UNINSURED RISKS Uninsured Risks [Policy Text Block] Uninsured Risks [Policy Text Block] EMPLOYEE BENEFIT PLAN Postemployment Benefit Plans, Policy [Policy Text Block] LOSS AND OTHER UNFAVORABLE CONTRACTS Loss and Other Unfavorable Contracts [Policy Text Block] Loss and Other Unfavorable Contracts [Policy Text Block] EQUITY BASED COMPENSATION Compensation Related Costs, Policy [Policy Text Block] FOREIGN CURRENCY TRANSLATION Foreign Currency Transactions and Translations Policy [Policy Text Block] COMPREHENSIVE (LOSS) INCOME Comprehensive Income, Policy [Policy Text Block] CONTINGENCIES Commitments and Contingencies, Policy [Policy Text Block] DERIVATIVE INSTRUMENTS Derivatives, Policy [Policy Text Block] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] EARNINGS PER SHARE Earnings Per Share, Policy [Policy Text Block] INVESTMENT IN JOINT VENTURES Equity Method Investments [Policy Text Block] Accounts payable Accounts Payable, Current Accrued expenses Accrued Liabilities, Current Accrued salary and benefits Employee-related Liabilities, Current Accrued professional fees Accrued Professional Fees, Current Total Accounts Payable and Accrued Liabilities, Current Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] WhiteRabbit.ai Inc. WhiteRabbit.ai Inc. [Member] WhiteRabbit.ai Inc. [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Equity investment loan to company outstanding Payments to Fund Long-term Loans to Related Parties Statement of Stockholders' Equity [Abstract] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Accumulated Deficit Retained Earnings [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance (in shares) Shares, Outstanding Beginning balance, value Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Issuance of stock upon exercise of options (in shares) Issuance of stock upon exercise of options Share-Based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Gross, Value Share-Based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Gross, Value Stock-based compensation (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Stock-based compensation APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition Forfeiture of restricted stock (in shares) Shares Issued, Shares, Share-based Payment Arrangement, Forfeited Forfeiture of restricted stock Shares Issued, Value, Share-based Payment Arrangement, Forfeited Non-cash severance (in shares) Non Cash Severance Shares Non Cash Severance Shares Purchase of noncontrolling interests Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Issuance of stock for acquisitions (in shares) Stock Issued During Period, Shares, Acquisitions Issuance of stock for acquisitions Stock Issued During Period, Value, Acquisitions Sale to noncontrolling interests, net of taxes Noncontrolling Interest, Increase from Sale of Parent Equity Interest Special distribution from noncontrolling interest Noncontrolling Interest, Decrease From Special Distribution Noncontrolling Interest, Decrease From Special Distribution Contributions from noncontrolling interests Contributions from noncontrolling interests Distributions paid to noncontrolling interests Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Re-measurement of noncontrolling interest upon change in control Increase In Noncontrolling Interest Due To Step Acquisition Increase In Noncontrolling Interest Due To Step Acquisition Change in cumulative foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent Change in fair value of cash flow hedge, net of taxes Ending balance, value Ending balance (in shares) Schedule of assets held for sale Disclosure of Long Lived Assets Held-for-sale [Table Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Term Loan Term Loan [Member] Notes Payable, Other Payables Notes Payable, Other Payables [Member] Capital Lease Obligations Capital Lease Obligations [Member] First Lien Term Loans First Lien Term Loan [Member] Term Loan Agreement collateralized by NJIN's tangible and intangible assets Restated Agreement [Member] Restated Agreement [Member] Short-term Debt, Type [Axis] Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Short-term Debt, Type [Domain] Promissory note Commercial Paper [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Long-term Debt Discount on First Lien Term Loans Debt Instrument, Unamortized Discount Promissory note payable to the former owner of a practice acquired at an interest rate of 1.5% due through 2019 Short-term Debt Equipment notes payable at interest rates ranging from 4.4% to 5.6%, due through 2020, collateralized by medical equipment Loans Payable, Noncurrent Obligations under capital leases at interest rates ranging from 3.7% to 9.3%, due through 2022, collateralized by medical and office equipment (1) Capital Lease Obligations Total debt obligations Long-term Debt, Short-term Debt and Capital Lease Obligations, Including Current Maturities Long-term Debt, Short-term Debt and Capital Lease Obligations, Including Current Maturities Less current portion Long-term Debt, Short-term Debt and Capital Lease Obligations, Current Maturities Long-term Debt, Short-term Debt and Capital Lease Obligations, Current Maturities Long-term portion debt obligations Long-term Debt, Short-term Debt and Capital Lease Obligations, Excluding Current Maturities Long-term Debt, Short-term Debt and Capital Lease Obligations, Excluding Current Maturities Debt instrument, interest rate Debt Instrument, Interest Rate, Stated Percentage Debt instrument, maturity date Debt Instrument, Maturity Date Beginning balance Equity contributions in existing and purchase of interest in joint ventures Equity contributions in existing and purchase of interest in joint ventures Equity contributions in existing joint ventures Equity in earnings in these joint ventures Income (Loss) from Equity Method Investments Sale of ownership interest Dissolution of GSRN Gain (Loss) on Disposition of Stock in Subsidiary or Equity Method Investee Nulogix return of capital Equity interest acquiree remeasurement loss Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss Distribution of earnings Proceeds from Equity Method Investment, Distribution Ending balance Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Management Service Contracts Management Service Contracts [Member] Covenant not to compete and other contracts Covenant Not To Compete [Member] Developed Technology Developed technology [Member] Developed technology [Member] Trade Names amortized Trade Names Amortized [Member] Trade Names Amortized [Member] Trade Names indefinite life Trade Names Indefinite Life [Member] Trade Names Indefinite Life [Member] Software in development Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Amortization year 2020 Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months Amortization year 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Two Amortization year 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Three Amortization year 2023 Finite-Lived Intangible Assets, Amortization Expense, Year Four Amortization year 2024 Finite-Lived Intangible Assets, Amortization Expense, Year Five Amortization year thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five Amortiztion total Finite-Lived Intangible Assets, Net Weighted average amortization period remaining in years Weighted average amortization period remaining in years Weighted average amortization period remaining in years SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTSRADNET, INC. AND SUBSIDIARIES SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] ASSETS Assets [Abstract] CURRENT ASSETS Assets, Current [Abstract] Cash and cash equivalents Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Due from affiliates Due from Related Parties, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Assets held for sale Total current assets Assets, Current PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS Property, Plant and Equipment, Net, Including and Excluding Capital Leased Asset [Abstract] Property and equipment, net Operating lease right-of-use-assets Total property, equipment and right-of-use-assets Property Plant and Equipment Net Including Right of Use Assets Property Plant and Equipment Net Including Right of Use Assets OTHER ASSETS Other Assets [Abstract] Goodwill Other intangible assets Intangible Assets, Net (Excluding Goodwill) Deferred financing costs Debt Issuance Costs, Noncurrent, Net Investment in joint ventures Deferred tax assets Deferred Tax Assets, Gross, Noncurrent Deposits and other Deposits Assets Total assets Assets LIABILITIES AND EQUITY Liabilities and Equity [Abstract] CURRENT LIABILITIES Liabilities, Current [Abstract] Accounts payable, accrued expenses and other Due to affiliates Due to Affiliate, Current Deferred revenue related to software sales Deferred Revenue Current portion of deferred rent Deferred Rent Credit, Current Current portion of finance lease liability Current portion of operating lease liability Current portion of notes payable Notes Payable, Current Current portion of obligations under capital leases Capital Lease Obligations, Current Total current liabilities Liabilities, Current LONG-TERM LIABILITIES Liabilities, Noncurrent [Abstract] Deferred rent, net of current portion Deferred Rent Credit, Noncurrent Long-term finance lease liability Long-term operating lease liability Notes payable, net of current portion Notes Payable, Noncurrent Obligations under capital lease, net of current portion Capital Lease Obligations, Noncurrent Other non-current liabilities Other Liabilities, Noncurrent Total liabilities Liabilities EQUITY Stockholders' Equity Attributable to Parent [Abstract] Common stock - $.0001 par value, 200,000,000 shares authorized; 50,314,328 and 48,977,485 shares issued and outstanding at December 31, 2019 and 2018 respectively Common Stock, Value, Issued Additional paid-in-capital Additional Paid in Capital Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Retained Earnings (Accumulated Deficit) Total RadNet, Inc.'s stockholders' equity Stockholders' Equity Attributable to Parent Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Total equity Total liabilities and equity Liabilities and Equity Schedule of components of income tax expense Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of reconciliation of income tax expense Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of deferred tax assets and liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of unrecognized tax benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Restated Agreement Face Value Debt Instrument, Face Amount Discount Debt Instrument, Unamortized Discount (Premium), Net Total Carrying Value Long-term Debt, Gross QUARTERLY RESULTS OF OPERATIONS (unaudited) Quarterly Financial Information [Text Block] Net revenue Total operating expenses Operating Expenses Total other expenses Total other expenses Total other expenses Equity in earnings of joint ventures Benefit from (provision for) income taxes Net (loss) income Net income (loss) attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Net (loss) income attributable to Radnet, Inc. common stockholders Basic net (loss) income attributable to Radnet, Inc. common stockholders (loss) earnings per share (in dollars per share) Diluted net (loss) income attributable to Radnet, Inc. common stockholders (loss) earnings per share (in dollars per share) Weighted average shares outstanding, basic (in shares) Weighted average shares outstanding, diluted (in shares) Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Restated Plan Restated Plan [Member] Future Service Future Service [Member] Future Services [Member] Shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Share-based payment award, award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Share-based payment award, expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Options outstanding Exercisable shares Unrecognized stock-based compensation expense Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Unrecognized expense weighted average period Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Awards issued to date Awards issued to date Awards issued to date RSA's unvested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Options granted Compensation expense Share-based Payment Arrangement, Expense Options cancelled Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period RSA's forfeited Shares available for future issuance, options, warrants, shares of restricted stock and other bonus awards Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance Securities Financing Transaction [Axis] Securities Financing Transaction [Axis] Securities Financing Transaction [Domain] Securities Financing Transaction [Domain] 2016 Caps 2016 Caps [Member] 2019 SWAPS 2019 SWAPS [Member] 2019 SWAPS [Member] 2019 SWAPS1 2019 SWAPS1 [Member] 2019 SWAPS1 [Member] Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] Settled Litigation Settled Litigation [Member] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] US Attorneys Office For The Western District of New York US Attorneys Office For The Western District of New York [Member] US Attorneys Office For The Western District of New York [Member] Net service fee revenue Investment Advisory, Management and Administrative Service Investment Advisory, Management and Administrative Service [Member] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] eRAD eRAD [Member] Imaging On Call Software developed for internal use Developed Technology Rights [Member] Barclays Barclays [Member] Barclays [Member] SunTrust SunTrust [Member] SunTrust [Member] Reinsurance Policy, Type [Axis] Reinsurance Policy, Type [Axis] Reinsurance Policy [Domain] Reinsurance Policy [Domain] Health Insurance Health Insurance [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Blue Shield Blue Shield [Member] Blue Shield [Member] Radiologix Radiologix [Member] Credit Derivatives Contract Type [Axis] Credit Derivatives Contract Type [Axis] Credit Derivatives Contract Type [Domain] Credit Derivatives Contract Type [Domain] September 2020 September 2020 [Member] October 2020 October 2020 [Member] October 2023 October 2023 [Member] October 2023 [Member] October 2025 October 2025 [Member] October 2025 [Member] LIBOR London Interbank Offered Rate (LIBOR) [Member] Medic Vision Medic Vision [Member] Turner Imaging Systems Turner Imaging Systems [Member] Turner Imaging Systems [Member] Turner Imaging Turner Imaging [Member] Santa Monica Imaging Group Santa Monica Imaging Group [Member] Primedex Health Systems Inc. and Radiologix Primedex Health Systems Inc. and Radiologix [Member] Primedex Health Systems Inc. and Radiologix [Member] Glendale Advanced Imaging Glendale Advanced Imaging [Member] RadNet RadNet [Member] RadNet [Member] Cedars Sinai Medical Center Cedars Sinai Medical Center [Member] Cedars Sinai Medical Center [Member] Business Combination, Separately Recognized Transactions [Axis] Business Combination, Separately Recognized Transactions [Axis] Business Combination, Separately Recognized Transactions [Domain] Business Combination, Separately Recognized Transactions [Domain] Joint Venture Joint Venture [Member] Factored accounts receivable Contracts Receivable, Factored Amount Contracts Receivable, Factored Amount Factoring receivable Contracts Receivable, Factoring Receivable Contracts Receivable, Factoring Receivable Meaningful use incentive income Meaningful use incentive income Meaningful use incentive Deferred revenue liability Contract with Customer, Liability, Current Capitalized software costs, gross Capitalized Computer Software, Gross Deferred financing costs, net of accumulated amortization Debt Issuance Costs, Net PP&E useful life Property, Plant and Equipment, Useful Life Indefinite lived intangible assets Indefinite-lived Intangible Assets (Excluding Goodwill) Goodwill impairment Write off of the reporting unit trade name Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Workers' compensation liability, current Workers' Compensation Liability, Current Medical malpractice deductible per incidence Medical malpractice deductible per incidence Medical malpractice deductible per incidence Self-insurance accrual Self Insurance Reserve Stop loss policy claim amount Medical Insurance, Stop Loss Policy Claim Amount Medical Insurance, Stop Loss Policy Claim Amount Employer matching contribution, percent Defined Contribution Plan, Employer Matching Contribution, Percent of Match Employee contribution, percent Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Expected employee contribution Defined Contribution Plan, Cost Contract loss accrual Contract loss accrual Contract loss accrual Unfavorable lease contracts acquired, gross Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Unfavorable Lease Contracts, Gross Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Unfavorable Lease Contracts, Gross Unfavorable lease contracts acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Unfavorable Lease Contracts Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Unfavorable Lease Contracts Contract loss accrual, written off Contract Loss Accrual, Written Off Contract Loss Accrual, Written Off Unfavorable contract liability Off-market Lease, Unfavorable Loss contingency accrual liability Loss Contingency Accrual Litigation settlement Litigation Settlement, Amount Awarded from Other Party Notional amounts Derivative Asset, Notional Amount Basis spread on variable rate Derivative, Basis Spread on Variable Rate Interest rate caps premium liability Financial Guarantee Insurance Contracts, Unearned Premium Revenue Total credit facilities outstanding Long-term Line of Credit Investment at cost Option to purchase additional equity method investment Equity Method Investments, Option To Purchase Additional Equity Method Investment Equity Method Investments, Option To Purchase Additional Equity Method Investment Ownership interest percentage acquired Equity Method Investments, Ownership Interest Percentage Acquired Equity Method Investments, Ownership Interest Percentage Acquired Initial ownership percentage after dilution Equity Method Investment, Initial Ownership Percentage After Dilution Equity Method Investment, Initial Ownership Percentage After Dilution Total net assets Shares purchased Equity Method Investment, Shares Purchased Equity Method Investment, Shares Purchased Convertible promissory note Preferred stock issued upon conversion (in shares) Convertible Preferred Stock, Shares Issued upon Conversion Payments to fund loan to related parties Number of unconsolidated joint ventures Number of Unconsolidated Joint Ventures Number of Unconsolidated Joint Ventures Economic interest Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage Additional equity interest acquired Additional equity interest acquired Additional equity interest acquired Investment owned, at fair value Investment Owned, at Fair Value Loss on equity method investment Income Statement [Abstract] REVENUE Revenues [Abstract] Service fee revenue Health Care Organization, Patient Service Revenue Less Provision for Bad Debts OPERATING EXPENSES Operating Expenses [Abstract] Cost of operations, excluding depreciation and amortization Cost of Revenue Loss (gain) on sale and disposal of equipment and other Loss on impairment Severance costs Severance Costs Total operating expenses INCOME FROM OPERATIONS Operating Income (Loss) OTHER INCOME AND EXPENSES Other Expenses [Abstract] Interest expense Interest Expense, Debt Gain on re-measurement of pre-existing interest Gain on sale of imaging centers and medical practice Other expenses (income) Other Nonoperating Income (Expense) Total other expenses (income) Nonoperating Income (Expense) INCOME BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Provision for income taxes NET INCOME Net income attributable to noncontrolling interests NET INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS (in dollars per share) DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS (in dollars per share) Weighted average shares outstanding, diluted (in shares) Schedule of property and equipment Property, Plant and Equipment [Table Text Block] LEASES Lessee, Operating Leases [Text Block] LEASES Lessee, Finance Leases [Text Block] ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] DeepHealth, Inc. DeepHealth, Inc. [Member] DeepHealth, Inc. [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] RadNet stock issued in acquisition (shares) Pricing Level I Pricing Level I [Member] Pricing Level I [Member] Pricing Level II Pricing Level II [Member] Pricing Level II [Member] Pricing Level III Pricing Level III [Member] Pricing Level III [Member] Pricing Level IV Pricing Level IV [Member] Pricing Level IV [Member] Pricing Level V Pricing Level V [Member] Pricing Level V [Member] Leverage ratio, greater than Debt Instrument, Covenant, Liquidity Ratio Required, Minimum Debt Instrument, Covenant, Liquidity Ratio Required, Minimum Leverage ratio, less than Debt Instrument, Covenant, Leverage Ratio, Maximum Debt Instrument, Covenant, Leverage Ratio, Maximum Commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Unused capacity, commitment fee percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Medium-term Notes Medium-term Notes [Member] Amendment No. 7 First Lien Credit Agreement First Lien Credit Agreement Seventh Amendment [Member] First Lien Credit Agreement Seventh Amendment [Member] Letter of Credit Letter of Credit [Member] Lender Name [Axis] Lender Name [Axis] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Amendment No. 6 First Lien Credit Agreement First Lien Credit Agreement Sixth Amendment [Member] First Lien Credit Agreement Sixth Amendment [Member] Credit facilities available Line of Credit Facility, Maximum Borrowing Capacity Net of accumulated amortization Accumulated Amortization of Other Deferred Costs Total carrying value Debt, unamortized discount Letters of credit outstanding, amount Letters of Credit Outstanding, Amount Credit facility, borrowings available Line of Credit Facility, Remaining Borrowing Capacity Line of credit facility, increase borrowing capacity Line of Credit Facility, Increase Borrowing Capacity Line of Credit Facility, Increase Borrowing Capacity Issuance costs Debt Issuance Costs, Gross Debt instrument, unamortized discount, current Debt Instrument, Unamortized Discount, Current Amortization of deferred charges Amortization of Deferred Charges Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Periodic payment, principal Debt Instrument, Periodic Payment, Principal Face value Credit facilities, increase (decrease) Line of Credit Facility, Increase (Decrease), Net Debt periodic payment Debt Instrument, Periodic Payment Debt periodic payment, percent of total amount Debt Instrument, Periodic Payment, Percent Debt Instrument, Periodic Payment, Percent Debt periodic payment, amortization increase Debt Instrument, Periodic Payment Terms, Amortization Increase Debt Instrument, Periodic Payment Terms, Amortization Increase NATURE OF BUSINESS Business Description and Basis of Presentation [Text Block] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] Deferred rent Lessee Operating Lease Deferred Rent Lessee Operating Lease Deferred Rent Contract liabilities Lessee Operating Lease Lease Incentives Lessee Operating Lease Lease Incentives Finance lease, liability Equipment, net Operating lease, term of contract Lessee, Operating Lease, Term of Contract Operating lease, renewal term Lessee, Operating Lease, Renewal Term Lease term of contract Lessee Lease Term of Contract Lessee Lease Term of Contract Operating lease not yet commenced Lessee Operating Lease Lease Not Yet Commenced Undiscounted Amount Lessee Operating Lease Lease Not Yet Commenced Undiscounted Amount Operating lease, lease not yet commenced, term of contract Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Ownership [Axis] Ownership [Axis] Ownership [Domain] Ownership [Domain] Noncompete Agreements Noncompete Agreements [Member] Trade Names Trade Names [Member] Dignity Health. Dignity Health. [Member] Dignity Health. [Member] Jefferson Health Jefferson Health [Member] Jefferson Health [Member] Nulogix,Inc. Nulogix,Inc. [Member] Nulogix,Inc. [Member] Washington Heights Medical Management, LLC Washington Heights Medical Management, LLC [Member] Washington Heights Medical Management, LLC [Member] Women's Imaging Specialists in Healthcare Women's Imaging Specialists in Healthcare [Member] Women's Imaging Specialists in Healthcare [Member] Beach Imaging Group, LLC Beach Imaging Group, LLC [Member] Ventura County Imaging Group, LLC. Ventura County Imaging Group, LLC. [Member] Ventura County Imaging Group, LLC. [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Breastlink Medical Breastlink Medical [Member] Advanced Imaging at Timonium Advanced Imaging at Timonium [Member] Rhode Island Medical Imaging, Inc Rhode Island Medical Imaging, Inc [Member] Oncology practices Oncology practices [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Operating lease liabilities acquired Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating Lease Liabilities Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating Lease Liabilities Other assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Right-of-use assets acquired Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Right Of Use Asset Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Right Of Use Asset Goodwill acquired Intangible assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Current Finance lease liabilities acquired Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Finance Lease Liabilities Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Finance Lease Liabilities Value of RadNet stock issued in acquisition Equipment acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment Noncontrolling interest, ownership percentage Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Other current assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Net working capital acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Working Capital Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Working Capital Equipment debt assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment Debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment Debt Bank debt assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Bank Debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Bank Debt Fair value of investment Gain on step up valuation Cash acquired from acquisition Cash Acquired from Acquisition Contingent consideration to guarantee share value issued Business Combination, Contingent Consideration, Liability Payments to acquire business Business acquisition, percentage of voting interests acquired Business Acquisition, Percentage of Voting Interests Acquired Payments to acquire equity method investments, Assets Payments to Acquire Equity Method Investments Assets Contributed Payments to Acquire Equity Method Investments Assets Contributed Equity interest percentage in exchange for assets Equity Method Investment Ownership Percentage In Exchange for Assets Contributed Equity Method Investment Ownership Percentage In Exchange for Assets Contributed Payments to acquire equity method investments, cash Payments to Acquire Equity Method Investments Cash Payments to Acquire Equity Method Investments Cash Equity interest percentage in exchange for cash Equity Method Investment Ownership Percentage In Exchange for Cash Equity Method Investment Ownership Percentage In Exchange for Cash Proceeds from sale of business Transfer of fixed assets to new joint venture Transfer from Investments Proceeds in excess of book value Proceeds in excess of book value Proceeds in excess of book value Statement of Comprehensive Income [Abstract] NET INCOME Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax COMPREHENSIVE INCOME Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Less comprehensive income attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS Comprehensive Income (Loss), Net of Tax, Attributable to Parent SUBSEQUENT EVENTS Subsequent Events [Text Block] GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] EX-101.PRE 12 rdnt-20191231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 chart-c596de076de05269b73.jpg COMPARSION OF CUMULATIVE FIVE YEAR RETURN begin 644 chart-c596de076de05269b73.jpg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end XML 14 R2.htm IDEA: XBRL DOCUMENT v3.20.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
CURRENT ASSETS    
Cash and cash equivalents $ 40,165 $ 10,389
Accounts receivable 154,763 148,919
Due from affiliates 1,242 595
Prepaid expenses and other current assets 45,004 46,288
Assets held for sale 2,041 2,499
Total current assets 243,215 208,690
PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS    
Property and equipment, net 366,746 345,729
Operating lease right-of-use-assets 445,477  
Total property, equipment and right-of-use-assets 812,223 345,729
OTHER ASSETS    
Goodwill 440,981 418,093
Other intangible assets 42,994 40,593
Deferred financing costs 1,559 1,354
Investment in joint ventures 34,470 37,973
Deferred tax assets 34,548 31,506
Deposits and other 36,996 25,392
Total assets 1,646,986 1,109,330
CURRENT LIABILITIES    
Accounts payable, accrued expenses and other 207,585 181,028
Due to affiliates 14,347 13,089
Deferred revenue related to software sales 1,316 2,398
Current portion of deferred rent 0 3,735
Current portion of finance lease liability 3,283  
Current portion of operating lease liability 61,206  
Current portion of notes payable 39,691 33,653
Current portion of obligations under capital leases 0 5,614
Total current liabilities 327,428 239,517
LONG-TERM LIABILITIES    
Deferred rent, net of current portion 0 31,542
Long-term finance lease liability 3,264  
Long-term operating lease liability 420,922  
Notes payable, net of current portion 652,704 626,507
Obligations under capital lease, net of current portion 0 6,505
Other non-current liabilities 9,529 5,006
Total liabilities 1,413,847 909,077
EQUITY    
Common stock - $.0001 par value, 200,000,000 shares authorized; 50,314,328 and 48,977,485 shares issued and outstanding at December 31, 2019 and 2018 respectively 5 5
Additional paid-in-capital 262,865 242,835
Accumulated other comprehensive (loss) income (8,026) 2,259
Accumulated deficit (103,159) (117,915)
Total RadNet, Inc.'s stockholders' equity 151,685 127,184
Noncontrolling interests 81,454 73,069
Total equity 233,139 200,253
Total liabilities and equity $ 1,646,986 $ 1,109,330
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.20.1
CONSOLIDATED STATEMENT OF EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
Radnet, Inc. Stockholders' Equity
Noncontrolling Interest
Beginning balance (in shares) at Dec. 31, 2016   46,574,904          
Beginning balance, value at Dec. 31, 2016 $ 52,053 $ 4 $ 198,387 $ 306 $ (150,211) $ 48,486 $ 3,567
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation (in shares)   867,248          
Stock-based compensation 7,834 $ 1 7,833     7,834  
Non cash severance 1,047            
Issuance of stock for acquisitions (in shares)   281,763          
Issuance of stock for acquisitions 2,500   2,500     2,500  
Sale to noncontrolling interests, net of taxes 3,541   3,541     3,541  
Contributions from noncontrolling interests 4,304           4,304
Distributions paid to noncontrolling interests (1,528)           (1,528)
Change in cumulative foreign currency translation adjustment 26     26   26  
Change in fair value of cash flow hedge, net of taxes (880)     (880)   (880)  
Net income 2,075       53 53 2,022
Ending balance, value at Dec. 31, 2017 69,925 $ 5 212,261 (548) (150,158) 61,560 8,365
Ending balance (in shares) at Dec. 31, 2017   47,723,915          
Beginning balance (in shares) at Dec. 31, 2016   46,574,904          
Beginning balance, value at Dec. 31, 2016 52,053 $ 4 198,387 306 (150,211) 48,486 3,567
Ending balance, value at Dec. 31, 2018 200,253 $ 5 242,835 2,259 (117,915) 127,184 73,069
Ending balance (in shares) at Dec. 31, 2018   48,977,485          
Beginning balance (in shares) at Dec. 31, 2017   47,723,915          
Beginning balance, value at Dec. 31, 2017 69,925 $ 5 212,261 (548) (150,158) 61,560 8,365
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of stock upon exercise of options (in shares)   10,000          
Issuance of stock upon exercise of options 20   20     20  
Stock-based compensation (in shares)   713,160          
Stock-based compensation 7,719 $ 0 7,719     7,719  
Forfeiture of restricted stock (in shares)   (1,150)          
Forfeiture of restricted stock (7)   (7)     (7)  
Non cash severance 0            
Purchase of noncontrolling interests (200)   (43)     (43) (157)
Issuance of stock for acquisitions (in shares)   531,560          
Issuance of stock for acquisitions 8,000   8,000     8,000  
Sale to noncontrolling interests, net of taxes 34,657   11,991     11,991 22,666
Special distribution from noncontrolling interest (6,281)   2,894     2,894 (9,175)
Contributions from noncontrolling interests 2,640           2,640
Distributions paid to noncontrolling interests (1,427)           (1,427)
Re-measurement of noncontrolling interest upon change in control 44,267           44,267
Change in cumulative foreign currency translation adjustment (69)     (69)   (69)  
Change in fair value of cash flow hedge, net of taxes 2,876     2,876   2,876  
Net income 38,133       32,243 32,243 5,890
Ending balance, value at Dec. 31, 2018 200,253 $ 5 242,835 2,259 (117,915) 127,184 73,069
Ending balance (in shares) at Dec. 31, 2018   48,977,485          
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of stock upon exercise of options (in shares)   12,500          
Issuance of stock upon exercise of options 75   75     75  
Stock-based compensation (in shares)   771,042          
Stock-based compensation 8,735   8,735     8,735  
Forfeiture of restricted stock (in shares)   (1,500)          
Forfeiture of restricted stock (5)   (5)     (5)  
Non-cash severance (in shares)   12,692          
Non cash severance 188   188        
Issuance of stock for acquisitions (in shares)   542,109          
Issuance of stock for acquisitions 7,500   7,500     7,500  
Sale to noncontrolling interests, net of taxes 5,545   3,537     3,537 2,008
Contributions from noncontrolling interests 750           750
Distributions paid to noncontrolling interests (3,057)           (3,057)
Change in cumulative foreign currency translation adjustment (32)     (32)   (32)  
Change in fair value of cash flow hedge, net of taxes (10,253)     (10,253)   (10,253)  
Net income 23,440       14,756 14,756 8,684
Ending balance, value at Dec. 31, 2019 $ 233,139 $ 5 $ 262,865 $ (8,026) $ (103,159) $ 151,685 $ 81,454
Ending balance (in shares) at Dec. 31, 2019   50,314,328          
XML 16 R63.htm IDEA: XBRL DOCUMENT v3.20.1
INCOME TAXES (Details - Narrative) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Operating Loss Carryforwards [Line Items]        
Tax cuts and jobs act, change in tax rate, income tax expense (benefit)   $ 13,600    
Deferred tax assets, tax benefit may not be realized $ 193,200      
Deferred tax liabilities goodwill 24,637 19,780    
Unrecognized tax benefits 4,320 $ 4,629 $ 3,615 $ 3,861
Unrecognized tax benefits, tax impact if recognized 3,500      
Unrecognized tax benefits, income tax penalties and interest accrued during period 30      
Unrecognized tax benefits, income tax penalties and interest accrued 300      
Domestic Tax Authority        
Operating Loss Carryforwards [Line Items]        
Net operating loss carryforward 136,200      
Operating loss carryforwards, subject to expiration $ 124,700      
Operating loss ending expiration date Dec. 31, 2037      
State and Local Jurisdiction        
Operating Loss Carryforwards [Line Items]        
Net operating loss carryforward $ 98,600      
Operating loss ending expiration date Dec. 31, 2039      
Tax Year 2018 | Domestic Tax Authority        
Operating Loss Carryforwards [Line Items]        
Net operating loss carryforward $ 11,500      
Raven Holdings | Domestic Tax Authority        
Operating Loss Carryforwards [Line Items]        
Operating loss carryforwards, subject to expiration $ 24,600      
XML 17 R67.htm IDEA: XBRL DOCUMENT v3.20.1
STOCK-BASED COMPENSATION (Details-Outstanding options and warrants) - Equity Option
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2019
USD ($)
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]  
Begining Balance (in shares) | shares 513,282
Granted (in shares) | shares 89,200
Exercised (in shares) | shares (12,500)
Canceled, forfeited or expired (in shares) | shares (111,031)
Ending Balance (in shares) | shares 478,951
Exercisable at the end (in shares) | shares 148,456
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]  
Begining Balance (in dollars per share) | $ / shares $ 7.44
Granted (in dollars per share) | $ / shares 10.93
Exercised (in dollars per share) | $ / shares 6.00
Canceled, forfeited or expired (in dollars per share) | $ / shares 0.79
Ending Balance (in dollars per share) | $ / shares 8.21
Exercisable at the end (in dollars per share) | $ / shares $ 7.29
Weighted Average Remaining Contractual Life  
Ending Balance 7 years 3 months 29 days
Exercisable at the end 6 years 5 months 1 day
Aggregate Intrinsic Value  
Aggregate value outstanding | $ $ 5,790,763
Aggregate value exercisable | $ $ 1,931,633
XML 18 R48.htm IDEA: XBRL DOCUMENT v3.20.1
PROPERTY AND EQUIPMENT (Details - Narrative) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Property, Plant and Equipment [Line Items]      
Property and equipment, gross $ 938,154 $ 909,212  
Depreciation and amortization expense 77,500 70,200 $ 64,200
Construction in Progress      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 42,400    
Medical Equipment      
Property, Plant and Equipment [Line Items]      
Construction in progress, gross 15,900    
Computer and Office Equipment      
Property, Plant and Equipment [Line Items]      
Construction in progress, gross 2,300    
Leasehold improvements      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 377,417 $ 337,878  
Construction in progress, gross $ 24,200    
XML 19 R44.htm IDEA: XBRL DOCUMENT v3.20.1
GOODWILL AND OTHER INTANGIBLE ASSETS (Details - Schedule of Goodwill) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Goodwill [Roll Forward]    
Goodwill, beginning balance $ 418,093 $ 256,776
Goodwill transferred to other assets   (1,059)
Goodwill disposed of through sale or transfer (123) (80)
Goodwill, impairment loss   (3,800)
Goodwill, ending balance 440,981 418,093
Imaging Services Company of New York    
Goodwill [Roll Forward]    
Goodwill acquired through acquisitions   2,692
MemorialCare Medical Foundation    
Goodwill [Roll Forward]    
Goodwill acquired through acquisitions   545
Womens Imaging Specialists    
Goodwill [Roll Forward]    
Goodwill acquired through acquisitions   4,268
Valley Metabolic Imaging    
Goodwill [Roll Forward]    
Goodwill acquired through acquisitions   1,469
Sierra Imaging Associates    
Goodwill [Roll Forward]    
Goodwill acquired through acquisitions   1,147
Washington Heights Medical Management    
Goodwill [Roll Forward]    
Goodwill acquired through acquisitions   2,303
Medical Arts Radiological Group, PC    
Goodwill [Roll Forward]    
Goodwill acquired through acquisitions 722 41,469
Arcadia Radiology Imaging    
Goodwill [Roll Forward]    
Goodwill acquired through acquisitions   2,582
Southern California Diagnostic Imaging, Inc    
Goodwill [Roll Forward]    
Goodwill acquired through acquisitions   41
Orange County Diagnostics Imaging Center    
Goodwill [Roll Forward]    
Goodwill acquired through acquisitions   3,618
New Jersey Imaging Network, LLC    
Goodwill [Roll Forward]    
Goodwill acquired through acquisitions   $ 106,122
Dignity Health    
Goodwill [Roll Forward]    
Goodwill acquired through acquisitions 1  
West Valley Imaging Group, LLC    
Goodwill [Roll Forward]    
Goodwill acquired through acquisitions 2,490  
Hudson Valley Radiology Associates    
Goodwill [Roll Forward]    
Goodwill acquired through acquisitions 3,125  
Kern Radiology Imaging Systems Inc.    
Goodwill [Roll Forward]    
Goodwill acquired through acquisitions 10,507  
Zilkha Radiology    
Goodwill [Roll Forward]    
Goodwill acquired through acquisitions 2,577  
Ramic Mahwah LLC    
Goodwill [Roll Forward]    
Goodwill acquired through acquisitions 231  
Garden State Radiology Network LLC    
Goodwill [Roll Forward]    
Goodwill acquired through acquisitions 2,021  
Nulogix, Inc.    
Goodwill [Roll Forward]    
Goodwill acquired through acquisitions $ 1,337  
XML 20 R40.htm IDEA: XBRL DOCUMENT v3.20.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Investment in Joint Ventures) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Accounting Policies [Abstract]                      
Beginning balance       $ 37,973       $ 52,435 $ 37,973 $ 52,435  
Equity contributions in existing and purchase of interest in joint ventures                 103 2,000  
Equity in earnings in these joint ventures $ 2,278 $ 1,955 $ 2,244 $ 1,873 $ 1,830 $ 2,822 $ 3,748 $ 2,977 8,350 11,377 $ 13,554
Sale of ownership interest                 (134)    
Dissolution of GSRN                 (1,428)    
Nulogix return of capital                 (792) 0 0
Equity interest acquiree remeasurement loss                 (1,004) (2,993)  
Distribution of earnings                 (8,598) (24,846)  
Ending balance $ 34,470       $ 37,973       $ 34,470 $ 37,973 $ 52,435
XML 21 R21.htm IDEA: XBRL DOCUMENT v3.20.1
SUBSEQUENT EVENTS
12 Months Ended
Dec. 31, 2019
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTS
 
On March 11, 2020, we announced a definitive agreement to acquire DeepHealth, Inc. ("DeepHealth"). DeepHealth is developing solutions in machine learning and artificial intelligence to assist radiologists in interpreting images and improving patient care. The close is planned for April 1, 2020 and we will issue approximately 1.0 million RadNet common stock shares to complete the acquisition.
XML 22 R25.htm IDEA: XBRL DOCUMENT v3.20.1
FACILITY ACQUISITIONS AND DISPOSITIONS (Tables)
12 Months Ended
Dec. 31, 2019
Business Combinations [Abstract]  
Schedule of assets held for sale The following table summarizes the major categories of assets which remain classified as held for sale in the accompanying consolidated balance sheets at December 31, 2019 (in thousands):
Property and equipment, net
$1,049
Goodwill
992

Total assets held for sale
$2,041

XML 23 R29.htm IDEA: XBRL DOCUMENT v3.20.1
NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Tables)
12 Months Ended
Dec. 31, 2019
Debt Disclosure [Abstract]  
Schedule of revolving credit facility, notes payable, and capital lease obligations
Revolving credit facility, notes payable, and capital lease obligations:
 
 
December 31, 2019
 
December 31, 2018
First Lien Term Loans collateralized by RadNet's tangible and intangible assets
$
649,824

 
$
587,191

Discount on First Lien Term Loans
(13,579
)
 
(15,112
)
Term Loan Agreement collateralized by NJIN's tangible and intangible assets
55,875

 
59,250

Revolving Credit Facility

 
28,000

Promissory note payable to the former owner of a practice acquired at an interest rate of 1.5% due through 2019

 
199

Equipment notes payable at interest rates ranging from 4.4% to 5.6%, due through 2020, collateralized by medical equipment
275

 
632

Obligations under capital leases at interest rates ranging from 3.7% to 9.3%, due through 2022, collateralized by medical and office equipment (1)

 
12,119

Total debt obligations
692,395

 
672,279

Less current portion
(39,691
)
 
(39,267
)
Long-term portion debt obligations
$
652,704

 
$
633,012


Schedule of annual principal maturities of notes payable
The following is a listing of annual principal maturities of notes payable exclusive of all related discounts and repayments on our revolving credit facilities for years ending December 31 (in thousands):

2020
$
43,571

2021
43,670

2022
44,795

2023
573,938

Total notes payable obligations
$
705,974


Schedule of term loans and financing activity
Included in our consolidated balance sheets at December 31, 2019 are $636.2 million of First Lien Term Loans and $55.9 million of SunTrust Term Loan debt for a combined total of $692.1 million (net of unamortized discounts of $13.6 million) in thousands:

 
Face Value
 
Discount
 
Total Carrying
Value
First Lien Term Loans
$
649,824

 
$
(13,579
)
 
$
636,245

Term Loan Agreement
55,875

 

 
55,875

Total Term Loans
$
705,699

 
$
(13,579
)
 
$
692,120


Schedule of leverage ratio Interest rates and fees of the applicable margin for borrowing under the SunTrust Restated Credit Agreement adjust depending on our leverage ratio, according to the following table:

Pricing Level
Leverage Ratio
Applicable Margin for Eurodollar Loans
Applicable Margin for Base Rate Loans
Applicable Margin for Letter of Credit Fees
Applicable Percentage for Commitment Fee
I
Greater than or equal to 3.00:1.00
2.75%
per annum
1.75%
per annum
2.75%
per annum
0.45%
per annum
II
Less than 3.00:1.00 but greater than or equal to 2.50:1.00
2.25%
per annum
1.25%
per annum
2.25%
per annum
0.40%
per annum
III
Less than 2.50:1.00 but greater than or equal to
2.00:1.00
2.00%
per annum
1.00%
per annum
2.00%
per annum
0.35%
per annum
IV
Less than 2.00:1.00 but greater than or equal to 1.50:1.00
1.75%
per annum
0.75%
per annum
1.75%
per annum
0.30%
per annum
V
Less than 1.50:1.00
1.50%
per annum
0.50%
per annum
1.50%
per annum
0.30%
per annum

First Lien Term Loans bear interest at either an Adjusted Eurodollar Rate or a Base Rate plus an applicable margin. Rates of the applicable margin for borrowing under the First Lien Credit Agreement will alter depending on our leverage ratio, according to the following schedule:
First Lien Leverage Ratio
Eurodollar Rate Spread
Base Rate Spread
> 5.50x
4.50%
3.50%
> 4.00x but ≤ 5.50x
3.75%
2.75%
>3.50x but ≤ 4.00x
3.50%
2.50%
≤ 3.50x
3.25%
2.25%

XML 24 R38.htm IDEA: XBRL DOCUMENT v3.20.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Fair Value Measurements) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
First Lien Term Loans $ 705,699 $ 646,441
Interest Rate Cap    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
2016 CAPS - Interest Rate Contracts 1,081  
2016 CAPS - Interest Rate Contracts   3,316
Interest Rate Swap    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
2016 CAPS - Interest Rate Contracts 9,477  
Fair Value, Inputs, Level 1 | Interest Rate Cap    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
2016 CAPS - Interest Rate Contracts 0  
2016 CAPS - Interest Rate Contracts   0
Fair Value, Inputs, Level 1 | Interest Rate Swap    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
2016 CAPS - Interest Rate Contracts 0  
Fair Value, Inputs, Level 2 | Interest Rate Cap    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
2016 CAPS - Interest Rate Contracts 1,081  
2016 CAPS - Interest Rate Contracts   3,316
Fair Value, Inputs, Level 2 | Interest Rate Swap    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
2016 CAPS - Interest Rate Contracts 9,477  
Fair Value, Inputs, Level 3 | Interest Rate Cap    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
2016 CAPS - Interest Rate Contracts 0  
2016 CAPS - Interest Rate Contracts   0
Fair Value, Inputs, Level 3 | Interest Rate Swap    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
2016 CAPS - Interest Rate Contracts 0  
Estimate of Fair Value Measurement    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
First Lien Term Loans 708,948 633,229
Estimate of Fair Value Measurement | Fair Value, Inputs, Level 1    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
First Lien Term Loans 0 0
Estimate of Fair Value Measurement | Fair Value, Inputs, Level 2    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
First Lien Term Loans 708,948 633,229
Estimate of Fair Value Measurement | Fair Value, Inputs, Level 3    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
First Lien Term Loans $ 0 $ 0
XML 25 R34.htm IDEA: XBRL DOCUMENT v3.20.1
NATURE OF BUSINESS (Details Narrative)
$ in Millions
12 Months Ended
Dec. 31, 2019
USD ($)
Center
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Number of centers | Center 335    
Schedule of Equity Method Investments [Line Items]      
BRMG and NY Groups revenues $ 157.4 $ 132.9 $ 134.6
BRMG and NY Groups operating expenses 157.4 132.9 134.6
Management services provided to BRMG and NY Groups 618.9 505.2 $ 435.5
BRMG and NY Groups accounts receivable 100.3 88.9  
BRMG and NY Groups accounts payable $ 7.0 $ 5.6  
Beverly Radiology Medical Group III | Chief Executive Officer      
Schedule of Equity Method Investments [Line Items]      
Equity interest percentage 99.00%    
Beverly Radiology Medical Group III | Board Member      
Schedule of Equity Method Investments [Line Items]      
Equity interest percentage 1.00%    
ScriptSender LLC      
Schedule of Equity Method Investments [Line Items]      
Equity interest percentage 49.00%    
XML 26 R30.htm IDEA: XBRL DOCUMENT v3.20.1
LEASES (Tables)
12 Months Ended
Dec. 31, 2019
Leases [Abstract]  
Lease, cost
The components of lease expense were as follows:
 
 
 
Twelve months ended

(In thousands)
December 31, 2019

 
 
Operating lease cost
$
95,348

 
 
Finance lease cost:
 
     Depreciation of leased equipment
$
3,135

     Interest on lease liabilities
395

Total finance lease cost
$
3,530


Supplemental cash flow information related to leases was as follows:
 
Twelve months ended

(In thousands)
December 31, 2019

 
 
Cash paid for amounts included in the measurement of lease liabilities:
 
     Operating cash flows from operating leases
$
95,922

     Operating cash flows from financing leases
395

     Financing cash flows from financing leases
5,939

Right-of-use & Equipment assets obtained in exchange for lease obligations:
 
     Operating leases(1) 
482,399

     Financing leases
14,105


(1) Amounts for the twelve months ended December 31, 2019 include the transition adjustment for the adoption of Topic 842 discussed in Note 3, Recent Account Standards, for further information.
Assets and liabilities lessee
Supplemental balance sheet information related to leases was as follows:
(In thousands, except lease term and discount rates)
 
 
December 31, 2019

 
 
Operating Leases
 
Operating lease right-of-use assets
$
445,477

Current portion of operating lease liability
61,206

Operating lease liabilities
420,922

     Total operating lease liabilities
$
482,128

 
 
Finance Leases
 
Equipment at cost
$
14,105

Accumulated depreciation
(3,135
)
Equipment, net
$
10,970

Current portion of finance lease
$
3,283

Finance lease liabilities
3,264

Total finance lease liabilities
$
6,547

 
 
Weighted Average Remaining Lease Term
 
Operating leases - years
8.8

Finance leases - years
3.3

 
 
Weighted Average Discount Rate
 
Operating leases
6.4
%
Finance leases
4.4
%

Maturities of finance lease liability
Maturities of lease liabilities were as follows:
(In thousands)
 
 
 
Operating

Financing

Year Ending December 31,
Leases

Leases

2020
$
89,881

$
3,492

2021
88,848

2,624

2022
80,932

702

2023
69,916

11

2024
54,517

10

Thereafter
262,027


Total Lease Payments
646,121

6,839

Less imputed interest
(163,993
)
(292
)
Total
$
482,128

$
6,547


Maturities of operating lease liability
Maturities of lease liabilities were as follows:
(In thousands)
 
 
 
Operating

Financing

Year Ending December 31,
Leases

Leases

2020
$
89,881

$
3,492

2021
88,848

2,624

2022
80,932

702

2023
69,916

11

2024
54,517

10

Thereafter
262,027


Total Lease Payments
646,121

6,839

Less imputed interest
(163,993
)
(292
)
Total
$
482,128

$
6,547


As previously disclosed in our 2018 Annual Report on Form 10-K and under the previous lease accounting, maturities of operating lease liabilities were as follows as of December 31, 2018 (in thousands):
 
Facilities
 
Equipment
 
Total
2019
$
75,588

 
$
14,924

 
$
90,512

2020
66,116

 
14,385

 
80,501

2021
57,826

 
12,966

 
70,792

2022
48,542

 
10,264

 
58,806

2023
38,800

 
7,095

 
45,895

Thereafter
160,327

 
5,144

 
165,471

 
$
447,199

 
$
64,778

 
$
511,977


XML 27 R13.htm IDEA: XBRL DOCUMENT v3.20.1
PROPERTY AND EQUIPMENT
12 Months Ended
Dec. 31, 2019
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT PROPERTY AND EQUIPMENT
 
Property and equipment and accumulated depreciation and amortization are as follows (in thousands):
 
 
 
December 31,
 
2019
 
2018
Land
$
250

 
$
250

Medical equipment
425,892

 
449,776

Computer and office equipment, furniture and fixtures
120,490

 
102,798

Software development costs

 
6,391

Leasehold improvements
377,417

 
337,878

Equipment under financing/capital lease
14,105

 
12,119

Total property and equipment cost
938,154

 
909,212

Accumulated depreciation
(571,408
)
 
(563,483
)
Total property and equipment
$
366,746

 
$
345,729


 
Included in our property and equipment at December 31, 2019 is approximately $42.4 million total of construction in process amounts consisting of $15.9 million in medical equipment, $2.3 million in computer and office equipment, and $24.2 million in leasehold improvements.

Depreciation and amortization expense of property and equipment, including amortization of equipment under finance/capital leases, for the years ended December 31, 2019, 2018 and 2017 was $77.5 million, $70.2 million, and $64.2 million, respectively.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.20.1
INCOME TAXES
12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
  
For the years ended December 31, 2019, 2018 and 2017, we recognized income tax expense comprised of the following (in thousands):
 
 
December 31,
 
2019
 
2018
 
2017
Federal current tax
$
(161
)
 
$
(765
)
 
$
871

State current tax
7,715

 
7,263

 
4,906

Other current tax
22

 
20

 
23

Federal deferred tax
3,396

 
(2,020
)
 
21,389

State deferred tax
(4,743
)
 
(4,104
)
 
(2,879
)
 
 
 
 
 
 
Income tax expense
$
6,229

 
$
394

 
$
24,310


 
A reconciliation of the statutory U.S. federal rate and effective rates is as follows:
 
Years Ended December 31,
 
2019
 
2018
 
2017
Federal tax
$
6,231

 
21.00
 %
 
$
8,256

 
21.00
 %
 
$
8,971

 
34.00
 %
State franchise tax, net of federal benefit
3,891

 
13.12
 %
 
1,332

 
3.39
 %
 
1,799

 
6.82
 %
Other Non deductible expenses
674

 
2.27
 %
 
471

 
1.20
 %
 
91

 
0.35
 %
Noncontrolling interests in partnerships
(1,824
)
 
(6.15
)%
 
(1,237
)
 
(3.15
)%
 
(687
)
 
(2.61
)%
Changes in valuation allowance
(462
)
 
(1.56
)%
 
1,760

 
4.48
 %
 
(1,045
)
 
(3.96
)%
Tax Cuts and Jobs Act

 
 %
 

 
 %
 
13,527

 
51.27
 %
Gain on change in control

 
 %
 
(8,303
)
 
(21.12
)%
 

 
 %
Deferred true-ups and other
(761
)
 
(2.56
)%
 
(4,254
)
 
(10.82
)%
 
(194
)
 
(0.74
)%
Other reconciling items
(1,520
)
 
(5.12
)%
 
2,369

 
6.02
 %
 
1,848

 
7.00
 %
 
 
 
 
 
 
 
 
 
 
 
 
Income tax expense
$
6,229

 
21.00
 %
 
$
394

 
1.00
 %
 
$
24,310

 
92.13
 %

 
Pursuant to the federal tax legislation that was enacted on December 22, 2017 ("Tax Act"), the Company re-measured its existing deferred tax assets and liabilities based on 21%, the current rate at which they are expected to reverse in the future. In 2017, the Company recorded provisional amounts for certain enactment-date efforts of the Act by applying the guidance in SAB 118 because it had not yet completed our enactment-date effects of the Act. The Company has completed analysis of Tax Act's income tax effects. In total, the Company recorded a non-cash charge of 13.6 million, which is included as a component of income tax expense from continuing operations in 2017. Upon further analysis of certain aspects of the Tax Act and refinement of the calculations during the 12 months ended December 31, 2018, the Company found an immaterial adjustment was necessary.

Deferred income taxes reflect the net tax effects of temporary differences between carrying amounts of assets and liabilities for financial and income tax reporting purposes and operating loss carryforwards.
 
Our deferred tax assets and liabilities comprise the following (in thousands):
 
December 31,
Deferred tax assets:
2019
 
2018
Net operating losses
$
34,490

 
$
46,875

Accrued expenses
4,280

 
3,421

Operating lease liability
126,546

 

Straight-Line rent adjustment

 
9,811

Unfavorable contract liability

 
1,354

Equity compensation
1,374

 
1,065

Allowance for doubtful accounts
27,220

 
14,850

Other
4,616

 
2,815

Valuation allowance
(5,348
)
 
(5,810
)
Total Deferred Tax Assets
$
193,178

 
$
74,381

Deferred tax liabilities:
 
 
 
Property and equipment
(6,450
)
 
(6,194
)
Goodwill
(24,637
)
 
(19,780
)
Intangibles
(6,669
)
 
(8,110
)
Operating lease right-of-use asset
(115,364
)
 

Non accrual experience method reserve

 
(1,446
)
Other
(5,510
)
 
(7,345
)
Total Deferred Tax Liabilities
$
(158,630
)
 
$
(42,875
)
 
 
 
 
Net Deferred Tax Asset
$
34,548

 
$
31,506



 
As of December 31, 2019, the Company had federal net operating loss carryforwards of approximately $136.2 million, which comprise of definite and indefinite net operating losses. We had federal net operating loss carryforwards of approximately $124.7 million, which expire at various intervals from the years 2023 to 2037, and had carryforwards of $11.5 million of net operating losses generated in 2018, which do not expire. Federal net operating losses generated following December 31, 2017 carryover indefinitely and may generally be used to offset up to 80% of future taxable net income. The Company also had state net operating loss carryforwards of approximately $98.6 million, which expire at various intervals from the years 2020 through 2039. As of December 31, 2019, $24.6 million of our federal net operating loss carryforwards acquired in connection with the 2011 acquisition of Raven Holdings U.S., Inc. and the 2019 acquisition of Nulogix Health, Inc. are subject to limitations related to their utilization under Section 382 of the Internal Revenue Code. Future ownership changes as determined under Section 382 of the Internal Revenue Code could further limit the utilization of net operating loss carryforwards.
   
We considered all evidence available when determining whether deferred tax assets are more likely-than-not to be realized, including projected future taxable income, scheduled reversals of deferred tax liabilities, prudent tax planning strategies, and recent financial operations. The evaluation of this evidence requires significant judgment about the forecasts of future taxable income, based on the plans and estimates we are using to manage the underlying businesses. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income. As of December 31, 2019, we have determined that deferred tax assets of $193.2 million are more likely-than-not to be realized. We have also taken into consideration deferred tax liabilities of $24.6 million are related to book basis in goodwill that has an indefinite life.
 
We file consolidated income tax returns in the U.S. federal jurisdiction and various states and foreign jurisdictions. We continue to reinvest earnings of the non-US entities for the foreseeable future and therefore have not recognized any U.S. tax expense on these earnings. With limited exceptions, we are no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for years before 2015. We do not anticipate the results of any open examinations would result in a material change to its financial position.
 
At December 31, 2019, the Company has unrecognized tax benefits of $4.3 million of which $3.5 million will affect the effective tax rate if recognized.
 
A reconciliation of the total gross amounts of unrecognized tax benefits for the years ended are as follows (in thousands):
 
December 31,
 
2019
 
2018
 
2017
Balance at beginning of year
$
4,629

 
$
3,615

 
$
3,861

Increases related to prior year tax positions
(34
)
 
896

 
1

Increases related to current year tax positions
119

 
111

 

Expiration of the statute of limitations for the assessment of taxes
(393
)
 

 

Increase (decrease) related to change in rate
(1
)
 
7

 
(247
)
Balance at end of year
$
4,320

 
$
4,629

 
$
3,615



We believe it is reasonably possible it will not materially reduce its unrecognized tax benefits within the next twelve months.
 
The Company recognizes accrued interest and penalties related to unrecognized tax benefits in income tax expense. During the year ended December 31, 2019 the Company accrued approximately $30,000 of interest and penalties. As of December 31, 2019, accrued interest and penalties amounted to approximately $300,000.
XML 29 R72.htm IDEA: XBRL DOCUMENT v3.20.1
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - Accounts Receivable-Allowance for Bad Debts
$ in Thousands
12 Months Ended
Dec. 31, 2017
USD ($)
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]  
Balance at Beginning of Year $ 20,674
Additional Charges Against Income 46,555
Deductions from Reserve (32,585)
Balance at End of Year $ 34,644
XML 30 R51.htm IDEA: XBRL DOCUMENT v3.20.1
NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Annual Note Payable Maturities)
$ in Thousands
Dec. 31, 2019
USD ($)
Maturities of Notes Payables [Abstract]  
2020 $ 43,571
2021 43,670
2022 44,795
2023 573,938
Total notes payable obligations $ 705,974
XML 31 R55.htm IDEA: XBRL DOCUMENT v3.20.1
NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Margin Spread Based on Leverage Ratio, Debt Instrument) (Details) - Restated Agreement
Aug. 31, 2018
Pricing Level I  
Debt Instrument [Line Items]  
Leverage ratio, greater than 3.00
Pricing Level II  
Debt Instrument [Line Items]  
Leverage ratio, greater than 2.50
Leverage ratio, less than 3.00
Pricing Level III  
Debt Instrument [Line Items]  
Leverage ratio, greater than 2.00
Leverage ratio, less than 2.50
Pricing Level IV  
Debt Instrument [Line Items]  
Leverage ratio, greater than 1.50
Leverage ratio, less than 2.00
Pricing Level V  
Debt Instrument [Line Items]  
Leverage ratio, less than 1.50
Revolving Credit Facility | Pricing Level I  
Debt Instrument [Line Items]  
Commitment fee percentage 2.75%
Unused capacity, commitment fee percentage 0.45%
Revolving Credit Facility | Pricing Level I | Eurodollar  
Debt Instrument [Line Items]  
Basis spread on variable rate 2.75%
Revolving Credit Facility | Pricing Level I | Base Rate  
Debt Instrument [Line Items]  
Basis spread on variable rate 1.75%
Revolving Credit Facility | Pricing Level II  
Debt Instrument [Line Items]  
Commitment fee percentage 2.25%
Unused capacity, commitment fee percentage 0.40%
Revolving Credit Facility | Pricing Level II | Eurodollar  
Debt Instrument [Line Items]  
Basis spread on variable rate 2.25%
Revolving Credit Facility | Pricing Level II | Base Rate  
Debt Instrument [Line Items]  
Basis spread on variable rate 1.25%
Revolving Credit Facility | Pricing Level III  
Debt Instrument [Line Items]  
Commitment fee percentage 2.00%
Unused capacity, commitment fee percentage 0.35%
Revolving Credit Facility | Pricing Level III | Eurodollar  
Debt Instrument [Line Items]  
Basis spread on variable rate 2.00%
Revolving Credit Facility | Pricing Level III | Base Rate  
Debt Instrument [Line Items]  
Basis spread on variable rate 1.00%
Revolving Credit Facility | Pricing Level IV  
Debt Instrument [Line Items]  
Commitment fee percentage 1.75%
Unused capacity, commitment fee percentage 0.30%
Revolving Credit Facility | Pricing Level IV | Eurodollar  
Debt Instrument [Line Items]  
Basis spread on variable rate 1.75%
Revolving Credit Facility | Pricing Level IV | Base Rate  
Debt Instrument [Line Items]  
Basis spread on variable rate 0.75%
Revolving Credit Facility | Pricing Level V  
Debt Instrument [Line Items]  
Commitment fee percentage 1.50%
Unused capacity, commitment fee percentage 0.30%
Revolving Credit Facility | Pricing Level V | Eurodollar  
Debt Instrument [Line Items]  
Basis spread on variable rate 1.50%
Revolving Credit Facility | Pricing Level V | Base Rate  
Debt Instrument [Line Items]  
Basis spread on variable rate 0.50%
XML 32 R59.htm IDEA: XBRL DOCUMENT v3.20.1
LEASES (Details - Supplemental Balance Sheet)
$ in Thousands
Dec. 31, 2019
USD ($)
Finance Lease Assets And Liabilities Lessee [Abstract]  
Operating lease right-of-use assets $ 445,477
Current portion of operating lease liability 61,206
Operating lease liabilities 420,922
Total operating lease liabilities 482,128
Operating Lease Assets And Liabilities Lessee [Abstract]  
Equipment at cost 14,105
Accumulated depreciation (3,135)
Equipment, net 10,970
Current portion of finance lease 3,283
Finance lease liabilities 3,264
Total finance lease liabilities $ 6,547
Weighted Average Remaining Lease Term [Abstract]  
Operating leases - years 8 years 9 months 18 days
Finance leases - years 3 years 3 months 18 days
Leases Weighted Average Discount Rate [Abstract]  
Operating leases 6.40%
Finance leases 4.40%
XML 33 R35.htm IDEA: XBRL DOCUMENT v3.20.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Summary of net revenue) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Revenue from External Customer [Line Items]                      
Service fee revenue, net of contractual allowances and discounts                 $ 1,028,236 $ 868,741  
Total revenue $ 300,840 $ 292,692 $ 289,097 $ 271,549 $ 257,211 $ 242,148 $ 244,395 $ 231,392 1,154,179 975,146 $ 922,186
Health Care, Patient Service                      
Revenue from External Customer [Line Items]                      
Service fee revenue, net of contractual allowances and discounts                 1,028,236 868,741 857,178
Provision for bad debts                     (46,555)
Commercial insurance                      
Revenue from External Customer [Line Items]                      
Service fee revenue, net of contractual allowances and discounts                 642,341 542,011 534,224
Medicare                      
Revenue from External Customer [Line Items]                      
Service fee revenue, net of contractual allowances and discounts                 237,427 192,881 179,678
Medicaid                      
Revenue from External Customer [Line Items]                      
Service fee revenue, net of contractual allowances and discounts                 28,283 25,615 24,133
Workers' compensation/personal injury                      
Revenue from External Customer [Line Items]                      
Service fee revenue, net of contractual allowances and discounts                 42,792 34,193 32,969
Other patient revenue                      
Revenue from External Customer [Line Items]                      
Service fee revenue, net of contractual allowances and discounts                 23,862 25,117 29,882
Management fee revenue                      
Revenue from External Customer [Line Items]                      
Service fee revenue, net of contractual allowances and discounts                 11,659 13,882 13,127
Imaging on call and software                      
Revenue from External Customer [Line Items]                      
Service fee revenue, net of contractual allowances and discounts                 17,317 16,261 18,116
Other                      
Revenue from External Customer [Line Items]                      
Service fee revenue, net of contractual allowances and discounts                 24,555 18,781 25,049
Net service fee revenue                      
Revenue from External Customer [Line Items]                      
Service fee revenue, net of contractual allowances and discounts                 1,028,236 868,741 810,623
Revenue under capitation arrangements                      
Revenue from External Customer [Line Items]                      
Service fee revenue, net of contractual allowances and discounts                 $ 125,943 $ 106,405 $ 111,563
ZIP 35 0000790526-20-000003-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000790526-20-000003-xbrl.zip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

OSF+ 1!U,7!B(UB'%9B4DP6 MFQO2ZV ;X-B>3EO!>\C>7LEN4@F8JR_PK]I633B4ZX1KV(D\K$KX;SD"E=;L!",V:O3ATBUL8E!ZCJ M45B6/)K74?-JF%7Y^L:OGEOIG(4ZP*XA%17S12M=;":8"\R!U09K#'7BO$XI M%X4)A)\ZSBN13JD!'SRHS/E3)G\6BHGS1N\/=TM)>7,^4#&/\Q$>YJ-KR63%6S^4G_:I!4_))<,/\CDFKZT35R+_QU(^N:MPE(7QK>Y2N MB529RJNAT=A2/A!#I]C(,I)!#"H5DJK)T)*8>D3IK2LHWUOPEA.%82TOPC=G ME$C=5M\"<^%72:U??7S_DR;P4R4!-3":V:KKKAHIZ^<\<%COI<] V[6^([PL M0!$Q: ^_PBM-X@6.R2P<8WU8_::4T&+667 .N"5=[5-IK<#"=&2,[B,4J^"? MYS(>9K#Y,L>($ TWH%LCDJ"QNBK,YY#L=*KCR:H]]C 8U:0'5@ M50PP+=FMR>Q1VX"-TJCY8F M0*SQ-;-!8^ZP=D1!Q&'NZ=+!FM](!%-AC$#2PFM4#JLW$7D792[4W\:Q(\B=6G:MTIG$$<."\1^89( M$3Y*2M8U5VJNF/WEY_'H&S4%B&)& 0:KK"0@8^(V]"LEMV6E;%'K/-6M""M= M%;"*L*!R%$K3,%^$:K1K2)'2B:;4JXAN\VQU>9$J96YV54ES(@7Q31@4&%' M,XQ:3A\+&M^2%+24CC-C!MEZS_?:EVW6HZ&M",P5!;" _;O3AO* MTN^>+)1E;TU/L:W,#7>-CY!Q$[T7"KUD2SB14XKQE40*&KFJ5*7T@DL:9.HP M#(>9:<(T%RF=S"PL$Y5H6^4.TKY@G^!U-%^R!AL'AF0E:FS- W(9Z+8P*$>C M)=F)L(9S53NB'T*Y[DS"6F6*&BXJWR_8C4(^9UE8K0TL,S5D%E0!S[D"2>TFE%R['C_%:)640"?5Y*/9L&OL%(@!C" M<@?X4C:""SJDC1P4)>4'\X#H8!HL@$2AEFJZ_F!=*S_A#F2*1J,:^"F_SWAH MO20K0ZW&D=%4-VX-2@.Q=\R[6CY%AE4:*[XK[#4295 1!HKI*/&O1\!S95-G M&DN@Q78N\J.T&/8$E=7%9A2/@/!2GX-_!BBQ37,EV MU/J3P@?3I63N;1QT);3@46\OD_6+873**"[0KH:183ZAR6Q-.$IF(L="VJJ6)>)#%F0K_A]*M:[X;;AD:-FH:3> 85\]HK M4(^4NX%08I.!/4&SH;K: RFE0@+J*I30#2:Y*U4'Z\;'\.6!^RK+[<=F*P,6 M]C76MU'QFW&YM2ZU-)>83/256'+S8!JY1=PUY"*2\$X'&,I-;$@&*M#5SHD[ M6JII'PUJTR#^%2%!PZ[QC!T)[\HA9]F:"3K-F\%D>I,FNH*65RQQ4C)L^>F0 M"N'UX&UPY_FP76SFEU#!@"@0QP7;>Z]54%'>Y/EM F*080I.]F%4PR-B99%O M0U[2.]^<&,2HZW#+8Y.P*B_C\)4/$G]@4TLPAR;(2).\ MVFBK@:@<$6(O%,*J*4"JTLM42D@)$.ERF.9]U>_XL74GN4G![*PON;,ZP*8V MXA>R@[7LE_W@IN%YLOBV(%.EUS:MX&9+-NKWSVMK=G>O;QCI??&P/54/H;# MLU1NG_IKHODI6X:"W1<0":RBNB_U4=,$*[V[[YI-=:5AH1NF5_D,RCI *YN- M<]FGLBQ,XBH)57QHNSKFW:YC*R9"O,@6<#QR8O96W=C7=%71'2!UQT1[I.R1 M:MN1DHU/4S$M(L3_+YDH\H8S]!C^*DD*%5A='T$0^9B*FNDO.".,/%)DH7HP M=7\SY4#=0\SW0(J_"N=-ML*A<_]3[(FT)[)M)U(U=31;4!N])E<;/"[+5 AA MU$HP,@)V% ^^!B5;F;*3YCR^ MS]1_Y;I6:HBI^H',$1,AHC_)M!((IX[0RA$I]@W3B4A9.E9E+S===9LUL*K^ M<<.L)EI>>L^ZS:F4TWAJC6PKN6V37 -QY/DSJJ:D;AQ>.J7,?WG;2DB(%6(K MQ&T38D(]9RMHQ;(@3J,9*\!'*\I6E-LFRH8^EHP"%?( *[)69-LFLA7 .D'_ M2Y@^P@<,(+?&V&L$0C6R]]!0WHD7U?5.HZC.ZBNKK_:@K[QY @-1S<[2LD^I M;&DJBXI 5WGQ-*3Z\RP3>04+,DV2 (-4AQC*?7I-4T^W;*QS(Y6S/+K/;B"ALBQ2YJ'"><9_]&7)?JB95' +YZBP2+234]8=W2]'J$U8>[M<%6NHE4S%\+_)NGWIC M'K0F+4TEK&[51 14UDV-;DK@$$/R0"TC0:=:>'E62 LHGL,[/T O2\!2BF7) MR]=**QZS>O*/(I@R74JLV5E4SJ-L,($ODK761)HAL >0IT&(%1JJ5U+2J+8ZSD=*!%$I"0.NJ),:S4Q,PRR2+,#$K6,NM&XJ&%)C=N077CC YT2I:D.-2[V<*O]2XH M-">K@/%R76.ZH/#5UTL J"&6O&!!F,$&)+=F%7N WZU4=@4FL2:U7*0OJ1)K M+Y(E.8I9D\%V.%AF7JC5"W]>)1BDHF(IDJIOK##T&A(URPI>>F/9[,P+4-Z) M>P=E85J$ 56^PC=*1" N,5J*K9D\X0BDDKK?K4N089UIZ2'!5W0>\'8MZB FI*74B!]B;I;% MKVN8)-995[Z7S9P)G+2.HXQ01 *X)3%%Q V&Y6!PP E2CRA*+;Z,5+-"+U_A MP"KBB7<#NH%<"FHR)OD%DU5U;\VZ;RN,7FE6XB>@_/]+@H)G)4Q-%@+EOI5, M@GA603+0$XQ M36Z?WPA?9O/H^[YNUR>P]_J/1F!>A>#U6W46T@>&K%:QJ". M\)SA#KR3&*-?8^?:(](>!&#A;Q"$I=@3X#8O^'%_'70N=;,\!6&B!J7(IQ\X MK^%Z([3M@+N&C4!+2#/5E#O85:2M-,?*[7'PD94A/U3LX,-QP6RP6(8X$TS^ MA(TOI%57X?S#XEV?[USLGDR\?@1HBL(O:-,1)@J]:MU=60Z3(K+T0-UCT_=2 MY@_B9=*$@G)@!AX,-PI&A9K-E2W!FHX?LGH&PB>ZDK!"+?&_V6JF66M>=8,9 M.MH$-)L7%A].HVET^5WPX%-NQHF=>=05%A$74R!9DDHJC'72MEYA-&F)>S@7 M3D,Y/,X]P#SF)8="(,;YPW:A:@8LJ*=,CB8/F5!@RDYD[2\Q4(\C[-Y<\I7Q M;\$SP>9[G-' 5XO .]:[F)!G8$=ED*4E"F4?? MM"^H7E4VS%!!@G66A@4&6=EOF^RK! I+>R"D9^I5=#>YY67.0WMX,H!98H?0 MN];9!G;RV4*IA-\EO6-HMODKGTFA:72CD_0+L_F0D>0VQL[=50ID=OT4Q[#! M]5# OV4646I/8?M.(8@T-I7A0TA(B3#[HNAT4Z2'5=FJE%T%>;ANO#0D*: _ MCY,TI@J!/ TE]$J.2- MSGP;&NXB+R8<"S@ MG+@,@O.8-"M/7#-AO,*/7FEFU=!6S1X#>PS:=@P(WTF8AIR::NF.YH30T3SR MU*M YO7JK>1*%N:(&Z>.CXN&Q-98](^GQL*JKJ-178V]>=@+,U%6&.3(5#9' M:BM"U%+$D4BWE[+_14+X)6_+4H;]S+8-W1D.)P/^3GOP"MFGG'N-BU >3A7[ MHD)I97R-\0BZ%U\)S2@!&!;>O@VR235PP)1W4 $J5W)9?'!]/RUH5^66PN_6 M!&?,3CF<#C>4 FUQI2\3(>/7RHR, ZFTO)EYH$?)DAJ.B=)O*F^6O=+N%")V MGJD>*18*N;= $'K9'7G=5&5S7.R@D03X84SAU^9 8"26_1I $!R=:2+'7FT0 MA%Y.2JW9U6"XSP[.3[B&V::HP M@3F?$P<>@BD?/)5A1M$YHT,(32>0':=J6X11:\UEJK:KFK^O<&Q]$L+YD,#W M1DH,&!&@[=L8^S8'C);26 F"M;):X, ?#8<'R]@T":[#$;Q%\%NO^^*?%K^Z M56,?7GXM3G@X^*H.O$6M$R[Z[B:LV^@AB)*2AK*\@+P>ZAL,$COFK.-*7%9& ML[ @F[=\BK@^7>)20M]V@W ZR&M@5YG_7QLW0'61]B:3D'JSRP84L9CR#XBT M!.'(,ZF.U"8WUZ;LJYV*A3]8?^4AH18J2+G!-A2LP @/H8J?6%25 (-R,LO) MN'K$B#J?0S*G> UR!S#Y4$&N W+#_"7',C@E]BS8,]"V\X" M19EDCT]Y(D"!QYGG&T!D=$@C;*1C1=B*<.M$6-HLE8A7$E=]3U;DVL>4,3## M_435'0:AAST%CBJ=;P7]V 1]6GB@H7/!7#X5\QOD>HU,[X2MK@WRW((DWA4; M=LR<4U$[L@"MK#LU>P,P*FX51X+*L0B]G[H!WGW41A%2/D_NY,B5: M(5B-X\7QZ(;J'RG\ZMM,&P,BC8)(+2_7EIFK4WF"J;$=(B24ID3O7&\0'GWJ MRN1RMG\2?A7!"Q_)XS0(F3 3,M6?5: 5!HV)>J J"#,)HA8>WO0%J+1H*75& MF,M,>)J_*!8D &:?;*9AXZL8JU_N['6E8=.U!EDF?*OZX36/Q"DNF%;E=\U^ MT"3)B.%NR@T6BRF%Z5CO,RI6/Y3J5#5-=VU$LC4?JF5YI/0G52]Q^ACYE4:' M<5+## XGZEU)MEL)HS=T?I6ZE_0N[!A/53.U5)@.S ):0EF*NLMUS+ MD5>4.8-3%'E:A3B,0'7X!+P$9*$A/$A_.$*JH)3T^BK!KFY>B%J?&61U8R#- MKUMB9)BVP=5 $GC %^.$J0,1I0'YNGASJ7=(B2'7JFQ^>JY$+FL@UP1CFI+ M7B(")E-",MC2>:/WL\X#LR/&*U@J0AG8VA49[4E?5"6/&;,7P2J#(2]@)*I. MPZ"P9*N)-IXY:\(;UI59D=)V+=($SO;1"B(A,QA6&8U7P7^6KY 7$%*'W81!@636$A_VGFJV MPT"]$W]/># )303SF*D):N.5W*0>4:?IAS!'V)1&G\4_SM%4D&1FR"[)K@US M9F:+1.$KRR?& LT9\-$*6+CKLA2+UMA0#Q5-SG1S34)#;A9[B*O;BPO.-)8P M@C!34;3;&;MA=VRTZKY$C]@]O#:LZ39=-=&=IPWL%"2OP_3 M,I7'P^)X!'-M4I@1LR:5.E8^ ']?GX)\JMF!DO8NDWNAN$"[@\0##YDOKMMZOK*[<\]?)* M,Z\3^-(?!2@/(@'V)8>W:JLK?>&JJF0#DB\ *A1%]BE=F")!YN!P%?$" R5^ MSF&;SQ2CXI(5Z50P\Z5)PUKZ O=Q C=0P+G[ZJUPTN;LKV: 4R/PRWB)-G)# MBLNE["\AI2:Z8;X"XF-E2ICY44(M0 CKGD29-'H3'Z[IU&C$$/.^XF<<%+6* M@I;\K]8BWECX/E,=!$94^""JG@"*?O"!N\40\P=N5UEM(7DY,<@LTC1!BWH> M9D9U IF1&7P37J*X[N%"_7T61AQP+SM#2AIR#/!P(X7,X*C?\XQ<*>\^K/X8 M8PEE+H?UX<.%'C_Y\)54W7/*7@YHF_B4$0BS&94/1<9SJ-<$?"Q3(!;JCA#. M02N_-LZIR0>#93M:%]_"I'-LE2\&;0AL2UGD,3JNXD;I. MQDG+N&_"$Y)6Q-C=#\G)8@&522&-8=?:1RDD/>XSD0F#.9[5'&_U^6,/C4\U81K6UD-&8 MHC%Y92Z%004_,X-+^MTBO@G3A(,P^MWL6_"[;SV=C^$T6E8/&#OO8NV8N.9K M&ALUX94@GV\D=J)EO:SU=Z&"U=Q&9Y[$F*V6&6\C=2.3[TD02NUKS)_B47C? M430 _U^&3=:L@'2JUNSN++E%;FE7RWV]F5U9VE!#'O*JEQ6#?B[(A>R,C-9Y*+65XPM+22GQL!/V:A MR:LA[RI_:9I3^OGU].[4P&83DEJ"53=,39I3S%%GDG)#13+ON63P8XV0(!.N2W-6(1E93X<[G,V\E-TG,YZ> MIJBB>+:M.VD'$]OXE*O>?J4]DH\P3O?(DY=ATD6/"-$TNA_P69 MCM39 M-VE&6:%[$T DAI"[!K8LW.1Q@()-9PI3TB)0R^R2D=#/>JY$[IRNJ9 M5.=*F1^5*'$YF';/&Q=%"M9.!C])T$4J.3,PC0@N-*E)W?&VC/+B/G!B>\-Q M(HL%J$0*W;C<2-#89[4??-$82^V6_.J5-7_H.J\LL\XK& M,"LH3<=];>0:XT;1"C8N]N^EO_:-KAIL")V$BKM'%YEY]NA;^KQ)S)WDPIC@ M+8U[<$,+QYNPNF(=Y^?2M-:6B XY:]>+31#,%<0Q79_(=Q)FC RB>J_CA[+L M8UAOI2!%AD(D8AYML56N0= PJ"ACY4S!99K21KJ&.O6,;Y.T\K?QL4IQH."6 M^6MU')DEAT2?M*FN9R*(?_[SI%'#&\&\^>8,.?3@@ZB>7*@,8M):.,^#>A MRDCF3UOD'\>A>KOBL9 YZ2]E4A$] M9TS+4 (LN1EE2H9O6NP:*'E3[U,I^J M448":(2H^+UQX*6!-/XK#P+!!;G $"J"@3VI7]&HFJ9&BY7 RSVZP',5:,0O MIJ'(L2-XBC/6/'/9,D,7@5YFT4Y5M-.913OM];@%8$?B#3_U$#SO^,LQ&A[R M8'EY#DY%!46O8JQ5P&E2 E)5B;SLK6X>7OUAN65 M?K$&BZ9V=E3N778+K@>:P%@[ )784G/EUZK1G.*R)C*F36UN&)P!=@1A/) _ M05D5K&235-[N8"U,L"H=O7JWHBC-QM"EYI?P"=3I!49^I0*5M4$<#>=VU'/L MU6CJ_KB8B_2.R%@]L5"68W* FD&J*)P!S$6H-*)+M9$HOP4&@>FTHF ;VP.??B'B\KYM[/[SZ_N?X9#3UI MB_&@;P2A>]!O9,I7> *- +V)AFL5P^8ROU//+2HCC2)$>/U09W ._GAI;E)N MDN^8)E$X46$E:8?!Q3B+T=$CR Q^S/@&(V,$3R!'5'TRGQ M,2Q5SQ:Z1D<.->0L6: A*I_$6J%TS%#3I%./6ZQC6 D+ZT 'PFI7T3^PJ +!82Q?(.QQ6?%UCV'2N/_W6BM[-DX>=ED6] MIXI2E>74J("*!IHC7G]!-O*2BO@FI2#.X2QQ):6$0NOSN'25UC>O]X5(X$DO MG2(/B11:=[96#S3/\TO]-9*W3 : )&1!<$@"7@NCQ)T'GRT7)=Q02@:6BM5. M)J+TLD7( 1T.KB1I+@6V5L^I;A1I]:CF5]%ZFP9./5UA,/SZD> !29OG):H; M6LT;/+;@?<\YLB(F^38YV5Y3JJ_=(12-5% M=.*5Z)*0N!Q$R.(2*6,*N_BL;CDNL+K7V M7;'Q3&/.E ]Y(Y4!WGK$)C.DU5J/LKL&"E! M/!U\L08"6YJS<:7V"^OJ"AT0DRL)(Y<&A309Z@6=2A^B[M"A0@Y1WF&I2)@T MG]UO6KDPH M9T68ZQ_*C+*99\Y@E4KAJU,&2/W'B2.I3A?%&$Q[S-$KF.A3*YN6!2%M8*X$2^P.QE,9=W' <* M&!2U;."BN@LVI^71!JZV=7T".+,^QC,D5(1_-R50 M]>/*:,1GG=@@9-P;,/>3>>C3PZ]AQA0QDM^33^]WNY?2 :>&Z21Z98K9GBE[ MIMI\IM; U$U[!P5[GL3@.C "XC):L]RGS+*57[9GPIZ) MMIV).^M(59*X@9);7@2IMQ %_KYDT[YEO%=8S9]B.-67CU2DDERG[AK?+4ON MLH7P"9AF9&.\@'/4&(?G+'2$_!;'U<#&(L.'QX,,MXKR:!1EHW*L$G^B'VFH M2EWE2+E]1N;JWREZ9)0/AEM@$AS!49HX&35=6D0[:F8$"_?CJ%FU[:7DK4Z8 M3YDY7>A,Y;PU50^UQCVX*!HY@!10=6*E:=YW @XM3MCDP.F/X!=;&_^OFL4RJML*$]S.H65)2*:.PBR'M+,J8KID3 &!CDQRER1>PF&31=4ZE7= M^'PMJPZFW4N MP+#>X3K(=I$+3)SQA]Q/3WR8A=19)"1E=]>PR2:WC;$^SIA2SKD&L13,8+!N 4K&,]Y A(/) M.K6RKAB;/E6A,6&N=I+A^8R"X>XA9E^8"'8]*INX$. F1 U;8PU%Q=R[>)DA MR@9!38I*H4(A5R=NLUB4C?$4ZRL';B3?"WQ1$ 6\2X7^VC26=0[<=W5;0PK.PL7+I$B4!\=Q@NJU76- M%@2\\97&2LRG>V='IK0B"C=WL@FM5J005/@&:5<,=X[EB.!\$ZSNSI(X%I&K M.+H80Q<8,B997'0#WN6""W0,7I8::E]]E (SJ,'*AE"5VOI)*H1J)7?/2J@( M4 5T0\WIL&60O$\-=@ZM$A,$IN.3UWE MB2->9BQB,JV>ZG54^0XJD1M/5>C_4<#='LA&6 M03PV-Y5&XYWRXIK2E,5A_(-!0 *?O7[_R7DNH^J,H#K9*X2ML_?75U_KTW$?R1@7QA_ M_K[C8($FS1WG7)^OZX -EGK$_"1-IHT?)Q94_9!R?E<;._H^T?8.T_K$^G L MT4+"NP#K,"J&44G=4E?-=+YCY9_P4Q3M+5:S8?.BZ@FIA0Z4==T,7RIIRMY* M3P7+PU#P0Y#+%*#GNOTN[W+C1_G\DG[&LZY2F#C!_5[WVW\ M75JWS=^\Q8NE_86US8K3?B*$:F@%-_9<-E"L;+$AMPV4.\SCOU!%WMA.K"2= MK@4LJJ)*_#?L?L="\_^7!_0N8FQF)JQ:8/@^) PLJ/N8AUVFL&G--2APKGI1 M]E^9*@NS\@J0'>AE_[(%S#F5GLY<<&-(25M(%PM3#W]%K2&H]M!SLBBY#3 E M+2?NUU],CR]?3@T7.):4X8;Q\ER/;&=)XX<$5LG[&Q%%I1@#'7\(- MJX ?1-N'P1.N3C.Z)!CQ$OEEO?FT[[J6IX$<\BCOF<=QYO#FT5VVL_)&N(=S M6-GONETI,R?<)*&B+$[!.&":HH;,,'/B&NE?Z_=N+&J?E,=I\"(6DI5>?!4I M]N>C(F.CEPK5KDIO4!&$94QEH-OY3>K4VOQ$9 A7K)[2KVSFRW5U"\$RR0\C MG BRP[%[L5 !Y_)%59;P%!U$L#]\/NZLY65W@WIQ8&GU@+V+I67TY'&:>('A MX=$=8/I#E9@L*C7NUE ASS;Z =6/2L/9(!VL/+'RJ]A7#1G(X<20]G,-#ZTT MWA OH3:FY,5-UL;K0^*,Y$N-7(#*[9DO%_@D4+1,Y(YQCQJ#G G>T$ZZ;B/Y MNW'"9:G=2J'EFJ&9P7V3"KCFA#:U<3;I5U47!$5)^46(A2'?AC2NA:$0I^TV MYV#=XK,Q&9HW)\4B9'A:3=P Q.N02WQ1D2D_"?_*<7NC$:]*^(3Q'P57IBHNA[O23>PC M,_L"/Y*ZDABGH(95,AN8R"@OVX/Z(DV(/_G/PHN,ZEYS.VA,?(S),)4=Z&^% M]GC8>ZJU)RO5$:=-C/@3E\2RQ?6'2!;@U2'%B$TY[(;:/YEKOT =EWF"O"4D M09A%(HWA<0,U5<";DT+5I#^F"3EH&/5U,KAN.LXGIILC@C:9T9%I2ZQ"*MJE./\>!!6CP\$TF>!VU^0SH.C@RQUF;9Q<@F H"22SP12F+>J M:#;B4M;]RCS=^X=X=$ YE6PI)KN U_ #W-M'!=P).J#(I.\%$" @E#IGU#+<1A<[&?I_J/ZOPT60 M CY+F*"%NY(Q;S!%(T5$5I(TVQKVIKH;ZH):ZM!LAG&I_X(1@N$Z8[E,VGE- MAE)Q$TL^F++!E-D@VK"5E),09DZ]:8-JFU4:FJHK_8W*5L9Z/E66FIF@M STI%0\[IY5L.;; MYHT^-:^>K[NJZC"L._O8UVLQA7N:#?$R M$7\ :]926^SSK-*HL8E&E1TZ1/WI?K[B*Y*=5HUVLZM<4=DKHKZ*9Z1Z:-_4 MMTOLO;2R)&2H[ B,Z+8XZ#CO4350X6-,"02=.@:1*A"45Z2-E0(&5N-:$;LE ML>Q%97PWS63\9XKX"*0EG!'B;K*N!*$<^MQ+OXB\UE HKYP026.H>="RA9"$ MD^IQOH>0;'9NA;*?F>^+B U?RA^/LR02F:^8W"HG@O7I;9DFIZP& M90C+:&.9,J!\MP1DX.N9!3$%C1H8,U4<4[6TN[YW/),\S]Q<+Q,U:$9E1)LQ-4XFN2O]$Y6#@0DDF9K123CEERK:)8)2,L#47D8;*]97DA7Z5J;N M9O!'D/*OE*O/,)#.O4'087-NDJC XH:%YO>^*QFYFTC/R=\OBQ1I;!K:[NA$I]\:3*=S,K=8P+#"AC1D K9!) M),#]0 @UI;C1-9*X0WI2!:%LZGFZC*0!G6',4(D>AMO_2!3UH.32U$]!1"&* MHTM=IR.5O,WF:,%6C:>JJI"LEN@OI0F"A="6S=?T;Y+.U2K7(L, *5$M;Q_X M5GEEZ&3%YUE!Y)X*\:[&0AEW>;,A2/-LRZ M&YWPNT9@EQ>?OLY,/O>*[8"WOQ%@92FX1811]6-A1I: Q@=[D=63F^O)<"Z0 M)K"T-E0F$I89><\Y)V.86XK"M,;E2M!94V MI>2.J05-FWE1I%F!_IFNCZ+$56D1DFL'.ECF"@TMV3@J3$I11ZQR(+)KGE;J M0E6QJ$J"%0G5?3M2KLGAHA5#3%P^;J8_G"V*_U"!8O00E M)A(^B(GHFCY1;R.)*+646\#F-27Q*HFPWNKJS0JW'!YT>[5LK$9?,U^^ MC%8:LE+&@5;)EZVIO6<"6M4MR5Q\P[U6^\"'B F#90>E7);?D XH:?K]+F0M-*[P#%%N'/1%!$U'-* C5= Z6)( F,8ZN, MAX[MB$J'*DZIP+T@22KNW"3/:#NE#E6-GQX7#'>!?2982[XR%7",(U,T5(\9 MR^C?V460F%+NR@%W!CD%JA4[IT)DT2=];IHFMV@1U"!?QD9E6%HT1^$/RF8M M,(9 \_[C%2%9D!NVRW6F43)F)]%HRN0:79NXHY+9OTLN4/G"HU3I^QB6ZEI# M+<_JC7-4)QYWY6RM"JJJ@4DR[5-2PXL7U/!"W_ZZ^[C;W/ZFL0>GT=*OWM[& M7>EJ(Z'BAB5G6(DW7E30JTK1]7*/JYGNG!_:W]61C(3J(D"6ZW*5&?89/DGO,L5OZ(-U2 M*[Z6BKA3G\"VN=,^[$SZXU\&%_#?R_8ZUQK%.D%I0!CJ?)%3A]42QX*E3-4. ME]SLN](IZITR=KAD.<1B& +4S3$XR<7;R22_]23UQ+W>.O,-&%]G;4"C@2$T MCB>IIE7*N!183_D]'1A5B7*-D#6I4LU]*J@WJ.QU6S;11%L-1+%D'W-7DAP\ M98Q@$.)X!3-8\A^ZE*O1M0"I&!=A%'#YF^SIJT,:3'%&27590YEQ^E% MPG^F\B9=1AG&B*.2F#G=LW'A+2M05]Q+CU2O*EK 0@9\?2Y46:"LO&>EH=J' M4KOA"HZ*M89LBJM:+Q.^"#N^(;: 0GY$N3/6/=9+:EW,9Q61[,:YRO%F+@ 1 MW9DJB/ZH=-."$BP,DY(ZK$-]$K U[Y0[%'(#LT $]7S;_7*K(=TZS2#15)46 M\I*0T"V;L'%(J.S"ME(J7S9XKU +UO/?;=.#K=5\[S01!3E?MQYSBJ8)&!,( M@=$*8TH\)(CQ1*1H?.O1G48'H<3MNR9*1,7=%)6#4;004@S;J*UU5WNW/JAI MO-$=OHJF,5KMEKI',V%B00#W]U082<4<*7,C&2/L&=ALM(A5ARMC!7AG"%2% M]4M2RC &BX39O"HX2M=X*S5)KE+6<-M([EZ<2YH)7=*@M*8"Z%,%@O[&)/6* MH./\/@LC4:DYH/ZH33![%4*NY]3'E71ZPY(@.DIZU!+'RJNG""DG$U'%B*/% MJKK+RP:M1WEL'R?)>24O< :HD6W+2C$" Q%\OERVJX%C'@6WF(\7JHN-/BLJ M))]5NN<$1NIXXC +E\Q5W4T-HX%N\O"N:85-A$MP#P>KGD@K5[JEFGRU^HN\ M&"]E(@#2"]X#A41F]AHDQ$RVI@00D8D;_5E-OG.?["#$OV3I(H9($,!QPLZ5 M-"0(+"J211+) MO'*89860[=$K#<^5=C5&3E8SE;B'X ,R"TRIWF5EP0V5)QO'AW@P9@C-)Y"Y M]/,4$.E?,1'I$:]))I=QR7G=ZI]*'_Y6H#=+-A4.14AF1VGF\K!R+$,H-R7, M"QU0,.@A=.]K7 ^_1/J0P0=OD:@TV%*NN*_8ZQH*VZ1)R@I_NG@S7.KZV^J^ M@?9&#/FLCN0H+XA]#*L\6GF1CHN($&.PG)5C+OTHB;)3*IVBY+RC,K#1J-ZU MSEYO>:G:SWL_JFL 93D&>;VJUI0.E2%9BMO/5>!%PWHK4=PU)O9QDJ;)+3E7 M3.EH>A9JG.KGVFB(:%4B^"2;)(IJD3*AK1$8DOS*'!40&O&N5A;#3$+DQGH@ M4C!S#?,-88"5KN\:$MJT;(S7;+",VW=.OC'>_W3E*1IOH*^N5:0"_+40JL4W M12(X8016\C*1"$;%A(+(^SLA=(UF$1?Q[7QG6[&1^Z(4-8*HDENHUHS][ITJ M/3995"8DAF5]TMYELD!TK3R\F5UG48Q!L%0-NK(M.%E:9C97TJ#D.;D-& #V M3^,7A,OBH<-+)2$'PX@E/(>J73*XG$M67F,.?D1,F^I.)MM&AIO4X%'?X1IE MC+(IR8I@,@%,/T4H @\1*_%ZW:ZN2=%L49P^Y,@6,@WDY/4ZUR 8._$H:>P MSV%F;LYM& 5R8<>@7K]@G3BOAC;Y5$"!T,;EAM3B:XJ[<97#TA@-X[(E#E(@ MY:.?X#_)B&)'54C^-[4T4F@H#$\U1(&LF<5(,:Q2&F(X"ZE@C7=V'.<]XC/1 M)(TIG$7UFK!Z>-!3N'0IY8-5\91V)$(VMG:%D@-MXL'#J+*4,MVP@(DY+K.= M0U!!^E8B=S(R7$E3J$_N6U4)2-4NCC,W@J'"?K%6]5SYBC?J)RX["LH^/FI7)79*7=AZM/KZ_^ M7^J"K2I)<9 FZ&=7],(DB2+R4HB>)8Y!^3-S/=-(8GH?"?[E'8B5 M-W0AZ'^?@EM!7"GLK),Y8SY%BJO$BTN&>XR:T/(I\%/#R#@>L5XV9!@0H?)5 MLXLBC4IRZ,JICJ%6K>HY<8&B32]1U-(Y5>Y7^37U2ED(K\7K/"Y>IXQ-5>)Y M'MF#4JQ+CTY6M#"9"CI]RQ_ $8P(BH)\YD%)92AS2,RB[D7++'\0\O?$47VC MXT'U'0J4U&JSH]%F<)-3!J[D DI2!=YP5TP0Y!I29;ST-3,?4&W"0\3?8AKZ MNFB0\_Q_4(Z99B.MW]BKHSR(261+HQ]Z)TR*3$AITJ+!G21E'V(C_R$$01_L5@6PD1_Y/$(EW+U!-NZ"_>K8Z)FWTW";+D%V7+4>QZ Q]B M-H=ZL]O"QM"WUDL" %#,HJ5X[,F+AWRXL"?*P3."F8W&L*?M 2.DX8 MCZMXNY4D<@!E:%7@#(DE=4A$:BM]V"9BE MS9BOX;R8LQDJ;]X,[!HP7(G-GA^^Y$;C#"*3?:]+Z-2-Y^,U+2Q=@CTCK3LC MNDR/A!9Q0NCW [AL38D*W'>#D.#JX M"*OI634"#%HZ>!P<+0&>%:O,AN5MF>LC6=,M8ED M[L*)1&G^0"7-94J&[AJZ5YZK*P3+!&5F!R7^E9+XU]IX^]YL\V@PU2*ZQ#BO M8-/A,5/-.(A]=OB=IIK4W3\0UYE[7*?,8ZDBWPW[#S%95$BOXYA$#>=[:;I$ MIS S".7K?U U3;I$6);OF)_Q(EG[@!7084S69^Y]7?VH(YO@P#;&S9]P,?=_ MBTE]1+-@3Z0DDVU5L5J96XURR9#BI/,<$K#N2YPB1I=!*+"$'TOB\K=K+P8JGO/DEU-1CUU4+KNOB2/3<@&Z-W.3JG47IS*NC>=0*BG04#CU-E MI_:AWQT\-*!5C4OJ5B^J3P V3HB8@R!)=:4^A0/*DBH)6O_6L-;C1!W__O]X M3AC\[5EV]O;-^=G5X.KU]>!LV!^^>36\>M4=GKT=#5^?C=Z\Z>.%X&V&%#$^ M75'Y776ORJGBS^;C8LR%1!7:FEZ7;XF=W8FUT?(-V.O"/,;4UNX%4M%ZBTS\ MJ/[%E%^?_VK/]L_:TI7]'_SKACJW\;C.\XITQL"X4LM\R/U M/T6QAX?_*\:,2'3#I:23";;6HCCH?;= #:O4!LWRJ&/XD'P[Y_PC*]CSWNCZ MU=LW9V_[K\Z'%]>CJ^ONV77OU<59_^)BU.M>6P5K%>S>%&S?ZE?!& @S^DYOV!VY\,]>EUPP^)=SN+D0 M2NAI4L)*92?%U@_F_C4?RC MB(4L&NIBT5#)B/K-CRI;(T@FN51,.[LZ6/G5?@^8=S M:JGSWDN7$0H)[X+'.W#O!F2;S^636.1F[19OPVB+;:A Y&Y53[P=+?VPO[NE MQWIE^&&68)$J7O="+CN+O<-A6:P74AL@Q1U4P8V7$OEA@!P@;M/.[*6H;JN- MN.5EY)*;\P_D"UFR M"8,__R=)OW0+7*TQF+:9(;1%;$IP5'&=1& MP%A,+U8VN+SB<0S;F!Z]+2R^;4[@-OJ6UA$5X:H&(X59^BNL/ZF;,];KHQD2 M86.M_WOQ$:LO$MV7)';F15X0\PQO"N7N0.'!I5)D_(?(RQA_$ L:0L?YB#U# M(PUY8RJBE+(VVZG%WG=/I!>[6[R8$/D*K#'VLI"XNFL-KM6:2VQLG>_M=L8, M2WAY;=IV\K'37OW7UV\O7XUZP]=OAOU>[^IR^+K;?_WZXNSM]?GK\UB:3B4=^U*XN^V^O+BY'KP?#5\.WW:NKUZ_?7ER\ M'75[@[>7YQ=O[*5F+[6]76IG]E+#2^T]_)_SR9N(?.F\#C-DG,2@E[W:[@-R MY!AWCD!$8#W:JF=/.60TZ&X?,I+WU-O+R^OKB\O+;G]X-GPS'%YV7[WI#2]Z M;R[ZK\[@NJK?4X<1:UH5@WWHVM^N/GYVWKV[PPBXAA6]?GLQ>-/O#J^O^Z-^ M[_+L5S3!&LF#O.6EG;)T-HE9)=PU$[U M-/DHII0--B@ZKCEQ].9/<(26+GR"^70^&54D[XE_G LNWB%S>NK\)A-3Y)+Q M=Q%P+XE+CL[LV0?I1)U] ]LV+L#S_2R9?GCK3C[[_6N=TC;,G#^+A)C8[V"' MUO@M)UO.88U57<_'UQ\^R_J==IJ;3RV(KY&C2,1!UKJ1M92%134\CC$4Y8 > MCKR4FP,OO##@3HB!6E05\E(E/_'2^+HB:4[ N12" M[!6F?Z%075G01TTG NZJ2IPHDO]6,5*[V/X/'DTM=#CJQB"#:9KVU\JK8JNY?)]5(Q2JB2/^=8XXGG' #O.;]Y234PNC1Y(N384QQP+E;[$ ML<%R&GV1&F@UN.\9?(_3:7=T";JC>2;/+A7$*U-2XQ@-)A0SG>R*TC"00&"7 MX51$X@;N>TN,]4 M(XV9:V1=C3..9_]&77 E <$DC$P QJ_>>'C#^CI*H88;>@97\'= MK'R'K(>WL$5.K_OBG^CS)O00L)WPLV4(J(Q,.E<^-;@O__;FJ]3H\!O=F,,^ZZS.8O3O^=-??CNAK3XHI0TZU"5A5/\[" "1S7U;,DV5J'WE^ M^EA;#YZN?WJQ5FX\SK/]0 M3=(;JG59EZI^R"&3NE N>V_QU4&._,#Y2Y?^+9YY_=X-GK]'P:]'\J:6[OII[/IYW;33VS3NS_T+NRFG]:F]R]_Z-5[\]I- M/_)-1_5>)W_X-EO7\[],TZ2( _3]D_3'OPCZS\$:N1S/=9'A81.H\*.N1ZN. MR1,) GUD%S-_WK_HG ^^;_O4[9[OZO _^_M99[")F6/W^T#W>WC>&3;==JV: MM]WPW6UXMW-N][NM$]_#?E]>=L[K:=4GSX\\AM5J(IELW;G1,/+MUH$Q_>;F KSM^@USFS\<@FRXYQ MZ0;;&'EB[HW9'[8[:';4[:G?T<7;4UK#;&O9O\ V. MOO;M[#0%X+0WW9(8G."F6U#NJ6VZ)3$XO4VW) 8GN.F6Q,"2&+008K1_D&BO M6^_"N=4D]XZ :N*3M?+8EHGO8<,O^I9AH;T3W\>&#SO#3>KG[(8?Z(;W>J-. MWQ[QMDY\+SM^V>G:8J2V3GP?P/7!1:?IB!\]?LRR:NQG?FWUC%KK %DA:H&" M0*FRY"P'O7^]06?8Q ]E]^\P]F\ SL8FIJ?=OY;L7[_3M_0ZA[M_%X/.J"F1 M?KJ9%DO/TCH/N:W>ASX6:>[B6MC=_Q0=[Q_WKFT MA$%MG?A>W*=AIQ'HU*J)VQW?X8Z?#SJ#IAJ%0^$,:F@OO@\O[*- A*'SR8M$ MYB03YU]Q*J9AEHM4!$:_]-:->Z/E;&[-OO&6?DABL3*"$V_-7J?IHG]^6VMV MSPF#OSW+KMY>C(;=J]Y@<'8^?'T]N.P.KZZO1N=O^L.K_JO75_@=K[+PC[^: M]^[ZRC@JZK.)[6OUM<;C[OWV<7"%]9^MCX[)5_37,UR-1BUAN'J,*-J[7,R= M\TV@RH?J;]4^626P__-8?QDCB0+P1N=T1?QO?*U8P$# MPG]W[F(X'WCC;^ MLN/%6RP"O/IBBRGCNW%#*GLZ]B+8?=CQF8#]HXWT:'O;LE5;+]GFNP5+E@H' ME%AX@^9THKPB"%?.1GF*C%."0X^3'*YE6/=4Y(D3QGY4X$D(8_A=B!^) M"_A2*A9P=)PD=MZ":>#TNB_^63N)ZXYOVP[E^=/M]/ 1#D=]0>FP5&^'W:SC M-B=]FT4\U/W;[J3"*2W/)I[5,,;S%ZIC-$N*".1!P$'UZ/#"(_\H8A^/FG,; M@CC@Y.'C?\)I#BP*-1HD 5H+1]FRK!;Z0BH@^Q M6M%#%E$F;G'<:Q0+?IWLT0OGA?,_?QGU^]V7[[T87#Y\//ZB=_$R]$R"TFSE+8:F' P:O69CR(K(E8^OVKETZ%7])XXIO+-7O9C6FT5 MJVM5K<#*!KP9:R^+%9%?T5^-D@0;I2HI43ZS8IR%0>BEH6 I\\$E\>"-WF02 M1B%\+>LX5_ G>"WN-'Y?OBA//3_' >'7],U# XQ8#F;APO'F"=BFK]..\TJD M4Y&Z]._7:2%*J98$-JYS*VA:.(LPH$ 7G)29=P._YC>"L8NF;CFS$ ,V(LMY MD6H+,!5@=/0B\/"K#15V!(3V<"^JO M>S=3ZJBY\.+,I:4OC_5IJ%FER$]*Q MA]V%'R:"E "\2ZU@)M*;T$=+)J&A+6"#<00N3N)61!'^OW[R_^+$,A8V>G9 M_LDLR81^$NMLK<'@Z[$H1TR2"(^H&35-"Z.7H_I9V -4B')8\:2KXWTC7EU^$Q1=1.(>MR7D.#<=$CE2N+CZ9/X+G M*LH2%XZ\[Q69J#ZV,D4Y[2810-,%+IR^X0;G%C>'#DX*%85R- M.+= 2S2_<@:#'PL1F_-I6NV*3=1QWDV,9]QZ?)/FL.QR/;:3;U=*I\C@)[V$ M2D/!U3G7SP)!2N:B_*X+FLV?*;&20D=[7Q3.KG$#[J9/ JW#<_@I,2 M+5$OI!MM_]NS?O?> MF,.^Z^G?U9:;K:42LV M!RPV3T=C:<7F@,7FZ2AOK=@%;!Z-ZY1*UV?9W]_3OF=I,B\ M.,A<1WSUQ2)W%N#N9#/*A'FYU]1:_$2J>)_]_9.9!BE3L02M^W%;O7'@:W,8 MM1:MO37L[MO=M[MO=]_NOMW]X]C]8S/]/Y30F:>F.]S5E/ZZQ42>EDC%[0W/ MW-[%)N'TO:^J)6NT1V#_1^#R8NCVSC8)U=D#8 _ ,1R ?M_M-;+*V0-@#\ ) M'(#1Z,P=#C9I2FD/@#T QW NI?N>7\3;,23'8"3297([$@\U7CZ@TJ0M$EI M'//$[>[;W;>[?YH3M[MO=_^4=__8$B37*[7$A"&2)92!6*3"#\OZ36^>P&3_ M2[^X1T3ZCXFGVEV ZA+HTU[ M8*V-1EWWO+O3?MZMO5J.UB$]8O&\Z+NCRYVVP+#B:<5S9^)Y?NY>7&X"9;'B MV4KQ;%5,][;:3-#N_V'M/U@[?6:'+ECBVD__\D+X^^=*,DR9 [/O$@H MXMA% C]AO!OY1Q?,AQB+_"@#1'UW,-JD_W)K;Z%CTC:'*5+/^VYWV-2B[*%; M5V[#-O/9E2 VU<5;(6R[$/;?>%*$=S$!#=K'BLE]@WX+07U,I>ZQA'*(![^\4Z=7:F^8D''DK MGU8^K7P^GD\XV+"D^=YY'KZS:.7Y\.39ZELKGVV6S^?#SME@DQC<$>C;8\M4 M*.GJA.KE\3RKR(N6VL,E\C@F@//&_ MG):K;$,Y-I1CY=/*IY5/*Y]6/H]//I\/W>Y@$RC@$83"K3P?GSP?D[X]ME3- M>^'%\,I)$3E%)IPP1@!=>+,M6.[8!+&U]_LIJ3TK5%:H3D2HGO>'FU2T'H^= M=TPB>"PE!\_[[J@[LKMY)+LY>*M2%D]987*"I45*BM4[1:JDTDK?! Y FF2N7"\ M/$_#<9%[XT@X>>)\] +\JUF[,$NB0*39:44C>F?NQ="2C)^,$CTP\1STW?[9 M)B3#5CRM>.Y?/(=6-(]&-(\^C'OA]@>V.\/I[OY%=ZN^;(^QVS/!'^S")]NR M\T/CGZO=X^.?ZTGN\BK6.Q"I$XV\U(;E5V+ MN.GLUE.SD04;]-JA<&[4N\8*IQ7.-J=CK7RV4C[;&IC;U>9W.[U-Z*GMWA_% MWG>;$D@V)'M"+J#=XY.8]RG-U>[Q\<_5[O'QS_4D]_AD0K*OPZC(16"#L@^W MUON;M'"Q<856^I9')YR-;:BM<%KA?'KAM$'9(Y//XP_,]7::XK)[?TA[;X.R MI^X$VCT^B7F?TESM'A__7.T>'_]<3W*/3R8H^\J+O-@7SJ>9$+GSVLN]'P_) M'']DG^1D)VYWW^Z^W?W3G+C=?;O[I[S[-A!W0H:_W>.3F/[Q M\<_U)/?X9 )QUUXV<[P8MAG_1?Q9A#=>).)\#>9QYP+P=,"7O^[#XWI2^-%9 MU^V=#RWZZ)"]/GO&VGW&>EUW,++P:'O&[!G;VQD;]MQ!OV_/F#UC]HSMZXSU MN^[Y8*>$#/:,V3-FSUC%'SL[CE*E8^N!^#G)O*^>GGM^=NY> MCC81O]:J\2/0U@/5D4G=LQD8)#DRDGY^Z0[/+=6YE<^6RF?WPCT[L^'@HY'/5J'F]R*Q9WVX M]7>:)+3[?U#[/W"[W:WL_\,R\W=FW+?S!NJ!_3YP1V>;T!&U]JHY)HURF&)U MV;UTNQ=6J*Q0[;+%["4(U?#,"E4[A>I80IP7E^"4]3?IO&YWLXV[>>E>-G+7 MGDS ^O=.LA"IE^/G(N%E0EN^ MR^]/*R;SO+_.P]E:3LH]WV:FNQ*+-?O:GJ/05NOHT 1ZT'5'C2D[*]!6H ]0 MH,\&[L69K;<[&O$\_J!IWQU>;.)0V.T_ANV_Z+MGO:8D]+&%S-_\68"_<)2Q MI_Y@X/8&%BS94AURH$+5[;K]X287@Q4J*U3KC(U+][*_B75L9:H%QLZAV#3# MOMO=2'/9S6S?9B*F^[RWSD#]@3HUZM_3/XT!16$L7DA^J%Z_^]V>- 7]@W]= M'X&Q)+Z(LL, M7O7#+)7KYSEA\+=GV>7Y=7=PV>\-^J.KX>CJ_*K[^M7U]?7EFS?#J]ZKBQ%^ MQZLL_..OYKV[_H!Q&)^N'$5D,2.A"6-0%_RS^;@X2>=>5#FMO2Z?1.Y:ZHLH MDG_]V[/N,_H9!N^KGQOF_CFD>37]CK?_?RV8KFYK^-1N7? MGM13W5K Z,=;WMMQ$@7PB'>YF#LZ)O[- MMIR)W>XJ]J)E%F:8:'P;QE[L MAU[D7"=Q$.;J,Q]%5D0Y?>17SD$F<1/8KEV7T=HW&EOR1Y'EX619T35GH\5. M*!0_SX0S 5V0W&+*=H\[X3S'1_:[+]^__A]OOGAY13_V7G[OP,-"N&YA7@'V M<9Z):.'D,"RX@T!&')*4+,<'\V_UPY/RX?C7B1Z.KX<#GY)]H=_%?L=1[\9W M+M+D)L1W>O!U)RL6BXAF#F-PZ7G9+"FBP!GS2&",^-P_BMBG)]^&^MJDN!P%#SNF!/#HYP)G[41%0?VOX2(B?C0OX M=BH629H[\**W<(LXO>Z+?W8>U4YHLER_45[WH7!_!:5X$XK;UAVD':S7/H;U M.T@=-DM'-$9 8D^&3%)-\_RL.\0Q\0LG/G+&7P0\@P7$Q'_-[HL0W#JP4 M=?6T5-R(N! =Q_D53Q69X/J8.HL9J!TX6/!=/'KZ6[ZWT-!J5!\3,)_@)Q@! M#4F..I2'$$YR3H<?"T M "8>@3(+2)W,18"7OI[@N,A =C*8W"Q-BND,]A*TR#CDC20]F$Z]&+9EFB:W MJ)0\_\\BS,)RH?](0,$ZL+IYP:.8\RZPGH-9XYRR8HPBD(/NBI8._(,>#0.2 M^P)"DLR="0B*X\^\=(K*#N9C+'*C:(".QA>BGLWI<7*#8+N^0:$]TFEIYQW] M+G;ZW=ZEZ]P*1WR%;P=25!8@@ +[<,GS]T^1QG 7@\@M7><:!@8K'X<>:@"/ M3PW?0EH\<(OI2W!)ADF43%'&G5?>%S@(DU!$ 4CI-0D;O)$>@*_U(KP0EPZJ MC'$49C/XHQH*#1)E/4YN#:VCQ(*O;! ;.>(I'DC0#<8K5T;.)V4.QH"#9JQ4 M7RM"+J5LX:5Y#,^:A0O2!QF<^7@*[XIYR1+U'1A!^2*77*K_).D7>A;^\ ]X MB%C"RS\7\ D<.PIO L80/A9_4)/*A3^+>?7PR[?PE!<81V(UD66H)6[E68?[ M/A6L&.$)8@*OSVDL5V#K3T*R'-Z!YHM JFAKGU^]^]X9+WF^J=(PJ9A[(8WJ M8O@=_ ;.UBV>PP#-"KU!R6V,C_Y0P-C"KR[;0,9:>>9J\?[^/@,5GGKC<9AW MO!!G6F3"N7I'7TO@U6DY7:EQ?=I#)X8U SNHX-5%U8!1!%"$/K:*TZO5<5IW MOMIYZIVJ:/O;GK_V/K!&XO%O^IQ\YZ]P?/ MAI?K@V>]._YTU]]V_J<6ONS88"\/RA7U>O?!G%A8Y51ZBZ\.!2>><53B(UIAMAT MLI6,BF1LPI!B)>,4)..DF>C>-KN2;:H&V4QF=H=L&>RT3F2SV3PU?NXDJ@A. M2JK/-B%!L%)MI;K-4MV_W&F-:CNE^MA<7F;)4IG&Y_#A"-,(FY3B[C3 \93= M45I1!M!S>\.SSB9$?:W5^$>@V.T!>#P*LHMAIPG3;L7?BO\IB'^_?UC:?R-X M[TD##7XU,%YA)N%@ <.]/ <&B$ 89QY^1;30PELF:>9*W"H"$Q;P<<1_J+_, M"4,<,.*-N:)RPN7@GRGA/D5U$1,,CW_;08#/6$2A0"XI1.G@K^6KPWP)+\_# M*8$*"37S=9%DB&3+$\3S9"'F@XMXXMTD*>6&4Q'.QP6,FO&\J8@#1@V&"%!> M.DDLA^OXD9?!Z]_%&EKDJE? ,A AV QZ0AE'BODH8'L+VU!]<)Q8,201!2#T_1PRFAS 3 MQ.EH-*2/,#+83APPS8(@X 3K\1 S.,XE?%")#N&TURY4$_K$3.L19BPKYG,O M!=$,%#ZLCG]Y3K]/B@S>G'U_,!B*$R\YJP=/-R@Y.X3*,0N(L8 8"XAI&R#& M EZ.8Z/;D;RVF)831BY8V(K=?(M,><2+X3J9ST5*13%A#"X_>JB/=!A:FA#< M))!XKQ2T-YF+?:(&9YO$WUNZ?Q:F8,_NB9S=(?9XZ]FS:\^N/;L'=W8'9VZ_ M?P+PP&,+I;PG]HATC95\X)RD_<'%FJ[QK4U'GY*??IA"U;OLNZ.1A?A8H=JE M4%U0_>\ M9YLQ6?%LJ7B>N;W!<6C/8_-XL2VI2+/_15;$A8@S A_^L(!?$4]<&/]1I,?9 M3.BL[UY<'A0XVSHN;9>I 2BZ2]M*R,K4+F6J[UZ>'U3/LY/QA7\E1D]%\2RA M_"=FV@W2AB>?0[36"P*QX6O%L@7A>NJ/1<6C/8W., MRV8N9OG?45J8O9Y[/CPH"]-Z+:V7J<&&FLW*E)6I]3+5.RS\RLEXPN]4AY+8 M\;'Y#74 2R;Y[?9@J@,SZ7H7[L!Z'*>C*@]-/,_=?F.782N>5CQ;()XCM]<[ M/PKQ/#:'F(+=VTKC8[;7V"5\83C<"%USSW1;JSI/2D,>I$R"HKS8"'9M9=+* MY/Z2+=VS3>*(K97);?SW /][*)?[IRV9[G9OI6Z^?(^@?-TN L('.S)4>:JM M5;R/*MNMUNY7-XX?8VJO!JGWP>FZ/_6S-?[4F: MM/_SEU&_U]^$O:&U-JWULZQ06J&T0KECH7Q^=KZG*.GJ/FXSX5U)ZP_=R[-]2'5KE;/5P:T7RNZY>]:U M(!LKE&T2RE[/'9X?E:;<)D31Q_\>ROW//;$1PG!G<.(;=G$ NQ@D!78+VT9L MUR[L 5(TW[<^]PI1>SFO23IKG5NF*-E&T/Y:": ,'^&,I MB$,A>;^\&+J]L^V#N]^R*E8]6/704N&PZJ&F'OI]MS>RZD&Z'"WM*;^FX_13 M#^MWX>3+!8I&M#2[J6?)'/XA/"+GQ-;N>4(-U\=%!B/%7NROBS3$?M_8_3M, ML]SYL_#27*0(Y!:>/Z,6XLZM<*8BQF[KU>=3+_;D5L#W;I*HP/[&V+4^37P1 M%*D$?1L?BL"UBHRVZ808PQ[QZJU!.1Q\<.KGS[ S.CXN3E+XBY?!I^ 7,'^*#6,O^QQ'YR?SN<2_97%RF\%PYOSNA!X8 MQG[$W##J%; 1YG(X$=90\\= M$1T_2C)<\X[S2> $Z/.IP+]R'W@7MW'FW0@G&6,R'J8^36$X1$F'BB5<<,0; MOC<#$78"V$0_#U&5P-RC?.8L(@\& PLF1PPON\IP1S)1_TJ&\Q,TO7]X,6SO MDI9GGF2\;_0=]9B&H>4S+]=_=XH\C$#>G3FQR4<*3)"!1&69*345(8;'SD3, M9S83/G]*/0+[MO"?;L,H,G8C@],:3N SL'!)D;]()B\6B?\%YH*2CY)!R[R5 M$MB/^FR!)OH5#HO>'!3[(H!=\Z:Q '#109-A)I#">_S]Q_??>\2FW"!AQ&N ML&2:>HO9TGE^_1G^LDBR,$]!*L4\S AE:G[DMS?XF;B XP5JBK86)N["&^?J M0ZX#^YJ""BSP3 0AC 5D$ ?C!2%!#ZDCJ"6UVM=O7G_5RYHE>]!S';.?\3<_SMU\)&8KW6_^,JW^-J^^V/C+ M/[;N3.W Z%@=A?& BE?1A3&;D\"?S3? 33CWHHI!W>NR5\6G &\M^=>_/>L^ MHY]AY+[ZN6'FGT.\JC^(6^=C,O=6?+#;,,AG/UY>=BZ[_;.!^L?P.V6_@E$; M>8M,_*C^Y67=6GVF8]@Z W'Y;'V$FU\XO/SNY;,5&YS_UNO?\;?-_O143SRV M1/Z#\D^C-N6?]MC2^C]TI[RA.T5=#0[<"B< Z&AM'O(;UN+QFYW;)/2);/XF MM71V\X]D\YN2E"?#/0@>YU.S@^T_G-P?6D[!0]=51R6/%\?1S\O*XY'(XVA' M9 *6-7"G\[S^_$AVZ2,@PH:6S_R %%A+A6BC9DE6B*P0583(]D9OXV7WVYO/ M/VQTX1V8L;49R6/K;*U6B6.;M-Z!B>-&O8NL.%IQW(\X'DD[S&/S1-^7$**C M,00W:^716@UW[(JLI4(TLKW_K!!M.9U!]Z#:WI^,2_HOC94] <.K=W84EE>K M9+)-JN_0Y'%P')Z E<BF;BO;ZZG[)03 388L_BW"!1&1/0M/8)M%N6**>>W&Q_;W_+0O3 M6F5\NC[3\0OYZ'+[5@96R*V0MUK(+R\?EW/W:2V:XZ75W8=TO/7\D&ASKWPP MAS*FA'6=-_ #_/)=?",R(FMEJM>WR(Q'G([)Q/D'$KDZ_X8_(E]DZV;64A[C M*JMF$&9^P9R?63%'^M__BLSQX4!Z8>P$ OXO0N[=&'X5XQ>0J=LKK\M69(EZ&P9*#0WRBDQ"Y4$.DL\WA%RQ)DC.56$)S)#_VXKCP MD)]VD:2Y ]- .7-ZW1?_)$+=29%*BN&)DK\CH*;=C@36YC&'1%#;C.3Q[<^['S"<^K\U$3"/_R MR[7S_-E/GSY^>/8]Z ?\%SKJ8883ES3E\R+*PQ?S)/!(YICA*U-4P*"^X,0C M!^H_X+=BJ1XS%KXW%[0ULLW=S[(TEQCL@K'@O:2&;G+J*(QI]FLW!!VQP+16!.TX@32;I,RQ=( MEF18C-^11CH0($43+TR=&R\J!-X!(IV#&C6E!EX]A5]%3R0W1"6/9/>WL]"? M25YQUN?E"9CB#99,^" C[WN:? U!>PO8WY5SK?1I_9ROTL4]NUL//+YJW\$; M5_JATS]GJ7K(PIN*%^-4>%]>>!-8A!^]Z-9;9O"J'V:I7+_'7Y1[-^^1KN*_ M]CH#!SX2P0'96*8[>/K462--;IQ!J6E2,0>91C5&VCU%B:\V*( /;CB"%5<0 MYC7H]+:>%YW)+!/2@-_X.7\]ZY^[X/5M-9 H],;2-H5[,\45]9-I#)\*6/WA MS^D6Y/!-J]C;>MBLK7D5-V:+;QK:^<7EUH.;A%]17'<_N%UL.#T,NTL4F=AV MC#L:4FF+1,*#41DRZ6YY1/J=[D[.ZS1) FS8L9V3LP_SMZ4-.38QRG=D?_>' MN[:_/Q1@;X=?7>AH*8B,&RPR3^(7#7DR68>=B&BBPKFFF\A MO[W.<'OYQ2C F*(7U2MSXR=>;+7"19[E<*IQ!')AY8IU'FANXRST=6_5TNTC!JOBU7 LP3'8Z6V@]^\T_L$5?&AMY)+^B3[ 3U+O8[KHH. M4=1Z ATM _?^''YE>DX[O7VZ._(Q83AP"*1>U=B M)R/;L0\RV($+L@M_DN(#9SM9H9U>V;VS75B1^W740.IW,T9M0%2O[Y.X _Z_ M,/HR\\Q; +1^3>G?D1,P=/V[+ H7+B4&_I.D7_:CXS%\L(-=;[U&[W?Z+57H MPQU=-3M6Z+UNMUU.SZ[6Z4X%NL6MLZV3R!XK]TA=&=G6(;CSDU?L;\4XI6;$ M_1$K=Y=2D-)3_+>7AM3$\IWRU][$.2_]\W^_>Y-][SJ_B#CYZOR,TR^U.^[+ M>]E76-G[5UF6^"%H+!"HWSK7'>?YLU]^_O@,6]I*]?4E(_RH=I+A.'\ M7 09*,M_>U$DEL:KJH_]!?Y+C_[YWQ^OGGU/M\/F G*^BQCM:A".@G2X1'!= MX9&C]M:5FVL7 ;KST9:J*D^<*8B&!YO GL JQ[%Z->B 7]6,):C$/E*MU" M\3]8USS" X5P"CA]^.%FVWBK.&MGM/6$72<6W/?>^TK8PPGLB%/$$^\F2>G& M@4,5) 1[@27Q*/H15NDXB9,BJSNAZA; A,DY' @H@B.*W5] M[7>[YP<2@=.7=$_?T1@?4ZBB.@#*!:\#=E]>E>K^_2E-"G"<&)KU^[_?_037 M8^G%A?G*ZJUZ<4V/O28733^W_,2S[^M1/0^NAW@*>WMG9,]T]NAQ:%N B%Q? M/5X\;["+B]]CS<+1XUL/P\>PMAY"UB8%=2 >+TE\KV$7O'C)WN+,NWGZ5-,J M6G]"_VE>K!WX1.5UCG/868JJ-=&W_C[\QJW=G[W&M1SG$V@DV%C<5;"+:K<; MZS %B,2S#BH)3KD(L$/W)Y#T4+L02L?091".BWQST ]*Q9;&%0[6][(93@H3 MUJ0D47_VA]\Y,/LXF8?^2H9+INPM3./!MU[9GYUNO=$&8<=?0=ZFJ&"+&.Z9 MUZ$WC<$K"?VL=GW5TT_AS3V75"4D67G+_A-0Y)B>;RZ^\LQWUMXV/,!'!S?T M!]L=2Y2 (DWI$ME:89]O";3 ,JN[H[.:.O-QO%0^&R61$%6#]-Z3^>ITJXU M>]#;)FX&.S@D.+RMPWNGKLBURS7<6)%?I3[X;=W0?5L\*G; M!&3_?_XRZODY>:U]C4EJ6YO499>P\/!'T" M65'4U35V(^*%AD7R6)L5T!M<"IXZI0+PZ M)-3><5+3V_)[F WRIJF@4UUFOE@):9(*&6%#+2#2CH-L&7 78"R&K!1>&XR\ MB\D$DVB@C'5YO?@J?%U<#V][EZ;B!@:/X=7?0.DNG:O5]U=),%3P$H]4/@M3 MT-?P\4!EI8W]P"I0]3179@10:868!9 9O#*])XL.*+SX!88?^=YJ^[;B>%FD:%#=5]N'R[VC>^&LWQENO_\H@[P ]F5+%'2KE[!CGVF@NH7<] (8*O2P0MC([U'X"EX MN=ZV5>HW^'S5X*UR]TC.GFUNKLM=[&)C>>:O=+F^B\'O%=]>F&F=T8<[H]J? M6(T**OS&50H_EZF;>A2PU_V&9/LO"?S^71;!V2VK@#J.PS3=^X@&#B]W88-6 MZ,\(/B(ETILC;F!;N'#G(Z!I=U M\-[Q_!>#+1-9F^#Y\UL186@AN1/2KVPD94QMDP*ZV(EA7+4V5Y&53Y47W469 M\AZ\V?Z6# EU;W8+SVA7-3>[=V:W720RFM9B79XV6T4''S&,I;?MWN59;IE? M&^R@>F,+ [R["RUC4QG?;#U^$HM\VTSS[V Z@=K+X>\_TR0R;6:^]V)O*F/L MO_QRO5I^\.!TL[(K7>/?MBLE'.S"YY/ XU:EEL^V16WN* IZN2W+SYT(R:=+ MYMY]:VP+N-E%(,(B)+=6C":]QD9*L0)FU Q+"X%L^J !,38"ZM*+\IGOK29W MUQ5FK2I&"J%0S=G$>0M^69P8>!SW'D#.=C0'QZD^S[>E"*)RA:_5P>U$S5DJ7UB)0MI&*G(S1-WRT-S!U=]E:O/K%>E;6N[T7NC9/( #(VFI[":CL27$Z?]UX=/WM4\M[4IRC1U*<6_*:[2+WLBNKL?I70H.FDW9K[52=^FDTH6 ML/[&>DE[G2*]"7U01Y+60J%^.8JVE8Y:%Y;;2];WV&KR!CO"G!GZ:9=UQ%LS M*^XM1K8; ]KZ]$IX_:^0YPI!8O_NR\@'Z7>_E]SIC MKQA%5NLG^FO=C$2R*:(, &X=DSJ]_,[.J8:E&4UO6[)I/+L." P M#*A 18N69!JJ1;_F::9\XD:W(NFBLAE4O%DE;\!1N$H^7)/K:&6;:#'BL8&0 MRDGQ _6;)=)AU^:,XIR"/-"I2>IV%E#1:;IE3N/YWI,.= 3J=>E-R%_Q\2WC M:E?G91\^Y'8R_3H.L+QN:6"(Q4;4*QC0[_>(@T0:BWOA^G,I=6<\^(Z:,PZ' MIL25_WT=\#34'ZJA(]&41[H"#P@K#E7]9*;V3NGBF05PQ ML5=RKFC_XQ1.J M\G+!D((](:AH8+5GX\!"A27M=%S<[5F%B0P:C)ISI-(K 9CKH5TR[:%=@5@ M ;"B_M$, M5%$ M,.&5F-+YXE?=!TX.!^ZH[11>[@#ZLO\Q=2+QC8]&3M3@CIJ0E'"]K(?6"77/ M,W>A&:'4+8 ?P?X<3 @D0VD="8PZ:"V5 R(1)UQJ_S3,%0UP;Z6<.ZG4 MD I=.0;4JJ23*P(#$YQ=GWO*4M3;*\,;J^F_&<9SE'9X2YC!F9TO=JP4>^*E MZ8/\ZTQI^C%:"1^UP2X3_A_RM7@_83+4HG%Y)Z.VZ:D/#U,?FV&OMB__%YV1 MZ[ZM:SN8_^L]=C"7NN%G#FIUVAS] YP,)8I,>".XD<,(ZS[RK3N2NC'JSI%Q M!RJPCWSX/CY+0\AAA3+^[2H&L.G:,34<"BT=ZAN2U$SI_0.X,OT]Z!D.Q_&_ MI]6MI?*;*AAY0*5&S^.@6>W2C !=PIL<,$MD^%4TH6GYWDO"KY1+: 5^0$@? M505)EH:2\13DKE,F1@8OR9D'E)=G!=N+0>%5FRY*5!1ILAA9:6HE>L7FZ'UWEAKLD4O+M C1HWAR$KI+-RSJW M,HJ*O/D_8R\SAF?+F((DZOC^YO/[)-B(]R^;6'[V/7AZ6[CRYO/5;_J+R\D2 M:X9D;BF6S[X1)Z@ 0O\^E]5^.ABD6,!4N./ZB!,B(H1?Z7U5JR8 _/2\)=M& MY52*8:1E64RMHE.: M!!*28B6CJC]=Z-"UYX-1%3!TZ<*A1-:P1AQJ4 M\!"* /%K/=]#A"U?X[YQZ Q5C):K[GI"$!$O!W*7K77*>*)*)BUZ*^UG#C^@M1_!^7ZE727VVM0M>8I:_'6%Z8Z; MTO2)D7:MO(/YF5IBK?%J_\:!9(&?4"_4M!V.:LFJ'1N_W7R[5I-+R>2K,*>Q MBG'/Z#+)2+A<6QM43K9H(VGO5RD +^([0(Q4_I&+![Q*"4[Y:JFDZRPB1,LX.B-Q(=24W MCH'P*DAOA6KRB=KW#B>4SS9R6C=\N(I^1*T*PE?62B\E1<*!0*N[E./MO'J? M"<#:\Q]6[/IU9CQEO4O4,CF^/RW)LSDS3VYV_L^KZQ+MPQ/IL$+]TG8(8WMJ M26K+=!#<>OVXH;3S."5_J(99*$%740Q5/RV'%HH$U#LH:9B">9GW&T4[5;3S M:O4WY6G#$8 )DM1NEWF94ALZO*5L8=?U'Y#_RBPZ'7&(IE:2*2"[Q*$[$]U? M0 V6_C,J2/Q.H;RN%'(HG4PE=VSJO DV-I>:&T8),-7.BT4N-Z%$#*Y4$D*Y MW&[D9N5>G87'2 !$A,Q?#'7WKA$?4[YTF$_E*+/EXI4O)F5CR>,SS+_NI%,V M,@MH?[\K)M&;IO;W*X:&OV??X*'7VLW'"/ 96%)R*5NXKOKTOU\T7]#OGR>2C> MZ']D(8"'HLW!#4:HO^!FO/]^,<1KC<;X(T@^57N3+^P-?WFK'UK^K-7>\EFQ MCYYKQ37GISQ>F[L*A",_BOS9VQR:M.'*LSB0_5T^G_L3S2FGO[S8Q'CHHBH@ MH74"7<,@N?W!B^K/NO%DBJ7N0GOY/Q+&EY0IF(YJ;EEKCG^2]]Q^Y)X5!U$G M:R#&,M%T#N. 599=#YV0ID-6%(Q/'9*/8+SF;LTYWM&X3$8I*TS"QPF M!7R9TU3K1OME]P9CC27.U_4QO+(>!J,+'M_!S>V?\NV7\B@>F(ETUFT4\2&7 MAD*]Q..K4I+Q4 0@YJ:&JV;7\6ALP[1AUQ%K;,9<,,AGD,\@7Q;Y.HUUP6YEA[*>KO1;GUL:*,W1@Z,#0 MP='00:N0S_YDZ*!@=G"SMGJ2;"F8*=@Y&I6^U6RF#;V/6*WUS>/+?2;I(137YLS:+B!B4- M2AJ4/%R4/+K\@?>^[)R3]A"QF/AANS%NA(W%/! X'IW"%-@\?>;#:?]-?S@: MU7303T=K'K%J:NRB6B+?T!CE!OF>"_G:A3(%#PWY3B?'X$/% OO -,WS0KST M:$)!QF Z%C0N%/$T:&S0N$YHW"^6P'(L:'QTOH*SW[CCO5(3,^"K.+5(U6_/ M??B-.O#^%3MSS&0\&AVY>1)Q*V.?U1'WSHX)^=869!F\JR/>-4^B[N5TW *? ME,A.AYD?O_:)(P!;[9VHV8>"X,:0.@Y4;C:Z!HT-&A\Z&AN.?'P^@1L!^Z=9 M6;8?[J1\L9ZX7$Q#?NI9#P6=3]UZ.U3<+>)4,+AK<-?@;CUPM^HJ@[H7 ZKL M1.^.B1]SX87+TYQ/L2YVV#'UX<9J-'0P[)MN=X8.#!T,BU7WG@P='-<4-?HU M7X!Y=?W^R^=+]O';E\],%6-^N2Y2A%E/_.Z?1$SRU*W2>N)>YXC2, SN'1;N MF;X)]5%7U21E\I?L&%,/HUW]'@%B@&"PPF"%P8I' 7+TAMZ7VW]QBS#2H>'GUA-W MCXW=8CD0Q^+(K[76?S3FSC[0V%2Y&S0^ C0^:6Y\=!GMGP7WX)63V&5Q*)CC MV<*+G/OCZ4)?O SCT'#3&%,&_PS^&?P[5?P['2? Y5^Q$RU 6#/! Q3?(3:C M^=-WO(C=@_R.@V(IXX>EBIXU"XV,/#!=M% ?$6--'0@*MT[!G#(H?-PH? +M M&M:B\-$Y [#C'3;."<3KF> AJ!'8/ =UBSG\2?QP0JI*,3J$YV4Y]:D-C.C-^AL$9_O@A":ET[$V,\.4AS;@,, M3B!YP#1A,H:6066#R@:5ZX3*8&]UCA^/3\UG$,6!AYJ'[<]FJ(A$OOW=J,PU M14X3QC7X9_#/X)_!O]-U&7R)X /38R[YQFZZW!Z8UFJLKU,G@Q*.!D,*AA0, M*9P4*13L/U#['KR[UHWJB?"=8E5J1]9P^M1-T,/$W;/F3EKCUA-Y3;;%T>!M MNU@"Y4&B[:&UQ-MC)]MWEQ^_?+O4C8YN+_ZW4(>C U.PVXW^\0<"C1UY[&C< M+=:,W*"Q0>,ZH7'[% KJ3JBYP]? OW="Q_?8Q ^PMX,_$RSB/T[(H0%&X>EX M-(Q1>#1XNSO/PR&>>#W_WHL!W M72?3D^)T/!NG%.TVUN&QX6ZAL)_!78.[-<#=0CK&D>&N\6[@-*K;VV]7[WZ_ MO7CWZ9+=?F'?+C[ IQ9^W#A^9;MZHV+G^%QT#I&Q_PQ*&I0T*%F+JMU[:*]61YZF$/ M1;$U1ME!8F_'8*_!WH/%WJJR?8X @TG)^#NY^9._T\_,AES'$Z_5@.U6N_G+ MV\P._XS#R)DL=J0'[7L3\E=\_(T3P=KV.K7E_P0/V*4W%F.F=[N+UWP0MIB- M1"#OKM.R6+O9&N[RC>R]/YOS ,X5^2R:"O:<)QWL]*3/BV95X#K]R8&[\:(W MW<&\DJGW?P@&)M #W#T80G=3QK&YW,CQ>(1)S?Z$^<$=]QR;GHK@\Y ]"-?% M_W+[K]@)'7Q0-K_-C\=I, :+3_F]8*&X"\0=CP"I0HPTXK(QIDM/_& FWP3H M-Q8S6"D*X#GV,'7L*7/"E:"D;K8;37D$.PEPH![SYR)0R\AC^'%$V(R3]@(1 M+?"-^+M-V.Z$\"1\Q?''%FW\)]Y&AT9Z\0,V=L*Y'^*_)VP'X M'^$9_ ,\9\#/V#^Y M%_-@P135)'>GB8IISM$X?)S?#W^7'0DP%OY- /[&X@#VO$Z#JYZA9%;,*7;8 M72+[=?P]^TH/*=O-:4*MIM1[)'79P$74I__]HOF"?H>CV/KW-="Z=68BA%MZ M8-_\&5]1@Q^<<31]<]YL#-K#=E__Z/RB-3C;=UT^#\4;_8^WRVK7B\3Y H\@ M7/_[1>_%9M>,?&$78/MB19>4G[5ZN_ULS_XB!4B9T[+:<$5^2E>]\N'^74U7 M'KL%01 "@]^0LI)<>WZE97R1]\>M:Z?)L MD?QC1]&L\61 O6M0%\F5JR_%5P6K%[^^9%>>'0@>BK^? :>D?[VJ-ZSJB78O M?OV%O9]R[VX=_ZQ+MDR=I8^TIUK=;Y+B22 ?P6P _/ M>U:KNXM220/V;?A^/K2:G5WTW3)@WY)B,&ATRR63UD?Y?28I>8.^V?=T(SN4 ME097D3.WK'ZK4'6O@>[CT&WUK'YWEXT/3QFZO9XU[.^RQ.:$@=MOM':9M["+ M,.J&8(P.@"UOV%UF[?1S&J0!I3OQ>A0(_OTUGP 0WG#W M@2]"#&Y, P6__0/ET6*&K-[WXUE*)Z/[SE],^!C!Q3JNP6;^6,X3^2(T&(/3C1EG[]= M6>S]+47+OU[>LGG@PS MB]'?BY 2#^)1*/Z*X6$,[&="Z 633O(^SY_^A'LO .1>- V9*)-Z M4W$&T8M?+>:)B(4BN'=LP29")!=QP* GY%28I<@"[X&/ #VSR/? P^([?-D: MM!M]!@^Y@*H'@2;%(5I/-%F-[A\ VO2&C5YYK*E=FIE$M I25O:36_-%)ER! M6+M<.Y^D-A"MW;;>^R#-,;]/IZR%B4)29T&748SX')2;'\Z,1ZBRE! G6&C M4YJ4+621A;_=0I6LQ+N)RQ4'P;#;K0 $>T2@$M(!1%8)7&FTV.APP%2E21(CG=:_46#^'D=()G,DO. M',Q?5QF+K][43K3O1'L[N/SBX; Q;+:['?VC5RZ_>/!H?O%Y9TLN\):/MGU6 M^4=/^]IQE;=O+Z),;OC\D>3BO?9HVG%"<%C+C.!ZX$'G&?!@8V"H5IFC15*B MCJ#,VF!&H9SB9V4>RRBB]9T=JE@_C2Y'=NY3.NM)WG%=4K?WD%GF\L 1TDR> M!_Y$4%$P6,N!X+@9#)V$E@HRX.]AY-O?7X_(+XDA!C"DR=+>$Z4\7X.LE[MH M6_:L#4CZG:[5;E8Z ^#9VI35BE#KU!S'$-GS$EFO.[3ZPT)]JFI'9,=F)-_\ ME"Q+-*'V#C2AW2/BP#KOM J@86U9^A%P[@-'J7.KWR_2%[W^#.S0]?IWL>.2 MNDX90G_%SGR&24P!!CC=DKAX8+UX6\V^U1T6*K:KG0"N%=K6E5<>&'X.AM:@ M5^D$J_JSUP/AHI_%&/?.PG@^=YU- [0/7(AW>]:P5X0]UI8+GA*SJR=.=<#8 M.#\HG*JG9EC!@;]$6*&S)O>I3&?3=6W__JNLV-YGC?WN2:#=[%J=YBZF1M5/ M[M>*9NK*J8\,OUN#EM7K[[6'2?V%PX'HM:L5$4>IA0R'Z'H_* >546U+1JX* M90Q59\OWSZU>][PX4WRF!C.'I14?0C;,J0#$ ,%@Q9%K2Q_$/!"V(Z<=8#R% MSWPXSK^/.%3M,?FY;Y27%?9S;G3E !IZTGRA8?>EE;SGE*#+*>2-6QAIV#,E=.1K6\$7 N M;.5(K3G*AAF.+80&RN5>9R_4EH4:Y?,8L7M8J-[@\+#[V%31VPWMDDI?YJY' MLS]K%=I33_K,1-D<=*Q>IU ]VF,GK*UX.0(I8JCL@*ALV.U:[7[Y*2)UHK$# M''50=%OM;A7;HE_SB;+_5;R/WY6GVLY33\ZD+X,_F6!_:UV@8+% H/M(]G.8 M<<>+A(?FE\4<+XP#^<]1' )$PI!%_ <]Z,(:(.!AN3@*G;'0?;-AO4BXPO9G ML]@#9*54,8O%D:,[\<]X\%V@D@!/!OQ>N+2>3SG'6FVH:^OGJA.@GW[,+)-J M 9'OY]QK-EY=^P]:(=36_JYO/+-B3K35MD7C>;/1[W1;7?W#3("O]:C=:H3I M&H*K< *\F=I4K"%D+?M!UA>)EX3$UZR0^"@J< H,&@]*\O2W0,-& O#O82/>0,V(N#?="U>JU= M#-0U4-\2H>J9BR#T/4_% M-\4/)Y294;.YZR^$@-?>R<='PA,3)TK>&=+^X_G<#Y9:;FR;+9X.J*MB6#'Z MN^!MV\8V9[WA-*[.V@+H;&RPNAWN9YCQH--H[G@$]C(L!_6&957#9=N#*B![ MB$'T)W41IQ\RMV;Y:*NBZ,7VH^\FS6?';^PNZQST^[&-/+YV\T%52>>OP6A^, #7!OEJ!*X- I7L 6F$&R"& ]S M0'O:BJ3=@EKH^/0G.L'!9I3]1./Y'? ODQ=F\L+J[Z'=;5[8R;MA3-Y7Q3-$ M_L9G\[?L,F'FW[9,$3D4#V)]<-,D?IG$K^>&E4G\,HE?AR*63.+7,W"'$D.T M#-A+9" 5G@UEH%X"V?M6O[N+] ,#]6WS)!H]D_=55=X7,Q;%;ACRP&JU3=[7 MCH#;MLY-VM>NDNJLSDH$UL"V$MCVMTBN"K*^=A*XK7/:5Q*X6TK]&FV++:4Y M4X%P>03_C7SFB0?FS/@=?DGEU5C,I;7A// X)F(Q'C$[#G"9]"%\1<#'#JAI M=XO,RUR9U 5KZZ2N--(=VG!8F3H6J@P<.#XZG54_#6S7 _/63N5]/ MA/2!Y7X!(+K[S_VJ,RRY&Y8+[9=/T#C$C*_MX=(FF%Z96:H]\HCLXNI5P^;(.I/GAI@MPFR/WF=@G9\;J.\9ZN=6:R=%X ;H)L2]GQ"W,2=VPX[/K7YK M%ZVF#' !N#WKO&<,X1VE;5F#G6AO!K:_]AKM74:XCSB>?9.)7\^6PD;Y"E4> M18$SBF48)O)UC>IR4Y(02U7Y^![;[&=#U#-_S.54AD;QB%[Q;]8YFKT"]T,- M8 \:G?W'KS=![]" 5TGCEP,,5G^A82R/37,SQ=@4HQZTA^V^_M$Q0>I:!P9, MD/H E,=3#U)7Y?F0;/Q+PL8OJQK*>4AN)!.A/@;Z-Q%J$Z$V$>H#ET="R>CMI]V[ O@W;V]9YIXBF8*!>(DC=-D%J$Z2N-XZ^ M;/7/K<' 1*EW!=VA-=A)LQ<#W5]?GK6M9JM=Q*@ST'T4NF>M1ON5*<:NK!B[ MOD%=?WU8Z^"BDOWGJ$G>/?!*5FJW*F@:?HC!V@^"AM?('OHT?F;F@RCX]_J! M$B9B:R*V!^4H-Q'; ]"B3,2V&C= CI?+'MH7&[GYH1D ]<%-$[@U@=OGAI4) MW)K [:&()1.X?0;N,&A:_>:Y@?J>BUS;UF"X"^7 0'UK:?%YTT1M]QRU;3;Z M)FIKHK9UQM&7_8[5-:7%NP+NN37H&N#N*&;;M;J=IHG9[B9FVV_T?CIF>^*S MM)=30, (SKBT<&A/Q3AV1;@4]<60LX"7JK4F\".:LK]B'N#> MX*\RM%_K7N>Y@QYH%D'KO-'>?Q;!=MP[,!#V]MO+?"\)!I5D%NTE[^&3'X8, M&0UW!=WWV GG?BC95-(TOWZL^2=%_[ZV]8=@0)FHUP%1,E>)^[(Z# M=(8CK$7>:@%=GEGM M ; #MX)HY:4Y+?"T>](37/LP5[[X=1N6X?]1!$N^*4 MCD?3?\9*,T:0)6HIT&P)K:S1KR4[W W[*P.G$J_>/YP,-]L_-[L"+=\)2(R^ MG_+@KF3[HB,%7%[Q=!A,O"!6B;\%8L;Q M\@,V$KA'SAY@%1H11Y\OWU$4\+%@'KI^*E0D6\VFU6PV2_@,&*# MOSG4/W9>LM#=4EZPX\],-OA>2A9,D/'42AJJ!7-5*30)\R\^/:T:&!Y0'<(^ MD.: :@5JQ,H.OI:@1K"LIU@PM0;[J#5@%8B%0X!Q77'\97=@-;M= _4]0[UC M=7M] _4]0]WJ#4SQP8$5'QR_($Q$8"!6X-=B+:3 M %['&G8.O&3@&;N3]HK,SS3BXM=^H[O34K7C$]552:&+,4960/I4;I%UX#!C M/\:XR9ZN84\J_*#?/$#@/+,[$$7+T.JUR\N64P1=U^IT3*N /9LPK4:SLK:A MN9CRAFZ".TGF^J\K3]75V/YL!-O"M R/V3RP86++/V$YL4BRTZY%]. 'WY.L-N1J MB.C<9;#H3#(76@/TSMD,OY(4<-TX/Z(INX!7CF>9>L*/3@![^>0(C]WB$I]@ M"3C3C1#L;_\Q:+>;;S\Y?\4.O&=!KWW/YYB.Q+Z)T(\#6X3T5.LM'-KU'RCK M#"@0*R@C[KAT.,R!!"C $FS";4>-S:T=7ZDGM[OU@3HBYXYCLB(6?<813B=> M86SP7S^,%8Z]1R;B+=B4(\O )\?X#;CQ!Q^OZ($'XPSWQ+5M/F?\+A""<+)! M"/ !MG0/G!3XSY471D$L\344MA9KUSY\M:UQR?8]4B6(%T\<#X29@Z-L(_B# M_*KCJ;I"!^NC')2!7LQU2BPBRT?&3OG%OM_(!HCP#S: M#7X$?W#U[Q] BKKR^!R.EL)=&S%MBX MGPS$2V .P!K@/@4//. XJK@X]G+8\*:+7[=5"-=& M8WF02?!W'OQQ3 5X/XT/R$J>>5 W0\D=E^RB7KZW_$$4UEB,IQT22I8OE)\2 M7DKY:_@A"GSW">K>P]2QIR#' M;"Q'X'DQB[7\H)UA 3^\XHL=^9A:J;LSU(ZC'8I8^TW5%@?B]0RN%I@4*)\%,E*#[[K XU3/_P5L681;[#71J,*)N4-EE MW_C8\5W_;L$^?7K/SE[\=O/M^L6K!KMP0Q_1*@\,]%,@# 18_OCMC")J(:#0 M,00OA$6!(R#89MB[(?+M[U*/%NCUB&7-^\M6HY>40J$_1#8 @>7/>[]HGN/F MO">.EP&INV!M>'#-$=EU#"=R?@#3N_+8R =K<@7/3KQ/U+('_G3Z1%6P-0=, M3'1_AH3S,ZR_XVS"G8"X+AEN(IB!59GE W[@@*@$::JQ&;Z-UF&F'X=F+;)= MQ$3J0-65]%6A>VJE#]E$LGVE4/.DI4@91:O7[):J/-3F"X:Z5M,BW M4$<5*',R42%"HN3QF.<'32T'*GC44=Q"+@C>6%5#+S;;O2*$Z1B M_9;L]J2P!W:;&@KD_>#8ZR[A7]B&3=9J\QB#)S&U"DAX?M+:J)1E/:S@6.MX MX4IG.N,J?:)-^87& ";-;OZ.WG!_5JYF>S\[K[E[-(.=-9/7.76D3AHG,MD\ M.J+:N7/5IT2L>2>@'+1*:L4:C)*4+=AB.)>2W5T8QOA$]O(559M0RQL)2A;Q M'R90]-1M_2'8E*/% U"3FF*XWRY=96R:,FI.OX).O.4""*6R1_#P"M]'8N)3 M8#_%?BN7#?1\EUN":Y?48WN7AM8<:Y^RUQHFDT%RC\YR5>ZB7N^ M]UK9"=I6VNS?V.@U0:R!I0$Z*.@;9*>F^Z-\D,/H'T4MK8,[D68Y3<28VJUC MSDD<^<%"9K>DX%OG 0]U#$Y_"$<$LHL\,/FGSCQ,\JU2H#%.R?TRJP6?=;@+ MU^1/)B'8YJ.%LO!I9DVE;.]);Y0Y6IE$S^<\ MZ?E.3WKXN+Y+XS734A]X!;"CV)5L(\D5"&MMERGTW=G6BN(FIJG,74K+"(5@ M5Y&8L7.+?>8>OR,1^9\AY0W&8:@'*EQXW%V$#D'_8Y*^^-[W9)8M/?,EO145 M-TTS%I_B+;/8Q$'YDKAO;R[?H_C^S -[RO!SE(CU<^G7IB5BGKE<@T+TV\7% MU\Q]?99:T#.WK#UDOQI8DS&0#87X";B(^)Z&]$Q$@6.3RUHIG#)](+D Q<,: MV*MT)%Q'8&[ME$#D0,NFU,1"EWA0H>99[C0W?"0[+5 TTRK)5&":01E% $]XXM5&HP M)N./7$R^KF>-HE@)%2N^H?,UQ$M".&/!8 &#%*N\+T[SJQ+,@ MK5A+.XVV#HJR< FN5P6.IT8]48X)9F('Y%%()MBL':YBY;S>^!W\MI6,OB'. M"7"!;<9..)5?&0$VHJ]B'H.F@VH9O2?[I==I9JMR;BREB6L<)X17F>:H/PLO MI*\T5'+/,M0<7:BIOI. $+:SE)B^)!K">!0%' UYL.]]6WV"L-!+**_,>K\" MCH_3";J.4+E)3N8"D,B2$\&_?4"XR &8BGMR+1#M1AC6G[O<1D=&0HV2J Q- M_6PW!HT3R.D2G2/E8EJGH<@\T@K2$-@%5 (.%SJ&_T9P4Z,%JAO:,S05W(VF M-B=Z',.+ E(G<-P?8'>2MY!AD2DNI&K4A+DT%.6.ZK&XK8ONUB@H5""\@NCA MU(]=V1U^).NQ@*4'E N5>WR$AMS:D]=VL'39=Q71!@0T%RC H[(J M22$B2D)DA.H3T-K"C%H&T$RR52R5(D$:7*)88M-^#*Q1]2"1"K&@-65F#"B9 M,S600->:/:4Z3=YV>L4;084,3U=%-M@JNPD)2@G,Y:94DHO<$+VF$<.-F0 *-[S8(%P !5@"N(4]PNXNQ442?U V+S M"0@L-N.+].;0X<#5FA**H0/$PS&+*7(B-$_5SL,TPDE?\VI9N5DQQ^EU*BK= M1'\TB 3_@80"4CKZ[CTL@4TD'&*F!\($7?.9FUG/E*P<(<'M+6->U@-1]REN M5HF@6\GJI3+SDTJZI+() NR,6)/J2O_J33T=I2>>T[_<[NZ4<_HS"QS&](_A ML#%LMKL=_:-7;OQ'J_WH_(_><,NLCBT?;?NL\H]J^+(]=R_=>?.W=3K)RJ21 M5NL91HT\U_B/L);S/^J!")TZC9RIS]289QWRD3^P#Z]"H_7-U!F#C#.8\>R8 M4:3ON,&,4\",=>TPSERMY"(. MF*D;&JLQC77:5GNEM8.A,4-CAL8JH['><=#7L3DOOKIQN%1RM+D\;\5":3]B MH53JO:H,%?M6NUW$ZU!;IGX$O/O 4:HS+#(TR2"40:A-0>BNU6D5&952?\EX MZ/X7$IG+[;E+(F&E,-D]=A:?@%H[A:Y6V%I7'GEHZ%EX5*Q!3X.>NT?/IM4O M-LNK=NAYE.9P2"G:F+E+8YR.4K]L6?U"D??:,L)3XG=U1:EAI\@(5X-2!J4V MHM2@?5 H=5I&\-8ZQ-/2Z0:@TS4+31FMG4Y7*]2M*[\\,/0\;UN#81%]SZ"G M0<\]1.3ZUOGP.!PV1VD1IR7YL[GK+P1V0O?M[Z]'U,PP6Z!_E&KHP#KO'%0L MQE@V=4>I_:LL%3XG;U1*GB0M<@E4&JXT&J$S..Q1UV:A11Y,IFBG)&LDNM'"L2 MH0>GW;6[13I@U$^[JQ4&UY5Q'AAV&MO8X&>=\?/<)%C75]H'(FWY/!%':AL? MH,YI#!F#5 :I3@ZIVIW>(2'4:5G&R?AV?T+#4+$9_-]MUP]SHTQ.2[DSQHV:M'Z#4*?-I4[+G(X"[H4X9A#D*W7W8)\J].X$=KFG0N!_<<4^U]")G-*]43/8V*?1VE(Z]XESFS.GDZEC#SD&U93(H57>4.D ^=3(V]"<1KF9P.3-^AQE:=:Q6MU*4[A7+Z[,0:O"Z5CA\T"!AW9'P #G;:=GILD6G MX]G^S!C@QL Y9@YY8/AYUJHV\?MXQ+K!Y@/$YDH;.1X.+A^UJ1Z(US/!PSB0 M'4O!3I_#G\0/)XR<8Z_&/COO%T'IP\%<8US5'@4[0ZO7*3+3TF"AP<+GMZ., MB;]; -"O#X)>-_+=,2QQ,?XSQOYI[/+=U>V'BT<0LO.8#NH'8Q'H,W;F/]C8 MC[$QRW\TZ7^[AI]Z/WYGS]:KBI7;+6;O[S-;!HEBS-9 MR#\Y'J!!]*8'I]X5,OSDMJJ!)CW^QHE@;7L=?#\&0K#W."CZ(Y!#J0UGX=@= MU :.N]C6A2?C$#AE^[>+BZ],N158-.41>Q L#@5S0H:Z9KOY-@]D^F/K;8/] M(9^;X*^0%?%O2,>T$OAQP%SG;]B!QY8T LM]C 5 M'CT FM*#$TWI(=I8(,+8C4*+S0/_WAD+6)S-?-@IC@!W101; - $8<2],:T^ M81-N1WX04DY#% AO#/^<3(0=Z;X5E\2';]T+Q5PP =A?T !\Y+FW.9Z$( M[AU;L+$8R?+#&?^.IYTC2LI6N7 . %W88!_S@ #XQ=@SUTFA@2O*&D9\Z9^Q M)]L"T9'52=&E$V+2IORB;0-'XQ[L@!XBF. *2T /IW[LCN$^(S82.,;&@>_' M<_E&+*H4/VPW#E5%):VB&N+#*=3EAXW:X6E-R> WSK<7]+X+>:B!V\= MPDCDHX_QAFB5N1_HLE=$1.W1TSV9B>8" ;AC.^[*V^&J%<%Z(LI@N::=,1LM M=,$LD )F =\#6HKP$8J&=>&-X]B6%"#NN1MSH#SI:/7%^P&%Y&(I(L8$GPI=Q6)XS3]AP)!XLB,OXGG*VXC=\ M[\XG/I)LOL&N/&!H,P &V$,"(Z."8<;6Z3Z!0 M>"0]B+5\#3:1N'IL(RP;[!_^ \ QL!1D +1CGS@#]T!C<^9X=2-!&, 044+A MNB +EO9#=X)@@5M?Q8>1T(@+I).B5'HMAI<\<5M+0@.N7B*3O$TVCH5FX2C7 MI( &$AG[@$)XJ8%0 H.>@7\ZXQ@8388GW7,@0%2#)WZ 27YV($@R WHOR2\? MAX=RE*LKR)>\#U,7 B CQ*(Y7V @(@2A.!88H-!LS@5*A3^, 'KJ'+X2N\E7 M<#,)\^ VZ .AHQ#X%D EX'.QAB\X,R1ACL?U26-@>>6$U ^E'%"0!!Y#NH5_ M.HJ?^*XSIBEO0*:1D+O)L12#NT_\"S)#X98_@C)ZF!963M')XJL!: MXFE*/A&&SWQ@UV.X2QNU-;QH'M"+^0RLR@A'_2"&;%&?$/-PI87@H"4"_L.S M&K0_#8(/("IF(Q'(&^JT+-9NMH:%E[.*[P3>.RC\99*295Y]7OC+;VJ'UFO< MV/1#_GEYEYE-R6*K)3?#RBEVML-=OK&[/+"%?DX#OY)YVJ"*J4__^T7S!?T.Y['U[VO <>O,@-E>@R#\YL_XBB?PP1E'TS?#86/8 M;'<[^D?O%^TILX%]\WDHWNA_O%T.B[Q(0C>)%[#5?K$YLB/?V!O^\O;%K\N> M4_E9:\M'VSZK_*,:ONQ9\U>>RZO<:OV46[DU_\%(BTL*$:/-@:1%A]Q7.@35:E/-%<#8,9FS"C3%:>_/U"$9 MVCT5VJT^ +X!;'#ZMUMB^>?S"!MKX)7$\PU&T-%V8#AO6;U"TYZ/H U#K>BLKO+@ MX!"Z;;4&!J$-0A\+0O=;5J=C>MH>CPO#$P^JKDG\/9^+CO5;QZF^]XK$N0X' M3XT!67<,/,"&) :IZHY49SVKURRB:QX.9SL9IP0-=%LM@:RRS_R!:9XM"PC7 M=,(]%19[8-C9MGKGR^4^!CL-=M8#.P>]2A,,3 [![J6\'D:W;@J=:C=0%H?W M62!4 \OIL?/6EN.>%&,U2&F0TB!E)4+?ZK:+E,#5%B4K-OY;==4+Z-;8 MOQBCYS3QO=-L'/VH9X/O!M]3EU:C2'WO,>+[FJ%;E>!4YFA[&8ZUUNQ^ADU4 M7!K\\UE'JKP9TXR^!JC110OVU<4!$7_CL_E;=JDSC&FJC&X*.*%Y%,L5TK#& M]3^OKBTUM<4)Y=@D[-8K%<8XD(.@;.!4'KX#CFO'+BF1Y:9&' ="K"'"3\FH M+\S^>J]@_DV$ $Q;A#78+SV^9<3< 0W?H,%)83R;X7 7P.;O8L%&W*4!&.%4 MB(B-><31404?UF7F1;G9$VLW4W(0!LZXF0'$]'P8"34]-R1Z$"Y.HX*O3LW\ MD"KNL-3\$';F> Q'CH6PA_!5N7$B-67#F05R*F=]!TZT&X/S0;.K?[1W/G"B MWSZ &1#-/;[L:0,XCBL+?8WT?J?$WPV)OP]91@[*HN./%0=_9!R#Z3C^**3- ME *#&1LQPTPI,)BQ'C/V,:6@65-Y]>)7&EQ)0ZCQ'U@.?<]='$GYW(V3=W[R M??=&WGV10K=IM?JF;:AL1K36*MI=0:%*H$,C=6(QIZN%QTK$ H:WO75 M9"YL6P]@M@5H,2-7'&5GHE:O:YWW.Z;=57UHZ0B0JCNPAH7<)P:I:B"E#OVL MIV-O_^$'WS%>JH/_9Q3A#YU[RB"PXR"@Y'V9&0K/R>ZAKL-'CNM$BPT=*H\S MD^C%KV?MCM5L'GWND&GY?#((W6E:@[9!Z--%:&-P'HO!>1/Y]O>I[XY%$/XG MN24INX>O MH.P1( 8(!BL,5ABLV)5A4U.[9DV2U)4L1[AY>CE"AD!)A4L[JG')F8-C_!0^ SL? M%DTCGT<9G&IUK?->$2RM+<<_ L9^X#C5:5OMKHEW&IRJ$*<.*WZ^IO?9X39) MV45+I3^$ROP5((<93Y*$'2\2'N8(6VP*FV(3YX= -2A$>3V+%DUYQ +, M0@I$R$+8JC.!N_R+@;SB]6"(-$GH$EE.M VV!6\$5 8?\//TX\L]B#T MRMC>:67I[,HZ*N!XL!+\'D8\B%['\=#"7NZ<)5<[R(6(O"74'PD7 <^DI2TL54S81I**;I/#S:] M% %35^S*SOR POZ=@$<#>8_IIR,_"*AW6I@V]PN%Y_CX']@K;%QA0Y8@'AQ MOA$@TACP#1D%(.4,.\O0UZ<^$%LD@AESD[9W'LY#;; O\/DDCF#=S&=9I$V6 M1A)^R)]]"[%*3(+YTEKZC_ +046-IL+X]&?PE:426<3MN_Y,Z!^^*_D$_+& M\ E):WB:41P"1H;J,NEV ,B1'\#Z,^X1:C#Q Q%CX^!SB$-QQX+O +2>( M,OBIYP.]*C.)SA3&\+T5=C#C"P2N^CMM*!3B>XZ=:6;08+>P)40@#[_C^3BD M-@ZHCQ!A)ZR7(()ZM3^*. B-E*%(I**SJ5Z'F@DA@L#1;5O,$P,OAETZP%PC MY&Z&OSQQ6U](2L-?'2]&F(]XZ,CKYF[HXR>A@VS]G@>.'XXPHB5 M':SM@ I\,A8U/.S&DIJ$-Z4[1\Q+4!8(+W81J>#+;HPZ9U9"(E&"H@!')A*E M9?[T08%@]W!P_!,A%[PR6LQER]'3,8$,60R#A@T +-FX:Y3:056:CN7WBH[E=,C$!-A1)TITBV;@<^Z;. M?="$2+'0W )=$DXD=P/T@M0(5#%'SFG#-QH,E"ID6G9&?L-.U,FRD(,O@:?PNL9:5*!'X/"AYJ-3##'OQ)S=( C M('([E;:YV^GFQ_1C[U_\K>.-*9(%^3@.]R)S?B=#SB!42F\)0B7")T2=GP?N U][!%%_6S.S]RB+O!P\!E/-AV\!T4 MB2QC!IT%M"8AN<=D(FCW)-T?G% TV#^T5J0M#U :)M1]D\U=3H;3V,==@5CB MR+-!>T)@-!@R2/J&XR$_%DJ[?=EJ-AG<@8MF%VQ8<-!JI-4#[#]$K==G"\$# M.@YP6'5J@D+**C4'6V/((5-;LN RIEJ>;V/R0&U:LG]M>\)_ M0< )XK>2S^-R4P=^!>B,?>\_4;" B>C,44/U/9$#B;5DY(Z%$M(*;5+U^<&/ MW3'\#@*(/LEJM[A):2%FMTB=M@ N<%#X'6X__?(="(YHVF"'PL[WZK&1O^+C M6QIEWR@U%X'\N^JGCOW-GK[UK%.OU9G_>,Y>VK*--CP44AMMT'/F@*G*D4-\ M+W/<6!U7ZBSYS,R*.T5GA'J+DT[QIZ,Y7HE/^$B,BOF'+CU[5O<;/0Z M_=Y _S@OU[=X\&)SK%*U+3XOUO>WN\^VQ4][V7'E8:O6C!_1_L"NP0?1WW,C M3';8PG-[!_L3#6<9=%@_C^$D$X E*#;]?*^<._<.J@=@9:3-9]#VN"?M_+E3 MK9YWPO"^\[">=:0T]KCL6IUVN\I#UW-"M$F3-+1[;+3;ZEOGO>[QT^[195\^ M04K'&,UV/.51>HJ$/O#\IK/AT.H6:FF^>H%E#O2<7;&.0-8<.A:VNL!4NV5L MROJCH3&'-IA#9XKKOLKD5E3&=@^L?6&[:PU[E8ZN-KI_G?GQ@:'G6:MI#?J5 MULD>& .O(+MZ=R'$FB9Q??15,O V]?I IJ\^B"1?88Q23,ZCSH76Z21\#A_^ M<&8R!>%EX3>>=QMMG2508MN4&8!94*LYX+3=XAMLGU>RP1D?"YW(D8OG8\:6 MHW/V_$F)G;:ZV.NZ66X$+GQ'[9(R5;&$3^7SXR<_'(G6^52[?) MB1T28V6.H4S: 7(+N4L[3-&WW'8M(+1R&ZX=_ZHI6\6=^\I.3Z7'KK(I)\:A'QZRB#EN5'LD20])@13VC\AY%T@LA4W M.F?;\2A).G#JD<7\_W7L,?X59#D5D\2;_.9EUS2D6F ME6!C)*#ACYAI&-,3;,.;>"@3Z]*MT[*8'B@F$X$D)G3-@DSK(ZQRPN])1C4F M14Y%9M%0_VD4+T0@]PMO@%?<8;8<:,E8-R$+OR3T8!5Y9)GOEI'=$A,T?6.V MH"3K/(;4@K;S&E'AM5X.&\T*] W**-=303 SE<"-Z!2,Y:4%8N)2Y3G=R98D*#740U8L"2?$NBSLMV M-1JK)Z+LU6!6,$H'2M_SL0(!T[2$'26E?TM, -6>L4_%0\!:7"R7R+"B;/D? MXJ9'5W6'%198 J@S #/%/JLU6^7DPFX\+_5,&Y6%&.^EA/V8<*^=9R<^ T1W ML:L:,0F+R.(=#VR7+\(U-34/5%;GST AH\K0"65_H]"TIY(#I@K8V=_^8]!N M-]]^= )@D9\:6[%SI"OJ],D MP/F6;#F/^0M]- N4S&B:+X5,=/DYJ#4QET71N/K%3.KK"(YO0LF7#.34._#C MWV(.\ ;07&A^B UEX?%_QB!Y)0KTV1GR/;FH+ -_L;I:LL"+5\!1ZYFA"3:G,:J,,"RPP28&0*JD.6K#K?UY=6YM8 M0&*]$;&\2-Z9D/R+7=+ZZM%?=IJ-HEZ*U=622IZETVUD G#:GZ#^S'J*])KS&L9'.KNE!6=4=G-WDL44", /^0 MPK S0RG+IS]L-UH56#Z*6<6>8E&P.^VS*2=IP3:K@%&]0H*)IGX>..&Y6FMI].X8?5%AU=0.VP,F^UN1__HE2NH;;4?K:CM#8L5N59?-GM8 M+SNV\EU3I[GDA\][W4')%NQ?F#9SXCGQIXL"'Y0B9A#@%!! #R)ZSX-@ >_> MJ,3MY-V;.$T]Y\#N0!PE[HZUIN9SUX@>71GH[I/=^]VA-6A76NEIBC&>00[L MC\A,(?8>"['/6AVK5^W,MD*U*,][Z44*7@VQ&V(_,&+O=_I6NUND3KVF]U=Q MUX7::L7;0AME:R=W8+;M'I-[/6MP7@B1'SEN;77+(Y J1XZ3F)#8:A>1J 8I M#5(:1EFU;#]T5YCT0Y9R?N4OL0.7./9CC&.60=J:ZH*%=/G'X'/ ROYYLV?U MAX4L^\)0J:>*9R5DJ<9!5<$]UM=E> M,R6* JJH"NDYB-:V?V>LF:,TQ-@JB:LPW1)SX9EB+AJ]1IP;5+$I6 M;V]IK&!ZH#QM5U^\I29O6#B=:S06Y4?\/?@T_Y+_U&6P,^=5>G_LVF^POL7> MXSQ)3_;6N,*!TO@A* G_]!UBS&FM'KSB*7TXI*A;.D^VA\B-\R.:IAO1#4/> MTK)GSLHFSZM[L\"NE6O>K;2.I9WI#B*/099F<8=A7*88M-5L5M#Z2_:?32]Q MICU&9C2WPF[%OO]S>]4UW>3R3??DD\E3?E\V?"SS);[@Y*M?W&[R_O;T$O"*EE57DE[!MPO#G<&P35N (G+ M=YW%&IT M]3K>-I"N%=+5J<[G[2I[AU3<0:2:SN.QBC&<$;G,9!_X8"\,#]HTT!VQP\0ZGP-.OFMIP@56&S MY"V:\>#.\4!F?R-[5;.EY0?(>99T;TX;YV[5:8@;Z7ZQ+0>;1)0*>S MN29^ZV?= @7S^RD@56^A15;?H3Z5CV_\^"<#3KLL3T^I\9,FL&](8#O(^*L4 M_@<#X64.>S,/!!\;\%8$WE16;01L90QDQWD9I3C+'NK:_W87O66]1J_Y8P?8 M6V?8/B_2O_BU"S#_QNT-T#-J0G4DC]PS3_'$ TY,ACVCF#)@+C_S:&,_0@N-1+I(?TK0^9E&KI MWVXT6[\4/U*I>'4WJ]3^]+=QK!O.$$!@NHL$:NN#.EN!G0(ZG=Q9#JHY#6?/ M4&V7>G<>JB6G@]2.J^PN(/I5#8MM%+_UVT<"C6K"CYS)^U?, Q V;G9,[00> M<3S;F7-W?>PRPS2HM;W0LT)Q9$AE,S;+5P4<09K(?K#NL\Z@^P#75A+U\MEX MVT5...4R!4C.SV2"!ZZ# 7O,!+?M.$",PH38?#)>DH)*@U$I=._I$5;NIGQ* M_2[;GPD:[XRK -(3BT?V'KL;T'V9@G BF:!L LP@M&WA"IDP@AD$/G[PX(2B MNLS_JG)#?A(;ES3@5E\']I\#0R_2+,UW6K@V2I3J_/[$B\;YYAX3<@PO3N3] M*T;\1)SD*HL7I;Y*PQ _' "*=_>D4C1O_'? %\)CF?R9R41=B\)6.IPMFO)( MI<3IHHK]N#'[CB["720O6G!#T;C-=B=0R"32BX" M-SV2RIG.S@>$BX@]&P2/G%*EH+#I:=B@X+":C?<6QJ,_U2MPU[;O:3@A$%QG M!@@H?\=A[L#,HND33MA@E_@&,V0EKZ8/3F/(RA/Y9@7;=05Q,5*Y..9](1XK M'D&2D#+:YIA=B\()E#-OL8XN%B"T%XK)^9A^9N.AB%2<")/>74&YT(&0P]^R M;\F7,J3E +@0SMJL6P'-_+E"6YY3U:YUG?Z9Y-S]UEAM=L6^LXQ:>TVX D MBC+)X2B%EKL72'7[26S#4M_.?'DBD+1L.T"-/=I [UCAN(&K6 SLV@! 6,8] M4LXQ*"WH20!_QS,OG:CPLLU2%,/FQ(V]>+:DHRO? %Y)G@5OCVWQB/8"W_FW"/S<$/D0Q3?LKMUH=="]\'AQ M;.+IR^YQ^XN=,%N9#H?J<666=(+ MXV-B+1"*JPSCIY'V1H +7UBC M]LV,,Q%YKGHFR/!*: ?.2./T*]4]$(AT??L3J?XE2E^.A;4[VR*H^)+(AVUA6AZ<0SZR-NYZ]I1(ZJN?T+2R:7S-?04L M#Y"B-WNXRYDICU,UPP]&KA-.T>M0LIU@>8F1:664$VB+O">!V MZ3">Q],1B M)-B1<8^PP9:.OM$LTJ9)N&*FK2?4C(&F#;-T%4>N$0CX+M /;3%KS]PD!M=@ MA8"W,%T9E-Z87:&Y4K89;.I'>,+]3_F]6&49]-<\WRC',Y@$R%1ZP=-@ ;_C MJ/"H-C-+EX^4>@S):KGTYB0 >0CM/*ZRSGVI@Y)_\J=#*T_ 1$XNVE+M-BB' MNIR&N8>[VH12)YZ0L#S X4@3$I[$I ZNG=UKG^D>[7#^7_J/]7%K- MS3U;VMW-G[7Z!3\[?]IGQU275XVO@4,N2\QVI/O4YU:MJIN<=T5WL"/G77T2:?&3NX3GOX5.2 M!:)->K!)S&WL\S:^B@!M$90/>"/OT\P+N(M3;6GQO$.ZSCJZ>,->QZ3JRF^MD=I+X7"JXGS6]=3;LH+F3':QSR"59 M808UGA,U6@8U#&H8KF%0XRJC@_B7QW)T*,0[P&.(/7<$A\W*#&'M5\ M@QH&-0S7,*CQ1=JK]' O_] MR,25 86UYH@&-?8H+ UJ&-0P7,.@QM&KV!6,[ZP ='5L?'8@#91DPS0YJ2!M MR^F/8!]JYE#A%EMIAWD:>[':-"EIJS3BV!S<]UBNV06[NKK*M!RD>1&JEZ'< M;U4[2T8Y)/O@L!)VG9X!L*;91@0TGH;&S] $7>Y9^LY M$7,.*@B/DFZJIKO[.D9 ?\FW:'@/?PJX'2%>ITT9PLIT@JH&954\-:*J;7V) ML:&.#9"0PBWI79N::9+^ XGX4 M.R[):W].#3-Q2E(Z(%(J'W;F+I=W@\3C 0#@O?>"+4!ZAWI8-I XC6T$:G?C ML6!G4F2KZ/-HW MKSW8TL=N\T?;NM]5_9%YUV&]:[C'=ST->Y\<]:K&^[(QZ*':M>Y(7FHH).3? M>;']M/L)]^X<&FO4GG:S720,M(L#@W$>3'#0Q=09@[ QE[^/RV^9RS_=RV^; MRS_=R^^8RS_=R^^:RS_1R[]-_!P&!4X5!?R(KVL$__24Q]W&Y'>>"G>=]4BR ML]:K/9'"1K@];V;@RR)I&X^AP#8P%#HMX4<5Q^UVK-YY$;NGIM>W;KA*)5=X MP%S>D.ZQDF[_O%#:L8:=@:%= M0[N&=@^,=O_V'X-VJUWDSFMZ?X9V#>T:VC6T:VC7T&Z-:?>\V;.&YT7"K#6] MOTVT6Y>,P:K.^3&7CL[.VAN"0VGJ\"-QQ"+GWCU^=JSNL$CZ3VUEQ!&(@@-' MJ;;5+Y178E#*H-1&*6IXE$&H"A&J523N;_#)X-,F?"H2C#;X9/"I/02J# M5!N.UK<&G>$AH=3))*)^6:YA/^N4=3?LM9_6[G%W,+0&@T+)FD7A4%M&>LQ> M\)-%[X$UZ!;*K##H;="[_NC=M(:=(BX<@]X&O>N/WOVA-6SU#7H;]#Y*].YU MK5[KW*"W0>^C1.]VOVTUVP:_#7X?)W[WNWVK5:C!S^'A][%E(6TJT?^YF^O MS8W]&(O MRV1HS-"8H;$---;N6]UVD2"RH3%#8X;&GF:O=:Q!OU"+!$-CAL8,C3W1I5V! MR\^0F"$Q0V*[=:L;&C,T9FAL@SEF=7H#:]@Y+L=B5?- ]S5VJ[()1VQU@VLG M$'4E7,O?5CQ=@##YF [4:CU'?3UY#GOUWJR&Y-6S"4-Q6BMO4JZ"N%)>,S;7]V=SW MA)S;F1L(F)W?9[#V*+%V4\G+86'MTCC*7>+M+O2;:@>@5[6K/P2;\GO!0A'< M.\ 2N![ ': X M2C<2DNO@+-! S+D3X*UR^.Q/'_:VH#N.@\PT4OPVQ_'CL ;(=BRV /\&J"N@2-H([GMF>,YLWB6&P\-VD7@_R"E MPUVPEYUFHPG/N:X<5UQ R9&KNP;9Q7 MC7SCJP_JHB-^8N1PUA9M@26W+Z#B"/0;8>. :4<-WKW\84^Y!YA.LY/#$-%P M+"8TR]?6A^7I8;7"#-\.<;ANJ*@(<1],TRF;^C0/#OKVGXTAON/O!%B%K:-%#PVS]0'KV\0BRG@KV.G=".PY P M-H2U'2!"9 ,9#C)7[-)2\[JEV9TPDK&/@\?7T'="B4\F[1#_F-!M@R'[(^:0 MVQG<+=+.O>_>XU;6,)1T/23@#",(T-T0 IL< 4V.A.L_U$^0UE-!_/WFDGWY MR"YO;J\^7]Q>WK#7=#MK^=H#,%(V1]TN # C&P5D"L:D]9$V^7OCIL'NA <" MP@5^"Q^+.7+)+-(%@&P.8$?(SGZ[N/CZRE+:IL*SJMZG=65\A\VN2)91MPEP(9305^1YQO3AI187'>HM[024K_KAW% MBC.ZW6!7"-$-&WCZZOC-3:<+!)@1L0*8^#$77KCA<)E+R&L48U")E/=/OH%P M1@GDE8N1S$)D^ *A(5HHA!# P>*9"/"2)MR._*Q>D# O? R0>NS -^BF48$2 M"Y]4A!461"Y,WVVPBU1-L9CR:6I8 +:[^&U "XU8 M0@4:_RZV]>WR7Y?7OP.'HKMHO65?" T5RJ5<)Q N.HOQ\@4HO;+!O"0T%2 +(7V&K&;*0Q$#OS;[K MD??@:B$\&DX<,6X0Z#;M&JWR34ND4$X68QAF!5+0^YHPX.U$9T#W'O*4A13X M6><_W1&^;>K,%=%J$" ;E2U ]*P.'5_+]RP!7"ISRI<"V M SQUAO^N?F/UU \BP5=% Y)NL^2WF*/1B\@&[!S82NJ^01ZN>&T&VU#5!5MW MS(,Q6G;!G1)%*=;J5^)VDL6DTXG@C7) (,"!QXTIZ!0B8J^E!U^*6=P%,A,A M7L.JK[6C+9":[N=4F9%2.%8\ZMX1#^%*4$Q)!8DNODU'\TET.LA_\#" FGX MDA%Y7#R7$AN>44 M6Y*35R7N(B*3MX=$0^!/!'F.8"V])CG; :\CB59Z*10M8'O]6W(4E'3H>'D0 MKBO]22E]DY<6_@QO010DU2I,J%4Y121A:1D%.'R'_]:T8F7BP$#X@@=>5LU' MV4P*51Y,]$)0ILCG$6X#2TA+9OAS?CMQ*+3S.4/(>I.I/UJ3"WV;''"H"@M[ MZA$D4TF8 BI]$1^CDSF,I":;/AS&<&AXTG8!.\B'ASIFYN%[DNFA[WG"M> R M_>_?A9C3DE[.=$JA.4(WM7K ]EU7D(2Q\AO7"$ :.^JZP'UCC*CC"J&P$250 M/;40%\0\IX[AY7S\6>6ESH*RFDZ%P6;,(*/7PB^BTCO$_8V\R.) MFR@1[\GR,#QC0U^[K&Y+%DDJI,CAF:1+:#F(=/5#FSTC^ 60)G(EA2J55[+R M1+Y*=%\5[I>)?25M1^3[ 9DWKNL_X/UK?3@G0S;J$TK=R!\":!GL,<*@%(/I M! 'LSDX"/@FGRZOM1%5*9U_CB""JQRVZ9-=GQ5L:*FJP5-O.L+/8HZUG-1$\ M6OIGVT]4'_@[Z&0Q;!ZC8?HJI':AOOLP]64032E?2MX"G6!8"YW0]"EIA[A1 M6W+P4&:_H++._A!2"9:DEKE[9X8),L U5[]])F$-'P 9 JJQ)\#\U7HP*!84 M*DS"+8!5- &L661P-'H*7JK7PIEJ1W$U=<])NY//'26_5[5M;<%FE7LK$;-D MF+T67H"0UR@*']D8(/+@>436&?].;/J>.RZE6JP1DUF3%=4!? _3ZVJ&0)K- MVLTFEJTVI3<,J;SR@WVG!SPC!.E%+V,7%" M9N*\-^K9D+WS\2MGZ!%J-]]^O+AY1_]LO7VEQ-'8(1^%PJ.+F_>DW?I@6+)^ MLY]\$S^ W_67I8&[;L?I-CVFO@1Z9>12F)8S5'Q<:4$'8BK ;+O'2,=8N$1G M&K/Q$'IU'F[RQ%@J_BM=[:D)1F@+O\/%^C-2R=F=[X_)(DVQ'[6XB0@"21U$ MF/H+CI?X*FA;VK[D4HM<\A4A*))C*SFD7/7 V.'OZ)]*_,U(OG?P9.H%7P6B M#CS1'65#0*D?5X!D\Q?IS6FK7'*,U-=L*/7)>4!*GY#Y.IHPP @(?#+I$%,I M)09%@^+Q&58YQ<@\DC1>K,+\92>X"L'04_*6-(G('*$T#^@!O? /9#^)>V2_ MH*#8+@?=A7:E+=#$G"$SEX\IISC4.)$$$9:S$@!_/1\YS@25#;G>%E5)F7WP MN!\D-O98YR&0=H=:M_0GIUEJB>H#VT&N)X,JZ/-O8* _ZVNQ,;P02=864E05 MXS A*FB9R L>0]$O<= '!\5L>CWD-U*B405JM9*%,18RS]/M)?$7?RNTY%Y5 MA 6!@XXZ?]-%6EOO90H@&PE!;K10D%N,6$L8X6L3Q5S?^58&JR(UBM6,T34@ M[9IT[1 #D3)[B^XJETVX_JX(8]':T>;%.F1-S!SI"O?C432)W50-1KR%+:?H M*C>V9@,Z^)!\51HQJ&(UV!>Z,/)P5$X5:48/?O)HHG[.D>F0G8)8/):& M5.(!QUM)60!A"V"Q$X01K:R/PL?(4->[X4WRS5+RS7*3LR--OMF-#XD\I-Y" M4P0Y'!0GR&3G4?;$&'T/FF. @9TJ/\":QC+A#B,$EK:;/1(2+OI30(H@D:'U MKC6Y1"?D-O#)4+)0&PPW>B]\)28%D"LWI/J$Y&.4$CDRC0<*68](I 01&5_Y MP%X^JK< X_(G=*_GRK.\>/_^R^_7MS?LV^7[RZM_7;S[=,E>LYMXA(PCDK%Y M\FU+[_ :/BVCWP%%I34\LI%VZZ%P:06[HE>RN-&EH1.-@=$@G\[+E1S:F M9:D\1<'1KM6Z5K+]S+[)9P5V@H#C.:CYH6D!6[6T%T-YW?!-(";PFR,@H@GJ MM(!Y5EKVD*I DG/0TO D19# F]=A0'H\V^TS_] TPR6 N,-Z!FSKH$L7><[ MZL7$K_';,J,SLW<,P:-]@1]FE@,KCMUS-U:>N82VE%N.DE'(#8S'59;Y,D#P M 2?*EG3*U>E]"HN@ \^3 M'B5$PCN5SY%X$/ CL&:EM11OW@4RM_6@S,/_N0-8]?0W7%W_Z_+Z]LNWJTR^ MUI4'1ACR4;P191C*1%_'OE]]N_X]=7']@E__O M]ZNOGX%%)]SY:X!NI$C>0"8G)L> D>XM:0IFB7XLYJ =.#S)(@XU"@W\X%Q J3*@,9]$"-LC#&=HH3 M'F!TX2^W>F1UAX47:+!/6%@]]5W*' # ZCJ((&OV:SF+_NE YO-B.39*42:S M.)W 0'D+E#^O+8:68)9IJ<3:M F6<=28:-;3=O7N]YNKZ\N;&U!]/K\#/>CV MZLMU1LW406D43.?2YXVA81U:OKCYG5W[#?KT=;.5"0+_KO^F \%6/CVL2-DR M/?[&B0 J-M8MNSP L&A>]@$CO([F@YR]0S8'E%<"_=!HE8G!FGEB<&02\)EX M\(/OY"81RL;+V$(\YR4/IXD_T$Y2G'V*-:.#(.-M! S_NTR%GONA+BL>J6,P MX,IA'"J;JH%W0\VS5.G_/ Z ($*A;"IM]9&NFGM);E%+497,:4M>!<;@2 >( M,XD%$=@&D:POE@GH,C21"8]GK/\T,9'-,'B@@H$4V^2ZBP"^'SZ9QZI>B&J' MR9](>5PJ;1L-[LB_D\#-^'DQTHDN-V<41TGNN_:R8(H4[E=@4@&\ $$V2=?/ M^BO)DL$F"]+@47^Y"_PP3$YDZ^!9* .>'IG$*I] Y2IH=Y=T=I+]3G=#N<@4 MDG0 XWBPYD'*R17>S\%5N3/2ZVQ@?AM98AHMA4PP4LB1YA8Y88K&AE4^-45' M^6D26DNBM!G+6-(?8>)FJE-95TE(5J4#RGAT)AA++*%\CKR%42HTPI$#^(.F5B:YKTDL/; M1)54YNW:M3.;29YY^BG1:^>X&!.2R>E@Y8S0[MY2Z.J3QJU +&E^W0LW@W3E M#)9LQY*KHM[8+4$5>,M+QZPDF=272P#)5*EEO:8R@*1U0\QX':&$4E$(4K>2 MRL@UFWS0=7 JHBMU5LTXGPB")/D %I(-;&2&TF2B')8:7QOL]WD:[0;NG]0! MK#T5\DITB[BK&4KXA11!EC?J!^OVJ8 D[BFVA[VK)C*NC7[C3(N*+"1RA8+K M>E1L*K8U+/1IN_KMRY[M"[Q)YT(P- %]_.U ,G0HE4 M("7?0?D9@[8#FG4&TW(ZEBP+6_-07OHLM6Y:9YJ%*F#YD.;T"E4V$ 1D%B?; M2U1(5-K$.*2@8JIW23-LAKZ5F:IM#>Y$FLB2*2.0FH>R:64PU18J%998="9" MF[P5@Y^V]D.K9$0=.8Z!.,ENR>C068V0;&Q,I%5Z0/Z;8<:9*8ODDLQ;2V7: M)G%@NDC\W 4KN1)JHZ$:@67"N6H$"2*JORV/.O(0MVAK7$MEM#/\JV[Z)'!202>*Q0&NE'$WKQ%,0E^?/ M'6D*XG,%I3Y]N?[MM519+VYN+BEB_(=(72X4:?.Q%RVI'$K/.%L?FGFE6A$D MI&6I_'/*DLB1HK-9F5%UX1EJ0>9'QL]&>A(_G!!8[ZV?[EQF!2SO',^3J3%/ MS5Q5&YIIW2#32FP>3AG.BPB7^AMY&[MDX(6':\) !,>RHM[9 08$G62Q&>[?*C(:JF)2;#K(>GZ>[C/?.SYY=;K'U[3'#8\]98<2+>5/@)A&^H2@9=D@ MPI?*T/&NO&PQOZ1AW5 H$YRF'2X#=VG=S-0)W5Q0?B5M+110^XJ4V=/G*RC" M,EM?<3H&.>N#\B9F,\SF)"PD_W&NT[7>8<*AE_:4>*33TY):'X="\V!9W$9Y M6V1!@*(TQK+_Q"U)-4?HKZ7>6BKA72&):O6I2ZBE796N:&7]U-DZA)$?!/X# M%5BMG,GQJ*95AN-2E?:MC$QL7*&;G_J*,5#&1!*J1Z1;NII\O;I/@;5U)ZY6OM M):&F?-U*$B-<6LM217M_D\SCTZ *,$:6"QZ$P-D7:79Z2L.XV0+6X6,/IC5-:DL%E/A-4JZ[: MF4=:.\7"Q'G@N/!%TI1ZJI71';((P)G//(!EAO39.3O#Z];R7J_R%;:2[QV0 M^X@J1LE]<2^SD&6G.M_^CKE8V..*2^FD2BER'\V$[*$$._EG#* 8R(TT$O@@ MIPSN=5UDB!4^MLCTX\AOI7AB5-=J-IOX_^)>R1 ,!-U6:#:C:E\X*1W%YJH: M1W-S2W[(^ .G]E+JMWDFE9 H/OE(>M:H !95?_F]37!HL/=*"&CA<0=J(I'Z M!L"A<)%-"1*M*I((!9_\!=>�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ÿ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

]:@,%IX@O^0S.+^+"S_1VIW5Q %?#MCJ! M9#<+[GD]FB\Q*,;C !;L@%Z/ ]?6[=YUDG]9OB_L'E!66>9N$OTLKT N8)]F M^7EQ.0%"=E? 3B]!NOW>.5O^J+@X6L"O'/+G\J&>5/T*8?77Y2JPQOQ+/H:- MN@9.N2K][K:7!+ \KS">N%!2>/W/WO:BQ;BWGS!N2 M6=@W=\SD7C^[M@P&M#"ZA@WVY#,MYG:GX*O65IG-,SBO&WO/\ZR\"JP/"0N9 MC4I[(A?@%"RY,2XF)7"NQ3!WKUL#FK?W=].*W;!1:]F]+K0WZVWNT=?[5R,= M/-&B<:YLD?O[:M:4#E_F1V>S//O[R+'#3]GX2W936NOY:E;MW_XWI67NMPZO M Y/N/IML-\7=P4M[P>"\ ?ES64L$^Q*#X!H8 !C1BU7'0L"52XT!G)-_G>83 M*P;L+V]CHUJT6&27:83W-WTY$%L@899[<2V!FD=UDNM<-Q\&<>7&4@ M3-SNYI[!O3 $7I[/,N!.MZ *A0?NG$VG<#M[7:U?+5B/%4M7;3'N1'LE,F8Y M2#9@Y2_50B?%?-MMX.;VY_/B>IK-,G>76LA7FY,/O?*P%TU5> MK?U6K9>99N=_ TOX1<]RJY!ML,#J#[OKPY&3?(TRJ%1,>[&U"9*/K12TC:_N MUY7478I.X#D@@=*^P B$.ZSZ?+PH80UPCF?%8EX=W\B:A\M3&52?KIZ5IY*1 MI1\GRH&:YG##TKXJ6#0YJ%S8\;!1ZU:;7!<.7F()77Y\<$;WFBU[JWE3F2:( M!#]8AB+>0*L^@J69V"LX,)&^!HDC^-)S(UC=B^O%V-&D MZPH"]0;64WX%C&RI^60EJ?G@K3H.6J]L#04K#NPI>\K;7&BEB:MD:C"']>;5 M>F>Y7V;%<_95XL7<"YM?B[,2WF4.5A28&ODDJ#>\]7J^6_=\Y?7\8ZJS<'>J MOO@QM\N ;X&Y98VR\KB^Z).U ^U;^?64]7I:? 0_9R NAI8(EWPUS"_RF3.T M8.&MX2?>*G58.^U7S()S%S9QTL-^(X.=@XV;U<\\PE3K]N?ES[82 MKE;R%B 9W!Z7U6L, EO 8+\( L;K+;#>K-RK7L8O9 2BJ?3F;@'6'XB-,8C MI9W8?O+[>[?W!UC"E3-(L\DCEOSC%A?CMVP&$FT7)N3=,UJU<"!$D%U/NON; M_]SJI:Q[*!4?K3%5Y0I5KPG*=MTU:3L%F[[*#GY'VYM9\V% Q8+8;]_P'C<% M%E]_YG19Q4RCFJ:MDAU9OALY6JETF'^J ^5;?AMX(9_/BG+J7]6J9G 0,NOQ M^JOANU[C-6J^5OHMWKK*M_"7H_B&S"M_L'[T538$@P X!WYKA1=P/+C/F;V] MOV&QL(LK%^.Y,S,:4AZT%/^TJ'3[JK5T>/KN:4&F;8FO_2EJ#5;,V))QN%5 M>*ZUOSY";. #34'UXYL?!T&'TF*'$ [BWGLX6[YB@&S3&:!V^+ MTAE*54C$LJB!!7QVIJ=7)?_*AY=+)[>ZCO!;[OMH>549DP/K6EMA70EVJRD' M=70)%E2K\RM85-X.=-6B[3A(*VO "@\04U:=^1#7EY8Q7+3E22WNY!'N(0ZX M+8KDSJ@5H+1"M-IG:W6,/J^,,7O$9OZP/- ?O15<"RZ0BW5\H46:51BQWCPK M@I<"WMD>SD'*QF#+#V_JX/7*MKDMOZI>8370M?*<%672.$V-TJ@^N!C-2C!Y M)N #CS+"4/:S\B'6/;^PXH [R)'UD.3O(/O6DH'Y=3/+;,B+MH#2FC7:R/W6K MG+8JA^ H6%$[QX\6<$'06GE@Y<,X.Z_B#R,_$7(8C.$ASHX:S9P3Y>,WQ;BX MO/'QW*4D_$7K#][*S%:N<%.1#/M34I MO0FY#!RYH-+9NJ6^N-\<#^^UKT%86K%=;19&^8:E#YG6NIJRE\Z7QDC1-0FS;N7^=IRIO2>I$O0,#V9:,N+N$!NWBQF&^& MDC#O+Y1T,@'BN!P!J9='OU1HYNY,G;-_Y.!B)MGXZ'K=)9VYY^GDW=+OV?^Q?@8C_@GQ93ZU\69U5\J]HZFTHK MZZUK@DOPGT8T5&ZJM['^]R*;6<$ _$L00?)H?R%8MN&16H1-)WZTKO3P8MUN.%.#5M&]C]Z;SVSADW- M?K45<+QRU)M62F.>W"&4\'&0W.7/U=F(VPLLKJU";,DLR]IM\>1?>[ \Q]:= MMGYU1=C57W;"8L<;7+OH33[<=B>;D2L6E]8:K;(-\*NCRN5LL@ ^N;:65OCG M#W#*8#?-?[P]U+FS2;>4F^[<7 S@#H^WLH0]U;?K+#(;_[2*WFM>7S2QLJ"# MDV '*U=_S295GI"@V\0J04<(+\6J^ZESL;J$0W:I??*SG_,0G.9 4UZH_%#' M(#$\^]8O^,D15<[-XM[69?+-]ZUK:G]_2V!R-=;U:*E>94N6'&!%:M434.< MM];5M<1\-:VG7.[!8&V SZC9A55I,6Q>[7CE$%?,MH>F6@ARG#XL7#C%NZ_; M;:-E8JAA=!!1F=4JV;B5BW#E$_>6'>Q0K'1 Q4<'+U%4&;>#D%;=^$JAY(V ? 6[U@LM[>620E(R'1.-5,\)0Q4,O:4"%(&,.GQNS< M6=1'@/V=;2-B3VPC^BV?7>:S4MNY>]ZAM^U#9E36_GUI&C/USL8AFHA08<2H M9 ;9%M]4QW7!)>,H:34.$3!$:"AI%&E*8ZHE2:M+,:8L)'\['U5K(>0V=E7DJPAX7VO[1EDOK:L\]&.P/ME !W[!(DM M'+"1WK'+XF=PLWQZM)CZ<9Y5G' QK2IUP.\%ZWA16]?.5RYFP%Z/]TSN:51& M$HV%BC_8?/#9:N%+9_T"ROK640W M39K!_F,XR[Z ?U;%Y7JF0M%"QJ"$()-B(2-,113QA- DQ2E!<4C4CG.4>Z#" M7ZU#/2N+R;_R;#R_VH'L3MZENQ+>%J3,IQ/>=?;?Q!5C/ JP>(545@_DL6)W1K+7:I8U'%1=>S?NLQ5=7<0""YHD4\#_N(X$& M0RM.F1$A(UQ%"I$0A3R.@00TL4-H4TUW(X&/N M@P\?PCZ<2A8\05GSOS)N6/ )4.61 MKF$'?7U&U=T)*W/!UTK8P)6/7,(&M,O.U*(:71-SAHQ.D]@P:5*N[,2:)#%$ M8LP4V_ +ZT.-B^NS2MI]7-9FGU2-2+8@QX\LUM5+@^_XMLF:P>_ ;1I^F%E] M/;_Y,,XF<[C"4N+4$M]3A0UH?J_X3_Q6]T!8]'A3775%6$ZJ^"X4&^GN672( M!I(K"J-8$4&%,5@K%JL86]$129%( _]:@>EY)"5DVRCA?6VWN>ZSUN_WK'9N M!P]"=^L<(@8(W0O^^RA*:&>;-WHAK BR/\]LK?:^Q8B0#>4H)3#6B< )XO#K M-([![E <13I.8Q+V*49< =2[8E*E9+?-2C]8PL&]D4U56. VX]&YO4>31FM" M-4Z3)%9*4:6I3ED,@L58TH K5%6E:@TT3C='#U> MUTE_XU/'[2E)4RQ\$GT>9._'B_&]7 M,N@1V2YLXL).' "RN(8#*J\R6X#G8D! (?.^A6/8N&#&* 0"4= 0T2@V@FF, M+06@B#+$#5JG@ _9C:LY^U14JG$[293=Q/MN(X/'!_8V2: S63DOZMZ0U1!> MK]PL4.,S)92:2 N##(^-T4@P2>U9$HP3JK7^9F'\7KA9]L+-B[FK-+7G5JVZ MXL[C'3,XKMRS#MJVXG'[#.P+U/A)R*0"IU(C:AA-"$EY%$528DKC!%SK^%DZ MTM71G$S.C[L+JJ@#]YIW/OS&-1)GFJ0L#8E&/$(" [MK>^8,Q0H/J4?6W],O8AUD.D B)5;U2PM?O+HT/5/M43TG@[4T:3M4MXQ 5-(@,&'TG! M]XTQM91A<)(H23>R=ETYP@\YN$-(T38)$YL@\>D2UX^W8P%'OP8?(:_N6W<& MWW26'RUQO)?U&I4-?U:]8]5HM\3,RSPT1/_,2YKR+AT1(I3DD8EBAL*0$V9# MG*G26L5IS ^C0&-7AVU%/EL8-OCL[CHOQ/H1U+XT9U2N8#$VT+7W-;S:UDB5%65K,:IELZWW:^"3_Y7/)JTR MS*IT(CCUD"$6??1X4!=B5DVH%_;&:Z68J]4M9>"ZL_U91-G?\,G%*!\/!T$, MEP.53$:9J\F;+F;G5PZV=AT&9L^9*4&;H!I/28)BI**4@M0;I51;#+"X_3J?+(BP-R7P-BZU@MERJ?U[-RZUA[8\L^K(JA/K5DF'O192 M/=4C]S;K)I3K/CUUVH3BP :+"&:)20@89 D5BD0T,1&+%,8*X8/QU,DADAKJ MN;1J6NV0![NKMZ=WQXXUX3W#N=(@0-*$1L;(-#4HM/01*RU2S=BWS'@?(DF$ MQ[)7BO@&:6_!6@40"4_B2$2:X)3K.)(ATC110C(D"6,;]?[?I'AJGW2QJ\]/ M>\QZ=U$^M3,M-'$^PV02A6$4PX>(V[EI,05:H"B6H8CIAG.PQSC?(4H&>KPY MLK%+R;#_^%^[DI\B0V)">,C Z(S@!ZZMFE :) 33_:F)!Y7#'")98-9G>O#; M%\6(5@6_"(U@4N!$QH8I'B?EW]%NVG/N3IW90_!6\-(%;CQ MC":(4)RD@J81^&)A2)")H@3OHE![]N']&2R/H#/&Z5,&O@R7731V%R.<))(: M%IF8)4A(B@F0"<+*1$3KC=+"9^&R]T59Y)B\1 ]=-I$_@E%D.,,A$8@K2F/& MP$./4)B0B&J.GHN'WA<%\)YC--_"(Y>M6CIPN!@!OF8,:)4^/P\ MKN;%+"/CSML '72"314L0J$39J'YE0IV 46%) R&*M]>5I]V?& MB5?'^A;'NIDJJNI9'Q8@!CR:/TZ2Y80G.RYU4GP-_F7?LG&B+5G^E@_=2-@Z MCPY\79R/[/B10?#A.#X.?GCS]E\?+;AP[24/*_QR>[H.E&99Q )/_==B6 )Q M_I&-Q_E-ZU&KMWT+_W.W_M&68 MBI!K1-"M/E2+Z'VMRTGUXB<.FOG]S/[7RLT_K(\);PSGGP^W<16&8R-J-Z[R M.^HW=+F?S79VQF6BSZZNS084UZ#B )(+A[=LT=-K9O7.*,X^!=7N7ETOA#FPLQB*S_G$SF:U:.IVOFYQ/N( 'GLG*]R$"E,A#(LQ MUJ&A2' 6)6$,5H\!BX=CDI!7LJJ^\\D>T#O8B^Z(B?:D3 =5_<=&,&H?I-6D M=J,TY*&.&&)@-]EJ$$$4D%8<12D.J?F68;\OT'=0^E6L5 DZ9CZW9:^$]2S\%9GMBN^_ I&PUD9"(D@BCB&#-(A-) MKBQ CJ8&)Q$AH>PM,/G[Y"+[7,SLU2XX"6Z9&]!XEY08YJ._WN:7V3BQ<9.; MALP^S$9PR_RKQQ-N58_ HVNRJWM0#HMPR;'JC7 'P23WPQCMH+J!&_A! M))Y)W\LR4E=7P;BFE!KW>1W@>Q#\:2-J51RM#L[],BL6TT$%/?[G'R>_O/FQ M54EC1S?=6TFS[;:Q*Y-9WK>YPH;]5HMLLL .XQSG=[?3M MNW.ULX!$H)-:' MU40CZ8I]K'"2*DJ(3"G3*&0"C!@E.=%"I+L@S#XX](/PD?M[-YEA=]*?2W5P MCARZ18OM,0:8>:/$M[]]R6S_&[Q@9N'M+^RP[F%P=N,D >PHW/S&U^ZX267? M&@7C+#O_^Q(V>S(\.@=9-/OI'Q?NSQ,(KPE'@T,F8R9B9@@/B4(F,9;P,-%) MK)%)#Z:D!^^%5G>VHGM,[C=A0$M"^\32D*WV&QY%@N$(ZYAI2K1A2AI+&-SV MX%)T&/T6AT44\D4T6LA6TTT22A-C@=+4A"P"CTICZUMC),OFQUVV 2I:&A+-0R5"0.$Y122P1:"2YYL@&I=)][?3@6!_DV1?-! M< JF-HCY:LCRFO<]<,9Y/8O%&K%@:X/Y"K[FK Q.@:]&R\1Y;3P[)V=TMI@_ M'N%\5\IH]=YH0047BH&2,(R$H1'&4H8FB*78;%+&4]#T5BS6A\ _:E@O%\&N!M!V&*@\6W78Z]IBYXHA[10O0>Q/NE=2X7D_E-8$;9Y:2 M-9^7:V&0=>P0.Y9[=^R0E:?TCQZRJ\80+4RN&&L<"J9B94(J0HO6Z$9R)B9. M!=MESL$#XASJWPS.CN[&VW[S_-ZU#J@Z'W\\'=8[;585/IG#*\OE^-;(A3_P M@\3PE++)Y^!0\IA0%7.)$R9#&C'AB20!LS/M=1A&W'8Y/\SR:38:)AX4":YW MCNEM[NC^J6UG[X3V8V]84>?W:U^^J10M0 B#* ZY@O](P8V6B%=4(DBD>Z62 M'0,4ATL1HB?P5XL)ML]8A6H*SPV)8L)CGD9,<:ETR"GQTYZ1,&*SQ?L;13(/ M5R=MR]9UI9,L8;C.A*MB/"S76Q:SWLF$M4):"5&:,JT8(](BE0E462"4F*A7 M@.@[0UH]$<9W5^3FM-+V4LI]H$Z ]R D2MAPEBEL8SCB"BF=,0KD61B@A^ M.G&X4H/V:,G:HWQR?\SW/IUE6:[ '^V]ZMEY-AQE6X O5]U5V_QS=VK>\I^] MZDL!LN1__D,1+'\NM^3MJR<>C@\;-CXL%HK%A-%8)"3A.$&ID97AR6,F.F[3 M ,Z'$\0[EJ15^[8..=,AM_=G(]SNMQ[HW F%&I\5+ JC$ 4# LB#AT1P%'JB M2%6J9:\%SD_S68&Z$.^7NG;/HKT(KT2AQDMED5(,@3O"26I,:%@JD\H$ ()1 MAX)RVB$=+&]QZ^.CFT\WTWS%T'Q;^P8GU\"_GSNV-!7NS]UMO)K>R0HWSFZ, M$J$Q(2*1$AM!-+@QE;B)N"&]DM5^R*B+8^])G.P-;$>UYYR8F%&$+=@*39/( M$)&2.MR52/[M.FCZ$!T'YZOV6>]5.ZOE-_!603(V%5^AU"DF:4RCB"E*DH35 MWFJ*(K,!Y'ZGM[H',? 4!(=#]U#[<4CM+OB.=Y\*_7V47< F_)2-OV0W)3SJGU>S:O_V MORG+K5DYO+73=:S^"4[Q-!_[1IXCFH@0S A&)3,HHABE.O8LS@CC*+%U"=4M M0!7,'_QU>@^)?(.H!WYTU..T6%BG8=*.033AM%M"(-GNO0FG(/.S0$\.)\JA M2!/E4!0+G:8QX:E.N(S@[ZBR,,%QD9U'.;"-%HL(]8LH\> (2 ]4L<=XR.X2;1.:MI=,+VB_ M9OF]$QUKXB.A($QPY7 J8Q1A$%1Q'8Y%-.ZUK>E;$%D7HJ0S M\">RX+^+T61>MPFL]^2[5\_SR:YEZO.K6;&XO *J]?A[=I[HVI*L"SPIUIS? MZGL6Y"&KY5,#3.*-V]RU$S4-#M8$R6?'P2<[Q?3*U<:[>*O?&]L%GE]';(?*O^?FB=KG@:2?@:'R&Q=O^.S#AOMX$>O/Y*UNT[-VR FA^-9J! MBP:7#VMHO]9YP 8MWV90=:=;BVED.](K@)4&?:4:J>W:>_[.+3./8?=FV;AU M.\NIY]EJ)M*V^CM5$5':CNP)!=>H+NADAJC>T%M@T_\$ M5K"U4MET-%\?%ER):&"_G<<$YU\\:5?,5O%:EZV,&/<P.%$& Y+9E#68V33$L2W&5&C9"L.@$QJ5*BE M,-A0HD5L:!5\,G',>ZV3N,\'[) 8#@URDJN>)AU84V4)87K<.R$UP009IA%' MJ4RU5BA&0#^1JF4,2]*-=,B=WMUAB0&,Q!: P3XRY/US?GM6&5$J4<@@9)0 MWSQ<UN& D1/V-$8ZRR=_/A!($ZE,\M$CA#/;$4<$Z<,Z?N8>; M]1&-1SYS":('%@JR*WCTVN^*J-@2DUYQ5U3(6QY0HJC&:9P29A(6VAF,$0); M)9%V./9&NFL[[LX6])4]4N63$%-8V -BRG1FHX%5J',=->6L>FU'M_N,D(6- MC4,XE92E..$QB4U*0A;KRBC5F+(-C+Z=X)8.4O2P;5!=G8D>JVJ^>#GC97@[ M5FIC7\4R:CQ>H87>*[) \[3ZSB*I*3%<"!UQDU(55ZTD6-E"G/M4U.D\G[;/ M;VCS$X[O+QIBB+*Q'2.WM0\-2.* *((=TQZ5D6?R8966]+8$LK,?E@F[UPSH S*@RR36 M9CUOC9FH9_!ST\J\7K^+T0,0M]X6\/E)"3)S.' IS/\"8CT.@D_%')[TK>IX M0]PX-I*$P(0R EM0B)2!BI ['GT,'LW[#,A5A%- M[@;$.8&B;!"0C)1@MG&_),8UEO[ MI"DHJM;A'/2)HN--*[^K$QVXZ7]N@N[3S^Z^HVL!OG-NU?N+4SOHL/IM;Z>\_/YIK[@/>D'B@=<]!"K6!LCZI:XMU&A(6D\/SO71D4H M26(0[ 8K#@14%9MIR=BM*<^NIL@^S$'<"\$\5JRH7H-:D_6Y2=ZG.(C9LV%K M $G"@7AH2!4)56KB$(R&&M2$R"C!95?;U*"2SZG*#VS>KYPM;$ M$07VA@BIIB8R6A%%&5WV]:E$]DH4'=;S[> 0'5P+5U\2QF4[;@5L[9NT&J.6 M*$.U3%.$0\%5F*"H0FI+DI0+W6O+Z.&3U@.*1 \!5\&Y5';T35,M.KBK\FP/ M 5O1.-N*B41P)@TAQM (M%Q2=[;$,A0',9?X@(P;V,'^1I;W?>JR%:;'0H;@ MV%!N9(H(C>)X&;,3X@%CR@_(YF"H3T?WM2OTP3G1TWPZ?RKRT9]9>06NX!Q^ M_R_W$N4R>?I;-LDNJW;%MV_CS0G-.\,?U=G20>M?5FKWS)"R84BFN62I4)(B M2@A)*,&B$L,R3O5&S'-C?%W-=GGYRZPHMXRM4_^F-UO> M[;3E'LMGJD%TSP[=*%2XY6H(F48FP3K!P,,HBDE%'1B$>+0!AW@P00E+&P]#U61O313*",=:.R@C@F(>FTJC(W C#F5X]B&31(CZ M"US=/G"F;Q)I$K4A%X@J.[],2A FB'#C220%AR[ M>D<$8P].1MBXED3H"$<:A9(E)(ZYY$NMQ7'"-S#Y[G(R]B\U=L^']%G[^SIT MYLE>B)[.1N.G>" K\V%JC)K3*1 K+^=T@6-[3P1DXK>#-&+T==5.MF;*0JGWV14 M4TJ2,$TI36,D0A,BI2L18D*3IALB9(^V:#]D<;BF*.[+%1Y9@5:_X1W8B+V3 M'6M5=_#0#BSA+(I-&NN(IW6V Q..OB4.YP&271]H+'NAM7:FK7^?!RBL58^8 M&J5,&D:Q$H8G*D7U3->$B)!OS'2]R^G9NX+:.=/2<\#VU>?YQC[/']EXG-\$ MO^7S[*P8MR9,;,VS[.K@>*=F\ "OIF_&)4T&)C$X35!"(\4YL;,$! UK>"[" M\$8;0\].C3^!Y0%T/8@(]UP3W),;$_R/7MNA,*)-TL5P%$LN4F5[V"2C*8]K M&!9"I!3/TH]Y)%GM7OOY(AT7VN19%#=:V"&'(:&VMU&EINXW2%(3]TH5'5J0 M=]'! ;LJZAN[*OLP)FDK8V.HP"*-B58:*8I3SM-:)QF\V3#=E3'9N_+I$?2@ M)_/QU5J\W5H\'>6S6;:T$4%"%.!^S//R:>9B/"X^C\I#,A=9"Z$DCD(626D2 M':,0C$=B:J#?2*?I1C*U9W/1'T%U LT!/!N6?:9A;]XD15*F$$I$J(5)#8N1 MU$Q5LMI&O7N-:/9F+CZ6K':V%V5_PUB^I<'(FW1(DA@>JS!."#8BH@BS**K! M7\-(\F=B,-Y)"8=K,7X/!J-HTBI1!"XK)2&)0IP@(2G!5:,: L70.QJ(%VL@F-_4$'E^& M_20+\K:Z[F]G08H6*KAFA*8"&ZF,9EK$$:IR45A&8%1V/M46#HV0W?BYSB-4 M1U.=3'$!VVAWL<-J"O4ZS[:A#MD4ST5@3)P;4R,>G)BOF$=+T:M]A,>&F:TB5@H$0$_1A-<3R]-5)QNI,;NLBH/45ST M#9#SFLY^HKGY:S9QUF8K1.EF0@Z#*,_.KY:FY"^S8C%U-F/P@ZW8)>CGE0O< M9_CG'Y>89[/1V<)/@EP?2TG8LE_P(CNO1%]03F=Y!I+_W(;L@K*:=QJ\+'C?^HX(\&KQ$\R 1%@F(CDCJ[Q03=&"WTF*@FAM/$?PWST5]O M\\MLG, 6S6_:+<+-SE0;T^S+FBJX4WJXDZ\.WA%&IU7_O9;]5P'1_N-480O2 M'7-DB$ZQ85B:Q!"65!69B9 B.9S)=99^T+,G(-DG)/"JB=I['R+049,8H2$- MXX0JRB6.&!><4%FYM0D'JOIFX^Y?"MWTB%32!O/;BY6)6UTE)C6ABI VAF,M M< PD4\=#*(KE@S I#ONL=RZ693T-2&W9I,>!+MV0Z#H*XM \'M M7M?;;]RDPG.L$(\JM%"@OZP:.+)EOHFGPCHT[+RH6>XCR?U"HV/XTV3[=8BQ MB$$2::JT)I*Q"ALT%8;K6V.UK2-L!EF]O_BCL+'L)4YZ38-W$%8YF_^UG(G5 M4(,' >^=9[9>$FL)!2HG4+,0&28X5 MU2%1O [WRY3L I/>"PGM5S(];;):'Y0UL:'!'8CKV8=KIMEP".]Q-"^F/V': MQ1+\C_;RGZQ8'YW[3[[XAYX5XR'<]->5P5)+ZZ)<7;@]5P]"[TIWW#] MU5K[ZW-^=NUWO?K^-[N#)TJUMD7N[ZM9?9,IR(&CLUF>_7V47< F_)2-OV0W M)3SJGU>S:O_VORG+K5DYO+73=7+R$YSB:3[.'2,?T42$"B-&)3,HHABENNH: M9H1QE(#1_$#R_@;9<$Q=@#)L!2BSX,L5B):;H #1.PS*Q5DY&H[@XD'PA^.) MS(<);[8&,=_\$9_\\N9'L)+@,;]E,Q!'/@8:#@(#;V;3WKZ_RPUP\=":']$_H36=-MQAU// MMSCU78(ENZE0+IWM,]MV[%LS0*8F!J ]"[[>OB8#VBC^;J9/]DT8M D'$(5X M& &M8)D@P3F1PA)&;(LC.-JI/&(?\@DGUE6NK%]LPTA5?7X M(6;5?DAP6T=G9Q3H9XKT;&K3)F1 "4V!1$)&0(&$,A$J2H!T=,)B&BF\T8/[ MA!'$R^/OX2P/SPL#?IH4UZ/SQDJV0F5-$:T(E+X%!FMR5Q*$0Z2E,&F4)"B- M8I7:4S^YS@^SI@HTLAAY@DN3QF )$\ZD,B"UDC@2.J5J M=>I0+;+F]X@L;^+$S?L]4QFV(B *!0#F06^LE:(4+I"'#L+KI-)\O7\RE:HP)8^5U)YDG#;[&7KRS:R:,FU M,.M;JO"F,)1*)!.>8,U%K"G1.J&:V@E6"J4R:0:(/$BJV%F]SX0Z'E^/WK<; M! )E.'3OEHW[EB0"MYH-DA"+1#.&I4!1'$<, T$H16-EX@:VX F2Y!F1QY.$ M!]V+]/!C%*\SVV4VFJSDOS8E#5Q@ X5.XEPLK$5D&UN*\<@->+4)5)]?M5"E MH,AL>\[%:))-+$@4K+,:=UL^-,7Q;?,9^TE?>/T87.5C/QNU!!)Y0LYE3T'I MY.+"QM4_Y]M*9ZLH,!!"F8_'6SJS+BR!?%F!O5TSINV7[TFTVJ"S*WD=YRZF M;*OVX>JQG=@V'YV/IJY)RT89X=F8U!-FJPJ ?/D"?L*L'3 +CSGWPPC@)O"E MX:@\7Y2EJ]AUT4K[Q;/%C<7?MTT97Z=PB[INWC:F536XL"#X-D$$P1HK&?IN M<0T[>;XBOE(OO]A_?=I(SAIX]+@H%[/\_<7;8G+INA$\J?P+* 5\FE-XC,UP M1./B_.\W6Q(>,M8HDAA<4F*0B%/!C*H3'D91>M2JRN5A@BD#]S422$5Q*.,: MM3"B28C>5/.;%["&^8.? RY&#I)O:A-KLT7^YC\_N2J@\;CX8D]\[F94E8OK MZVP&%%:Z3;RV;1:![;.[!!K(W;'5<>.KT?D5R)MK)[9L)\;H8N03$RM,5",> M9^?GOKC#D5N'7=MF%IVPB>0R7FOS< M::;_^0\LT,^TRNP\7HG\X+:T6)1 _N6//RW%U$9N==>DW$ZOO6,FO,K4MJ4= MVBKL6O>KQ>AH^!VE7_=8YE/9GV*'S^N_UI= W$;9M'/Q;7V61]M< 2(!7]\K+%O*@_F+D%N4^^C(;SJY_"\%@@.U#X M/WX^L\T?LZ-S8+!L6N8_U?]H[Y6]H5OW#/YO\W5VG9/_YXW-@?YS/K1_S9:_ MK9;M'Z3D?_Q<7[3^.TSN^%WSJRWW_@PJPHKW:GEGQ7Q>7/]\EIW_?3FS M^^ M33'[Z1^Y^_/SRK$1.(+VF;1_]C=:^0[DS6'NC+ND$U-L)X\3I%4#C6:0$:PIGOJPY%ZJ.L;.D3G-BVOORTMF CKS%.K<+0DZ%> M>EJ-OBZCFY4'E'"+\<)NL+VFU@#OE[U C8M1DTL['_B "!:].P4\0"R\+W[5 MHL:=F?29\&)=S+V=\>YF-B]0J_7CZ=? F1#!/Y#[\Z@=V!>'W<=@N GI:-N* MI6*.&N6&8;T![/"L&JQ]7DT%G?!6&Y %<]512ZYU-MA5XM_7A4VW>NE/UR'KYPU^.[!L%A8,[(^[)ZWLGJ^,V-W)[1]6P"M@AV>8HQE M&M,02XV(0C2INL1)(B/1K8#J0#004+GWH@JM\]@_G2M1?]X)_VZK?'U)E:P[ MA=G\D8^V5 8?8GAM#3-3#EH%GSY8^]^+R7G5;C"_"N)\F,W*X'0TR4;+4%GL MX8KJ1O7X]+=XV9]N R.GV62>!;\5$[CZK@[WT]].?JF_N Z5-/]2W),6;\,E MM9\X"&)]' 2_3_T \[HEK$IE.4';=Q4'X;AM_3"#A:WE(K&0)C:&1Q@E)#5( M:K'1F/Z$*@[Y;ZH7EW'YW[%YQ MNV?V9T4R^ZD@!!E3R10;"%Y,J@HQFX$HKVS(OTH(U"7M8&Z!T'0I K=#P;7; M(E\AOYKL" >>%FNT-S -9\5UL"CWFH4EO"GV(:G02@F%TI0;9$P< 942(I$R M.I2"K&1A&^?*TT+=ZW5[JU=X;QOJLR3,HS(_M\3Y!2SB,I^\^<^+T>>\^UJ? MJ6?Y[>E5JV1]&?S0)R(>]91-E^'"_=G=WA:T96_'- JYP4R&)&)QF* XPJDB M,D:4\8W"QE4I-]3S-!O-_K"O])PIZ=&@7;2?8<\[-#1;V78[D8&D"L[R? )W M&"[.?9ZV9PDEFB@3(Q&-$\492T+#4"Q"%@)12:,C%>JDX]+Y>VCL&=I9?12' M^%*0&C8,:&MLP:?V,/.52-+JJ<",2I SMB*1@GV52&6E#6()1S+9@&'8?D ? M3=8'S M[!N7]^?4G^;3N3OHVK%?A35N69VN@L%A$:^4H-MV7)#EMJ5\7%S>!%-WKN?Y M((C<;^#=_EX& "I?_F1R?CRP4OX/NZZ;;9@%KG)PGQ7J1#6<'Z5*]-2M1(.C*N*DO-L#7U@N;_UM/?NT"$W,8J[J@D]7I/LE[9HQI+5?@^[:9T+ M=60XBA*<4J*HH(;R&@!0X&2SZ_+I8GY/I[US*T%?F$LV-#*:N *V85#FG_.9 M*VZR56J3,M__H;=0'Y$==*<-XFE*$ZX1)4DUR\; ^0NZ?NBG]>KCHIR76\#& M#XR#\?%F$K"[]FJK<$?E86M<7V%V<,NR(9O%^*:M;9>P":[$T.K#3> $/?QL MJ6_8X/[,@T^C:[#7%M=!;'%'X<-J=,"V<+S5X[]/0#7-2O> "PNM<#.V''HZ M/PY^+K46IU_#290M@_$Q=.QLR9YU"T6M]MN$ M\U#(E(=48% R(8\KB/K88=3W83TZTNR)[!X_DF"SO*L[*[+"EW;M'D &UCOQ MP'FV:785PL-^VK>,4J\RZD!EU%(H[0'FA^)6^(A+@YE@,C6AC",[(Z^J)$?@ M1L;I.AW4PVPLW]^!Q'"@S+YM7%5G!J<5[Y:)IY6D=*B]7\]S'Q-<8_CLVF'0 MVSZ.)X>1[S_OQH\T5$8X9HE1BMOP<1++"DW<:!ZO9;IJF>_:">$]WE]$\ 9; M4A,'?.1]1@E6YT;8D_11J%<_XZ'U.D3=%M>K WHVM[A1(U.-AG!&7?#QJACF MP4GI["PXBY6?:V.K(C1OK.T_?D=)"T"929RPQ(X'2B-A^X!E-;$\,3@5L@<+ MS(X.).IA+.JVT>]BM8G5'L(.=@ASM:E47U0LC]+&/V2)3%4BF5&$)+8Y0RI9 M'3SFF/42RSO8D\<]VM]U*V-IL[K#X'\OP%4#3\O%&F;Y938;>F]M-4KD%+F; M3SV#-W+;I^BJ@NTHR^^;1%F@9 M1V ,1X@EB87]T0E/4E3Q:)1HO#$=N"/A_$#SZ4^X,9ACXWP=6J%#X(U^V3.O M<"KV C]&V_!CBJ28*A;"(<>@?6/-"3C 2<03PA7:R)YUZ@!7(WP[]X!WIX?# M\X#OB-)9.6M?+?#O=E?1]9]_G-0UU\<.YZ">*%H!E>T]YL+4*\D=*LFM!%WV M:P[R)@2#1!+!GY2'DJ0L49$MB_8N>00FXN-#, >I4+:-@.W.TO]T:_QE,^@Z MV&\0AC>>GTH8L<,ETBCA"( )_E:!KB^/Q#+T5:+H.)F4/6M MS!R097D^&YU9%_^L^)Q_@]B.:(59K4!'%C=?:16"3.=AE5U+8I*2#1?_V[@/ M[ZLC^U"?V+.H[#B,>(YL?,60\3!%PC"-#(X-B')43_L6,=Z?LVT.],\/[3OY*/P:G[P, .SYCI*@I:4V8 ,J31&*MM0&<5?*FU7Q(UFA:7%8YP1@CGHU MGRQ4P=W\P(1".,&QE1@V.81,6!\IQ4F;'S!3B B0+BP.8Z$D1=A7@2=1G,28 MW4TZ]SUG@Q^T!7]T[>K-J%)G:EF+[":WMEX^&;I)I(^%!-QE44]YI^X@ =7C M-=N39O@^#8T0> $,I<\C>TIG^;CX\E!\PM>9I+ L MG&('N\905Q6\) (]8Y] IV2OR)7M;U0P;-;$ ,MBJ\Z0KQ"6=_K7 M))0$YUSP%LHR,RDG$8FYE(3(E-<6?\3BU&RD8K?/GT]]&J03@"HN!E**WE$A M\>$2NB?II7E=36"Q\4$@S'0Z_LU+NOXK9 MWSZ7]P@ P.>()5E1NFK E+"*L/5K"=76L^6<4N,I/4RE"#=ZN9>.=[7]9C&# M=_P BRG64$B:\4"$0]BD%'1"2"20D)(E$2<&ZZ@2#IKS$&\ .?MZ1?1&]?%CM:GDK#^_*>KN H> !X@^!/]_U\!JJ?,KI M=46X/[[J\X?I\S_M#*+_JVQL^FEN1U:-2C?)JIKC>9[-'L7@+U"/"](@><5) MBA-!2:0$XEC11-65Q9K1+8BI/>IQ=XQE;>HW9WC3F0YG1&Q6_KPJ\9796C$?G2['PPK3[/3S.FI).850J2*P50BE)4)K(N$K*:<05VFBN[Y'' M_>$LS^;AL&GWS4=AHDL#X? 9^7O4]ZONIWS_NM$;^: M4ZDI,S%CDD?<(*HKT"9-#=^L\N^1]_VQU;W5RT/KD/DQDZ_J_1FK]Z$K'%QC M_KH =SK.2GC5H%S,+O/9C:.7EZ;3[_/86TBK282%E%I%812&5(,9OS3<0RGH M!F1*O3]Q<7'?&Q'.GPJ[%25]Q'Q%)* M7/7NZS2%C_;IO2^/L#K!&IYQ>7X=9NDHHJ^*_ADK^EUD0BT ] RDP<=L.++M M FU$Y _'\7'PTBR NWE?HF:P ]-24L,X,I*'*A(BK0:I)9H(GFX,=N@U ^>. MRIY4^Z#<.7VXOV]OY_#=JWO_/1@#>G8.1)0M>?YFHUC'%>:\6@-.(N#&&F 1 MV/Y8VSJ=))6@!8U^[VP*LM\,)M@?$(<9L#YYB8;(,_Y,&8'4/PL$?I3_)UD%6Y]@>"]>! M:* #@5]3_2_*/LC*,$26@VP#]Z% %P1/Z$J@.JSF<7;)^=DX!(##!Y MK>%_SH;!Z'J:.=:OP/9J=G[O'(%Q,,NGQ8PT]RV*U4OCZ5<[E64T M#/Z!W)_G:13^ M*,+Z<[E6U)Z5>48]KI-X@G0/1^&'3HBH(B^+0J$2%B1$B ME5A5I0$Q$BIZ2(NJZJ1%E6$U0&&G*;M'G;[J8G5]EI<7#')WG.^?W7CUZR]P*-P@[0A,.S!T) M%$9<1$3$B:0ICK6*,=;JJ6F_\/#2?K)3<_[5D^_]19_8C&M@+1;3R??M?%=^ MNR*-%B=4A"QE5,9*4.#ND(K8,;J=T('#IW;8/H31JQ/Q!]*=J_[JI#\GE?]$ MKMZ&F%_'[E^S^37_MV9^I!$P.ACR,B06KY,E*/W_V7O3[K:1+$WXK^!XNF8R MSZ%5L2_.F3HG(A!1[9Y,.]OI[)YZO_2!*?]SLJ?3!]L5.TO M*O9S\%^8 =\19A.TM. 4:LB(UI0 #5F6O+<5>=(0P ?)=!Y;HF^K"OZ!E&= M9_4+#*%=H#'_\CWZ.1V-_XC^-?RZK+VK&OF[3-V'62WE>=[C_%__XY/J['>& M?EY2:F@28X64#LPXULK8. HR]$O@*#R:(><0^_VO\^OI>)1;\.7.-M"!AWMP MRV2DH@1(V)_<#__)?WT_^B6Y?4AN7U]9G80EL0:! AL%#6<6@1AQ*K3,#_= 0TLVQBPU".]L M4_(]J34FA[L(_>4:]K_^]NE#9[0S5.,*JP;43A"*I#!6.<,X,SA'-9/.@6-; MZ Y!]5^3R74Z^BT,=%]:[@8*9E$/H#IQWMGP=N'\PSR49?S10,WD&2.>E'8< M2R>9!Z=2SE'OHB.N\S2[8)AI>RS+_2&(+[:J1D(LC&MUSW<(1/L1_@HFNJR/ M?CIXHLO*)F._R=?C>1@:U$AQ_ %K>-J1+Y*53D'LM$38._E. (I<++VW7PS( M!CP6CZJ(+?6TLIYZ6@)Z4AQBM3.$_#F;_K3X?2WH.VC>:1,S%5LZZC%,?L_G MN0>@EJ,))^.[8*2G*V9ZZG^5S,(DO.OT>NZW,L MFV*8_!$2;2&[/BTP_^Q! M>T\KBX._+MQM4T.-"P2*DNL&42DM0YAB":TQ,65NT<,6.Z? RHCZ!?SBY6*Z M\>1S\L>OQ4H^)W.^]Z1I!JYV9L .7^QB5G5]8^,O''X? PU!&-%>##U=1+ " M!_S]Q&_5Q'\\FN35%8L"]JVC5[/1F-/QS>PA?/8Z_98.Q_>A[OTJBCS(P^31 M_G!^G6:N=QB4?I=]Y4TRF$3?DN$\S5 [G?=OHT'(O@083W,:FRCY.DDS9K1I M+^K[U1C?^9O.*,_]S^-OZ2@)Y?6C\2S<89AZG\[27L7I3_NWHZSH.C#BA/N< M31)_)P$*TTY4]M74XUDR#+K:.T/_S%L6TC_NTY%7T0])XSI.EDUY1B@#@>&Q M4S'%#,8"L6*P')7&;004RQ8,K]Y4Y?Z;U&_X:M/K6&BG8[57RK;[6/&OJ[[XJ7!VU& ME50Q,(S&*C:8*B^6A7Q;:-T&5^4A*\[K6_'-08IUK?@C@ZF?]6V;LU1K]N^. M ./+CJ+F1SSR))W>AW&^WLA_]_;]_5;_H3 5?N^"O_ UYZCVEC=8KK?!BD5W MZ>QV?!UY"Y[MM_<$YM/T9C[TMOTF^!"S='+GWW<=>:>_<@RXJG+=;OH(:Q?/ MOOU(^*Y-E5\'+RI))#B-)9%,80 5Y- *1T,QNA4<,^/4IKHLG!0W\(A,?_8K M>KT^@OX_,UN?7BO_(/ZI?\^6Z&>_0D_8KPIRWT[3_KOK^22 *0Q!79_PGJ/L M:,QN[G%4V6,O)+]M\0W#X:B?W ^\9Y'M59#IM9T+WUB5BJ)-_7;YPINB22L2N*C M K J9;_U;_T9;YB.;YZ0,S>?S2=IU8#8W+_['*(AG_UE]'#<_\>;+3.]M3]S M$B"1(80R+02 C"QF>A/_R[=EMP9A#,>":H@=X-A:XGVV8H":A-RH)T>0[[R. MQU?J[==]B(A-YNF;5NQBB'')C=^ M$=XEPX?D^]1?ZL^WDV+]3K\HRZ59V;RUW7T.D.&;?;[&*H4IXPH;I"A@5#HB M%E_C3Q'\+3Y85"KO7HF? X_1*FC#S]6O&P5+.%P)L4.0A\]S)/;3X;!X]?^\ M 6^RG_U2]A<_;]F)SX-@4@*/UJ?Q73):O]N'P?7L]IV45P(0)CC]TR)7T/=* M(+F?IN\6_]CBGB[2,\L\! Y+_ECV)K\4@G_Z:?&F]=>>>(D_ZU/=M;IKM?Q: M8J]/M90'2!QJ!<2C4<.-G"8^**=93R7# 2M1N!%'KP4":-UJ-U5ON>OI@G=V MXSV_=[>#:V^?FHH/O^*=AMU.OY*=1MU.OY*=QMU.OY*=)MU.OX:=_NQ_G6;Q MD6Z_7\5^AV*!5[[5AQ60GNU6+])349+GIU:CV?=9O7^2P2B$OP>CM833 M^58G/W/!*LG+8DY79/Q;0A;]5!Q CRY@+72QSUR7?VFBRZIQLN)G/NP^W1<0 M50:44&*AB+F.,>/*,&.,U'G>S%H#-MLOGDCT;4GQ?? /^/DA'7Y+?_$W>KM> M^EE49"^[,Y[X+HBPF1D#'7'(!*8,,089:O)VDZZ6(G6+L%&.G M&#O%V#+%B"M=%B"&%G J@5>(F!-(#<'%>=HI*C8*M0]7C&X\GW1ZL=.+G5[L M]&++]2*J<+,"*ZTDWELT@=H) &=RO>@ 1C&KP6%T_KV=7NST8J<7.[W88>Q_?YQ>5*$TXHR5(Z0]@4XREZ;3CIUV[+1C M*[0C*R?X !E+I;ED#"#@L(T5+K2C].IRCX"<]3D[6I)IXE%8!PBNYV4W]2K!_68UTIB 46^,3R[@IQAE= M6O_I:KV]"T"?LQSML/RR)#Q1TG#$+1*<,8DY-D(5G)]."H9 N^O2%IO]83S[ M/#;Y3M8L44RAAB+-J@N6U*]TRQ6:9UQ MQ@ZK'5:/P"HML2H@U)02R;7E3A/E#[ZZP*I?HDVBU'84E#0*55KK5(T.JAU4 MCX!J9>*TXI8(;T^YBJF"&F)-BEX!&ULICLSE-97&:Q2J?IDZJ'90;0=4984N M%"(:TQA #F-%F$5.%?7KL8UQ?*0'W&C:O5F\$M3AM<-K*_!*88E7%$O!E%%, M*LHA9](JL< K4."0V%(#B>!&(8EZ$FZ2XG>@;",HSQN(CR1?*2J3KPA"Z)#@ ML6*,:>_](B$6I]% FM>ZY.M3T'PT[4JN2'U9U_;G3\^;]R3.>?_3Z^CS8B#3 M]V,I=%YDR'*CMI24J57'L*&(0,L1EU8;YR&,'4(AY>H1O3$(IEVIU>5V+\=O M?:_/U!)RT9.86Z4(VNHO7R#X69FDC0TGH251280=UR$VA3/P:P@I1W4T;M>? MI.TPWV&^P_QAF!>5%))"'#*N&""0 Z@1+U"FN+++5& PEC&3/@5(;Z6 FCV,8PKW8DCFL%_3_3R?@ZF=X& M>1$(HI\ZS'>8OSC,HS(#K;G&Q+HX*QGA$L6\\.ZM(RB&J)T9Z [S'>8[S!^$ M>5*FQCAR&%$01L%:22B$"K. >0T(P-P>&TYH M3"SVYWO)-,-$D0SX4$($M7W9G'B3IW>&3\()T8&[;2GT\P7T([EU5FEL9E([ MH+30ED'%J;6:R@S/*#;(&-"ZW/H3$']\4/P5.T%#<_MS[F>16L\GW7_()]WG M$I9>O]9R-%;I3A988V45U))JHKW/S2PMRF 0!DRW.X6>;6NVJVJQJ2T-K+?6 M E^ H;U\Q/)*<[*6@E 3 ^(@12BV$F-7-"?'&,D:(F,-Y+V;!"KK&C,ZG+8$ MIY769*?B6"(*'1!&$@?XHMW1.NZ-[)&\'XWEJCND=DA]#4BM-"93&7,&F I5 M8\R%IBFQF!RG8X5;VIC<*%!A!]0.J.T :K4M&4!F.&9$*@==!BZX2R4CG_WX+O3G,5\T,X!!K(OS;KZ'8&]#P0 M>=XH?"1I*BH-R3'"4EOI3.RD-01BK0O.'6\X;9F):4W2] E3IH/1=7J324@T'-RD73G3.I(K;U3[H#? ;\#_N' KS0K6R2)98YQ'%LNL$["'>-39V&N#R-$"E:UD;AP#7,J;,@$2>5E=N;^-;V8/R22-!B.O@;(6[#!<^EBKD\^ +AYL20R-TD>ZGPWFF!>?6>Q]7.Y[2T^?.\2I MM=;I HS0J\>\!UJ95LZX[E%LN$3, H]S$X,,\TI 0_@A-#DG22MW4.^@WD%] M?ZA7FH>!- (""Z6#3#HNE*,9T;73A@)#:J"\K3N3W(&] WL']OW!7ND_AIHK M0RU"A"LBH+ &ZPSL,11 QW5,6ZTW>=QAO<-ZA_7]L5YI8>::20B--^?0<4(P MES W[)8QIVD=7/;U9HPZK'=8[["^/]8K7=#4*(<-$%I9:B3@TL39W KG-+?. M'GE>;RI%W C@UW)'&- .\1WB+P+QL-)(#5R@_(ICZE#L ,!.R8!X#"#02*E# MK'N]*>$.U!VH+[C7^ODIWE>?R>U[%9!.:F@6'L^28:1&HWGXJ^*N'(U][+%_ M/9Y[Y=:,L:@GE_TO33YGZVT@*7D,@*&Q#=31,=<46>6?H^"G=0H)>*37NU]F MN@YKUB.XULF*N_:Z,V@O5;$:U$R2-9)"=8IF4[)=$JF'B4C>)F@4XQZAT9A!J@E4OGC/"E<&D,5KF/4 M_./9^%K4#"1U\IQU:J93,YV:J47-(%"J&:IB0)W6E-I8QPH:IXJ&$FF!0ZK) M.H ZV$U[0C07 >RT3*=E.BWS7"V#6%F! "4R'+(8.(X--B[F!3F58AH=RT[W M=$*R%BU#..FT3*=E.BW3.BU#2BW#*+=*"(XX<3IF,D;+(Q/0$!XY_6B/VH<;#D;I MV]N,X_X=1.!/QS]@]N-#_HU?QL/KQY[XM'>U_2:R/Y),XTTA1W&,8J6!5I0; MH2C64F!BN$:,">BO^>>D\L&3KN"'CY]MQ**WT=J4@T=&#:SKX5\GXWL/F>^_ M#I/13(VN[7_/!UE)6CR8]H?CZ7R2?O9?HX?C_C_>9,L1?OPM'::9YGQ++.?. M6 V1H[$ $"MC<[T?]#]6;\O"/"8TB1W#G%'-I'6<2%2XHY3$2.=*W^]Z>JUF M!U\'OHE2;P+N@Y*=S-,W?_GUT\=?[:?/?XO4ASBR__[[^U]_L1\^/SKY(-N\ M-P=$5Z_UZ!*%BL0):/K*%T\?O93 MTN_/[^;#9)9>>\_E?N)=DES(LAX:9-8YZJ?#8?'J_WGC3]CA9W_C_<7/6Q[\\R ,]_B0/D2?QG?)AB-QETR^ M#D;Y[27SV7CQB]POR7[S,+B>W?IW^XE M%R7>/%X7F5^"XS_]]&;#ORPN_\1+3[U6^TO[?:RUM9_->LJ\32T"=3W[%IL6 MI_VLIC["L'=.E;_-[CY^@=U_@=78(@_!9WGEA^17O?GB D:(/5L\?O:>XXF$ M_^7H^IX5BMVUL76$8)\?V7LR"(L!AB)EM.2FXHXK9S!CBE(.@!!$%'3(RBI_ M\-[[N/;7R7BZBV_NT0_K[Y^_WZ\,HD) M(208,)(:;6-&E-9%O$]+J/0&I<[!ZDATZNCU]$C6]9R_I-?AWLO@W NDEEJ" MU4IU/:$>K"2T"5*+N79.@L6T1,DTIB_F.BQ?JPVP!-&>D'6V%;;65;@ C^ 5 MX)"#LF0+$X@-1T)BXC3%'$'#>R#! MC._NY[-TDN6LQC=#.?>*F8A_25?_W&;[K_]_0L!Y@TB_AJ*3@Q MR)_4D7%*2D0D1IKFB*<"4+[1/'LRR^L6F^G?YXJMK&]P"0(](B_;EG8N7 MFSX81M MK1U^3>;VC,$HRL%+PDHDE+4L=OZ(;"E5ABY.R0JR#2Z(DUG5)JD=60]+> EX M?#6GY9_39)K>CH?7T>#N?N)50I"'[CB\ 6T!*C/5M$+&>$/+8O\'AYQ27/ O M.(7@\0[SLW/8B\U\7]G+^GA;.>\1R"_:8VX5W-MJH"\1WJ@L4<$R1IQP1"2# M@!OD.-1YK3]&CKD-XH/3Y82;A3?F/<&[ _$Y'8B7TN*W_SJ=1#>#43(*=?Q_ M[B?W@T"T.PPR<\Z4[,W"GI2PMTP; Z7PSKF*$7'(D(*/5L78T@T^VI-9];SC M^%_3X?7O89--OK.9,J@Q'$9ZL.-E?VU'[0M&-BN+O+"%BC,E 3+2,F<9*9KW M_%'<$'0\LI]KT$^#;-2#L#GRV!8A^]4I#62@32.H>\54AMK96^/#A*4(XZ MQ$ X(K%22E).8@(Y*5I"0HTGJZ4&NPXX ME#L-91#ZV#XZ6=C]4C? :OV&W^ M80! M;N,H/"&^ZS'1E.$>$;C#]SD>CO\^G\X&-]^;/A^WA?3SS+H^=RW!^;>%2E:V MF@FBK:)"2ZYCQF*-8TH71Q(&Y?XIP"9Y0C%C/4Y.RCO1>W.']-W-;[47\XOTZOH\$H&L\GC^5-DEFTN/6#+[%@5.7R.OCKHF@PC9)[?Z-_>-3,TN'WY]]:KD7^Y6DU D&EOU=P9K@0&G " M(3%06R)CP TG1FA#7J[;SXQ'T]EDGCW ^W"\_#I)IXM7Y:#;-7A]X-(R^AG^P)*ZE M5$(DE!9,0._H*HEUV/_J>AJ,_13YY[VG^XL#[]M?(_+B<8\5@HP[#"PC :$$N&R/38.H!B= M&*YUU:CNV&%RM9F JW.+AUO;(:Y:Y],?=9 _<\.HY['C]GM>(GJEXS@0@:3O/))_XET:P5NNEI_.^T%H8YFMVGT/4TFTR@=!7^T M+>[F$::IREIZ..".TIC^TOSYEWY(IHTK:RQ+9861%D7$\@(=I(K M3*4M:CXM,%AMS)4[;,%%;0L.&C1HIW%)B*@D%(WQ[B8PDG.EI<&8%E,R@&$& MD.,6G=>UZ.P +V+3JAZ^CC5831QVT_MK]^$#W]+A]ZO-.XL.]%).$_U93B@2 M"@:6$4L14-1*?[YTQG\"(P ,A['UUWSA"44\RA@%X$_/G%.D^OWL"/]K\CV$ M]OR/$^_D_#Q(O@R&@]D@G7H9_^B=@$GE5^4((S.?3':-H?%7]@)!G#_=,8@4 M)C'#A9Q@;U_BRA@:@ DC,1%6!HG"EF'*"RPR8U3\I!NV\SH;DXR4,1]___#Y MM^A7]3>E?[;91"/_RT^_VSBR_^]7^^$W^]NQ@XWVN*TSGDST6_\VO9X/TX\W MZX+D5>.&+'T.KSPI+%(*Y&1P/(@0A/DCH22+U<+<@(JP4&.E\;B$D!+JB&1 M+12W-Y@6O/C,HL6*1/?YDBRF%85%63CPT^@AG:39*7TRF*;AB)ZYW/F,HN"\ M7]B4HLJ[5Y)Y+1P0U$W_.?QBEU:,V\W^.;_9/R?=^U<]_*6;_/.*-_]53_Y9 M]^VZL1L7-G8#22) RFAES"X%L7*8$$4 I@(3&1=<"UP#:+9UEE0/1,51N;'* M2D9Z&'3$OZ^R;K)3)6>@2EB968FY#-SD!#DMA&9(V:*)Q7(#(=N81K"W*JFG MWI&)'B"7K4HN[:RBUL)*KY#.M(!9A]V59*%H.RN!28;LSM MVPQ8-FVT!>X)6F?O5VMM\P68X%> '@[*;+03P'"CB8(0QRI62@&P,%+$0^H8 M]-1DIT!/TCH[H]MOCB[@W)S9J6DR3"9YR=*7=)3>##K^WBUHK!!\2JZ)PSH6 M1"NIB50Z7KB,2BB[T=UG[^Z'X^]I^BG->I]/:-,(Z@%0:S]SZ[S'5J&TK5;P M$@%)2D(N#K'%3#CM'+&4<@L(70 2"K5!R/4<0-;4OL9[D%TV!?:E'N?N)^.; M=#KUVY4,HYOT^)EO9TP2L@.:%>Y,:Y7 4%+)B%6((AXOR+EX;(W=@&:QVK]6 M%MNES1M*R'NDP:[2%I%<=H?#5P%!4:'A4M9"9I$R,&9.:PETY!,=^<16)24J3>-:.6@ID\Y9K2B& M!K'B3"VH-/'&3)Q]2ER;=AH0X#TJFB.]/PLNBM=\_NYT6*?#$*T0Z##-(;%" MQU@"(BU9L'[Y(Q"T&TUZQ^FPFKPN 7L -4=I>A8Z[$1\.H=U6#>DNZHM54IC M9Z6&+M: *@ZU\^+L((<"",4Y?_F6*A&]?68S59Q^"5P#*S,QRF:IZ9.=+\Z2 MF&N#8LN%83!&!J-%YPM3W%0Z7YQ"?KD8U%1C8S0A4BY(LU ,+'VR36KG=3;: MI,*B+'ND>M$G^Q\??_Z/]Q_^&IE/-G[_.7+*O/_Y_>>_9>U31OWZ_K/Z.?K9 MJAJ:I_:YV6.>%1W0%H1('3TT6X1N%3&U .[(7JX@Q[M[M6).8BPLA<)RA(V7 M16V7JPN@JTBL].9)"RR4\N:)XU@P4KP5$DK8T_P*.Z^S(;'-ZHU,*+PQ&T\R ML7V7D2B$R_CO^I1^&P^_A;ZM_B2]'LRBFZ0?K.KW7C0:S])EO7#>YKQ"N!"- MOWC#DWWE]-G"\.X9UF!A1M8U[F8E>=,KN]6B-7Q% =>6+/OS=K+XDOOD:_KV MRR1-_O$VN?&+\"X9/B3?I\%,W4Z*]3O]HE3L:F7S:E"H3T-QY\<#UOM:*HV-T9=;ULG"4M)>-6-;FXPF_0IN?Z0SO[7-)HEHZ^#!=O!8%3^F,V- M[)I;+JRY!0N,16!(\^DO,BDNL,GRN?J"6-CS9$Z@; M@/@JTR^=JCH#584KA'L,@ MA!>MJBZM,#1D$T+^+O)RO=4UN^#6I<>GQ.7 KI Z(D6I0!I)C6+O@X#8RJ)W MR1A+\0:P5]'Z^ZA@S$VO%^M]_HX)Q#W*ZZPVW93^8V2E&Q/9]2;N CBKLK;& M &LB!066 R60P'9!E>N 5'4 _,S,.:0]6.NHY_,!^*N)QBSM?*2^3M*,Z']+ M+.;#O[W_\,Q(S.OL[BKTBR@9.A0WP"(.L(F=?]U[#W'!V@H A:J)(,:G=#H+ MG6'+G7W!DP'M"5YKC6GK#@:MTA1M=18N$.0&1ZUW)/5]^R#Z^6+@U'Z\2;__//A M_<]T,KY.IK=!]PL$T4^70(S2'=TO J6D'%/N$$X3AK?"*_BFZGONO MNO7K\_7VB3*D5^W"LU*;$,R\0B$4(F.%YD1Q6V3P8@@QWFCA_.UV/)D%=:+' MDTDV8&/7(,GE)[8J!3.^\[O='R3#7Y/[=-).Z]T^Q[Q5.J*M]OX2H2O*[FL@ MM"..8:!B"8!'+XF++B;#H/<1G@==<7KHKL?A9:V<+JW#[J4=JI>3@5<[=(*1 M7K'04__GZ&LX?-]X#R B5^1/P>;3*_:GWIK51J"W)2R_,5[[U9X'JB0,"!&/ M>"H9MK&T A(DQ2)5#RCR:H>BB[DYMH5:H^"M-;>OR:J>,6HJ;?^$ M RLY$AB(&#A%I&:JR'\3C<6CE6L[4%,3+R^N,PW=?D-W[B?:CV7C:3$1?'42 M^"Y3B*]X9@KE%=XTA>@I4Q@RT^.;FW X+H>2'S'\=_[EZ9UZHJN/W\_>_.4' M^&.X_/S+(X):&\O;!?KVHA+DP\0)HYD.LSD5-A8S HMC.<,<;+"25!D3*M)8 MGUUO]'C]W+UNK3_0';]?*819A1S- U9RQC5GL7.0(@YT40$#B3,;?OG^$*Z) M1 CU(#PE>VK[8'QI)_&,N='+PI?9-BZ,U^?O5X)E,,8XMI+$2G*#*>7<+2A_ M%"%HF34+I2+OJFFL+ :V^"%9Y2:JP/3]J#^+-PG*\[60 @F/.6\1&00(0V[MPOH!B^*3XJVF4SE'/51K!TC[ M#=^YG\Q_3J?3J)^+2'0?6A;&H\ZM/;AS1%8B9]9;3@TH9$RPT!-&"2F*/K5% M%-%CD7TZ XIEC]7;OGFL:+2_4Z15"J.M)OQ5J@A2J@B ..4TAD)+QKEU@ENQ M:/[ @!UM_$]G\[V*0/6._KE\%7%II^H@H&^#4"X,!M';C!*1OTTRH 1+69[? ^5'/^6^.6=?(\*FM-H M,(J2?M_+6O:!A\'L-NMC2*[']QF*QS=15$P-"14?OP78)9/K:?3[_75H7/@P M#M_#_*FI]]S2C?S'\/9WX<$&_2STE3W<#Y_']X-^) CZ\=DK>!5%OZ7A1OW= MREZ^)M-> '-T-_9K-QCEN/9/>W52[O$M&#B2N;]4=!]OJIU3N]G\'3<& PZM M K'%G(HZ8*3VQJG5N9/X%@KR!0R",2.(BM(<3YV3CIU$!U_E2F;B/L:1BR\ M^=L7*NU?\L,LE1B=O M'@\>Y)<0]'E^(.2^2F!,"4I((.^<808B*P.,'H7&$%=5' MR 6;Q005FV=>O18\&FII3_>_+I0_^]''_P3?WY(A]_27_R-WS87HB"!@Z\C MW#RGZ*E7..L#8EY/100$M*3$XH#$A B*D.-*4D2XC M(*FC=D_0:CT.R=%@? M >??O)_T^6'<)"89[SKPS\P)0%UO[298>06L5D'ND4F1$4QKZ QD!5B%=O&3 M_'7'@O5VDC;7D4=(C]=:--B9T!/ %3=#92VL*3BS4_PE M#R\O%!Y$Y3&?.(J1XII"XX\:WEW1&"X4GN2Q>)[":TR/<4![DI^TQ*"E[DGS M@\MWY@SJS_2=?/;LJ:_XU.3BW]+18#Q9(Q;U/L,!N8KKN9[5:9,'?UTORS;I9-(?)M^G6Y)-67JX/[Z[GPRF:6BWC\:C/%_MHV6RU^!//V8)K^31!-?W\)U']/"'S_W++AM"RUYS M;035L;/,J5@00AR,B\0EI RB3:>YPN.XY(%,_ACV2,O"<-J0\LS12;Z(=0K M%)*[!,*C7,D+,>Y%WNK>!F%]N!WT;Z/$P^1^,OXVN/8HN9]/IO-D-%NP.BJ_ M^N'W0?07'-[5 4S%-<++?YTG'EL>!N6(ANOL[?\V'RZJ+ECT0S*-DOQ+>]D5 MWFQ^V_(+WOQX%451Z[3@I>GFS41OK;IZ\^MSW?W;?/1YXA=D4W?W"M',:PZ" M+(;W>Y64'78SH9K.OTP'UX-0T!/&?O0>4_<+'9^#Y;\?**&H.KG:F0H[=^H??7 M1?%1C>U%\P!57?F^0D^OJ],#BKQ>MR:='N7*U>[H/J2Y=AN,,@4W')05BZ$R MJS_^EHZ24(*5ETEFNG)=I5YU9G3?W2NJ26^R4M+,'HRGLXP,K#TB,4IG66%> MOS^_F^>%><5HM^R$ZV7&^UE-'T8D*B/X@<,^1H0*;# !. 84$>S-%M16([%1 MN:G*&U>5^_YX\]&KLLEB#TQ8^!TVZI"SP!.A,+JO2W_%FG/HLX%ETVAZ[Z]V M$X)FWG%>U%T63M!N/_^JA1[SMH:7(RM^5X^0TR=K? G46A(98Z*P-%@3A?2B MQE=KP2LUOD8!*K2"UM@XAE8('KN"EA7Z4S;+I7$PFGO!G1U\'7AXB7#SFY-S M!%O 9+$ MFX2]JP)JDLGDNT>KUW:M'JN[KQYDF%UM-OW4I@F];=L:B\M49..;7DG44,:< MC!D#W%AG54R7;'"8QP:=8--/,#IMWTVG]&J31Z?./=\\GN=-VZ%Q( G.[Q>O M(X,M##G8YL.M")93MC0WPG!EM43"8>[E H %_*&R.R;O'B0)IX2Q1%>;A;GU M12@+/W5>#AZN-)"<8 -1Z:(*[A1'EBF"I2,64:_"B@V,_?\/GXW^ZR2]&\SO M/J0MVD^(&_1/?XRJW3F')LA.D;=<3Z9N[:Q%6]L)P&L0@$4A\^)@^J@/VLBU'],TKZ:* M?&MPJVOPOLP&;XS*JCT*G9.:QM0)8R7!RL$% 5W,(=X14 QFNNT1Y+V)HXCL M"51K47GK:L9;I<;:1&17J]XJ3')V<#U]1]2IE=KSGO:TK,(0DW*&!Y4QM%@: MX9C7<\I:H(L@"B#*8=!J=17HU)W:=3* MC#),K77>JY0QH4HH;"TEFC--G#78N%-DI5ND0AEF/41.PHWPLK!X+<0)9?)_ M6?/0\2@\JA=$I0J3QK'$0$-JJ,"64XUPX6G1F''7\.'R!)4J>S,OT)ZH=89Y M:XD77E-L]A7#G(!RB$&,K(Z=-IP9)"TU&#J0F__8&J!V5"(V<:!Z2>2_Y(CC M#O4=ZAM%/:KV 0H&@4.2 88 4;' JG#Z,0;*7$8I:F?@7VU.+$]('I4..RV5 MTAD&29KD63J'* JIQ*6AH\KK/0&I5H01_QXI%W%IB\P&U_(S3TLG5(J!IXG) MYH;#'R(P[0R5M$J'MBEZW&G.UZXY=Z7T""LGA3(B!>N=?#J+9^/Z6C1G>\&+(N(LQ-A8B&\=^8[%T1B!EE'C2]BZVX-/BQEM& MM+DO"]HA6@I>\4:I8/8C.\MX[I)OR6"8=:K/QM'U)'F(YO=^LY-,LEJCR[QP M>X?2K_/X%%XE*O,Y>D] M2=RQ$I\Y*W&%A7@W__ Z]^13!-QM\AHOD>>XCOJ*E>GP^=Y.-WA%2]K;('#? MGC4+I87QH:-OXJD9,D%:\U$)&1?I@I'[B/8RC4?J0CYC8>S.B'P8_EOL7?1A?1:P7&:_NPH_A M#/I^Y$\HX45_Z/RW\2"SN.6<"W^)?09AY [IVO-4AWC\YHW ;7DCBXD=/V5? M^\-@XR9Y?5=.O_EW;[EV<21;N[/%"(]=*QON;S"=SALG:J6T/*EK&/L7()0< M8QY;;34/B1%_H)-6$76 OQL\#_[O6,V_(O1LES5;NN7*'>)5_.*_9WX7,BT? MPKC!&D]O8)MG4=OIS1_M!Q6\/$[DZJ4CN3YU3*8V96DBFZ0X7-O=@D<'RX1W3Q;T\\2AA);+JW%R9%P,1K@O2\,R5#% KEK9B?/VKF:U) MLIAG?I1([N\G8W_R\S?F[_WX\2IY)GYO_+,RWZ8U,UG_K+,0*\"4PSI,*S!" M.QSK#4NQF$O@,A\YS<83_'4RGD[W@/OCJ?1'\9K+W1IB:PCPDJM-UI6Z<'<5 M?0S2-)@66]YK7)]7RM* <59PJ04"L:,TZ/9L^D387R#%X65I9NZW>SU6W_;M M;931.<1;!\'%']P,BKEP_7P:;5BWX&@N^)VC<4[>?0()*">)&T8 851CJZS? M?B*5#18]YL"[?I)NX1K91/1&$>)+;3A^)+JX43HC< ^ !D)%8;/7=_>1\3B] M4S#S4UXR\U-CF=8Q9(1AK0Q3%(NPTY*Q6"N[T0ZU.F9F.6'F-IE\3=?T=US9 M[[>MA7FCDVC"SJ=_W*?^!'Q]%>49RU59>/!7BKZD44GL'@HJ,_M?YN^R\7N% M>Y'4,X:L%:&.1J-)GQ=.V=(Y7'4)+R(>5W^PZ*DEW7H$K2\&QU&=8Y*V51&_ M^,WE/X:WO\M40/^G,#@HQ.&FLW=+O;^;"IT!K37D!D #,%><&Q7**)# 1@!. MS5OP)"'[SH_#VM@XO7)+)B'&F#UCR&^D@S"<+)S&U'58::_S['PRO@Z,Y9/H M4W:L"W-*=#)-\Q_OA_-I=GJ[O_=+EJ6H[[S!&8S\@>I3%GY?*,?U-V2%$E\6 M884BQ[?KP)GIY&3H[]@;%*^\LX*S<3[5:>CMT"3YZK5SV)I><1S,E/1Z$'5: M#-DJ ;)1(KHO__Y>^U6_<)\=%;Z05X1BB.AQA/CXS>--P_F%,'Z<_OW)U\@S MN.%/PY5<7"7[DLUK%*_F;W_TY0-+O9MD8B_Q_?,"LI\"O!KH::]U_<]FA==U M]F_WDS2Y[I:WIN4MK=^C"UN; FFX8>PHS=+XVGM_\>OLIXA>4?!' ]+;YK5] M6:'?LP:/X3(G"9CFC""@+6%6.,PP X0HZ+QO9,&VN%0U,NDA-9CF:/HX^H]D M,@B^2( 8W QU7=8+FKY4G5E M5CY3:OR-Z,MHGO]B>P+K+=H12*>;4;<_-<=!TT'R:$A6!CI:P3C@G" I'.<4 M^$-*@*1UE +D=@QT["!Y'"2#EQ!^62\@\8& O*23S*G\#7(%P!_1E_DLU X) M0)KS0%['HNZGN$B9XP)"Q3$B1$+.8_]?IAG/? DBC(7R)177YX?QI2NNIGP) M?+6%SJY!7Z(#5PDN6J85I:(@YEA#(\/K4$K'>D0(SH6"!-B17.6$*1S'"'C,;([.!Q[G#7 M5A^CBSPTZ4H4S@/N0@V-ZRI1%L@[ZY2VL2,6^2.0%H;!/&TA_#$)(/:"NLJ- MYY-+5U7-N0BHBS6\%+I*8@X%H324Q( Y9A54@GMO(* +"/\2VZ 4ZM!U%H[ M8=AJ*ZOCZ^DQ5^UAKL@*,=.;FU ]^2U]O,PT*7H*RUJ;4"ZZ5AY:*64-Y?S- M$@XQ628HA$(<0@>=%4APK8APBF BJ5*Q@LP^K=<65<7AL>QB*7Y-)T%1>_74 M-D:B.KMJ:_8(R/XZ"VRVC*WKK,.%N8:.H!U2QT%98A-S1KGT;JD_72,HB,'^ MH)U)76P@@#MHD3NIJ\=2[BUS9)^@_,%2TPM,D??Y[@V_+_7D]O+Z)]5KJ5J7 M5?BGT*,AR4=4<6"L[46VIOJX[Q'FDQKZ* MCCH>M.Z,TESSW:_)]XQBX^KY*N+SCG:R^\GXV^ ZG6;&\K_GR<0+J3>J]\65 M0^_:_60PZ@_ND^'V#K7*$<3;W)P;).<&N*F'!F3?SG&.RBG9ACKG/<,0Q,3: M*$B%];J*!L(?+*'=X2AZGW POA[TB_7_=;$ CVNJO77&ZDR-!IC+#YOL5/HPY^6; +Q1Y/1^J$5::BIR,+T]LDYP$8Y_A.D\EP$/IE Z]D MOS^?!*@'>KU5HJ(EH5WX3$Z(-(H>;@?]VRA\W]/7ZH_O_(?FN9_NM5'FUP>? M?CY\1 ^MJ[:>OU::-?,&=J5^/QVF>==X:. =AQ<>!M.T/A[1NAK$#Y3&M; Z M9(OVUY>04%4R6"WITJZ.H.?^?<^-3J.^_^:L(SD(Y23][WF0SR"324%4%XYZ M11=TZO7D+#1![S,H873]9R\OF1SGQ%@5EJZM(MQ;V-1P+$UF!2^&O]FOV;%S M:1NG!L'>#DFZU@]A+2D;@X]7$]<(?>P([/T8/X_GPNBIJH7;O'?1_ M1,E-8!GX.LB D4>L X1*P2W('V]RL'B3$)2^7].^]_L"E=!2UA][M[_!-/'? MU@_HG,Z__+VX1+AK+SD+-(1%& [NO)K)?YZFL[ EL]L]GO JLN$*>V1.%IIW M7>5N)A)W\!FH&%M)1O0$\YI!OPV>U"XRH-R_ MG*39-TZ]\Q9^'=S.S,TL?84%+U"4?!E_RP^&6[WLC$LI*05"+N;4&H$X%H H[UAC$$/"%&UE K.NV#+? MIVKFQ-&CYAC>6G9;V]3MS^5LMGS?WST?"2Z8\O59;_F)>2_=VRL^7?GP31KT M4[\_"8?NV2-*,XP\>$0U]Z)^3NU[?.AY%\(KG*5=0K=-6;(S2^CF0=.;27;R M^+J.@*:%N.3-L&'F.#%0:<:<0LIA2OW)AG-LO%P[M,_D+[-T\UWZN)':DD,Y MZ:#$/44OTTV/CDPC$Q>)_X+O5K- G&+ MV,W*V,4O:39Y<53H\W!XW$/E/QF;>5]./?!N=.5DZ$7_*/=R/Y$7I6<61KQ2 MB;GR1WL8^U<8D$'D)15Q3/GF[-[5)Q$$@G*X-#]O!4CBQ?>-4>YTH&\PAO\_.3Q^*,(G?#>#?I01UV?J^SJ]2>;# MV=8;%%< [C-!YOP3^>T 8PUW\>0@R.58T/H'0;8@(_[B(6)5#,X+6/WD-4Z& MO V$AE>7\;021!>^^G7=51@:.?\:9+@('8I>)MKER-I>-K.VMSE)\JCMR?*K MQ63$/.;XIC)DM_BR=<7X)LO?%J'H23Z::_DIG8S^D5TMJTE90#+,X?*GZL%L M7J1 IU&>R5E.U5MD5_+)O$LW?A$\6699:W"C=Y4."%B9S$@D,(IB)&,9(T$! MRBKO!'&(*@TWYC-M\U47(_?B-/_;C2=Y2=[&V)[@/8ML>B.&.T,2B_U9ZSZL MHPI -EL$$,:RS-*OX\D@#&'YDGJU?NEJNCDG=(F\);R/\$1_K;A+01OL5@:Y MUEB .6 ^S4\==TG(E>;S=$)N(GQE!NZ-LMJFX8RJ(Y@PB*T,Q$'.(4MC:(0! ME G# (G97G#>;P;\^QJ@_"(50*Q)["_F4V[(;'#L)VFE,G*1N;NNE'$GQ5"G MO"AHVI\,OBSTQX^9';D-UFS[V,K\O+0\):U86X2?JNX,ORF+QDNQG6U_D' / M7])TE-44),%4AYSJ?#;VMQ5X"/QSY&_96A/ZPSY5GC\><#2I\A: 4Q53GJ'V M?+S^X;AS_6X-&H47O@P'T]L0'F]<&^*2S0%HRF/-G06&**(4XBK$Q8EPP(9Y MA UKP\:2-3O5Z9,!Q<6.O?RX8=RH&U:9-;SB9']?#9-G-CL43MS,\X*,4(X\ MR,N?IE?1FHP_&C!:!&VF&P&L[1JY$KI:A*S*;QGDWS%)_6>]HLQNL1KI^6T9 MBA(;FOH)3R:OC'ZTQ']A?L;SF?^*?#'*".L>0+]-OJ6;MB'[[:J!.,XX1/F" MW.;%,&7-4/(U"8>P8N#AVN8'E=S"6/#Q=F2%R6=9F/@RD^8\CC]X7349]!_+ MFJS,;_^M\($^WJPFOH,PA I./1SW__%F2STH<,[$C#L"N#^U(H:<8!H)$#NH MG!+V;G.A*),,/5DXNO,Z\(VW;OWD/M0=3^;I M'#6)+J/%61E#5V[Z_@6]^RSL,?N"#I]A M=P(<[4D+U)6[;Y:[DZ[O0:0/:W\]I@+6D.JY.SF0DI\!1D![-C!D&SG M8$@('A_^B,CCKT'VS-?X?J]=$E'J\V8D97M:2HYS7-\Y0+OJFOZUIS5?JSOY3^;*46..M7Z/:B<>'?OA%E:TRW M#R^Y#S\OR^L7D29_)NQVXY2[4=: 9CM2UH>&O7BM,VIJV:QGG['>O[)A&2^[ MVG_UY^E9%EQ*LA!L^M_S9!@B0GC!.=!MQV/;4;TY7+F3972IAOT)0[3^]&@8 M9CTQ6O\=; L++\NX.]%X2=& G6ATHM%IC4XT#A(-<$7.2C2Z0&1MCG43GO79 MKFJ-C1T_I]-I[D OG>9L].;7QWSK0.G;E&]]7AMR&F.(SDKC=1)0OZ?<2<#K MEH!.![QV"?!^+S@G">@BS2=PB+M8\XMBLG2NP1XIW?/\U [)*"+AC?NMS7A#'>K MO=M+;M+]O9#U/XU-I&>E$3O1.*&Q[$2C$XU.:W2B. LN&/&Z28"UILKXD83K( M>!2MD&=$[]^_KU"H9M,1K\J[K>N^EF,+EW>1^&\*0R?N_%+=5FD-%K0ZO7SF MY%9JKWII3T\OAGO;9H!%$Y-RSF7%IN,= **,:A--823)U&B'/K M-H8HK?*1YASO@WZQMEL&)8G504GUT9(^FQH:/#WRDH(> )N4I,=2D?8"];/7 M$VD^)RY8V9QIN12A9<:KT1%:".)RA!; 0'&'8@:IBRDBQ@%-, .(:>-B U>H M&I_<^H(IH3T2<-2 *[J%E/;X^5:%CAA[#W4P\EN]/^/V5:1F%69%F,FMLS-%96YN:W7,IC3AK1,9E5R]MN[9# *NN9+,DQ&_<4\P/O$ M'WN2V9)!_NIH?_PD?N]?_G>2R=Q4.AUC%RMH8D4MC+4S0"B'+%- 2QE8/_^< M[..IU.-DK%+'?/CXV48R^I__0R (?XH.X\-=4I"GTVF:?KS/F(]'7W_.,/PD M%Z[E@C EL/4F7&&L-01D01:) 8(5+EQN">!8.QD'A4^I\*N7O=5R0BR63])! M[KS.)A?N$2O@LKDZZ1[/3ZTU$'N+1: $$"ECH2)8&4F\8?/JI_+\#A $J68\ MCDE,+'*.R_#6&$CD?P>>?/Z=U]EX_I^M^LW^MLF1N_YS5=IWLWKNLP_';"/: MBUMTG]4X9C%W$?A6CQH0-W-LV()Q=3V^7[C\OX439#*Y?M8QO:Y<41N'K171 M/YS])]32C2*7?IG, \.]ASW+'1>G?M.+\;-)-$H?HFFQH,7\NVQLUC!W8OR_ M%AY--)OX(_Q]XL_A_>]9'* _OO,_)E\*51CNR.HN$@ MO]Z@)/Q?F-KI;9H>,?TY<(WELWJS)\]M>O"%LL' ?_1# M/?-JZSOEO<^;FT%_$$(=UX-I?SB>SB>!E'R2+L8B9+MR%YXP__#T@^ELV MAB8=A3$?(:0R+88,E]/1LH!*?L;UGP_+.9U6QB1YD1C<^8_F$S/G?ADG,^_! M^.T,HXJ3Z6UT,QP_A!L93,,5;B;CNV*%BI$[2^%Y2*91>G-3W%98S7F81N.] M[LPA^K=DE EB?A*7_M//WJG_3//9!IE6"PL3%B13#^$H%Z0T%["[='8[SM8M M1'R^9^];WFZR9'HO;SH;S9#-C0LS(/PCI+TPVC0;E!HF'FSYFH*GO8!"]BWW MF3\]C8J39W9T*-XTR@+@&<:V;=%5Y!_->[7CE4>K/-%]TO]'X,7+[CR$N^XS M)]9[OUY"[[WGG6UTF+HZF(6/!R$N+KZXXUXQ>"(=#A:#,W)@EL,WPD,%R&>R MXL]+XS#\=]0?SJ?YC+TOX_FL@.,@J*\P(C7)8VSY;_M#_^'*;\.2#@+J_7U> M^ZOT9_X+I[/I<9-0ZU>@YZ'6 ^J2BCU8(0A(Q7-$P1HJ4L\\M5C=^\1 M,Q]6$%,Q%T=% $)U\\*U7S,DWYN,_1$D"4@I+5UA(+'&U/_!K"$8 "J5/Z=K M81!S0F&V[I6OGDA^7MSTYA0D^>_0JUA03D%2V/(A?5#]?E#Y_KM^ MG8Q'XZ#LLU=7!@Z5;UJX6=/?[\.^!@<"H%VG\;=TSQ%$A-(KVN XN(]KV^V= MBH4S\9!.2UOS4P(4LE$,#"312&\"($0PS;HT _E@43@:68(@WQF2M MRL*GH(8^WOP^355XKO.7".\4-#H@\'UNPKZERSU?J*'@NBPM[4U._]NT&)39 M (T-YX9":/SIS/\E::82M/-28!1G*Z&[;7&*./7W[#W$3QNQX#,4 TRO<'.S MR09A1%:^6E%(*%;,0'!2&MYT5B8!*,=$.N$81EI Z&)*N-]T8S D2D"\<].S M/[Q(!__K6SIM[;[C?7- $C42G0U;/A_=)-_&DRSC&W;=>S)AM<(E5@Z48>[[ MHW;#:Q W7@R>3HM#4*]R@EA.CEJHE=RFY">W9/6#)W4_6)DFH(0AQ:76AACJ MH,+$>"VCXZ!\(%1@W>14PX&7XWQ = 4;TS&+ U9F5 J#$LY[X>3<3^Y#C*N0 M@>OT2SY O12.+" 21"($1 I_Y=0>"H=+<;&Q%00SR?TO$2/,VR,2Q(5JZ?]# MR5/B<3J+OE[Y5M*.8E"2"E7-_F\Z?1N$*Z9S,HIU/ZU\K)9 MS'$X[F='^?#-U^,R$) ;MLQ0WL\G_=O%UU8^_I";6'\"F_O[&4]#J.?N+LN, MYP&@;'#[MV02WNS%?)B.OLYN<_7X;/C0YP.OMM*/1;IM39L*7AF+C)P)13^$ M0H HF,)[V9*2E_]._FLZF?W7IV3T-4^G MAY^*:&?%X_TP0O" M0IA&Z=>QEXQ%O#(3**_QKH?C+%J9>JLY*H;9^MT*YC.[_#&&$(+V"HRDI;>F MJ?)2 CF'_E\&".Q $!AOC(U4F^9WF\!\RE<[R$WMTH(;DI:@G3;52J;%RA!Y MKM2FWC8/_8E]ZN7'6^)9&OV_MY^2[[D&RVMA1]'=?#;/YA_GHI<-H Z9G9YW ML_(7ALDTT\CC49H]PE6DO-7,4PK#[YD4KNGNK!!VY2R0Z?$B@;+4Q%E];J:X M2Z5<%(P46CE+,7WU-S99N9-+58@,E $P 2""P#DJ_%%8_WIS8_!_\_. MC2$;F/G]>9Q\DB9W0?/ELK,L7^TFVQY\14'7%NWZDB?;[E%].7I MN]CY<;Q#4)LIUA],HY"P3S/[LBR@"'@=K(X8]_[RY&O>KI"GSX;AW5[M^R^[ MSJ,!U2:.S'0$;:$_1?X:^0SQX"3=IB$BX*]8?&](_7IW.EBB))K.OX1T6N9J M^PMZY7=HEK7YE.HSZ].\RC/^0+%[3#WSSI&+N?6N$W4,26X<\X)BD60&8XDJ MI6G:2.^ "\: E=X9CQV1+KR5.BNI,_%&;5W#F/]<%!-X1Z3H2\A5?=CCD?\[ M2UXETV(P_/3=LTZYA5JO7!SFM[NE&2YK&&GA4.B\_O60^&R]^D7.C29O'J>]R"\DGA@;#9]X2>SUL;W9-NKI^EP5AK&_5$C>O[L= M7'L!^*G8=@3J41'_\W] !G[:WAJ[W #\YO4\]_[4*LWV_CZ]&J?:>;1CYVM= MA$=91K)5::2 _7.UI#!*O8J]WKXBSUN%QGE3MOFI+63%;'P=?GB?^67SJ??< MIC\>*]0-K,D+R/9Z"Z9L@ #A# 3\)=5T&XWUJUB0%W79&H#!>DU=J.$]&L[8 MP_EZ/ ^'A$946UT/_R]-/ND+ZNQ=#/S[@Q"!JW8X9/*>P-;GZ_ 8W_&@>2C/UARPF0"4BF6>H;2?\ZZ MO-P!_%F^R2Z1:+]/4BFMP08PK'3,J>1:Q;'!<>:3:$8)4^#)NM:U0L4J]463 MC@KN0;S9 7.$G]+%?UJMI=XODH'CT68OK;_,\6J/ EK7">L?6G@&ZS]SY^)S5'-YL>)]M M"7T\NKX5\M47D)M& B;'>"W/6X[3:CM4NC3(>2T7UO3@W#Z.KO?YO?WPT6QXY(% M(!J,<@D+&-BDG0F]4UV12U?DT@Z?HJM[Z.H>7L.YMZM[Z.H>SOCHUR6>6K(@ M;4T\/?=!3?!:,PK?C",PZ\,/O:NAH;%D$+KSKNL\;^LIR[8K(;XN6=5&I7'R M,'!91%.A5\R:_=;[PKNTU46FK20I2VD41$YP9J&DADC%K12.X%@(12F1NTII M%L,U&BZGD0AU::HSJI-XKOXI&$EWZ)^]'?DV.NI[(I15^!IC)GFLG)(.:J9C M'E/K$:H,8\Q:*O;).14X_3AZA$&IS>FG]J/RLMT%MP1EPW ]JV#2GC@6)8XE M% @P9#@E $G!!+8LX-AY'#.G]5,X_G4Q,N84!M?;6RP[>WM&Q\-/51+[_YG< MW?\4V47IV8+#;?QEMB3V2O_(^[*STV1^3*RT?7?'Q$[OK[AIJ]K]X,O\[^G\ M_I&%].OQTQ,I/WX_>_.7'V (Z,[O__+L&WA]J8[]K%.@ "MI"&+"J 6&RY#& M8T@PB[QYTOZ_WHK)#3=SK6;Q8Z%>WH]LH5S<>+(7=7B]QHL(U,.R,U]MS.XT M[9_6XX6>8?9G7[A7XC[2"<.TI!82 :C!@H#@C1J/=*((VRA7W@?N>U#UU@MV M2'H0-%?JV+9\5U?1L_S$L1Y%]&R7(K\#5:1@@@.=\?9O%A)LS/Z5BX3-^DR= M9,DZO/R^ZG25S^/[03\2!&54;//I-'?B/XQG:81[T:'4G&E!4;9CIHJD;7/Y?9K9R=;P]JIM@8"JS# MF!/-@010$X+#,5QJ9I"I4#/%!"JJH?/G=FZI4\X"2+"&EDHM_:>?Y K;>9W- MJ8FG+(1;G5EV1#'_HN=GY\O[O8 M0RT<46 *N@+32RDP/9/8XTKI72\;4WD_JS +YPSN"P[9C"YR5X%>%V!L0ZU6 M5V/7^KG?6*)K:ZU;85 K#PH/(>-SSV7 ME;'@>0:U@7!BK1:L/5VSCS]H^V/DD)=C,:TC7$KH#V[3G,.QBNQK#.(,]!-@I MDMK/V\#V /\0B]MB_*_[(TT1]5Q4?AO!$MB62B*MP1H"P2$AFF./;*F$=!P# MN&.R^1+8'\:C?L/8)@C4W>#0V>^7QN_3)2LYG\]C!OU1C-<>;VBI%3AU5]8Y M."T(E^<2A("&,8ZAA4AH@QU!7L,!(IW2(4.]IVYK3J,)U/-WUKDK77#T%3SW MJPF.+MB/N]#HJPJ-5CI)9L]E';R80.?Y'(8P*.O8&!;2^PL.2V+K>>E:?VU![-6_[[?^ND]K9GX-4OS^_F^?UA-<5 MDO2&@QAG53.P /0/NQ -V1+1G%.GA,"QPLXA+9BP&:*U=EA9QO=%=&5_JASV MC6&\=LKQ8P6AQ$(;3-*VRJAG'B9$:W6"+:?0C]+C.8SK"6&>8<3C^)SK.00^ M,"GIUV. !/">C($.$P9!' /LM9[B!"MM!3U@QD)S7@SH2=X<.?$6%7?>(9"S M=W&VI&I7F-J[6&X7RUU3::Q4:5I@($0<&\$0L$))C 7&4@!-G(W11@)Z:X]E MT^EGW$,"=^'<5Y-]7IUSUN6>]\$T+^E6B&E.)2)$&!3"24Y; MXH]7&G*EB9%\+[W57 UG/)_9@N:7D?*/U_R-8T^ MI7?)8+3LP(D^IY.[+M7\2E+-ZY1ST=OH>YI,7@$/\(+\9-TZ4UDF<0V7!A,@ MH")*<7^<<"A89PIP[ 223U=]+8!6X&P)L^S% #+XF.&NF.2WT[3_[GH^"9OR MYB_B2FR2?UQPKO;< Y4KI_JZL'66F=8=H.,EZ"Q7#CFJ-5' ".I/\QH$T F' MK-)/'^4;@!R^PO5!KFLJ;X6OU_FXK\W'C1=L*)^2V2/IH!G%H*ZYX$&'O M JXY/^\CO8B_)+.YO_KWW?2]B)&8$DTQQA10:#E0B&"-#6=Q+#&NT/=ZO2$9 MXH83R&(A)7#:A+U"2,,5/A-BVS"D-&*\MA%-/(8*@)XL):KBPE_JT4 MR1C$',>GIB,N'G*03K=.*XT>TDGZ..WP4S?W)$5J,86@\OD5^]E1I+[A;QYW M]/(+L48I4E^0=+5E$S.>"ZV#YJ'O##&\P)J\%!GI:U^+=@;E.FK:V18+=L S MP]4(U$4D"RYXHY8CC2YBHRZ-\?QO:3*)["A<=F7&2ZL#NL\5Q:?('MJ9T._6 MO,40;TLN[[E;@P "+UU$?7%UTBV)17,$R[8L2K25& $ $7)4NE@+0OR_8P<9 MI(<%MQ9#F^-Y^L$_W.=L5M@OXS JK+%J:2%[0L"+'H/9@>X20(?+F918Q\K% MC!+B+ 9::LAC#SH2:XH@@OOU'[P$V'"/R%H)/%N'M;;Z\$?8<=AJW[%9T-$R M*T"!,X##6$%G8ZH,L9('2V<1Y]B1C0*,?2U=."5]?A@W9^!$3Y Z.2:[ TO# M0L=(.7T8*!QK+!R4 @@5NLV4%SI&F5(&@H,U?=/"AGH,U9GB;[\>OX"#&CK/ MH&&S(!0E"*T,\!->3YJC!Y ]">LS8DEYR'A@KBD%6FX,%3E(\0^^->=K4=*C\"3$,&=A M$2Y23EG)?*TM -A0 ABWDEF$.='!5!BM&7'/.PPT*I^P5C+8ULGFN9;6/M>4 M?/:_3Y.;63KIR! ?Q:LH\6J!/T#$T.,T-H8SP%E^H)!06!(#^%R[HL(6- Y> MQ% /H%3W4QV965N"D1,2!726J0KE5@V9U\+NCD$Q1A-+B[GPSJI'W5TLY*UD1",',T9I):0:S1D+)P;N($ M,(PDWX@E;S52)Y=R5&\-[\5(^.LZ:1V]U=AO]?5X'J@@CAI(=UZ="+N6X ): M%:1D%6H9H&&,8V@A\O8;.X(@(8!(I[0%<$/#/6+)&]-E1"!_9JRS//KY.]S: M!J$.MZ\!MQY3X+6..#D_S#;(#+="FKWV\YYL4G^?3V>#F^\K!%$D3(-J9D4. MO*L:;D)E7%R+NSCXXPLZA)Q=!<->%+#Q[*_K10]I=)M\2Z.@7 (8DF$T7A\2 MX0$5W23]!6U8,KJ.[M+K@(8H78P:CF:WR2S_JM%X%GU/9Q[#=_Z5?GH=GCA* M[N\GXS\\#&?I\/OS%R!72/^R2R.A2G&S!<9RPRU%V@CM_'DI)CC&.!9$"K Z MR7MK6"#\\6$\^ULZ,XM'JIZ=GGEJHDN=Q7;$!K:07T9^E8;5,>_/7,ZK*/I\ MFT[3S4U_\!=8;F$T&$6A,]__=G9;,,G-TLG=<<(,G_W):#8^5H2>'%& "Y= M4<&DTQC$3 & +!0*"4RP$1@Y"1S:+Y^Q18;"A(*/-\;?7MC51V85_-=T,ONO M3\GH:ZK^&$RSGWY)/(SF=[^D.9WJH[,,RF+=A19>&TCQ7)EY:1W:"D6^G;6S M2HZZA4QR'\[+8R@SX9L7LFGWD_3;8#R?>M4>%.-P/,U"V-%X/@D62D1JY%=E M&'U*PQ3GR"^.\V(;>1*%_XK",UX;G<$1.>^=-_KB%Q]Y=N6>B1Y_/J3 R*+ M(FP0H+%(+?_Z-[,65)$@"1 H0 4@QV.9V*HJE^=L>/1V9+>Y!Y7;=5+=LPGHR-^M*7=MJU^*SZWJZA]G(7WXM MX/]I,KH*E_!+O_% #8;6#3LUOCWT%G!5C"#M@#/= 4^=^QW=P>>V^Z,9I$O4 M\(D:O@@R05)'*;$,9JOSDF&%A*8<(@,)@<9+3SE#*YGP]\-+,[\(KG'VY^$X M1H8:V8=F,9T^R5GK8D_2/JR MU3YH'85 $G])_"7QUQ!_S7I>2CWRS"EML51!#@):6(): ^HHV(?X:T%T2="G M\"!-N;HINKH2V6S/97VJ$?\9]$Y"8?0U( 6@E$ O+5;"6TR@UI4](JU:PZ#\ M)"#?C#]^G<1:Y2?:9G?0.V.L#T^F!=C9Q!U/&:8-1@E"+)?(48DQC)DYEK!2 M;RJH_&K+XWW!]+MY#EC0!,T$S:Y D]1)X5YJR#".;"\"*!V F?-.Y":MY7#; MX.8Z:+;3")F"U(KPN,Y:=F:>.,$>!PBQ6E5R9:E& E+""0]8!-B""H\>4;$] M'F/3Y^.R:2GO"]2F3=N]DH].(;ZKJO8D,2]J'4P8\A@[(P,28R-@*F*(O3A@ M-(BOM'7<'^:_DX&,^I(EG">\-Y M*ZP.?9YXWHXM3+PK#= 1 P\WVMY)*9GW5D#.!#)&&*M %7\R8I7M9V/@Q3[[ MQV53$]&GI$T<=U:EGI/F/&:PN9I8),VR)$TUY!3%QQ7'32(1 :Q"IN6K.OZLSTVVX@CB;X M)W$V>DZ1XEU)R4[1F\2\5I9(BT@!Z(DE$AC%(=>LBA0+);;W)F.#]N,R:G$$ M^&E3C70*\%U5M2<)^089J,.<*>.,D\1;SPR2!A4!)!=L92(/!OGO8Q_S/I!M MYE$DE">4=P3E!-9%%M(S)+VBC"&K%;-,"UPH=@L8$=MG2ZU!>1O1)=H7)P[1 M8^U\O^T\),ZO#="+:QT-')+42Z LH< M.OR?18=_VBB'9%PC$A0S(]@Y8C%CAE=G=(;;;2,'1^-Q$,+[P0P[;Q:!3@G$ M+C5J2 +Q/ 1BH_"4MUP0+627^.0"W;=C0:=>,D3[GB?THR< D M \]7!C8J?(75EDLE'=-(6VB8]J9R9YWQVR8_[R];"\*^Y(D*Z@][HH+:BC:A MNG$':!#VP3_UF#S-_QGDR)H)3P&GB-+@1U%#L+(0.H(,L\8&&.5-Z0>;//S. MSYJ_O-_"]^V[CZX'0>^__D,@"'_N/:#/N0=36\#T;Q]7"OO?C"\GM]G'P6^V M( D)H(_\!7HTN?SGJT?H#(3A@CE))'68"42YQ;!D12"">_BZED#,6P.QQ,P2 MAIP@P293^5>=1Y X^2RQRMK[P%>]+ B6NPC0:9!+?WCSUKS[L^M]5/^?^[!* M?M9'1Z\.OU_N;_96L++5COMP>9-=+499)%JZO9N,HV)Y=[W< MA^ZWNVP\RW0VSJZ'\X]1%#Z_(277!FIOK8>:"*NPPM5<&TMM8T.Z &4G$,?4 M".>W'I"L:C8%D] MSVW4$>7W IG4^/8]_R'QT*Q8J$=)#7.6/#2'.,"I]Q,\9!71'ODDFCQN':ZQ M3B1#!]H/!Z37Z%@<+BW^/>,N+?[Y+?Y#MLFS2MSP65C8P:AW673WCJ[!]^XN MW\UX_!&$VW]X,MXNF. 9A_61HV)6*6*M$PX##B @5)?!+H:\7[QZNEHRF:1]EF8CO#>FKRQ5G/&UBUH#<)=EKBM/?MC.C],XNBTQ!&NQ1&- M#7T!$5R%_X>06LQ9(8XL88"OM&UXN3@2K8LCS@Y20I;$41)'21SM,QFAD$:T MED;($.T19IYXHACQAAA72B.)F(>[2R/^(FGT7'OQ=O/HNYEAT(%(7%OC_# ? MS+/USM9IMVTJ -<@[(-< B0!0)@@*(R'FI: <\18N>*-Y+.HQE>_3,*$/'$4 M:XKS[C#V,E5H,GY84?YR-^79M@\<)OJ,X]#6YP"O!B&X37R\SN9^&%&$[P2O#J!KP$H$MX&:JMU=HPR245V#O,36DN.B#) M2F/\%N'5FAU)^C+U'CRJP/V[>?B@14ORM/H5%2!%M0YD6!#./)72"$$@$P*5 M 6^+N28K/ET^O>W'N9^!(#KMOO6=PF-7%>(I@I#4FI):Y:",6>K,(*J(=*@T M1)VS$JX2LV\*PM;,3)3ZXXXT!!#B33RC+$'!.5NC.* M^946/;:0EP8%U27Y\A2XU"P M(T6))N !6CDDV!I-[:<*H#YHU; \G9R A,-NX' -#%$-0XHMLL !S87@2 -! MF*H.QS6U*X7Z6\.P/7,2]K%HL]U2]RW'8P]N%L?D+1J4ZQ+8C]+G6Z<\&Y$7 MB8%@GF J$3:.4T\M+U$+))?N*=1ND5;=PUPUQ_+HW!7O.53 P MVFC&B F@C(KB1486%>EWEACD%@A:]E1,+1O6Y,^!(?L\9P$0Q(,)RL8&L$K M9CS"!- @(*SFDA)L2HO!!6&A5U+R=Q0,+[/V-W.Z!=]?D]63% S?-3+]4!!4 MS3SVV#_DQ76P)S;NK#2O2JUE4VO91PU9"'@=L180 M((U<;.?(-.5,TJJX5#J)[-,])@]W[LKZ""5"@.Y(KRY5CR:)=1X22^(Z14M2 M23B@X3]",Z\4EF6*EC#2TY44K7W%WY[+%)'["[HE>97D59)7'9=7$-:,3E)Y MQJG@#L4\-^N-\^4A@I3,FI5$M^^1!$#Z&+::W'U\(FN/[?J;S9)6WD:Y'7W6+GLT'\\5\,OW6 M^\O%AXO>=9D+/(WY&['O=5;-9/[6K#><]0:SLL?T[ 4MI5>'T/CV/8URNNV< M$7SU=,RGN ?:KIWSEDV@G_D('+!E.C;ZMGN M2E?3K8:>O[K?T_1O.?F"R\D7CJ33]0$W 3N+/9 Z6I_/0I][]^JS6>A3Z%2] MI6BOB@R/J#_UEB/M;/_%+<>S430)-S+/".( 8ND(UL1 B(Q@J'";D01H8>(W22\U@). _QRLNH:JF_>^B567Z,U56,7X"#-0/:: M'KJ3(_6[[[W1CPGAR<3HN, BL!98!EJFL,;8(4(X UXI4@HL:Y!Z.B5H3R9& M:\?RHH]HFPTCH87]X,9WF%5+\WSN8Q1ZM*R/I4Z(TNM[#:*\Y%PY7@AGH# MD!*$PD@Z0\M^_1Y#;LG3V:KWH?UXH7NV5Y(9W!>R3=W;615[ZIKT:(%$05VF M(J316 2#5@4KUV//)"ZC:!@P#U=:1&RB,'=!U4Z:$N(+V&8'_N-2B&> Q]-7 MR&0< VD ML+=%\ :E(P011IV2OJC%]) 3I?2>E5R[$6=\@=LL,T\ZKF-P/ ,=1VO[TWO& MD+000(>)Y1X35^DX :%=23O97<>U%D2%?2Y/HB7Q&8#J1('$Z_I=9(FQ%"H* M=+ :&6!P&?ED@*YF7+:LX]H->;(+<;Y^W)ED@Q?DAV_#KK[*KA9AB6/=9MD4 M:G:4]$][A;IHF+,H-O!W+& ],D!QY[4MCR6E%W@EC^()G1FFOI[Y\F@R7Y2] MYD_S5GN.I'/'8U&RIP=)!GA-$Z69801PSZT,J%3.J^5Y!#5JI07W)MKW,7SN M/V7Z O%TUIA0G91N1#BJ[6N- 48JZ%WC+"""*%[&D(+2U\)!5!;:WQP@ N7UR&O^!Z5;KLA77AQ&,[BI'2/ M!=7GK'0I;]3X4 NX\$P2QH22UEE7!;4,IV /2K>U\'"K23Y)YW8)G>>&2,[J M,F'I,/6 **H]0IH%:"[+A!W76QVE;JASVPTQ@PM,D\X][:3:L+'B+II.1J-P MW]XP=G7)9O-9^*MW-YC.Q]ET=C.\VS7:W%U@K^&*@DPV'%R',!820XV-YD9X MH9G#W@*C'(5TTZCRGX?C27B@;V_*R2Z^]H+PU?;'L0*U&5ON(G#/E)[Y1-'' M&^V7,1<2.JH%5%#HJ&0#[+ /H-2*8ZRVT:L[0W&]@MV$Q(U=P#8U;2=QF7*5 M3A:DJ'9'%=:68.405!(P2(TA)JI( K!!'&Q:=?)27+:8E8MPFZ<[G83B>2+Q M5-%'ZK0'@* Q'$+.%(%&&VJHR]$'K<7*;W7&NC,4VU&1.*G(4P7F.:A(5N?S M4F:$ 5)YK*S CLB UPC2 %KC(-TTG_>EN&PM:AL&=.I /$\27&8POGZ"(/>4CTK6H;S1NQ=AB+;0'&'%#1?@2$U4%C19^I>7) M$QJW6((W8YM=9]-I=A6^H&:S;#[[GVI!5+4>.T=Q-T$\86U6 !S5\CV]>!O]DP50@?3'G!+=,$2RV(UV7.L4*6;]KB>#>\MQA]YNP@:8XI)RHI MZ;W#M-$FU#J$F866L^!HFZ"K7=V)7$"Q M/]Z^AVTY/)!1'GJII3>O*YZ>>U MUCFKK7.!G068.0@T)@9RIJTMD:^]XX?QO5\6^][(%N\#]^DF0H<]UC.+^2RG M<__3Y-.LIR[/MH^P!#5/H1>"(B,4-QQII\(75.5A"X3D2D[)&@7NQN&B.:1; MYR'\=S:=7 UF-U%8"P31SZGSU/&KS^/%$*K=7T&!@(:QV%^1<@TT@I62A!#S MK9@#MP?4RSS=?:*JB[HN=58\;=6&:]O5>:H 4591J877,/BC5>VL4!ALVK!B M8R1N'R=.JNTX\72B&*(UAB!'4CF*B<$4(\N=IKKJ, &,V*K#Q/: 2JHMJ;;S M56V<-(K0,11>R M3AC62&)@)*7$$D>@] ML*4O\ST6LX7+]@[G=TKY/,H1 +41&[$=G$%@% / &Q[^+=DOD"&2+8W8Z=5X MOA'$XS)40!^.3;$$ZC;,W_QH0IXI>>AH5.T)HA/55:V:..V159H(Y1&4CM.* M $-ZCV@[Z/PUFUYFF\&S.U[F49TBID2AA]Z>\]=:1 L%TJU>/"=U+CYZ/&UV&=-TIM+0782>NT8YRCV/&T M*L9CFM&6L/ZD%M\^#)T\Z7-!ZKFA4]:>M)0&QU[$F!E&*4/8DPJ=5F*V=T]Z MQX!V\J3/K#MQE0#>FT\7V>O%79&=.XE]Z4_VD'>=90UAP[(V3".I!4/:QGZH MP8>NZ#V,MGR%T?*)4]Z\T;^Z^L=B-K\-P'V,O++][A7\]-O5I$/A4\)=H^J< M,,:E=PIH;@W R#I?G0IK[A'>YE1X&Q"VU3FJU;X2G81B2GHZ65R2VOM47!B! M%=5:*J8@=)PE-%'@=U&:@7PDN!#="4 M,2L @JK*-Q12;45ZLPT,6^JT!$Z?73VIQ--5B:(NWT1,A[(.-IWOM(E[!Q/@N-T"S&J; !W"$. MJTH^KOC&1#R;JM[VFE+TQ6'Z>R?5FU3OO@$9$%F.K8 M%@G #J%ZVVURP2_ V8:T.IH5_!#--UG^1SGH[/.YS&NM>S_,[ M/.YS&FO"\>F/->'X],>:<'SZ8SU+')])GDCA]?7F@]]Z6<%OOHU/-9E>9=-J M'/#NM]YL,AI>]?X#Y/^WU4P\.:WES>)/5^^TY]GZSSU,SMK]\]PD;347APQ- MD$9S=@$!TLAAHB#3E#,9_EO46$DGD7VZ@ZTK=J;.QMGUL-UV>P_C_'V$6CV1 MVW;Q6]GE*:9XL)CBKB!_D6CL/NIIW04,$BZ\TQ1J +$Q#F-4,J5@*(R]WXGS M"$R6I*5E-K\I/7\A-+*@D'-/Q':.:5 MPK+HM>:$D9X^W1%BK=746AX3;K6J)]E,2?Z=H\TDZJY."@G&%"!,2DYDP"IU M%;FZXY#[W6RF=E.CDLF43*:NB(QD,IVMR12LH[KZ0WG&J> .*!K3:;6\L\0Z6/8";F9K*:3$H%G9C51A&K8Z]BBUD":$W\JCCW02V8G M^J K]8NMIG:SVB2Z@*VVDD]F4W%D]_OYX-,HJ]YO11X5B_1V<1M^/UM+X_UZV(Z6PS&\]Y\ MTIO?9+WK+&R)P2@_2AQEGX>S49X[&CX;S'M?![->5I"C12XKFUUF$3P]A/J] MB*W>#Z\"%'OJS638O>HF.AH-/P]%P/LQFO4^#67'#:O9>/$H$?[?U;XN!7"["4X9I MF@[F62].Q17L6!4_O,LB)2!V63WML+O'Z*CY!=AT^#%^9 M7.>7"S/>^Q2>Y.YN]"W.:GSO\V)X-1A?YL_Q0>D>A*+W*;L<+.*CS7LW@ZO> M>#+O?WHVR?%47TT=N%8;6O-5%[V-C"#=A4]07&(0!?)L-\Z^7>^%_ MS<(CU.?3Q>7R^9A/YH/1$Q,R"$\W?GTYF-U$SK3IYRQ><>M%W$P+-5A// >4 M2>0PQ!(H!;71T )!K>5"27O?=P\#-8OY+.S;/TT^S<*0J\;+91YVB\$\NE1- M; U=Y\5J[\A>F*11^..!@MH"$L7V'^8K.UKDZQ5PF^^#R3CB)"S6<"4IH7<] MG=SF@QZ.%W&?3NZ"L(F/%B^4P^.B]Y=PA0"::=[ZHKF=*B@,9G?-#5GNLEQJ M3,.TCK/;\@%RW Y&EXM1>8^KQ;1"!T2]V_ <-U&@QBXJ(5C(=PQS22AV ME#85&JZCJ@\CZPUOPT*'7T3IL.PSD\OC<;C_;#:8?KOHG&YY1 MWX*F6O:OK M_1ET3-@YH["K\MD?!Y'8$%7Y5LK"QIZ&6>Y=#<.[015<1L64S;]FV3ALLNDT ME[N5Y Z_>$*719D>]F@0S/E:CIN/$1XBW"17BW>+Z=UDEI5]M0N4A+='D]FL MN%NXSM?!]&KVTE4_@%5SS]!Z^JSWOO/^X?(FNUJ,LG?7U?H$7*M\#M7XZI=Z M!C]&P_!CN*(>32[_^2J7X?'EARRN7X#Y:Q(KV @BC!!&%974L[)VAA"NI'A= ME]D *8VW EA)E %8B.!C%+Z&!XP8_JH25MF5FK_X/O!5+PO"^B[:S]-%]NKP MR_,NJ/--+*PHMZ?#(*!S@V4R"EYRW&X_Y";,9!$UV^S'GYXWJ./KY&WS.7G^:9H-_OAY< MATGX:3#Z.O@V"[?Z_#\D$U62Q&_\]CREU\+<'V:C*X:YGZ-:&QVM.[C4# _Z\5_:'T=8T'(UMOC;7!B[SN. MV1-]0UL'P_?KHK'5@?L.!^H;'YYM;Y]O$KADG-YZWZL\>%GPHY H(!QG5%6N(5LZM!U_XHWJO/(Q\ MG\VRZ9, M*,^"%'".[@U:[:@XW">H3>+6[BNR8_?0W]7>>3:89E!Q'K4](FDVOWK,]. M8;6KBO+(@/E?_R$01*WV9NV^4CD2W?%A/AW$N[W^93C.>GEF:IT7=L;VG*C[ MU# O@'$&>T:@8D8HZ$M7"0#M&'U>3:P:<]64QQF/$U[/=WN:X]_9='(UF-TT MP'?\!EWRE4X"6Z)1FL>A$ Q+X""S(OA'T#->^DI482SVBJUV_"79%S#Y2\?D M+_UE?#WX,ID6F5/AP[AFR6EZ#K&H64PK@OJS2IGP,2!6>%/V(H!"%7[U(W=,U@[!>:N:M.3!"VIS_*)IP)Z0[42 'G%"+5EJT4MJ'/@@*!M M1^G"/J:M-AGJ'&Y/S=%T_UH$Y9H7"(3MDR==G[$)S&IL&J48PAQ9K8'W'@-/ M0>E>0@$TV@*;IC') 9]EE> > Y-]W"I[>&>5Y3GIQ&.&EZBS3+ASDA*J$4?2 M, (]8&6_/ T@,>O3V':!5UO*#K VMD+ M(=R2-B9]04\;PJ?F>^:$E>=K#DM"&ZUDH0'<()A_2IQVUE?):9X;O3[I.L[E M'O,Z&6PSP:6S6O"1)70H5T8@(*PQAG"H"="V#-0(B9W?&CKMZ"74 M%S!YB"J(_K,.HJ#$*"&>40B\D--0J JB7 M%?]\\"+7VYW+-5G:EGO3=;2/V^6\N&+'D;RGP; M=H018>\3L ]V@PZ)KG62"]=5F=Y@1["RG *D+29:(E>Z& PZOM[%^.-T,MOC M.:_$?<@/:;,D__T[=5-(@N3X!$FCM,UPKA'7FCAB@$0824C*4V\.L&5;"Y)V MK!Y.^EBTF33=63ER-L&,>PWE&BUA=^XJ=\(NW=D./*W^J3DQOTYCC[CYM[PC M=/:OQ?#NQ L(UP4D8".AQ2C$">; 0*4)(3'=LR0@<\P+YY[1QHUDZFJ*?QT- MQG,UOG+5+._-WF=]TNI)]_'$&,[ _#\/%*(:A18!K2 0.OC8A@EMF"LS0;W% MSSC?'\Q\GDZNMP-#K'K+*U$&[4,2%I/??$6NB4 M\D&+(EA!V#'-5\A 'H=P-=L!O6_&\\'X\_#3*"O=WO*C_26 DC[#_!#98\<# M\TZANZM:^#2QW:B# K$C(?;*,*,=(=A[Y*O8-U+XN;9I.V.[I>M=B4\ M 6R?FI];;ZI3;B2Z%K>B;@B@.0Q:6 )C)>46(&=QE1;'A=2[XW:/[BUC\BP- MZ^3>G@8.4:.5CI52,4BO(_#>'?]E]F^-2R$M(_901IU' _H.X7UKFKE(\-S:G':7=WS-A98 M%!6C.0G$=!A)EWNWV?QF$IF^\[+2$S8BURD9)AM]HH2B5//@S%'HI66R\N4@ MX=C+S6S(!X6[>=F3&=P-YV%X_\ZNS&36ILI)K4Y/7!5T&5MK+;A&H 0@X[' MP%'E/2((4H[+PPNI+-GP\&)+<+75B8:TVG_^>(RV\_'46JB5/\L*) P:>I1! M2I@#EB C"="*R*JG&P6>/==OL>FO[;74GO9IJCQ*GELJ/VP%_(U(#38BZ'=@ MF&8$0H:-5;[JD.P1>B[W?@/PMY2 W\>D51K#TP?_J;G%CY0=-K9?*AG:?:#' M(+=HW1J(2^A,Y(-DV@/$J<3.5FWW'"8;9BGO+Y9,19_A0UHLQR.;SB!7HL>#851BB/.N36 0*&X+OTE%/Y^KFW+(;K-$]0VZ_/)2)YNQD4>RJ:; MK/@B"-\\E)^TMK3MD'Y2AR/)M-G^D_\O.>@6'W1%[CX^R4S>$ MGAEI!RRA-880P742//<**D$X#6\RZK56KC*$ #%F/1E(PQP*NVIOSA@F?;K' MYG6/K& M%H9]"EIE-^^L3,D-F-_/(P-E]7XKUPY3%Q=G."[:%]X;WF@XSEZ7%AI$X'=[ M&M]S=\QG>#@.$FW^$Q'[,Q+7/D.QRI$:=GC];2^/I6:]R76O>JP7_]QFE]GM MIVQ:C"X@HQ=5]]:7Z_?F-UDO\A8-QM]Z-X.KWG46H#$8]<;!])S4R=F3V:QW M.9A.OP6C;]F,J!-=_KI-8WD_#TW]1O MP]GR8QL^#%OETD1FB>FW/^=+\XS$HTN)QYX/:6-V@58$7B],XZA)C[?UHG^] M&5[>Y)1[T^$LBTMYE5T/PU-G>9N6N.7+EZO;()M=]'I_S3J^602J:\.YEUYI M[CW1T&FOC1)EDQ4O@3'KV[,_N7L^+#[]([N M]H;*XBR$+33O?1E,AY/%+.RD>3;]$IZU=SV=W.;"YELVF,Z"U$*X-Y^$_\6\ MGV^ZN)]6-LW>MTEM#2G'-8$(<:.=9]0Q*52Y391$=,4:.JA,67X:?O9K&/'D MZMYOPKM_"],:+:[VM@R\6!O9?O&R5#LNKNUCHJ7W.1O'=[(HA*)J$]7>NIKT MQI-YN<6"!/)/BIY[5[F>Q$[-\:-V52[??@KR31X=N8:<'17]L6X'W\IG'X5W M/F6]Q2PVSIN$Z;H.DJBWN(LO!/A=G+_KQ7P1T#8?_)83EL>)&.9;*\S.QX96 M#\L^R=$UFP\>E>C?6U;+!@N-$A@)X+ EE!*")&&L2H45$J[4*NX+A!_B5*GQ MU2^3 )4_+8*6O!KF#]\:O*2X6'5IOJ] !N'E=++X?!.ELKSH=#I<<3GN+^7 T_'?! M_+((NF':^U ^+18HWB'>^4U$\#B,_'T6'G(1Y?Q5$/F^T :3KT%[S&Z&=[W+ MF\'X<]"%@UE8P_"3V["'KEYXV3!ABU%0HHMI3#HL'C[_=O-)'U7E]Q?A8BSP;AO4)ZQ0,@%[V);R(%6F#+X/A*%?R7V_"OJR6,\YU M>"-?FJMFE]V\;GJ6;[W;2?AG-/QGT..OYV%'O(Y&5-APP;:89D5E2#^:#:-% MW.J]H/;C3HV&TWWKHK L^D$ W&17BU$6Z^.""3.+FJ1P'Q]M\ML/5US$:#V\'(1+_6-Q]3DVW^L-/DT6Q9X-FS&[',SFLT>,IVIX MGP;1X IWB3^(CSLK^I:&98_&T*SW-;P?CP>>LP$2$UNA;_.!3 M*;&CK_QFO'SZ^)/PQ4DN#89?LGH,86GFO3"J>9#20<3&XL/%*#QI6(_XE7Z\ M;[4[HI;.*K4=AG*YN%T$01*O5V.PL@2[IL._QL!!>-*&2,K'_MC^W;__1V'C MA$UXS(ABQ@/ !3!2LU+E>PR-9D_5T2]I24NZ[S\/OKV=S'7VOH37BX_:-G;0 M)'XD2-2:GMU0>EP4L:"PI+F?,1_\,TBH8&5.EONU@.U3$N(0JXQJ(@VH'*5< M:@\QX8*JG+O_T%E1W84QW/ON+$=K>1*4Q04.WQE_">JM%[3).#=V2WLP M[*[7?_G0"R,N8!KYZBLM.LNR7&N62K2TB:=9_*R0!5%.!&T["0KYW]&:&7\K M!A 'EA4%JJ66#7]4MPX/%XWRW,H,/\I^N\SN\J?N5VIW' SH2;!JITV3NCDS M_3+($1]I%'WW?B\\=SZ6^*W&]&:_A?49EY;XIV^%WBG=I&J\A8K]5(PK )CF MTU=&HH*5,;P3PKE(F-KT<&W>(5/G_LG:+$C^!B+B=OM4& P'48&D/@^!P<3A M0>$A[9D3$@C!RL.S&.D6*UQ2?VD\=VWFO+R>8U,%1R[PW@)C<:J+T-C>)[QQ MLH"5-]I1K( $FG*KG2DFW&I/";]G63XQV^'/-V$K7<[?7+]??KZW)<"/A/Y; M6X)>;D(,KJ]S^1V=N_S/Z+_D>B]*U.%U0WTU,@0" M'0Q;IC1'83,*7B;T$ P11*]K'BAAB3>6.^4DU 1QX0"J3KN80>+5TDJX4O,7 MWP>^"B[SY> N)L],%]FK3BR:RK=4T*S!^Z@C"5'MQGK'SY'7JC>XC;'07"(_ M+:XK4Z@P#[+PE%>Y=3*8E<=-L]X/N=46++)@B,Q^?$AU=&^K/)&=4Z70/-SR MC^\GM8"7W]>OP:GX3_@SC*//[+@,8!W>S M[*?JCZ:DR3/Y7BVK!99U%A"]>KJ8H+@'E;_[N?K2P\_@,Q\]]UGK'W7P9J=6 MG;%1W4X\LVY]L$\.K50).P\N?_FUP/*GR>BJX1_U@FMT!J4W!RG*VO-<['$W M-'WC\ZJ)2(L?%U^DQ3_?Q>>[R/]C[X.G!Z-!?B@_#Q[AYV%QH!W\Q>@-'@@4 MWZ\U\%;54^L6O/M54QPVHGG42T090P@!Q)GQ@I5YPEY81?7VX=.6>E+T&6J3 MO*1[?:@[)6&Z5)&99,DQR!+<:&]#L/".6>2X-(08)X L.P(R1YC87I;P=BHO M^PRVVMXFR9(D2Y(L:4^64+*4)50;+R4W2#+,@&;26%3*$@2=VT&6L)9DB6#P MI&7)J87 WHPOIY&4Z5ZF^MUT6&;&%"F]98K*.9,>+Q0&[J>3VU_CW!?E?[$.L)KZ5T^?-K?0S^4L MN_J?4RCKF*&Y#IFR1B93DE-%+:((<02)IJA(>_((0>PV1>92*&Z)3-$6,H5L MLR5*9PWPA+2C0)IHD%QH%=Q723'1###/%56VXK/!7IN5)*@](8VWA;0VK=9D MG.[3.+U<3*>QZ*MU\_0HN2G601;7RE'%.F?IA;8,LK%/.\1V.Q=4M5 Q%+]V2SOM!!_,/CM*8:HTP;_NA"Q$ T: M.&RPUL'<)M1!#"AUQ)7E8 ![M-);Z*G*H.QJ413UWH/_+S'1_=VUNKL;A;G] M-,H^% OX[OJ7>OGV&C&6J^5[>Y %IQ-+3BK_6%&_!O2R$1,#!$#/A-5(0LXA MPYB[,OJ,)=NXZ+9ET&]OMI^7_D\0/E<(H]IJ-TY8!0-N"28F>-S"*UC%R$0P MY[\/A),)?][Q[]X/5V6NP(_W(N%%2Y'A.*^GWQ79AV11/+!E+AOA-(R B@E4 ME#M-A+':H3(=,YX7.[1)HX9J7:H,#I,OQ'#LQH/85R]\\WU8D)T-\-CK+KQW ML'.KTR$F3 ?.IP'L=;AF-:X])89I 25&1C*E!)>%YG9&"UF7;.P%UZV%QE?[ M]^\/SIVUM!,ZCP.=:]6NJ UK 9S&D'EEG?4:,""E+]4NP%:9O<+S9?;S)FH7 MD4,B]7@4[]D$T1L5HMGX:H?:T+TP[!U9D<:Z*3C^*@X"(&VX( H IZRVPC!G MD3=5(@X"VO%-$W'VQN])^L%).B057_\-8/#&83<9AMK_% M6HG9,"?#F1'ZS(PW4&?6Q;](W+FH.'X M/@M"SL5PT;.+Z;"D)\J+9XJNQEUIIG^OEWXU"X3KJHH1%FM2)/+N=F (GM0.NPVT[4!%724"X9IM(2 !""/KPN?2U"$=G4>%G= M>6IEY^T0/EJWU?:SURYVT?;[D.#;J/_#Z+8__.]!OLMFP6?'SU_>;SSY]MU'UX.PEVU]5F@7/GQ\ M9_[?:ZT^.-LS[_[\JWO[07U\\^[M*@5!-F)DEXWD7,&X_C7R5';N*3LS>?G7?QK.P[4O'WO0=W>/5(AWP GHJ&]2 MT3U.QEE.QO8Z$GGV(@?K_%MT+)M\O?AS__6-#,WONH]S42'$9K[TMXY].W MG'9Z%K%W$S9.-IW% ][XWF <).7H_D>W69;SL(8G^=,BS)0H'J1FRXPL>M-X MX5A)-9S-%OF1<4'/7!),\P?/LZ.M^92IB650_UF3L$I 194 1DAA.3E3\9(7'?)9?O6FOOGGK-S18(8GVZG[\H^*Y<@K?R>WM9%SL MH(*B,1)KADT1*7U+"L3\P]X@Y]->O@J[,SQIH:;SL.KRHSCZ@@CR1&VB(!L :1G'T@&G@3)&2HL\IZV!,?_G?[)\ M+8J@ WPRZO#WV32 +EXQQV!\]>=!<(H7MP7Z7@C5!@!?S[++GZX6TZ^3L%^S M\:L_7,=]DU-M/6FU;KN*.;5WK'C-ME_-^'C=W4>LIGV46B%F(7#8. N=-%:0 MN(\\0M1"Q1[=1Y_6[Z-/#_=174.\)G1UP$T4Q-*>]M#U='*;B\9(X!ME>2XT MNQKI[JA-V;5P8,Y2?Q6,NWG89N.KW) KM5"T82^#X;J+S-C('N.U/8:YHX MY#V&0C'"%2G[15#/H%V)_&VM DI7Z%T][L)"6V./Y;_]^.VN &CU;JZ]BRNV M:I(1+OJ2KBUNV<4>BU9]TR;KU[RQ!]\'HHX>$22\-$Y SPAR,!CE%9$L ^B1 MOB&[[@/W6S:]',[B66P']P$DHD_HVB:86^^#KUE8VZR>@HLM(XXUQ^OCZ]&8 MGYF*/+C!*5[/]1HD@D(8:0X%-EYPQP1?QM $:'*]4D(YQ@HJ8"$$!D,G*G=. M0R3TL[&ZM?=9"3I^S%GB(P]JE)NSQ>WM8%H<7XY&%;@*%/7F82?.BF6K6XK< M.S)>'D0^KK;7ARHW>?Y=AH^VT7XP+WDJA.F M$R6OGBY_*.Y!R':DFZA[#)\O^0AWG87T="G<&O9=;UWT^S!/])=&7 JP/+J4 MB@//='<6P> S7_[SY9?\:_XJV'PJC'SP.?O.DJGT@;)(?'+YO1_FUR D3>&7 MYB@Y3Y D8'0!&.^SV\$PDI]^Y^Z?48[ (\'-4G_5#@)@""A@M.;3,*<1(6?U/*6DQ\>8%!SWBNP7XPPSUD4 G MW98P(3WQSQYA;6TINDA=6NN!PMP99C"EU$FO :SH]:3';*5Q28NBJW*,2K^H M\MA_C0Y[ZP)M,;L*7GC^:$VIAC:4:?R"M,FHF03:T0BT-/ 3'/CF[NZI3L*I M]57^8Y'S?)[1F];'UQ$[1=8N%E!:& B-AHQ;")U1M*P]PP PT'HN7;Z?9F_* M7-@_3B>SI]E7OI.?)60?K:]O. :2TS. Z$F3"1=P%:#N#2NA1T*@2$-J(2(! MM]26;H47P*V0):V%Z^Q%>'V!:]$*C'?T+B"X:)5]*0'YB'1M&E\W3?]C'^O9 MG--4TGT;X_]D_;N3/)%YLCM]:8"PVE^P1F!J%; &$:FQXQ:@TE^ UCP2UXS: M_4TLW;W7OZE(:FNF^B]W6]?< 8CZM%5W('$X'C7\SY, KI0$C;9OG!%#8ND5 M09); C!SY>$LU$RS%?ZWG5V12D(!I[..4SOK M,#$M;91=]:,4O\Z&,;EX,BU;8J0CD#-AY"HL'8EK$AHI/*?.4F"4,81Z(&!% M5LV%<:KM,Q)?[+[%M#9U.N<40=@'.#%JGGM:^^F>NDA:=PQ@$FLB.: 4 \3=:9SCHX)X#L-+[C'E\ZACFU8YCG MRV5D\LJWM3&WX7VT":;.65B<\U$.!*AV<#3%QDFFE(6" M V(9UV46*!*$V@Y5J^PF+7;T8\0%:E5:)&'0(6'0G8'O720\WAT9 ER?[F(< M7@E,@32:6 $)8*5$@)( LF%[Y(>-[/.^5@V YE0=]R"?]S]NB(=28#R0$LMF M&XUN%Q^SZ2UJ,?CQ2/_DV,DBUJQAO*9O2.8BD1K *4EFS*UK1E.**!Z0Z&(]@%0>V%(TX (.>@XB"L59S0&!B$ MN):(&$("&EREXI#&3P3OMV$R6U5Q]_WRA_QXW\\QAWT9'#F&3Z+X._>_?Y\3 M>U3OMW+MEY/"%^,]0Y+?90_;2.E9[/C>E[CEP^N"I*>()GR:Y%2V=Y'-=CPO MN'WGD_E@U MO13[/AS__(:?*&UY?9],L$MY^RN9?LVQ<,&Z-)K-AI S*:3_S M?NN1/[2_A^[W8QF@_O1L.")3A^8YR[M9'L:#A^'=YX?3L9 M9]^6W&$%K_ H0"Y,XH_A%X-Y[^MD,;HJJ($_Q0F9AHI MXAFNGB5_LN%T>8L.S=M%K]M^XRT=O[>3<3&Z7'_-/L;):GYN)K/YV\G\ M;UG06=7\-2N;']>*+6BY,+2^8'M@_BNH_8:S?+$ORU7^%-=\N3]RNN%![VO5 MA']06,*]NSP_.6[OG"K\M_"D\VST;:^TKF$+\+JA%97>8^&D,HACIAW6I(K> M$4!6'/Z];8$B4]M/IN5;\7M/,P@_8^##"_'0OJ_(6W=;Y]U865O7]B_\>?$R M?OVG85B.X67QSOUFZRW8$SN/>FY%R#$" MS&"'D66.H."BXB6W(M9Z&V[%?1C]D;BS(M;.*=BBMD5M8 MZH.UR+WHG 68,SP'6WN8=VH)BKTP"7=YQLWB&(V&$E9KKQ E84<(RX"AAE;) MR5+!R,M::.[(>/Y3(1Z+QC(?)S:LT5;!AUKLYE*WU9,SUH=0]!'? R5O8T_5 M5,Q[7BE1F]E,G'F\&XM*V7AMD.)Z?[W -8\+[$:UN<;V&B1S;F13GXF,;0%5G2VYT7>KFH M#U;F+V%%7D )C8C EE,O-3/*4L!XU8*?!-?0Z08E--; $(^-Q<0"0*UCLO(; M!?/Z>4[DM?=Y&27T:)P=,%_V MXOHT+G#O].1T&:OEJZ?3X(I;4'E05NK.$T6?TQ'BB=#VO?I#4#;_ZTQ)AL]C M@:N4A=??@2[U.[&C?C_LN45S-7;/ M+^XFR6A'THB0:)3W$*Z=!9Y+R%%,(]*H2'OWP"O%5LY.MP[J!/>^B-ZL1G=: MX=_<9SP'<=ZG(%'6G67%8AKXN0T\U:@>@1+#L,$8C;0EDA)$ ;4QY0PUN-C^9>) KGA,JQ?.J:+ ]5E\?:LN:<89<"-XGJJ@$24:TX0)% % MHTR4_%'A:P*V%V58:Z#=9[;&W%H3=GM2M<,+[@X:6VW M7=2APX;N_^0AK@,)NT.)@#740,%NK9/6J5' 68P1498;* FQMK)G%?,'E '% M4G39GJ6(]#EJTYY=W?&[;*-$"M0MXR:-[[C'UTD;M$-Z9IV:(;6: <@@@J2$ MV#I,E ?(J:I P4/57ANS%ZJ9(S8UP>DTASDEB])7U)L=2=;MC-'):L<3$$YC MUR=&K"%:8:(YJ!Q/KP4^G#18KE:7[4[8I^TR;R>JRC.V:M+XCGM\R2K=S2J5 MC0 HX\01A[$5CAE*K9:@#'XP)&![M$&;ZJ'(F'JT)BFZ6-\JX*1,TC,I-MB* MHO$8'\ M/6@7<8KJOC7"2VZ5P)XP3560)@Z7]@JPSLO5EB1[LU>>)D!\JI?XPS:2NYHM MS[0;A(G>[ #H.X-TCYT%T!'8+%@T*BBMX PI30WA2B(B#:UL%L'= =VAG8I/ M=K=I=@_.K^]J>]I&3>KY_MT?ZZ]9V+KSV/%QG.7U-->QPKYHVQ[;&X]&]SIT M%:VRPP?QJU7K]K)I^W71SWUR>SN)SQ";1(8_B@Z25P&-'6G$V_SW")K+YD*O MG,Y/D_%B5G;>/()'[^B67^UX&N3VY/&VIXUYSV:]\63>FRT^_2.[G,=>X8/Q MM][U(H;C>K.BKW99C7;1"_>8+=O#!P51(.HJ9Q,H>\M?56 :;PZFG$R_>);:;ICX==EV=;\=/"F'-2V: =1BR03D "#DD=2R[."I M"(:D;5JT^PFJ?YQ.9B_V9V+;U[_[?%.5O=K;+;9@?;;^E/#EJUL\4T&7D&_' M2=R12PCT>X/;8'A4'^V9*X$V*G$4MH01Q+!C4&,M#?*B/$2F'H@5:U6-1I/+ M*!D>WPNNP.X>5O4A/0)=KBA[WHR\6%W.7IC%4?ACYV4-8N8Q6HS=-'E'K:O# MZ,1-V5(6_6>Y06G M0+E[ETQGA8'8O]_N.C@#DX9[5]A*%[V_#N9@'7' & M^WQ]NO6VBK ?-5_D*1M^R4;![(E3$[G*XCG:OC<#1(VD7""DXS X4]S8L &0 M,I5+39%:,7YL=IU-IT]NA2CJWHR#13F\6N1D8T'1Y]'V]Z6:#TM>^$UO2E7? M'>,']0GC >!K*<6WMGT&7P;#4=XX_@G[)C>"RA!490L]<,Z.*1C^A_\]R/?> MC'HEH7#(4 8I,$@K[R1"G'JJ)3I;I8>Y\5QH___HMZ_]&]_^5OO??N MPU]^^?BA]\[WWOWJWJN/;]Z]_=#[83$>+*ZB /_QR;/WJ\WX*39YN%W&MH[> M8A\;JZ/.]GT>EX+(8I;-[]J]KCP9K-ID5D,,BUQ:CX M<2\;7-Y4_OMH,)OW\L%5/YM5M,,Y#637XMD[V6#-YLPO_G$\71C.&I-[-9@/ M@F,Y*SB$@Z+(*82OIY/;!^L1 )'7<.3Z8QA[<@]O>]>5_.GEBB4WO JNK7Y< M@'B%R=UP'%#3;S 5WTVSNZ"C\N.+V>)33/.9AVN,"M[B61!U\7ACF-,>YRK<(U&#&1&;=T2S[FELV^=H/8TCY+FRS?+J'X\O1XBK+#R4+JI7(U;J8 MY@<@@ZN(@>)ZX[#6LUGPFYW3.>62CKS^.H_O'8EQ85E]SURY,Z:/S$ &5*+4""$;Z@@"@94//J,C09U3 M:<&2^\X :<6S(GOM?1XEH%H5/&'ZXL%=N7+YX5P\UZOV3(!>^,K5\'(0+>UJ MHU0_SEF[;P??XOHN:8/S35:?!9;DP#_DZS19S,*J1H[AR^QN'C\KC+L M[*H&-YF47>9T(Y:G QB'CQ!9)8+5A[^0\,&D79TRP>I&>[<%0_+EEF#CV_?2 M'T^7/@S'27J>/PSSK6B[:.L\8.E>Z5ZG<*^.]O86+]4,8G-G>*67,*3?@7;I MR9E8H3EJ:RZB$=\KS?2>BW[P>59)G^&ZB[7KWA4YL+=9.$G^M;8FY\^#:0\_ MM/O/31RABDU3_+U?\0 TII]<]T]6UVF03_N2Y^TOIGO/A)ZY_S MZB>M?\ZK_Z36/[9V5*W!H3H]CR>U[XK#WI@V;0?SP4\[L@)^G^Y3APB;;#?L M[]8GH%-[^GN)O+1;TVY-NS7MUK1;TVY-NS7MUK1;TVY-NS7MUK1;TVY-NS7M MUK1;.[Q;NY*DU484]M4?WF;S9A?%:?8E&R^RCC&;;#FV[\UKLN5C/U_(3SA$ M-(OE5\M:+(P=5 Q21['!4%D'$:ZX]AR"_F&]V/MBD1]O: ?_.Q:8/=G+#"\K MZO'S%?4<]NGZ>OICH 2ELBV5.*5 MMCS/(ANUA&PA^T#RA.R$[(3LER$;U9T'"3)!.3/% &4 <<^JP]BVS2#K(Q M 'VQOGU=0G9"=D+V?62S1L\3!I0RQ$.@N36Q%[FM=#8C3KU$9XO6_&P,^SCI M[(3LA.R7(ELTFNM1CIRQPD,O@&/>6EKJ;(X5-2ODG<\BNRT_FY" ;)J0G9"= MD/TR9#?ZI:. 8 \MEXQR)B#@*O*&F>:K_1+?Q;9;?G9!/4A$0G9"=D)V2]" M-H(U>24-_C'33%F))8# 4\1*1BBNG70KC%#/(KLE/QM1WD>P32K([A]S'W,5 MTJL_?,PI'NK6DB4MTNSQI3K%;(U-H8?K V?.,<7($T:]--@@R5GI"'-O/4$/ MH?>NFMZ2SDHG<)DRI@Z& 9I?30L$==$>6$(D-1YS2,= M4-$/WC'D5]@;-L-@6[XKXWT(UQ)H) PF#!X=!ANDI)Q#;;TDF %*!+646[ \ MZA%N)2"\&0;;\C(Y[0O29F0X83!AL!L8;% XXK$(QR"ECML%@ MBR>DJ(]$F[D/"8,)@]W (*H/.K@!@DH@O*!!XS >7,(2@PPI#[>*R;1WEHE$ MGZ(VSS(3!A,&NX%!4F-0,,F1X)92AKEV# .\I%=EBF^I!]OR!Q'M\_7LW@F# M"8-'AT%6'PO&E'I%L6.4"LZL0QRA$H-:,JZWPV"+YX./*WZV/)\,*=V M;^EL\'AA)FJ8&>2!$L@Z;(4UU%B%1'4$B%A=F19YFW_*)S%G #_$ 2 ,_E[* MFSLUK76TJ"& USDK@FI!,0/.QX1Q(@AS5;#22BJW04U++AK$?<923EI"34=0 M@UBM:XC7V"@N*+=.,0HP+D,; EA?YW"^!#4M.540]D6JA4ZHZ0IJ2(T:+&(J MEG':"X@U!.'/2M=@ '>!C4MN4$0]*$D"34)-=U #:/U419"0CGO.:=!L!M. M "IYS3D,IIMY.6I:.\@*J &IAC>AIBNH$:0.?"/O%%&20FBUT5!B6.H:0;!! M6Z&F+;\&]!EA"34)-9U #04U:I1W5A"+O,2<4AM;P)2A:JH,Q6 ;U+3EUP34 M\*1K$FH.A)H?UL$&U=4GWELF*/'"&N4)D4+"JL$*\-IM$0YXV?G.+(P^O+0V^V4RF_GIY+:8 M_S]G\YO)U9OQEVPVC\1A^SU6Z@M^D(J68X%ZIQ#>595[BBAF-8HAAL(@(93$ MVBA.D6>HK$(S#HJ5UL/;H[BM3,0^(FU&'A.*$XJ/$\6-\$T <*PB58Y;S9'0 MD*LR;Y$[::%L#\5MN:=]>9@LJH3BA.(NHYB!^NC"(:2589II9+ 1Q"A15>%X MS-A*0Y3M4=Q6-F0?\38S3A**$XJ/$\6H1K%ERE"$,&"<"(6HU[H\2N& "MJ: M7]Q>?5U?\C8S8!**$XJ/$\6DH8L%1MPQXAFDB E%I<*5+@;6MZ:+6SLFQ7W> M:D?"A.*$XN-$,:M3Z!0V&E*%(&24:*0T0FK98TF)E1Y+VZ.XK1J_OD 'Z?B2 M4)Q0W&D4BT8BK++>&&45UC[\/Z):5HFP6B/>6G2KM2I!V!?X('6ZQX+BTRHI MU-DXNQ[.>]=A=_5^N)M.O@QG<0N''?%C;YAOOMY\\-OYUAGR1L64@M1HC(75 M@$D!">:H;+%&77"1[>/@_3CXK4SW*"=[YX/A39(^8!^UBMN4,]4!Y=A=%*W3 M@;Q10L4,E8PI&7Q2)IQW2OI*!QH/%-X%1JV=S$K69M?>8U%N"6PG ;9&Y95 MGBO'&2&"6^2L!P95-22$XYUT5FL'J *VF12?P); =D"PL=I #%8A0M1++JE% M'$FC2=5S25%M5_I_O@1LK9USLE8S!Q/8$M@.YXR)&FM060P YAX9P@4 PJBR M.%) PZ#:'FLO.XW<* ._3U)A?D)15U26 +5]")$FDC!'@J%(I>,\V(6E?6@] M='P7&+7FC%'09H)=4ED); <$&ZIUEE,*0Z4-]1I@KZ41S%3Y--+@)\[P-@-; MBZ=V;:JJ!+8$MH/9AX(TVIMY%=!FL816:NZDIYQ4449#Y1.Y:YMAK?4*S3XA MB:CO>"HNWV;SW@^CR6Q6G9&E0^\5*#;"(A0R334%$")%A T6)J^HB130:J4- M[J_324!>//0^T%&93(DJ*5'E]#&[#K*-Z H%D@J.K9(.]3F0B,$O1.#GJR$9&QBDCHA?,<**T)H-17APB< E'RW5%LJ5SKNK(%L2UXBZQ-VD"+@I"X3] X* M/5%#3U()A==62,X8\ACQJJA7 7(2E[G&NBUYB7RP_2E2]!+T#L@]!!HM$J& MA'(:.T0R8#%VT+IESU?K-5JIX5L#O9:\1 S[F)RVVCNMTKMXB%A6V)5GB8/Y M?#K\M)@//HVRWGS2"^L8]\MT,AJ%)PM?GF?3;#8_UUH\!% -0@FHY)@#XQ0P M4%B!2=FRE0EIU(&*B9QP)BK(F6SI<9:LPS(%>",.W JK5$4=;J&46"58+5#K!B: DKPIT2 M"%G""61*8:)%E8RF 4]Z3V>:R+^U >A+9D ::1D(8PY MX<)ZAHFP E*H*T)-2 5%5+&BDT$M%2/O5M;R/<:+\2Y(G29[N2YYU@D?4M@O6WDL#))5. M (R4Y[2R78!S_L7.3VOI#+1/0)N<$\ET20(D"9!V! @&M>4"C!/(X]@8A#-# MC1<853E3%/LM+)?V^F'A%'Y- B0)D X*$%3G,G.%K%) 1W^(I8XY6WE^BC# MMA @;26IR#[$IVV"G%:]MA[,AI>]\.VI7TD%8RP,06G:">H/Y"J(O:TZ"(6B"4D#%?WH3_ M4ZI*]$":\)58Y^907PU9[ ;U5B.?">H)ZN< ==(HD/;"6J4%BEFAAEC"J*M* MSC@V8*5 >G.HKP87=H,Z.HDZF 3U!/5#.OFD4;6MC,2$*$:%YPP))@4M6_=0 M;Q5<"2!NBO7'V_!_+=MC1R4_F0()Z@OH+HRT;,34*T8 DY(+Z%P6.LJ=Q$2M$)NLCG4VW;R MV4E _4R:7=CA:#'/KDXBD2!E-1TT*B%KX80ATQP(910"7%K(G%15!%)9M];E M*'?A$2A>NF42*$F@'*E P:(N=Z5U3)@301""!*?1400>>)-,F"90D4-H1* S6E@W1RDD!(30* M8FBY [1JMV$,=ROTKR\1*)U.<$D")0F4)%!:$BB8U:FQTDL@M-,: "= C+A4 M]:]6,+V30&D[^$)/NY_/:77C^&L6[Y1=]09A$(//69'X,NM-%O/9?#".#[.& MQPGO@+VT_9]-UU'NZ9O:N=_HU[*A;Q@F:D"&P8*2*R3VF;M-W=BQ6= M<_#YG &*&[QUP FH,/">6XZ<0PK#*LD%(K)RMKP[0%&+ .7@(%R\": )H <% M**U;BSI.D2"6SXH[X='3P!- #TY@&+0X";7DD!,H/384\V]%%4[/!XTZQX MVIX/^O^W]ZW-C=M*FY]W?P7*Y[W,;,D>WD5.WI,JWI0X\=B.Y4DV^R5%2Y#% M,Q2I\&*/SZ_?;H 4*4N^2)8L6D:JQI%$$D0#Z'[ZAH;9D<2>!,&@>\B@6EV> MQ>S9/4GM2@IHM#VOY]B&5B%HS]<6C[][.8-NS@8U.X:ZWRKN>BFY MK<7$]P1];Y>OS'H/K&Z;NHK>&\ERNYJKZ*Y9A4$L2W6D;?#5QJQ$7>K(VB;] MK(*O!%^MS5>J)-5;07N.I+A=3W,]RU,4V;=5I]I;[G>]KK\-OMJ8<0=\I>Y' M563!5_O 5TK-5X[KNUI/5V5'U7Q-5Q7#*H,.NJ_Y\G.C@BOQU<9L,N K0Q5Z MH."KEO"55N\TEF7?Z,FNV9446[85Q3#TJEQ_SS2\+=A7;0[G";X2?/4"OC+T MVK[2#*-K:]V>:ZB6J1J*T3.K$V_,GOW<-+.5^&IS43BSHROBM%O!5RWA*U-O MX)4&__5TN:>8JM6U#4=6*_O*ZBK/33Y9B:\V&3PS-EI04/"5X*OU^4J6ZHU% MJJGKOJ]9EJ/U%-O4=,/PJV.;)*FW4'%F$WRUR;Q+9:-E:'8;VOK$SC*J?M]( MVS R. %A7 3ET"S\TB X"F-Z.&8S_%E6I/_<$L6/O9&->1@#G^>?-1,X9DO< MSOX$C#,R61T.=&-DJIIZI0TE:M'N2-5IT#6Z UVWNO#.3\%S.O_BOK*OM[S% MJR0:0A.G9Y<^D57R7_\P%5G^@92\#8P'#0R6NB_^O%Q0,R]H% !_G@=I?G>9 M!G'&627SPFP0)5F1TDMHQ8F2P;<#-BCXM4\CRFX[M+UNUS(M55<F:EF:" MO-!4W=![F@Q_#^L4C(,;2N"]].\BS.^@H1N: MY1/H);;YQSC,Z45P=17F1T'(#EP[@K\$Z66#F24*CV>IJA65I/4G1?\4S;7]ZK<(3@1&VO^Z"EL;1>2;NV-,]PT>KZERUW#T0TPS&S)-"S#,Q37-!5+ M=Q6C!;BIO1 W^\55!F(,N?.&R8+'4-+U#$N3>IHFV[JI>QH8IHXC==VN(WF& MKY@-E)1=I6=W+=< (%'A0EGWS/ DKVOSI]_[>O_NDE M\7^'OR\&QV=T8>NK\P&U[E55R[.8? G2P9C(3-HH$H.X((X!50=8;A%D\2@$ MX1PBZ%VGE#(0!8$8#$#G>)@AU4 M2(J=FT9 .I -0$/L:1I&I!P6U@:,S"T@"MR8%3 :4VCQ.[P"^G7W4C7@02W M- W0 M3:D608AJ<94L\U'<_H]I2NXE-3HPH+BR?]B^ ']]A<92[BT+]G><5HU, M0=X=7J4T^'88C& 0/@?1;7"7H2(S3N>5'U72T!=MZ3W)U5T-4-"7 @-W?9] M4Y*4^\K/+D;SR5E_1C\:=\\Y/*7*H"T1%;\WFXM17$3S1K#$/:#\R.X!P%%Y ME?GY\#MT?E!]7T+[93@!KC^EM^0BF00+GN#;<)B/X2/0<96D0YIBXGH43#/Z MN?JP1*VO,LH;?M^'\\W+5ZC_^4-UT_UK9K>^UM(:TIM3LH]S.N%JF'74JHIT MVR>>O0$0,$D9H'PN@ U29 !HW!T',2I.Z!,!O<<+LYGJEX$*!(IG1;KOPA+FLN6 P&5;/ MM-R>[IF6)=F*HX,9Z'N6V9,7$$,(:2&D-R6DB64+R8R2&6Y.80TQ,7N>)F"C M@VS--B5<=R5+YX,*.S5?-M8)_A5O_QSFT/9@V=KV;X*H=%(EHP9:DF=-](HD M-26I*NT&.N]QG"R]7ESI*_(1L[.S8DK3&["T^;!CK #F%SB9'->3$U+Z+RA(R*'+D/)%.8#&'24Q2E5]A( M%2)-P^P;Y]@9BV*OKD";F5 @)1C2O^$%%'^I2!^4UF88,YD9EG0G*6^(RT6T M/]G-Z"\- PP",$.4?@\S1ORT#/_C@SBE@O6?R_I?9H#XWQFY M8&L,1A1%FTP /+WL-$H6W@NR:!K7B4]]:RR\^(M]+ M J9%.DTR+CZ" 1A-PUHX?#WJ'Y%K$%]I$$5W>)E.F4)6NZNF7 =!C>D#AMH5 MZ8>?;/N9709)-)8]9OH#E%TV_( M;T?QWQQA$&5!&'60@B+ED4=\R2@(4_B8TE'$A#$TFC>RY-@]H#[!0(4S><\" M3EE&\]DWE^>W_ !]Q$X^-K]<,L^](J5ESW& ,Q)37#&8LH5KA:: :,^:W"73 MB!/2*5<(O!;>0L-ISJFBWZ<4,8,-\#P=K$M5'WDVV?V6@R(?)VGX[V V*@T^ MY(,&;\N3='&,\"J,TU,#53-"B*]#+$VD^T-636F)P44TK!+6,%"=XF!S6.=:.UTZ"2OX(5LC-CNE]?. M??<"6Z0S;\KA &<96R$/F7)/,EK._A+:A3[*F,#6XE,MVS_EDM,N>MPGJ\.DWN6F+@/7_(;F',GC;SWL0J M]M,XR\E_!9/I#^1/0*5K&UI MYG"'?V7R%85!I0&@TLB$)_KV0*M@!D>IN]R1*/R&F@EH;0OW=U8;AQ486>0+ M;2=?2-U;^YA+.88AIFDV]!+@><%=ZI_*TLK;F&FYXU] ;4@66 MLU(_Q)!*2LIWW(C'$H5 MJ0X^?E ^ 2D&?!82VS%?%X\%;U>L_ M6XTH/AAA>+$.HLW(7".4=D3.V!(N1X3'44(6D2W7+J[U# FF4^@K<\BGS 3'"]#3(II'ZD8N#-XQ,\,;P%TU MR6AJH2!@>%:[J6E:+'S+7!B57O.@6M/*V3EK3$@I+_A@<=G$G4"S M3>6K"*!.*V#AK1T2 KL^9 M66"I(X@EJ)U$*:#8H*C!!>8 M3+JB44AO:!U"X&-<1N0PYZ[C MG)^R3V1I:'_7'6M!;CBY)2M=19*GK:^X;#=%NH!^'51_$/F.Q MS_C1?<9E,0A'5(.H]QR?,4_-<#V74\Q?5T2Y,LW>UV%<QA23S9JICCR"/@JC9K2][[OL"[P*IIP,P48DS&#D"0[Q ML-H)-0JQ)B;+U>%)8R6)]WI4;>?AU5/9-HYJK(8$79?PHBOFV$8PP=R>21G[AXVQ=MQ=(G5NC>K=51$48=%LNOP=J>*@.(:KK-W>"B\+E3$ M8N2H%Y21[F10\&ARE5"%*#X/X@QORPQPGB/#4^ZP@'01PW@P]4CPB>"3MO') M_7!M0WW!O,S.\BS,9KVUD"=_80('^UZWR+1QL>;%FF_9FB_S?:H,,C3C@N&8 MFT3UN4%#6F5<3:9YG>119W. ]G\3)O?RDO&Y.>Z((GH-C\$[BKC2FZXH6!-A MDC8R=1HY2$F9$LD3># E"E,G]X6/6F"H_)D4+/>D3'U&8VYZ5YG:;FG8U:F8 M/C?LRN3Z6WJ5A3E]P2%2_"O>7M4)./CQ]O;V".0GK) CD)_K'US!?3+\)"]8 M1^S$,%R>W#9C"5O*#_S+,C?*$3M:Q68)N?7&N25;.U)Z$]+;*A_SP3%C&PFP M(F6Y"VV6QW=$;,R7PTM5A7+N72KUL'HS0SG>.RZS_53,P'-LV= \69*\GJXK MN@,_&)+6 &:#SG:7A8\_4T,=VY:!9^UQ[#HN;1MVY":6 M&F.IT4MB#0\T5VX<+&\JM\3<#R-LR5G_.DNUKC5B.QH>X^TIDJ]KCF/W9-N4 M-,GL6H9IN(Y 0(& VT- 12 @(F"Y*_:N$>+$BM_E!J&%$"@3/5_F]YZ4APPW MHY=P"TBS=&,G5@@DO8^DRBI(^K))7@)>_&S).:6)G..FX4;^8",JOK\8YEAX MIJQLV7K/T5U7MQ2O9\B&W7-L39(436"8P+#M89@J,(P=EU0*LIGO"@1<-@=- MEXVMHIWRM#MN3#1JM8EDL.W!E;J2X??D?*)U=3!5;+3=2W= M[CI6MZ?[/5U5'JY(>+0/F?2QH M/]C<27\"B.X#D?8,(*H 9*4RKFP2]QM'WO4&7OWE&WA??U#6+)4L%M0K+"AC M8SO"'=G1/$.7NHJDZXKJ6++G&%W+5]6>TO6M!<7N#:W$5]IR^/N.]W$^<2:W M[?@PL[K6M35/[TFZV?/5KJ%;%K2F:9RJFY.F2:9F^+=F2I;H]3W8-I[?.B+WT+,'@72VC MEEJJJRRG01(EZ>=_2.R_!>2/$P3]%5:8Y@GYTC* 1_FWAA:X+_ MZ56EFT+P"_J$X-^9X+=\75-ZINS(9E?O]7Q3=S7/L3W7-PW35/T7"_[^W#FO M9[-S7@4$M(DKM@8!3Z\OW1(0(.@3$+ S"+#]GMLJMMS5]:XB.9+5D[N&##QJV9ZU:4S@&_0_"OG?)I;8GEOHR<5ER$+^ M"_J$_-^9_-YNMTU74/7/,ET-$?3+5M3NK;JJ.JF;8(@&Y->E-P*MU"K MN&)K$/#T^C)4 0&"/@$!.X, 1>N9OF%YBM]S==_7;5,UK*[B&TY7-4W76F?$ M3I.(FL8&LZR>7_3\-J5(3;0I9WOASSX\8/RD?Q/^!W! M\+28P$-X@$J,XW^!/-?S%$FV?M/^O/0.2!Q,X#U9FG^N=H^>C7X/HH+!J1T/ M?RM@RD9W,+%E4EWFS4YXN806'2SR>L VY.+7/BV/K#O$BMU*U[44"X/PBJYT MNY*O^KX-5IAIF\JA='C[[; 7#/)#U_-_;U]+*_VRY?V-ZI?]DAQZ?N$>MA_ZO3/_:.[8MC?X6N/6='\!O: MC3L)TNLPYMT+BCRI?N#"GOW"M\5:UI$A66I7?]FV7=EX9&\M?Y/^V.;Q9-%61W149I, MR 7-:'HC)G8M'2K5BPG=(]WNB5YW#(.AGT,;BU\QIP >+^T$B,-7KU:H<^L#\A\O M(&2=?F\L4^%_>+=Y<+F7\O-Y6/QX:.BRH5B226595V9!<4F235^5),M6557V M>TJW:_AJ3Y*ZAN?;OE2%[HOL\#H(II_KH'VU C(['I;NOJST%!W,)P(<@UIF M_*;]5;;QU^-M7-Y-J?T]S&:WS^[J)2E+N:G7X1>F^AV0(@[YNXIL>$"&=!!. M@BC[Y\$A2B*8*WGGPHR)UC*Y61>6K@:O#\BNO MAJTOT65EWM\)S@AYTC)YTI5G\D31[9YAVCW5MFW5DAS-,YD\D0W?UU736$V> M\)#1\#)QDRR'W_WO>.3E??F"B49=EFC49A&C&1U=UX6($2)&B)A%$?/A*1EC MU8E\GBWU-,V%Z?1>;) M_>,Z[J7#/_\,O4T=;RG.T%OR1NM^I&VX]AEZKF.;AN'XCF2HNN8JIN1:GN5I MCBN[OB7A7H:W>H9>9G1P"#^BB/R<%9-)D-YMHK?SQQ'0V0%NP+?\+#)D MJ]LP'R.GS9U_VCSXM#P,]?-ZYY]NF=56F.PWM-WAU0X?DZ6'4^FU1T[*-M9( MLR\IJ74WPL0_J?92OXF8"/LZOV.G/!B1G"[@4PNV.NX\?+GC6=_B<8@>S09I MR,^FQN(^?!F\@ZB@>B2W9*&_=:/[*?H6Z0GFYG7I,42-"A6]WKQN4:H L^WO MXSR??O[TZ?;V]@AN.[I.;C[9Z6 <@LGXB0ZO@_03:.?!IZXEZ8KQ"1J4)=DR MS*YD2I(F:>JG-!C&-/_+_ :O4"7Y:)Q/UAET%T=T!&.:4WZZ1J6*E+QU$0Q/ M:=[!"T<=$A"/1L$MJC'-^SX\K,'D2:7]E(H/4WK80:OFX:]XZ&J?3G.>+J9A MMIAD?JR%>8OJ@2:EI3.Z;ROVC4&3LB%HLB90.PU2%EI; 9 "D<@ 2>[1G'"%H%GJV.9VI+9W3?5FS[\,PP5?BG8..J M.<,S^EUZ@:'EW $"91LRJ2K'EWHD8XL8TYE!$(.0[*%=I5A5CB4J>MBT#V_>9\."K@OI-FC< /@ (1)B5/]0M?L7-4S-=HLJ!MLM M:CU4I5_ E*!U;VC=-YB2)8%3[Q:GN/]/!H-)-71ISO]G6>L[ ,\!(:XI">)A M!55WQ+Y.*<.3RGMW-L@31 ]98NBA=!"]\)$ (.H:C2WH"_D2Q,%U^1RWN^:M M,,2M:S"6@CA/TC+KC0U>A[7E!.D@"NXR^!!_(^X!Y'K(>#BF!1D<'V&4SZ" M%K;T LA=IS<=S'V-BB'O4.751,82D+AKGA.T"DA< Q)%U.R=0Z(.'[OR/"3* MTOJ!LU^2D '( @P%+)IF3],P(BJ'(KU3XM ]I(D&G8-))DL9A,)\? M4C[R>!() ML ICT(8Q*, %W# #=.X<]9<96%PS!(T<7*(W_S76!-O\R6_!+< M$5YF3Q>8N6NF%+0*S%P#,[663NF^+=GV8689X3/@LZGI-68&+P3-.EGR-#DB M*DN93.D08 1QZ2=NH2TQ[3BF_E)$%:@8SW>GQI4[=0:'<_C'&JGQ<1D<-KVQ M$<49R,@T2*&CY39D?I)!'DX8,N+_.[.7\@L^?[/D )Q]1 =.[E@."5@'3:\"T MWM(IW;M100 MM J07@.DEYT(W88IW;+ MZR++B;(RG#>2F+:&YYV7@C+[\6%UX44.\&KDU!*X!6ZW2_ )6@5N/P.W'S@D M:N=3NF]+MK6X;<%'69$W%C>>AVYCD]"]) MFWSSRHN >]7P\2R"O6@V1X,7 MHBJGRA);5#MOC&D%$ IP$/0NAF@ M?* H_SLOP'X?<(>K%V!__4%9O8[Z8JN-N^>6NBCQ_3HEOM^.3FJU5'KN&SJT M5B?MPD>]*]_?,[>VHZ>I(6+!18/X?Q>X<0U^ )&#D8GS"-K\P)17U$9!"[R@ MK#))I9I^ :5P3*PRA/ RC?"7(J9$5D4>03OX0- J7"?K5#.16CJG^[9FVXQ3 M@";=.I%@$QN[:TPZX^6T:E?)J#S"ZS$(6PN7^H?F(T6YROBY)?"J'?P@:!5X MM0Y>B?); J\6\&KM4I$57ITF,:)%D2?IG8"L-R#:!*W[2>L^0I8HGR4@:P&R MM)="%KKVTG# CG9A%8KMVR =,JPZ&XW" >8?\YI4 KI:)>($K?M)ZSY"ERAS M):!K ;KT+4(7&&*'_F0:)7>4$B],Z8!56!1 UD*!)VC=3UKW$CCP4M.XGK?N($%)5YYB:3*8TSCFQH9'4('8T H5@INW)7 MV!W6_&-E\%]\2(LEJK^W8^T+6@4VK8--HIC.FYT^[G9CELORTC1\SZ[2(;)E M*5Q^_YRPW(N?CHA#TVL\"?K+D;?&85W0U6!6-0=NF>%"2J$5GD,_]_JF^=(2 MCA(B4] JX.%Q>!!U+=ZKZ2);JJSHDB9ILFKHGX;H?-M V5+ BD=PZY<@9N=5 M\),O)6VSH/64PVWV=NYRTX3+;>=\(6@5N+4&;BFBSL5[Q:W2Y69(DJYUYTZU MDM=.D^@#%?&0/!?%3F'6V=F(LL'/,-X.C)5.. P2R;KPP[6#(02M K#6 2Q1 MZ.)] Q8F]<$_X],T#2<4K"T&68>ROFZZPY/>00S?<$-'YKARBE5+8W)Q1'X. ML-;H"X"ILJ_N:% 95V>#/$%,+(TK61A7.^<%0:O JG6P2E2X>*]8M&5L(;^&880M J &L=P!)U+=XK8#WL#536QJW-> ,W:&T)-V#K.$'0 M*I!J':02A2O>*U+)FJ: 606?5,W2/MW(78 MI?0"2NMBU5)<8O !B/$--_M& M4[1X9CGBE=7#C1YKPTY CPXX%I9&E26,JIVS@J!5'"XW>^+U#Y>[GV$X%(?+ MB@BI+9A.FU.ZZ"4P7-,=B87,56AAX]',Z'=,8020?%PA-]Y&* M08FT[O9VQ*5/E\]Q7PBPVCTS"%H%6*T#5J(HR_L&JZ4VU?J%-!=MJF7X]:A) MM8AKPJ[:*U80M JH6@>J1(V6]PI5=:_ --L((NN6;I358=8^8(?938@_ M\9 =1< PY4L0!]<:^8 M9RBF8DJR!>);,KN?XG^%<4IODN@&R!BD "LY($Y.TTFT+@Y>5,T1E[7'(.P2 M6B0G2;#H1^S3:5[&HZ32D1A,$G@:$[E^H6E&[\CQ)+@.V4_Y;9)^ZY"3$[?# MT.DF2,.DR$B$")5F),1L,UY.&BZG-(P[''B+^#+%,W6<(/Z&)F(PG(1Q>?P. M5I6^9I ;9EF!+[IB=\%SV2U\Q5DIW[#=5&+9_"@0M5T22= J$/4YB"I*WPA$ MG2%JD"[%U(U:EBO"+)_$\F"Y"FT$T@JD;8VD$K0*I'T.THK"/>\6:5D@$6O, M289IO5(@D2>@* @:BL2!Q@MNPB'YY8C\&N3_?B9.81UZ; YAB9\S\>LGNT2O M69J+QM\B@HD[7_R"5@%.JQ*JR$?""MP/; IDZ1L8"5;YNR*OC2\G8/F@W.\7 M5UDX#,&(HID(F[6,/02M0KH_*=U5(=WW5+JK:TMW-XDS-!A P%^PL[8IGE^* MAW-/*2M\0,Z+JR@<$'LP2(HX1X]7+TPG @%:QD*"5H$ 3R* )A!@]PCP'&)* M.?^/3+54WS!\5^GV)-V5'$>S=,/7-4^1'4-U]'4&ZCRYI2E*?!O(26-ZQSQ M43'DGIP,AB;(BY02K/I#@CP/!F.XA#&2/!$I<[M>6H)6(?E7)505GIT62/Z- MZ/Y_:PW-7UW?K^/Z9\3%41G!N+ -LM,BS8J ;YOM8R%*^$V5%"'P6\8Q@E8A M\)\A\$68>2\%OK*VP.\)@?\V5I2@50C\E06^(C3\O13XRI8U?$LRA,!O&<<( M6H7 ?X; %QK^7@K\+6OX0N#O?D4)6H7 7WWK@'QT?-IOZ:SNVZK=P@3^7^?B MA!S'61Y@:KV7# K,U6_;RA6B2= JQ/#C8KCO_MS26=VW5;LM,=P?C.DD$$*X M!5,L:!5">!TA[-HG+9W5?5NUVQ+";A -BHA[*D["^-M5D F]N T3+F@5(GD= MD7QB.RV=U7U;M=L2R2?!%8V$,&[35 M:Q_61H6;I?:G4HCH861T.+ MHZ'G%)_S"[^E$G3?$&);BL]Y2G$CM#!&6S?C@E9AC*XCDSV_U])9W;=5NRV9 M[-%1&(="(K=MO@6MN[5(MVE++>O05E_)OM[R%J^2: A-S(I'KMQ[K%R#N8]@ M*TWJ@XL&-KWRO7M2[F_06<.3 M$I!P^,^#3)5]2[5LVY!-2^]JDJ.:GJ)ILNWT--_J6@?-U-XW[()9N1_'.9T0 MV3@JR\6S8NK]8C()TKM7G>S77UZG24R7<%RY8$P?UD5/-V774'7;5BU/LDW5 MZ\EFSU(U5[F_8![LZ2*O;@,!^L<_G=J77R_\_O/'< L]6UUX-CKQKR++P]'= M)GIQWDCCQ_K+*?V["%,&;JS$-3O? -XP#C(R+*([,@B*C!V-$&9P?9JD[.U7E-4'XI6" M0GC[%1T'T0BK1F-#;/L#OZ'#3U4H8GB*-1@4^3A)@:KA6X/<]^<(UIYT!&OZ MP][>1RZIYL/79&5_G<2/V32S45<.]H+6"]L[]2\[Y/C4/6J)%?>:,RJ6[G[2 MNM?T-1=M6R:5W;()JKT@IY_Y"16E66#P>TRHH.\-T+?$-/XYN0W2 M(4%6I>DU31FK'G58 )L=:=?9U\$07"OH>Q/T+>%:=QS2$?&_TT'!#I$\&XW" M 4W9P9%>F-)!GJ3[.AR;CG*]IJ.O]K@_78A[9P[4@Q_/S_[P+\A9C]B7EV<7 MI_Z?*WHL2P>69FXOJKFBUW0;W?KU].P/8I^G99 3&@S&9$K3+(G)[3C):*,H>C"=TB!%QV>4W+*BZ%=W)*/ GT&$ M;M,D!@+R D.0R-QP>Q*BFW8Y;K-[P#+Y1N!S/T^B*5[!'UD?N!-WTB'HAD#?H!N>3HM.^8/;HK(M*KVGA57O&?H*<9;4WHX M]QL>.CL.)^Q:&+-7QL&$=C!,.N!OSG(:##MX-8CO^/O@%8, ?9;,QYPG;*CF M+@=X^B_W53/_]8_SMC[6.?QR;(D3L9=R7G"'TCP&QF6B2 9 M]@9&/2Y]X.Q6;*%LASG!?;=#KM&_#8*/,)=T%H#1]O (9LLFH3&>[$;NT,[O MD(1APGZ#Z1OAX8CL0=8"+ P8BK)M(!XZP-SW69A3]-9#OVF6!7 3-L_:0M)A MS3#B6*-%.H5%F.&!CD#-!!F'Q[*+:(AOAA'@J[53+4@L1S2ZPY=A S \HS"= ML*_0=KW&YT8A6S(,^!JN5* *.HD= MQIA"&488)C'%L,%-F.:PKK'?R6B%R, KR8R6BK*G(D+/#/W4L1V,^UQ1&E?A M'2[>RK#.*(G@&RX?OLPRC/Z4D1]HK1$^"AD#-B4"XUC^ZY E9H1EBL8J8: V MS*R("Z%'\*FXT".Q'TO?W_B.<_>N?8FD="/..Q"7^0_;Z&A^=5]-9?%UR&-V MX^TM?&_EA)X$7L:+WA+Y]F\CW#NU?[(O?CT])_XBXMO>'?[*LZDX; MI=C64!WDV0W8.3@@P? 65//.8R[<_1T:@6H"U02JO5%"WSNJ_7+V\RGY'43X MQ5>_WR''Q\?"9$5P^R49QVQ)_<>%?^KZ MJ(*<^+\?7UZV60-[#$WH1Y_FRWPML?#R'96K7(!5:+%2VP M6F!UFWN$OGN,LR]^95NH+\].SOV+-LNPK4#9O1WD?%M1+XR#>! &4;6M:.VZVIR/ M/IRG(;0WA0;MP2 I^';JLNV/;1YS 9:[ LL7%/?8YDR)+K2G"^\]0J@NB;W] MK^K+53*\^_%__\^G<3Z)?OS_4$L#!!0 ( *V%<%#1]N%"(AP .E& 0 1 M MYL__>%IYU@.D#!'\\>SJU>69!;%#7(07'\_N[/..W1T,SO[QRU]^_I_S\]^O MIT.K1QQ_!3&WNA0"#EWK$?&E]=6%[+LUIV1E?27T.WH Y^G .?(]_///Q'S[PT!Q!5Y#@0=E%ID'J-0=T ?D(K"!; M P=^/%MROOYP$+D3+RS<7\O4]8#!JC@G&_JHM($5.#%9#(W*1UFH-W%\'+=%.DX1=AQ@%V8GZ?"N/S^$:UOGK__OV%>ALW96Y90X'V MZN+WVZ&M!'WVRU\L2PD>K=:$<@L7!#8'[%Y!,LK/Y= PQ?#YY=6Y9#E0F"%Q M %?JF68Z#:J +J#'68+H/$'T2M!P9EVT(VC\ZO5N5"36K!T5 M$=P^J'A_ :@C12W$YO!S^+3V :J''4A4 MF#%93 M*/[H=+OCN]',MB:=;YWK8=_JC'KRX?2NW[/ZOT_Z([MO_WR1QY;KQV?0'>-? MU._\J(7 81,-8&Z:-X;+SJ12L/!A))1=1-6#'"!O7Q*+L.D$]_;R_=O+UUL) MSOIKV,'?3B),!GTF'^]+@B$RG0#?7+Y_0L@;2JP:7",C81G%/VD=;3%L*FTK?G?'(WL\'/0Z,R&2Z\ZP,^KV+?MS MOS\[)I-8.: 3("(BOH0<"3IW%$X65XVDWJG9U%!2UE\SN(]U)L6C-9[W__ 1 MW[076!&%7DYO:V:4/1/_W?9',VM\8_5_NQO,OAV[<-AXW@5L>>.1QRW,73D: MO9#>-162+:74[=B?K9OA^.NQ&L#,$).58&PIW #T (>$L0$68H$[RJT"J5Z* M;]I)<7P[F?8_"P]C\*5O_74XMNV_68.1>-P_B74^%F&E(FW'&9C"HQ?>ZU;" M&T_ZT\YL(!H()V 1>/)%377C/QE[//%AP'$P$M(2X(>T>C> =Y8CWO M.&)99PHK$Y&."%?6)/RS3A$GP&3" M1=%B+04QUIQ0BPER3@:BD1A'@$I7YN'Y%2;IJ591"BG1?2E*3,,Q:<2G+-)%^+1;\L_%BR+'P:CWM?!\.A$MEX]KD_%:'* MK#/Z-%!)4R77;[>1 M=,:@J\ZM=.]6U/UIZA9DU=*(M\9:*_#"RMY6X"?#7"V'2/''\PA@KV(N05\K M[\("W5;>4:<6F5M1MR?1)[)I$Y0WQ*6/R'\LB8W4H(5V(WX2[M"W'OPJ/%I[=_6FQ-ZE99*V:P%J MBX,G"P;(CW1B;.>9Z!#4"JG@=58)Z2B=C>+03J%#L SG%67CN=RE\.6]A3O[ M!KJ0 F\*N SF^_,Y=.1XR;_;F[P=NZN5>\'YK))[E@+I>HCETF(1'=;=*_N5 M-0]HL82&0 M@UX(1.>K1L2YTX2C>82H&<8'1?Z KGE]#+/KCVZI$!;9:B?_0 M5.+I#I11O@^Z.%(AMO$JBV!:!_+J38D#F17+\3F*0PB2DZ =UU5X@3? TPK@5BS1%\DY ?/P"+X2S<(.P/&JHVFXAIT9H:T586(^*(DPZDGY'W)7R M,,+. C&?)*P115=0_?J9Q!S@/LGZSY"U[:_700D-X*4/"V\AVDI4M9)\5R_) M-'(KQ&XI]"?1B2%I>:"U 9Y:H16"_!JA2=26PGU\$AN1QN%Z&D"?H;PJR5!& M,E#PQS?.;<*J#(0^HKHJB:BBD3Z^6&HD%U4XGE_[#&'(&@YW 4I_2J%,N4>= MV=VT+\_G7M_9@U'?/J8D?'[\MDOKUF+1;S@*LU^8"$6I)$O 4>9W1_GD6@_. M(:4JL1;L PI_=XC O3R_A9J:J]98:W-W!:^K(G47=:32=B XX"<=:"_I[*C$ M*Y?6\*KJ%#X0[T%$%%TQ/HC'9_*PVP5K)+R>8)%I*.$M$.L]A,LR(SJ>]>/[ ML'^WIOTOX^&7P>B3U9WV>X-9ZH#?J&=U.Y/!K#,,%[N3D'6RR)S6DO A>!*# M/IL:-.A:;PTN2Y)?.RA*R0$R2945DI4*RT^&HXE@;P%=(&P+]H%[#53W0_@ M*5C(G3E$GENQ:ONOU:Y"KF9/VA509@6D68HVBV KHLY2Y)V4;!]"[L%[/L", M4W6-JU6)CC^;J%IU_/&0ZOAW2U)M)63_[2A+B&RO%&UCGCUT5*M1A6S8GC3J M.".HK266'*&5<^RY]2/76ZV2%'9^]Z0DZ3.\DI*3KK277HL-K?UV>=*:%Z4U M,TA70P*:WNO=1T>U&E+,Y.Q'0R0)EJ+AI!M:D;79=]@>O7Z3XK)DDV(G/3B^ MG8U)4.Y2CK\LOK26SGDSH99"ZG1QEN*89V);Q6"-,M;(JY"MK9'6LL539:+=9KC3PVO7H\J>2 M]:A*1L>WU/SF \HA]393R'PO6\JJC7@:X-&[#3^4B.FWN\YTUI\.OPF/P;X; MYFMBG>25'><[#'SAO?.A9+CBO*FT)'$!^6GA81F!@3[ +J-A1W-;C>ZR^[ M5CSM=^4J&!:KEN&9/1,+9&?:.Z8M]RGT9'7'B9A&FQD%F &GQ?2KA-;;T;)B M.-/^4)6$G'2DIS*;=D9VIWML%="JQG,[E[\Q-KT)_+'D^%FUM([\&%J4WAV@ M+\#S%3'"A_]-?1MS(R]=A%7WFTFP,3;]?"O[/(;=_=SOW0W[UF @_OK2&=ZI MU4O%"&*!&PYNODF;&-7R/XFP,.BM,B1MD>JGY/N2*=E2H$>93K$Y<;ZK P*R M,%E$B;BC!*W<#6'GOLIA:K[J;8^_5LJ%!&:ME,]3 M/5HDZ%*=Q'X,.SV)/JIPPOQ]2%BAJ15DX>A/D^DZM>_^]R0OW";5J<6@3W*^ M+4ER5DOI^+*;MG_/X!^^8*#_ )M;QSR4W@,IV_"T[Z[M_F]W,OW1_](_,N\^ M-WQ;.AUU6/3VZZ&ZC!49SY(!TYF]"/.0TOMW1$)<^ MB?BZ=";=WG:FWV0"V!Y\&@UN!MU.-JDX&0\'W<%17>-I-MKQA3J*'I1R[U66 M)=CUF]NO2PYT-9=N]N9>W.=IOE;(I0\H%D_9!%)["6ACJ[M+%[7R+]Q/V$[^ M4<>6Z-E279_4H$)&-P!1F0^#MQ#(,5^U<8-V[J=6(0KWI[93"-F[I;JWTOV? MM*)"6@,L3">78S3 OQ*$^1?Q4XS:IZK%67]_M1%T&'%1-B24KD7;>3VC028NLH;RO< MM:I0S%UMI0JGL+!.)G'C$>13*")U_SDD7]9+K0X4$]%;Z4#8MSQ1)!BP:-#] M22'RHGJ.?$&CO,'K2_&O)-G37-A1-R>AY@70*H_=!J,VKWTI_^TBT/_J3/?/ M%T_,_0#6:X3G1#X*'V!, NK5,_D(!D4*+7#/. 4._WC&J;3/4O[4Q?Q?'3%Q MWMM?.Q/[ZA:N[B$]LS!8P8]G92^0Y\EAC9 P7V!%W)<]?J+$7W\\>[JG'OJ M.%R=65S0^_$,$XS]U0>7K #" _%"LG%F!0W7D"+BSE1#UZ?A28&+;3- M.:HBWS/SOP-H5-E5KID)6A26V-M!Z,"QPL9'$&Z^ F'GE.I"(4F M+XXU(:(Z 6L:&\QN7-]>WBGBFP'F4"PK7'%&Y46*D-/Z=EL9+&&M!,WR!+?. M7"$L3UOP=J;6?9 CY$:SC<^0&$SDKW*6M[:9@:O(8D'A0E@.(04JQ@8Y*I,8 MLU3Y>GL]9!+38O^<4 >X"(BI@XA'%IM0"CD1U30R8*4L*?LXA.(A5'[=##[Q M:R]M-YJWWX$Y'J'9$W_JO'A8ZI)4SILN)8R))\(.9MG=!MQ@PUGDR18F"MP* M+AP0LJ5HU ^$%LA@]A_E%9L!8[YDHB>,3GC+<@V!L\PHQK";(UK7PKRUZUI68/,VL3&_%6HHXE%%S6 PR//6K+&! M;(H%UUXBZ+DYCHK/#22>B"DCON2%@>13"!B7>8A07W),5+XV8+J'U1]@XPG(=[Y*^A> _P]J+T6\OT\N ^R1FEL M_K.,9:H\QO,,:+Z#HQC5F]2GAC)EV/<_OM5=/>-(N_#>C($>0?Z5T.^RO%50 MS>HYAKBLDV,8W/AC5G^&'NLZ.PJ;,46+)1_/[UC0^#G&N-C%,:CQ'9Z#!T)E MZ_!+C5BY5\^BQKK.CD*-*P?@D\Q__*E#'O7XDL;=YG"=2KYWW'_[P7FY\3PY M.Q=^G$XSF"W1',(,;!LVY%B3^R[YG'YK*&/Y3]?H3'OH)<^-2ZE5AK$!\4HO MY:7217!".!O+UK0Y?$ K"&2O+Z]^*)"=?6I>$B'Z_F*0EN^$S1(&*MX:M\/2 M%H]GL^1 ^.<0(&MNG8&S/O0NQ@*WZ+C.-1/8L[R5\9Z'R7D?J6(36%RDT>UO.9;FQH7*@;0 MO2*$W5"R&A'LR&?$\^0B$Q[>8!F&F[4W3L8:>_H L1BI$>$SH@H5<)BWI)H6 MA[>AV4\J1<1FOKIT"Y[0RE]%#+6"V%Z2:Y_"+7=DZYA#8BT32K!1M$YA$'K< M(MR RQI0D]B=*&CD3, F_%.>@"KGK[+M,YZWVD(]U6$*8NF 4F MQ(]KB.$<\5NP$>O#-9P*<?2L_R2+^T!;Z+=,B0\1%FX MYB!.D^G&H@V2%Z 6*3V.%3RW45 V)1J"F:8>&J/V #VRABZ'SA*'AW*REJVZ M@7DQ=T]>_.&;P!3G;73Y.\.9T/!@, O]::>7I3SSY/#K8G\^AXZ\5RO6Z^#S M[\+-A'(S!LLO12D$GT1'!'>7,@^+<#>(G[)1].YHC,W!;\U:SOO= YY#>\9Q M0B[:.Y$GO:4SM"2>.UBMJ0A9PK(F(<\M (P+P#-L\TTFEY"KP)!P6]/.="9O M(5\2-UTH1"SQP!L_"N>&+=$ZU$41='?F'-(>\OP !IUI44/MB$5:'"644Q8N=S9A)PP'F@:5WFWX-5$1 M V9]W)+GYKGFZ9.SU??6\AODK:$.M7%>RF>7L%).PN?&^N!I6G-9AH[C^"M? M??RE!]<4.@BD/9*M((VU/QIN,N?K&K0S+#6EF::4\2&"./B <6=!(2R>':AM M9:+]*2?9EF6-^+(C?KO-&:V$>D&,HZ?V;)?#'#ZO$A,;R5X6)V P_F;M;GN*MI9(!*$N(^"C)ZT/4=CN31&T)G MX$F$16O"DB12@W:FN6F5H@O2\UT1K-X"#!;A0E5B1YHT-$\S$ZHG C@A>)+ ]GP76'JA9'W8'+I/JE3E6.K86/SV RMWAAW!?%9 MILI?&&@@/5.2VB&I;'3H/ M&AU7ZL'@_P&.C@1,LVSH6YFV@&GX4P9:GAH%;#E0Y%3Q6-+2.$^RDE&$RT\W M;:KXU0&8S_8 EQ\$[OEP1G)WQ?(CT!+6N,&H-+V_PKF8I6+I*SMP4?72O!4D MO>6:XZ'LC7D,_!-2G*\)9V^8Z(85#UPV;6PBF]F/#(@P)[-;GL^\MVA_\)Q[ MGM;<]S;*B^>U!3ID!;U*J:K%@'V%,ND,W4YP0%]6CY;'?.2!E[Q8VP <7*[! M[HXB62;NR#RZ49-P4]U@>^HCVO9$?W;E+O/@&K0S=H^DC/9AL'!+'SCX^%HU MF\6F+X_3$>'?@J++4";#[K ;SJ?\Y;>=,)@V+AJ;E+HGU'E"*?D77S3CRN4? M7"1Z9>&L_%.N/&?([:E5N923^)5YBWZ&SAOBY])DU:\-9V6,H8:3]%O#&9DM M*=2QDGUO.C./1,=*ZNWA,T3R_HAP%Y3A"\_/;**0\YI02AZ# F3B51*5MP4R MS60GW!.\$&'T2MZ>LY>$\N@/@-UTL9/QO8<6:C!9UZ?ROLTM$-YQYN+6GG#] M-XU5_\GQ?%?JPAX'38OTOVGTQ(S:_^AID1H\>HS)^APRUYDJO!47%E#?%MH4 M0MOV8$8&MX7-R9B![#+3H-WA%YQ;".2G>^>^=Y<*>&(6JMX:E\],,>0BYPN2 M+GE.'"4OS/-<@OI$R+TJ(3[SV%32O0[E+,I%QN7,)]TR?FK;O@@F-[6LF7Q' M-"2WHAI3Y5L3+)4BA[88#Y"*@J)=4H,B4IXWE0 MN#8Q#87'V^N)6,W@0KB$&E*;>*@!261^)W6;"=_:E7?KRM?31DT/SM'8X430 M^?KR]647K+.:4O'.O#@O(?1-%0=O7@3Y[ZK(?VH 7LZ*/5>W]KDR-;)+O?+,P M*"@KN-X*PCP5S][.82+LR;*G>7]X3R$L,LHX"6M&5!2;J*Q7LPL"XV+@UL.2 MKE;3$L8XYJL5G")'&:D'Z!4^2UKUTL!YFJ%4Q\5+84+#PTMAX8N&AR\OA D- M#X:SL((N? IN9Z0N #LQMML3P7>VL 8L+Y1XD#H,E4A3'B,X_DU(=_EU7V8 M\*1K8IR93K,F8/A&N,45^W':%D;(1I$W\>1WWU,T!GL"P5&7G%?,\KRU!7XI M^U9B-A4\R=RSPTNPRDR89 HT([Q"SBU8/H)E82^CXIV)3#Q _)EX4MM9GH>R M5P:R(!QCF@%NDG!T!M"LY>1\YFHG3 <*B=5.1ZV7"UO"18"+"V*HWE_ M^.EF.TOH^AXKU13>YEDS#%TWD$U UJU+)/HB$7L<-$=:PJ M)6:BBV?$;VYH8B,H& P-2%7-G+I&YBTF-O'E:719#P?-"<4().GJJG6S)8P! M$X(+@R9K[4/*@@QF#\Z1@W)N67TS ^7GXQGU69Z3_-/#RV &GKH^E]R@Z 8"#4NRV7^S=3.3/* ISR5P;*(DUGF&C7<))O81Y#=W:'<^$ MP0T+/M4M:Y0NX5=ANH1[%)Q?='A%U;YM@0^OBG<8R2LDT)TB]KWJKF-=HT/& MJ"E.*'3( DLCEGS?D<7.Q 1BX,F3.<+OB!8E]?UOZ/9\F\7.P6@LN!O-I_+YF-*I@C+V:%=2* MO15=W,OI7KI6U;0QS\8'GBD(CG*%Y"I2AL-N[GQWLZ8OB\7F'!K,X%? EH)2 M+LLVRM0WBR\%1A?4"YRV SG\FEQ/;UO^3&(N6Q8O?8PT6#&G4/:C\D[?($AN M!VP#>+CZ=-7ZFV4C)CJJI^ #3T8K%5QKFANWEU-%>EQ*,+^5U0; 0&X9#Q9$ MK=6M;V:@R5TB^86-^WO$7P%4O NE>6\@,T36N(O"TN!VFHC/& K+ #L@7V.W M%80!!K:"W$TSKDPN[_!5Q,Z0LO1.U415<):%$/[MT\U5GL?&[WZ%[\ES]<$\ M9*63I;%;B8_EV#[IW*>],$J\39'J3=)#__H+4-1H#IOF#Q^ MJD*AZE___?O-^-W74,Y&T\D??\%_0+^\"Q,W]:/)U1]_^?TS''T^N;CXY=__ M[9_^]?\ _,_QI_?O3J=N<1,F\WO/N+]/R MKZ.O!N"NT+OE#^/1Y*__DO^P9A;>?9^-_F7FKL.->3]U9KYL^WH^O_V77W_] M]NW;'[[;S9=L5 M&KG__/M/WW^CRZ^QUOK7Y;\^?#H;K?LP58M__9_?WG]>CA-&D]G<3%SXY=_^ MZ=V[.SC*Z3A\"O%=_N_OGRZ>55(:/PGS/[CIS:_YGW\]=_Y)_7;_OSZMII.LGT\EL.A[YO#"/S3@3 M[O-U"/.=G=U9L-WN?31EVE*NPWSDS/C@OJZMI?&.?YZG/_,.>!G/_K88S7_L MT]^-A=OKYNPRGIC9]?EX^FTO&FRMH-WN3F]NRW"=%LGH:W@_GK?FTZ2ZL)NOA-RN%:8^> M[:BAI0Y77H,5BK;4Q4_!32?Y]%EN6)3T=^#3[\_#I,01_/]1[>]GJ8[7VW;V%B@ MD>Z\#^;1W'+D_5(J,>.+29R6-\LYWM6_ZC4TW^'E7TZFLYU3O;U4\QW[+:V* M,B$1'C6]R55:%>>C2;9K++_=J\_[5-C/<$[,V)'&Q_2LUN8']GEQF^K**KD9 M/[4Y[36.796TV^W*1J#J-338X0_3"L?,FD\;[$*U;7;=MXUTXD-F>9),CQ>S MT23,=G9DT_>M=&9?":=J^68Z^_)X/@TQE.7R:+X3F=-F\7YD;-:Z1[NG^-#Z MFAE,9O?JSN!3^#H=?TV;W4EJ?#1_L!M,_(FY':45>4?&G>,YO,J^AO1,Q\[E M5\4?CX(6!EV]T9YA^C1M#YNJ+0\< MH--@YQ>3V;Q<7F57O(SLJ3L]0UE]RV^NB9Z'_&@ERA/3WKC7MS.HP5<2UEMI MK&<8OH3RYOW4[+ZV:;")OH9<3?"M77$CP_M83I,&N&PJ7Z#?Y@US5\^WE6FM M4Q4/E0I%V^YBY1U^GSI:ZW0ULNXNV4@'_VMARGDHQS\^A=EB_/RZOEI'J]?0 M>H=_GYA%6LS!U^GS3Y5TU^W[,^4@]XOF6FADP)^"2_6O7,C2/IN:G'A3^IWC MV%FPH>Z-LY_*QX39CR]E.L*,JX3RKG*M=F[?[6[?>AKI_+U$=#'Z;S->+)F5 M]K#$SO$H_LAFSY57X:[.[UM/IYVO>#8>6%TS0YE/W5^7NEIV'PMI\JO<<6PO MU6+']N7V?K6TW_'+Q3S[1V>_\\O;>R>NO^1^5.%Z[9K;'^"GV:+>.)Y6T&)W MJTDM5BZYB^88Z>W-CRA^7\?/H:C** M(V>>B@4?I^.1JV!%W:^6#CO^8)DO1U^7X#4TE,WU=C^X,U-.TF]G'T/Y^=J4 M%?C50.7=#_/%7;*M[$/8X+NK4VOW 'C[^$.:? M0CKA%LT.<4O]'0ZVV9.SQQ.THJ1W0%T;!^',V"W&2UGQ??K[ZO//]XU M'+[/P\1G"U0'3:_5/1]ZD-N_[\%XZIYAO6IU^0XUFIE=OAI=S.#*F-M?\QS\ M&L;SV?UOEK,""*^>M?[SZM?%Q@X^\4\X693E$Y/WV-@P_N,OJ3_% ;44VE 6 M'0^ D'7 "'*@A%8@ M96$ZL"U<_A&.='OM-R-1^=XK'WT!]&Z932@E"0ED5P M2ANPUE(@UNEHM?$Z\BJC?,*[H]*]FY8^E'_\!?_R[EL875W/ES_>U6)*]Q,= MGS]27GWQZRROR5PCC.;AYKY\?GS=T:Q.6X(P#; KDARR1#9 YS1R$6,*EF,+ MC&("A'@$S'BKE:*>HDH+8CU5R%NC2F,H=L66LW2.37^$L+('[\6:G64+DP"C MPDAP3DE (2T5J@P"I[$AFE,N"#FXD<:_9,BKPS''DPTGIP,2+0+(GCU$L3TN[ITK^](AKL-U.; M9_QP>#H4&EZI=C\0JAPTQ=O5VX;AZXI*IXOP97H4X_));@6[R-KO"R-)D#)J MP"18$)8&"#:M/.\<<4P8(UB-G:0;7;=A>C0%5&=$6#UF>F%"7T>!YU\6$ED= M@](0(G= C16 F0S )'>26R_-H0=37M3]VW=Z_^-5\71D4F5-*M MF10*&-8>1!1)SF(:&4D5"EX.7=-L>/J;@:G[E3^9WSGN5S@&-I4IK.6>2(<2 MP;& R&T2P F20-+N%J*/T3!Q.!WX:Z1#DV!U18JG#S8N[7AT=>?-O)L9VPL6 MADH1D+# O*80O*? E3>@J'!&*8IL=(?30[Q&>C2.6%<<>0BZL.SZ/2H_=G-D M>\'":NQ)3.TI[@A$'2U0PA$089C%EB8TP^$ %=&@L*&@0CI*%?%16)^.55M#X%2OD1\-X]6?Z/%A.G$'2!^/Q0KN M::11!5 1"0B!M9=5J&*A>-XU*S-A1LJ"">$GR M$1ITPM$:FT:?L)7<(^&4DR'4L'QWKJO6(D?S6/4L>%1BR,ZRA<M=W@T"5-7A/C9D^!BXL8+OW1K+Y?S,9^7 M([N8Y_WORS0/:CJ9)X!35ZXN)O-0AMDV\C330$$$XM%@!=9Z!4G%DT"S>X,Q M+C!JE$O#>T5J3O,^'+WAW!]3]V)=P:S6B*5!*4$8(&\M&,V2Y*9C)"ZF%6AJ M;%7=W.GW,78 LIT)1=.;F^EDV>7ER\=M,M"+3XN(N+&$<2#68TAG H<@ M@P?,!#;<",SKW//VQ9?])NNEY%,?H\Y\AAY":W\T(W\Q60EMV_R#UIW03YZ&>= <5!VZD"UN%DM_^:68]BP;UEW, M^)P3ZT.87\8OYOMV-[)]:BJT4@Y3)L RQL H(2$&E11(FD#!C"7,!F^":YH^ MK4/8%:T^Y7>/D^#OPP@\&=EIB",WVB89[RY<"$(1]RJ"5TBF5144>&0L)(B) MI4E21!@?3IYN;',-DZ<5U+KBRV^CR;1<2FT[]::7GQ8TZ:'!"@HV[:Z0U%$% MAI (SG&6T2/$#UX#&H#\V@"NG1U:S]*&K3N+EA\46(9((\/ 2)3 B4/@K,&@ M:1+&4, 8BQ[?:]QULH)_]M/O"F2I]51@\%R3M#$@ 43J $0H(IB,WI,:;G8= MO3P^8'I>'I4U0>G.^CR[7L:]G5WG=?W5C'-PF:/YB2G+'*1NI_95I7R!?9 * M.0=:I(W=&T,!V:1N(.J4,D$S*0;OEE]C1G^R0[>#6=?/.G*PSM3[M.$GB:_Z M.XYUQ8J$E[-!:Y#2$_"6(*!.)]64(ZZ2'(F='/PAV1Q#&H:JPT<:YPF5)Y%' M*SWPV5:LT)08*R,#BYT"Y@(%1C4'';.E B$O8@WK7TNT$HZ!T@E+S?'-GK 9'C?9)64$$#]X9HCF:M(-8 MM^+SDV3"'Z;S3/7+>)=2V(S_5$X7MSM%TITU% Y)$T72&:Q-ZT0Q2H%@Z@!C MHX@RB-?RT.S&;:+!4ZD3;XX/H8JS]L:R1=+& M-$ZC XEP4L:$T8 5E^ DEA1Q$K!%KT/&J,61-H#J;BNYCRH[NY@\O'J>Y=#6 M(S\R9?;PF,VF;OG;)#>M#;JZ=H^I46_AA(XTR>=@M4CR&+8& O<82Z([ M)G5NK+L40VIN/MV"V-VNE(2GT7RVTRS\_,,B^[/C;/SABD5@V"?A/'LC,I*4 M_J@98;J&3M.-[V8C^TU-5+H^?1[RK"9Q>5;-4W-7T2)*$H2@29F7*HTU! LY M5@<8I[WU6&->Y[ER-_Z:#9X]#>*TFQT_AQ7.ORGNDW1]')LL-3UFZDI'X,/M MV*>,ZC3^/@L;5__AE17JB+/C4X&%/CH^.J+JY$P<4:J93!*8/.(U])=N7A?6 M8$1GJ'5G(WLREJ/G8]EJ'-M!$L^,"BBA7.F" ML8][ERXF^">S6:-8]O/,;(G&Y0,:6ZBSM5SA7:0^)GF*8,[S-;T B;D'18VV M3J=_C8-UG^N!.TV#^4B>EF)S;@R-^='DD_0ZS$?NT>^RW="<#RD)+^-S#_&. MFIU=QGP;>SZ>?NLO,NCZ:^&/H1Q-?>)KF7EU&N[^N_>-_/IJ"DL8X1SG9[.1 M@$I:X8* 6G_MR!UR'[X2"L<&%&Q MQJ/,;JX>.N-8J[AV*-S'T3P[1V\7Y5CL,J&^S13?:>_;MYFF=UO6%P M9_$BV! )4P:\(1@$E1[RS@K4)[4Z:A14&'Q F8XXTQ*>!YN2UB@/CSK)#H[L M5T%!)#W5^/2(X+,3*1@Y.2&$'C%V@LGQ^1&KD16HFTO.EAG2*IH=GC9?1SE! MQ/FT/)TN[#PNQB\S9J\_?S86*[@)6!L=0?@@ $EN@+CTA^%*>D6"-;X&=[JY M_.SN1&H2Q^[N1N\?<&47PSL]_+_>1 M(VELO2"M6WG!@\.(I=-=BAR)U/( 45D,A&K"G6*(HQI2\Y-;4GC]%.P%[L[\ M Y_LP)=QE29U,NDCBK6\#_O MYJZU(VXUC&-GOH%F-,D+XG)RY\TXNNO_SDOYK>4*F:5 P@0H1"AP9SCXD,8K MF!+<*J4UKR%TRS>U*36-Y""8@P^E#BXD=2;IIP1HW08#&(>S:%_UHXE]XU5[;/=(ZA*\<)[;8E/FR27 M)D!(9RO(;&9UCNC@3)""ULF,A=Z2V-(2H%W1Z?.U*<.Q2=#DJ!MA,MME,UQ? MH(C(ZJ1G)@$M_0!41@_,I[]JHIE17*>#MH83,WY3IN7&(#SXL'EYDY+&F%]R M98>W-/Z+)R"]/'5VERR.SR614AZSXQ-Q?,+%"<6"'K%S(<@I1F=UKCG)VSE[ M&@?R8#*D)O-H/X>O:7@3M\X)8.UW.>T"BH@XD%$:B,1$($K8NT-2:1D%KQ.3 MX>T8?AM KJOSX'@Q&TW";)9V)IM4\ S@R722@<@Q]*>360*I7$U5F>_FER:? MD^4U_<4DZ?"+[&VSHF?Q FDK+<-I0^ &)Y63!_ "6U!,Q!B9 M( K5,/K@-V>*;@/1_OAT%_KN[KW!3NMAE>(%YH@8$AP@AA/&7CO AM"<;1-+ M18,EL8Z;MGCC?&H$T9[Y](C2@8QZ44'!.4HO;< M>NZQJV5N>EL6Z[8@;)F:K;FEZ6JHPUCBNHP'NTM85G7+@"3-W M*K2F"C%>P^!(WH2-NAT<^S]\=B=IWUFV$"X:162.34\-$*-%&C?RD'9)2K73 MZ=BMD=J*O"F#=1MH]J^XKW)X9?]XUK[H C MJ](2"SG;:3J-8TYR*FI$72!ORH^Z,XA[?@ETYS17\R70FDH*%)$T"@DPQ!L0 M/L>PED:#EY1%D\&H$U*H&\-\WR^!FL&U,]]L\V-I<_TR/7()K3*DX?A%[OGF M"!&5RQ9&4J](#JON.0,>C +B0O8P',:QZ+85(TJ(DSH'-\308DPZH)0()&]D:D!-/O@T?IGGIL>>'X*:>>=Y,!7NQ*L-M9&09.LBH2S MP)#BX#.8*LD2H 57W%(F6)T0%=W$K.R!E5V#W@=YL\_APQ#R+QX#0%>DYI8: M"NR$9800H"(Z4"'IY8%@!$)2&C25F),:'E;ZK1*O64A[-([MJQE4JZ%0V3R( M9=*\J1% .4(0%:,)9^$MCE89YVJ86]';-G T!FK/MT,/3^#KW ZMJ:3 (7I- M';FP;?=\.-8-K5PS[%&Y7J^0ROI].KKZ$ M\N8TV/D2P>5Q_CFX1;F+8_M44W@=+=/- MWNL>5GOV?TIBW2JPO6B?U]-R?C^.JDKGTS)%1)YR3QCHG(C9$ZG!JF *8-E M]#;H4,=#IT_AJFG^- EB'WO2#HZ\_+3 1)/@& >69(5TH., VBH%*JDB/FKG MF:VQM_1[ =3FWG(@>-U+V/=9V9=/I5<)XBL)UNL*%DF)B 'AF 0^[H$CDX1 M;@)P'C'74B"#:R1"8F^*+HU#V9?I,]']_MGB@WJ9SM-]_&(.J[%(6ZNP(0F9 M-+_F-R()GI(8!QY[IATVG/L:%O=>+W1:/;A:A;A7XU/P^YE#?RY8&$%BY$HD ME'/@$"(#**Y]^HE[+Q5FT==X)-/K-4Z;I&H$R3ZX\SXO@LMX4@8_JBH_/RM3 M$*)XSG\$EAH%%F$'1*$ PBDEK%?8DAHO9GJ]JVF3,75![$6GKTB6C64*Q-,: MH%(!H\H"ETDRQ,X9D,P[0M/9[G0-FU"_3_!:U=9KHMB;\?K(^V6P.S-^M)<^ M38FYCQE[5UV%H I1;RT8DE819EZ %(2D1:6T(EH+4BT?S! CTK4G@+>';A\' MVL5LMLC!;R[C4J&8_3Y)DW>1?C%9RG43OSXL5O8AFSWDU?H\G[J_7M[N"@O= M:KL%M12Q[.^!#?* J%-@*,4@)0J2>!Q%;.AZY@VP>6 S\<)5N$\:*?!0BA#A- N#3$J<$F"!1LU!Y30I=AYQGT-;;2C3'8#(N]@IFD( M"^$^)>N?@[\*]R' CT-,.'P*;FQFLU$L MXSS)M3YG+N?8.^X<8G72T73T=/N54+^;^>F;\[]/RF#&H[\'_R3;02A'7TU6 MNV9'Y6B6P#Y=E'E6E@Y4-3;^PQLKJ):&26Z3"!@Y1!HL1)TOIQ/>3AODDA8Z M>+>T5\#\3J>H*_)O ;X]=:[2%'+L7- Y:0BC"IB,^;&0I4!I))8'+A"N\62F MH_?O/>AO+8';FP%H%23GB>&R[R%5A0(8!2 M%@&507DO+?:XDB;YOWIQ@[;;0^?G-6JUS[,.WD417Z1=X'%%W[1)(HSO[GN]%PG&8A+CUJG]#B4((X8R."(B*&"S!!A#A :@@A"BD MGKV%&*HXTBBWFL"HPZ="CU2N*=CN75=AJ!$V. LNZR T4@<<6PTB>*\0QL&+ M&AI:=Z&<&CH\NP"P,V)-)]/[*(YW@UJMB6T$VE2FR,$=Y3+5&28$<@N@$!LZU M)E$S9>OX[G;TDJDEMK2#WV[^O/8TK!UE1VMTUE]OTM57F:JYHRASK6P,/21F M;O 6YA!I:GO!0B;944N*(<-<\W7A4I2%,Y;I$EZ#'!"(R2E5R<1RS+C/3.$5")%6R\4ELD!MD<4 MN/ND8(0;;VB.9JL9F/Q.F\EF!$#E.%+(:H,$TJ-S8""RZ1J6'OZH98AQ%A.@0PNWL-M>SY MPY,_X^9_&:7A+F;SM!3+L^^KR_W>#0?45EBE'!(H M*6@A4. 7/> M@I'2614D#]5L'GTJ>8T0K1OP!KC#/2R9V/3NMJ[F(JG$,F+OP4EN@*$DX@0F M.$2./2,Y?%JH883J* A&UUM;0TAV+B*NI-E* N+]MP47"DGG F!'TJHBP6=/ M30\!$1T-\B+(X=OKFY:JFH"I.Z^FV?PR[DYW]NR[PE)!HJ;+++4DYXAP0#U3 MJ?[@0_J_C+1&N)..9>G#9NDG-Z-Z^'0UWZ?AM@QNM 0H_3P.*S?LHYOL,_CW M38;(?8H7P89(F#+@#<$@J/2@?=*W$P0DQJ0>JSK!:AM MLI!Y0(0)4"@!RIU)\GZ0# 13@B=Q36L^_!!;S?*D:< Z(\ATZK^-QN.E'\RS M$.07-[=F5.Y(-%"E>.&]ML2GX?*E%4]%#3)'W'2.Z.!,D*).#N=N+-D-LZ4= MV+HBS>=T6);YM78^.[?><;SXLA"(),A(&I,+ K0F'BQF%/(-'C,TB"3/#]U2 MW2P5ZB/4@==RZN)'<[7I0?JJ\3I-G!NW3#N]#&MQMWG.TN)XLI?.OF3OF4W^ MT6UU8;E]_SF,_?FTS#'(7O1I6+TY#7,S&O_\V2![^<&4Y?)127N]>[+++N^! M-J4[Z;[E^YF:3!9F_%24_.RN@U^T.645NS: Z5GUY!Z2RWA?H+\NM;T'/7%4 M[J21%<0O?5TWM/V/Z,K75"2"&\0R9&@PG& M ^8^1UA-H^516&\'[[/8!F4:@ZL[FV(,91G\>4C(;V3Y5JMBE0H*;Q$).1"O MID%"\#Y"J@N!X6F)&*:"4,U<1[TRPK0&7]<$JK)95J!1E6H*9[C#,BG'6!@$ M-H0AT# MI!%2<"(=S"%$#8YHA:C%++@:3M?=&)_:($[SN+5NDOI9A^E 8?VYT4_!32=N M&8I^:>[/2V^1"//C]\\K-#_=K<6S&,,R1OVGI]D%_U>_:GN?YUO=??:LJ8A<&KJ\MO >@0PJ=8_1G O=.X45I5;5.!E?KT+7/HX] M<^O#-)\\.7V*'=^_BEAJL?N3:V-5!?:(AICZI"WC()=Y@8+C8)!E.' MM*P1 MY>CU:G\= -DSO5Y&VZCZWNF0Z@K+D;(8$Q!*.Z ,"4"6IMT=*82-X@&)&K&0 M.\KDU2'/FD:S9ZZ=7)O)5;B8W*O!.4S8\M+FX1'IT7@\_9:OVO=GWAZ5%P81 M0GU @+4(P&E:H$AH!#%-GR?&:HQJ&+M>KYK9"[0#(>79Q+CY8DDP M6*I71ZSV\1L"AQY^-;FZ2- >2J27U12&4.D1(N P2XN)YCC#V9*#F7:*.*TI MKW'OK-\DFQH \>#3;L-8/X;2K78OR4/:H1"M':Q5?$BLK UK]V;R'::%NO46 MCBJ!]O#='Y(=87+;MK! M4D#$FZ3-&00:!PF4($HEB1+'&I;/=NWH0]C2&@!T<'1[:=G=O/[;?GS]/IC9PSB/O%^&*\A&M3@M[YC54=O+O^1P( >\$]@@4)V/)EF) M^*GFEP+2R^\*?DS.CX[E$>/D]/P4GXI3RAD]%?I<'!^=G/?HX_^TJY_RKG$9 M?Y_=O=.O&!*M8@U%$&GE"8\A+?"D?EEJ@1,9TO[@)1=*"ZEK.!9V<&-R^*Q. MNT*LJ]/UZ0A>I*.IR)07I0K#C K46B A"# D4O!*V*27<^NU2D,U@_6=;X\= M]5%J_7![MN?^9N:+,NWXX3$;Z^3J:.*?CNF [;AYTKX?&;N,N?/1_%B*LJ=; MHW_N*EIPQ3$73H'$#H/Q1D(TE$!P6INF\)T3Z. MA75#^;_!E%^^36O0:U5#H1%3T3,)F#H'7@0+7BZOR3RG44FK=3,Y-M\JJPX' M,ZYL'38+UO*!CKFR;4@5 .B5+G MT\6V9WM5JRB8,D[ZF,>N"6AE$^!IPP9+(L,B;]URL-?0@R'4@4@.BD]/@BD< MRJ=41>$(=D(O78^(!HTM@4B8 >V#-<$CPL7@WT/USZ?#D!P*GXYB4@<;(-6S M>@J%C%>(&C#<4B Y^*Y).$/"0C 6.,*^AOM!-\^?>F5673B[HE=..A7"@UY^ MB")5SG,KP;!;D=6DQ[0WAH*W*WXKQG386VB"&;ML+( MJ -)N0?$HP0A=:18>V)MC6@2W2C0@V+=X< .DFP[%.N]ZRI(1"&=A0Q83+J@ M1%I#B.F I Z9_(R3L#H9VKM1L(='N .A'2+E=BC>^U95Y#13/(>DXE%G:+*3 M,@X9&B6I2_*_-37$VFX4\,$1[D!D!\FW[3K4OE45RB@?"(Y@C'= 3=KSE=," M/&N14,LC M@-?(B]N- C\HYM6%MROZ/1_)['PQ7Y3AM]%D=+.XJ:;/5ZRA,"Y:;*T%9K@% MK!P#8R4&+X@)R 07^[S?KCB*583>^G"L*BK2]B-Q-B)*Y@5P%BDXDW,J.RLC M1H)&6D.)ZC@-:),,V)00MBU8![;@+B9)$\S[1Z5DPE7K*B(Q7.;8]40&#MYB M?)<7PS&!)*66AY>YX8>GLP^(;K60'1[CLBK8'.<>:BNH5E2Q:,%*+M)9BPW@ MD-^5&.X\HY(X-?B;\6&QK@ZV@^-=U@@;H]U#986B)%I)/6BE!!CD/7"-.*A M@N.,HG0T#%U['Q3KZD [/-(EN;PYTMU75N!(G%!9TJ"2Y4P>!'A,>B<+WAG, M:)ZDH:OPPR)=#6@'1KHOUZ$,)BN&]3GW6%<1)';6"IECT25Y%Q?BCN2$]RD/8]P!$089K&EVO$P]).I MD1FMMH(/AZWG\^+#=.(.YLUT50:=/<4;*@@GA)/ 4>-(-@C045E0#)/1)..1F&FWJ@ M8YK40JT/IKP(3E61)2]*%4(3*5PZ>*S##+AV"+R@"KB-4L4<*T!6DL%>CK=" MD+877?E3.9VMNS*N5*Z0YTP*Q)'F6&%VE*AP>LX8$N=G\ICHDU=E6*\U1]/V M4-O-\OUG_;*BI0.Q4"'3,*#H[T\>,G5&:Q" D M+UIV0$.;W02A(8;42[_?/]IWX] MZ=2'K6?\CI(%LMX&@RG8F'8+0I0'1H-)XE- #E.*C#']J4@_]7Z3,+"]0!$X MBX(S"H1[#BY8#3%*#,X(:["E4I#!2P*-SN2T)=BZ$GA_ZO"CL2-U_"1M'3_B MM/QF2K\76S;74EC'<^K( J1F##&(6D7TH..V&,C.<=U8IWV1*$#IGD703(0E"Y<*,]V)6I0H+BK%*DAD%[Y-RR5%27&E2 M9,$1K[$TR'.#&Y%+7SG)VD+S8$UFRS)X:DT8KGI_08'7%)"#L[88-_V-$@0]J%KCDZ_$S8S_/29*23O!JR=*TC.BPC[/E?\,Z?:>Q ^[G M)@KC6.!<*HB:.8C>>'!(LB0CI/V:92-&J'%CT8W@.R"6GDQO\G_O M9G7B5RE7:O)R0Z6%P%08I4C2G3@&R2@%RI6!('"4FN/@0R55N,]7'?TPL3E$ M!\2]=^66Q@J+322(,G :*3 &>T"2:+!4 M2\Q2W:1.]M%VD_$-;]=L%NG^;" YQ=9>YHY MS@F1!DDCJ>$_TVZ"O4XM&P>BU1L?]LJ/7"4/+^=6*A^3&&&, NH2DI*3O)\K M+BE6GN,:.H3NYMJL"ZHT@ET/O-E;]G\J:4:*G14B /)!Y0@P%IA4Z2=J<]#6 M'.ZPAB3?T:5J1U;V>KCURXR/Y?0VE/,?'\=F,D_'Z-G?%J/;#8:+ VLJ8@C: M.)&C"5D)1I@ PB3 TVH1R$OGK1Y\ J(FIKL2@YJ$L5]J_6DZ]=]&XW$:Q,5D M;B97(SL.JUUZ]4][DZQ"G8774B.K%2BN*3#- G@B)03$]/*5.U&##ZS<&=W: M 72PQ&N2<$52'T2@2<# -*G%3%D*.;$\H, HXHIPPVH\9^K/G0A!,^;E4Q^A("*J/C\_0R2LRUM>E M20?X];O]O+!1+#7-$W,[FIMQSC:=4Y/NOP]5J;3 U =L",I+2"3=!RW3PC,P MRG&&B0OXQN_17_6A^9(_23^'K=/PU[: M$?W.^[1%G\S].W.?MWXR69AQ+K\J_ABLJ3?'S??3R=674-ZU+.QY= M+>'9FJ&H4@6%0\SHR"A(H@7HB 0H8RQ$:I%#:4=RL4>@TID%6A$+WJ4#1V-A5& ^ M_SETV\9@:-PBZJ^1Q[L23C7<5)%DKL@EY<")]F"5E8 Y-L!T?O#DK5-V^/FH M7A>7#\3]%;)Y5RZK9ELJDBZ89I$M/;$L2)T4 <-<.OBHL5@S;0FKX>O=4:JK M5\7E V$?HO[U$(ZVO!I-/M^6P?CC]'M_.7D?OH;27(5/N1M#5--V]3E/],5D M-B\7>197A88XD"X>*![CO/5:.-%)KF%\\B:1.6T+3[Y'2+A/@[/VW-J:.R MDA[7_@%6\?0I#(E8:Q> HE2A2ULW>*84"$JMXXP@X6L8;=O53/N>X"W'RP&X M=F>Z?;HI_CXQ-PFT;',^7067W&K W5&VD%1XDM](!>$1I ,P0C *@^=:6B*$ MHM4> ??BN3,P0K6!=E9]\V)]*ZL5%J MD/EA##,RNJ@M#F*PS],&1J1FX.U:#WL_-9-[B:7"N%8C(+SP3Y1&QAY&L*W*_;L?R^R2=7T*FJA.0<2(@=L5 "LB05A ML2/>)0CD8+,!#8Q#S4$\8 WZN9YT:.J6MZ,L4<7$B3P^4PA+=7*,S\[/T,G1 M.3Y"9\?R^(2WIDTU!V&;R!T &*;!!Y??#D61](F0?7"1TZMGPM%15"TGSAM1 MUIHEV/053.?!CH<'#.CL>P?;Q^9&=L.7'TA8;/)M&):@&3,@N"0K^$@,P@SV M-O*MKX9NYW7 0L&#Y#PHRV[;$?_NGY&L>]+336O;C?WMJR$;'])LC[&WK5C! M"!/!Y62&AKDD*.?$K4EG!TH\2Z(S^4\U-Z[1E[+I2TS=$@$T_C\,J]L/1G;ES^?M# M'@HVU40AK334* _!4@_(*0Y".0?I;\QCQ6*L$_*QH]>HK5&P1YA;/_>WG"P= M7-FN:[WMD_N_%J9,XMWXQZ!>CQ[ +$Y^(,1[%'SD]\XL(/?WUH'5GEL_SJ?OKTJGF:4BFKMOK<.JW MM7^YF,_RBDL3<'F[Y&2:E+_D3K5+AFU]^C1;=-YTVR? YX6=A;\MTE9W]C6T M"^V+ECHD6A;8RA^7\?/H:C**(V>>;NP?I^.1V_S,J+/V'Z+8EZ.O2T"&TJ,S M4T[R!?;'4'Z^-F7O$[7JUKD9E7G'#K\%,UN4=[+!0/IV,4G3MPPT>C'YC^EH M,O_O]&/JXU#Z]Y_AQUVND)$9GYJYN:S4R_9UU"QTSW_\%N;74_^(X='551FN MDJ"2W^AN43\KE"YLU"(PS8!Q+Y/*XP@8DN,/6$,YURX'<^K/HK-^!'=3F]V0 M'B;M8A*GY9T6NK+W[HQW4;ON@F)M&6((8^YXM&'P2:<; MY\BT?Y2[LB =,K96:+E"BAEAE-41"%<2C)0P3X1$$[C1HZCVR-DABFO'9_$?C9SV06S>R[Z4K M#$9!?\@*N/KX0YA_"E_#9+&I9^TO[57[V];H_2<%(]QX0S5$G(AHB-3 I'&0 M6* 3,[2.MM*3T59'FT,JUP")CS-@L>SJH@>1A^Q([#)GO:!W@#V62&8GW;:6== MH93_L&86_NV?_C]02P,$% @ K85P4 A$"QT+G0 EXX' !4 !R9&YT M+3(P,3DQ,C,Q7V1E9BYX;6SLO=F6&SF2)GP_3Y%_SG5F8E_Z=,T_ M3[ZD/_VT[O3#ZL-T,OO]W^)_/J?S[(=O\\F_S4=WV7WZ)A^EB]6S[Q:+AW_[ MY9>O7[_^_.US,?TY+VY_00#@7[:]]K:(WWXJF_T4?_H)HI\P_/G;?/SC#X'# MV7SU[ H/*9O'OXX7VP[/&]-?UG_<-OUNZ*]XU19**7]9_77;=#[9U3 ,"G_Y M/V_??%Q!\M-D-E^DLU'VX__Z'S_\L$:NR*?9A^SFA_CO;Q^N7@Q2I.-9MOAY ME-__$O_\BQJ-\N5L,7^?/J:?IYF:C<,OQ3(;NV\/V6R>S0,UJT'OBNSF+S\6 MX]DB8 8E1&O$_F?E 1:/#]E??IQ/[A^F ;A?.B+79HMT,FU.]:MQ^B'^4_RY M.>TOAVF%=)//YOET,H[OL$ZG4>$^WF79XBBQ1SMV2][[M BSSUVVF(S2:6U: M=X[2.N$?%^&_<;*\OG'_M9PL'D^A=V_G[LB<7]^8='[GI_G7D]3@X #=DIO? M/Q3977A))E^R-_E\?A56K_NL-O&'A^N4E>N'K%BMA;6A_WZ$E@@.!L+[]+8" MJJ\:MO)XGXXFTZ#^:A3>@OEDQ5^8(>UD_I!OOE:;94\>J#ORY_,P!_TUFXY] M7GQ,5S/^-T@KA:XOH4_KM M.'4[FK9-PD98VU\V&Z83*#LR0D<$5WX'*W3MB,0/V2B?Q=5G-6%=WT1+<[G( MB\??/OIL'"S-Z8=@>@;-%QVB:^VK2QMT,KY+S)TB=WBQJ/5U9).KV:W>3%_4K&Q^BK/D+[ M!*^^F'Q^5-2'>[5/V-OP5A0!B>QIIS>[#6^%G\RB7V/5]B2:3QFP?78^+A_" M6''GFDZ?NV9.8N'8(-V27=E74GV$%@E^EU>8C73]'/.TP$[5[XUK_D'W)IU_"/&?"PR>+[?9Z-C;IPR2\D6ME/,I/_2'/Q=*+ MK6CLO^G^M ITP'3UAYX9EK=I<3N9?7PHLG2LP^_CZ]F;[$M8$V^CL3G)N\.F MZI,'#I#-/B^N9O-%L3H4G9TH43'=\[W[.F9G_ ME!7W;_+TN%N_Q4>V4,3HCNIJR'N_9"H'__S(M%EDQ??R0S9?3E\>YU0BM/D+G!/\V M2Y?A9<[&36C^;I#^R"Z7DUK'\^T]H16&/V2C,/XFQ"C,L^&1LW%:C(_R<;1C M2^1-8QS#^X#9XZ(/W6<7HFON#;6'*X=5A;YZ/?5)B6&%V5!^%5\X(=[=4C8 MJ;I]VBC=$WZ]7,3XV1C"?/U0!OG\(])11=<;C]P]@Q_FRV9\/!^@0W*K62U5 M^K9#Y/+S//NO95C2W)>LBBKL:=\),2>_=!7[MT3L_7U:/%[??)SDBO>Z0_8K/ZA^$$Y:+)J/VS]BV\;ML\2$+*]RR M718/C-\CL^VNG&=<02M:>C7&VLM$6HQ*/C8?G[.RS=<+K^DOX\G]+YLVOZ2O MXT/W9 2627XQFY"NJ$\K!(#6)"I\CADG^>RG<7:3+J>+FB3N':=#@O/[=#)K M3N^+85HG=S7Z3_?9_>>LJ$OKKC':)O0NC%>,EI^SG[;0U"3WP$A[B0Y*,YFM M0NW>A*^;UI&N=M)-U\_-OBVRV3CZ=+M_\DYG3I\$[)K+6GQ^Q4S,/IYX()^R MH\IU6K])-.O^\>I^6\Y]NT_3AE[AV_9)-%_/RE]5J M]A. F\SR_[GY.=E2$EC)KL+'+?[3]',V_3'.BK_\",N>FQGSI 4_5B=H3QAYBP@$8L,/JRG\WT;3?)Z- M__+CHEC9I)L?\]DB:+1;QXV&V3N[79\\]ZD$Z]NGR6=SUJF^32IJ^JU^B M/%.$5J?:%S;9# M 7:V3PBFE@J @6!(6*L4M&K#FP<$PV2G[=JI NRUFP^(OYG<\NZ0^F-IPWFT MX 4OPU:"\P@_4'F?SU9'-V]?[(AV"/Z[MHG5F&+J%?1A]L2>6NY;N(]"7EI\RK]^ED?#7;!.0=E?C!?HE'FEMHM$" ,8I0 V4 MO"*)<&WIH\N0?IOH]*8)H]'R?KF*85GE&;^HD[+.)CRN%57'2+BPBC$GB.& M"X20I;;$@ E6?U' %Z(A'2'5E[9\B'Z7638NSP6/JL;N#HE$#BGEL;>$!I;" M:HIMN1?STIO:>D N0P]:@>6XT+_WU,=?DM7Z=)=/ V+S-5\V8#F:+/:*LTJW M!'()L1&60L<#X9H0_K3!QJ;^]$^'+=0.P.GK?7Z7SZ(#(F 6AKZ]FBVR(IOO M5X,JW1()L&* .>TM<\@0(M664V,IKZT&;-AJT $X?:E!6'F*F(MAL_6_5[/O MU?E#X,?GQ=>T&!_0C!-'2C10&%N,B::6&4 9*HTB I0F>G@;AA8]B]V"U9?R MK *#GD=0'O(X5B>^:L9IZN>$):C7$'6-G4GOM2&R(56_R_X[[ M@-!T.5Z=_!3S6[ULXAX3WX M679MY5S-Y\ML7'+;Q?RZZSD)T8A"3N(K#PAA)![ME%A*KNN;!)UY+ 8_L[: M7(9%>MWKK=]LNB[@]6!&^?N=WPQ $<),]3_7?M\&K.6QB/ /6(6H!AH8X M2+2%6Z0LJ3^'\TO7W1YA/;,"KBRCUO6ORJ@)\P!H;!4"$G(@E;00E3@QX>J? M9(D_J/IU@&KM3=B[?!;K='YG]19#R^N<=\E(UH#VT6I-L59DFDEBKI'.0A0&EUQ*@+7U&--@20/"'$N>) M0/6U0+R=S/)BY*['!]OP>\^).+;B V]HUM8;$RG;/',>:=E-[=X-=-7^B0]6H0HF830'J8-8<86] MHVQ@6U^L0[I+ (>P.7NNS_-](29_7:-9<_=VRB,2ZBGE@J.P*U%6"2&9*$U* M H!ID.A\\7[E,V%<>]HJ<;F:[9E=E]FG_.,B>WAF#>Z;PNJ,E6"(N# ,>06@ M!QY0"5W)I^&4UM>EBW42]P5F7U/;OFR>@$\VN9V991',O='S"L%J-EY]FZY/ MUK?GC#J["7T^I=]VAMZMS<8#$V"_A"2> 0H9L%0Y*@3S'()RST08:7!R#"_6 M^WT1DCCW>Q'O3DRG\>;$7X/,XGWLU[-GY315$5[WV>WS_?J[;'%]$S"HH?OU M'Y9 BC!BBDM'-/:* ,:VLTW0B_I^%72QQP�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�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htm IDEA: XBRL DOCUMENT v3.20.1
INCOME TAXES (Tables)
12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
Schedule of components of income tax expense
For the years ended December 31, 2019, 2018 and 2017, we recognized income tax expense comprised of the following (in thousands):
 
 
December 31,
 
2019
 
2018
 
2017
Federal current tax
$
(161
)
 
$
(765
)
 
$
871

State current tax
7,715

 
7,263

 
4,906

Other current tax
22

 
20

 
23

Federal deferred tax
3,396

 
(2,020
)
 
21,389

State deferred tax
(4,743
)
 
(4,104
)
 
(2,879
)
 
 
 
 
 
 
Income tax expense
$
6,229

 
$
394

 
$
24,310


Schedule of reconciliation of income tax expense
A reconciliation of the statutory U.S. federal rate and effective rates is as follows:
 
Years Ended December 31,
 
2019
 
2018
 
2017
Federal tax
$
6,231

 
21.00
 %
 
$
8,256

 
21.00
 %
 
$
8,971

 
34.00
 %
State franchise tax, net of federal benefit
3,891

 
13.12
 %
 
1,332

 
3.39
 %
 
1,799

 
6.82
 %
Other Non deductible expenses
674

 
2.27
 %
 
471

 
1.20
 %
 
91

 
0.35
 %
Noncontrolling interests in partnerships
(1,824
)
 
(6.15
)%
 
(1,237
)
 
(3.15
)%
 
(687
)
 
(2.61
)%
Changes in valuation allowance
(462
)
 
(1.56
)%
 
1,760

 
4.48
 %
 
(1,045
)
 
(3.96
)%
Tax Cuts and Jobs Act

 
 %
 

 
 %
 
13,527

 
51.27
 %
Gain on change in control

 
 %
 
(8,303
)
 
(21.12
)%
 

 
 %
Deferred true-ups and other
(761
)
 
(2.56
)%
 
(4,254
)
 
(10.82
)%
 
(194
)
 
(0.74
)%
Other reconciling items
(1,520
)
 
(5.12
)%
 
2,369

 
6.02
 %
 
1,848

 
7.00
 %
 
 
 
 
 
 
 
 
 
 
 
 
Income tax expense
$
6,229

 
21.00
 %
 
$
394

 
1.00
 %
 
$
24,310

 
92.13
 %

Schedule of deferred tax assets and liabilities
Our deferred tax assets and liabilities comprise the following (in thousands):
 
December 31,
Deferred tax assets:
2019
 
2018
Net operating losses
$
34,490

 
$
46,875

Accrued expenses
4,280

 
3,421

Operating lease liability
126,546

 

Straight-Line rent adjustment

 
9,811

Unfavorable contract liability

 
1,354

Equity compensation
1,374

 
1,065

Allowance for doubtful accounts
27,220

 
14,850

Other
4,616

 
2,815

Valuation allowance
(5,348
)
 
(5,810
)
Total Deferred Tax Assets
$
193,178

 
$
74,381

Deferred tax liabilities:
 
 
 
Property and equipment
(6,450
)
 
(6,194
)
Goodwill
(24,637
)
 
(19,780
)
Intangibles
(6,669
)
 
(8,110
)
Operating lease right-of-use asset
(115,364
)
 

Non accrual experience method reserve

 
(1,446
)
Other
(5,510
)
 
(7,345
)
Total Deferred Tax Liabilities
$
(158,630
)
 
$
(42,875
)
 
 
 
 
Net Deferred Tax Asset
$
34,548

 
$
31,506


Schedule of unrecognized tax benefits
A reconciliation of the total gross amounts of unrecognized tax benefits for the years ended are as follows (in thousands):
 
December 31,
 
2019
 
2018
 
2017
Balance at beginning of year
$
4,629

 
$
3,615

 
$
3,861

Increases related to prior year tax positions
(34
)
 
896

 
1

Increases related to current year tax positions
119

 
111

 

Expiration of the statute of limitations for the assessment of taxes
(393
)
 

 

Increase (decrease) related to change in rate
(1
)
 
7

 
(247
)
Balance at end of year
$
4,320

 
$
4,629

 
$
3,615


XML 37 R39.htm IDEA: XBRL DOCUMENT v3.20.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Earnings Per Share) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Accounting Policies [Abstract]                      
Net income attributable to RadNet, Inc. common stockholders $ 10,397 $ 3,195 $ 4,899 $ (3,733) $ 29,136 $ 5,039 $ 5,406 $ (7,338) $ 14,756 $ 32,243 $ 53
BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS                      
Weighted average number of common shares outstanding during the period (in shares) 49,905 49,807 49,703 49,554 48,633 48,011 47,969 47,823 49,674,858 48,114,275 46,880,775
Basic net income per share attributable to RadNet, inc. common stockholders (in dollars per share) $ 0.21 $ 0.06 $ 0.10 $ (0.08) $ 0.60 $ 0.10 $ 0.11 $ (0.15) $ 0.30 $ 0.67 $ 0
DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS                      
Weighted average number of common shares outstanding during the period (in shares) 49,905 49,807 49,703 49,554 48,633 48,011 47,969 47,823 49,674,858 48,114,275 46,880,775
Add nonvested restricted stock subject only to service vesting (in shares)                 208,963 180,631 274,940
Add additional shares issuable upon exercise of stock options and warrants (in shares)                 360,185 384,093 246,206
Weighted average number of common shares used in calculating diluted net income per share (in shares) 50,634 50,360 50,145 49,554 49,259 48,615 48,526 47,823 50,244,006 48,678,999 47,401,921
Diluted net income per share attributable to RadNet, Inc. common stockholders (in dollars per share) $ 0.21 $ 0.06 $ 0.10 $ (0.08) $ 0.59 $ 0.10 $ 0.11 $ (0.15) $ 0.29 $ 0.66 $ 0
Stock options excluded from the computation of diluted per share amounts:                      
Weighted average shares for which the exercise price exceeds average market price of common stock (in shares)                 0 6,250 175,037
XML 38 R12.htm IDEA: XBRL DOCUMENT v3.20.1
GOODWILL AND OTHER INTANGIBLE ASSETS
12 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS
 
Goodwill is recorded as a result of business combinations. Activity in goodwill for the years ended December 31, 2018 and 2019 is provided below (in thousands):
Balance as of December 31, 2017
$256,776
 Goodwill acquired through the acquisition of Imaging Services Company of New York, LLC
2,692

 Goodwill acquired through the acquisition of certain assets of MemorialCare Medical Foundation
545

 Goodwill transferred to assets held for sale
(1,059
)
 Goodwill acquired through the acquisition of Women's Imaging Specialists in Healthcare
4268

 Goodwill acquired through the acquisition of Valley Metabolic Imaging
1,469

 Goodwill acquired through the acquisition of Sierra Imaging Associates
1,147

 Goodwill disposed through the sale of plastic surgery unit
(80
)
 Goodwill acquired through the acquisition of Washington Heights Medical Management
2,303

 Goodwill acquired through the acquisition of Medical Arts Radiological Group, P.C.
41,469

 Goodwill acquired through the acquisition of Arcadia Radiology Imaging Services, LLC
2,582

 Goodwill acquired through the acquisition of Southern California Diagnostic Imaging, Inc.
41

 Goodwill acquired through the acquisition of Orange County Diagnostics Imaging Center, Inc.
3,618

 Goodwill acquired through assuming operational control of New Jersey Imaging Network, LLC
106,122

 Goodwill impaired in the Imaging On Call reporting unit
(3,800
)
Balance as of December 31, 2018
418,093

Adjustments to our preliminary allocation of the purchase price of Medical Arts Radiological Group, P.C.
722

Goodwill acquired through the acquisition of certain assets of Dignity Health
1

Goodwill acquired through the acquisition of certain assets of West Valley Imaging Center, LLC
2,490

Goodwill disposed through sale of assets
(123
)
Goodwill acquired by Lenox Hill Radiology through the membership purchase of HVRA
3,125

Goodwill acquired through the acquisition of certain assets of Kern Radiology, Inc.
10,507

Goodwill acquired through the acquisition of certain assets of Zilkha Radiology, Inc.
2,577

Goodwill acquired through the acquisition of certain assets of Ramic Mahwah, LLC
231

Goodwill acquired through the acquisition of GSRN
2,021

Goodwill acquired through the acquisition of Nulogix
1,337

Balance as of December 31, 2019
$440,981

 
The amount of goodwill from these acquisitions that is deductible for tax purposes as of December 31, 2019 is $160.5 million.
 
Other intangible assets are primarily related to our business combinations and software development. They include the estimated fair values of such items as service agreements, customer lists, covenants not to compete, acquired technologies, and trade names.
 
Total amortization expense was $3.1 million, $2.7 million, and $2.6 million for the years ended December 31, 2019, 2018 and 2017, respectively. Intangible assets are amortized using the straight-line method over their useful life determined at acquisition. Management service agreements are amortized over 25 years using the straight line method. Software development is capitalized and amortized over the useful life of the software when placed into service. Trade names are reviewed annually for impairment.

The following table shows annual amortization expense, by asset classes that will be recorded over the next five years (in thousands): 
 
2020
 
2021
 
2022
 
2023
 
2024
 
Thereafter
 
Total
 
Weighted average amortization period remaining in years
Management Service Contracts
$
2,287

 
$
2,287

 
$
2,287

 
$
2,287

 
$
2,287

 
$
15,820

 
$
27,255

 
11.9

Covenant not to compete and other contracts
759

 
699

 
650

 
537

 
129

 
142

 
2,916

 
4.4

Developed Technology
244

 
244

 
142

 

 

 

 
630

 
2.6

Trade Names amortized
142

 
69

 
69

 
61

 
58

 
219

 
618

 
8.4

Trade Names indefinite life

 

 

 

 

 
11,270

 
11,270

 

Software in development

 

 

 

 

 
305

 
305

 

Total Annual Amortization
$
3,432

 
$
3,299

 
$
3,148

 
$
2,885

 
$
2,474

 
$
27,756

 
$
42,994

 
 

XML 39 R16.htm IDEA: XBRL DOCUMENT v3.20.1
LEASES (Notes)
12 Months Ended
Dec. 31, 2019
Leases [Abstract]  
LEASES LEASES
Adoption of Standard

In February 2016, the FASB issued a new standard related to leases to increase transparency and comparability among organizations by requiring the recognition of right-of-use (“ROU”) assets and lease liabilities on the balance sheet for all leases with terms in excess of twelve months. Sufficient disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The standard was effective for us beginning January 1, 2019. We have elected the optional transition method to apply the standard as of the effective date and therefore, we will not apply the standard to the comparative periods presented in the consolidated financial statements. We also elected the transition package of three practical expedients permitted within the standard, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs.

The adoption of the standard had a material impact on our condensed consolidated balance sheets, but did not have material impact on our condensed consolidated income statements or cash flows. Adoption of the standard resulted in the recognition of an operating lease liability of $455.5 million. Operating lease ROU assets were recorded in the amount of $419.0 million. Inclusive in the adoption was the transfer of $35.3 million in deferred rent liability and $792,000 in unfavorable rental contract liabilities to operating lease ROU assets. For finance leases, the effect of the adoption amounted to a finance lease liability of $12.1 million, which was transfered from capital lease debt and a finance right of use assets in the amount of $14.1 million which remained in property, plant and equipment.
Lease Liability

We have operating leases for medical facilities, administrative offices, warehouse space and major medical equipment. We lease the premises at which these facilities are located and do not have options to purchase the facilities we rent. Our most common initial term varies in length from 5 to 15 years. Including renewal options negotiated with the landlord, we can have a total span of 10 to 35 years at the facilities we lease. We also lease smaller satellite X-Ray locations on mutually renewable terms, usually lasting one year. Additionally, we have operating and finance leases for certain medical and office equipment, with lease terms generally lasting from 5 to 8 years. Our Incremental Borrowing Rate ("IBR") used to discount the stream of lease payments
is closely related to the interest rates charged on our collateralized debt obligations and our IBR is adjusted when those rates experience a substantial change.

The components of lease expense were as follows:
 
 
 
Twelve months ended

(In thousands)
December 31, 2019

 
 
Operating lease cost
$
95,348

 
 
Finance lease cost:
 
     Depreciation of leased equipment
$
3,135

     Interest on lease liabilities
395

Total finance lease cost
$
3,530


Supplemental cash flow information related to leases was as follows:
 
Twelve months ended

(In thousands)
December 31, 2019

 
 
Cash paid for amounts included in the measurement of lease liabilities:
 
     Operating cash flows from operating leases
$
95,922

     Operating cash flows from financing leases
395

     Financing cash flows from financing leases
5,939

Right-of-use & Equipment assets obtained in exchange for lease obligations:
 
     Operating leases(1) 
482,399

     Financing leases
14,105


(1) Amounts for the twelve months ended December 31, 2019 include the transition adjustment for the adoption of Topic 842 discussed in Note 3, Recent Account Standards, for further information.

Supplemental balance sheet information related to leases was as follows:
(In thousands, except lease term and discount rates)
 
 
December 31, 2019

 
 
Operating Leases
 
Operating lease right-of-use assets
$
445,477

Current portion of operating lease liability
61,206

Operating lease liabilities
420,922

     Total operating lease liabilities
$
482,128

 
 
Finance Leases
 
Equipment at cost
$
14,105

Accumulated depreciation
(3,135
)
Equipment, net
$
10,970

Current portion of finance lease
$
3,283

Finance lease liabilities
3,264

Total finance lease liabilities
$
6,547

 
 
Weighted Average Remaining Lease Term
 
Operating leases - years
8.8

Finance leases - years
3.3

 
 
Weighted Average Discount Rate
 
Operating leases
6.4
%
Finance leases
4.4
%




Maturities of lease liabilities were as follows:
(In thousands)
 
 
 
Operating

Financing

Year Ending December 31,
Leases

Leases

2020
$
89,881

$
3,492

2021
88,848

2,624

2022
80,932

702

2023
69,916

11

2024
54,517

10

Thereafter
262,027


Total Lease Payments
646,121

6,839

Less imputed interest
(163,993
)
(292
)
Total
$
482,128

$
6,547



As of December 31, 2019, we have additional operating leases for facilities and medical equipment that have not yet commenced of approximately $16.4 million. These operating leases will commence in 2020 with lease terms of 1 to 16 years.


As previously disclosed in our 2018 Annual Report on Form 10-K and under the previous lease accounting, maturities of operating lease liabilities were as follows as of December 31, 2018 (in thousands):
 
Facilities
 
Equipment
 
Total
2019
$
75,588

 
$
14,924

 
$
90,512

2020
66,116

 
14,385

 
80,501

2021
57,826

 
12,966

 
70,792

2022
48,542

 
10,264

 
58,806

2023
38,800

 
7,095

 
45,895

Thereafter
160,327

 
5,144

 
165,471

 
$
447,199

 
$
64,778

 
$
511,977


LEASES LEASES
Adoption of Standard

In February 2016, the FASB issued a new standard related to leases to increase transparency and comparability among organizations by requiring the recognition of right-of-use (“ROU”) assets and lease liabilities on the balance sheet for all leases with terms in excess of twelve months. Sufficient disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The standard was effective for us beginning January 1, 2019. We have elected the optional transition method to apply the standard as of the effective date and therefore, we will not apply the standard to the comparative periods presented in the consolidated financial statements. We also elected the transition package of three practical expedients permitted within the standard, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs.

The adoption of the standard had a material impact on our condensed consolidated balance sheets, but did not have material impact on our condensed consolidated income statements or cash flows. Adoption of the standard resulted in the recognition of an operating lease liability of $455.5 million. Operating lease ROU assets were recorded in the amount of $419.0 million. Inclusive in the adoption was the transfer of $35.3 million in deferred rent liability and $792,000 in unfavorable rental contract liabilities to operating lease ROU assets. For finance leases, the effect of the adoption amounted to a finance lease liability of $12.1 million, which was transfered from capital lease debt and a finance right of use assets in the amount of $14.1 million which remained in property, plant and equipment.
Lease Liability

We have operating leases for medical facilities, administrative offices, warehouse space and major medical equipment. We lease the premises at which these facilities are located and do not have options to purchase the facilities we rent. Our most common initial term varies in length from 5 to 15 years. Including renewal options negotiated with the landlord, we can have a total span of 10 to 35 years at the facilities we lease. We also lease smaller satellite X-Ray locations on mutually renewable terms, usually lasting one year. Additionally, we have operating and finance leases for certain medical and office equipment, with lease terms generally lasting from 5 to 8 years. Our Incremental Borrowing Rate ("IBR") used to discount the stream of lease payments
is closely related to the interest rates charged on our collateralized debt obligations and our IBR is adjusted when those rates experience a substantial change.

The components of lease expense were as follows:
 
 
 
Twelve months ended

(In thousands)
December 31, 2019

 
 
Operating lease cost
$
95,348

 
 
Finance lease cost:
 
     Depreciation of leased equipment
$
3,135

     Interest on lease liabilities
395

Total finance lease cost
$
3,530


Supplemental cash flow information related to leases was as follows:
 
Twelve months ended

(In thousands)
December 31, 2019

 
 
Cash paid for amounts included in the measurement of lease liabilities:
 
     Operating cash flows from operating leases
$
95,922

     Operating cash flows from financing leases
395

     Financing cash flows from financing leases
5,939

Right-of-use & Equipment assets obtained in exchange for lease obligations:
 
     Operating leases(1) 
482,399

     Financing leases
14,105


(1) Amounts for the twelve months ended December 31, 2019 include the transition adjustment for the adoption of Topic 842 discussed in Note 3, Recent Account Standards, for further information.

Supplemental balance sheet information related to leases was as follows:
(In thousands, except lease term and discount rates)
 
 
December 31, 2019

 
 
Operating Leases
 
Operating lease right-of-use assets
$
445,477

Current portion of operating lease liability
61,206

Operating lease liabilities
420,922

     Total operating lease liabilities
$
482,128

 
 
Finance Leases
 
Equipment at cost
$
14,105

Accumulated depreciation
(3,135
)
Equipment, net
$
10,970

Current portion of finance lease
$
3,283

Finance lease liabilities
3,264

Total finance lease liabilities
$
6,547

 
 
Weighted Average Remaining Lease Term
 
Operating leases - years
8.8

Finance leases - years
3.3

 
 
Weighted Average Discount Rate
 
Operating leases
6.4
%
Finance leases
4.4
%




Maturities of lease liabilities were as follows:
(In thousands)
 
 
 
Operating

Financing

Year Ending December 31,
Leases

Leases

2020
$
89,881

$
3,492

2021
88,848

2,624

2022
80,932

702

2023
69,916

11

2024
54,517

10

Thereafter
262,027


Total Lease Payments
646,121

6,839

Less imputed interest
(163,993
)
(292
)
Total
$
482,128

$
6,547



As of December 31, 2019, we have additional operating leases for facilities and medical equipment that have not yet commenced of approximately $16.4 million. These operating leases will commence in 2020 with lease terms of 1 to 16 years.


As previously disclosed in our 2018 Annual Report on Form 10-K and under the previous lease accounting, maturities of operating lease liabilities were as follows as of December 31, 2018 (in thousands):
 
Facilities
 
Equipment
 
Total
2019
$
75,588

 
$
14,924

 
$
90,512

2020
66,116

 
14,385

 
80,501

2021
57,826

 
12,966

 
70,792

2022
48,542

 
10,264

 
58,806

2023
38,800

 
7,095

 
45,895

Thereafter
160,327

 
5,144

 
165,471

 
$
447,199

 
$
64,778

 
$
511,977


XML 40 R58.htm IDEA: XBRL DOCUMENT v3.20.1
LEASES (Details - Supplemental Cash Flows)
$ in Thousands
12 Months Ended
Dec. 31, 2019
USD ($)
Cash paid for amounts included in the measurement of lease liabilities:  
Operating cash flows from operating leases $ 95,922
Operating cash flows from financing leases 395
Financing cash flows from financing leases 5,939
Right-of-use & Equipment assets obtained in exchange for lease obligations:  
Operating leases 482,399
Financing leases $ 14,105
XML 41 R50.htm IDEA: XBRL DOCUMENT v3.20.1
NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Schedule of Debt) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Debt Instrument [Line Items]    
Equipment notes payable at interest rates ranging from 4.4% to 5.6%, due through 2020, collateralized by medical equipment $ 275 $ 632
Obligations under capital leases at interest rates ranging from 3.7% to 9.3%, due through 2022, collateralized by medical and office equipment (1) 0 12,119
Total debt obligations 692,395 672,279
Less current portion (39,691) (39,267)
Long-term portion debt obligations 652,704 633,012
Promissory note    
Debt Instrument [Line Items]    
Promissory note payable to the former owner of a practice acquired at an interest rate of 1.5% due through 2019 $ 0 199
Debt instrument, interest rate 1.50%  
Debt instrument, maturity date Dec. 31, 2019  
Term Loan | First Lien Term Loans    
Debt Instrument [Line Items]    
Debt $ 649,824 587,191
Discount on First Lien Term Loans (13,579) (15,112)
Term Loan | Term Loan Agreement collateralized by NJIN's tangible and intangible assets    
Debt Instrument [Line Items]    
Debt 55,875 59,250
Line of Credit | Revolving Credit Facility    
Debt Instrument [Line Items]    
Debt $ 0 $ 28,000
Notes Payable, Other Payables    
Debt Instrument [Line Items]    
Debt instrument, maturity date Dec. 31, 2020  
Capital Lease Obligations    
Debt Instrument [Line Items]    
Debt instrument, maturity date Dec. 31, 2022  
Minimum | Notes Payable, Other Payables    
Debt Instrument [Line Items]    
Debt instrument, interest rate 4.40%  
Minimum | Capital Lease Obligations    
Debt Instrument [Line Items]    
Debt instrument, interest rate 3.70%  
Maximum | Notes Payable, Other Payables    
Debt Instrument [Line Items]    
Debt instrument, interest rate 5.60%  
Maximum | Capital Lease Obligations    
Debt Instrument [Line Items]    
Debt instrument, interest rate 9.30%  
XML 42 R54.htm IDEA: XBRL DOCUMENT v3.20.1
NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Margin Spread Based on Leverage Ratio) - Line of Credit - Revolving Credit Facility - First Lien Credit Agreement
Jul. 01, 2016
Eurodollar | 5.50x  
Line of Credit Facility [Line Items]  
Basis spread on variable rate 4.50%
Eurodollar | 4.00x but ≤ 5.50x  
Line of Credit Facility [Line Items]  
Basis spread on variable rate 3.75%
Eurodollar | 3.50x but ≤ 4.00x  
Line of Credit Facility [Line Items]  
Basis spread on variable rate 3.50%
Eurodollar | ≤ 3.50x  
Line of Credit Facility [Line Items]  
Basis spread on variable rate 3.25%
Base Rate | 5.50x  
Line of Credit Facility [Line Items]  
Basis spread on variable rate 3.50%
Base Rate | 4.00x but ≤ 5.50x  
Line of Credit Facility [Line Items]  
Basis spread on variable rate 2.75%
Base Rate | 3.50x but ≤ 4.00x  
Line of Credit Facility [Line Items]  
Basis spread on variable rate 2.50%
Base Rate | ≤ 3.50x  
Line of Credit Facility [Line Items]  
Basis spread on variable rate 2.25%
XML 43 R62.htm IDEA: XBRL DOCUMENT v3.20.1
INCOME TAXES (Details - Reconciliation of the statutory U.S. federal rate and effective rates) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Tax Disclosure [Abstract]                      
Federal tax                 $ 6,231 $ 8,256 $ 8,971
State franchise tax, net of federal benefit                 3,891 1,332 1,799
Other Non deductible expenses                 674 471 91
Noncontrolling interests in partnerships                 (1,824) (1,237) (687)
Changes in valuation allowance                 (462) 1,760 (1,045)
Tax Cuts and Jobs Act                 0 0 13,527
Gain on change in control                 0 (8,303) 0
Deferred true-ups and other                 (761) (4,254) (194)
Other reconciling items                 (1,520) 2,369 1,848
Income tax expense $ 2,673 $ 1,816 $ 2,969 $ (1,230) $ (2,441) $ 2,827 $ 2,505 $ (2,497) $ 6,229 $ 394 $ 24,310
Federal tax, percent                 21.00% 21.00% 34.00%
State franchise tax, net of federal benefit, percent                 13.12% 3.39% 6.82%
Other Non deductible expenses, percent                 2.27% 1.20% 0.35%
Noncontrolling interests in partnerships, percent                 (6.15%) (3.15%) (2.61%)
Changes in valuation allowance, percent                 (1.56%) 4.48% (3.96%)
Tax Cuts and Jobs Act, percent                 0.00% 0.00% 51.27%
Gain on change in control, percent                 0.00% (21.12%) 0.00%
Deferred true-ups and other, percent                 (2.56%) (10.82%) (0.74%)
Other reconciling items, percent                 (5.12%) 6.02% 7.00%
Income tax expense (benefit), percent                 21.00% 1.00% 92.13%
XML 44 R66.htm IDEA: XBRL DOCUMENT v3.20.1
STOCK-BASED COMPENSATION (Details - Narrative) - USD ($)
$ in Thousands
12 Months Ended 24 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Unrecognized stock-based compensation expense $ 710,861  
Unrecognized expense weighted average period 1 year 9 months 18 days  
Maximum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based payment award, award vesting period 5 years  
Share-based payment award, expiration period 10 years  
Minimum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based payment award, award vesting period 3 years  
Share-based payment award, expiration period 5 years  
Equity Option    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Options outstanding 478,951 513,282
Exercisable shares 148,456  
Options granted 89,200  
Restricted Stock    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Awards issued to date 6,118,276  
RSA's unvested 387,934  
RSA's forfeited 1,500  
Future Service    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Options granted 66,600  
Compensation expense $ 1,000  
Restated Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares authorized 14,000,000  
Stock-based compensation (in shares)   14,875,694
Options cancelled 3,281,040  
RSA's forfeited 61,703  
Shares available for future issuance, options, warrants, shares of restricted stock and other bonus awards 2,467,049  
Restated Plan | Maximum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based payment award, award vesting period 5 years  
Share-based payment award, expiration period 10 years  
Restated Plan | Minimum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based payment award, award vesting period 3 years  
Share-based payment award, expiration period 5 years  
XML 45 R3.htm IDEA: XBRL DOCUMENT v3.20.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Dec. 31, 2019
Dec. 31, 2018
Statement of Financial Position [Abstract]    
Common stock - par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock - authorized (in shares) 200,000,000 200,000,000
Common stock - issued (in shares) 50,314,328 48,977,485
Common stock - outstanding (in shares) 50,314,328 48,977,485
XML 46 R7.htm IDEA: XBRL DOCUMENT v3.20.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES      
Net income $ 23,440 $ 38,133 $ 2,075
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 80,607 72,899 66,796
Amortization of operating lease right-of-use assets 66,842    
Provision for bad debts 0 0 46,555
Equity in earnings of joint ventures, net of dividends 248 13,469 (4,864)
Amortization and write off of deferred financing costs and loan discount 4,184 3,898 3,483
Loss (gain) on sale and disposal of equipment and other 2,383 (2,054) 1,142
Gain on sale of imaging centers 0 0 (3,146)
Gain on re-measurement of pre-existing interest (768) (39,539) 0
Loss on impairment 0 3,937 0
Stock-based compensation 8,730 7,662 6,787
Other non cash item in other expenses (559) 0 0
Non cash severance 188 0 1,047
Change in value of contingent consideration (3,123) 1,749 0
Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:      
Accounts receivable (17,482) 2,145 (37,164)
Other current assets (3,557) (9,248) 1,461
Other assets (2,326) (1,687) (801)
Deferred taxes (3,888) (6,935) 19,504
Operating lease liability (66,831)    
Deferred rent 0 6,312 2,135
Deferred revenue (1,082) (208) 1,034
Accounts payable, accrued expenses and other 17,316 26,221 36,181
Net cash provided by operating activities 104,322 116,754 142,225
CASH FLOWS FROM INVESTING ACTIVITIES      
Purchase of imaging facilities (27,150) (73,192) (27,612)
Investment at cost (143) (2,200) (500)
Purchase of property and equipment (74,153) (72,180) (61,336)
Proceeds from sale of equipment 1,160 2,575 852
Proceeds from the sale of equity interests in a joint venture 132 0 0
Proceeds from sale of imaging and medical practice assets 0 0 8,429
Proceeds from sale of internal use software 0 248 492
Nulogix return of capital 792 0 0
Cash contribution from partner in JV formation 0 0 1,473
Equity contributions in existing and purchase of interest in joint ventures (103) (2,000) (1,118)
Net cash used in investing activities (99,465) (146,749) (79,320)
CASH FLOWS FROM FINANCING ACTIVITIES      
Principal payments on notes and leases payable (6,494) (6,072) (6,836)
Payments on term loan debt (40,742) (33,830) (196,666)
Proceeds from debt issuance, net of issuance costs 97,144 0 164,938
Distributions paid to noncontrolling interests (3,057) (1,427) (1,528)
Proceeds from sale of noncontrolling interest 5,275 0 7,720
Contributions from noncontrolling partners 750 2,640 125
Proceeds from revolving credit facility 261,200 204,300 200,800
Payments on revolving credit facility (289,200) (176,300) (200,800)
Purchase of noncontrolling interests 0 (200) 0
Proceeds from issuance of common stock upon exercise of options 75 20 0
Net cash provided by (used in) financing activities 24,951 (10,869) (32,247)
EFFECT OF EXCHANGE RATE CHANGES ON CASH (32) (69) 26
NET INCREASE (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS 29,776 (40,933) 30,684
CASH AND CASH EQUIVALENTS, beginning of period 10,389 51,322 20,638
CASH AND CASH EQUIVALENTS, end of period 40,165 10,389 51,322
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION      
Cash paid during the period for interest 46,254 37,016 34,197
Cash paid during the period for income taxes 5,884 4,933 4,939
Equipment acquired and leasehold improvements 51,700 47,800 18,500
Capital lease debt 51 6,700 5,500
Gain (loss) on equity method investment (134)    
Contingent consideration liability adjustment (3,123) 1,749 0
Medical Arts Radiology      
Adjustments to reconcile net income to net cash provided by operating activities:      
Change in value of contingent consideration   1,700  
Contingent consideration liability adjustment   1,700  
Business consideration liability adjustment recorded amount 2,400    
Noncontrolling Interest      
CASH FLOWS FROM OPERATING ACTIVITIES      
Net income 8,684 5,890 2,022
Special distribution from noncontrolling interest 9,200    
Radnet, Inc. Stockholders' Equity      
CASH FLOWS FROM OPERATING ACTIVITIES      
Net income 14,756 $ 32,243 $ 53
Special distribution from noncontrolling interest $ 3,000    
XML 47 R45.htm IDEA: XBRL DOCUMENT v3.20.1
GOODWILL AND OTHER INTANGIBLE ASSETS (Details - Narrative) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]      
Goodwill deductible for tax purposes $ 160.5    
Amortization expense $ 3.1 $ 2.7 $ 2.6
Amortization period 25 years    
XML 48 R41.htm IDEA: XBRL DOCUMENT v3.20.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Key Financial Data on Joint Ventures) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Balance Sheet Data:      
Current assets $ 27,427 $ 28,317  
Noncurrent assets 61,037 45,912  
Current liabilities (9,217) (4,300)  
Noncurrent liabilities (18,872) (4,898)  
Total net assets 60,375 65,031  
Book value of RadNet joint venture interests 28,001 30,030  
Cost in excess of book value of acquired joint venture interests accounted for as equity method goodwill 6,469 7,943  
Total value of RadNet joint venture interests 34,470 37,973 $ 52,435
Total book value of other joint venture partner interests 32,374 35,001  
Net revenue 108,051 155,820 188,849
Net Income From Joint Ventures $ 18,624 $ 24,596 $ 28,644
XML 49 R49.htm IDEA: XBRL DOCUMENT v3.20.1
ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Payables and Accruals [Abstract]    
Accounts payable $ 64,300 $ 68,040
Accrued expenses 83,853 60,958
Accrued salary and benefits 42,003 37,167
Accrued professional fees 17,429 14,863
Total $ 207,585 $ 181,028
XML 50 R28.htm IDEA: XBRL DOCUMENT v3.20.1
ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)
12 Months Ended
Dec. 31, 2019
Payables and Accruals [Abstract]  
Schedule of accounts payable and accrued expenses
Accounts payable and accrued expenses were comprised of the following (in thousands):
 
 
December 31,
 
2019
 
2018
Accounts payable
$
64,300

 
$
68,040

Accrued expenses
83,853

 
60,958

Accrued salary and benefits
42,003

 
37,167

Accrued professional fees
17,429

 
14,863

Total
$
207,585

 
$
181,028


XML 51 R20.htm IDEA: XBRL DOCUMENT v3.20.1
RELATED PARTY TRANSACTIONS
12 Months Ended
Dec. 31, 2019
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS
As stated in Note 2, Summary of Significant Accounting Policies, we have an equity investment in WhiteRabbit.ai Inc.. In addition to our equity investment, we have a loan of $2.5 million to the company outstanding at December 31, 2019.
XML 52 R24.htm IDEA: XBRL DOCUMENT v3.20.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Schedule of service fee revenue

Our total net revenues for the years ended December 31, 2019, 2018, and 2017 are presented in the table below (in thousands):
 
 
2019
 
2018
 
2017
Commercial insurance
$
642,341

 
$
542,011

 
$
534,224

Medicare
237,427

 
192,881

 
179,678

Medicaid
28,283

 
25,615

 
24,133

Workers' compensation/personal injury
42,792

 
34,193

 
32,969

Other patient revenue
23,862

 
25,117

 
29,882

Management fee revenue
11,659

 
13,882

 
13,127

Imaging on call and software
17,317

 
16,261

 
18,116

Other
24,555

 
18,781

 
25,049

Service fee revenue, net of contractual allowances and discounts
1,028,236

 
868,741

 
857,178

Provision for bad debts

 

 
(46,555
)
Net service fee revenue
1,028,236

 
868,741

 
810,623

Revenue under capitation arrangements
125,943

 
106,405

 
111,563

Total net revenue
$
1,154,179

 
$
975,146

 
$
922,186


Schedule of effect of derivative instruments on comprehensive income
For the twelve months ended December 31, 2019
 
 
 
Effective Interest Rate Swap
Amount of Loss Recognized on Derivative, net of taxes
Location of Loss Recognized
in Income on Derivative
Interest rate contracts
$(5,870)
Other Comprehensive Loss

A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive income (loss), net of taxes is as follows (amounts in thousands):

 
Interest Rate Contracts
 
 
 
 
For the twelve months ended
Amount of (Loss) Gain Recognized on Derivative, net of taxes
Location of Loss Recognized
in Income on Derivative
December 31, 2019
$(4,383)
Other Comprehensive Loss
December 31, 2018
2,876
Other Comprehensive Income
December 31, 2017
(880)
Other Comprehensive Loss
Schedule of fair value of assets and liabilities
The table below summarizes the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets in our consolidated balance sheets, as follows (in thousands):

 
As of December 31, 2019
 
Level 1
 
Level 2
 
Level 3
 
Total
Current and long term liabilities
 

 
 

 
 

 
 

2016 CAPS - Interest Rate Contracts
$

 
$
1,081

 
$

 
$
1,081

2019 SWAPS - Interest Rate Contracts
$

 
$
9,477

 
$

 
$
9,477

 
 
As of December 31, 2018
 
Level 1
 
Level 2
 
Level 3
 
Total
Current assets
 

 
 

 
 

 
 

2016 CAPS - Interest Rate Contracts
$

 
$
3,316

 
$

 
$
3,316


The table below summarizes the estimated fair value and carrying amount of our SunTrust (Term Loan Agreement) and Barclays (First Lien Term Loans) long-term debt as follows (in thousands):
 
 
As of December 31, 2019
 
Level 1
 
Level 2
 
Level 3
 
Total Fair Value
 
Total Face Value
Term Loan Agreement and First Lien Term Loans
$

 
$
708,948

 
$

 
$
708,948

 
$
705,699

 
 
As of December 31, 2018
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Total Face Value
Term Loan Agreement and First Lien Term Loans
$

 
$
633,229

 
$

 
$
633,229

 
$
646,441


Schedule of earnings per share Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):
 
 
Years Ended December 31,
 
2019
 
2018
 
2017
Net income attributable to RadNet, Inc. common stockholders
$
14,756

 
$
32,243

 
$
53

 
 
 
 
 
 
BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
 
 
 
 
 
Weighted average number of common shares outstanding during the period
49,674,858

 
48,114,275

 
46,880,775

Basic net income per share attributable to RadNet, Inc. common stockholders
$
0.30

 
$
0.67

 
$

DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
 
 
 
 
 
Weighted average number of common shares outstanding during the period
49,674,858

 
48,114,275

 
46,880,775

Add nonvested restricted stock subject only to service vesting
208,963

 
180,631

 
274,940

Add additional shares issuable upon exercise of stock options and warrants
360,185

 
384,093

 
246,206

Weighted average number of common shares used in calculating diluted net income per share
50,244,006

 
48,678,999

 
47,401,921

Diluted net income per share attributable to RadNet, Inc. common stockholders
$
0.29

 
$
0.66

 
$

 
 
 
 
 
 
Stock options excluded from the computation of diluted per share amounts:
 
 
 
 
 
Weighted average shares for which the exercise price exceeds average market price of common stock

 
6,250

 
175,037


Schedule of investment in joint ventures
The following table is a summary of our investment in joint ventures during the years ended December 31, 2019 and December 31, 2018 (in thousands):
 
Balance as of December 31, 2017
$
52,435

Equity contributions in existing and purchase of interest in joint ventures
2,000

Equity in earnings in these joint ventures
11,377

Disposition of equity method interest upon acquisition of control in NJIN
(2,993
)
Distribution of earnings
(24,846
)
Balance as of December 31, 2018
$
37,973

Equity contributions in existing and purchase of interest in joint ventures
103

Equity in earnings in these joint ventures
8,350

Sale of ownership interest
(134
)
Dissolution of GSRN
(1,428
)
Nulogix return of capital
(792
)
Nulogix change in control
(1,004
)
Distribution of earnings
(8,598
)
Balance as of December 31, 2019
$
34,470


Joint venture investment and financial information
The following table is a summary of key unaudited financial data for these joint ventures as of December 31, 2019 and 2018, respectively, and for the years ended December 31, 2019, 2018 and 2017, respectively, (in thousands):

 
December 31,
Balance Sheet Data:
2019
 
2018
Current assets
$
27,427

 
$
28,317

Noncurrent assets
61,037

 
45,912

Current liabilities
(9,217
)
 
(4,300
)
Noncurrent liabilities
(18,872
)
 
(4,898
)
Total net assets
$
60,375

 
$
65,031

Book value of RadNet joint venture interests
$
28,001

 
$
30,030

Cost in excess of book value of acquired joint venture interests accounted for as equity method goodwill
6,469

 
7,943

Total value of RadNet joint venture interests
$
34,470

 
$
37,973

Total book value of other joint venture partner interests
$
32,374

 
$
35,001

  
 
2019
 
2018
 
2017
Net revenue
$
108,051

 
$
155,820

 
$
188,849

Net income
$
18,624

 
$
24,596

 
$
28,644


XML 54 R10.htm IDEA: XBRL DOCUMENT v3.20.1
RECENT ACCOUNTING STANDARDS
12 Months Ended
Dec. 31, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]  
RECENT ACCOUNTING STANDARDS RECENT ACCOUNTING STANDARDS
 
Accounting standards adopted

In February 2016, the FASB issued Accounting Standard Update ("ASU") No. 2016-02, Leases (Topic 842) (ASU 2016-02), which amends the existing accounting standards for leases. In September 2017, the FASB issued ASU No. 2017-13 which provides additional clarification and implementation guidance on the previously issued ASU No. 2016-02. Subsequently, in July 2018, the FASB issued ASU No 2018-10, Codification Improvements to Topic 842, Leases, and ASU No. 2018-11, Targeted Improvement, to clarify and amend the guidance in ASU No. 2016-02. The amendments in this update were effective for fiscal years (and interim reporting periods within fiscal years) beginning after December 15, 2018, with early adoption permitted for all entities. Under the new guidance, a lessee is required to recognize a lease liability and right-of-use asset for all leases with terms in excess of twelve months. The new guidance also requires additional disclosures to enable users of financial statements to understand the amount, timing, and potential uncertainty of cash flows arising from leases. Consistent with current guidance, a
lessee’s recognition, measurement, and presentation of expenses and cash flows arising from a lease will continue to depend primarily on its classification. We have elected the optional transition method to apply the standard as of the effective date and therefore, we will not apply the standard to the comparative periods presented in the consolidated financial statements. We elected the transition package of three practical expedients permitted within the standard, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs. See Note 9, Leases, for more information.
In February 2018, the FASB issued ASU No. 2018-02 (“ASU 2018-02”), Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. ASU 2018-02 allows for the reclassification of certain income tax effects related to the Tax Cuts and Jobs Act between “Accumulated other comprehensive income” and “Retained earnings.” This ASU relates to the requirement that adjustments to deferred tax liabilities and assets related to a change in tax laws or rates to be included in “Income from continuing operations”, even in situations where the related items were originally recognized in “Other comprehensive income” (rather than in “Income from continuing operations”). Subsequently, in March 2018, the FASB issued ASU No. 2018-05, Income Taxes, to clarify and amend guidance in ASU 2018-02. ASU 2018-02 and ASU 2018-05 are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. Adoption of this ASU is to be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the tax laws or rates were recognized. The adoption had no significant impact on the our results of operations, financial position and cash flows.

In April 2019, the FASB issued ASU 2019-04, ("ASU 2019-04"), Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, which, among other things, clarifies certain hedge accounting guidance. For the year ended 2017, we elected to early adopt ASU 2017-12, Targeted Improvements to Accounting for Hedging Activities, (Topic 815), for which this current ASU 2019-04 amends. For those entities that have already adopted ASU 2017-12, the hedging amendments in ASU 2019-04 are effective as of the beginning of the first annual reporting period beginning after 25 April 2019 and early adoption is permitted. We elected early adoption of ASU 2019-04 and the adoption had no effect on our financial statements.

Accounting standards not yet adopted
 
In June 2016, the FASB issued ASU No. 2016-13 ("ASU 2016-13), Financial Instruments - Credit Losses. ASU 2016-13 replaces the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The standard will be effective for us beginning after December 15, 2019, with early adoption permitted. We are currently evaluating the impact of this standard on our consolidated financial statements, including accounting policies, processes, and systems.

In August 2018, the FASB issued ASU No. 2018-15 (“ASU 2018-15”), Intangibles-Goodwill and Other-Internal-Use Software. ASU 2018-15 aligns the requirements for deferring implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This ASU is effective in the first quarter of 2020 with early adoption permitted and can be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We are currently assessing the impact of the adoption of this ASU on our results of operations, financial position and cash flows.

In December 2019, the FASB issued ASU 2019-12 ("ASU 2019-12"), Income Taxes (Topic 740). ASU 2019-12 removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other areas of the standard. ASU 2019-12 will be effective beginning in the first quarter of 2021. Early adoption is permitted. Certain amendments in this update must be applied on a prospective basis, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings/(deficit) in the period of adoption. We are currently evaluating the impact this ASU will have on our financial statements and related disclosures as well as the timing of adoption.

In January 2020, the FASB issued ASU 2020-01 ("ASU 2020-01"), Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815), clarifying the interaction between accounting standards related to equity securities, equity method investments, and certain derivatives. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020. We do not expect the adoption of this guidance will have a material impact on its consolidated financial statements.
XML 55 R14.htm IDEA: XBRL DOCUMENT v3.20.1
ACCOUNTS PAYABLE AND ACCRUED EXPENSES
12 Months Ended
Dec. 31, 2019
Payables and Accruals [Abstract]  
ACCOUNTS PAYABLE AND ACCRUED EXPENSES ACCOUNTS PAYABLE AND ACCRUED EXPENSES
 
Accounts payable and accrued expenses were comprised of the following (in thousands):
 
 
December 31,
 
2019
 
2018
Accounts payable
$
64,300

 
$
68,040

Accrued expenses
83,853

 
60,958

Accrued salary and benefits
42,003

 
37,167

Accrued professional fees
17,429

 
14,863

Total
$
207,585

 
$
181,028


XML 56 R18.htm IDEA: XBRL DOCUMENT v3.20.1
STOCK-BASED COMPENSATION
12 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
 
Stock Incentive Plans
 
Options
 
We have one long-term equity incentive plan which we refer to as the 2006 Equity Incentive Plan, which we first amended and restated as of April 20, 2015 and again on March 9, 2017 (“the Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. We have reserved for issuance under the 2017 Restated Plan 14,000,000 shares of common stock. We can issue options, stock awards, stock appreciation rights, stock units and cash awards under the 2017 Restated Plan. Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options generally vest over three to five years and expire five to ten years from the date of grant.
  
As of December 31, 2019, we had outstanding options to acquire 478,951 shares of our common stock, of which options to acquire 148,456 shares were exercisable. The following summarizes all of our option transactions for the twelve months ended December 31, 2019:
Outstanding Options
Under the 2006 Plan
 
Shares
 
Weighted Average
Exercise price
Per Common Share
 
Weighted Average
Remaining
Contractual
Life(in years)
 
Aggregate
Intrinsic
Value
Balance, December 31, 2018
 
513,282

 
$
7.44

 
 
 
 
Granted
 
89,200

 
10.93

 
 
 
 
Exercised
 
(12,500
)
 
6.00

 
 
 
 
Canceled, forfeited or expired
 
(111,031
)
 
0.79

 
 
 
 
Balance, December 31, 2019
 
478,951

 
8.21

 
7.33
 
$
5,790,763

Exercisable at December 31, 2019
 
148,456

 
7.29

 
6.42
 
1,931,633


 
Aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between our closing stock price on December 31, 2019 and the exercise price, multiplied by the number of in-the-money options as applicable) that would have been received by the holder had all holders exercised their options on December 31, 2019. As of December 31, 2019, total unrecognized stock-based compensation expense related to non-vested employee awards was $710,861 which is expected to be recognized over a weighted average period of approximately 1.8 years.
  
Restricted Stock Awards (“RSA’s”)
 
The Restated Plan permits the award of restricted stock awards (“RSA’s”). As of December 31, 2019, we have issued a total of 6,118,276 RSA’s of which 387,934 were unvested at December 31, 2019 . The following summarizes all unvested RSA’s activities during the twelve months ended December 31, 2019:
 
 
RSA's
 
Weighted-Average
Remaining
Contractual
Term (Years)
 
Weighted-Average
Fair Value
RSA's unvested at December 31, 2018
277,504

 
 
 
$
9.77

Changes during the period
 
 
 
 
 
Granted
636,656

 
 
 
$
11.78

Vested
(524,726
)
 
 
 
$
11.03

Forfeited
(1,500
)
 
 
 
$
12.76

RSA's unvested at December 31, 2019
387,934

 
1.13
 
$
11.61


 
We determine the fair value of all RSA’s based of the closing price of our common stock on award date.
   
Other stock bonus awards
 
The Restated Plan also permits the award of stock bonuses not subject to any future service period. These awards are valued and expensed based on the closing price of our common stock on the date of award. During the twelve months ended December 31, 2019 we issued 66,600 shares relating to these awards, amounting to $1.0 million of compensation expense.
 
Plan summary
 
In summary, of the 14,000,000 shares of common stock reserved for issuance under the Restated Plan, at December 31, 2019, we had issued 14,875,694 total shares between options, RSA’s and other stock awards. With options cancelled and RSA’s forfeited amounting to 3,281,040 and 61,703 shares, respectively, there remain 2,467,049 shares available under the Restated Plan for future issuance.
XML 57 R37.htm IDEA: XBRL DOCUMENT v3.20.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Derivatives) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Offsetting Assets [Line Items]      
Change in fair value of cash flow hedge, net of taxes $ (10,253)    
Change in fair value of cash flow hedge, net of taxes 10,253 $ (2,876) $ 880
Interest Rate Cap      
Offsetting Assets [Line Items]      
Change in fair value of cash flow hedge, net of taxes (4,383)    
Change in fair value of cash flow hedge, net of taxes   $ 2,876 $ (880)
Interest Rate Swap      
Offsetting Assets [Line Items]      
Change in fair value of cash flow hedge, net of taxes $ (5,870)    
XML 58 R33.htm IDEA: XBRL DOCUMENT v3.20.1
QUARTERLY RESULTS OF OPERATIONS (Tables)
12 Months Ended
Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]  
Schedule of quarterly financial information The operating results in any quarter are not necessarily indicative of the results that may be expected for any future period (in thousands except per share data).
 
 
2019 Quarter Ended
 
2018 Quarter Ended
 
Mar 31
 
June 30
 
Sept 30
 
Dec 31
 
Mar 31
 
June 30
 
Sept 30
 
Dec 31
Statement of Operations Data:
 

 
 

 
 

 
 

 
 

 
 

 
 

 
 

Net  revenue
$
271,549

 
$
289,097

 
$
292,692

 
$
300,840

 
$
231,392

 
$
244,395

 
$
242,148

 
$
257,211

Total operating expenses
264,279

 
267,113

 
275,842

 
277,571

 
232,280

 
228,525

 
225,700

 
257,755

Total other expenses
12,295

 
13,668

 
11,897

 
10,194

 
10,040

 
10,646

 
10,670

 
(27,620
)
Equity in earnings of joint ventures
(1,873
)
 
(2,244
)
 
(1,955
)
 
(2,278
)
 
(2,977
)
 
(3,748
)
 
(2,822
)
 
(1,830
)
Benefit from (provision for) income taxes
1,230

 
(2,969
)
 
(1,816
)
 
(2,673
)
 
2,497

 
(2,505
)
 
(2,827
)
 
2,441

Net (loss) income
(1,922
)
 
7,591

 
5,092

 
12,680

 
(5,454
)
 
6,467

 
5,773

 
31,347

Net income (loss) attributable to noncontrolling interests
1,811

 
2,692

 
1,897

 
2,283

 
1,884

 
1,061

 
734

 
2,211

Net (loss) income attributable to Radnet, Inc. common stockholders
$
(3,733
)
 
$
4,899

 
$
3,195

 
$
10,397

 
$
(7,338
)
 
$
5,406

 
$
5,039

 
$
29,136

Basic net (loss) income attributable to Radnet, Inc. common stockholders (loss) earnings per share:
$
(0.08
)
 
$
0.10

 
$
0.06

 
$
0.21

 
$
(0.15
)
 
$
0.11

 
$
0.10

 
$
0.60

Diluted net (loss) income attributable to Radnet, Inc. common stockholders (loss) earnings per share:
$
(0.08
)
 
$
0.10

 
$
0.06

 
$
0.21

 
$
(0.15
)
 
$
0.11

 
$
0.10

 
$
0.59

Weighted average shares outstanding
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic
49,554

 
49,703

 
49,807

 
49,905

 
47,823

 
47,969

 
48,011

 
48,633

   Diluted
49,554

 
50,145

 
50,360

 
50,634

 
47,823

 
48,526

 
48,615

 
49,259


XML 59 R52.htm IDEA: XBRL DOCUMENT v3.20.1
NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Narrative) - USD ($)
12 Months Ended
Apr. 18, 2019
Aug. 31, 2018
Jul. 01, 2016
Dec. 31, 2019
Dec. 31, 2018
Aug. 22, 2017
Debt Instrument [Line Items]            
Deferred financing costs, net of accumulated amortization       $ 1,600,000 $ 1,400,000  
Restated Agreement            
Debt Instrument [Line Items]            
Credit facilities, increase (decrease)   $ 90,000,000.0        
Barclays            
Debt Instrument [Line Items]            
Net of accumulated amortization       1,600,000    
Term Loan            
Debt Instrument [Line Items]            
Total carrying value       692,120,000    
Debt, unamortized discount       13,579,000    
Face value       705,699,000    
Term Loan | First Lien Term Loans            
Debt Instrument [Line Items]            
Total carrying value       636,245,000    
Debt, unamortized discount       13,579,000    
Face value       649,824,000    
Term Loan | First Lien Term Loans | Maximum            
Debt Instrument [Line Items]            
Face value       100,000,000.0    
Term Loan | Restated Agreement            
Debt Instrument [Line Items]            
Credit facilities available   60,000,000.0        
Total carrying value       55,875,000    
Debt, unamortized discount       0    
Face value       55,875,000    
Term Loan | Barclays | First Lien Term Loans            
Debt Instrument [Line Items]            
Periodic payment, principal       9,700,000    
Term Loan | SunTrust            
Debt Instrument [Line Items]            
Debt periodic payment         $ 750,000  
Debt periodic payment, percent of total amount         5.00%  
Debt periodic payment, amortization increase         $ 375,000  
Medium-term Notes | Amendment No. 6 First Lien Credit Agreement            
Debt Instrument [Line Items]            
Total credit facilities outstanding           $ 100,000,000.0
Amendment No. 7 First Lien Credit Agreement            
Debt Instrument [Line Items]            
Issuance costs $ 4,400,000          
Debt instrument, unamortized discount, current 2,100,000          
Deferred financing costs, net of accumulated amortization 683,000          
Amortization of deferred charges 1,600,000          
Revolving Credit Facility            
Debt Instrument [Line Items]            
Letters of credit outstanding, amount       $ 5,900,000    
Effective interest rate       7.25%    
Revolving Credit Facility | Barclays            
Debt Instrument [Line Items]            
Credit facility, borrowings available       $ 131,700,000    
Revolving Credit Facility | Line of Credit | First Lien Credit Agreement | Eurodollar | 3.50x but ≤ 4.00x            
Debt Instrument [Line Items]            
Basis spread on variable rate     3.50%      
Revolving Credit Facility | Line of Credit | First Lien Credit Agreement | Base Rate | 3.50x but ≤ 4.00x            
Debt Instrument [Line Items]            
Basis spread on variable rate     2.50%      
Revolving Credit Facility | Line of Credit | Amendment No. 6 First Lien Credit Agreement            
Debt Instrument [Line Items]            
Line of credit facility, increase borrowing capacity $ 20,000,000.0          
Revolving Credit Facility | Line of Credit | Amendment No. 6 First Lien Credit Agreement | Eurodollar            
Debt Instrument [Line Items]            
Effective interest rate       2.01%    
Revolving Credit Facility | Line of Credit | Amendment No. 6 First Lien Credit Agreement | Eurodollar | 3.50x but ≤ 4.00x            
Debt Instrument [Line Items]            
Basis spread on variable rate       3.50%    
Revolving Credit Facility | Line of Credit | Amendment No. 6 First Lien Credit Agreement | Base Rate            
Debt Instrument [Line Items]            
Effective interest rate       4.75%    
Revolving Credit Facility | Line of Credit | Amendment No. 6 First Lien Credit Agreement | Base Rate | 3.50x but ≤ 4.00x            
Debt Instrument [Line Items]            
Basis spread on variable rate       2.50%    
Revolving Credit Facility | Line of Credit | Barclays | First Lien Credit Agreement            
Debt Instrument [Line Items]            
Credit facilities available       $ 137,500,000    
Total credit facilities outstanding       0    
Revolving Credit Facility | Line of Credit | SunTrust            
Debt Instrument [Line Items]            
Credit facilities available       30,000,000.0    
Revolving Credit Facility | Line of Credit | SunTrust | First Lien Credit Agreement            
Debt Instrument [Line Items]            
Total credit facilities outstanding       $ 0    
Revolving Credit Facility | Line of Credit | SunTrust | Restated Agreement            
Debt Instrument [Line Items]            
Credit facilities available   $ 30,000,000.0        
Revolving Credit Facility | Letter of Credit | Barclays            
Debt Instrument [Line Items]            
Commitment fee percentage       0.25%    
Unused capacity, commitment fee percentage       0.50%    
XML 60 R56.htm IDEA: XBRL DOCUMENT v3.20.1
LEASES (Details - Additional Information) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Jan. 01, 2019
Lessee, Lease, Description [Line Items]    
Total $ 482,128  
Operating lease right-of-use assets 445,477  
Finance lease, liability 6,547  
Equipment, net 10,970  
Operating lease not yet commenced $ 16,400  
Minimum    
Lessee, Lease, Description [Line Items]    
Operating lease, term of contract 5 years  
Operating lease, renewal term 10 years  
Lease term of contract 5 years  
Operating lease, lease not yet commenced, term of contract 1 year  
Maximum    
Lessee, Lease, Description [Line Items]    
Operating lease, term of contract 15 years  
Operating lease, renewal term 35 years  
Lease term of contract 8 years  
Operating lease, lease not yet commenced, term of contract 16 years  
Accounting Standards Update 2016-02    
Lessee, Lease, Description [Line Items]    
Total   $ 455,500
Operating lease right-of-use assets   419,000
Deferred rent   35,300
Contract liabilities   792
Finance lease, liability   12,100
Equipment, net   $ 14,100
XML 61 R71.htm IDEA: XBRL DOCUMENT v3.20.1
SUBSEQUENT EVENTS (Details Narrative)
shares in Millions
Apr. 01, 2020
shares
DeepHealth, Inc. | Subsequent Event  
Subsequent Event [Line Items]  
RadNet stock issued in acquisition (shares) 1.0
XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 401 611 1 false 158 0 false 6 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.radnet.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001000 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.radnet.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.radnet.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.radnet.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1003000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME Sheet http://www.radnet.com/role/ConsolidatedStatementsOfComprehensiveLossIncome CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME Statements 5 false false R6.htm 1004000 - Statement - CONSOLIDATED STATEMENT OF EQUITY Sheet http://www.radnet.com/role/ConsolidatedStatementOfEquity CONSOLIDATED STATEMENT OF EQUITY Statements 6 false false R7.htm 1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 2101100 - Disclosure - NATURE OF BUSINESS Sheet http://www.radnet.com/role/NatureOfBusiness NATURE OF BUSINESS Notes 8 false false R9.htm 2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.radnet.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 2103100 - Disclosure - RECENT ACCOUNTING STANDARDS Sheet http://www.radnet.com/role/RecentAccountingStandards RECENT ACCOUNTING STANDARDS Notes 10 false false R11.htm 2105100 - Disclosure - FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS Sheet http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositions FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS Notes 11 false false R12.htm 2107100 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Sheet http://www.radnet.com/role/GoodwillAndOtherIntangibleAssets GOODWILL AND OTHER INTANGIBLE ASSETS Notes 12 false false R13.htm 2108100 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://www.radnet.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 13 false false R14.htm 2109100 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES Sheet http://www.radnet.com/role/AccountsPayableAndAccruedExpenses ACCOUNTS PAYABLE AND ACCRUED EXPENSES Notes 14 false false R15.htm 2110100 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES Notes http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeases NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES Notes 15 false false R16.htm 2111100 - Disclosure - LEASES (Notes) Notes http://www.radnet.com/role/LeasesNotes LEASES (Notes) Notes 16 false false R17.htm 2113100 - Disclosure - INCOME TAXES Sheet http://www.radnet.com/role/IncomeTaxes INCOME TAXES Notes 17 false false R18.htm 2114100 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.radnet.com/role/StockBasedCompensation STOCK-BASED COMPENSATION Notes 18 false false R19.htm 2116100 - Disclosure - QUARTERLY RESULTS OF OPERATIONS (unaudited) Sheet http://www.radnet.com/role/QuarterlyResultsOfOperationsUnaudited QUARTERLY RESULTS OF OPERATIONS (unaudited) Notes 19 false false R20.htm 2117100 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.radnet.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 20 false false R21.htm 2118100 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.radnet.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 21 false false R22.htm 2119100 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS Sheet http://www.radnet.com/role/ScheduleIiValuationAndQualifyingAccounts SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS Notes 22 false false R23.htm 2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 23 false false R24.htm 2302302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.radnet.com/role/SummaryOfSignificantAccountingPolicies 24 false false R25.htm 2305301 - Disclosure - FACILITY ACQUISITIONS AND DISPOSITIONS (Tables) Sheet http://www.radnet.com/role/FacilityAcquisitionsAndDispositionsTables FACILITY ACQUISITIONS AND DISPOSITIONS (Tables) Tables 25 false false R26.htm 2307301 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Sheet http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsTables GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Tables http://www.radnet.com/role/GoodwillAndOtherIntangibleAssets 26 false false R27.htm 2308301 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://www.radnet.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://www.radnet.com/role/PropertyAndEquipment 27 false false R28.htm 2309301 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Sheet http://www.radnet.com/role/AccountsPayableAndAccruedExpensesTables ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Tables http://www.radnet.com/role/AccountsPayableAndAccruedExpenses 28 false false R29.htm 2310301 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Tables) Notes http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesTables NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Tables) Tables http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeases 29 false false R30.htm 2311301 - Disclosure - LEASES (Tables) Sheet http://www.radnet.com/role/LeasesTables LEASES (Tables) Tables http://www.radnet.com/role/LeasesNotes 30 false false R31.htm 2313301 - Disclosure - INCOME TAXES (Tables) Sheet http://www.radnet.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://www.radnet.com/role/IncomeTaxes 31 false false R32.htm 2314301 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.radnet.com/role/StockBasedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://www.radnet.com/role/StockBasedCompensation 32 false false R33.htm 2316301 - Disclosure - QUARTERLY RESULTS OF OPERATIONS (Tables) Sheet http://www.radnet.com/role/QuarterlyResultsOfOperationsTables QUARTERLY RESULTS OF OPERATIONS (Tables) Tables http://www.radnet.com/role/QuarterlyResultsOfOperationsUnaudited 33 false false R34.htm 2401401 - Disclosure - NATURE OF BUSINESS (Details Narrative) Sheet http://www.radnet.com/role/NatureOfBusinessDetailsNarrative NATURE OF BUSINESS (Details Narrative) Details http://www.radnet.com/role/NatureOfBusiness 34 false false R35.htm 2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Summary of net revenue) Sheet http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummaryOfNetRevenue SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Summary of net revenue) Details http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesTables 35 false false R36.htm 2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Narrative) Sheet http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Narrative) Details http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesTables 36 false false R37.htm 2402405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Derivatives) Sheet http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsDerivatives SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Derivatives) Details http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesTables 37 false false R38.htm 2402406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Fair Value Measurements) Sheet http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsFairValueMeasurements SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Fair Value Measurements) Details http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesTables 38 false false R39.htm 2402407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Earnings Per Share) Sheet http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsEarningsPerShare SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Earnings Per Share) Details http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesTables 39 false false R40.htm 2402408 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Investment in Joint Ventures) Sheet http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsInvestmentInJointVentures SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Investment in Joint Ventures) Details http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesTables 40 false false R41.htm 2402409 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Key Financial Data on Joint Ventures) Sheet http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsKeyFinancialDataOnJointVentures SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Key Financial Data on Joint Ventures) Details http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesTables 41 false false R42.htm 2405402 - Disclosure - FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS (Details - Narrative) Sheet http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS (Details - Narrative) Details http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositions 42 false false R43.htm 2405403 - Disclosure - FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS (Details - Assets held for sale) Sheet http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsAssetsHeldForSale FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS (Details - Assets held for sale) Details http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositions 43 false false R44.htm 2407402 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Details - Schedule of Goodwill) Sheet http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill GOODWILL AND OTHER INTANGIBLE ASSETS (Details - Schedule of Goodwill) Details http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsTables 44 false false R45.htm 2407403 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Details - Narrative) Sheet http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative GOODWILL AND OTHER INTANGIBLE ASSETS (Details - Narrative) Details http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsTables 45 false false R46.htm 2407404 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Details - Annual Amortization Schedule) Sheet http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsAnnualAmortizationSchedule GOODWILL AND OTHER INTANGIBLE ASSETS (Details - Annual Amortization Schedule) Details http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsTables 46 false false R47.htm 2408402 - Disclosure - PROPERTY AND EQUIPMENT (Details) Sheet http://www.radnet.com/role/PropertyAndEquipmentDetails PROPERTY AND EQUIPMENT (Details) Details http://www.radnet.com/role/PropertyAndEquipmentTables 47 false false R48.htm 2408403 - Disclosure - PROPERTY AND EQUIPMENT (Details - Narrative) Sheet http://www.radnet.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details - Narrative) Details http://www.radnet.com/role/PropertyAndEquipmentTables 48 false false R49.htm 2409402 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) Sheet http://www.radnet.com/role/AccountsPayableAndAccruedExpensesDetails ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) Details http://www.radnet.com/role/AccountsPayableAndAccruedExpensesTables 49 false false R50.htm 2410402 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Schedule of Debt) Notes http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Schedule of Debt) Details http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesTables 50 false false R51.htm 2410403 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Annual Note Payable Maturities) Notes http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsAnnualNotePayableMaturities NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Annual Note Payable Maturities) Details http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesTables 51 false false R52.htm 2410404 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Narrative) Notes http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Narrative) Details http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesTables 52 false false R53.htm 2410405 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Term Loans) Notes http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsTermLoans NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Term Loans) Details http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesTables 53 false false R54.htm 2410406 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Margin Spread Based on Leverage Ratio) Notes http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Margin Spread Based on Leverage Ratio) Details http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesTables 54 false false R55.htm 2410407 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Margin Spread Based on Leverage Ratio, Debt Instrument) (Details) Notes http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Margin Spread Based on Leverage Ratio, Debt Instrument) (Details) Details http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesTables 55 false false R56.htm 2411402 - Disclosure - LEASES (Details - Additional Information) Sheet http://www.radnet.com/role/LeasesDetailsAdditionalInformation LEASES (Details - Additional Information) Details http://www.radnet.com/role/LeasesTables 56 false false R57.htm 2411403 - Disclosure - LEASES (Details - Lease Cost) Sheet http://www.radnet.com/role/LeasesDetailsLeaseCost LEASES (Details - Lease Cost) Details http://www.radnet.com/role/LeasesTables 57 false false R58.htm 2411404 - Disclosure - LEASES (Details - Supplemental Cash Flows) Sheet http://www.radnet.com/role/LeasesDetailsSupplementalCashFlows LEASES (Details - Supplemental Cash Flows) Details http://www.radnet.com/role/LeasesTables 58 false false R59.htm 2411405 - Disclosure - LEASES (Details - Supplemental Balance Sheet) Sheet http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet LEASES (Details - Supplemental Balance Sheet) Details http://www.radnet.com/role/LeasesTables 59 false false R60.htm 2411406 - Disclosure - LEASES (Details - Maturities of Operating and Finance Lease) Sheet http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease LEASES (Details - Maturities of Operating and Finance Lease) Details http://www.radnet.com/role/LeasesTables 60 false false R61.htm 2413402 - Disclosure - INCOME TAXES (Details - Income tax expense) Sheet http://www.radnet.com/role/IncomeTaxesDetailsIncomeTaxExpense INCOME TAXES (Details - Income tax expense) Details http://www.radnet.com/role/IncomeTaxesTables 61 false false R62.htm 2413403 - Disclosure - INCOME TAXES (Details - Reconciliation of the statutory U.S. federal rate and effective rates) Sheet http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates INCOME TAXES (Details - Reconciliation of the statutory U.S. federal rate and effective rates) Details http://www.radnet.com/role/IncomeTaxesTables 62 false false R63.htm 2413404 - Disclosure - INCOME TAXES (Details - Narrative) Sheet http://www.radnet.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details - Narrative) Details http://www.radnet.com/role/IncomeTaxesTables 63 false false R64.htm 2413405 - Disclosure - NCOME TAXES (Details - Deferred tax assets and liabilities) Sheet http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities NCOME TAXES (Details - Deferred tax assets and liabilities) Details 64 false false R65.htm 2413406 - Disclosure - INCOME TAXES (Details - Unrecognized tax benefit) Sheet http://www.radnet.com/role/IncomeTaxesDetailsUnrecognizedTaxBenefit INCOME TAXES (Details - Unrecognized tax benefit) Details http://www.radnet.com/role/IncomeTaxesTables 65 false false R66.htm 2414402 - Disclosure - STOCK-BASED COMPENSATION (Details - Narrative) Sheet http://www.radnet.com/role/StockBasedCompensationDetailsNarrative STOCK-BASED COMPENSATION (Details - Narrative) Details http://www.radnet.com/role/StockBasedCompensationTables 66 false false R67.htm 2414403 - Disclosure - STOCK-BASED COMPENSATION (Details-Outstanding options and warrants) Sheet http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants STOCK-BASED COMPENSATION (Details-Outstanding options and warrants) Details http://www.radnet.com/role/StockBasedCompensationTables 67 false false R68.htm 2414404 - Disclosure - STOCK-BASED COMPENSATION (Details - RSU's) Sheet http://www.radnet.com/role/StockBasedCompensationDetailsRsus STOCK-BASED COMPENSATION (Details - RSU's) Details http://www.radnet.com/role/StockBasedCompensationTables 68 false false R69.htm 2416402 - Disclosure - QUARTERLY RESULTS OF OPERATIONS (unaudited) (Details - Statements of Operations) Sheet http://www.radnet.com/role/QuarterlyResultsOfOperationsUnauditedDetailsStatementsOfOperations QUARTERLY RESULTS OF OPERATIONS (unaudited) (Details - Statements of Operations) Details http://www.radnet.com/role/QuarterlyResultsOfOperationsTables 69 false false R70.htm 2417401 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://www.radnet.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://www.radnet.com/role/RelatedPartyTransactions 70 false false R71.htm 2418401 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://www.radnet.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://www.radnet.com/role/SubsequentEvents 71 false false R72.htm 2419401 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) Sheet http://www.radnet.com/role/ScheduleIiValuationAndQualifyingAccountsDetails SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) Details http://www.radnet.com/role/ScheduleIiValuationAndQualifyingAccounts 72 false false R9999.htm Uncategorized Items - radnet10k2019document.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - radnet10k2019document.htm Cover 73 false false All Reports Book All Reports radnet10k2019document.htm a10k2019exhibit211.htm a10k2019exhibit231.htm q42019exhibit311.htm q42019exhibit312.htm q42019exhibit321.htm q42019exhibit322.htm rdnt-20191231.xsd rdnt-20191231_cal.xml rdnt-20191231_def.xml rdnt-20191231_lab.xml rdnt-20191231_pre.xml chart-c596de076de05269b73.jpg http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 true true XML 63 R47.htm IDEA: XBRL DOCUMENT v3.20.1
PROPERTY AND EQUIPMENT (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 938,154 $ 909,212
Accumulated depreciation (571,408) (563,483)
Total property and equipment 366,746 345,729
Land    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 250 250
Medical equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 425,892 449,776
Computer and office equipment, furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 120,490 102,798
Software development costs    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 0 6,391
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 377,417 337,878
Equipment under financing/capital lease    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 14,105 $ 12,119
XML 64 R43.htm IDEA: XBRL DOCUMENT v3.20.1
FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS (Details - Assets held for sale) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Long Lived Assets Held-for-sale [Line Items]    
Total assets held for sale $ 2,041 $ 2,499
Property and equipment, net    
Long Lived Assets Held-for-sale [Line Items]    
Total assets held for sale 1,049  
Goodwill    
Long Lived Assets Held-for-sale [Line Items]    
Total assets held for sale $ 992  
XML 65 R60.htm IDEA: XBRL DOCUMENT v3.20.1
LEASES (Details - Maturities of Operating and Finance Lease)
$ in Thousands
Dec. 31, 2019
USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]  
2020 $ 89,881
2021 88,848
2022 80,932
2023 69,916
2024 54,517
Thereafter 262,027
Total Lease Payments 646,121
Less imputed interest (163,993)
Total 482,128
Finance Lease, Liability, Payment, Due [Abstract]  
2020 3,492
2021 2,624
2022 702
2023 11
2024 10
Thereafter 0
Total Lease Payments 6,839
Less imputed interest (292)
Total 6,547
2019 90,512
2020 80,501
2021 70,792
2022 58,806
2023 45,895
Thereafter 165,471
Total operating lease payments 511,977
Equipment  
Finance Lease, Liability, Payment, Due [Abstract]  
2019 14,924
2020 14,385
2021 12,966
2022 10,264
2023 7,095
Thereafter 5,144
Total operating lease payments 64,778
Facilities  
Finance Lease, Liability, Payment, Due [Abstract]  
2019 75,588
2020 66,116
2021 57,826
2022 48,542
2023 38,800
Thereafter 160,327
Total operating lease payments $ 447,199
XML 66 R64.htm IDEA: XBRL DOCUMENT v3.20.1
NCOME TAXES (Details - Deferred tax assets and liabilities) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Deferred tax assets:    
Net operating losses $ 34,490 $ 46,875
Accrued expenses 4,280 3,421
Operating lease liability 126,546  
Straight-Line rent adjustment 0 9,811
Unfavorable contract liability 0 1,354
Equity compensation 1,374 1,065
Allowance for doubtful accounts 27,220 14,850
Other 4,616 2,815
Valuation allowance (5,348) (5,810)
Total Deferred Tax Assets 193,178 74,381
Deferred tax liabilities:    
Property and equipment (6,450) (6,194)
Goodwill (24,637) (19,780)
Intangibles (6,669) (8,110)
Operating lease right-of-use asset (115,364)  
Non accrual experience method reserve 0 (1,446)
Other (5,510) (7,345)
Total Deferred Tax Liabilities (158,630) (42,875)
Net Deferred Tax Asset $ 34,548 $ 31,506
XML 67 R9.htm IDEA: XBRL DOCUMENT v3.20.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
PRINCIPLES OF CONSOLIDATION – The operating activities of subsidiaries are included in the accompanying consolidated financial statements (“financial statements”) from the date of acquisition. Investments in companies in which we have the ability to exercise significant influence, but not control, are accounted for by the equity method. All intercompany transactions and balances, with our consolidated entities and the unsettled amount of intercompany transactions with our equity method investees, have been eliminated in consolidation. As stated in Note 1 above, the Group consists of VIEs and we consolidate the operating activities and balance sheets of each. Additionally, we determined that our unconsolidated joint venture, ScriptSender, LLC, is also a VIE as it is dependent on our operational funding but we are not a primary beneficiary since RadNet does not have the power to direct the activities of the entity that most significantly impact the entity’s economic performance.

USE OF ESTIMATES - The financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP), which requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect various matters, including our reported amounts of assets and liabilities in our consolidated balance sheets at the dates of the financial statements; our disclosure of contingent assets and liabilities at the dates of the financial statements; and our reported amounts of revenues and expenses in our consolidated statements of operations during the reporting periods. These estimates involve judgments with respect to numerous factors that are difficult to predict and are beyond management’s control. As a result, actual amounts could materially differ from these estimates.
 
RECLASSIFICATION – For the year 2017, we have reclassified certain amounts within other income and expenses on the consolidated statement of operations and proceeds from issuance of debt on the consolidated statement of cash flows to conform to our 2018 and 2019 presentation. For the year 2018, we have reclassified certain amounts within other expenses on the consolidated statement of cash flows to conform to our 2019 presentation. For the years 2018 and 2017, we have reclassified certain amounts within our reconciliation of the statutory U.S. federal rate and effective rates to conform to our 2019 presentation.
 
REVENUES – Our revenues generally relate to net patient fees received from various payors and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided
by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.
 
As it relates to the consolidated medical group, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by them as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to others centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.
 
Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual allowances under managed care and commercial insurance plans are based upon historical collection experience from such payors in accordance with the underlying contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have price concessions applied. We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect.

Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.

On January 1, 2018, we adopted the new revenue recognition accounting standard issued by the Financial Accounting Standards Board (“FASB”) and codified in the ASC as topic 606 (“ASC 606”). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding our revenue recognition policies and significant judgments employed in the determination of revenue.

We applied the modified retrospective approach to all contracts when adopting ASC 606. As a result, at the adoption of ASC 606 the majority of what was previously classified as the provision for bad debts in the statement of operations are now reflected as implicit price concessions and therefore included as a reduction to net operating revenues in 2018 and later. For changes in credit issues not assessed at the date of service, we will prospectively recognize those amounts in other operating expenses on the statement of operations. For periods prior to the adoption of ASC 606, the provision for bad debts has been presented consistent with the previous revenue recognition standards that required it to be presented separately as a component of net operating revenues. As part of the adoption of ASC 606 allowance for doubtful accounts was reclassified to be a component of net patient accounts receivable. Other than these changes in presentation on the consolidated statement of operations and consolidated balance sheet, the adoption of ASC 606 did not have a material impact on the consolidated financial statements. As part of the adoption of ASC 606, we elected two of the available practical expedients provided for in the standard. First, we did not adjust the transaction price for any financing components as those were deemed to be insignificant. Additionally, we expensed all incremental customer contract acquisition costs as incurred as such costs are not material and would be amortized over a period less than one year.

Our total net revenues for the years ended December 31, 2019, 2018, and 2017 are presented in the table below (in thousands):
 
 
2019
 
2018
 
2017
Commercial insurance
$
642,341

 
$
542,011

 
$
534,224

Medicare
237,427

 
192,881

 
179,678

Medicaid
28,283

 
25,615

 
24,133

Workers' compensation/personal injury
42,792

 
34,193

 
32,969

Other patient revenue
23,862

 
25,117

 
29,882

Management fee revenue
11,659

 
13,882

 
13,127

Imaging on call and software
17,317

 
16,261

 
18,116

Other
24,555

 
18,781

 
25,049

Service fee revenue, net of contractual allowances and discounts
1,028,236

 
868,741

 
857,178

Provision for bad debts

 

 
(46,555
)
Net service fee revenue
1,028,236

 
868,741

 
810,623

Revenue under capitation arrangements
125,943

 
106,405

 
111,563

Total net revenue
$
1,154,179

 
$
975,146

 
$
922,186


 
ACCOUNTS RECEIVABLE – Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. We continuously monitor collections from our payors and record an estimated price concession based upon specific payor collection issues that we have identified and our historical experience.

In 2019 and 2018 we entered into factoring agreements with various institutions and sold certain accounts receivable under non-recourse agreements. These transactions are accounted for as a reduction in accounts receivable as the agreements transfer effective control over and risk related to the receivables to the buyers. The aggregate amounts factored under these facilities, net of discounts recorded to reflect market interest rates, was $9.0 million during the year ended December 31, 2019 and $20.5 million during the year ended December 31, 2018.

Proceeds on notes receivable are reflected as operating activities on our statement of cash flows and on our balance sheet as prepaid expenses and other current assets for the current portion and deposits and other for the long term portion. At December 31, 2019 we have $24.2 million remaining to be collected on these agreements. We do not utilize factoring arrangements as an integral part of our financing for working capital.
 
MEANINGFUL USE INCENTIVE – Under the American Recovery and Reinvestment Act of 2009, a program was enacted that provides financial incentives for providers that successfully implement and utilize electronic health record technology to improve patient care. Our software development team in Canada developed a Radiology Information System (RIS) software platform that has been awarded meaningful use certification. We recorded the meaningful use incentive within non-operating income. The program ended in 2017 and we recorded approximately $250,000 to other income during the twelve months ended December 31, 2017 relating to this incentive. 
 
SOFTWARE REVENUE RECOGNITION – Our subsidiary, eRAD, Inc., sells Picture Archiving Communications Systems (“PACS”) and related services, primarily in the United States. The PACS systems sold by eRAD are primarily composed of certain elements: hardware, software, installation and training, and support. Sales are made primarily through eRAD’s sales force and generally include hardware, software, installation, training and first-year warranty support. Hardware, which is not unique or special purpose, is purchased from a third-party and resold to eRAD’s customers with a small mark-up.
 
We have determined that our core software products, such as PACS, are essential to most of our arrangements as hardware, software and related services are sold as an integrated package. Revenue is recognized when a performance obligation is satisfied by transferring a promised good or service to a customer.
  
For the years ended December 31, 2019, 2018 and 2017, we recorded approximately $10.1 million, $6.8 million, and $6.1 million, respectively, in revenue related to our eRAD business which is included in net service fee revenue in our consolidated statement of operations. At December 31, 2019 we had a deferred revenue liability of approximately $1.3 million associated with eRAD sales which we expect to recognize into revenue over the next 12 months.
 
SOFTWARE DEVELOPMENT COSTS – When we develop our own software solutions through our eRad subsidiary, we capitalize and amortize those costs over their useful life. Costs related to the research and development of new software products
and enhancements to existing software products all for resale to our customers are expensed as incurred. If we enter into agreements where we license our software to outside customers, we have recorded the receipt of these funds against the capitalized software costs.

Our most major software development to date was the Radiology Information System, a front desk patient tracking software, which had total capitalized costs of approximately $6.4 million and was fully amortized as of December 31, 2018.

CONCENTRATION OF CREDIT RISKS – Financial instruments that potentially subject us to credit risk are primarily cash equivalents and accounts receivable. We have placed our cash and cash equivalents with one major financial institution. At times, the cash in the financial institution is temporarily in excess of the amount insured by the Federal Deposit Insurance Corporation, or FDIC. Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. We continuously monitor collections and maintain an allowance for bad debts based upon our historical collection experience. In addition, we have notes receivable stemming from our factoring of accounts receivable as stated above. Companies with which we factor our receivables are well known established buyers of such instruments, have agreed to assume the full risk of their collection, and to date have made all payments due to us in a timely manner.
 
CASH AND CASH EQUIVALENTS – We consider all highly liquid investments that mature in three months or less when purchased to be cash equivalents. The carrying amount of cash and cash equivalents approximates the fair market value.
 
DEFERRED FINANCING COSTS – Costs of financing are deferred and amortized using the effective interest rate method. Deferred financing costs are solely related to our Barclays Revolving Credit Facilities. Deferred financing costs, net of accumulated amortization, were $1.6 million and $1.4 million for the twelve months ended December 31, 2019 and 2018, respectively. See Note 8, Revolving Credit Facility, Notes Payable, and Capital Leases for more information on our revolving lines of credit.
 
INVENTORIES – Inventories, consisting mainly of medical supplies, are stated at the lower of cost or net realizable value with cost determined by the first-in, first-out method.
 
PROPERTY AND EQUIPMENT – Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are provided using the straight-line method over the estimated useful lives, which range from 3 to 15 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 3 to 15 years. Maintenance and repairs are charged to expense as incurred.
 
BUSINESS COMBINATION – When the qualifications for business combination accounting treatment are met, it requires us to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.
 
GOODWILL AND INDEFINITE LIVED INTANGIBLES – Goodwill totaled $441.0 million and $418.1 million at December 31, 2019 and December 31, 2018, respectively. Indefinite lived intangible assets at December 31, 2019 were $11.3 million and $9.8 million at December 31, 2018 and are associated with the value of certain trade name intangibles. Goodwill and trade name intangibles are recorded as a result of business combinations. When we determine the carrying value of goodwill exceeds its fair value, an impairment charge would be recognized which should not exceed the total amount of goodwill allocated to that reporting unit. We determined fair values for each of the reporting units using the market approach, when available and appropriate, or the income approach, or a combination of both. We assess the valuation methodology based upon the relevance and availability of the data at the time we perform the valuation. If multiple valuation methodologies are used, the results are weighted appropriately. We tested both goodwill and trade name intangibles for impairment on October 1, 2019, noting no impairment, and have not identified any indicators of impairment through December 31, 2019.

During the testing of goodwill and trade name intangibles at October 1, 2018, our Teleradiology reporting unit, Imaging On Call, (IOC), experienced a reduction of professional medical group clients and a loss of a contract with a major local health provider during 2018. This affected its estimated fair value and resulted in impairment charges to our reporting unit of $3.9 million for the twelve months ended December 31, 2018, with goodwill representing $3.8 million of the total and the remainder being its
trade name of approximately $100,000. The estimated fair value of IOC reporting unit was determined by using the discounted cash flow method.

LONG-LIVED ASSETS – We evaluate our long-lived assets (property and equipment) and intangibles, other than goodwill, for impairment when events or changes indicate the carrying amount of an asset may not be recoverable. Accounting standards requires that if the sum of the undiscounted expected future cash flows from a long-lived asset or definite-lived intangible is less than the carrying value of that asset, an asset impairment charge must be recognized. The amount of the impairment charge is calculated as the excess of the asset’s carrying value over its fair value, which generally represents the discounted future cash flows from that asset or in the case of assets we expect to sell, at fair value less costs to sell. We determined that there were no events or changes in circumstances that indicated our long-lived assets were impaired during any periods presented.
 
INCOME TAXES – Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income in determining whether our net deferred tax assets are more likely than not to be realized. Income taxes are further explained in Note 10, Income Taxes. 
LEASES - We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liability, and long term operating lease liability in our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liability, and long-term finance lease liability in our consolidated balance sheets.  ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. We use the implicit rate when readily determinable. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We include options to extend a lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For a contract in which we are a lessee that contains fixed payments for both lease and non-lease components, we have elected to account for the components as a single lease component, as permitted. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. See Note 9, Leases, for more information.

UNINSURED RISKS – On November 1, 2008 we obtained a fully funded and insured workers’ compensation policy, thereby eliminating any uninsured risks for employee injuries occurring on or after that date. This fully funded policy remained in effect through November 1, 2013 and continues to cover any claims incurred through this date.
 
On November 1, 2013 we entered into a high-deductible workers’ compensation insurance policy. We have recorded liabilities of $3.8 million and $2.8 million for each of the years ending December 31, 2019 and December 31, 2018, respectively, for the estimated future cash obligations associated with the unpaid portion of the workers compensation claims incurred.
 
We and our affiliated physicians carry an annual medical malpractice insurance policy that protects us for claims that are filed during the policy year and that fall within policy limits. The policy has a deductible for which is $10,000 per incidence for the years ending December 31, 2019 and December 31, 2018, respectively.
 
In December 2008, in order to eliminate the exposure for claims not reported during the regular malpractice policy period, we purchased a medical malpractice claims made tail policy, which provides coverage for any claims reported in the event that our medical malpractice policy expires. As of December 31, 2019, this policy remains in effect.
 
We have entered into an arrangement with Blue Shield to administer and process claims under a self-insured plan that provides health insurance coverage for our employees and dependents. We have recorded liabilities as of December 31, 2019 and 2018 of $4.9 million and $4.8 million, respectively, for the estimated future cash obligations associated with the unpaid portion of the medical and dental claims incurred by our participants. Additionally, we entered into an agreement with Blue Shield for a stop loss policy that provides coverage for any claims that exceed $250,000 up to a maximum of $1.0 million in order for us to limit our exposure for unusual or catastrophic claims. 

EMPLOYEE BENEFIT PLAN – We adopted a profit-sharing/savings plan pursuant to Section 401(k) of the Internal Revenue Code that covers substantially all non-professional employees. Eligible employees may contribute on a tax-deferred basis a percentage of compensation, up to the maximum allowable under tax law. Employee contributions vest immediately. As of
January 1, 2017, RadNet provides a matching contribution in the amount to a maximum of 1.0% per 4.0% of employee contribution. RadNet contributed $2.6 million for the year ended December 31, 2018 and is expected to contribute approximately $3.0 million for the plan year ended December 31, 2019.
 
LOSS AND OTHER UNFAVORABLE CONTRACTS – We assess the profitability of our contracts to provide management services to our contracted physician groups and identify those contracts where current operating results or forecasts indicate probable future losses. Anticipated future revenue is compared to anticipated costs and if the anticipated future cost exceeds the revenue, a loss contract accrual is recorded. In connection with the acquisition of Radiologix in November 2006, we acquired certain management service agreements which met this criterion and recorded to other non-current liabilities an $8.9 million loss contract accrual. Of the $4.6 million ending balance at December 31, 2018, approximately $4.0 million, ($2.8 million net of taxes), was settled against the purchase consideration of Hudson Valley Radiology Associates, P.L.L.C. (HVRA) by our VIE entity Lenox Hill Radiology and Medical Associates, P.C. and the remaining balance of approximately $558,000 was written off upon ending a contract with a physician group. See Note 4, Facility Acquisitions, Assets Held for Sale and Dispositions for further information on the purchase of HVRA.
 
Related to acquisition activity, we entered into certain operating lease commitments for facilities where the fair market rent differs from the lease contract rate. We recorded an unfavorable contract liability representing the difference between the total value of the fair market rent and the contract rent over the current term of the lease applicable from the date of acquisition. As of December 31, 2018, the unfavorable contract liability on these leases was $2.2 million. This balance was transferred to operating lease right-of-use assets in conjunction with adoption of Accounting Standard Update No. 2016-02, Leases, which amended the accounting standards for leases. See Note 9, Leases, for further information.
 
EQUITY BASED COMPENSATION – We have one long-term incentive plan that we adopted in 2006 and which we first amended and restated as of April 20, 2015, and again on March 9, 2017 (the “Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. We have reserved for issuance under the Restated Plan 14,000,000 shares of common stock. We can issue options, stock awards, stock appreciation rights, stock units and cash awards under the Restated Plan. Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options and warrants generally vest over three to five years and expire five to ten years from date of grant. The compensation expense associated with option grants is calculated based on a valuation model, typically the Black–Scholes model, which requires certain management assumptions with respect to volatility. The compensation expense recognized for all equity-based awards is recognized over the awards’ service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees. See Note 11 Stock-Based Compensation for more information.
 
FOREIGN CURRENCY TRANSLATION – The functional currency of our foreign subsidiaries is the local currency. In accordance with ASC 830, Foreign Currency Matters, assets and liabilities denominated in foreign currencies are translated using the exchange rate at the balance sheet dates. Revenues and expenses are translated using average exchange rates prevailing during the reporting period. Any translation adjustments resulting from this process are shown separately as a component of accumulated other comprehensive income (loss). Foreign currency transaction gains and losses are included in the determination of net income.
 
COMPREHENSIVE INCOME (LOSS) – Accounting guidance establishes rules for reporting and displaying comprehensive income (loss) and its components. Our unrealized gains or losses on foreign currency translation adjustments and our interest rate cap and swap agreements are included in comprehensive income (loss). The components of comprehensive income (loss) for the three years in the period ended December 31, 2019 are included in the consolidated statements of comprehensive income (loss).
CONTINGENCIES - We are party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business. With respect to these matters, we evaluate the developments on a regular basis and accrue a liability when we believe a loss is probable and the amount can be reasonably estimated. We believe that the amount or any estimable range of reasonably possible or probable loss will not, either individually or in the aggregate, have a material adverse effect on our business and consolidated financial statements. However, the outcome of these matters is inherently uncertain. Therefore, if one or more of these matters were resolved against us for amounts in excess of management's expectations, our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable, could be materially adversely affected.
In the second quarter of 2019, we accrued a liability of $2.3 million related to allegations by the US Attorney's Office for the Western District of New York that RadNet submitted certain claims which incorrectly identified the physician who furnished the radiology services.  The final settlement, which admits no wrong-doing on behalf of RadNet, was $2.2 million and paid in September 2019.

DERIVATIVE INSTRUMENTS

2016 CAPS

In the fourth quarter of 2016, we entered into two forward interest rate cap agreements ("2016 Caps"). The 2016 Caps will mature in September and October 2020. The 2016 Caps had notional amounts of $150,000,000 and $350,000,000, respectively, which were designated at inception as cash flow hedges of future cash interest payments associated with portions of our variable rate bank debt. Under these arrangements, we purchased a cap on 3 month LIBOR at 2.0%. We are liable for a $5.3 million premium to enter into the caps which is being accrued to current liabilities on our balance sheet and paid over the life of the 2016 Caps.
 
At inception, we designated our 2016 Caps as cash flow hedges of floating-rate borrowings. In accordance with ASC Topic 815, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss of the hedge (i.e. change in fair value) is reported as a component of accumulated other comprehensive income in the consolidated statement of equity. See Fair Value Measurements section below for the fair value of the 2016 Caps at December 31, 2019.
 
A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive income (loss), net of taxes is as follows (amounts in thousands):

 
Interest Rate Contracts
 
 
 
 
For the twelve months ended
Amount of (Loss) Gain Recognized on Derivative, net of taxes
Location of Loss Recognized
in Income on Derivative
December 31, 2019
$(4,383)
Other Comprehensive Loss
December 31, 2018
2,876
Other Comprehensive Income
December 31, 2017
(880)
Other Comprehensive Loss
 
2019 SWAPS
In the second quarter of 2019, we entered into four forward interest rate agreements ("2019 swaps"). The 2019 swaps have total notional amounts of $500,000,000, consisting of two agreements of $50,000,000 each and two agreements of $200,000,000 each. The 2019 swaps will secure a constant interest rate associated with portions of our variable rate bank debt and have an effective date of October 13, 2020. They will mature in October 2023 for the two smaller notional and October 2025 for the two larger notional. Under these arrangements, we arranged the 2019 swaps with locked in 1 month LIBOR rates at 1.96% for the two $50,000,000 notional and at 2.05% for the two $200,000,000 notional.
At inception, we designated our 2019 swaps as cash flow hedges of floating-rate borrowings. In accordance with ASC Topic 815, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss of the hedge (i.e. change in fair value) is reported as a component of comprehensive loss in the consolidated statement of equity.  See Fair Value Measurements section below for the fair value of the 2019 swaps at December 31, 2019.

For the twelve months ended December 31, 2019
 
 
 
Effective Interest Rate Swap
Amount of Loss Recognized on Derivative, net of taxes
Location of Loss Recognized
in Income on Derivative
Interest rate contracts
$(5,870)
Other Comprehensive Loss



FAIR VALUE MEASUREMENTS – Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement:
 
Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
 
Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.
 
Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.

Derivatives:

The table below summarizes the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets in our consolidated balance sheets, as follows (in thousands):

 
As of December 31, 2019
 
Level 1
 
Level 2
 
Level 3
 
Total
Current and long term liabilities
 

 
 

 
 

 
 

2016 CAPS - Interest Rate Contracts
$

 
$
1,081

 
$

 
$
1,081

2019 SWAPS - Interest Rate Contracts
$

 
$
9,477

 
$

 
$
9,477

 
 
As of December 31, 2018
 
Level 1
 
Level 2
 
Level 3
 
Total
Current assets
 

 
 

 
 

 
 

2016 CAPS - Interest Rate Contracts
$

 
$
3,316

 
$

 
$
3,316



The estimated fair value of these contracts was determined using Level 2 inputs. More specifically, the fair value was determined by calculating the value of the difference between the fixed interest rate of the interest rate swaps and the counterparty’s forward LIBOR curve. The forward LIBOR curve is readily available in the public markets or can be derived from information available in the public markets.
 
Long Term Debt

The table below summarizes the estimated fair value and carrying amount of our SunTrust (Term Loan Agreement) and Barclays (First Lien Term Loans) long-term debt as follows (in thousands):
 
 
As of December 31, 2019
 
Level 1
 
Level 2
 
Level 3
 
Total Fair Value
 
Total Face Value
Term Loan Agreement and First Lien Term Loans
$

 
$
708,948

 
$

 
$
708,948

 
$
705,699

 
 
As of December 31, 2018
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Total Face Value
Term Loan Agreement and First Lien Term Loans
$

 
$
633,229

 
$

 
$
633,229

 
$
646,441


 
Our Barclays revolving credit facility had no aggregate principal amount outstanding as of December 31, 2019 and a $28.0 million principal amount outstanding as of December 31, 2018. Our SunTrust revolving credit facility had no aggregate principal amount outstanding for the periods ending December 31, 2019 and December 31, 2018, respectively.
 
The estimated fair values of our long-term debt, which is discussed in Note 8, was determined using Level 2 inputs for the Barclays and SunTrust term loans. Level 2 inputs primarily related to comparable market prices.
 
We consider the carrying amounts of cash and cash equivalents, receivables, other current assets, current liabilities and other notes payables to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment. Additionally, we consider the carrying amount of our capital lease obligations to approximate their fair value because the weighted average interest rate used to formulate the carrying amounts approximates current market rates.
 
EARNINGS PER SHARE - Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):
 
 
Years Ended December 31,
 
2019
 
2018
 
2017
Net income attributable to RadNet, Inc. common stockholders
$
14,756

 
$
32,243

 
$
53

 
 
 
 
 
 
BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
 
 
 
 
 
Weighted average number of common shares outstanding during the period
49,674,858

 
48,114,275

 
46,880,775

Basic net income per share attributable to RadNet, Inc. common stockholders
$
0.30

 
$
0.67

 
$

DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
 
 
 
 
 
Weighted average number of common shares outstanding during the period
49,674,858

 
48,114,275

 
46,880,775

Add nonvested restricted stock subject only to service vesting
208,963

 
180,631

 
274,940

Add additional shares issuable upon exercise of stock options and warrants
360,185

 
384,093

 
246,206

Weighted average number of common shares used in calculating diluted net income per share
50,244,006

 
48,678,999

 
47,401,921

Diluted net income per share attributable to RadNet, Inc. common stockholders
$
0.29

 
$
0.66

 
$

 
 
 
 
 
 
Stock options excluded from the computation of diluted per share amounts:
 
 
 
 
 
Weighted average shares for which the exercise price exceeds average market price of common stock

 
6,250

 
175,037



EQUITY INVESTMENTS AT FAIR VALUE- As of December 31, 2019, we have three equity investments for which a fair value is not readily determinable and we do not have significant influence and therefore the total amounts invested are recognized at cost. In accordance with accounting guidance, if there is no readily determinable fair value, the guidance allows entities the ability to measure investments at cost less impairment, whereby impairment is based on a qualitative assessment.
 
Medic Vision:
 
Medic Vision, based in Israel, specializes in software packages that provide compliant radiation dose structured reporting and enhanced images from reduced dose CT scans.
 
On March 24, 2017, we acquired an initial 12.50% equity interest in Medic Vision - Imaging Solutions Ltd for $1.0 million. We also received an option to exercise warrants to acquire up to an additional 12.50% equity interest for $1.4 million within one year from the initial share purchase date, if exercised in full. On March 1, 2018 we exercised our warrant in part and acquired an additional 1.96% for $200,000. Our initial equity interest has been diluted to 12.25% and our total equity investment stands at 14.21%.
 
In accordance with accounting guidance, as we exercise no significant influence over Medic Vision’s operations, the investment is recorded at its cost of $1.2 million, given that the fair value is not readily determinable. No impairment in our investment was noted as of the year ended December 31, 2019.
 
Turner Imaging:
 
Turner Imaging Systems, based in Utah, develops and markets portable X-ray imaging systems that provide a user the ability to acquire X-ray images wherever and whenever they are needed. On February 1, 2018, we purchased 2.1 million preferred shares in Turner Imaging Systems for $2.0 million. On January 1, 2019 we funded a convertible promissory note in the amount of $143,000 that converted to an additional 80,000 preferred shares on October 11, 2019. No impairment in our investment was noted for the year ended December 31, 2019.

WhiteRabbit.ai Inc:
WhiteRabbit.ai Inc., based in California, is currently developing an artificial intelligence suite which aims to improve the speed and accuracy of cancer detection in radiology and improve patient care. On November 5, 2019 we acquired an equity interest in the company for $1.0 million and also loaned the company $2.5 million in support of its operations. No impairment in our investment was noted for the year ended December 31, 2019.
 
INVESTMENT IN JOINT VENTURES – We have 12 unconsolidated joint ventures with ownership interests ranging from 35% to 55%. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers.  Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture.  Our investment in these joint ventures is accounted for under the equity method, as we do not have a controlling financial interest in such ventures. We evaluate our investment in joint ventures, including cost in excess of book value (equity method goodwill) for impairment whenever indicators of impairment exist. No indicators of impairment existed as of December 31, 2019.
 
Sale of joint venture interest:
On April 1, 2017, we formed in conjuncture with Cedars Sinai Medical Center (“CSMC”) the Santa Monica Imaging Group, LLC (“SMIG”), consisting of two multi-modality imaging centers located in Santa Monica, CA with RadNet holding a 40% economic interest and CSMC holding a 60% economic interest. RadNet accounts for our share of the venture under the equity method. On January 1, 2019, CSMC purchased from the us an additional five percent economic interest in SMIG valued at $134,000. As a result of the transaction, our economic interest in SMIG has been reduced to 35%. We recorded a loss of $2,000 on the transaction.

Change in control of existing joint ventures

On October 6, 2014, we acquired a 49% equity interest in Garden State Radiology Network, LLC ("GSRN") for cash consideration of $2.2 million. The venture consisted of two imaging centers located in New Jersey. On August 1, 2019, the entity was dissolved by transferring ownership of the assets of the centers with each partner receiving full ownership of one center. See Note 4, Facility Acquisitions and Dispositions, for further information.

On April 12, 2018 we acquired 25% share capital in Nulogix, Inc. for cash consideration of $2.0 million. On August 1, 2019 we completed via the issuance of RadNet common stock valued at $1.5 million, the acquisition of the remaining 75% economic interest and we now consolidate the financial statements of Nulogix.  See Note 4, Facility Acquisitions and Dispositions, for further information.

On October 1, 2018, we obtained control over the operations of NJIN through an agreement with the other equity interest holder for no cash consideration. As such, we consolidated the financial statements of NJIN effective that date. The economic interest of each party remained the same after consolidation. See Note 4, Facility Acquisitions and Dispositions, to the consolidated financial statements contain herein for further information.

Joint venture investment and financial information
 
The following table is a summary of our investment in joint ventures during the years ended December 31, 2019 and December 31, 2018 (in thousands):
 
Balance as of December 31, 2017
$
52,435

Equity contributions in existing and purchase of interest in joint ventures
2,000

Equity in earnings in these joint ventures
11,377

Disposition of equity method interest upon acquisition of control in NJIN
(2,993
)
Distribution of earnings
(24,846
)
Balance as of December 31, 2018
$
37,973

Equity contributions in existing and purchase of interest in joint ventures
103

Equity in earnings in these joint ventures
8,350

Sale of ownership interest
(134
)
Dissolution of GSRN
(1,428
)
Nulogix return of capital
(792
)
Nulogix change in control
(1,004
)
Distribution of earnings
(8,598
)
Balance as of December 31, 2019
$
34,470



We charged management service fees from the centers underlying these joint ventures of approximately $11.4 million, $13.8 million and $13.1 million for the years ended December 31, 2019, 2018 and 2017, respectively . We eliminate any unrealized portion of our management service fees with our equity in earnings of joint ventures.
 
The following table is a summary of key unaudited financial data for these joint ventures as of December 31, 2019 and 2018, respectively, and for the years ended December 31, 2019, 2018 and 2017, respectively, (in thousands):

 
December 31,
Balance Sheet Data:
2019
 
2018
Current assets
$
27,427

 
$
28,317

Noncurrent assets
61,037

 
45,912

Current liabilities
(9,217
)
 
(4,300
)
Noncurrent liabilities
(18,872
)
 
(4,898
)
Total net assets
$
60,375

 
$
65,031

Book value of RadNet joint venture interests
$
28,001

 
$
30,030

Cost in excess of book value of acquired joint venture interests accounted for as equity method goodwill
6,469

 
7,943

Total value of RadNet joint venture interests
$
34,470

 
$
37,973

Total book value of other joint venture partner interests
$
32,374

 
$
35,001

  
 
2019
 
2018
 
2017
Net revenue
$
108,051

 
$
155,820

 
$
188,849

Net income
$
18,624

 
$
24,596

 
$
28,644


XML 68 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Cover Page - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2019
Mar. 09, 2020
Jun. 30, 2019
Cover page.      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2019    
Document Transition Report false    
Entity File Number 001-33307    
Entity Registrant Name RadNet, Inc.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 13-3326724    
Entity Address, Address Line One 1510 Cotner Avenue    
Entity Address, City or Town Los Angeles,    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 90025    
City Area Code 310    
Local Phone Number 478-7808    
Title of 12(b) Security Common Stock, $.0001 par value    
Trading Symbol RDNT    
Security Exchange Name NASDAQ    
Entity a Well-known Seasoned Issuer No    
Entity a Voluntary Filer No    
Entity's Reporting Status Current Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 576.6
Entity Common Stock, Shares Outstanding   50,694,375  
Entity Central Index Key 0000790526    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2019    
Documents Incorporated by Reference
Portions of the registrant’s definitive proxy statement for the 2020 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this annual report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the close of the registrant’s fiscal year.
 

   
XML 69 R5.htm IDEA: XBRL DOCUMENT v3.20.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Statement of Comprehensive Income [Abstract]      
NET INCOME $ 23,440 $ 38,133 $ 2,075
Foreign currency translation adjustments (32) (69) 26
Change in fair value of cash flow hedge, net of taxes (10,253)    
Change in fair value of cash flow hedge, net of taxes (10,253) 2,876 (880)
COMPREHENSIVE INCOME 13,155 40,940 1,221
Less comprehensive income attributable to noncontrolling interests 8,684 5,890 2,022
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS $ 4,471 $ 35,050 $ (801)
XML 70 R68.htm IDEA: XBRL DOCUMENT v3.20.1
STOCK-BASED COMPENSATION (Details - RSU's) - Restricted Stock
12 Months Ended
Dec. 31, 2019
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]  
RSA's outstanding, beginning balance | shares 277,504
RSA's granted | shares 636,656
RSA's vested | shares (524,726)
RSA's forfeited | shares (1,500)
RSA's outstanding, ending balance | shares 387,934
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Weighted-average fair value, beginning balance | $ / shares $ 9.77
Weighted-average fair value, granted | $ / shares 11.78
Weighted-average fair value, vested | $ / shares 11.03
Weighted average grant date fair value | $ / shares 12.76
Weighted-average fair value, ending balance | $ / shares $ 11.61
Weighted-Average Remaining Contractual Term (Years) 1 year 1 month 17 days
XML 71 R9999.htm IDEA: XBRL DOCUMENT v3.20.1
Label Element Value
Assets transferred to Advanced Imaging at Timonium Crossing, LLC rdnt_AssetsTransferredToAdvancedImagingAtTimoniumCrossingLlc $ 4,600,000
Acquisition of Diagnostic Imaging Associates, cash rdnt_AcquisitionOfDiagnosticImagingAssociatesCash 13,000,000.0
Acquisition of RadSite, LLC, cash rdnt_AcquisitionOfRadsiteLlcCash 856,000
Assets transferred to Santa Monica Imaging Group LLC rdnt_AssetsTransferredToSantaMonicaImagingGroupLlc 2,500,000
Acquisition of RadSite, LLC, for common stock rdnt_AcquisitionOfRadsiteLlcForCommonStock 1,000,000.0
Acquisition of Diagnostic Imaging Associates, for RadNet common stock rdnt_AcquisitionOfDiagnosticImagingAssociatesForRadnetCommonStock 1,500,000
New Jersey Imaging Network, LLC [Member]  
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain 39,500,000
Business Combination, Step Acquisition, Cash Acquired rdnt_BusinessCombinationStepAcquisitionCashAcquired 5,400,000
Business Combination, Step Acquisition, Adjustment Of Investment Balance rdnt_BusinessCombinationStepAcquisitionAdjustmentOfInvestmentBalance $ 44,300,000
Equity Method Investment, Ownership Percentage us-gaap_EquityMethodInvestmentOwnershipPercentage 49.00%
Medical Arts Radiology [Member]  
Business Combination, Liabilities Arising from Contingencies, Amount Recognized us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized $ 700,000
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable 8,000,000.0
Business Combination, Consideration Transferred, Liabilities Incurred us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred 2,700,000
Ventura County Imaging Group, LLC [Member]  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment $ 4,300,000
Hudson Valley Radiology Associates [Member] | Variable Interest Entity, Not Primary Beneficiary [Member]  
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued 440,207
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned $ 6,000,000.0
XML 72 R22.htm IDEA: XBRL DOCUMENT v3.20.1
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
12 Months Ended
Dec. 31, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTSRADNET, INC. AND SUBSIDIARIES Financial Statement Schedules
  
SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS
RADNET, INC. AND SUBSIDIARIES
 
Balance at Beginning of Year
 
Additional Charges Against Income
 
Deductions from Reserve
 
Balance at End of Year
 
 
 
 
 
 
 
 
Year Ended December 31, 2017
 
 
 
 
 
 
 
     Accounts Receivable-Allowance for Bad Debts
$
20,674

 
$
46,555

 
$
(32,585
)
 
$
34,644


All other schedules are omitted because they are not applicable or the required information is shown in the consolidated financial statements or notes thereto.
EXCEL 73 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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htm IDEA: XBRL DOCUMENT v3.20.1
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
12 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of goodwill and other intangible assets Activity in goodwill for the years ended December 31, 2018 and 2019 is provided below (in thousands):
Balance as of December 31, 2017
$256,776
 Goodwill acquired through the acquisition of Imaging Services Company of New York, LLC
2,692

 Goodwill acquired through the acquisition of certain assets of MemorialCare Medical Foundation
545

 Goodwill transferred to assets held for sale
(1,059
)
 Goodwill acquired through the acquisition of Women's Imaging Specialists in Healthcare
4268

 Goodwill acquired through the acquisition of Valley Metabolic Imaging
1,469

 Goodwill acquired through the acquisition of Sierra Imaging Associates
1,147

 Goodwill disposed through the sale of plastic surgery unit
(80
)
 Goodwill acquired through the acquisition of Washington Heights Medical Management
2,303

 Goodwill acquired through the acquisition of Medical Arts Radiological Group, P.C.
41,469

 Goodwill acquired through the acquisition of Arcadia Radiology Imaging Services, LLC
2,582

 Goodwill acquired through the acquisition of Southern California Diagnostic Imaging, Inc.
41

 Goodwill acquired through the acquisition of Orange County Diagnostics Imaging Center, Inc.
3,618

 Goodwill acquired through assuming operational control of New Jersey Imaging Network, LLC
106,122

 Goodwill impaired in the Imaging On Call reporting unit
(3,800
)
Balance as of December 31, 2018
418,093

Adjustments to our preliminary allocation of the purchase price of Medical Arts Radiological Group, P.C.
722

Goodwill acquired through the acquisition of certain assets of Dignity Health
1

Goodwill acquired through the acquisition of certain assets of West Valley Imaging Center, LLC
2,490

Goodwill disposed through sale of assets
(123
)
Goodwill acquired by Lenox Hill Radiology through the membership purchase of HVRA
3,125

Goodwill acquired through the acquisition of certain assets of Kern Radiology, Inc.
10,507

Goodwill acquired through the acquisition of certain assets of Zilkha Radiology, Inc.
2,577

Goodwill acquired through the acquisition of certain assets of Ramic Mahwah, LLC
231

Goodwill acquired through the acquisition of GSRN
2,021

Goodwill acquired through the acquisition of Nulogix
1,337

Balance as of December 31, 2019
$440,981

Schedule of annual amortization expense
The following table shows annual amortization expense, by asset classes that will be recorded over the next five years (in thousands): 
 
2020
 
2021
 
2022
 
2023
 
2024
 
Thereafter
 
Total
 
Weighted average amortization period remaining in years
Management Service Contracts
$
2,287

 
$
2,287

 
$
2,287

 
$
2,287

 
$
2,287

 
$
15,820

 
$
27,255

 
11.9

Covenant not to compete and other contracts
759

 
699

 
650

 
537

 
129

 
142

 
2,916

 
4.4

Developed Technology
244

 
244

 
142

 

 

 

 
630

 
2.6

Trade Names amortized
142

 
69

 
69

 
61

 
58

 
219

 
618

 
8.4

Trade Names indefinite life

 

 

 

 

 
11,270

 
11,270

 

Software in development

 

 

 

 

 
305

 
305

 

Total Annual Amortization
$
3,432

 
$
3,299

 
$
3,148

 
$
2,885

 
$
2,474

 
$
27,756

 
$
42,994

 
 

 

XML 75 R46.htm IDEA: XBRL DOCUMENT v3.20.1
GOODWILL AND OTHER INTANGIBLE ASSETS (Details - Annual Amortization Schedule)
$ in Thousands
12 Months Ended
Dec. 31, 2019
USD ($)
Finite-Lived Intangible Assets [Line Items]  
Amortization year 2020 $ 3,432
Amortization year 2021 3,299
Amortization year 2022 3,148
Amortization year 2023 2,885
Amortization year 2024 2,474
Amortization year thereafter 27,756
Amortiztion total 42,994
Management Service Contracts  
Finite-Lived Intangible Assets [Line Items]  
Amortization year 2020 2,287
Amortization year 2021 2,287
Amortization year 2022 2,287
Amortization year 2023 2,287
Amortization year 2024 2,287
Amortization year thereafter 15,820
Amortiztion total $ 27,255
Weighted average amortization period remaining in years 11 years 10 months 24 days
Covenant not to compete and other contracts  
Finite-Lived Intangible Assets [Line Items]  
Amortization year 2020 $ 759
Amortization year 2021 699
Amortization year 2022 650
Amortization year 2023 537
Amortization year 2024 129
Amortization year thereafter 142
Amortiztion total $ 2,916
Weighted average amortization period remaining in years 4 years 4 months 24 days
Developed Technology  
Finite-Lived Intangible Assets [Line Items]  
Amortization year 2020 $ 244
Amortization year 2021 244
Amortization year 2022 142
Amortization year 2023 0
Amortization year 2024 0
Amortization year thereafter 0
Amortiztion total $ 630
Weighted average amortization period remaining in years 2 years 7 months 6 days
Trade Names amortized  
Finite-Lived Intangible Assets [Line Items]  
Amortization year 2020 $ 142
Amortization year 2021 69
Amortization year 2022 69
Amortization year 2023 61
Amortization year 2024 58
Amortization year thereafter 219
Amortiztion total $ 618
Weighted average amortization period remaining in years 8 years 4 months 24 days
Trade Names indefinite life  
Finite-Lived Intangible Assets [Line Items]  
Amortization year 2020 $ 0
Amortization year 2021 0
Amortization year 2022 0
Amortization year 2023 0
Amortization year 2024 0
Amortization year thereafter 11,270
Amortiztion total 11,270
Software in development  
Finite-Lived Intangible Assets [Line Items]  
Amortization year 2020 0
Amortization year 2021 0
Amortization year 2022 0
Amortization year 2023 0
Amortization year 2024 0
Amortization year thereafter 305
Amortiztion total $ 305
Weighted average amortization period remaining in years 0 years
XML 76 R42.htm IDEA: XBRL DOCUMENT v3.20.1
FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS (Details - Narrative) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Aug. 01, 2019
Apr. 01, 2019
Mar. 01, 2019
Feb. 28, 2019
Feb. 01, 2019
Jan. 01, 2019
Dec. 03, 2018
Nov. 05, 2018
Nov. 01, 2018
Oct. 01, 2018
Sep. 01, 2018
Apr. 12, 2018
Apr. 01, 2018
Feb. 22, 2018
Jan. 01, 2018
Sep. 01, 2017
Jul. 01, 2017
Apr. 28, 2017
Apr. 01, 2017
Nov. 06, 2014
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Aug. 01, 2017
Business Acquisition [Line Items]                                                
Sale of ownership interest                                         $ (134)      
Fixed assets acquired                             $ 15,000                  
Goodwill acquired                                         440,981 $ 418,093 $ 256,776  
Fair value of investment                                         28,001 30,030    
Gain on step up valuation                                         768 39,539 0  
Capital lease assumed                             4,000                  
Proceeds from sale of business                                         132 0 0  
Severance costs                                         $ 1,619 $ 1,931 $ 1,821  
Breastlink Medical                                                
Business Acquisition [Line Items]                                                
Sale of ownership interest                               $ 845                
Proceeds from sale of business                               2,800                
Severance costs                               $ 1,200                
Advanced Imaging at Timonium                                                
Business Acquisition [Line Items]                                                
Proceeds from sale of business                                 $ 3,900              
Transfer of fixed assets to new joint venture                                 1,100              
Proceeds in excess of book value                                 $ 2,800              
Rhode Island Medical Imaging, Inc                                                
Business Acquisition [Line Items]                                                
Sale of ownership interest                                   $ 1,900            
Proceeds from sale of business                                   $ 4,500            
West Valley Imaging Group, LLC                                                
Business Acquisition [Line Items]                                                
Proceeds from sale of business                                     $ 5,900          
Transfer of fixed assets to new joint venture                                     3,000          
Proceeds in excess of book value                                     1,800          
Oncology practices                                                
Business Acquisition [Line Items]                                                
Sale of ownership interest                                     361          
Proceeds from sale of business                                     $ 1,200          
Garden State Radiology Network LLC                                                
Business Acquisition [Line Items]                                                
Equity interest percentage 49.00%                                              
Sale of ownership interest $ 1,300                                              
Fixed assets acquired 679                                              
Operating lease liabilities acquired 426                                              
Other assets acquired 1                                              
Right-of-use assets acquired 426                                              
Goodwill acquired $ 2,000                                              
Payments to acquire equity method investments                                       $ 2,200        
Nulogix, Inc.                                                
Business Acquisition [Line Items]                                                
Equity interest percentage 75.00%                     25.00%                        
Sale of ownership interest $ (504)                                              
Payments to acquire equity method investments $ 1,500                     $ 2,000                        
Jefferson Health                                                
Business Acquisition [Line Items]                                                
Equity interest percentage 51.00%                                              
New Jersey Imaging Network, LLC                                                
Business Acquisition [Line Items]                                                
Equity interest percentage                   49.00%                            
Fixed assets acquired $ 3,100                 $ 34,400                            
Goodwill acquired                   106,100                            
Unfavorable lease contracts acquired                   1,000                            
Other current assets acquired                   235                            
Net working capital acquired                   11,600                            
Equipment debt assumed                   5,200                            
Bank debt assumed                   60,000                            
Fair value of investment                   42,500                            
Adjustment of New Jersey Imaging Network investment balance                   44,300                            
Gain on step up valuation                   39,500                            
Nulogix,Inc.                                                
Business Acquisition [Line Items]                                                
Fixed assets acquired 189                                              
Goodwill acquired 1,300                                              
Intangible assets acquired 732                                              
Deferred tax liability $ 278                                              
Kern Radiology Imaging Systems Inc.                                                
Business Acquisition [Line Items]                                                
Fixed assets acquired   $ 10,100                                            
Operating lease liabilities acquired   14,500                                            
Other assets acquired   36                                            
Right-of-use assets acquired   9,700                                            
Goodwill acquired   10,500                                            
Intangible assets acquired   3,400                                            
Consideration transferred   19,300                                            
Zilkha Radiology                                                
Business Acquisition [Line Items]                                                
Fixed assets acquired   2,200                                            
Operating lease liabilities acquired   5,100                                            
Right-of-use assets acquired   5,100                                            
Goodwill acquired   2,600                                            
Intangible assets acquired   100                                            
Consideration transferred   4,500                                            
Finance lease liabilities acquired   $ 332                                            
Hudson Valley Radiology Associates                                                
Business Acquisition [Line Items]                                                
Goodwill acquired       $ 3,100                                        
Intangible assets acquired       340                                        
Consideration transferred       680                                        
Value of RadNet stock issued in acquisition       6,000                                        
Equipment acquired       10                                        
West Valley Imaging Group, LLC                                                
Business Acquisition [Line Items]                                                
Fixed assets acquired         $ 300                                      
Other assets acquired         7                                      
Goodwill acquired         2,500                                      
Intangible assets acquired         200                                      
Consideration transferred         3,000                                      
Orange County Diagnostics Imaging Center                                                
Business Acquisition [Line Items]                                                
Fixed assets acquired             $ 2,800                                  
Other assets acquired             69                                  
Goodwill acquired             3,600                                  
Consideration transferred             6,600                                  
Other current assets acquired             23                                  
Arcadia Radiology Imaging                                                
Business Acquisition [Line Items]                                                
Goodwill acquired               $ 2,600                                
Consideration transferred               3,800                                
Equipment acquired               80                                
Other current assets acquired               20                                
Southern California Diagnostic Imaging, Inc                                                
Business Acquisition [Line Items]                                                
Goodwill acquired                 $ 41                              
Consideration transferred                 1,400                              
Equipment acquired                 110                              
Other current assets acquired                 18                              
Medical Arts Radiology                                                
Business Acquisition [Line Items]                                                
Fixed assets acquired                   16,000                            
Goodwill acquired                   40,700                            
Consideration transferred                   59,600                            
Unfavorable lease contracts acquired                   130                            
Other current assets acquired                   224                            
Net working capital acquired                   2,700                            
Equipment debt assumed                   2,700                            
Cash acquired from acquisition                   50,900                            
Contingent consideration to guarantee share value issued                   739                            
Payments to acquire business                   50,900                            
Washington Heights Medical Management, LLC                                                
Business Acquisition [Line Items]                                                
Fixed assets acquired                     $ 904                          
Goodwill acquired                     2,300                          
Other current assets acquired                     43                          
Payments to acquire business                     3,300                          
Women's Imaging Specialists in Healthcare                                                
Business Acquisition [Line Items]                                                
Fixed assets acquired                         $ 636                      
Goodwill acquired                         4,300                      
Payments to acquire business                         5,100                      
Valley Metabolic Imaging                                                
Business Acquisition [Line Items]                                                
Fixed assets acquired                         22                      
Goodwill acquired                         1,500                      
Payments to acquire business                         1,700                      
Sierra Imaging Associates                                                
Business Acquisition [Line Items]                                                
Fixed assets acquired                         270                      
Goodwill acquired                         1,100                      
Payments to acquire business                         1,500                      
Imaging Services Company of New York                                                
Business Acquisition [Line Items]                                                
Fixed assets acquired                           $ 3,000                    
Goodwill acquired                           2,700                    
Consideration transferred                           5,800                    
Ventura County Imaging Group, LLC.                                                
Business Acquisition [Line Items]                                                
Equity interest percentage     60.00%                                          
Payments to acquire equity method investments     $ 10,400                                          
Dignity Health. | Ventura County Imaging Group, LLC.                                                
Business Acquisition [Line Items]                                                
Equity interest percentage     40.00%                                          
Fixed assets acquired     $ 4,300                                          
Payments to acquire equity method investments     6,100                                          
Payments to acquire equity method investments, Assets     $ 800                                          
Equity interest percentage in exchange for assets     5.00%                                          
Payments to acquire equity method investments, cash     $ 5,300                                          
Equity interest percentage in exchange for cash     35.00%                                          
Leasehold improvements | Arcadia Radiology Imaging                                                
Business Acquisition [Line Items]                                                
Fixed assets acquired               819                                
Leasehold improvements | Southern California Diagnostic Imaging, Inc                                                
Business Acquisition [Line Items]                                                
Fixed assets acquired                 1,200                              
Noncompete Agreements | Hudson Valley Radiology Associates                                                
Business Acquisition [Line Items]                                                
Intangible assets acquired       50                                        
Noncompete Agreements | Orange County Diagnostics Imaging Center                                                
Business Acquisition [Line Items]                                                
Intangible assets acquired             $ 50                                  
Noncompete Agreements | Arcadia Radiology Imaging                                                
Business Acquisition [Line Items]                                                
Intangible assets acquired               $ 300                                
Noncompete Agreements | Southern California Diagnostic Imaging, Inc                                                
Business Acquisition [Line Items]                                                
Intangible assets acquired                 $ 50                              
Noncompete Agreements | Medical Arts Radiology                                                
Business Acquisition [Line Items]                                                
Intangible assets acquired                   24                            
Noncompete Agreements | Washington Heights Medical Management, LLC                                                
Business Acquisition [Line Items]                                                
Intangible assets acquired                     $ 50                          
Noncompete Agreements | Women's Imaging Specialists in Healthcare                                                
Business Acquisition [Line Items]                                                
Intangible assets acquired                         143                      
Noncompete Agreements | Valley Metabolic Imaging                                                
Business Acquisition [Line Items]                                                
Intangible assets acquired                         183                      
Noncompete Agreements | Sierra Imaging Associates                                                
Business Acquisition [Line Items]                                                
Intangible assets acquired                         83                      
Noncompete Agreements | Imaging Services Company of New York                                                
Business Acquisition [Line Items]                                                
Intangible assets acquired                           $ 100                    
Trade Names | New Jersey Imaging Network, LLC                                                
Business Acquisition [Line Items]                                                
Intangible assets acquired                   582                            
Trade Names | Hudson Valley Radiology Associates                                                
Business Acquisition [Line Items]                                                
Intangible assets acquired       380                                        
Trade Names | Medical Arts Radiology                                                
Business Acquisition [Line Items]                                                
Intangible assets acquired                   1,400                            
Trade Names | Women's Imaging Specialists in Healthcare                                                
Business Acquisition [Line Items]                                                
Intangible assets acquired                         $ 53                      
Common Stock | Medical Arts Radiology                                                
Business Acquisition [Line Items]                                                
Value of RadNet stock issued in acquisition                   $ 8,000                            
RadNet stock issued in acquisition (shares)                   531,560                            
Primedex Health Systems Inc. and Radiologix | Hudson Valley Radiology Associates                                                
Business Acquisition [Line Items]                                                
Unfavorable lease contracts acquired       $ 2,800                                        
MemorialCare Medical Foundation | Beach Imaging Group, LLC                                                
Business Acquisition [Line Items]                                                
Fixed assets acquired                             7,600                  
Goodwill acquired                             545                  
Equipment acquired                             7,400                  
Payments to acquire business                             22,300                  
Capital lease assumed                             $ 4,000                  
RadNet | Advanced Imaging at Timonium                                                
Business Acquisition [Line Items]                                                
Noncontrolling interest, ownership percentage                                 25.00%              
RadNet | West Valley Imaging Group, LLC                                                
Business Acquisition [Line Items]                                                
Noncontrolling interest, ownership percentage                                     25.00%          
RadNet | Beach Imaging Group, LLC                                                
Business Acquisition [Line Items]                                                
Business acquisition, percentage of voting interests acquired                             60.00%                  
MemorialCare Medical Foundation | Beach Imaging Group, LLC                                                
Business Acquisition [Line Items]                                                
Business acquisition, percentage of voting interests acquired                             40.00%                  
West Valley Imaging Group, LLC | West Valley Imaging Group, LLC                                                
Business Acquisition [Line Items]                                                
Payments to acquire equity method investments         $ 750                                      
Noncontrolling interest, ownership percentage         25.00%                                      
Santa Monica Imaging Group | RadNet                                                
Business Acquisition [Line Items]                                                
Equity interest percentage           35.00%                         40.00%         40.00%
Sale of ownership interest           $ (2)                                    
Santa Monica Imaging Group | Cedars Sinai Medical Center                                                
Business Acquisition [Line Items]                                                
Equity interest percentage                                     60.00%         60.00%
Additional equity interest acquired           5.00%                                    
Investment owned, at fair value           $ 134                                    
XML 77 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 78 R4.htm IDEA: XBRL DOCUMENT v3.20.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
REVENUE      
Service fee revenue, net of contractual allowances and discounts $ 1,028,236 $ 868,741  
Service fee revenue     $ 810,623
Total revenue 1,154,179 975,146 922,186
OPERATING EXPENSES      
Cost of operations, excluding depreciation and amortization 999,692 867,547 802,377
Depreciation and amortization 80,607 72,899 66,796
Loss (gain) on sale and disposal of equipment and other 2,383 (2,054) 1,142
Loss on impairment 0 3,937 0
Severance costs 1,619 1,931 1,821
Total operating expenses 1,084,301 944,260 872,136
INCOME FROM OPERATIONS 69,878 30,886 50,050
OTHER INCOME AND EXPENSES      
Interest expense 48,044 43,456 40,623
Equity in earnings of joint ventures (8,350) (11,377) (13,554)
Gain on re-measurement of pre-existing interest (768) (39,539) 0
Gain on sale of imaging centers and medical practice 0 0 (3,146)
Other expenses (income) 1,283 (181) (258)
Total other expenses (income) 40,209 (7,641) 23,665
INCOME BEFORE INCOME TAXES 29,669 38,527 26,385
Provision for income taxes (6,229) (394) (24,310)
NET INCOME 23,440 38,133 2,075
Net income attributable to noncontrolling interests 8,684 5,890 2,022
NET INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS $ 14,756 $ 32,243 $ 53
BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS (in dollars per share) $ 0.30 $ 0.67 $ 0
DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS (in dollars per share) $ 0.29 $ 0.66 $ 0
Weighted average shares outstanding, basic (in shares) 49,674,858 48,114,275 46,880,775
Weighted average shares outstanding, diluted (in shares) 50,244,006 48,678,999 47,401,921
Health Care, Patient Service      
REVENUE      
Service fee revenue, net of contractual allowances and discounts $ 1,028,236 $ 868,741 $ 857,178
Provision for bad debts     (46,555)
Revenue under capitation arrangements      
REVENUE      
Service fee revenue, net of contractual allowances and discounts $ 125,943 $ 106,405 $ 111,563
XML 79 radnet10k2019document_htm.xml IDEA: XBRL DOCUMENT 0000790526 2019-01-01 2019-12-31 0000790526 2020-03-09 0000790526 2019-06-30 0000790526 2018-12-31 0000790526 2019-12-31 0000790526 2018-01-01 2018-12-31 0000790526 2017-01-01 2017-12-31 0000790526 us-gaap:HealthCarePatientServiceMember 2017-01-01 2017-12-31 0000790526 rdnt:CapitationArrangementsMember 2019-01-01 2019-12-31 0000790526 rdnt:CapitationArrangementsMember 2017-01-01 2017-12-31 0000790526 rdnt:CapitationArrangementsMember 2018-01-01 2018-12-31 0000790526 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000790526 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-12-31 0000790526 rdnt:StockholdersEquityDeficitMember 2018-01-01 2018-12-31 0000790526 rdnt:StockholdersEquityDeficitMember 2017-01-01 2017-12-31 0000790526 2016-12-31 0000790526 rdnt:StockholdersEquityDeficitMember 2019-01-01 2019-12-31 0000790526 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-12-31 0000790526 us-gaap:NoncontrollingInterestMember 2017-01-01 2017-12-31 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000790526 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0000790526 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0000790526 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000790526 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0000790526 us-gaap:NoncontrollingInterestMember 2019-12-31 0000790526 rdnt:StockholdersEquityDeficitMember 2018-12-31 0000790526 us-gaap:NoncontrollingInterestMember 2018-12-31 0000790526 us-gaap:RetainedEarningsMember 2018-12-31 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000790526 rdnt:StockholdersEquityDeficitMember 2017-12-31 0000790526 us-gaap:CommonStockMember 2019-12-31 0000790526 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0000790526 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0000790526 us-gaap:CommonStockMember 2017-12-31 0000790526 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000790526 us-gaap:NoncontrollingInterestMember 2017-12-31 0000790526 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0000790526 rdnt:StockholdersEquityDeficitMember 2016-12-31 0000790526 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000790526 2017-12-31 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000790526 us-gaap:CommonStockMember 2016-12-31 0000790526 us-gaap:CommonStockMember 2018-12-31 0000790526 us-gaap:RetainedEarningsMember 2019-12-31 0000790526 rdnt:StockholdersEquityDeficitMember 2019-12-31 0000790526 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000790526 us-gaap:RetainedEarningsMember 2016-12-31 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000790526 us-gaap:RetainedEarningsMember 2017-12-31 0000790526 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000790526 us-gaap:NoncontrollingInterestMember 2016-12-31 0000790526 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000790526 rdnt:GardenStateRadiologyNetworkLLCMember 2019-08-01 2019-08-01 0000790526 rdnt:NulogixMember 2019-08-01 0000790526 rdnt:HudsonValleyRadiologyAssociatesMember us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2019-02-27 0000790526 rdnt:MedicalArtsRadiologyMember 2018-10-01 2018-10-01 0000790526 rdnt:NulogixMember 2018-04-12 0000790526 2017-04-01 2017-04-30 0000790526 2017-08-07 2017-08-07 0000790526 rdnt:NulogixMember 2019-08-01 2019-08-01 0000790526 2018-01-01 0000790526 2017-07-01 2017-07-31 0000790526 rdnt:NewJerseyImagingNetworkLLCMember 2018-10-01 2018-10-01 0000790526 rdnt:GardenStateRadiologyNetworkLLCMember 2019-08-01 0000790526 rdnt:MedicalArtsRadiologyMember 2019-12-31 0000790526 rdnt:MedicalArtsRadiologyMember 2018-10-01 0000790526 rdnt:NewJerseyImagingNetworkLLCMember 2018-10-01 0000790526 2017-10-05 2017-10-05 0000790526 rdnt:VenturaCountyImagingGroupLLCMember 2019-03-01 0000790526 rdnt:HudsonValleyRadiologyAssociatesMember 2019-02-28 2019-02-28 0000790526 rdnt:HudsonValleyRadiologyAssociatesMember us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2019-02-27 2019-02-27 0000790526 rdnt:MedicalArtsRadiologyMember 2018-01-01 2018-12-31 0000790526 rdnt:ScriptSenderMember 2019-12-31 0000790526 rdnt:BoardMemberMember rdnt:BeverlyRadiologyMedicalGroupIIIMember 2019-12-31 0000790526 srt:ChiefExecutiveOfficerMember rdnt:BeverlyRadiologyMedicalGroupIIIMember 2019-12-31 0000790526 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000790526 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000790526 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000790526 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000790526 us-gaap:InterestRateSwapMember 2019-01-01 2019-12-31 0000790526 rdnt:Medicare1Member 2018-01-01 2018-12-31 0000790526 us-gaap:HealthCarePatientServiceMember 2018-01-01 2018-12-31 0000790526 rdnt:PatientServicesNetMember 2017-01-01 2017-12-31 0000790526 us-gaap:HealthCareOtherMember 2018-01-01 2018-12-31 0000790526 rdnt:CommercialInsurance1Member 2018-01-01 2018-12-31 0000790526 rdnt:Medicaid1Member 2017-01-01 2017-12-31 0000790526 rdnt:HealthCareManagementServiceMember 2018-01-01 2018-12-31 0000790526 rdnt:HealthCareManagementServiceMember 2019-01-01 2019-12-31 0000790526 rdnt:CommercialInsurance1Member 2017-01-01 2017-12-31 0000790526 us-gaap:HealthCarePatientServiceMember 2019-01-01 2019-12-31 0000790526 rdnt:WorkersCompensationPersonalInjury1Member 2019-01-01 2019-12-31 0000790526 rdnt:CommercialInsurance1Member 2019-01-01 2019-12-31 0000790526 rdnt:ImagingOnCallMember 2017-01-01 2017-12-31 0000790526 rdnt:WorkersCompensationPersonalInjury1Member 2017-01-01 2017-12-31 0000790526 rdnt:HealthCareManagementServiceMember 2017-01-01 2017-12-31 0000790526 us-gaap:HealthCareOtherMember 2019-01-01 2019-12-31 0000790526 rdnt:ImagingOnCallMember 2019-01-01 2019-12-31 0000790526 rdnt:PatientServicesNetMember 2018-01-01 2018-12-31 0000790526 rdnt:Medicare1Member 2019-01-01 2019-12-31 0000790526 rdnt:ImagingOnCallMember 2018-01-01 2018-12-31 0000790526 rdnt:HealthCarePatientServiceOtherMember 2019-01-01 2019-12-31 0000790526 rdnt:Medicaid1Member 2019-01-01 2019-12-31 0000790526 rdnt:PatientServicesNetMember 2019-01-01 2019-12-31 0000790526 rdnt:WorkersCompensationPersonalInjury1Member 2018-01-01 2018-12-31 0000790526 rdnt:HealthCarePatientServiceOtherMember 2017-01-01 2017-12-31 0000790526 rdnt:HealthCarePatientServiceOtherMember 2018-01-01 2018-12-31 0000790526 rdnt:Medicare1Member 2017-01-01 2017-12-31 0000790526 us-gaap:HealthCareOtherMember 2017-01-01 2017-12-31 0000790526 rdnt:Medicaid1Member 2018-01-01 2018-12-31 0000790526 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000790526 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000790526 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000790526 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000790526 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000790526 us-gaap:InterestRateCapMember 2019-12-31 0000790526 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000790526 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000790526 us-gaap:InterestRateSwapMember 2019-12-31 0000790526 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000790526 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000790526 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000790526 us-gaap:InterestRateCapMember 2017-01-01 2017-12-31 0000790526 us-gaap:InterestRateCapMember 2018-01-01 2018-12-31 0000790526 us-gaap:InterestRateCapMember 2019-01-01 2019-12-31 0000790526 rdnt:SantaMonicaImagingMember rdnt:RadNetMember 2017-04-01 0000790526 us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0000790526 rdnt:DignityHealthMember srt:MinimumMember rdnt:JointVentureMember rdnt:GlendaleAdvancedImagingMember 2019-01-01 2019-12-31 0000790526 rdnt:SantaMonicaImagingMember rdnt:CedarsSinaiMedicalCenterMember 2019-01-01 0000790526 srt:MaximumMember 2019-01-01 2019-12-31 0000790526 rdnt:September2020CapMember 2019-12-31 0000790526 us-gaap:InterestRateSwapMember rdnt:A2019SWAPS1Member 2019-06-30 0000790526 rdnt:TurnerImagingSystemsMember 2018-02-01 2018-02-01 0000790526 us-gaap:InvestmentAdvisoryManagementAndAdministrativeServiceMember 2018-01-01 2018-12-31 0000790526 srt:MaximumMember rdnt:PropertyAndEquipmentMember 2019-01-01 2019-12-31 0000790526 rdnt:USAttorneysOfficeForTheWesternDistrictofNewYorkMember 2019-06-30 0000790526 us-gaap:InvestmentAdvisoryManagementAndAdministrativeServiceMember 2019-01-01 2019-12-31 0000790526 us-gaap:InterestRateSwapMember rdnt:A2019SWAPSMember 2019-06-30 0000790526 rdnt:TurnerImagingMember 2019-10-11 0000790526 us-gaap:InvestmentAdvisoryManagementAndAdministrativeServiceMember srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2019-01-01 2019-09-30 0000790526 rdnt:TurnerImagingMember us-gaap:CommercialPaperMember 2019-01-01 0000790526 rdnt:BlueShieldMember srt:MinimumMember 2019-12-31 0000790526 rdnt:RestatedPlanMember 2019-12-31 0000790526 rdnt:MedicVisionMember 2018-03-01 2018-03-01 0000790526 rdnt:ImagingOnCallMember 2018-01-01 2018-12-31 0000790526 rdnt:HealthInsuranceMember 2019-12-31 0000790526 rdnt:HudsonValleyRadiologyAssociatesMember rdnt:PrimedexHealthSystemsInc.andRadiologixMember 2019-02-28 0000790526 rdnt:WhiteRabbit.aiInc.Member 2019-11-05 2019-11-05 0000790526 rdnt:PatientServicesNetMember rdnt:ERADMember 2017-01-01 2017-12-31 0000790526 rdnt:MedicVisionMember 2017-03-24 0000790526 us-gaap:InvestmentAdvisoryManagementAndAdministrativeServiceMember 2017-01-01 2017-12-31 0000790526 rdnt:HealthInsuranceMember 2018-12-31 0000790526 us-gaap:InterestRateSwapMember rdnt:A2019SWAPS1Member us-gaap:LondonInterbankOfferedRateLIBORMember 2019-06-30 0000790526 rdnt:October2020CapMember 2019-12-31 0000790526 rdnt:Caps2016Member 2019-12-31 0000790526 rdnt:SantaMonicaImagingMember rdnt:RadNetMember 2019-01-01 0000790526 rdnt:MedicVisionMember 2017-03-24 2017-03-24 0000790526 rdnt:BarclaysMember 2019-12-31 0000790526 rdnt:SunTrustMember 2019-12-31 0000790526 rdnt:A2019SWAPSMember 2019-06-30 0000790526 rdnt:MedicVisionMember 2019-12-31 0000790526 rdnt:BarclaysMember 2018-12-31 0000790526 rdnt:USAttorneysOfficeForTheWesternDistrictofNewYorkMember us-gaap:SettledLitigationMember 2019-09-01 2019-09-30 0000790526 rdnt:PatientServicesNetMember rdnt:ERADMember 2018-01-01 2018-12-31 0000790526 rdnt:Caps2016Member us-gaap:LondonInterbankOfferedRateLIBORMember 2019-12-31 0000790526 rdnt:PatientServicesNetMember rdnt:ERADMember 2019-01-01 2019-12-31 0000790526 rdnt:October2025Member rdnt:A2019SWAPSMember 2019-06-30 0000790526 rdnt:NulogixMember 2018-04-12 2018-04-12 0000790526 rdnt:RadiologixMember 2006-11-30 0000790526 us-gaap:InterestRateSwapMember rdnt:A2019SWAPSMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-06-30 0000790526 rdnt:DignityHealthMember srt:MaximumMember rdnt:JointVentureMember rdnt:GlendaleAdvancedImagingMember 2019-01-01 2019-12-31 0000790526 rdnt:October2023Member rdnt:A2019SWAPSMember 2019-06-30 0000790526 rdnt:SantaMonicaImagingMember rdnt:CedarsSinaiMedicalCenterMember 2017-04-01 0000790526 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2019-01-01 2019-12-31 0000790526 us-gaap:InvestmentAdvisoryManagementAndAdministrativeServiceMember srt:MinimumMember rdnt:PropertyAndEquipmentMember 2019-01-01 2019-09-30 0000790526 rdnt:GardenStateRadiologyNetworkLLCMember 2014-10-06 2014-11-06 0000790526 rdnt:SantaMonicaImagingMember rdnt:RadNetMember 2019-01-01 2019-01-01 0000790526 rdnt:BlueShieldMember srt:MaximumMember 2019-12-31 0000790526 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000790526 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0000790526 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000790526 us-gaap:InterestRateCapMember 2018-12-31 0000790526 srt:MinimumMember rdnt:PropertyAndEquipmentMember 2019-01-01 2019-12-31 0000790526 srt:MinimumMember 2019-01-01 2019-12-31 0000790526 rdnt:SunTrustMember 2018-12-31 0000790526 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2019-01-01 2019-12-31 0000790526 rdnt:ValleyMetabolicImagingMember 2018-04-01 2018-04-01 0000790526 rdnt:RadNetMember rdnt:AdvancedImagingAtTimoniumMember 2017-07-01 0000790526 rdnt:OrangeCountyDiagnosticsImagingCenterMember us-gaap:NoncompeteAgreementsMember 2018-12-03 0000790526 rdnt:ZilkhaRadiologyMember 2019-04-01 0000790526 rdnt:MedicalArtsRadiologyMember us-gaap:NoncompeteAgreementsMember 2018-10-01 0000790526 rdnt:HudsonValleyRadiologyAssociatesMember 2019-02-28 0000790526 rdnt:NewJerseyImagingNetworkLLCMember 2018-10-01 0000790526 rdnt:KernRadiologyImagingSystemsInc.Member 2019-04-01 0000790526 rdnt:BreastlinkMedicalMember 2017-09-01 2017-09-01 0000790526 rdnt:WestValleyImagingGroupLLCMember 2019-02-01 2019-02-01 0000790526 rdnt:JeffersonHealthMember 2019-08-01 0000790526 rdnt:WashingtonHeightsMedicalManagementLLCMember 2018-09-01 0000790526 rdnt:ValleyMetabolicImagingMember 2018-04-01 0000790526 rdnt:ArcadiaRadiologyImagingMember us-gaap:NoncompeteAgreementsMember 2018-11-05 0000790526 rdnt:WestValleyImagingGroupLLCMember rdnt:WestValleyImagingGroupLLCMember 2019-02-01 0000790526 rdnt:DignityHealth.Member rdnt:VenturaCountyImagingGroupLLC.Member 2019-03-01 2019-03-01 0000790526 rdnt:NulogixInc.Member 2019-08-01 0000790526 rdnt:SouthernCaliforniaDiagnosticImagingIncMember 2018-11-01 0000790526 rdnt:AdvancedImagingAtTimoniumMember 2017-07-01 2017-07-01 0000790526 rdnt:SouthernCaliforniaDiagnosticImagingIncMember us-gaap:NoncompeteAgreementsMember 2018-11-01 0000790526 rdnt:ImagingServicesCompanyofNewYorkMember us-gaap:NoncompeteAgreementsMember 2018-02-22 0000790526 rdnt:WestValleyImagingGroupLLCMember 2019-02-01 0000790526 rdnt:RhodeIslandMedicalImagingIncMember 2017-04-28 2017-04-28 0000790526 rdnt:NewJerseyImagingNetworkLLCMember us-gaap:TradeNamesMember 2018-10-01 0000790526 rdnt:DignityHealth.Member rdnt:VenturaCountyImagingGroupLLC.Member 2019-03-01 0000790526 rdnt:WestValleyImagingGroupLLCMember 2017-04-01 2017-04-01 0000790526 rdnt:MedicalArtsRadiologyMember us-gaap:CommonStockMember 2018-10-01 0000790526 rdnt:SouthernCaliforniaDiagnosticImagingIncMember us-gaap:LeaseholdImprovementsMember 2018-11-01 0000790526 rdnt:SouthernCaliforniaDiagnosticImagingIncMember 2018-11-01 2018-11-01 0000790526 rdnt:MedicalArtsRadiologyMember us-gaap:TradeNamesMember 2018-10-01 0000790526 rdnt:SierraImagingAssociatesMember 2018-04-01 0000790526 rdnt:ImagingServicesCompanyofNewYorkMember 2018-02-22 0000790526 rdnt:ArcadiaRadiologyImagingMember 2018-11-05 0000790526 rdnt:KernRadiologyImagingSystemsInc.Member 2019-04-01 2019-04-01 0000790526 rdnt:MemorialCareMedicalFoundationMember rdnt:BeachImagingGroupLLCMember 2018-01-01 0000790526 rdnt:BeachImagingGroupLLCMember rdnt:MemorialCareMedicalFoundationMember 2018-01-01 2018-01-01 0000790526 rdnt:OrangeCountyDiagnosticsImagingCenterMember 2018-12-03 0000790526 rdnt:NewJerseyImagingNetworkLLCMember 2019-08-01 0000790526 rdnt:OncologyPracticesMember 2017-04-01 2017-04-01 0000790526 rdnt:WestValleyImagingGroupLLCMember rdnt:WestValleyImagingGroupLLCMember 2019-02-01 2019-02-01 0000790526 rdnt:HudsonValleyRadiologyAssociatesMember us-gaap:TradeNamesMember 2019-02-28 0000790526 rdnt:ZilkhaRadiologyMember 2019-04-01 2019-04-01 0000790526 rdnt:ValleyMetabolicImagingMember us-gaap:NoncompeteAgreementsMember 2018-04-01 0000790526 rdnt:WomensImagingSpecialistsinHealthcareMember us-gaap:NoncompeteAgreementsMember 2018-04-01 0000790526 rdnt:SierraImagingAssociatesMember us-gaap:NoncompeteAgreementsMember 2018-04-01 0000790526 rdnt:WomensImagingSpecialistsinHealthcareMember 2018-04-01 0000790526 rdnt:RadNetMember rdnt:WestValleyImagingGroupLLCMember 2017-04-01 0000790526 rdnt:VenturaCountyImagingGroupLLC.Member 2019-03-01 2019-03-01 0000790526 rdnt:NewJerseyImagingNetworkLLCMember 2018-10-01 2018-10-01 0000790526 rdnt:VenturaCountyImagingGroupLLC.Member 2019-03-01 0000790526 rdnt:SantaMonicaImagingMember rdnt:RadNetMember 2017-08-01 0000790526 rdnt:MedicalArtsRadiologyMember us-gaap:CommonStockMember 2018-10-01 2018-10-01 0000790526 rdnt:WashingtonHeightsMedicalManagementLLCMember us-gaap:NoncompeteAgreementsMember 2018-09-01 0000790526 rdnt:OrangeCountyDiagnosticsImagingCenterMember 2018-12-03 2018-12-03 0000790526 rdnt:SantaMonicaImagingMember rdnt:CedarsSinaiMedicalCenterMember 2017-08-01 0000790526 rdnt:BeachImagingGroupLLCMember rdnt:MemorialCareMedicalFoundationMember 2018-01-01 0000790526 rdnt:ArcadiaRadiologyImagingMember us-gaap:LeaseholdImprovementsMember 2018-11-05 0000790526 rdnt:ArcadiaRadiologyImagingMember 2018-11-05 2018-11-05 0000790526 rdnt:HudsonValleyRadiologyAssociatesMember us-gaap:NoncompeteAgreementsMember 2019-02-28 0000790526 rdnt:WomensImagingSpecialistsinHealthcareMember us-gaap:TradeNamesMember 2018-04-01 0000790526 rdnt:RadNetMember rdnt:BeachImagingGroupLLCMember 2018-01-01 0000790526 rdnt:WomensImagingSpecialistsinHealthcareMember 2018-04-01 2018-04-01 0000790526 rdnt:SierraImagingAssociatesMember 2018-04-01 2018-04-01 0000790526 rdnt:WashingtonHeightsMedicalManagementLLCMember 2018-09-01 2018-09-01 0000790526 rdnt:ImagingServicesCompanyofNewYorkMember 2018-02-22 2018-02-22 0000790526 rdnt:PropertyAndEquipmentMember 2019-12-31 0000790526 us-gaap:GoodwillMember 2019-12-31 0000790526 rdnt:DevelopedtechnologyMember 2019-01-01 2019-12-31 0000790526 rdnt:TradeNamesAmortizedMember 2019-12-31 0000790526 rdnt:CovenantNotToCompeteMember 2019-12-31 0000790526 rdnt:ManagementServiceContractsMember 2019-12-31 0000790526 us-gaap:SoftwareDevelopmentMember 2019-12-31 0000790526 rdnt:TradeNamesIndefiniteLifeMember 2019-12-31 0000790526 rdnt:DevelopedtechnologyMember 2019-12-31 0000790526 rdnt:CovenantNotToCompeteMember 2019-01-01 2019-12-31 0000790526 rdnt:ManagementServiceContractsMember 2019-01-01 2019-12-31 0000790526 rdnt:TradeNamesAmortizedMember 2019-01-01 2019-12-31 0000790526 rdnt:ValleyMetabolicImagingMember 2018-01-01 2018-12-31 0000790526 rdnt:WashingtonHeightsMedicalManagementMember 2018-01-01 2018-12-31 0000790526 rdnt:NulogixMember 2019-01-01 2019-12-31 0000790526 rdnt:RamicMahwahLLCMember 2019-01-01 2019-12-31 0000790526 rdnt:WomensImagingSpecialistsyMember 2018-01-01 2018-12-31 0000790526 rdnt:DignityHealthMember 2019-01-01 2019-12-31 0000790526 rdnt:MedicalArtsRadiologicalGroupPCMember 2018-01-01 2018-12-31 0000790526 rdnt:HudsonValleyRadiologyAssociatesMember 2019-01-01 2019-12-31 0000790526 rdnt:ImagingServicesCompanyofNewYorkMember 2018-01-01 2018-12-31 0000790526 rdnt:NewJerseyImagingNetworkLLCMember 2018-01-01 2018-12-31 0000790526 rdnt:WestValleyImagingGroupLLCMember 2019-01-01 2019-12-31 0000790526 rdnt:MedicalArtsRadiologicalGroupPCMember 2019-01-01 2019-12-31 0000790526 rdnt:OrangeCountyDiagnosticsImagingCenterMember 2018-01-01 2018-12-31 0000790526 rdnt:ZilkhaRadiologyMember 2019-01-01 2019-12-31 0000790526 rdnt:MemorialCareMedicalFoundationMember 2018-01-01 2018-12-31 0000790526 rdnt:GardenStateRadiologyNetworkLLCMember 2019-01-01 2019-12-31 0000790526 rdnt:KernRadiologyImagingSystemsInc.Member 2019-01-01 2019-12-31 0000790526 rdnt:SierraImagingAssociatesMember 2018-01-01 2018-12-31 0000790526 rdnt:SouthernCaliforniaDiagnosticImagingIncMember 2018-01-01 2018-12-31 0000790526 rdnt:ArcadiaRadiologyImagingMember 2018-01-01 2018-12-31 0000790526 us-gaap:SoftwareDevelopmentMember 2019-01-01 2019-12-31 0000790526 us-gaap:LeaseholdImprovementsMember 2019-12-31 0000790526 us-gaap:ConstructionInProgressMember 2019-12-31 0000790526 rdnt:MedicalEquipmentMember 2019-12-31 0000790526 rdnt:ComputerandOfficeEquipmentMember 2019-12-31 0000790526 us-gaap:EquipmentMember 2018-12-31 0000790526 us-gaap:SoftwareDevelopmentMember 2018-12-31 0000790526 us-gaap:LeaseholdImprovementsMember 2018-12-31 0000790526 us-gaap:FurnitureAndFixturesMember 2019-12-31 0000790526 us-gaap:EquipmentMember 2019-12-31 0000790526 us-gaap:FurnitureAndFixturesMember 2018-12-31 0000790526 us-gaap:AssetsHeldUnderCapitalLeasesMember 2018-12-31 0000790526 us-gaap:LandMember 2019-12-31 0000790526 us-gaap:LandMember 2018-12-31 0000790526 us-gaap:SoftwareDevelopmentMember 2019-12-31 0000790526 us-gaap:AssetsHeldUnderCapitalLeasesMember 2019-12-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:EurodollarMember rdnt:LeverageRatioOneMember 2016-07-01 2016-07-01 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember rdnt:LeverageRatioTwoMember 2016-07-01 2016-07-01 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember rdnt:LeverageRatioFourMember 2016-07-01 2016-07-01 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember rdnt:LeverageRatioThreeMember 2016-07-01 2016-07-01 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:EurodollarMember rdnt:LeverageRatioFourMember 2016-07-01 2016-07-01 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:EurodollarMember rdnt:LeverageRatioThreeMember 2016-07-01 2016-07-01 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember rdnt:LeverageRatioOneMember 2016-07-01 2016-07-01 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:EurodollarMember rdnt:LeverageRatioTwoMember 2016-07-01 2016-07-01 0000790526 us-gaap:CommercialPaperMember 2019-12-31 0000790526 rdnt:FirstLienTermLoanMember rdnt:TermLoanMember 2018-12-31 0000790526 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2018-12-31 0000790526 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-12-31 0000790526 rdnt:RestatedAgreementMember rdnt:TermLoanMember 2018-12-31 0000790526 rdnt:FirstLienTermLoanMember rdnt:TermLoanMember 2019-12-31 0000790526 us-gaap:CommercialPaperMember 2018-12-31 0000790526 rdnt:RestatedAgreementMember rdnt:TermLoanMember 2019-12-31 0000790526 rdnt:TermLoanMember 2019-12-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementSixthAmendmentMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2019-12-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember rdnt:BarclaysMember us-gaap:LineOfCreditMember 2019-12-31 0000790526 rdnt:SunTrustMember rdnt:TermLoanMember 2018-12-31 0000790526 rdnt:FirstLienCreditAgreementSeventhAmendmentMember 2019-04-18 0000790526 rdnt:SunTrustMember rdnt:TermLoanMember 2018-01-01 2018-12-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:BarclaysMember us-gaap:LetterOfCreditMember 2019-01-01 2019-12-31 0000790526 rdnt:RestatedAgreementMember rdnt:TermLoanMember 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:SunTrustMember us-gaap:LineOfCreditMember 2019-12-31 0000790526 rdnt:FirstLienCreditAgreementSeventhAmendmentMember 2019-04-18 2019-04-18 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementSixthAmendmentMember us-gaap:LineOfCreditMember us-gaap:EurodollarMember rdnt:LeverageRatioThreeMember 2019-01-01 2019-12-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:BarclaysMember 2019-12-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementSixthAmendmentMember us-gaap:LineOfCreditMember 2019-04-18 0000790526 us-gaap:RevolvingCreditFacilityMember 2019-12-31 0000790526 rdnt:FirstLienCreditAgreementSixthAmendmentMember us-gaap:MediumTermNotesMember 2017-08-22 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember rdnt:SunTrustMember us-gaap:LineOfCreditMember 2018-08-31 0000790526 srt:MaximumMember rdnt:FirstLienTermLoanMember rdnt:TermLoanMember 2019-12-31 0000790526 rdnt:FirstLienTermLoanMember rdnt:BarclaysMember rdnt:TermLoanMember 2019-01-01 2019-12-31 0000790526 rdnt:RestatedAgreementMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementSixthAmendmentMember us-gaap:LineOfCreditMember us-gaap:EurodollarMember 2019-12-31 0000790526 rdnt:BarclaysMember 2019-12-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember rdnt:SunTrustMember us-gaap:LineOfCreditMember 2019-12-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementSixthAmendmentMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember rdnt:LeverageRatioThreeMember 2019-01-01 2019-12-31 0000790526 us-gaap:NotesPayableOtherPayablesMember 2019-01-01 2019-12-31 0000790526 srt:MinimumMember us-gaap:CapitalLeaseObligationsMember 2019-12-31 0000790526 srt:MaximumMember us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000790526 srt:MaximumMember us-gaap:CapitalLeaseObligationsMember 2019-12-31 0000790526 us-gaap:CommercialPaperMember 2019-01-01 2019-12-31 0000790526 srt:MinimumMember us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000790526 us-gaap:CapitalLeaseObligationsMember 2019-01-01 2019-12-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember rdnt:PricingLevelIVMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:EurodollarMember rdnt:PricingLevelIVMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember rdnt:PricingLevelIIIMember 2018-08-31 2018-08-31 0000790526 rdnt:RestatedAgreementMember rdnt:PricingLevelIIMember 2018-08-31 0000790526 rdnt:RestatedAgreementMember rdnt:PricingLevelIIIMember 2018-08-31 0000790526 rdnt:RestatedAgreementMember rdnt:PricingLevelVMember 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:EurodollarMember rdnt:PricingLevelIIMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:BaseRateMember rdnt:PricingLevelIIMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember rdnt:PricingLevelVMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:EurodollarMember rdnt:PricingLevelIIIMember 2018-08-31 2018-08-31 0000790526 rdnt:RestatedAgreementMember rdnt:PricingLevelIVMember 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:BaseRateMember rdnt:PricingLevelIVMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember rdnt:PricingLevelIMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember rdnt:PricingLevelIIMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:BaseRateMember rdnt:PricingLevelIMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:BaseRateMember rdnt:PricingLevelVMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:EurodollarMember rdnt:PricingLevelVMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:EurodollarMember rdnt:PricingLevelIMember 2018-08-31 2018-08-31 0000790526 rdnt:RestatedAgreementMember rdnt:PricingLevelIMember 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:BaseRateMember rdnt:PricingLevelIIIMember 2018-08-31 2018-08-31 0000790526 srt:MaximumMember 2019-12-31 0000790526 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000790526 rdnt:FacilitiesMember 2019-12-31 0000790526 srt:MinimumMember 2019-12-31 0000790526 us-gaap:DomesticCountryMember 2019-12-31 0000790526 us-gaap:DomesticCountryMember us-gaap:TaxYear2018Member 2019-12-31 0000790526 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0000790526 rdnt:RavenHoldingsMember us-gaap:DomesticCountryMember 2019-12-31 0000790526 us-gaap:DomesticCountryMember 2019-01-01 2019-12-31 0000790526 us-gaap:StateAndLocalJurisdictionMember 2019-01-01 2019-12-31 0000790526 rdnt:FutureServiceMember 2019-01-01 2019-12-31 0000790526 us-gaap:StockOptionMember 2019-12-31 0000790526 rdnt:RestatedPlanMember 2019-01-01 2019-12-31 0000790526 srt:MaximumMember rdnt:RestatedPlanMember 2019-01-01 2019-12-31 0000790526 rdnt:RestatedPlanMember 2017-01-01 2018-12-31 0000790526 us-gaap:RestrictedStockMember 2019-12-31 0000790526 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0000790526 us-gaap:RestrictedStockMember 2018-12-31 0000790526 us-gaap:StockOptionMember 2019-01-01 2019-12-31 0000790526 us-gaap:StockOptionMember 2018-12-31 0000790526 srt:MinimumMember rdnt:RestatedPlanMember 2019-01-01 2019-12-31 0000790526 2019-01-01 2019-03-31 0000790526 2019-04-01 2019-06-30 0000790526 2018-01-01 2018-03-31 0000790526 2019-10-01 2019-12-31 0000790526 2018-10-01 2018-12-31 0000790526 2018-07-01 2018-09-30 0000790526 2019-07-01 2019-09-30 0000790526 2018-04-01 2018-06-30 0000790526 rdnt:WhiteRabbit.aiInc.Member 2019-12-31 2019-12-31 0000790526 rdnt:DeepHealthInc.Member us-gaap:SubsequentEventMember 2020-04-01 2020-04-01 0000790526 us-gaap:AllowanceForNotesReceivableMember 2017-01-01 2017-12-31 0000790526 us-gaap:AllowanceForNotesReceivableMember 2016-12-31 0000790526 us-gaap:AllowanceForNotesReceivableMember 2017-12-31 shares iso4217:USD shares rdnt:joint_venture iso4217:USD pure rdnt:Center false --12-31 FY 2019 0000790526 2.50 3.00 2.00 1.50 2.00 2.50 3.00 1.50 P5Y 10000 P0Y 0.0001 0.0001 200000000 200000000 48977485 50314328 48977485 50314328 0.0100 0.0200 0.0125 0.0225 0.0175 0.0275 0.0075 0.0175 0.0050 0.0150 0.093 0.056 0.037 0.044 0.015 2022-12-31 2020-12-31 2019-12-31 P1Y P10Y P5Y 0 0.0200 0.0225 0.0275 0.0175 0.0150 0.0035 0.0040 0.0045 0.0030 0.0030 2037-12-31 2039-12-31 P3Y P3Y P3Y P3Y P5Y P5Y 10-K true 2019-12-31 false 001-33307 RadNet, Inc. DE 13-3326724 1510 Cotner Avenue Los Angeles, CA 90025 310 478-7808 Common Stock, $.0001 par value RDNT NASDAQ No No Yes Yes Accelerated Filer false false false 576600000 50694375 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Portions of the registrant’s definitive proxy statement for the 2020 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this annual report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the close of the registrant’s fiscal year.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 40165000 10389000 154763000 148919000 1242000 595000 45004000 46288000 2041000 2499000 243215000 208690000 366746000 345729000 445477000 812223000 345729000 440981000 418093000 42994000 40593000 1559000 1354000 34470000 37973000 34548000 31506000 36996000 25392000 1646986000 1109330000 207585000 181028000 14347000 13089000 1316000 2398000 0 3735000 3283000 61206000 39691000 33653000 0 5614000 327428000 239517000 0 31542000 3264000 420922000 652704000 626507000 0 6505000 9529000 5006000 1413847000 909077000 5000 5000 262865000 242835000 -8026000 2259000 -103159000 -117915000 151685000 127184000 81454000 73069000 233139000 200253000 1646986000 1109330000 857178000 46555000 1028236000 868741000 810623000 125943000 106405000 111563000 1154179000 975146000 922186000 999692000 867547000 802377000 80607000 72899000 66796000 -2383000 2054000 -1142000 0 3937000 0 1619000 1931000 1821000 1084301000 944260000 872136000 69878000 30886000 50050000 48044000 43456000 40623000 8350000 11377000 13554000 768000 39539000 0 0 0 3146000 -1283000 181000 258000 -40209000 7641000 -23665000 29669000 38527000 26385000 6229000 394000 24310000 23440000 38133000 2075000 8684000 5890000 2022000 14756000 32243000 53000 0.30 0.67 0 0.29 0.66 0 49674858 48114275 46880775 50244006 48678999 47401921 23440000 38133000 2075000 -32000 -69000 26000 -10253000 2876000 -880000 13155000 40940000 1221000 8684000 5890000 2022000 4471000 35050000 -801000 46574904 4000 198387000 306000 -150211000 48486000 3567000 52053000 867248 1000 7833000 7834000 7834000 281763 2500000 2500000 2500000 3541000 3541000 3541000 4304000 4304000 1528000 1528000 26000 26000 26000 -880000 -880000 -880000 53000 53000 2022000 2075000 47723915 5000 212261000 -548000 -150158000 61560000 8365000 69925000 10000 20000 20000 20000 713160 0 7719000 7719000 7719000 1150 7000 7000 7000 531560 8000000 8000000 8000000 11991000 11991000 22666000 34657000 -2894000 -2894000 9175000 6281000 43000 43000 157000 200000 2640000 2640000 1427000 1427000 44267000 44267000 -69000 -69000 -69000 2876000 2876000 2876000 32243000 32243000 5890000 38133000 48977485 5000 242835000 2259000 -117915000 127184000 73069000 200253000 12500 75000 75000 75000 771042 8735000 8735000 8735000 1500 5000 5000 5000 12692 188000 188000 188000 542109 7500000 7500000 7500000 3537000 3537000 2008000 5545000 750000 750000 3057000 3057000 -32000 -32000 -32000 -10253000 -10253000 -10253000 14756000 14756000 8684000 23440000 50314328 5000 262865000 -8026000 -103159000 151685000 81454000 233139000 23440000 38133000 2075000 80607000 72899000 66796000 66842000 0 0 46555000 -248000 -13469000 4864000 4184000 3898000 3483000 -2383000 2054000 -1142000 0 0 3146000 768000 39539000 0 0 3937000 0 8730000 7662000 6787000 559000 0 0 188000 0 1047000 -3123000 1749000 0 17482000 -2145000 37164000 3557000 9248000 -1461000 2326000 1687000 801000 3888000 6935000 -19504000 66831000 0 6312000 2135000 -1082000 -208000 1034000 17316000 26221000 36181000 104322000 116754000 142225000 27150000 73192000 27612000 143000 2200000 500000 74153000 72180000 61336000 1160000 2575000 852000 132000 0 0 0 0 8429000 0 248000 492000 792000 0 0 0 0 1473000 103000 2000000 1118000 -99465000 -146749000 -79320000 6494000 6072000 6836000 40742000 33830000 196666000 97144000 0 164938000 3057000 1427000 1528000 5275000 0 7720000 750000 2640000 125000 261200000 204300000 200800000 289200000 176300000 200800000 0 200000 0 75000 20000 0 24951000 -10869000 -32247000 -32000 -69000 26000 29776000 -40933000 30684000 10389000 51322000 20638000 40165000 10389000 51322000 46254000 37016000 34197000 5884000 4933000 4939000 51700000 47800000 18500000 51000 6700000 5500000 4300000 440207 6000000.0 680000 0.49 0.49 1300000 1500000 0.75 0.25 0.25 -504000 44300000 0.49 39500000 5400000 50900000 2700000 8000000.0 700000 1700000 2400000 9200000 3000000.0 15000000.0 4000000.0 2500000 4600000 13000000.0 1500000 1000000.0 856000 NATURE OF BUSINESS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a national provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we operated directly or indirectly through joint ventures with hospitals, </span><span style="font-family:inherit;font-size:10pt;"><span>335</span></span><span style="font-family:inherit;font-size:10pt;"> centers located in California, Delaware, Florida, Maryland, New Jersey, and New York. Our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Our services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. The vast majority of our centers offer multi-modality imaging services. Our multi-modality strategy diversifies revenue streams, reduces exposure to reimbursement changes and provides patients and referring physicians one location to serve the needs of multiple procedures. In addition to our imaging services, we have certain other software subsidiaries which design and sell computerized systems for the imaging industry and internally develop Artificial Intelligence, and Imaging On Call LLC, which provides teleradiology services. Our operations comprise a single segment for financial reporting purposes.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of RadNet, Inc as well as its subsidiaries in which RadNet has a controlling financial interest. The consolidated financial statements also include certain variable interest entities in which we are the primary beneficiary (as described in more detail below). All material intercompany transactions and balances have been eliminated upon consolidation. . All of these affiliated entities are referred to collectively as “RadNet”, “we”, “us”, “our” or the “Company” in this report</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounting regulations stipulate that generally any entity with a) insufficient equity to finance its activities without additional subordinated financial support provided by any parties, or b) equity holders that, as a group, lack the characteristics which evidence a controlling financial interest, is considered a Variable Interest Entity (“VIE”). We consolidate all VIEs in which we are the primary beneficiary. We determine whether we are the primary beneficiary of a VIE through a qualitative analysis that identifies which variable interest holder has the controlling financial interest in the VIE. The variable interest holder who has both of the following has the controlling financial interest and is the primary beneficiary: (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. In performing our analysis, we consider all relevant facts and circumstances, including: the design and activities of the VIE, the terms of the contracts the VIE has entered into, the nature of the VIE’s variable interests issued and how they were negotiated with or marketed to potential investors, and which parties participated significantly in the design or redesign of the entity.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">VIEs that we consolidate as the primary beneficiary consist of professional corporations which are owned or controlled by individuals within our senior management, namely Howard G. Berger, M.D., our President and Chief Executive Officer, and John V. Crues, III, M.D., RadNet's Medical Director; both of whom are members of our Board of Directors. Dr. Berger owns, indirectly, </span><span style="font-family:inherit;font-size:10pt;"><span>99%</span></span><span style="font-family:inherit;font-size:10pt;"> of the equity interests in Beverly Radiology Medical Group III (BRMG) and a controlling interest in two professional corporations in New York City. BRMG is responsible for the professional medical services at nearly all of our facilities located in California. Dr. Crues owns six professional corporations which provide medical services in Delaware, Maryland, New Jersey and New York. Additionally, Dr. Crues is a </span><span style="font-family:inherit;font-size:10pt;"><span>1%</span></span><span style="font-family:inherit;font-size:10pt;"> owner of BRMG. These VIEs are collectively referred to as the consolidated medical group ("the Group").</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RadNet provides non-medical, technical and administrative services to the Group for which it receives a management fee, pursuant to the related management agreements. Through the management agreements we have exclusive authority over all non-medical decision making related to the ongoing business operations and we determine the annual budget. The Group has insignificant operating assets and liabilities, and de minimis equity. Through management agreements with us, substantially all cash flows of the Group after expenses, including professional salaries, are transferred to us. We consolidate the revenue and expenses, assets and liabilities of the Group.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Group on a combined basis recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$157.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$132.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$134.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> of revenue, net of management services fees to RadNet, for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively and $</span><span style="font-family:inherit;font-size:10pt;"><span>157.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$132.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$134.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> of operating expenses for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. RadNet, Inc. recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$618.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$505.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$435.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of total billed net service fee revenue for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively, for management services provided to them relating primarily to the technical portion of billed revenue.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The cash flows of the Group are included in the accompanying consolidated statements of cash flows. All intercompany balances and transactions have been eliminated in consolidation. In our consolidated balance sheets at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, we have included approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$100.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$88.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of accounts receivable and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$7.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$5.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> of accounts payable and accrued liabilities related to the Group, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The creditors of the Group do not have recourse to our general credit and there are no other arrangements that could expose us to losses on behalf of them. However, RadNet may be required to provide financial support to cover any operating expenses in excess of operating revenues.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also own a </span><span style="font-family:inherit;font-size:10pt;"><span>49%</span></span><span style="font-family:inherit;font-size:10pt;"> economic interest in ScriptSender, LLC, which provides secure data transmission services of medical information. Through a management agreement, RadNet provides management and accounting services and receives an agreed upon fee. ScriptSender LLC is dependent on the Company to finance its own activities, and as such we determined that it is a VIE but we are not a primary beneficiary since we do not have the power to direct the activities of the entity that most significantly impact the entity’s economic performance.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At all of our centers not serviced by the Group we have entered into long-term contracts (typically 40 years) with independent radiology groups to provide physician services at those centers. These radiology practices provide professional services, including supervision and interpretation of diagnostic imaging procedures, in our diagnostic imaging centers. The radiology practices maintain full control over the provision of professional services. Under these arrangements, in addition to obtaining technical fees for the use of our diagnostic imaging equipment and the provision of technical services, we provide management services and receive a fee based on the value of the services we provide. We own the diagnostic imaging equipment and, therefore, receive 100% of the technical reimbursements associated with imaging procedures. The radiology practice groups retain the professional reimbursements associated with imaging procedures after deducting management service fees paid to us and we have no economic controlling interest in these radiology practices as such, the financial results of these practices are not consolidated in our financial statements.</span></div> 335 0.99 0.01 157400000 132900000 134600000 157400000 132900000 134600000 618900000 505200000 435500000 100300000 88900000 7000000.0 5600000 0.49 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PRINCIPLES OF CONSOLIDATION – The operating activities of subsidiaries are included in the accompanying consolidated financial statements (“financial statements”) from the date of acquisition. Investments in companies in which we have the ability to exercise significant influence, but not control, are accounted for by the equity method. All intercompany transactions and balances, with our consolidated entities and the unsettled amount of intercompany transactions with our equity method investees, have been eliminated in consolidation. As stated in Note 1 above, the Group consists of VIEs and we consolidate the operating activities and balance sheets of each. Additionally, we determined that our unconsolidated joint venture, ScriptSender, LLC, is also a VIE as it is dependent on our operational funding but we are not a primary beneficiary since RadNet does not have the power to direct the activities of the entity that most significantly impact the entity’s economic performance. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">USE OF ESTIMATES - The financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP), which requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect various matters, including our reported amounts of assets and liabilities in our consolidated balance sheets at the dates of the financial statements; our disclosure of contingent assets and liabilities at the dates of the financial statements; and our reported amounts of revenues and expenses in our consolidated statements of operations during the reporting periods. These estimates involve judgments with respect to numerous factors that are difficult to predict and are beyond management’s control. As a result, actual amounts could materially differ from these estimates.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RECLASSIFICATION – For the year 2017, we have reclassified certain amounts within other income and expenses on the consolidated statement of operations and proceeds from issuance of debt on the consolidated statement of cash flows to conform to our 2018 and 2019 presentation. For the year 2018, we have reclassified certain amounts within other expenses on the consolidated statement of cash flows to conform to our 2019 presentation. For the years 2018 and 2017, we have reclassified certain amounts within our reconciliation of the statutory U.S. federal rate and effective rates to conform to our 2019 presentation.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">REVENUES – Our revenues generally relate to net patient fees received from various payors and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As it relates to the consolidated medical group, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by them as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to others centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual allowances under managed care and commercial insurance plans are based upon historical collection experience from such payors in accordance with the underlying contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have price concessions applied. We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2018, we adopted the new revenue recognition accounting standard issued by the Financial Accounting Standards Board (“FASB”) and codified in the ASC as topic 606 (“ASC 606”). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding our revenue recognition policies and significant judgments employed in the determination of revenue.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We applied the modified retrospective approach to all contracts when adopting ASC 606. As a result, at the adoption of ASC 606 the majority of what was previously classified as the provision for bad debts in the statement of operations are now reflected as implicit price concessions and therefore included as a reduction to net operating revenues in 2018 and later. For changes in credit issues not assessed at the date of service, we will prospectively recognize those amounts in other operating expenses on the statement of operations. For periods prior to the adoption of ASC 606, the provision for bad debts has been presented consistent with the previous revenue recognition standards that required it to be presented separately as a component of net operating revenues. As part of the adoption of ASC 606 allowance for doubtful accounts was reclassified to be a component of net patient accounts receivable. Other than these changes in presentation on the consolidated statement of operations and consolidated balance sheet, the adoption of ASC 606 did not have a material impact on the consolidated financial statements. As part of the adoption of ASC 606, we elected two of the available practical expedients provided for in the standard. First, we did not adjust the transaction price for any financing components as those were deemed to be insignificant. Additionally, we expensed all incremental customer contract acquisition costs as incurred as such costs are not material and would be amortized over a period less than one year.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our total net revenues for the years ended December 31, 2019, 2018, and 2017 are presented in the table below (in thousands):</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial insurance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>642,341</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>542,011</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>534,224</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>237,427</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>192,881</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,678</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,283</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,615</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,133</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Workers' compensation/personal injury</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,792</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,193</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,969</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other patient revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,862</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,117</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,882</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Management fee revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,659</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,882</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Imaging on call and software</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,317</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,261</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,116</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,555</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,781</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,049</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service fee revenue, net of contractual allowances and discounts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,028,236</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>868,741</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>857,178</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision for bad debts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(46,555</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service fee revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,028,236</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>868,741</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>810,623</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue under capitation arrangements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>125,943</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106,405</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111,563</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net revenue</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,154,179</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>975,146</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>922,186</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ACCOUNTS RECEIVABLE – Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. We continuously monitor collections from our payors and record an estimated price concession based upon specific payor collection issues that we have identified and our historical experience.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2019 and 2018 we entered into factoring agreements with various institutions and sold certain accounts receivable under non-recourse agreements. These transactions are accounted for as a reduction in accounts receivable as the agreements transfer effective control over and risk related to the receivables to the buyers. The aggregate amounts factored under these facilities, net of discounts recorded to reflect market interest rates, was </span><span style="font-family:inherit;font-size:10pt;"><span>$9.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$20.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds on notes receivable are reflected as operating activities on our statement of cash flows and on our balance sheet as prepaid expenses and other current assets for the current portion and deposits and other for the long term portion. At December 31, 2019 we have </span><span style="font-family:inherit;font-size:10pt;"><span>$24.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> remaining to be collected on these agreements. We do not utilize factoring arrangements as an integral part of our financing for working capital.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MEANINGFUL USE INCENTIVE – Under the American Recovery and Reinvestment Act of 2009, a program was enacted that provides financial incentives for providers that successfully implement and utilize electronic health record technology to improve patient care. Our software development team in Canada developed a Radiology Information System (RIS) software platform that has been awarded meaningful use certification. We recorded the meaningful use incentive within non-operating income. The program ended in 2017 and we recorded approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$250,000</span></span><span style="font-family:inherit;font-size:10pt;"> to other income during the twelve months ended December 31, 2017 relating to this incentive. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SOFTWARE REVENUE RECOGNITION – Our subsidiary, eRAD, Inc., sells Picture Archiving Communications Systems (“PACS”) and related services, primarily in the United States. The PACS systems sold by eRAD are primarily composed of certain elements: hardware, software, installation and training, and support. Sales are made primarily through eRAD’s sales force and generally include hardware, software, installation, training and first-year warranty support. Hardware, which is not unique or special purpose, is purchased from a third-party and resold to eRAD’s customers with a small mark-up.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have determined that our core software products, such as PACS, are essential to most of our arrangements as hardware, software and related services are sold as an integrated package. Revenue is recognized when a performance obligation is satisfied by transferring a promised good or service to a customer. </span></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, we recorded approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$10.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$6.8</span></span><span style="font-family:inherit;font-size:10pt;"> million, and </span><span style="font-family:inherit;font-size:10pt;"><span>$6.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in revenue related to our eRAD business which is included in net service fee revenue in our consolidated statement of operations. At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> we had a deferred revenue liability of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with eRAD sales which we expect to recognize into revenue over the next 12 months.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SOFTWARE DEVELOPMENT COSTS – When we develop our own software solutions through our eRad subsidiary, we capitalize and amortize those costs over their useful life. Costs related to the research and development of new software products </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and enhancements to existing software products all for resale to our customers are expensed as incurred. If we enter into agreements where we license our software to outside customers, we have recorded the receipt of these funds against the capitalized software costs. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our most major software development to date was the Radiology Information System, a front desk patient tracking software, which had total capitalized costs of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$6.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and was fully amortized as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CONCENTRATION OF CREDIT RISKS – Financial instruments that potentially subject us to credit risk are primarily cash equivalents and accounts receivable. We have placed our cash and cash equivalents with one major financial institution. At times, the cash in the financial institution is temporarily in excess of the amount insured by the Federal Deposit Insurance Corporation, or FDIC. Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. We continuously monitor collections and maintain an allowance for bad debts based upon our historical collection experience. In addition, we have notes receivable stemming from our factoring of accounts receivable as stated above. Companies with which we factor our receivables are well known established buyers of such instruments, have agreed to assume the full risk of their collection, and to date have made all payments due to us in a timely manner. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CASH AND CASH EQUIVALENTS – We consider all highly liquid investments that mature in three months or less when purchased to be cash equivalents. The carrying amount of cash and cash equivalents approximates the fair market value.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">DEFERRED FINANCING COSTS – Costs of financing are deferred and amortized using the effective interest rate method. Deferred financing costs are solely related to our Barclays Revolving Credit Facilities. Deferred financing costs, net of accumulated amortization, were </span><span style="font-family:inherit;font-size:10pt;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the twelve months ended </span><span style="font-family:inherit;font-size:10pt;text-align:left;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. See Note 8, Revolving Credit Facility, Notes Payable, and Capital Leases for more information on our revolving lines of credit.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">INVENTORIES – Inventories, consisting mainly of medical supplies, are stated at the lower of cost or net realizable value with cost determined by the first-in, first-out method.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PROPERTY AND EQUIPMENT – Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are provided using the straight-line method over the estimated useful lives, which range from </span><span style="font-family:inherit;font-size:10pt;"><span>3</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span><span style="font-family:inherit;font-size:10pt;">. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from </span><span style="font-family:inherit;font-size:10pt;"><span>3</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span><span style="font-family:inherit;font-size:10pt;">. Maintenance and repairs are charged to expense as incurred.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">BUSINESS COMBINATION – When the qualifications for business combination accounting treatment are met, it requires us to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GOODWILL AND INDEFINITE LIVED INTANGIBLES – Goodwill totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$441.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$418.1</span></span><span style="font-family:inherit;font-size:10pt;"> million at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. Indefinite lived intangible assets at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$11.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$9.8</span></span><span style="font-family:inherit;font-size:10pt;"> million at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and are associated with the value of certain trade name intangibles. Goodwill and trade name intangibles are recorded as a result of business combinations. When we determine the carrying value of goodwill exceeds its fair value, an impairment charge would be recognized which should not exceed the total amount of goodwill allocated to that reporting unit. We determined fair values for each of the reporting units using the market approach, when available and appropriate, or the income approach, or a combination of both. We assess the valuation methodology based upon the relevance and availability of the data at the time we perform the valuation. If multiple valuation methodologies are used, the results are weighted appropriately. We tested both goodwill and trade name intangibles for impairment on October 1, 2019, noting no impairment, and have not identified any indicators of impairment through December 31, 2019.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the testing of goodwill and trade name intangibles at October 1, 2018, our Teleradiology reporting unit, Imaging On Call, (IOC), experienced a reduction of professional medical group clients and a loss of a contract with a major local health provider during 2018. This affected its estimated fair value and resulted in impairment charges to our reporting unit of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.9</span></span><span style="font-family:inherit;font-size:10pt;"> million for the twelve months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, with goodwill representing </span><span style="font-family:inherit;font-size:10pt;"><span>$3.8</span></span><span style="font-family:inherit;font-size:10pt;"> million of the total and the remainder being its </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">trade name of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$100,000</span></span><span style="font-family:inherit;font-size:10pt;">. The estimated fair value of IOC reporting unit was determined by using the discounted cash flow method. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LONG-LIVED ASSETS – We evaluate our long-lived assets (property and equipment) and intangibles, other than goodwill, for impairment when events or changes indicate the carrying amount of an asset may not be recoverable. Accounting standards requires that if the sum of the undiscounted expected future cash flows from a long-lived asset or definite-lived intangible is less than the carrying value of that asset, an asset impairment charge must be recognized. The amount of the impairment charge is calculated as the excess of the asset’s carrying value over its fair value, which generally represents the discounted future cash flows from that asset or in the case of assets we expect to sell, at fair value less costs to sell. We determined that there were no events or changes in circumstances that indicated our long-lived assets were impaired during any periods presented.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">INCOME TAXES – Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income in determining whether our net deferred tax assets are more likely than not to be realized. Income taxes are further explained in Note 10, Income Taxes. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LEASES - We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liability, and long term operating lease liability in our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liability, and long-term finance lease liability in our consolidated balance sheets.  ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. We use the implicit rate when readily determinable. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We include options to extend a lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For a contract in which we are a lessee that contains fixed payments for both lease and non-lease components, we have elected to account for the components as a single lease component, as permitted. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. See Note 9, Leases, for more information. </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">UNINSURED RISKS – On November 1, 2008 we obtained a fully funded and insured workers’ compensation policy, thereby eliminating any uninsured risks for employee injuries occurring on or after that date. This fully funded policy remained in effect through November 1, 2013 and continues to cover any claims incurred through this date.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 1, 2013 we entered into a high-deductible workers’ compensation insurance policy. We have recorded liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> for each of the years ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, for the estimated future cash obligations associated with the unpaid portion of the workers compensation claims incurred.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and our affiliated physicians carry an annual medical malpractice insurance policy that protects us for claims that are filed during the policy year and that fall within policy limits. The policy has a deductible for which is </span><span style="font-family:inherit;font-size:10pt;"><span>$10,000</span></span><span style="font-family:inherit;font-size:10pt;"> per incidence for the years ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2008, in order to eliminate the exposure for claims not reported during the regular malpractice policy period, we purchased a medical malpractice claims made tail policy, which provides coverage for any claims reported in the event that our medical malpractice policy expires. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, this policy remains in effect.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have entered into an arrangement with Blue Shield to administer and process claims under a self-insured plan that provides health insurance coverage for our employees and dependents. We have recorded liabilities as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, for the estimated future cash obligations associated with the unpaid portion of the medical and dental claims incurred by our participants. Additionally, we entered into an agreement with Blue Shield for a stop loss policy that provides coverage for any claims that exceed </span><span style="font-family:inherit;font-size:10pt;"><span>$250,000</span></span><span style="font-family:inherit;font-size:10pt;"> up to a maximum of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in order for us to limit our exposure for unusual or catastrophic claims. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EMPLOYEE BENEFIT PLAN – We adopted a profit-sharing/savings plan pursuant to Section 401(k) of the Internal Revenue Code that covers substantially all non-professional employees. Eligible employees may contribute on a tax-deferred basis a percentage of compensation, up to the maximum allowable under tax law. Employee contributions vest immediately. As of </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 1, 2017, RadNet provides a matching contribution in the amount to a maximum of </span><span style="font-family:inherit;font-size:10pt;"><span>1.0%</span></span><span style="font-family:inherit;font-size:10pt;"> per </span><span style="font-family:inherit;font-size:10pt;"><span>4.0%</span></span><span style="font-family:inherit;font-size:10pt;"> of employee contribution. RadNet contributed </span><span style="font-family:inherit;font-size:10pt;"><span>$2.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;text-align:left;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;text-align:left;"> </span><span style="font-family:inherit;font-size:10pt;">and is expected to contribute approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the plan year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LOSS AND OTHER UNFAVORABLE CONTRACTS – We assess the profitability of our contracts to provide management services to our contracted physician groups and identify those contracts where current operating results or forecasts indicate probable future losses. Anticipated future revenue is compared to anticipated costs and if the anticipated future cost exceeds the revenue, a loss contract accrual is recorded. In connection with the acquisition of Radiologix in November 2006, we acquired certain management service agreements which met this criterion and recorded to other non-current liabilities an </span><span style="font-family:inherit;font-size:10pt;"><span>$8.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> loss contract accrual. Of the </span><span style="font-family:inherit;font-size:10pt;"><span>$4.6</span></span><span style="font-family:inherit;font-size:10pt;"> million ending balance at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, (</span><span style="font-family:inherit;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> net of taxes), was settled against the purchase consideration of Hudson Valley Radiology Associates, P.L.L.C. (HVRA) by our VIE entity Lenox Hill Radiology and Medical Associates, P.C. and the remaining balance of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$558,000</span></span><span style="font-family:inherit;font-size:10pt;"> was written off upon ending a contract with a physician group. See Note 4, Facility Acquisitions, Assets Held for Sale and Dispositions for further information on the purchase of HVRA.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Related to acquisition activity, we entered into certain operating lease commitments for facilities where the fair market rent differs from the lease contract rate. We recorded an unfavorable contract liability representing the difference between the total value of the fair market rent and the contract rent over the current term of the lease applicable from the date of acquisition. As of December 31, 2018, the unfavorable contract liability on these leases was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2</span></span><span style="font-family:inherit;font-size:10pt;"> million. This balance was transferred to operating lease right-of-use assets in conjunction with adoption of Accounting Standard Update No. 2016-02, Leases, which amended the accounting standards for leases. See Note 9, Leases, for further information.</span></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EQUITY BASED COMPENSATION – We have one long-term incentive plan that we adopted in 2006 and which we first amended and restated as of April 20, 2015, and again on March 9, 2017 (the “Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. We have reserved for issuance under the Restated Plan </span><span style="font-family:inherit;font-size:10pt;"><span>14,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock. We can issue options, stock awards, stock appreciation rights, stock units and cash awards under the Restated Plan. Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options and warrants generally vest over three to </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;"> and expire five to </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;"> from date of grant. The compensation expense associated with option grants is calculated based on a valuation model, typically the Black–Scholes model, which requires certain management assumptions with respect to volatility. The compensation expense recognized for all equity-based awards is recognized over the awards’ service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees. See Note 11 Stock-Based Compensation for more information.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">FOREIGN CURRENCY TRANSLATION – The functional currency of our foreign subsidiaries is the local currency. In accordance with ASC 830, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign Currency Matters</span><span style="font-family:inherit;font-size:10pt;">, assets and liabilities denominated in foreign currencies are translated using the exchange rate at the balance sheet dates. Revenues and expenses are translated using average exchange rates prevailing during the reporting period. Any translation adjustments resulting from this process are shown separately as a component of accumulated other comprehensive income (loss). Foreign currency transaction gains and losses are included in the determination of net income.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">COMPREHENSIVE INCOME (LOSS) – Accounting guidance</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">establishes rules for reporting and displaying comprehensive income (loss) and its components. Our unrealized gains or losses on foreign currency translation adjustments and our interest rate cap and swap agreements are included in comprehensive income (loss). The components of comprehensive income (loss) for the three years in the period ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are included in the consolidated statements of comprehensive income (loss).</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CONTINGENCIES - We are party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business. With respect to these matters, we evaluate the developments on a regular basis and accrue a liability when we believe a loss is probable and the amount can be reasonably estimated. We believe that the amount or any estimable range of reasonably possible or probable loss will not, either individually or in the aggregate, have a material adverse effect on our business and consolidated financial statements. However, the outcome of these matters is inherently uncertain. Therefore, if one or more of these matters were resolved against us for amounts in excess of management's expectations, our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable, could be materially adversely affected.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the second quarter of 2019, we accrued a liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to allegations by the US Attorney's Office for the Western District of New York that RadNet submitted certain claims which incorrectly identified the physician who furnished the radiology services.  The final settlement, which admits no wrong-doing on behalf of RadNet, was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and paid in September 2019.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">DERIVATIVE INSTRUMENTS </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016 CAPS</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the fourth quarter of 2016, we entered into two forward interest rate cap agreements ("2016 Caps"). The 2016 Caps will mature in September and October 2020. The 2016 Caps had notional amounts of </span><span style="font-family:inherit;font-size:10pt;"><span>$150,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$350,000,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, which were designated at inception as cash flow hedges of future cash interest payments associated with portions of our variable rate bank debt. Under these arrangements, we purchased a cap on 3 month LIBOR at </span><span style="font-family:inherit;font-size:10pt;"><span>2.0%</span></span><span style="font-family:inherit;font-size:10pt;">. We are liable for a </span><span style="font-family:inherit;font-size:10pt;"><span>$5.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> premium to enter into the caps which is being accrued to current liabilities on our balance sheet and paid over the life of the 2016 Caps.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At inception, we designated our 2016 Caps as cash flow hedges of floating-rate borrowings. In accordance with ASC Topic 815, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss of the hedge (i.e. change in fair value) is reported as a component of accumulated other comprehensive income in the consolidated statement of equity. See Fair Value Measurements section below for the fair value of the 2016 Caps at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive income (loss), net of taxes is as follows (amounts in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:30%;"/><td style="width:36%;"/><td style="width:34%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Interest Rate Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the twelve months ended</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount of (Loss) Gain Recognized on Derivative, net of taxes</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location of Loss Recognized<br/>in Income on Derivative</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(4,383)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other Comprehensive Loss</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,876</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(880)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other Comprehensive Loss</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2019 SWAPS</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the second quarter of 2019, we entered into four forward interest rate agreements ("2019 swaps"). The 2019 swaps have total notional amounts of </span><span style="font-family:inherit;font-size:10pt;"><span>$500,000,000</span></span><span style="font-family:inherit;font-size:10pt;">, consisting of two agreements of </span><span style="font-family:inherit;font-size:10pt;"><span>$50,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> each and two agreements of </span><span style="font-family:inherit;font-size:10pt;"><span>$200,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> each. The 2019 swaps will secure a constant interest rate associated with portions of our variable rate bank debt and have an effective date of October 13, 2020. They will mature in October 2023 for the two smaller notional and October 2025 for the two larger notional. Under these arrangements, we arranged the 2019 swaps with locked in 1 month LIBOR rates at </span><span style="font-family:inherit;font-size:10pt;"><span>1.96%</span></span><span style="font-family:inherit;font-size:10pt;"> for the two </span><span style="font-family:inherit;font-size:10pt;"><span>$50,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> notional and at </span><span style="font-family:inherit;font-size:10pt;"><span>2.05%</span></span><span style="font-family:inherit;font-size:10pt;"> for the two </span><span style="font-family:inherit;font-size:10pt;"><span>$200,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> notional. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At inception, we designated our 2019 swaps as cash flow hedges of floating-rate borrowings. In accordance with ASC Topic 815, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss of the hedge (i.e. change in fair value) is reported as a component of comprehensive loss in the consolidated statement of equity.  See Fair Value Measurements section below for the fair value of the 2019 swaps at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;text-align:left;">.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:30%;"/><td style="width:36%;"/><td style="width:34%;"/></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">For the twelve months ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Effective Interest Rate Swap</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount of Loss Recognized on Derivative, net of taxes</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location of Loss Recognized</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">in Income on Derivative</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(5,870)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other Comprehensive Loss</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">FAIR VALUE MEASUREMENTS – Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Derivatives:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below summarizes the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets in our consolidated balance sheets, as follows (in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current and long term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016 CAPS - Interest Rate Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,081</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,081</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 SWAPS - Interest Rate Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,477</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,477</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016 CAPS - Interest Rate Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,316</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,316</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair value of these contracts was determined using Level 2 inputs. More specifically, the fair value was determined by calculating the value of the difference between the fixed interest rate of the interest rate swaps and the counterparty’s forward LIBOR curve. The forward LIBOR curve is readily available in the public markets or can be derived from information available in the public markets.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Long Term Debt</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below summarizes the estimated fair value and carrying amount of our SunTrust (Term Loan Agreement) and Barclays (First Lien Term Loans) long-term debt as follows (in thousands):</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Face Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term Loan Agreement and First Lien Term Loans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>708,948</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>708,948</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>705,699</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Face Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term Loan Agreement and First Lien Term Loans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>633,229</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>633,229</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>646,441</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our Barclays revolving credit facility had </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount outstanding as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and a </span><span style="font-family:inherit;font-size:10pt;"><span>$28.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> principal amount outstanding as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. Our SunTrust revolving credit facility had </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount outstanding for the periods ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair values of our long-term debt, which is discussed in Note 8, was determined using Level 2 inputs for the Barclays and SunTrust term loans. Level 2 inputs primarily related to comparable market prices.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We consider the carrying amounts of cash and cash equivalents, receivables, other current assets, current liabilities and other notes payables to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment. Additionally, we consider the carrying amount of our capital lease obligations to approximate their fair value because the weighted average interest rate used to formulate the carrying amounts approximates current market rates.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EARNINGS PER SHARE - Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to RadNet, Inc. common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,756</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average number of common shares outstanding during the period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,674,858</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,114,275</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,880,775</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income per share attributable to RadNet, Inc. common stockholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.30</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.67</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average number of common shares outstanding during the period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,674,858</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,114,275</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,880,775</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Add nonvested restricted stock subject only to service vesting</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>208,963</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180,631</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274,940</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Add additional shares issuable upon exercise of stock options and warrants</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>360,185</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>384,093</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>246,206</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average number of common shares used in calculating diluted net income per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,244,006</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,678,999</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,401,921</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per share attributable to RadNet, Inc. common stockholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.66</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options excluded from the computation of diluted per share amounts:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares for which the exercise price exceeds average market price of common stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175,037</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EQUITY INVESTMENTS AT FAIR VALUE- As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have three equity investments for which a fair value is not readily determinable and we do not have significant influence and therefore the total amounts invested are recognized at cost. In accordance with accounting guidance</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">, </span><span style="font-family:inherit;font-size:10pt;">if there is no readily determinable fair value, the guidance allows entities the ability to measure investments at cost less impairment, whereby impairment is based on a qualitative assessment.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Medic Vision:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medic Vision, based in Israel, specializes in software packages that provide compliant radiation dose structured reporting and enhanced images from reduced dose CT scans.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 24, 2017, we acquired an initial </span><span style="font-family:inherit;font-size:10pt;"><span>12.50%</span></span><span style="font-family:inherit;font-size:10pt;"> equity interest in Medic Vision - Imaging Solutions Ltd for </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0</span></span><span style="font-family:inherit;font-size:10pt;"> million. We also received an option to exercise warrants to acquire up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>12.50%</span></span><span style="font-family:inherit;font-size:10pt;"> equity interest for </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4</span></span><span style="font-family:inherit;font-size:10pt;"> million within one year from the initial share purchase date, if exercised in full. On March 1, 2018 we exercised our warrant in part and acquired an additional </span><span style="font-family:inherit;font-size:10pt;"><span>1.96%</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;"><span>$200,000</span></span><span style="font-family:inherit;font-size:10pt;">. Our initial equity interest has been diluted to </span><span style="font-family:inherit;font-size:10pt;"><span>12.25%</span></span><span style="font-family:inherit;font-size:10pt;"> and our total equity investment stands at </span><span style="font-family:inherit;font-size:10pt;"><span>14.21%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with accounting guidance</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">, </span><span style="font-family:inherit;font-size:10pt;">as we exercise no significant influence over Medic Vision’s operations, the investment is recorded at its cost of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, given that the fair value is not readily determinable. No impairment in our investment was noted as of the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Turner Imaging:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Turner Imaging Systems, based in Utah, develops and markets portable X-ray imaging systems that provide a user the ability to acquire X-ray images wherever and whenever they are needed. On February 1, 2018, we purchased </span><span style="font-family:inherit;font-size:10pt;"><span>2.1</span></span><span style="font-family:inherit;font-size:10pt;"> million preferred shares in Turner Imaging Systems for </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0</span></span><span style="font-family:inherit;font-size:10pt;"> million. On January 1, 2019 we funded a convertible promissory note in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$143,000</span></span><span style="font-family:inherit;font-size:10pt;"> that converted to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>80,000</span></span><span style="font-family:inherit;font-size:10pt;"> preferred shares on October 11, 2019. No impairment in our investment was noted for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">WhiteRabbit.ai Inc:</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">WhiteRabbit.ai Inc., based in California, is currently developing an artificial intelligence suite which aims to improve the speed and accuracy of cancer detection in radiology and improve patient care. On November 5, 2019 we acquired an equity interest in the company for </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and also loaned the company </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> in support of its operations. No impairment in our investment was noted for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">INVESTMENT IN JOINT VENTURES – We have </span><span style="font-family:inherit;font-size:10pt;"><span>12</span></span><span style="font-family:inherit;font-size:10pt;"> unconsolidated joint ventures with ownership interests ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>35%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>55%</span></span><span style="font-family:inherit;font-size:10pt;">. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers.  Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture.  Our investment in these joint ventures is accounted for under the equity method, as we do not have a controlling financial interest in such ventures. We evaluate our investment in joint ventures, including cost in excess of book value (equity method goodwill) for impairment whenever indicators of impairment exist. No indicators of impairment existed as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Sale of joint venture interest:</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 1, 2017, we formed in conjuncture with Cedars Sinai Medical Center (“CSMC”) the Santa Monica Imaging Group, LLC (“SMIG”), consisting of two multi-modality imaging centers located in Santa Monica, CA with RadNet holding a </span><span style="font-family:inherit;font-size:10pt;"><span>40%</span></span><span style="font-family:inherit;font-size:10pt;"> economic interest and CSMC holding a </span><span style="font-family:inherit;font-size:10pt;"><span>60%</span></span><span style="font-family:inherit;font-size:10pt;"> economic interest. RadNet accounts for our share of the venture under the equity method. On January 1, 2019, CSMC purchased from the us an additional </span><span style="font-family:inherit;font-size:10pt;"><span>five percent</span></span><span style="font-family:inherit;font-size:10pt;"> economic interest in SMIG valued at </span><span style="font-family:inherit;font-size:10pt;"><span>$134,000</span></span><span style="font-family:inherit;font-size:10pt;">. As a result of the transaction, our economic interest in SMIG has been reduced to </span><span style="font-family:inherit;font-size:10pt;"><span>35%</span></span><span style="font-family:inherit;font-size:10pt;">. We recorded a loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$2,000</span></span><span style="font-family:inherit;font-size:10pt;"> on the transaction.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Change in control of existing joint ventures</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 6, 2014, we acquired a </span><span style="font-family:inherit;font-size:10pt;"><span>49%</span></span><span style="font-family:inherit;font-size:10pt;"> equity interest in Garden State Radiology Network, LLC ("GSRN") for cash consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;">. The venture consisted of two imaging centers located in New Jersey. On August 1, 2019, the entity was dissolved by transferring ownership of the assets of the centers with each partner receiving full ownership of one center. See Note 4, Facility Acquisitions and Dispositions, for further information.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 12, 2018 we acquired </span><span style="font-family:inherit;font-size:10pt;"><span>25%</span></span><span style="font-family:inherit;font-size:10pt;"> share capital in Nulogix, Inc. for cash consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. On August 1, 2019 we completed via the issuance of RadNet common stock valued at </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, the acquisition of the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>75%</span></span><span style="font-family:inherit;font-size:10pt;"> economic interest and we now consolidate the financial statements of Nulogix.  See Note 4, Facility Acquisitions and Dispositions, for further information.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 1, 2018, we obtained control over the operations of NJIN through an agreement with the other equity interest holder for no cash consideration. As such, we consolidated the financial statements of NJIN effective that date. The economic interest of each party remained the same after consolidation. See Note 4, Facility Acquisitions and Dispositions, to the consolidated financial statements contain herein for further information.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Joint venture investment and financial information</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table is a summary of our investment in joint ventures during the years ended </span><span style="font-family:inherit;font-size:10pt;text-align:left;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,435</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity contributions in existing and purchase of interest in joint ventures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity in earnings in these joint ventures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,377</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Disposition of equity method interest upon acquisition of control in NJIN</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,993</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distribution of earnings</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24,846</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,973</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity contributions in existing and purchase of interest in joint ventures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity in earnings in these joint ventures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,350</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sale of ownership interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(134</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dissolution of GSRN</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,428</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nulogix return of capital</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(792</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nulogix change in control</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,004</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distribution of earnings</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,598</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,470</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We charged management service fees from the centers underlying these joint ventures of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$11.4</span></span><span style="font-family:inherit;font-size:10pt;"> million, </span><span style="font-family:inherit;font-size:10pt;"><span>$13.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$13.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended December 31, 2019, 2018 and 2017, respectively . We eliminate any unrealized portion of our management service fees with our equity in earnings of joint ventures.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table is a summary of key unaudited financial data for these joint ventures as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, and for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively, (in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance Sheet Data:</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,427</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,317</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,037</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,912</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,217</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,300</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18,872</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,898</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,031</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Book value of RadNet joint venture interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,001</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,030</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost in excess of book value of acquired joint venture interests accounted for as equity method goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,469</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,943</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total value of RadNet joint venture interests</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,470</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,973</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total book value of other joint venture partner interests</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,374</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,001</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>108,051</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155,820</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>188,849</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,624</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,596</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,644</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PRINCIPLES OF CONSOLIDATION – The operating activities of subsidiaries are included in the accompanying consolidated financial statements (“financial statements”) from the date of acquisition. Investments in companies in which we have the ability to exercise significant influence, but not control, are accounted for by the equity method. All intercompany transactions and balances, with our consolidated entities and the unsettled amount of intercompany transactions with our equity method investees, have been eliminated in consolidation. As stated in Note 1 above, the Group consists of VIEs and we consolidate the operating activities and balance sheets of each. Additionally, we determined that our unconsolidated joint venture, ScriptSender, LLC, is also a VIE as it is dependent on our operational funding but we are not a primary beneficiary since RadNet does not have the power to direct the activities of the entity that most significantly impact the entity’s economic performance. </span></div> <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">USE OF ESTIMATES - The financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP), which requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect various matters, including our reported amounts of assets and liabilities in our consolidated balance sheets at the dates of the financial statements; our disclosure of contingent assets and liabilities at the dates of the financial statements; and our reported amounts of revenues and expenses in our consolidated statements of operations during the reporting periods. These estimates involve judgments with respect to numerous factors that are difficult to predict and are beyond management’s control. As a result, actual amounts could materially differ from these estimates.</span></div> RECLASSIFICATION – For the year 2017, we have reclassified certain amounts within other income and expenses on the consolidated statement of operations and proceeds from issuance of debt on the consolidated statement of cash flows to conform to our 2018 and 2019 presentation. For the year 2018, we have reclassified certain amounts within other expenses on the consolidated statement of cash flows to conform to our 2019 presentation. <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">REVENUES – Our revenues generally relate to net patient fees received from various payors and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As it relates to the consolidated medical group, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by them as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to others centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual allowances under managed care and commercial insurance plans are based upon historical collection experience from such payors in accordance with the underlying contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have price concessions applied. We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2018, we adopted the new revenue recognition accounting standard issued by the Financial Accounting Standards Board (“FASB”) and codified in the ASC as topic 606 (“ASC 606”). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding our revenue recognition policies and significant judgments employed in the determination of revenue.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We applied the modified retrospective approach to all contracts when adopting ASC 606. As a result, at the adoption of ASC 606 the majority of what was previously classified as the provision for bad debts in the statement of operations are now reflected as implicit price concessions and therefore included as a reduction to net operating revenues in 2018 and later. For changes in credit issues not assessed at the date of service, we will prospectively recognize those amounts in other operating expenses on the statement of operations. For periods prior to the adoption of ASC 606, the provision for bad debts has been presented consistent with the previous revenue recognition standards that required it to be presented separately as a component of net operating revenues. As part of the adoption of ASC 606 allowance for doubtful accounts was reclassified to be a component of net patient accounts receivable. Other than these changes in presentation on the consolidated statement of operations and consolidated balance sheet, the adoption of ASC 606 did not have a material impact on the consolidated financial statements. As part of the adoption of ASC 606, we elected two of the available practical expedients provided for in the standard. First, we did not adjust the transaction price for any financing components as those were deemed to be insignificant. Additionally, we expensed all incremental customer contract acquisition costs as incurred as such costs are not material and would be amortized over a period less than one year.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our total net revenues for the years ended December 31, 2019, 2018, and 2017 are presented in the table below (in thousands):</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial insurance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>642,341</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>542,011</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>534,224</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>237,427</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>192,881</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,678</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,283</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,615</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,133</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Workers' compensation/personal injury</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,792</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,193</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,969</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other patient revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,862</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,117</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,882</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Management fee revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,659</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,882</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Imaging on call and software</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,317</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,261</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,116</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,555</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,781</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,049</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service fee revenue, net of contractual allowances and discounts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,028,236</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>868,741</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>857,178</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision for bad debts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(46,555</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service fee revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,028,236</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>868,741</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>810,623</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue under capitation arrangements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>125,943</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106,405</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111,563</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net revenue</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,154,179</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>975,146</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>922,186</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 642341000 542011000 534224000 237427000 192881000 179678000 28283000 25615000 24133000 42792000 34193000 32969000 23862000 25117000 29882000 11659000 13882000 13127000 17317000 16261000 18116000 24555000 18781000 25049000 1028236000 868741000 857178000 46555000 1028236000 868741000 810623000 125943000 106405000 111563000 1154179000 975146000 922186000 <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ACCOUNTS RECEIVABLE – Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. We continuously monitor collections from our payors and record an estimated price concession based upon specific payor collection issues that we have identified and our historical experience.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2019 and 2018 we entered into factoring agreements with various institutions and sold certain accounts receivable under non-recourse agreements. These transactions are accounted for as a reduction in accounts receivable as the agreements transfer effective control over and risk related to the receivables to the buyers. The aggregate amounts factored under these facilities, net of discounts recorded to reflect market interest rates, was </span><span style="font-family:inherit;font-size:10pt;"><span>$9.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$20.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds on notes receivable are reflected as operating activities on our statement of cash flows and on our balance sheet as prepaid expenses and other current assets for the current portion and deposits and other for the long term portion. At December 31, 2019 we have </span><span style="font-family:inherit;font-size:10pt;"><span>$24.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> remaining to be collected on these agreements. We do not utilize factoring arrangements as an integral part of our financing for working capital.</span></div> 9000000.0 20500000 24200000 MEANINGFUL USE INCENTIVE – Under the American Recovery and Reinvestment Act of 2009, a program was enacted that provides financial incentives for providers that successfully implement and utilize electronic health record technology to improve patient care. Our software development team in Canada developed a Radiology Information System (RIS) software platform that has been awarded meaningful use certification. We recorded the meaningful use incentive within non-operating income. 250000 <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SOFTWARE REVENUE RECOGNITION – Our subsidiary, eRAD, Inc., sells Picture Archiving Communications Systems (“PACS”) and related services, primarily in the United States. The PACS systems sold by eRAD are primarily composed of certain elements: hardware, software, installation and training, and support. Sales are made primarily through eRAD’s sales force and generally include hardware, software, installation, training and first-year warranty support. Hardware, which is not unique or special purpose, is purchased from a third-party and resold to eRAD’s customers with a small mark-up.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have determined that our core software products, such as PACS, are essential to most of our arrangements as hardware, software and related services are sold as an integrated package. Revenue is recognized when a performance obligation is satisfied by transferring a promised good or service to a customer. </span></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, we recorded approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$10.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$6.8</span></span><span style="font-family:inherit;font-size:10pt;"> million, and </span><span style="font-family:inherit;font-size:10pt;"><span>$6.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in revenue related to our eRAD business which is included in net service fee revenue in our consolidated statement of operations. At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> we had a deferred revenue liability of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with eRAD sales which we expect to recognize into revenue over the next 12 months.</span></div> 10100000 6800000 6100000 1300000 <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SOFTWARE DEVELOPMENT COSTS – When we develop our own software solutions through our eRad subsidiary, we capitalize and amortize those costs over their useful life. Costs related to the research and development of new software products </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and enhancements to existing software products all for resale to our customers are expensed as incurred. If we enter into agreements where we license our software to outside customers, we have recorded the receipt of these funds against the capitalized software costs. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our most major software development to date was the Radiology Information System, a front desk patient tracking software, which had total capitalized costs of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$6.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and was fully amortized as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 6400000 CONCENTRATION OF CREDIT RISKS – Financial instruments that potentially subject us to credit risk are primarily cash equivalents and accounts receivable. We have placed our cash and cash equivalents with one major financial institution. At times, the cash in the financial institution is temporarily in excess of the amount insured by the Federal Deposit Insurance Corporation, or FDIC. Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. We continuously monitor collections and maintain an allowance for bad debts based upon our historical collection experience. In addition, we have notes receivable stemming from our factoring of accounts receivable as stated above. Companies with which we factor our receivables are well known established buyers of such instruments, have agreed to assume the full risk of their collection, and to date have made all payments due to us in a timely manner. <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CASH AND CASH EQUIVALENTS – We consider all highly liquid investments that mature in three months or less when purchased to be cash equivalents. The carrying amount of cash and cash equivalents approximates the fair market value.</span></div> <span style="font-family:inherit;font-size:10pt;">DEFERRED FINANCING COSTS – Costs of financing are deferred and amortized using the effective interest rate method. Deferred financing costs are solely related to our Barclays Revolving Credit Facilities. Deferred financing costs, net of accumulated amortization, were </span><span style="font-family:inherit;font-size:10pt;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the twelve months ended </span><span style="font-family:inherit;font-size:10pt;text-align:left;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span>, respectively 1600000 1400000 <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">INVENTORIES – Inventories, consisting mainly of medical supplies, are stated at the lower of cost or net realizable value with cost determined by the first-in, first-out method.</span></div> <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PROPERTY AND EQUIPMENT – Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are provided using the straight-line method over the estimated useful lives, which range from </span><span style="font-family:inherit;font-size:10pt;"><span>3</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span><span style="font-family:inherit;font-size:10pt;">. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from </span><span style="font-family:inherit;font-size:10pt;"><span>3</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span><span style="font-family:inherit;font-size:10pt;">. Maintenance and repairs are charged to expense as incurred.</span></div> P3Y P15Y P3Y P15Y <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">BUSINESS COMBINATION – When the qualifications for business combination accounting treatment are met, it requires us to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.</span></div> <span style="font-family:inherit;font-size:10pt;">GOODWILL AND INDEFINITE LIVED INTANGIBLES – Goodwill totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$441.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$418.1</span></span><span style="font-family:inherit;font-size:10pt;"> million at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. Indefinite lived intangible assets at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$11.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$9.8</span></span><span style="font-family:inherit;font-size:10pt;"> million at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span> and are associated with the value of certain trade name intangibles. Goodwill and trade name intangibles are recorded as a result of business combinations. When we determine the carrying value of goodwill exceeds its fair value, an impairment charge would be recognized which should not exceed the total amount of goodwill allocated to that reporting unit. We determined fair values for each of the reporting units using the market approach, when available and appropriate, or the income approach, or a combination of both. We assess the valuation methodology based upon the relevance and availability of the data at the time we perform the valuation. If multiple valuation methodologies are used, the results are weighted appropriately. 441000000.0 418100000 11300000 9800000 3900000 3800000 100000 <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LONG-LIVED ASSETS – We evaluate our long-lived assets (property and equipment) and intangibles, other than goodwill, for impairment when events or changes indicate the carrying amount of an asset may not be recoverable. Accounting standards requires that if the sum of the undiscounted expected future cash flows from a long-lived asset or definite-lived intangible is less than the carrying value of that asset, an asset impairment charge must be recognized. The amount of the impairment charge is calculated as the excess of the asset’s carrying value over its fair value, which generally represents the discounted future cash flows from that asset or in the case of assets we expect to sell, at fair value less costs to sell. We determined that there were no events or changes in circumstances that indicated our long-lived assets were impaired during any periods presented.</span></div> INCOME TAXES – Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income in determining whether our net deferred tax assets are more likely than not to be realized. LEASES - We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liability, and long term operating lease liability in our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liability, and long-term finance lease liability in our consolidated balance sheets.  ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. We use the implicit rate when readily determinable. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We include options to extend a lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For a contract in which we are a lessee that contains fixed payments for both lease and non-lease components, we have elected to account for the components as a single lease component, as permitted. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">UNINSURED RISKS – On November 1, 2008 we obtained a fully funded and insured workers’ compensation policy, thereby eliminating any uninsured risks for employee injuries occurring on or after that date. This fully funded policy remained in effect through November 1, 2013 and continues to cover any claims incurred through this date.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 1, 2013 we entered into a high-deductible workers’ compensation insurance policy. We have recorded liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> for each of the years ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, for the estimated future cash obligations associated with the unpaid portion of the workers compensation claims incurred.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and our affiliated physicians carry an annual medical malpractice insurance policy that protects us for claims that are filed during the policy year and that fall within policy limits. The policy has a deductible for which is </span><span style="font-family:inherit;font-size:10pt;"><span>$10,000</span></span><span style="font-family:inherit;font-size:10pt;"> per incidence for the years ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2008, in order to eliminate the exposure for claims not reported during the regular malpractice policy period, we purchased a medical malpractice claims made tail policy, which provides coverage for any claims reported in the event that our medical malpractice policy expires. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, this policy remains in effect.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><span style="font-family:inherit;font-size:10pt;">We have entered into an arrangement with Blue Shield to administer and process claims under a self-insured plan that provides health insurance coverage for our employees and dependents. We have recorded liabilities as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, for the estimated future cash obligations associated with the unpaid portion of the medical and dental claims incurred by our participants. Additionally, we entered into an agreement with Blue Shield for a stop loss policy that provides coverage for any claims that exceed </span><span style="font-family:inherit;font-size:10pt;"><span>$250,000</span></span><span style="font-family:inherit;font-size:10pt;"> up to a maximum of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span> in order for us to limit our exposure for unusual or catastrophic claims. 3800000 2800000 10000 4900000 4800000 250000 1000000.0 EMPLOYEE BENEFIT PLAN – We adopted a profit-sharing/savings plan pursuant to Section 401(k) of the Internal Revenue Code that covers substantially all non-professional employees. Eligible employees may contribute on a tax-deferred basis a percentage of compensation, up to the maximum allowable under tax law. Employee contributions vest immediately. 0.010 0.040 2600000 3000000.0 <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LOSS AND OTHER UNFAVORABLE CONTRACTS – We assess the profitability of our contracts to provide management services to our contracted physician groups and identify those contracts where current operating results or forecasts indicate probable future losses. Anticipated future revenue is compared to anticipated costs and if the anticipated future cost exceeds the revenue, a loss contract accrual is recorded. In connection with the acquisition of Radiologix in November 2006, we acquired certain management service agreements which met this criterion and recorded to other non-current liabilities an </span><span style="font-family:inherit;font-size:10pt;"><span>$8.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> loss contract accrual. Of the </span><span style="font-family:inherit;font-size:10pt;"><span>$4.6</span></span><span style="font-family:inherit;font-size:10pt;"> million ending balance at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, (</span><span style="font-family:inherit;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> net of taxes), was settled against the purchase consideration of Hudson Valley Radiology Associates, P.L.L.C. (HVRA) by our VIE entity Lenox Hill Radiology and Medical Associates, P.C. and the remaining balance of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$558,000</span></span><span style="font-family:inherit;font-size:10pt;"> was written off upon ending a contract with a physician group. See Note 4, Facility Acquisitions, Assets Held for Sale and Dispositions for further information on the purchase of HVRA.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Related to acquisition activity, we entered into certain operating lease commitments for facilities where the fair market rent differs from the lease contract rate. We recorded an unfavorable contract liability representing the difference between the total value of the fair market rent and the contract rent over the current term of the lease applicable from the date of acquisition. 8900000 4600000 4000000.0 2800000 558000 2200000 <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EQUITY BASED COMPENSATION – We have one long-term incentive plan that we adopted in 2006 and which we first amended and restated as of April 20, 2015, and again on March 9, 2017 (the “Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. We have reserved for issuance under the Restated Plan </span><span style="font-family:inherit;font-size:10pt;"><span>14,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock. We can issue options, stock awards, stock appreciation rights, stock units and cash awards under the Restated Plan. Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options and warrants generally vest over three to </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;"> and expire five to </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;"> from date of grant. The compensation expense associated with option grants is calculated based on a valuation model, typically the Black–Scholes model, which requires certain management assumptions with respect to volatility. The compensation expense recognized for all equity-based awards is recognized over the awards’ service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees. See Note 11 Stock-Based Compensation for more information.</span></div> 14000000 P5Y P10Y <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">FOREIGN CURRENCY TRANSLATION – The functional currency of our foreign subsidiaries is the local currency. In accordance with ASC 830, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign Currency Matters</span><span style="font-family:inherit;font-size:10pt;">, assets and liabilities denominated in foreign currencies are translated using the exchange rate at the balance sheet dates. Revenues and expenses are translated using average exchange rates prevailing during the reporting period. Any translation adjustments resulting from this process are shown separately as a component of accumulated other comprehensive income (loss). Foreign currency transaction gains and losses are included in the determination of net income.</span></div> <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">COMPREHENSIVE INCOME (LOSS) – Accounting guidance</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">establishes rules for reporting and displaying comprehensive income (loss) and its components. Our unrealized gains or losses on foreign currency translation adjustments and our interest rate cap and swap agreements are included in comprehensive income (loss). The components of comprehensive income (loss) for the three years in the period ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are included in the consolidated statements of comprehensive income (loss).</span></div> <div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CONTINGENCIES - We are party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business. With respect to these matters, we evaluate the developments on a regular basis and accrue a liability when we believe a loss is probable and the amount can be reasonably estimated. We believe that the amount or any estimable range of reasonably possible or probable loss will not, either individually or in the aggregate, have a material adverse effect on our business and consolidated financial statements. However, the outcome of these matters is inherently uncertain. Therefore, if one or more of these matters were resolved against us for amounts in excess of management's expectations, our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable, could be materially adversely affected.</span></div> 2300000 2200000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">DERIVATIVE INSTRUMENTS </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016 CAPS</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the fourth quarter of 2016, we entered into two forward interest rate cap agreements ("2016 Caps"). The 2016 Caps will mature in September and October 2020. The 2016 Caps had notional amounts of </span><span style="font-family:inherit;font-size:10pt;"><span>$150,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$350,000,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, which were designated at inception as cash flow hedges of future cash interest payments associated with portions of our variable rate bank debt. Under these arrangements, we purchased a cap on 3 month LIBOR at </span><span style="font-family:inherit;font-size:10pt;"><span>2.0%</span></span><span style="font-family:inherit;font-size:10pt;">. We are liable for a </span><span style="font-family:inherit;font-size:10pt;"><span>$5.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> premium to enter into the caps which is being accrued to current liabilities on our balance sheet and paid over the life of the 2016 Caps.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At inception, we designated our 2016 Caps as cash flow hedges of floating-rate borrowings. In accordance with ASC Topic 815, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss of the hedge (i.e. change in fair value) is reported as a component of accumulated other comprehensive income in the consolidated statement of equity. See Fair Value Measurements section below for the fair value of the 2016 Caps at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive income (loss), net of taxes is as follows (amounts in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:30%;"/><td style="width:36%;"/><td style="width:34%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Interest Rate Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the twelve months ended</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount of (Loss) Gain Recognized on Derivative, net of taxes</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location of Loss Recognized<br/>in Income on Derivative</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(4,383)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other Comprehensive Loss</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,876</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(880)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other Comprehensive Loss</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2019 SWAPS</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the second quarter of 2019, we entered into four forward interest rate agreements ("2019 swaps"). The 2019 swaps have total notional amounts of </span><span style="font-family:inherit;font-size:10pt;"><span>$500,000,000</span></span><span style="font-family:inherit;font-size:10pt;">, consisting of two agreements of </span><span style="font-family:inherit;font-size:10pt;"><span>$50,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> each and two agreements of </span><span style="font-family:inherit;font-size:10pt;"><span>$200,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> each. The 2019 swaps will secure a constant interest rate associated with portions of our variable rate bank debt and have an effective date of October 13, 2020. They will mature in October 2023 for the two smaller notional and October 2025 for the two larger notional. Under these arrangements, we arranged the 2019 swaps with locked in 1 month LIBOR rates at </span><span style="font-family:inherit;font-size:10pt;"><span>1.96%</span></span><span style="font-family:inherit;font-size:10pt;"> for the two </span><span style="font-family:inherit;font-size:10pt;"><span>$50,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> notional and at </span><span style="font-family:inherit;font-size:10pt;"><span>2.05%</span></span><span style="font-family:inherit;font-size:10pt;"> for the two </span><span style="font-family:inherit;font-size:10pt;"><span>$200,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> notional. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At inception, we designated our 2019 swaps as cash flow hedges of floating-rate borrowings. In accordance with ASC Topic 815, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss of the hedge (i.e. change in fair value) is reported as a component of comprehensive loss in the consolidated statement of equity.  See Fair Value Measurements section below for the fair value of the 2019 swaps at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;text-align:left;">.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:30%;"/><td style="width:36%;"/><td style="width:34%;"/></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">For the twelve months ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Effective Interest Rate Swap</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount of Loss Recognized on Derivative, net of taxes</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location of Loss Recognized</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">in Income on Derivative</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(5,870)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other Comprehensive Loss</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 150000000 350000000 0.020 5300000 -4383000 -2876000 880000 500000000 50000000 200000000 0.0196 50000000 0.0205 200000000 <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:30%;"/><td style="width:36%;"/><td style="width:34%;"/></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">For the twelve months ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Effective Interest Rate Swap</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount of Loss Recognized on Derivative, net of taxes</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location of Loss Recognized</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">in Income on Derivative</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(5,870)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other Comprehensive Loss</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive income (loss), net of taxes is as follows (amounts in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:30%;"/><td style="width:36%;"/><td style="width:34%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Interest Rate Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the twelve months ended</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount of (Loss) Gain Recognized on Derivative, net of taxes</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location of Loss Recognized<br/>in Income on Derivative</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(4,383)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other Comprehensive Loss</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,876</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(880)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other Comprehensive Loss</span></div></td></tr></table></div></div> -5870000 <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">FAIR VALUE MEASUREMENTS – Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Derivatives:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below summarizes the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets in our consolidated balance sheets, as follows (in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current and long term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016 CAPS - Interest Rate Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,081</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,081</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 SWAPS - Interest Rate Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,477</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,477</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016 CAPS - Interest Rate Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,316</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,316</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair value of these contracts was determined using Level 2 inputs. More specifically, the fair value was determined by calculating the value of the difference between the fixed interest rate of the interest rate swaps and the counterparty’s forward LIBOR curve. The forward LIBOR curve is readily available in the public markets or can be derived from information available in the public markets.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Long Term Debt</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below summarizes the estimated fair value and carrying amount of our SunTrust (Term Loan Agreement) and Barclays (First Lien Term Loans) long-term debt as follows (in thousands):</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Face Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term Loan Agreement and First Lien Term Loans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>708,948</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>708,948</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>705,699</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Face Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term Loan Agreement and First Lien Term Loans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>633,229</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>633,229</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>646,441</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our Barclays revolving credit facility had </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount outstanding as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and a </span><span style="font-family:inherit;font-size:10pt;"><span>$28.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> principal amount outstanding as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. Our SunTrust revolving credit facility had </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount outstanding for the periods ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair values of our long-term debt, which is discussed in Note 8, was determined using Level 2 inputs for the Barclays and SunTrust term loans. Level 2 inputs primarily related to comparable market prices.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We consider the carrying amounts of cash and cash equivalents, receivables, other current assets, current liabilities and other notes payables to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment. Additionally, we consider the carrying amount of our capital lease obligations to approximate their fair value because the weighted average interest rate used to formulate the carrying amounts approximates current market rates.</span></div> <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below summarizes the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets in our consolidated balance sheets, as follows (in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current and long term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016 CAPS - Interest Rate Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,081</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,081</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 SWAPS - Interest Rate Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,477</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,477</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016 CAPS - Interest Rate Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,316</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,316</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below summarizes the estimated fair value and carrying amount of our SunTrust (Term Loan Agreement) and Barclays (First Lien Term Loans) long-term debt as follows (in thousands):</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Face Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term Loan Agreement and First Lien Term Loans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>708,948</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>708,948</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>705,699</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Face Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term Loan Agreement and First Lien Term Loans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>633,229</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>633,229</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>646,441</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 1081000 0 1081000 0 9477000 0 9477000 0 -3316000 0 -3316000 0 708948000 0 708948000 705699000 0 633229000 0 633229000 646441000 0 28000000.0 0 <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EARNINGS PER SHARE - Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to RadNet, Inc. common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,756</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average number of common shares outstanding during the period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,674,858</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,114,275</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,880,775</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income per share attributable to RadNet, Inc. common stockholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.30</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.67</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average number of common shares outstanding during the period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,674,858</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,114,275</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,880,775</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Add nonvested restricted stock subject only to service vesting</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>208,963</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180,631</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274,940</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Add additional shares issuable upon exercise of stock options and warrants</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>360,185</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>384,093</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>246,206</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average number of common shares used in calculating diluted net income per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,244,006</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,678,999</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,401,921</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per share attributable to RadNet, Inc. common stockholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.66</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options excluded from the computation of diluted per share amounts:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares for which the exercise price exceeds average market price of common stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175,037</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):<div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to RadNet, Inc. common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,756</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average number of common shares outstanding during the period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,674,858</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,114,275</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,880,775</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income per share attributable to RadNet, Inc. common stockholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.30</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.67</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average number of common shares outstanding during the period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,674,858</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,114,275</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,880,775</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Add nonvested restricted stock subject only to service vesting</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>208,963</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180,631</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274,940</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Add additional shares issuable upon exercise of stock options and warrants</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>360,185</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>384,093</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>246,206</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average number of common shares used in calculating diluted net income per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,244,006</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,678,999</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,401,921</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per share attributable to RadNet, Inc. common stockholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.66</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options excluded from the computation of diluted per share amounts:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares for which the exercise price exceeds average market price of common stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175,037</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 14756000 32243000 53000 49674858 48114275 46880775 0.30 0.67 0 49674858 48114275 46880775 208963 180631 274940 360185 384093 246206 50244006 48678999 47401921 0.29 0.66 0 0 6250 175037 0.1250 1000000.0 0.1250 1400000 0.0196 200000 0.1225 0.1421 1200000 2100000 2000000.0 143000 80000 1000000.0 2500000 <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">INVESTMENT IN JOINT VENTURES – We have </span><span style="font-family:inherit;font-size:10pt;"><span>12</span></span><span style="font-family:inherit;font-size:10pt;"> unconsolidated joint ventures with ownership interests ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>35%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>55%</span></span><span style="font-family:inherit;font-size:10pt;">. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers.  Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture.  Our investment in these joint ventures is accounted for under the equity method, as we do not have a controlling financial interest in such ventures. We evaluate our investment in joint ventures, including cost in excess of book value (equity method goodwill) for impairment whenever indicators of impairment exist. No indicators of impairment existed as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Sale of joint venture interest:</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 1, 2017, we formed in conjuncture with Cedars Sinai Medical Center (“CSMC”) the Santa Monica Imaging Group, LLC (“SMIG”), consisting of two multi-modality imaging centers located in Santa Monica, CA with RadNet holding a </span><span style="font-family:inherit;font-size:10pt;"><span>40%</span></span><span style="font-family:inherit;font-size:10pt;"> economic interest and CSMC holding a </span><span style="font-family:inherit;font-size:10pt;"><span>60%</span></span><span style="font-family:inherit;font-size:10pt;"> economic interest. RadNet accounts for our share of the venture under the equity method. On January 1, 2019, CSMC purchased from the us an additional </span><span style="font-family:inherit;font-size:10pt;"><span>five percent</span></span><span style="font-family:inherit;font-size:10pt;"> economic interest in SMIG valued at </span><span style="font-family:inherit;font-size:10pt;"><span>$134,000</span></span><span style="font-family:inherit;font-size:10pt;">. As a result of the transaction, our economic interest in SMIG has been reduced to </span><span style="font-family:inherit;font-size:10pt;"><span>35%</span></span><span style="font-family:inherit;font-size:10pt;">. We recorded a loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$2,000</span></span><span style="font-family:inherit;font-size:10pt;"> on the transaction.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Change in control of existing joint ventures</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 6, 2014, we acquired a </span><span style="font-family:inherit;font-size:10pt;"><span>49%</span></span><span style="font-family:inherit;font-size:10pt;"> equity interest in Garden State Radiology Network, LLC ("GSRN") for cash consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;">. The venture consisted of two imaging centers located in New Jersey. On August 1, 2019, the entity was dissolved by transferring ownership of the assets of the centers with each partner receiving full ownership of one center. See Note 4, Facility Acquisitions and Dispositions, for further information.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 12, 2018 we acquired </span><span style="font-family:inherit;font-size:10pt;"><span>25%</span></span><span style="font-family:inherit;font-size:10pt;"> share capital in Nulogix, Inc. for cash consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. On August 1, 2019 we completed via the issuance of RadNet common stock valued at </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, the acquisition of the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>75%</span></span><span style="font-family:inherit;font-size:10pt;"> economic interest and we now consolidate the financial statements of Nulogix.  See Note 4, Facility Acquisitions and Dispositions, for further information.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 1, 2018, we obtained control over the operations of NJIN through an agreement with the other equity interest holder for no cash consideration. As such, we consolidated the financial statements of NJIN effective that date. The economic interest of each party remained the same after consolidation. See Note 4, Facility Acquisitions and Dispositions, to the consolidated financial statements contain herein for further information.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Joint venture investment and financial information</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table is a summary of our investment in joint ventures during the years ended </span><span style="font-family:inherit;font-size:10pt;text-align:left;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,435</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity contributions in existing and purchase of interest in joint ventures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity in earnings in these joint ventures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,377</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Disposition of equity method interest upon acquisition of control in NJIN</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,993</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distribution of earnings</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24,846</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,973</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity contributions in existing and purchase of interest in joint ventures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity in earnings in these joint ventures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,350</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sale of ownership interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(134</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dissolution of GSRN</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,428</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nulogix return of capital</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(792</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nulogix change in control</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,004</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distribution of earnings</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,598</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,470</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We charged management service fees from the centers underlying these joint ventures of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$11.4</span></span><span style="font-family:inherit;font-size:10pt;"> million, </span><span style="font-family:inherit;font-size:10pt;"><span>$13.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$13.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended December 31, 2019, 2018 and 2017, respectively . We eliminate any unrealized portion of our management service fees with our equity in earnings of joint ventures.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table is a summary of key unaudited financial data for these joint ventures as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, and for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively, (in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance Sheet Data:</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,427</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,317</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,037</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,912</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,217</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,300</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18,872</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,898</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,031</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Book value of RadNet joint venture interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,001</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,030</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost in excess of book value of acquired joint venture interests accounted for as equity method goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,469</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,943</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total value of RadNet joint venture interests</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,470</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,973</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total book value of other joint venture partner interests</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,374</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,001</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>108,051</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155,820</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>188,849</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,624</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,596</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,644</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 12 0.35 0.55 0.40 0.60 0.05 134000 0.35 -2000 0.49 2200000 0.25 2000000.0 1500000 0.75 <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table is a summary of our investment in joint ventures during the years ended </span><span style="font-family:inherit;font-size:10pt;text-align:left;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,435</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity contributions in existing and purchase of interest in joint ventures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity in earnings in these joint ventures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,377</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Disposition of equity method interest upon acquisition of control in NJIN</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,993</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distribution of earnings</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24,846</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,973</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity contributions in existing and purchase of interest in joint ventures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity in earnings in these joint ventures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,350</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sale of ownership interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(134</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dissolution of GSRN</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,428</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nulogix return of capital</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(792</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nulogix change in control</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,004</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distribution of earnings</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,598</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,470</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 52435000 2000000 11377000 2993000 24846000 37973000 103000 8350000 -134000 -1428000 792000 1004000 8598000 34470000 11400000 13800000 13100000 <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table is a summary of key unaudited financial data for these joint ventures as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, and for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively, (in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance Sheet Data:</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,427</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,317</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,037</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,912</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,217</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,300</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18,872</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,898</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,031</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Book value of RadNet joint venture interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,001</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,030</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost in excess of book value of acquired joint venture interests accounted for as equity method goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,469</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,943</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total value of RadNet joint venture interests</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,470</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,973</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total book value of other joint venture partner interests</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,374</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,001</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>108,051</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155,820</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>188,849</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,624</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,596</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,644</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 27427000 28317000 61037000 45912000 9217000 4300000 18872000 4898000 60375000 65031000 28001000 30030000 6469000 7943000 34470000 37973000 32374000 35001000 108051000 155820000 188849000 18624000 24596000 28644000 RECENT ACCOUNTING STANDARDS<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting standards adopted</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued Accounting Standard Update ("ASU") No. 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;"> (ASU 2016-02), which amends the existing accounting standards for leases. In September 2017, the FASB issued ASU No. 2017-13 which provides additional clarification and implementation guidance on the previously issued ASU No. 2016-02. Subsequently, in July 2018, the FASB issued ASU No 2018-10, Codification Improvements to Topic 842, Leases, and ASU No. 2018-11, Targeted Improvement, to clarify and amend the guidance in ASU No. 2016-02. The amendments in this update were effective for fiscal years (and interim reporting periods within fiscal years) beginning after December 15, 2018, with early adoption permitted for all entities. Under the new guidance, a lessee is required to recognize a lease liability and right-of-use asset for all leases with terms in excess of twelve months. The new guidance also requires additional disclosures to enable users of financial statements to understand the amount, timing, and potential uncertainty of cash flows arising from leases. Consistent with current guidance, a </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lessee’s recognition, measurement, and presentation of expenses and cash flows arising from a lease will continue to depend primarily on its classification. We have elected the optional transition method to apply the standard as of the effective date and therefore, we will not apply the standard to the comparative periods presented in the consolidated financial statements. We elected the transition package of three practical expedients permitted within the standard, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs. See Note 9, Leases, for more information.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU No. 2018-02 (“ASU 2018-02”), </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income</span><span style="font-family:inherit;font-size:10pt;">. ASU 2018-02 allows for the reclassification of certain income tax effects related to the Tax Cuts and Jobs Act between “Accumulated other comprehensive income” and “Retained earnings.” This ASU relates to the requirement that adjustments to deferred tax liabilities and assets related to a change in tax laws or rates to be included in “Income from continuing operations”, even in situations where the related items were originally recognized in “Other comprehensive income” (rather than in “Income from continuing operations”). Subsequently, in March 2018, the FASB issued ASU No. 2018-05, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes, </span><span style="font-family:inherit;font-size:10pt;">to clarify and amend guidance in ASU 2018-02. ASU 2018-02 and ASU 2018-05 are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. Adoption of this ASU is to be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the tax laws or rates were recognized. The adoption had no significant impact on the our results of operations, financial position and cash flows.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:2px;padding-top:2px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2019, the FASB issued ASU 2019-04, ("ASU 2019-04"), </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments</span><span style="font-family:inherit;font-size:10pt;">, which, among other things, clarifies certain hedge accounting guidance. For the year ended 2017, we elected to early adopt ASU 2017-12, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Targeted Improvements to Accounting for Hedging Activities</span><span style="font-family:inherit;font-size:10pt;">, (Topic 815), for which this current ASU 2019-04 amends. For those entities that have already adopted ASU 2017-12, the hedging amendments in ASU 2019-04 are effective as of the beginning of the first annual reporting period beginning after 25 April 2019 and early adoption is permitted. We elected early adoption of ASU 2019-04 and the adoption had no effect on our financial statements.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting standards not yet adopted</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13 ("ASU 2016-13), </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses.</span><span style="font-family:inherit;font-size:10pt;"> ASU 2016-13 replaces the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The standard will be effective for us beginning after December 15, 2019, with early adoption permitted. We are currently evaluating the impact of this standard on our consolidated financial statements, including accounting policies, processes, and systems.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU No. 2018-15 (“ASU 2018-15”), </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software.</span><span style="font-family:inherit;font-size:10pt;"> ASU 2018-15 aligns the requirements for deferring implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This ASU is effective in the first quarter of 2020 with early adoption permitted and can be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We are currently assessing the impact of the adoption of this ASU on our results of operations, financial position and cash flows.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued ASU 2019-12 ("ASU 2019-12"), </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes (Topic 740). </span><span style="font-family:inherit;font-size:10pt;">ASU 2019-12 removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other areas of the standard. ASU 2019-12 will be effective beginning in the first quarter of 2021. Early adoption is permitted. Certain amendments in this update must be applied on a prospective basis, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings/(deficit) in the period of adoption. We are currently evaluating the impact this ASU will have on our financial statements and related disclosures as well as the timing of adoption.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, the FASB issued ASU 2020-01 ("ASU 2020-01"), </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815), </span><span style="font-family:inherit;font-size:10pt;">clarifying the interaction between accounting standards related to equity securities, equity method investments, and certain derivatives. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020. We do not expect the adoption of this guidance will have a material impact on its consolidated financial statements.</span></div> FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisitions</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"/><span style="font-family:inherit;font-size:10pt;">On August 1, 2019 we completed a step-up acquisition upon the dissolution of our former </span><span style="font-family:inherit;font-size:10pt;"><span>49%</span></span><span style="font-family:inherit;font-size:10pt;"> owned joint venture, Garden State Radiology LLC ("GSRN"). GSRN consisted of two multi-modality centers operating in New Jersey. GSRN became our wholly owned subsidiary with the withdrawal of the </span><span style="font-family:inherit;font-size:10pt;"><span>51%</span></span><span style="font-family:inherit;font-size:10pt;"> majority partner for the full ownership of one center with no other consideration. We made a fair value determination of our original </span><span style="font-family:inherit;font-size:10pt;"><span>49%</span></span><span style="font-family:inherit;font-size:10pt;"> interest which resulted in a step-up gain of  approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;">. We determined a fair value of the remaining acquired imaging center of </span><span style="font-family:inherit;font-size:10pt;text-align:right;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in assets and </span><span style="font-family:inherit;font-size:10pt;"><span>$426,000</span></span><span style="font-family:inherit;font-size:10pt;"> in liabilities were recognized. We recorded </span><span style="font-family:inherit;font-size:10pt;text-align:right;"><span>$1,000</span></span><span style="font-family:inherit;font-size:10pt;"> in other assets, </span><span style="font-family:inherit;font-size:10pt;text-align:right;"><span>$679,000</span></span><span style="font-family:inherit;font-size:10pt;"> in fixed assets, </span><span style="font-family:inherit;font-size:10pt;text-align:right;"><span>$426,000</span></span><span style="font-family:inherit;font-size:10pt;"> in right-of-use assets, </span><span style="font-family:inherit;font-size:10pt;"><span>$426,000</span></span><span style="font-family:inherit;font-size:10pt;"> in operating lease liabilities, and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in goodwill.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 1, 2019 we completed a step-up acquisition of our former </span><span style="font-family:inherit;font-size:10pt;"><span>25%</span></span><span style="font-family:inherit;font-size:10pt;"> owned joint venture, Nulogix, via a stock issuance of RadNet common shares valued at </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> to obtain the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>75%</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding Nulogix shares. We made a fair value determination of the acquired assets and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$189,000</span></span><span style="font-family:inherit;font-size:10pt;"> in fixed assets, </span><span style="font-family:inherit;font-size:10pt;"><span>$732,000</span></span><span style="font-family:inherit;font-size:10pt;"> in intangible assets, </span><span style="font-family:inherit;font-size:10pt;"><span>$278,000</span></span><span style="font-family:inherit;font-size:10pt;"> in deferred tax liability and goodwill of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> were recorded. We also made a fair value determination of our </span><span style="font-family:inherit;font-size:10pt;"><span>25%</span></span><span style="font-family:inherit;font-size:10pt;"> pre-existing interest in the business and recognized a loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$504,000</span></span><span style="font-family:inherit;font-size:10pt;"> which is included in operating expenses within the consolidated statements of operations. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 1, 2019 we completed our acquisition of certain assets of Kern Radiology Imaging Systems Inc., consisting of four multi-modality imaging centers located in Bakersfield, California for purchase consideration of </span><span style="font-family:inherit;font-size:10pt;text-align:right;"><span>$19.3 million</span></span><span style="font-family:inherit;font-size:10pt;">. We made a fair value determination of the acquired assets and assumed liabilities and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$10.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in property and equipment, </span><span style="font-family:inherit;font-size:10pt;"><span>$9.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in right-of-use assets, </span><span style="font-family:inherit;font-size:10pt;"><span>$36,000</span></span><span style="font-family:inherit;font-size:10pt;"> in other assets, </span><span style="font-family:inherit;font-size:10pt;"><span>$3.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> in intangible assets, </span><span style="font-family:inherit;font-size:10pt;"><span>$14.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> in operating lease liabilities, and </span><span style="font-family:inherit;font-size:10pt;"><span>$10.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> in goodwill were recorded.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 1, 2019 we completed our acquisition of certain assets of Zilkha Radiology Inc. consisting of two multi-modality centers located in Islip, New York for purchase consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. We made a fair value determination of the acquired assets and assumed liabilities and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in property and equipment, </span><span style="font-family:inherit;font-size:10pt;"><span>$5.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in right-of-use assets, </span><span style="font-family:inherit;font-size:10pt;"><span>$100,000</span></span><span style="font-family:inherit;font-size:10pt;"> in intangible assets, </span><span style="font-family:inherit;font-size:10pt;"><span>$5.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in operating lease liabilities, </span><span style="font-family:inherit;font-size:10pt;"><span>$332,000</span></span><span style="font-family:inherit;font-size:10pt;"> in finance lease liabilities and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> in goodwill were recorded.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 28, 2019, one of VIE entities, Lenox Hill Radiology and Medical Imaging Associates, P.C. ("LHR"), purchased the membership interest of Hudson Valley Radiology Associates, P.L.L.C. ("HVRA") for </span><span style="font-family:inherit;font-size:10pt;"><span>$6.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of RadNet common stock and contingent consideration valued at </span><span style="font-family:inherit;font-size:10pt;"><span>$680,000</span></span><span style="font-family:inherit;font-size:10pt;"> to guarantee the share value issued for a period of six months post acquisition date. LHR has performed a fair value purchase price allocation and recorded equipment of </span><span style="font-family:inherit;font-size:10pt;"><span>$10,000</span></span><span style="font-family:inherit;font-size:10pt;">, a covenant not to compete of </span><span style="font-family:inherit;font-size:10pt;"><span>$50,000</span></span><span style="font-family:inherit;font-size:10pt;">, trade name of </span><span style="font-family:inherit;font-size:10pt;"><span>$380,000</span></span><span style="font-family:inherit;font-size:10pt;">, other intangible assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$340,000</span></span><span style="font-family:inherit;font-size:10pt;"> and goodwill of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> from the transaction. In connection with the acquisition, RadNet also settled against the purchase consideration, </span><span style="font-family:inherit;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of taxes, of an unfavorable vendor contract with HVRA stemming from the previous acquisition of Radiologix, Inc. in November 2006. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 1, 2019 our majority owned subsidiary, West Valley Imaging Group, LLC ("WVIG") completed its acquisition of certain assets of West Valley Imaging Center, LLC ("West Valley"), consisting of a single multi-modality imaging center located in West Hills, CA for purchase consideration of </span><span style="font-family:inherit;font-size:10pt;text-align:right;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> all of which was initially funded by the Company. We have made a fair value determination of the acquired assets and approximately </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;text-align:right;"><span>$300,000</span></span><span style="font-family:inherit;font-size:10pt;"> in equipment and fixed assets, </span><span style="font-family:inherit;font-size:10pt;"><span>$7,000</span></span><span style="font-family:inherit;font-size:10pt;"> in other assets, </span><span style="font-family:inherit;font-size:10pt;"><span>$200,000</span></span><span style="font-family:inherit;font-size:10pt;"> in intangible assets and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> in goodwill were recorded. Subsequent to the transaction, our partner in WVIG, Cedars Sinai Medical Center, contributed </span><span style="font-family:inherit;font-size:10pt;"><span>$750,000</span></span><span style="font-family:inherit;font-size:10pt;"> in cash to maintain its </span><span style="font-family:inherit;font-size:10pt;"><span>25%</span></span><span style="font-family:inherit;font-size:10pt;"> economic interest in the venture.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 3, 2018 we completed our acquisition of certain assets of Orange County Diagnostics Imaging Center consisting of five multi-modality imaging centers located in Orange County, California for purchase consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.6</span></span><span style="font-family:inherit;font-size:10pt;"> million. We have made a fair valuation determination of the acquired assets and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$23,000</span></span><span style="font-family:inherit;font-size:10pt;"> of current assets, </span><span style="font-family:inherit;font-size:10pt;"><span>$69,000</span></span><span style="font-family:inherit;font-size:10pt;"> of other assets, </span><span style="font-family:inherit;font-size:10pt;"><span>$2.8</span></span><span style="font-family:inherit;font-size:10pt;"> million of leaseholds and equipment, a </span><span style="font-family:inherit;font-size:10pt;"><span>$50,000</span></span><span style="font-family:inherit;font-size:10pt;"> of covenant not to compete, and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.6</span></span><span style="font-family:inherit;font-size:10pt;"> million of goodwill were recorded.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 5, 2018 we completed our acquisition of certain assets of Arcadia Radiology Imaging consisting of one multi-modality imaging center and one women’s center located in Arcadia, California for purchase consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.8</span></span><span style="font-family:inherit;font-size:10pt;"> million. We have made a fair value determination of the acquired assets and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$20,000</span></span><span style="font-family:inherit;font-size:10pt;"> of other assets, </span><span style="font-family:inherit;font-size:10pt;"><span>$819,000</span></span><span style="font-family:inherit;font-size:10pt;"> of leaseholds, </span><span style="font-family:inherit;font-size:10pt;"><span>$80,000</span></span><span style="font-family:inherit;font-size:10pt;"> equipment, </span><span style="font-family:inherit;font-size:10pt;"><span>$300,000</span></span><span style="font-family:inherit;font-size:10pt;"> in covenants not to compete, and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.6</span></span><span style="font-family:inherit;font-size:10pt;"> million of goodwill were recorded.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 1, 2018 we completed our acquisition of certain assets of Southern California Diagnostic Imaging consisting of a multi-modality imaging center located in Santa Ana, California for purchase consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4</span></span><span style="font-family:inherit;font-size:10pt;"> million. We have made a fair value determination of the acquired assets and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$18,000</span></span><span style="font-family:inherit;font-size:10pt;"> of other assets, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2</span></span><span style="font-family:inherit;font-size:10pt;"> million of leasehold improvements, </span><span style="font-family:inherit;font-size:10pt;"><span>$110,000</span></span><span style="font-family:inherit;font-size:10pt;"> of equipment, </span><span style="font-family:inherit;font-size:10pt;"><span>$50,000</span></span><span style="font-family:inherit;font-size:10pt;"> of covenants not to compete, and </span><span style="font-family:inherit;font-size:10pt;"><span>$41,000</span></span><span style="font-family:inherit;font-size:10pt;"> of goodwill were recorded.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 1, 2018 we obtained control over the operations of New Jersey Imaging Network (NJIN), formerly a joint venture, consisting of eighteen multi-modality imaging centers located throughout the state of New Jersey for no consideration through an agreement with the other equity interest holder. The change in control was effective upon the execution of an Irrevocable Proxy Agreement with the joint venture partner and third amendment of the operating agreement, which provided RadNet with the ability to make unilateral operating decisions. We have made a fair value determination of the acquired net assets and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$11.6</span></span><span style="font-family:inherit;font-size:10pt;"> million of net working capital, </span><span style="font-family:inherit;font-size:10pt;"><span>$235,000</span></span><span style="font-family:inherit;font-size:10pt;"> of other assets, </span><span style="font-family:inherit;font-size:10pt;"><span>$34.4</span></span><span style="font-family:inherit;font-size:10pt;"> million of property and equipment, </span><span style="font-family:inherit;font-size:10pt;"><span>$582,000</span></span><span style="font-family:inherit;font-size:10pt;"> of trade name. </span><span style="font-family:inherit;font-size:10pt;"><span>$106.1</span></span><span style="font-family:inherit;font-size:10pt;"> million of goodwill, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0</span></span><span style="font-family:inherit;font-size:10pt;"> million in net unfavorable lease contracts, </span><span style="font-family:inherit;font-size:10pt;"><span>$5.2</span></span><span style="font-family:inherit;font-size:10pt;"> million of assumed equipment debt, and </span><span style="font-family:inherit;font-size:10pt;"><span>$60.0</span></span><span style="font-family:inherit;font-size:10pt;"> million of assumed bank debt were recorded. We also made a</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">fair value determination of our </span><span style="font-family:inherit;font-size:10pt;"><span>49%</span></span><span style="font-family:inherit;font-size:10pt;"> pre existing interest in the business of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$42.5</span></span><span style="font-family:inherit;font-size:10pt;"> million and we recognized fair value of non controlling interest of </span><span style="font-family:inherit;font-size:10pt;"><span>$44.3</span></span><span style="font-family:inherit;font-size:10pt;"> million on the date of the transaction. The re-measurement in valuation from an existing equity investment in joint venture resulted in a gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$39.5</span></span><span style="font-family:inherit;font-size:10pt;"> million which is included in Other Income within the consolidated statements of operations.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 1, 2018 we acquired certain assets of Medical Arts Radiology consisting of a 10 multi-modality imaging centers located in Long Island, New York. Total purchase consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$59.6</span></span><span style="font-family:inherit;font-size:10pt;"> million consisted of cash in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$50.9</span></span><span style="font-family:inherit;font-size:10pt;"> million, issuance of </span><span style="font-family:inherit;font-size:10pt;"><span>531,560</span></span><span style="font-family:inherit;font-size:10pt;"> RadNet common shares valued at </span><span style="font-family:inherit;font-size:10pt;"><span>$8.0</span></span><span style="font-family:inherit;font-size:10pt;"> million on the acquisition date and contingent consideration valued at </span><span style="font-family:inherit;font-size:10pt;"><span>$739,000</span></span><span style="font-family:inherit;font-size:10pt;"> to guarantee the share value issued for a period of twelve months post acquisition date. We also assumed </span><span style="font-family:inherit;font-size:10pt;"><span>$2.7</span></span><span style="font-family:inherit;font-size:10pt;"> million in equipment debt. We have made a value determination of the acquired assets and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$2.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> of net working capital, </span><span style="font-family:inherit;font-size:10pt;"><span>$224,000</span></span><span style="font-family:inherit;font-size:10pt;"> of other assets,</span><span style="font-family:inherit;font-size:10pt;"><span>$16.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of property and equipment, </span><span style="font-family:inherit;font-size:10pt;"><span>$24,000</span></span><span style="font-family:inherit;font-size:10pt;"> in a covenant not to compete, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4</span></span><span style="font-family:inherit;font-size:10pt;"> million for its trade name, unfavorable lease contracts of </span><span style="font-family:inherit;font-size:10pt;"><span>$130,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$40.7</span></span><span style="font-family:inherit;font-size:10pt;"> million of goodwill were recorded.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On September 1, 2018 we completed our acquisition of certain assets of Washington Heights Medical Management, LLC, consisting of a multi-modality imaging center located in New York, New York, for </span><span style="font-family:inherit;font-size:10pt;"><span>$3.3</span></span><span style="font-family:inherit;font-size:10pt;"> million in cash. We have made a fair value determination of the acquired assets and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$43,000</span></span><span style="font-family:inherit;font-size:10pt;"> other assets, </span><span style="font-family:inherit;font-size:10pt;"><span>$904,000</span></span><span style="font-family:inherit;font-size:10pt;"> of leaseholds and equipment, </span><span style="font-family:inherit;font-size:10pt;"><span>$50,000</span></span><span style="font-family:inherit;font-size:10pt;"> in a covenant not to compete, and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.3</span></span><span style="font-family:inherit;font-size:10pt;"> million of goodwill were recorded.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 1, 2018 we completed our acquisition of certain assets of Women’s Imaging Specialists in Healthcare, consisting of a single multi-modality center located in the city of Fresno California, for purchase consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.1</span></span><span style="font-family:inherit;font-size:10pt;"> million in cash. We have made a fair value determination of the acquired assets and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$636,000</span></span><span style="font-family:inherit;font-size:10pt;"> of fixed assets and equipment, </span><span style="font-family:inherit;font-size:10pt;"><span>$143,000</span></span><span style="font-family:inherit;font-size:10pt;"> in intangible covenants not to compete, </span><span style="font-family:inherit;font-size:10pt;"><span>$53,000</span></span><span style="font-family:inherit;font-size:10pt;"> in intangible trade name, and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.3</span></span><span style="font-family:inherit;font-size:10pt;"> million in goodwill were recorded.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 1, 2018 we completed our acquisition of certain assets of Valley Metabolic Imaging LLC, consisting of a single multi-modality center located in Fresno, California, for purchase consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7</span></span><span style="font-family:inherit;font-size:10pt;"> million in cash. We have made a fair value determination of the acquired assets and approximately $</span><span style="font-family:inherit;font-size:10pt;"><span>22,000</span></span><span style="font-family:inherit;font-size:10pt;"> of fixed assets and equipment, </span><span style="font-family:inherit;font-size:10pt;"><span>$183,000</span></span><span style="font-family:inherit;font-size:10pt;"> in intangible covenants not to compete, and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5</span></span><span style="font-family:inherit;font-size:10pt;"> million in goodwill were recorded.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 1, 2018 we completed our acquisition of certain assets of Sierra Imaging Associates LLC, consisting of a single multi-modality center located in Clovis, California, for purchase consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5</span></span><span style="font-family:inherit;font-size:10pt;"> million in cash. We have made a fair value determination of the acquired assets and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$270,000</span></span><span style="font-family:inherit;font-size:10pt;"> of fixed assets and equipment, </span><span style="font-family:inherit;font-size:10pt;"><span>$83,000</span></span><span style="font-family:inherit;font-size:10pt;"> in intangible covenants not to compete, and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1</span></span><span style="font-family:inherit;font-size:10pt;"> million in goodwill were recorded.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 22, 2018 we completed our acquisition of certain assets of Imaging Services Company of New York, LLC, consisting of a single multi-modality center located in New York, New York, for purchase consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.8</span></span><span style="font-family:inherit;font-size:10pt;"> million. We have made a fair value determination of the acquired assets and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0</span></span><span style="font-family:inherit;font-size:10pt;"> million in fixed asset and equipment, a </span><span style="font-family:inherit;font-size:10pt;"><span>$100,000</span></span><span style="font-family:inherit;font-size:10pt;"> covenant not to compete, and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.7</span></span><span style="font-family:inherit;font-size:10pt;"> million in goodwill were recorded.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2018 we formed Beach Imaging Group, LLC (“Beach Imaging”) and contributed the operations of 24 imaging facilities spread across southern Los Angeles and Orange Counties. On the same day, MemorialCare Medical Foundation contributed </span><span style="font-family:inherit;font-size:10pt;"><span>$22.3</span></span><span style="font-family:inherit;font-size:10pt;"> million in cash, </span><span style="font-family:inherit;font-size:10pt;"><span>$7.6</span></span><span style="font-family:inherit;font-size:10pt;"> million in fixed assets, </span><span style="font-family:inherit;font-size:10pt;"><span>$7.4</span></span><span style="font-family:inherit;font-size:10pt;"> million in equipment, and </span><span style="font-family:inherit;font-size:10pt;"><span>$545,000</span></span><span style="font-family:inherit;font-size:10pt;"> in goodwill. As part of the formation, the Beach Imaging assumed </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0</span></span><span style="font-family:inherit;font-size:10pt;"> million in capital lease debt. As a result of the transaction, the Company will retain a </span><span style="font-family:inherit;font-size:10pt;"><span>60%</span></span><span style="font-family:inherit;font-size:10pt;"> controlling interest in Beach Imaging and MemorialCare Medical Foundation will retain a </span><span style="font-family:inherit;font-size:10pt;"><span>40%</span></span><span style="font-family:inherit;font-size:10pt;"> noncontrolling interest in Beach Imaging.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Joint venture formations</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 13, 2019 we formed a wholly owned subsidiary, Ventura County Imaging Group, LLC ("VCIG"). On March 1, 2019, Dignity Health joined as a venture partner. Total agreed contribution of both parties was </span><span style="font-family:inherit;font-size:10pt;"><span>$10.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of cash and assets with RadNet contributing net assets with a book value of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> for a </span><span style="font-family:inherit;font-size:10pt;"><span>60%</span></span><span style="font-family:inherit;font-size:10pt;"> economic interest and Dignity Health contributing </span><span style="font-family:inherit;font-size:10pt;"><span>$6.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash and assets for a </span><span style="font-family:inherit;font-size:10pt;"><span>40%</span></span><span style="font-family:inherit;font-size:10pt;"> economic interest. For its contribution, RadNet transferred net assets of three wholly owned multi-modality imaging centers. Dignity Health contributed approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$800,000</span></span><span style="font-family:inherit;font-size:10pt;"> in assets to acquire </span><span style="font-family:inherit;font-size:10pt;"><span>5%</span></span><span style="font-family:inherit;font-size:10pt;"> economic interest and paid RadNet </span><span style="font-family:inherit;font-size:10pt;"><span>$5.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> for an additional </span><span style="font-family:inherit;font-size:10pt;"><span>35%</span></span><span style="font-family:inherit;font-size:10pt;"> economic interest. We maintain controlling economic interest in VCIG and fully consolidate the results into our financial statements.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets held for sale</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective January 1, 2018 we agreed to sell certain assets of four women’s imaging centers to MemorialCare Medical Foundation. The sale was initially anticipated within 12 months of the effective date. We are currently in discussions with the buyer and expect to complete the sale in 2020. The following table summarizes the major categories of assets which remain classified as held for sale in the accompanying consolidated balance sheets at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:87%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$1,049</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>992</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets held for sale</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$2,041</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Dispositions</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 1, 2017, we formed in conjunction with Cedars Sinai Medical Center (“CSMC”) the Santa Monica Imaging Group, LLC (“SMIG”), consisting of two multi-modality imaging centers located in Santa Monica, CA. Upon formation, RadNet held a </span><span style="font-family:inherit;font-size:10pt;"><span>40%</span></span><span style="font-family:inherit;font-size:10pt;"> economic interest and CSMC held a </span><span style="font-family:inherit;font-size:10pt;"><span>60%</span></span><span style="font-family:inherit;font-size:10pt;"> economic interest. RadNet accounts for our share of the venture under the equity method. On January 1, 2019, CSMC purchased from us an additional </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> percent economic interest in SMIG valued at </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$134,000</span></span><span style="font-family:inherit;font-size:10pt;">. As a result of the transaction, our economic interest in SMIG has been reduced to </span><span style="font-family:inherit;font-size:10pt;"><span>35%</span></span><span style="font-family:inherit;font-size:10pt;">. We recorded a loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$2,000</span></span><span style="font-family:inherit;font-size:10pt;"> on the transaction.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On September 1, 2017 we completed the equity sale of a wholly owned breast oncology practice, Breastlink Medical Group, Inc., to Verity Medical Foundation for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:10pt;">. We recorded a gain of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$845,000</span></span><span style="font-family:inherit;font-size:10pt;"> and incurred severance expense of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> on this transaction.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 1, 2017 we formed a majority owned subsidiary, Advanced Imaging at Timonium Crossing, LLC, in conjunction with the University of Maryland St. Joseph Medical Center. As part of that transaction, we sold a </span><span style="font-family:inherit;font-size:10pt;"><span>25%</span></span><span style="font-family:inherit;font-size:10pt;"> noncontrolling interest in an imaging center of our wholly owned subsidiary, Advanced Imaging Partners, Inc., to the University of Maryland St. Joseph Medical Center for </span><span style="font-family:inherit;font-size:10pt;"><span>$3.9 million</span></span><span style="font-family:inherit;font-size:10pt;">. On the date of sale, the net book value of the </span><span style="font-family:inherit;font-size:10pt;"><span>25%</span></span><span style="font-family:inherit;font-size:10pt;"> interest was </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and the proceeds in excess of net book value amounting to </span><span style="font-family:inherit;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> were recorded to equity.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 28, 2017 we completed the sale of five imaging centers operating in Rhode Island to Rhode Island Medical Imaging, Inc. for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. We recorded a gain of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the second quarter with regard to this transaction and have no remaining imaging centers in the state.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 1, 2017 we received from Cedars Sinai Medical Center </span><span style="font-family:inherit;font-size:10pt;"><span>$5.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> in exchange for a </span><span style="font-family:inherit;font-size:10pt;"><span>25%</span></span><span style="font-family:inherit;font-size:10pt;"> noncontrolling interest in the West Valley Imaging Group, LLC (“WVI”). The determined net book value of the </span><span style="font-family:inherit;font-size:10pt;"><span>25%</span></span><span style="font-family:inherit;font-size:10pt;"> interest was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The proceeds in excess of the net book value, amounting to </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> net of taxes, were recorded to equity.</span></div><div style="line-height:120%;text-align:justify;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 1, 2017 we completed the sale of 2 wholly owned oncology practices to Cedars Sinai Medical Center in connection with the sale of non-controlling interest of the WVI subsidiary described above for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;">. We recorded a gain of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$361,000</span></span><span style="font-family:inherit;font-size:10pt;"> on this transaction.</span></div> 0.49 0.51 0.49 1300000 3100000 426000 1000 679000 426000 426000 2000000.0 0.25 1500000 0.75 189000 732000 278000 1300000 0.25 -504000 19300000 10100000 9700000 36000 3400000 14500000 10500000 4500000 2200000 5100000 100000 5100000 332000 2600000 6000000.0 680000 10000 50000 380000 340000 3100000 2800000 3000000.0 300000 7000 200000 2500000 750000 0.25 6600000 23000 69000 2800000 50000 3600000 3800000 20000 819000 80000 300000 2600000 1400000 18000 1200000 110000 50000 41000 11600000 235000 34400000 582000 106100000 1000000.0 5200000 60000000.0 0.49 42500000 44300000 39500000 59600000 50900000 531560 8000000.0 739000 2700000 2700000 224000 16000000.0 24000 1400000 130000 40700000 3300000 43000 904000 50000 2300000 5100000 636000 143000 53000 4300000 1700000 22000 183000 1500000 1500000 270000 83000 1100000 5800000 3000000.0 100000 2700000 22300000 7600000 7400000 545000 4000000.0 0.60 0.40 10400000 4300000 0.60 6100000 0.40 800000 0.05 5300000 0.35 The following table summarizes the major categories of assets which remain classified as held for sale in the accompanying consolidated balance sheets at <span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:87%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$1,049</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>992</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets held for sale</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$2,041</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1049000 992000 2041000 0.40 0.60 0.05 134000 0.35 -2000 2800000 845000 1200000 0.25 3900000 0.25 1100000 2800000 4500000 1900000 5900000 0.25 0.25 3000000.0 1800000 1200000 361000 GOODWILL AND OTHER INTANGIBLE ASSETS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill is recorded as a result of business combinations. Activity in goodwill for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> is provided below (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:85%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2017</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$256,776</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill acquired through the acquisition of Imaging Services Company of New York, LLC </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,692</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill acquired through the acquisition of certain assets of MemorialCare Medical Foundation </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>545</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill transferred to assets held for sale </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,059</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill acquired through the acquisition of Women's Imaging Specialists in Healthcare </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4268</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill acquired through the acquisition of Valley Metabolic Imaging </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,469</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill acquired through the acquisition of Sierra Imaging Associates </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,147</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill disposed through the sale of plastic surgery unit </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(80</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill acquired through the acquisition of Washington Heights Medical Management </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,303</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill acquired through the acquisition of Medical Arts Radiological Group, P.C. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,469</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill acquired through the acquisition of Arcadia Radiology Imaging Services, LLC</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,582</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill acquired through the acquisition of Southern California Diagnostic Imaging, Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill acquired through the acquisition of Orange County Diagnostics Imaging Center, Inc.</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,618</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill acquired through assuming operational control of New Jersey Imaging Network, LLC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106,122</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill impaired in the Imaging On Call reporting unit</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,800</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>418,093</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustments to our preliminary allocation of the purchase price of Medical Arts Radiological Group, P.C.</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>722</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired through the acquisition of certain assets of Dignity Health</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired through the acquisition of certain assets of West Valley Imaging Center, LLC</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,490</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill disposed through sale of assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(123</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired by Lenox Hill Radiology through the membership purchase of HVRA</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,125</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired through the acquisition of certain assets of Kern Radiology, Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,507</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired through the acquisition of certain assets of Zilkha Radiology, Inc.</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,577</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired through the acquisition of certain assets of Ramic Mahwah, LLC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>231</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired through the acquisition of GSRN</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,021</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired through the acquisition of Nulogix</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,337</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2019</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$440,981</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The amount of goodwill from these acquisitions that is deductible for tax purposes as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is </span><span style="font-family:inherit;font-size:10pt;"><span>$160.5</span></span><span style="font-family:inherit;font-size:10pt;"> million.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets are primarily related to our business combinations and software development. They include the estimated fair values of such items as service agreements, customer lists, covenants not to compete, acquired technologies, and trade names.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total amortization expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$2.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;text-align:left;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. Intangible assets are amortized using the straight-line method over their useful life determined at acquisition. Management service agreements are amortized over </span><span style="font-family:inherit;font-size:10pt;"><span>25 years</span></span><span style="font-family:inherit;font-size:10pt;"> using the straight line method. Software development is capitalized and amortized over the useful life of the software when placed into service. Trade names are reviewed annually for impairment.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table shows annual amortization expense, by asset classes that will be recorded over the next five years (in thousands): </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="31"/></tr><tr><td style="width:21%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Weighted average amortization period remaining in years</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Management Service Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,287</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,287</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,287</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,287</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,287</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>15,820</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>27,255</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Covenant not to compete and other contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>759</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>699</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>650</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>537</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,916</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Developed Technology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>244</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>244</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>630</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Trade Names amortized</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>618</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Trade Names indefinite life</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11,270</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11,270</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Software in development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>305</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>305</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total Annual Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,432</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,299</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,148</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,885</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,474</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>27,756</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>42,994</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> Activity in goodwill for the years ended <span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> is provided below (in thousands):</span><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:85%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2017</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$256,776</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill acquired through the acquisition of Imaging Services Company of New York, LLC </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,692</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill acquired through the acquisition of certain assets of MemorialCare Medical Foundation </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>545</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill transferred to assets held for sale </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,059</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill acquired through the acquisition of Women's Imaging Specialists in Healthcare </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4268</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill acquired through the acquisition of Valley Metabolic Imaging </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,469</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill acquired through the acquisition of Sierra Imaging Associates </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,147</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill disposed through the sale of plastic surgery unit </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(80</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill acquired through the acquisition of Washington Heights Medical Management </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,303</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill acquired through the acquisition of Medical Arts Radiological Group, P.C. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,469</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill acquired through the acquisition of Arcadia Radiology Imaging Services, LLC</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,582</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill acquired through the acquisition of Southern California Diagnostic Imaging, Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill acquired through the acquisition of Orange County Diagnostics Imaging Center, Inc.</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,618</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill acquired through assuming operational control of New Jersey Imaging Network, LLC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106,122</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Goodwill impaired in the Imaging On Call reporting unit</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,800</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>418,093</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustments to our preliminary allocation of the purchase price of Medical Arts Radiological Group, P.C.</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>722</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired through the acquisition of certain assets of Dignity Health</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired through the acquisition of certain assets of West Valley Imaging Center, LLC</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,490</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill disposed through sale of assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(123</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired by Lenox Hill Radiology through the membership purchase of HVRA</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,125</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired through the acquisition of certain assets of Kern Radiology, Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,507</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired through the acquisition of certain assets of Zilkha Radiology, Inc.</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,577</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired through the acquisition of certain assets of Ramic Mahwah, LLC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>231</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired through the acquisition of GSRN</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,021</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired through the acquisition of Nulogix</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,337</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2019</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$440,981</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 256776000 2692000 545000 -1059000 4268000 1469000 1147000 80000 2303000 41469000 2582000 41000 3618000 106122000 3800000 418093000 722000 1000 2490000 123000 3125000 10507000 2577000 231000 2021000 1337000 440981000 160500000 3100000 2700000 2600000 P25Y <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table shows annual amortization expense, by asset classes that will be recorded over the next five years (in thousands): </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="31"/></tr><tr><td style="width:21%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Weighted average amortization period remaining in years</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Management Service Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,287</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,287</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,287</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,287</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,287</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>15,820</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>27,255</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Covenant not to compete and other contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>759</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>699</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>650</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>537</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,916</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Developed Technology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>244</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>244</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>630</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Trade Names amortized</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>618</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Trade Names indefinite life</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11,270</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11,270</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Software in development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>305</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>305</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total Annual Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,432</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,299</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,148</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,885</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,474</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>27,756</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>42,994</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div> 2287000 2287000 2287000 2287000 2287000 15820000 27255000 P11Y10M24D 759000 699000 650000 537000 129000 142000 2916000 P4Y4M24D 244000 244000 142000 0 0 0 630000 P2Y7M6D 142000 69000 69000 61000 58000 219000 618000 P8Y4M24D 0 0 0 0 0 11270000 11270000 0 0 0 0 0 305000 305000 3432000 3299000 3148000 2885000 2474000 27756000 42994000 PROPERTY AND EQUIPMENT<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment and accumulated depreciation and amortization are as follows (in thousands):</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>250</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>250</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>425,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>449,776</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer and office equipment, furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120,490</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102,798</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Software development costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,391</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>377,417</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>337,878</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equipment under financing/capital lease</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,105</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,119</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total property and equipment cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>938,154</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>909,212</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(571,408</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(563,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total property and equipment</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>366,746</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>345,729</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in our property and equipment at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$42.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> total of construction in process amounts consisting of </span><span style="font-family:inherit;font-size:10pt;"><span>$15.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> in medical equipment, </span><span style="font-family:inherit;font-size:10pt;"><span>$2.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in computer and office equipment, and </span><span style="font-family:inherit;font-size:10pt;"><span>$24.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in leasehold improvements.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense of property and equipment, including amortization of equipment under finance/capital leases, for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$77.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$70.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$64.2 million</span></span>, respectively. <div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment and accumulated depreciation and amortization are as follows (in thousands):</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>250</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>250</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>425,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>449,776</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer and office equipment, furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120,490</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102,798</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Software development costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,391</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>377,417</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>337,878</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equipment under financing/capital lease</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,105</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,119</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total property and equipment cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>938,154</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>909,212</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(571,408</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(563,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total property and equipment</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>366,746</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>345,729</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 250000 250000 425892000 449776000 120490000 102798000 0 6391000 377417000 337878000 14105000 12119000 938154000 909212000 571408000 563483000 366746000 345729000 42400000 15900000 2300000 24200000 77500000 70200000 64200000 ACCOUNTS PAYABLE AND ACCRUED EXPENSES<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses were comprised of the following (in thousands):</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64,300</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,040</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83,853</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,958</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued salary and benefits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,003</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,167</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,429</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,863</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>207,585</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>181,028</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses were comprised of the following (in thousands):</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64,300</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,040</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83,853</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,958</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued salary and benefits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,003</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,167</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,429</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,863</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>207,585</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>181,028</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 64300000 68040000 83853000 60958000 42003000 37167000 17429000 14863000 207585000 181028000 NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES<div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Revolving credit facility, notes payable, and capital lease obligations</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">First Lien Term Loans collateralized by RadNet's tangible and intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>649,824</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>587,191</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount on First Lien Term Loans</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,579</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,112</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term Loan Agreement collateralized by NJIN's tangible and intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,875</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,250</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revolving Credit Facility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Promissory note payable to the former owner of a practice acquired at an interest rate of 1.5% due through 2019</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equipment notes payable at interest rates ranging from 4.4% to 5.6%, due through 2020, collateralized by medical equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>275</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>632</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Obligations under capital leases at interest rates ranging from 3.7% to 9.3%, due through 2022, collateralized by medical and office equipment </span><span style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">(1) </sub></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,119</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total debt obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>692,395</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>672,279</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less current portion</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39,691</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39,267</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term portion debt obligations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>652,704</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>633,012</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span><span style="font-family:inherit;font-size:10pt;">Obligations under capital leases were transferred to Finance Lease Liability at January 1, 2019 in accordance with the adoption of Accounting Standards Update No 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;">. See Note 9, Leases, for more information.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a listing of annual principal maturities of notes payable exclusive of all related discounts and repayments on our revolving credit facilities for years ending December 31 (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,571</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,670</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,795</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>573,938</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total notes payable obligations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>705,974</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Senior Credit Facilities:</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, our Barclays credit facilities were comprised of one tranche of term loans (“First Lien Term Loans”) and a revolving credit facility of </span><span style="font-family:inherit;font-size:10pt;"><span>$137.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> (the “Barclays Revolving Credit Facility”), both of which are provided pursuant to the Amended and Restated First Lien Credit and Guaranty Agreement dated July 1, 2016 (as amended, the "First Lien Credit Agreement"). </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;text-align:left;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;text-align:left;">, our SunTrust credit facilities, which relate to our consolidated subsidiary NJIN, were comprised of one term loan (the "SunTrust Term Loan") and a revolving credit facility of </span><span style="font-family:inherit;font-size:10pt;text-align:left;"><span>$30.0</span></span><span style="font-family:inherit;font-size:10pt;text-align:left;"> million (the "SunTrust Revolving Credit Facility") both of which are provided pursuant to the SunTrust Restated Credit Agreement.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we were in compliance with all covenants under our credit facilities. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred financing costs at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, net of accumulated amortization, was </span><span style="font-family:inherit;font-size:10pt;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and is specifically related to our Barclays Revolving Credit Facility. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in our consolidated balance sheets at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are </span><span style="font-family:inherit;font-size:10pt;"><span>$636.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of First Lien Term Loans and </span><span style="font-family:inherit;font-size:10pt;"><span>$55.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of SunTrust Term Loan debt for a combined total of </span><span style="font-family:inherit;font-size:10pt;"><span>$692.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> (net of unamortized discounts of </span><span style="font-family:inherit;font-size:10pt;"><span>$13.6 million</span></span><span style="font-family:inherit;font-size:10pt;">) in thousands:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Face Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Discount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Carrying</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">First Lien Term Loans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>649,824</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,579</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>636,245</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term Loan Agreement</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,875</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,875</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Term Loans</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>705,699</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,579</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>692,120</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We had </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding balance under our </span><span style="font-family:inherit;font-size:10pt;"><span>$137.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> Barclays Revolving Credit Facility at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and had reserved an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$5.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> for certain letters of credit. The remaining </span><span style="font-family:inherit;font-size:10pt;"><span>$131.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> of our Barclays Revolving Credit Facility was available to draw upon as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. We also had </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> balance under our </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0</span></span><span style="font-family:inherit;font-size:10pt;"> million SunTrust Revolving Credit Facility related to our consolidated subsidiary NJIN at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following relates to our Barclays financing activities:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2019 Amendments to the First Lien Credit Agreement:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 18, 2019 we entered into the following two new amendments to the First Lien Credit Agreement: (i) Amendment No. 6, Consent and Incremental Joinder Agreement to Credit and Guaranty Agreement dated as of April 18, 2019 (the “Sixth Amendment”); and (ii) Amendment No. 7 to Credit and Guaranty Agreement dated as of April 18, 2019 (the “Seventh Amendment”). The Sixth Amendment amended the First Lien Credit Agreement to issue </span><span style="font-family:inherit;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in incremental First Lien Term Loans and to add an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$20.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of revolving commitments to the Barclay's Revolving Credit Facility. The Seventh Amendment amends the First Lien Credit Agreement to extend the maturity date of the Barclays Revolving Credit Facility by an additional two years to July 1, 2023, unless sooner terminated in accordance with the terms of the First Lien Credit Agreement. Total issue costs added in relation to the amendments in 2019 amounted to approximately </span><span style="font-family:inherit;font-size:10pt;text-align:right;"><span>$4.4 million</span></span><span style="font-family:inherit;font-size:10pt;">. Of this amount, </span><span style="font-family:inherit;font-size:10pt;"><span>$2.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> was identified and capitalized as discount on debt, </span><span style="font-family:inherit;font-size:10pt;"><span>$683,000</span></span><span style="font-family:inherit;font-size:10pt;"> was capitalized as deferred financing costs, and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> was expensed. Amounts capitalized will be amortized over the remaining term of the agreement.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Terms of Barclays Credit Facilites:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">First Lien Term Loans:</span></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  </span></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest: </span><span style="font-family:inherit;font-size:10pt;">First Lien Term Loans bear interest at either an Adjusted Eurodollar Rate or a Base Rate plus an applicable margin. Rates of the applicable margin for borrowing under the First Lien Credit Agreement will alter depending on our leverage ratio, according to the following schedule:</span></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.453125%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:33%;"/><td style="width:33%;"/><td style="width:34%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">First Lien Leverage Ratio</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Eurodollar Rate Spread</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Base Rate Spread</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&gt; 5.50x</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.50%</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.50%</span></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&gt; 4.00x but ≤ 5.50x</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.75%</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.75%</span></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&gt;3.50x but ≤ 4.00x</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.50%</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.50%</span></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">≤ 3.50x</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.25%</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.25%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> the effective Adjusted Eurodollar Rate and the Base Rate for the First Lien Term Loans was </span><span style="font-family:inherit;font-size:10pt;"><span>2.01%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>4.75%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively and the applicable margin for Adjusted Eurodollar Rate and Base Rate borrowings was </span><span style="font-family:inherit;font-size:10pt;"><span>3.50%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>2.50%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Payments.</span><span style="font-family:inherit;font-size:10pt;"> The First Lien Credit Agreement provides for quarterly payments of principal under the First Lien Term Loans in the amount of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$9.7 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Maturity Date.</span><span style="font-family:inherit;font-size:10pt;"> The maturity date for the First Lien Term Loans shall be on the earliest to occur of (i) July 1, 2023, and (ii) the date on which all First Lien Term Loans shall become due and payable in full under the First Lien Credit Agreement, whether by acceleration or otherwise.</span></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Additional Borrowing. </span><span style="font-family:inherit;font-size:10pt;">Under the First Lien Credit Agreement, we can elect to request (i) an increase to the existing Barclays Revolving Credit Facility and/or (ii) issue additional First Lien Term Loans, provided that the aggregate amount of such increases and additions does not exceed (a) </span><span style="font-family:inherit;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and (b) as long as the First Lien Leverage Ratio (as defined in the First Lien Credit Agreement) would not exceed 4.00:1.00 after giving effect to such incremental facilities, an uncapped amount of incremental facilities, in each case subject to the conditions and limitations set forth in the First Lien Credit Agreement. Each </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lender approached to provide all or a portion of any incremental facility may elect or decline, in its sole discretion, to provide an incremental commitment or loan.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Barclays Revolving Credit Facility:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest:</span><span style="font-family:inherit;font-size:10pt;"> Revolving loans borrowed under the Revolving Credit Facility bear interest at either an Adjusted Eurodollar Rate or a Base Rate plus an applicable margin. Rates of the applicable margin for borrowing under the Revolving Credit Facility also change depending on our leverage ratio and are the same rates as noted in the schedule above for First Lien Term Loans. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the effective interest rate payable on revolving loans was </span><span style="font-family:inherit;font-size:10pt;"><span>7.25%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Letters of Credit: </span><span style="font-family:inherit;font-size:10pt;">For letters of credit issued under the Revolving Credit Facility, letter of credit fees accrue at the applicable margin of Adjusted Eurodollar Rate, currently </span><span style="font-family:inherit;font-size:10pt;"><span>3.50%</span></span><span style="font-family:inherit;font-size:10pt;"> , and fronting fees accrue at </span><span style="font-family:inherit;font-size:10pt;"><span>0.25%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum, in each case on the average aggregate daily maximum amount available to be drawn under all letters of credit issued under the First Lien Credit Agreement. In addition a commitment fee of </span><span style="font-family:inherit;font-size:10pt;"><span>0.50%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum accrues on the unused revolver commitments under the Revolving Credit Facility. </span></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Maturity Date: </span><span style="font-family:inherit;font-size:10pt;">The Revolving Credit Facility will terminate on the earliest to occur of (i) July 1, 2023, (ii) the date we voluntarily agree to permanently reduce the Revolving Credit Facility to zero pursuant to section 2.13(b) of the First Lien Credit Agreement, and (iii) the date the Revolving Credit Facility is terminated due to specific events of default pursuant to section 8.01 of the First Lien Credit Agreement.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following relates to our SunTrust financing activities:</span></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Amended and Restated Revolving Credit and Term Loan Agreement</span></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 31, 2018, our subsidiary, NJIN, entered into the Amended and Restated Revolving Credit and Term Loan Agreement (as amended, the "SunTrust Restated Credit Agreement") as borrower with SunTrust Bank and other financial institutions as lenders and to provide NJIN aggregate credit facilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$90.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> as categorized below:</span></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">SunTrust Term Loan: </span><span style="font-family:inherit;font-size:10pt;">Pursuant to the SunTrust Restated Credit Agreement, the lenders thereunder made a term loan to NJIN in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The SunTrust Term Loan is repayable in scheduled quarterly amounts (as described below) and has a maturity date of the earlier of (i) August 31, 2023 and (ii) the date on which the principal amount of the SunTrust Term Loan has been declared or automatically has become due and payable (whether by acceleration or otherwise).</span></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">SunTrust Revolving Credit Facility: </span><span style="font-family:inherit;font-size:10pt;">The SunTrust Restated Credit Agreement establishes a </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> revolving credit facility available to NJIN for funding requirements. The SunTrust Revolving Credit Facility terminates on the earliest of (i) August 31, 2023, (ii) the voluntary termination thereof by NJIN pursuant to Section 2.8 of the SunTrust Restated Credit Agreement, or (iii) the date on which all amounts outstanding under the SunTrust Restated Credit Agreement have been declared or have automatically become due and payable (whether by acceleration or otherwise). NJIN has not borrowed against the revolving credit line. </span></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest: </span><span style="font-family:inherit;font-size:10pt;">Interest rates and fees of the applicable margin for borrowing under the SunTrust Restated Credit Agreement adjust depending on our leverage ratio, according to the following table:</span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:93.1640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:10%;"/><td style="width:24%;"/><td style="width:16%;"/><td style="width:16%;"/><td style="width:17%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Pricing Level</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Leverage Ratio</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Applicable Margin for Eurodollar Loans</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Applicable Margin for Base Rate Loans</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Applicable Margin for Letter of Credit Fees</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Applicable Percentage for Commitment Fee</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">I</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Greater than or equal to 3.00:1.00</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.75%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.75%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.75%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.45%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">II</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less than 3.00:1.00 but greater than or equal to 2.50:1.00</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.25%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.25%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.25%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.40%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">III</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less than 2.50:1.00 but greater than or equal to</span></div><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.00:1.00</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.00%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.00%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.00%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.35%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IV</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less than 2.00:1.00 but greater than or equal to 1.50:1.00</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.75%</span></div><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.75%</span></div><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.75%</span></div><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.30%</span></div><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">V</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less than 1.50:1.00</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.50%</span></div><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.50%</span></div><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.50%</span></div><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.30%</span></div><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The loans and other obligations outstanding under the SunTrust Restated Credit Agreement currently bear applicable margin and fees based on Pricing Level III described above.The loans outstanding under the SunTrust Restated Credit Agreement currently bear interest based on a three month Eurodollar election, plus the applicable margin.</span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:6px;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Payments: </span><span style="font-family:inherit;font-size:10pt;">The scheduled amortization of the SunTrust Term Loan began December 31, 2018 with quarterly payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$750,000</span></span><span style="font-family:inherit;font-size:10pt;">, representing annual amortization equal to </span><span style="font-family:inherit;font-size:10pt;"><span>5.0%</span></span><span style="font-family:inherit;font-size:10pt;"> of the original principal amount of the SunTrust Term Loan. At scheduled intervals, the quarterly amortization increases by </span><span style="font-family:inherit;font-size:10pt;"><span>$375,000</span></span><span style="font-family:inherit;font-size:10pt;">, with the remaining balance to be paid at maturity.</span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Revolving credit facility, notes payable, and capital lease obligations</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">First Lien Term Loans collateralized by RadNet's tangible and intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>649,824</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>587,191</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount on First Lien Term Loans</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,579</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,112</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term Loan Agreement collateralized by NJIN's tangible and intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,875</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,250</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revolving Credit Facility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Promissory note payable to the former owner of a practice acquired at an interest rate of 1.5% due through 2019</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equipment notes payable at interest rates ranging from 4.4% to 5.6%, due through 2020, collateralized by medical equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>275</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>632</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Obligations under capital leases at interest rates ranging from 3.7% to 9.3%, due through 2022, collateralized by medical and office equipment </span><span style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">(1) </sub></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,119</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total debt obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>692,395</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>672,279</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less current portion</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39,691</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39,267</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term portion debt obligations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>652,704</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>633,012</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 649824000 587191000 13579000 15112000 55875000 59250000 0 28000000 0 199000 275000 632000 0 12119000 692395000 672279000 39691000 39267000 652704000 633012000 <div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a listing of annual principal maturities of notes payable exclusive of all related discounts and repayments on our revolving credit facilities for years ending December 31 (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,571</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,670</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,795</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>573,938</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total notes payable obligations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>705,974</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 43571000 43670000 44795000 573938000 705974000 137500000 30000000.0 1600000 <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in our consolidated balance sheets at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are </span><span style="font-family:inherit;font-size:10pt;"><span>$636.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of First Lien Term Loans and </span><span style="font-family:inherit;font-size:10pt;"><span>$55.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of SunTrust Term Loan debt for a combined total of </span><span style="font-family:inherit;font-size:10pt;"><span>$692.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> (net of unamortized discounts of </span><span style="font-family:inherit;font-size:10pt;"><span>$13.6 million</span></span><span style="font-family:inherit;font-size:10pt;">) in thousands:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Face Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Discount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Carrying</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">First Lien Term Loans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>649,824</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,579</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>636,245</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term Loan Agreement</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,875</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,875</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Term Loans</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>705,699</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,579</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>692,120</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 636200000 55900000 692100000 13600000 649824000 13579000 636245000 55875000 0 55875000 705699000 13579000 692120000 0 137500000 5900000 131700000 0 30000000.0 100000000.0 20000000.0 4400000 2100000 683000 1600000 0.0450 0.0350 0.0375 0.0275 0.0350 0.0250 0.0325 0.0225 0.0201 0.0475 0.0350 0.0250 9700000 100000000.0 0.0725 0.0350 0.0025 0.0050 90000000.0 60000000.0 30000000.0 <span style="font-family:inherit;font-size:10pt;">Interest rates and fees of the applicable margin for borrowing under the SunTrust Restated Credit Agreement adjust depending on our leverage ratio, according to the following table:</span><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:93.1640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:10%;"/><td style="width:24%;"/><td style="width:16%;"/><td style="width:16%;"/><td style="width:17%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Pricing Level</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Leverage Ratio</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Applicable Margin for Eurodollar Loans</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Applicable Margin for Base Rate Loans</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Applicable Margin for Letter of Credit Fees</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Applicable Percentage for Commitment Fee</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">I</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Greater than or equal to 3.00:1.00</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.75%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.75%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.75%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.45%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">II</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less than 3.00:1.00 but greater than or equal to 2.50:1.00</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.25%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.25%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.25%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.40%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">III</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less than 2.50:1.00 but greater than or equal to</span></div><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.00:1.00</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.00%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.00%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.00%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.35%</span></div><div style="padding-top:0px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IV</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less than 2.00:1.00 but greater than or equal to 1.50:1.00</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.75%</span></div><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.75%</span></div><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.75%</span></div><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.30%</span></div><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">V</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less than 1.50:1.00</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.50%</span></div><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.50%</span></div><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.50%</span></div><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.30%</span></div><div style="padding-top:3px;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">per annum</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">First Lien Term Loans bear interest at either an Adjusted Eurodollar Rate or a Base Rate plus an applicable margin. Rates of the applicable margin for borrowing under the First Lien Credit Agreement will alter depending on our leverage ratio, according to the following schedule:</span><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.453125%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:33%;"/><td style="width:33%;"/><td style="width:34%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">First Lien Leverage Ratio</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Eurodollar Rate Spread</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Base Rate Spread</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&gt; 5.50x</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.50%</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.50%</span></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&gt; 4.00x but ≤ 5.50x</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.75%</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.75%</span></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&gt;3.50x but ≤ 4.00x</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.50%</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.50%</span></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">≤ 3.50x</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.25%</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.25%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 750000 0.050 375000 LEASES<div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Adoption of Standard</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#333333;">In February 2016, the FASB issued a new standard related to leases to increase transparency and comparability among organizations by requiring the recognition of right-of-use (“ROU”) assets and lease liabilities on the balance sheet </span><span style="font-family:inherit;font-size:10pt;">for all leases with terms in excess of twelve months.</span><span style="font-family:inherit;font-size:10pt;color:#333333;"> Sufficient disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The standard was effective for us beginning January 1, 2019. </span><span style="font-family:inherit;font-size:10pt;">We have elected the optional transition method to apply the standard as of the effective date and therefore, we will not apply the standard to the comparative periods presented in the consolidated financial statements. We also elected the transition package of three practical expedients permitted within the standard, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#333333;">The adoption of the standard had a material impact on our condensed consolidated balance sheets, but did not have material impact on our condensed consolidated income statements or cash flows. Adoption of the standard resulted in the recognition</span><span style="font-family:inherit;font-size:10pt;"> of an operating lease liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$455.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. Operating lease ROU assets were recorded in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$419.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. Inclusive in the adoption was the transfer of </span><span style="font-family:inherit;font-size:10pt;"><span>$35.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in deferred rent liability and </span><span style="font-family:inherit;font-size:10pt;"><span>$792,000</span></span><span style="font-family:inherit;font-size:10pt;"> in unfavorable rental contract liabilities to operating lease ROU assets. For finance leases, the effect of the adoption amounted to a finance lease liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$12.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was transfered from capital lease debt and a finance right of use assets in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> which remained in property, plant and equipment.</span></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Lease Liability</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have operating leases for medical facilities, administrative offices, warehouse space and major medical equipment. We lease the premises at which these facilities are located and do not have options to purchase the facilities we rent. Our most common initial term varies in length from </span><span style="font-family:inherit;font-size:10pt;">5</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span><span style="font-family:inherit;font-size:10pt;">. Including renewal options negotiated with the landlord, we can have a total span of </span><span style="font-family:inherit;font-size:10pt;">10</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>35 years</span></span><span style="font-family:inherit;font-size:10pt;"> at the facilities we lease. We also lease smaller satellite X-Ray locations on mutually renewable terms, usually lasting one year. Additionally, we have operating and finance leases for certain medical and office equipment, with lease terms generally lasting from </span><span style="font-family:inherit;font-size:10pt;">5</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>8 years</span></span><span style="font-family:inherit;font-size:10pt;">. Our Incremental Borrowing Rate ("IBR") used to discount the stream of lease payments </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">is closely related to the interest rates charged on our collateralized debt obligations and our IBR is adjusted when those rates experience a substantial change.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of lease expense were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Twelve months ended</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(In thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95,348</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Finance lease cost:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Depreciation of leased equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,135</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>395</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total finance lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,530</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to leases was as follows:</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Twelve months ended</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(In thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95,922</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Operating cash flows from financing leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>395</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Financing cash flows from financing leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,939</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use &amp; Equipment assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Operating leases</span><span style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>482,399</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Financing leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,105</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></span><span style="font-family:inherit;font-size:10pt;">Amounts for the twelve months ended December 31, 2019 include the transition adjustment for the adoption of Topic 842 discussed in Note 3, Recent Account Standards, for further information.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental balance sheet information related to leases was as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(In thousands, except lease term and discount rates)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>445,477</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of operating lease liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,206</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>420,922</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>482,128</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance Leases</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equipment at cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,135</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,970</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of finance lease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,283</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,264</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total finance lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,547</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted Average Remaining Lease Term</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases - years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases - years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted Average Discount Rate</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturities of lease liabilities were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financing</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December 31,</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Leases</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Leases</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,881</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,492</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,848</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,624</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,932</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>702</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,916</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,517</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>262,027</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total Lease Payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>646,121</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,839</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(163,993</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(292</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>482,128</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,547</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have additional operating leases for facilities and medical equipment that have not yet commenced of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$16.4 million</span></span><span style="font-family:inherit;font-size:10pt;">. These operating leases will commence in 2020 with lease terms of </span><span style="font-family:inherit;font-size:10pt;">1</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>16 years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As previously disclosed in our 2018 Annual Report on Form 10-K and under the previous lease accounting, maturities of operating lease liabilities were as follows as of December 31, 2018 (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Facilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,588</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,924</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90,512</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,116</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,385</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,501</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,826</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,966</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,792</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,542</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,264</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,806</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,800</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,095</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,895</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>160,327</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,144</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>165,471</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>447,199</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64,778</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>511,977</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> LEASES<div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Adoption of Standard</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#333333;">In February 2016, the FASB issued a new standard related to leases to increase transparency and comparability among organizations by requiring the recognition of right-of-use (“ROU”) assets and lease liabilities on the balance sheet </span><span style="font-family:inherit;font-size:10pt;">for all leases with terms in excess of twelve months.</span><span style="font-family:inherit;font-size:10pt;color:#333333;"> Sufficient disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The standard was effective for us beginning January 1, 2019. </span><span style="font-family:inherit;font-size:10pt;">We have elected the optional transition method to apply the standard as of the effective date and therefore, we will not apply the standard to the comparative periods presented in the consolidated financial statements. We also elected the transition package of three practical expedients permitted within the standard, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#333333;">The adoption of the standard had a material impact on our condensed consolidated balance sheets, but did not have material impact on our condensed consolidated income statements or cash flows. Adoption of the standard resulted in the recognition</span><span style="font-family:inherit;font-size:10pt;"> of an operating lease liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$455.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. Operating lease ROU assets were recorded in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$419.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. Inclusive in the adoption was the transfer of </span><span style="font-family:inherit;font-size:10pt;"><span>$35.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in deferred rent liability and </span><span style="font-family:inherit;font-size:10pt;"><span>$792,000</span></span><span style="font-family:inherit;font-size:10pt;"> in unfavorable rental contract liabilities to operating lease ROU assets. For finance leases, the effect of the adoption amounted to a finance lease liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$12.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was transfered from capital lease debt and a finance right of use assets in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> which remained in property, plant and equipment.</span></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Lease Liability</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have operating leases for medical facilities, administrative offices, warehouse space and major medical equipment. We lease the premises at which these facilities are located and do not have options to purchase the facilities we rent. Our most common initial term varies in length from </span><span style="font-family:inherit;font-size:10pt;">5</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span><span style="font-family:inherit;font-size:10pt;">. Including renewal options negotiated with the landlord, we can have a total span of </span><span style="font-family:inherit;font-size:10pt;">10</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>35 years</span></span><span style="font-family:inherit;font-size:10pt;"> at the facilities we lease. We also lease smaller satellite X-Ray locations on mutually renewable terms, usually lasting one year. Additionally, we have operating and finance leases for certain medical and office equipment, with lease terms generally lasting from </span><span style="font-family:inherit;font-size:10pt;">5</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>8 years</span></span><span style="font-family:inherit;font-size:10pt;">. Our Incremental Borrowing Rate ("IBR") used to discount the stream of lease payments </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">is closely related to the interest rates charged on our collateralized debt obligations and our IBR is adjusted when those rates experience a substantial change.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of lease expense were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Twelve months ended</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(In thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95,348</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Finance lease cost:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Depreciation of leased equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,135</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>395</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total finance lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,530</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to leases was as follows:</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Twelve months ended</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(In thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95,922</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Operating cash flows from financing leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>395</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Financing cash flows from financing leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,939</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use &amp; Equipment assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Operating leases</span><span style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>482,399</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Financing leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,105</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></span><span style="font-family:inherit;font-size:10pt;">Amounts for the twelve months ended December 31, 2019 include the transition adjustment for the adoption of Topic 842 discussed in Note 3, Recent Account Standards, for further information.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental balance sheet information related to leases was as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(In thousands, except lease term and discount rates)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>445,477</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of operating lease liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,206</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>420,922</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>482,128</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance Leases</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equipment at cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,135</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,970</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of finance lease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,283</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,264</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total finance lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,547</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted Average Remaining Lease Term</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases - years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases - years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted Average Discount Rate</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturities of lease liabilities were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financing</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December 31,</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Leases</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Leases</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,881</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,492</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,848</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,624</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,932</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>702</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,916</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,517</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>262,027</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total Lease Payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>646,121</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,839</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(163,993</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(292</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>482,128</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,547</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have additional operating leases for facilities and medical equipment that have not yet commenced of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$16.4 million</span></span><span style="font-family:inherit;font-size:10pt;">. These operating leases will commence in 2020 with lease terms of </span><span style="font-family:inherit;font-size:10pt;">1</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>16 years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As previously disclosed in our 2018 Annual Report on Form 10-K and under the previous lease accounting, maturities of operating lease liabilities were as follows as of December 31, 2018 (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Facilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,588</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,924</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90,512</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,116</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,385</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,501</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,826</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,966</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,792</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,542</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,264</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,806</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,800</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,095</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,895</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>160,327</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,144</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>165,471</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>447,199</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64,778</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>511,977</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 455500000 419000000.0 35300000 792000 12100000 14100000 P15Y P35Y P8Y <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of lease expense were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Twelve months ended</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(In thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95,348</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Finance lease cost:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Depreciation of leased equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,135</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>395</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total finance lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,530</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to leases was as follows:</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Twelve months ended</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(In thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95,922</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Operating cash flows from financing leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>395</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Financing cash flows from financing leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,939</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use &amp; Equipment assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Operating leases</span><span style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>482,399</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Financing leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,105</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></span><span style="font-family:inherit;font-size:10pt;">Amounts for the twelve months ended December 31, 2019 include the transition adjustment for the adoption of Topic 842 discussed in Note 3, Recent Account Standards, for further information.</span></div> 95348000 3135000 395000 3530000 95922000 395000 5939000 482399000 14105000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental balance sheet information related to leases was as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(In thousands, except lease term and discount rates)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>445,477</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of operating lease liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,206</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>420,922</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>482,128</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance Leases</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equipment at cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,135</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,970</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of finance lease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,283</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,264</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total finance lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,547</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted Average Remaining Lease Term</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases - years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases - years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted Average Discount Rate</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 445477000 61206000 420922000 482128000 14105000 3135000 10970000 3283000 3264000 6547000 P8Y9M18D P3Y3M18D 0.064 0.044 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturities of lease liabilities were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financing</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December 31,</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Leases</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Leases</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,881</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,492</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,848</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,624</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,932</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>702</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,916</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,517</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>262,027</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total Lease Payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>646,121</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,839</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(163,993</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(292</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>482,128</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,547</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As previously disclosed in our 2018 Annual Report on Form 10-K and under the previous lease accounting, maturities of operating lease liabilities were as follows as of December 31, 2018 (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Facilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,588</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,924</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90,512</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,116</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,385</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,501</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,826</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,966</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,792</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,542</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,264</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,806</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,800</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,095</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,895</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>160,327</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,144</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>165,471</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>447,199</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64,778</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>511,977</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturities of lease liabilities were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financing</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December 31,</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Leases</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Leases</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,881</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,492</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,848</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,624</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,932</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>702</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,916</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,517</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>262,027</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total Lease Payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>646,121</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,839</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(163,993</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(292</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>482,128</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,547</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 89881000 3492000 88848000 2624000 80932000 702000 69916000 11000 54517000 10000 262027000 0 646121000 6839000 163993000 292000 482128000 6547000 16400000 P16Y 75588000 14924000 90512000 66116000 14385000 80501000 57826000 12966000 70792000 48542000 10264000 58806000 38800000 7095000 45895000 160327000 5144000 165471000 447199000 64778000 511977000 INCOME TAXES<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, we recognized income tax expense comprised of the following (in thousands):</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal current tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(161</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(765</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>871</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State current tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,715</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,263</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,906</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal deferred tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,396</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,020</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,389</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State deferred tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,743</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,104</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,879</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>394</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,310</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the statutory U.S. federal rate and effective rates is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="20" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Federal tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6,231</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>21.00</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>8,256</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>21.00</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>8,971</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>34.00</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">State franchise tax, net of federal benefit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,891</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>13.12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,332</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3.39</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,799</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6.82</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other Non deductible expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>674</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2.27</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>471</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1.20</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.35</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Noncontrolling interests in partnerships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,824</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(6.15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,237</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(3.15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(687</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2.61</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Changes in valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(462</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1.56</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,760</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4.48</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,045</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(3.96</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Tax Cuts and Jobs Act</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>13,527</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>51.27</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gain on change in control</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(8,303</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(21.12</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Deferred true-ups and other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(761</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2.56</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(4,254</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(10.82</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(194</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(0.74</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other reconciling items</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,520</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(5.12</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,369</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6.02</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,848</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7.00</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Income tax expense</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>21.00</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>394</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1.00</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>24,310</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>92.13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the federal tax legislation that was enacted on December 22, 2017 ("Tax Act"), the Company re-measured its existing deferred tax assets and liabilities based on </span><span style="font-family:inherit;font-size:10pt;">21%</span><span style="font-family:inherit;font-size:10pt;">, the current rate at which they are expected to reverse in the future. In 2017, the Company recorded provisional amounts for certain enactment-date efforts of the Act by applying the guidance in SAB 118 because it had not yet completed our enactment-date effects of the Act. The Company has completed analysis of Tax Act's income tax effects. In total, the Company recorded a non-cash charge of </span><span style="font-family:inherit;font-size:10pt;"><span>13.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, which is included as a component of income tax expense from continuing operations in 2017. Upon further analysis of certain aspects of the Tax Act and refinement of the calculations during the 12 months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company found an immaterial adjustment was necessary.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes reflect the net tax effects of temporary differences between carrying amounts of assets and liabilities for financial and income tax reporting purposes and operating loss carryforwards.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our deferred tax assets and liabilities comprise the following (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,490</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,875</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,280</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,421</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>126,546</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Straight-Line rent adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,811</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unfavorable contract liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,354</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,374</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,065</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,220</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,850</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,616</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,815</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,348</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,810</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Deferred Tax Assets</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>193,178</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,381</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,450</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,194</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24,637</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19,780</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,669</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,110</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use asset</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(115,364</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non accrual experience method reserve</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,446</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,510</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,345</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Deferred Tax Liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(158,630</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42,875</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net Deferred Tax Asset</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,548</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,506</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had federal net operating loss carryforwards of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$136.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, which comprise of definite and indefinite net operating losses. We had federal net operating loss carryforwards of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$124.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, which expire at various intervals from the years 2023 to 2037, and had carryforwards of </span><span style="font-family:inherit;font-size:10pt;"><span>$11.5</span></span><span style="font-family:inherit;font-size:10pt;"> million of net operating losses generated in 2018, which do not expire. Federal net operating losses generated following </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;"> carryover indefinitely and may generally be used to offset up to 80% of future taxable net income. The Company also had state net operating loss carryforwards of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$98.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, which expire at various intervals from the years 2020 through 2039. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$24.6</span></span><span style="font-family:inherit;font-size:10pt;"> million of our federal net operating loss carryforwards acquired in connection with the 2011 acquisition of Raven Holdings U.S., Inc. and the 2019 acquisition of Nulogix Health, Inc. are subject to limitations related to their utilization under Section 382 of the Internal Revenue Code. Future ownership changes as determined under Section 382 of the Internal Revenue Code could further limit the utilization of net operating loss carryforwards.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">   </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We considered all evidence available when determining whether deferred tax assets are more likely-than-not to be realized, including projected future taxable income, scheduled reversals of deferred tax liabilities, prudent tax planning strategies, and recent financial operations. The evaluation of this evidence requires significant judgment about the forecasts of future taxable income, based on the plans and estimates we are using to manage the underlying businesses. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have determined that deferred tax assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$193.2</span></span><span style="font-family:inherit;font-size:10pt;"> million are more likely-than-not to be realized. We have also taken into consideration deferred tax liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$24.6</span></span><span style="font-family:inherit;font-size:10pt;"> million are related to book basis in goodwill that has an indefinite life.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We file consolidated income tax returns in the U.S. federal jurisdiction and various states and foreign jurisdictions. We continue to reinvest earnings of the non-US entities for the foreseeable future and therefore have not recognized any U.S. tax expense on these earnings. With limited exceptions, we are no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for years before 2015. We do not anticipate the results of any open examinations would result in a material change to its financial position.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company has unrecognized tax benefits of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> of which </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> will affect the effective tax rate if recognized.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the total gross amounts of unrecognized tax benefits for the years ended are as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at beginning of year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,629</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,615</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,861</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases related to prior year tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>896</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases related to current year tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expiration of the statute of limitations for the assessment of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(393</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increase (decrease) related to change in rate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(247</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,629</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,615</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe it is reasonably possible it will not materially reduce its unrecognized tax benefits within the next twelve months.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes accrued interest and penalties related to unrecognized tax benefits in income tax expense. During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> the Company accrued approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$30,000</span></span><span style="font-family:inherit;font-size:10pt;"> of interest and penalties. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, accrued interest and penalties amounted to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$300,000</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div> <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, we recognized income tax expense comprised of the following (in thousands):</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal current tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(161</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(765</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>871</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State current tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,715</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,263</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,906</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal deferred tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,396</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,020</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,389</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State deferred tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,743</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,104</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,879</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>394</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,310</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -161000 -765000 871000 7715000 7263000 4906000 22000 20000 23000 3396000 -2020000 21389000 -4743000 -4104000 -2879000 6229000 394000 24310000 <div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the statutory U.S. federal rate and effective rates is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="20" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Federal tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6,231</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>21.00</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>8,256</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>21.00</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>8,971</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>34.00</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">State franchise tax, net of federal benefit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,891</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>13.12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,332</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3.39</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,799</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6.82</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other Non deductible expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>674</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2.27</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>471</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1.20</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.35</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Noncontrolling interests in partnerships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,824</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(6.15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,237</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(3.15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(687</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2.61</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Changes in valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(462</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1.56</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,760</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4.48</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,045</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(3.96</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Tax Cuts and Jobs Act</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>13,527</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>51.27</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gain on change in control</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(8,303</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(21.12</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Deferred true-ups and other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(761</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2.56</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(4,254</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(10.82</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(194</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(0.74</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other reconciling items</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,520</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(5.12</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,369</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6.02</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,848</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7.00</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Income tax expense</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>21.00</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>394</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1.00</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>24,310</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>92.13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> %</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 6231000 0.2100 8256000 0.2100 8971000 0.3400 3891000 0.1312 1332000 0.0339 1799000 0.0682 674000 0.0227 471000 0.0120 91000 0.0035 1824000 -0.0615 1237000 -0.0315 687000 -0.0261 -462000 -0.0156 1760000 0.0448 -1045000 -0.0396 0 0 0 0 13527000 0.5127 0 0 -8303000 -0.2112 0 0 -761000 -0.0256 -4254000 -0.1082 -194000 -0.0074 -1520000 -0.0512 2369000 0.0602 1848000 0.0700 6229000 0.2100 394000 0.0100 24310000 0.9213 13600000 <div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our deferred tax assets and liabilities comprise the following (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,490</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,875</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,280</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,421</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>126,546</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Straight-Line rent adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,811</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unfavorable contract liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,354</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,374</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,065</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,220</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,850</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,616</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,815</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,348</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,810</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Deferred Tax Assets</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>193,178</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,381</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,450</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,194</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24,637</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19,780</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,669</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,110</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use asset</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(115,364</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non accrual experience method reserve</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,446</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,510</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,345</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Deferred Tax Liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(158,630</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42,875</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net Deferred Tax Asset</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,548</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,506</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 34490000 46875000 4280000 3421000 126546000 0 9811000 0 1354000 1374000 1065000 27220000 14850000 4616000 2815000 5348000 5810000 193178000 74381000 6450000 6194000 24637000 19780000 6669000 8110000 115364000 0 1446000 5510000 7345000 158630000 42875000 34548000 31506000 136200000 124700000 11500000 98600000 24600000 193200000 24600000 4300000 3500000 <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the total gross amounts of unrecognized tax benefits for the years ended are as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at beginning of year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,629</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,615</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,861</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases related to prior year tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>896</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases related to current year tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expiration of the statute of limitations for the assessment of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(393</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increase (decrease) related to change in rate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(247</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,629</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,615</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 4629000 3615000 3861000 34000 896000 1000 119000 111000 0 393000 0 0 -1000 7000 -247000 4320000 4629000 3615000 30000 300000 STOCK-BASED COMPENSATION<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Incentive Plans</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Options</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have one long-term equity incentive plan which we refer to as the 2006 Equity Incentive Plan, which we first amended and restated as of April 20, 2015 and again on March 9, 2017 (“the Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. We have reserved for issuance under the 2017 Restated Plan </span><span style="font-family:inherit;font-size:10pt;"><span>14,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock. We can issue options, stock awards, stock appreciation rights, stock units and cash awards under the 2017 Restated Plan. Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options generally vest over </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;"> and expire </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;"> from the date of grant.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had outstanding options to acquire </span><span style="font-family:inherit;font-size:10pt;"><span>478,951</span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock, of which options to acquire </span><span style="font-family:inherit;font-size:10pt;"><span>148,456</span></span><span style="font-family:inherit;font-size:10pt;"> shares were exercisable. The following summarizes all of our option transactions for the twelve months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding Options</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Under the 2006 Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise price</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Per Common Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Life(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>513,282</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.44</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,200</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.93</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,500</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.00</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled, forfeited or expired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(111,031</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>478,951</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.21</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.33</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,790,763</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>148,456</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.42</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,931,633</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between our closing stock price on </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and the exercise price, multiplied by the number of in-the-money options as applicable) that would have been received by the holder had all holders exercised their options on </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, total unrecognized stock-based compensation expense related to non-vested employee awards was </span><span style="font-family:inherit;font-size:10pt;"><span>$710,861</span></span><span style="font-family:inherit;font-size:10pt;"> which is expected to be recognized over a weighted average period of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>1.8 years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Awards (“RSA’s”)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Restated Plan permits the award of restricted stock awards (“RSA’s”). As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have issued a total of </span><span style="font-family:inherit;font-size:10pt;"><span>6,118,276</span></span><span style="font-family:inherit;font-size:10pt;"> RSA’s of which </span><span style="font-family:inherit;font-size:10pt;"><span>387,934</span></span><span style="font-family:inherit;font-size:10pt;"> were unvested at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> . The following summarizes all unvested RSA’s activities during the twelve months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RSA's</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RSA's unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277,504</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.77</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes during the period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>636,656</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.78</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(524,726</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.03</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RSA's unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>387,934</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.13</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.61</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine the fair value of all RSA’s based of the closing price of our common stock on award date.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">   </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other stock bonus awards</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Restated Plan also permits the award of stock bonuses not subject to any future service period. These awards are valued and expensed based on the closing price of our common stock on the date of award. During the twelve months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> we issued </span><span style="font-family:inherit;font-size:10pt;"><span>66,600</span></span><span style="font-family:inherit;font-size:10pt;"> shares relating to these awards, amounting to </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of compensation expense.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Plan summary</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In summary, of the </span><span style="font-family:inherit;font-size:10pt;"><span>14,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock reserved for issuance under the Restated Plan, at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had issued </span><span style="font-family:inherit;font-size:10pt;"><span>14,875,694</span></span><span style="font-family:inherit;font-size:10pt;"> total shares between options, RSA’s and other stock awards. With options cancelled and RSA’s forfeited amounting to </span><span style="font-family:inherit;font-size:10pt;"><span>3,281,040</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>61,703</span></span><span style="font-family:inherit;font-size:10pt;"> shares, respectively, there remain </span><span style="font-family:inherit;font-size:10pt;"><span>2,467,049</span></span><span style="font-family:inherit;font-size:10pt;"> shares available under the Restated Plan for future issuance.</span></div> 14000000 P5Y P10Y 478951 148456 The following summarizes all of our option transactions for the twelve months ended <span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding Options</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Under the 2006 Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise price</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Per Common Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Life(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>513,282</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.44</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,200</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.93</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,500</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.00</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled, forfeited or expired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(111,031</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>478,951</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.21</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.33</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,790,763</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>148,456</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.42</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,931,633</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 513282 7.44 89200 10.93 12500 6.00 111031 0.79 478951 8.21 P7Y3M29D 5790763000 148456 7.29 P6Y5M1D 1931633000 710861000 P1Y9M18D 6118276 387934 The following summarizes all unvested RSA’s activities during the twelve months ended <span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RSA's</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RSA's unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277,504</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.77</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes during the period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>636,656</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.78</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(524,726</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.03</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RSA's unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>387,934</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.13</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.61</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 277504 9.77 636656 11.78 524726 11.03 1500 12.76 387934 P1Y1M17D 11.61 66600 1000000.0 14000000 14875694 3281040 61703 2467049 QUARTERLY RESULTS OF OPERATIONS (unaudited)<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth a summary of our unaudited quarterly operating results for each of the last eight quarters in the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">. This quarterly data has been derived from our unaudited consolidated interim financial statements which, in our opinion, have been prepared on substantially the same basis as the audited financial statements contained elsewhere in this report and include all normal recurring adjustments necessary for a fair presentation of the financial information for the periods presented. These unaudited quarterly results should be read in conjunction with our financial statements and notes thereto, included elsewhere in this report. The operating results in any quarter are not necessarily indicative of the results that may be expected for any future period (in thousands except per share data).</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 Quarter Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018 Quarter Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Mar 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Sept 30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Dec 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Mar 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Sept 30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Dec 31</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Statement of Operations Data:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net  revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>271,549</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>289,097</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>292,692</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>300,840</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>231,392</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>244,395</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>242,148</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>257,211</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>264,279</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>267,113</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>275,842</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>277,571</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>232,280</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>228,525</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>225,700</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>257,755</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total other expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>12,295</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>13,668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11,897</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>10,194</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>10,040</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>10,646</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>10,670</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(27,620</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Equity in earnings of joint ventures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,873</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2,244</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,955</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2,278</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2,977</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(3,748</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2,822</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,830</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Benefit from (provision for) income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,230</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2,969</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,816</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2,673</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,497</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2,505</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2,827</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,441</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net (loss) income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,922</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7,591</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>5,092</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>12,680</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(5,454</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6,467</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>5,773</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>31,347</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net income (loss) attributable to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,811</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,692</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,897</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,283</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,884</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,061</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>734</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,211</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net (loss) income attributable to Radnet, Inc. common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(3,733</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4,899</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,195</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>10,397</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(7,338</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>5,406</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>5,039</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>29,136</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Basic net (loss) income attributable to Radnet, Inc. common stockholders (loss) earnings per share:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(0.08</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.06</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(0.15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Diluted net (loss) income attributable to Radnet, Inc. common stockholders (loss) earnings per share:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(0.08</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.10</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.06</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.21</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(0.15</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.11</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.10</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.59</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Weighted average shares outstanding</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Basic</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>49,554</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>49,703</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>49,807</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>49,905</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>47,823</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>47,969</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>48,011</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>48,633</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">   Diluted</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>49,554</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>50,145</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>50,360</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>50,634</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>47,823</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>48,526</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>48,615</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>49,259</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> The operating results in any quarter are not necessarily indicative of the results that may be expected for any future period (in thousands except per share data).<div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 Quarter Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018 Quarter Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Mar 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Sept 30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Dec 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Mar 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Sept 30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Dec 31</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Statement of Operations Data:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net  revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>271,549</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>289,097</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>292,692</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>300,840</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>231,392</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>244,395</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>242,148</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>257,211</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>264,279</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>267,113</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>275,842</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>277,571</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>232,280</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>228,525</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>225,700</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>257,755</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total other expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>12,295</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>13,668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11,897</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>10,194</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>10,040</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>10,646</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>10,670</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(27,620</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Equity in earnings of joint ventures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,873</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2,244</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,955</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2,278</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2,977</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(3,748</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2,822</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,830</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Benefit from (provision for) income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,230</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2,969</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,816</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2,673</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,497</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2,505</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2,827</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,441</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net (loss) income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,922</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7,591</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>5,092</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>12,680</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(5,454</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6,467</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>5,773</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>31,347</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net income (loss) attributable to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,811</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,692</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,897</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,283</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,884</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,061</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>734</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,211</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net (loss) income attributable to Radnet, Inc. common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(3,733</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4,899</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,195</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>10,397</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(7,338</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>5,406</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>5,039</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>29,136</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Basic net (loss) income attributable to Radnet, Inc. common stockholders (loss) earnings per share:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(0.08</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.06</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(0.15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Diluted net (loss) income attributable to Radnet, Inc. common stockholders (loss) earnings per share:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(0.08</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.10</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.06</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.21</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(0.15</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.11</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.10</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eeeeee;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.59</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Weighted average shares outstanding</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Basic</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>49,554</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>49,703</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>49,807</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>49,905</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>47,823</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>47,969</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>48,011</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eeeeee;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>48,633</span></span></div></td><td style="vertical-align:bottom;background-color:#eeeeee;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">   Diluted</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>49,554</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>50,145</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>50,360</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>50,634</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>47,823</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>48,526</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>48,615</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>49,259</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 271549000 289097000 292692000 300840000 231392000 244395000 242148000 257211000 264279000 267113000 275842000 277571000 232280000 228525000 225700000 257755000 12295000 13668000 11897000 10194000 10040000 10646000 10670000 -27620000 1873000 2244000 1955000 2278000 2977000 3748000 2822000 1830000 -1230000 2969000 1816000 2673000 -2497000 2505000 2827000 -2441000 -1922000 7591000 5092000 12680000 -5454000 6467000 5773000 31347000 1811000 2692000 1897000 2283000 1884000 1061000 734000 2211000 -3733000 4899000 3195000 10397000 -7338000 5406000 5039000 29136000 -0.08 0.10 0.06 0.21 -0.15 0.11 0.10 0.60 -0.08 0.10 0.06 0.21 -0.15 0.11 0.10 0.59 49554 49703 49807 49905 47823 47969 48011 48633 49554 50145 50360 50634 47823 48526 48615 49259 RELATED PARTY TRANSACTIONS<div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As stated in Note 2, Summary of Significant Accounting Policies, we have an equity investment in WhiteRabbit.ai Inc.. In addition to our equity investment, we have a loan of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the company outstanding at </span><span style="font-family:inherit;font-size:10pt;text-align:left;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;text-align:left;">.</span></div> 2500000 SUBSEQUENT EVENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 11, 2020, we announced a definitive agreement to acquire DeepHealth, Inc. ("DeepHealth"). DeepHealth is developing solutions in machine learning and artificial intelligence to assist radiologists in interpreting images and improving patient care. The close is planned for April 1, 2020 and we will issue approximately </span><span style="font-family:inherit;font-size:10pt;"><span>1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> RadNet common stock shares to complete the acquisition.</span></div> 1000000.0 Financial Statement Schedules<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RADNET, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at Beginning of Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional Charges Against Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deductions from Reserve</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at End of Year</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31, 2017</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Accounts Receivable-Allowance for Bad Debts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,674</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,555</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32,585</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,644</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All other schedules are omitted because they are not applicable or the required information is shown in the consolidated financial statements or notes thereto.</span></div> 20674000 46555000 32585000 34644000 XML 80 R69.htm IDEA: XBRL DOCUMENT v3.20.1
QUARTERLY RESULTS OF OPERATIONS (unaudited) (Details - Statements of Operations) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]                      
Net revenue $ 300,840 $ 292,692 $ 289,097 $ 271,549 $ 257,211 $ 242,148 $ 244,395 $ 231,392 $ 1,154,179 $ 975,146 $ 922,186
Total operating expenses 277,571 275,842 267,113 264,279 257,755 225,700 228,525 232,280 1,084,301 944,260 872,136
Total other expenses 10,194 11,897 13,668 12,295 (27,620) 10,670 10,646 10,040      
Equity in earnings of joint ventures (2,278) (1,955) (2,244) (1,873) (1,830) (2,822) (3,748) (2,977) (8,350) (11,377) (13,554)
Benefit from (provision for) income taxes (2,673) (1,816) (2,969) 1,230 2,441 (2,827) (2,505) 2,497 (6,229) (394) (24,310)
Net (loss) income 12,680 5,092 7,591 (1,922) 31,347 5,773 6,467 (5,454) 23,440 38,133 2,075
Net income (loss) attributable to noncontrolling interests 2,283 1,897 2,692 1,811 2,211 734 1,061 1,884 8,684 5,890 2,022
Net (loss) income attributable to Radnet, Inc. common stockholders $ 10,397 $ 3,195 $ 4,899 $ (3,733) $ 29,136 $ 5,039 $ 5,406 $ (7,338) $ 14,756 $ 32,243 $ 53
Basic net (loss) income attributable to Radnet, Inc. common stockholders (loss) earnings per share (in dollars per share) $ 0.21 $ 0.06 $ 0.10 $ (0.08) $ 0.60 $ 0.10 $ 0.11 $ (0.15) $ 0.30 $ 0.67 $ 0
Diluted net (loss) income attributable to Radnet, Inc. common stockholders (loss) earnings per share (in dollars per share) $ 0.21 $ 0.06 $ 0.10 $ (0.08) $ 0.59 $ 0.10 $ 0.11 $ (0.15) $ 0.29 $ 0.66 $ 0
Weighted average shares outstanding, basic (in shares) 49,905 49,807 49,703 49,554 48,633 48,011 47,969 47,823 49,674,858 48,114,275 46,880,775
Weighted average shares outstanding, diluted (in shares) 50,634 50,360 50,145 49,554 49,259 48,615 48,526 47,823 50,244,006 48,678,999 47,401,921
XML 81 R61.htm IDEA: XBRL DOCUMENT v3.20.1
INCOME TAXES (Details - Income tax expense) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Tax Disclosure [Abstract]                      
Federal current tax                 $ (161) $ (765) $ 871
State current tax                 7,715 7,263 4,906
Other current tax                 22 20 23
Federal deferred tax                 3,396 (2,020) 21,389
State deferred tax                 (4,743) (4,104) (2,879)
Income tax expense $ 2,673 $ 1,816 $ 2,969 $ (1,230) $ (2,441) $ 2,827 $ 2,505 $ (2,497) $ 6,229 $ 394 $ 24,310
XML 82 R65.htm IDEA: XBRL DOCUMENT v3.20.1
INCOME TAXES (Details - Unrecognized tax benefit) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Unrecognized tax benefit, Balance at beginning of year $ 4,629 $ 3,615 $ 3,861
Decrease related to prior year tax positions (34)    
Increases related to prior year tax positions   896 1
Increases related to current year tax positions 119 111 0
Expiration of the statute of limitations for the assessment of taxes (393) 0 0
Increase (decrease) related to change in rate (1) 7 (247)
Unrecognized tax benefit, Balance at end of year $ 4,320 $ 4,629 $ 3,615
XML 83 R8.htm IDEA: XBRL DOCUMENT v3.20.1
NATURE OF BUSINESS
12 Months Ended
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF BUSINESS NATURE OF BUSINESS
 
We are a national provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. At December 31, 2019, we operated directly or indirectly through joint ventures with hospitals, 335 centers located in California, Delaware, Florida, Maryland, New Jersey, and New York. Our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Our services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. The vast majority of our centers offer multi-modality imaging services. Our multi-modality strategy diversifies revenue streams, reduces exposure to reimbursement changes and provides patients and referring physicians one location to serve the needs of multiple procedures. In addition to our imaging services, we have certain other software subsidiaries which design and sell computerized systems for the imaging industry and internally develop Artificial Intelligence, and Imaging On Call LLC, which provides teleradiology services. Our operations comprise a single segment for financial reporting purposes.
 
The consolidated financial statements include the accounts of RadNet, Inc as well as its subsidiaries in which RadNet has a controlling financial interest. The consolidated financial statements also include certain variable interest entities in which we are the primary beneficiary (as described in more detail below). All material intercompany transactions and balances have been eliminated upon consolidation. . All of these affiliated entities are referred to collectively as “RadNet”, “we”, “us”, “our” or the “Company” in this report
Accounting regulations stipulate that generally any entity with a) insufficient equity to finance its activities without additional subordinated financial support provided by any parties, or b) equity holders that, as a group, lack the characteristics which evidence a controlling financial interest, is considered a Variable Interest Entity (“VIE”). We consolidate all VIEs in which we are the primary beneficiary. We determine whether we are the primary beneficiary of a VIE through a qualitative analysis that identifies which variable interest holder has the controlling financial interest in the VIE. The variable interest holder who has both of the following has the controlling financial interest and is the primary beneficiary: (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. In performing our analysis, we consider all relevant facts and circumstances, including: the design and activities of the VIE, the terms of the contracts the VIE has entered into, the nature of the VIE’s variable interests issued and how they were negotiated with or marketed to potential investors, and which parties participated significantly in the design or redesign of the entity.

VIEs that we consolidate as the primary beneficiary consist of professional corporations which are owned or controlled by individuals within our senior management, namely Howard G. Berger, M.D., our President and Chief Executive Officer, and John V. Crues, III, M.D., RadNet's Medical Director; both of whom are members of our Board of Directors. Dr. Berger owns, indirectly, 99% of the equity interests in Beverly Radiology Medical Group III (BRMG) and a controlling interest in two professional corporations in New York City. BRMG is responsible for the professional medical services at nearly all of our facilities located in California. Dr. Crues owns six professional corporations which provide medical services in Delaware, Maryland, New Jersey and New York. Additionally, Dr. Crues is a 1% owner of BRMG. These VIEs are collectively referred to as the consolidated medical group ("the Group").
RadNet provides non-medical, technical and administrative services to the Group for which it receives a management fee, pursuant to the related management agreements. Through the management agreements we have exclusive authority over all non-medical decision making related to the ongoing business operations and we determine the annual budget. The Group has insignificant operating assets and liabilities, and de minimis equity. Through management agreements with us, substantially all cash flows of the Group after expenses, including professional salaries, are transferred to us. We consolidate the revenue and expenses, assets and liabilities of the Group.

The Group on a combined basis recognized $157.4 million, $132.9 million, and $134.6 million of revenue, net of management services fees to RadNet, for the years ended December 31, 2019, 2018, and 2017, respectively and $157.4 million, $132.9 million, and $134.6 million of operating expenses for the years ended December 31, 2019, 2018, and 2017, respectively. RadNet, Inc. recognized $618.9 million, $505.2 million, and $435.5 million of total billed net service fee revenue for the years ended December 31, 2019, 2018, and 2017, respectively, for management services provided to them relating primarily to the technical portion of billed revenue.
 
The cash flows of the Group are included in the accompanying consolidated statements of cash flows. All intercompany balances and transactions have been eliminated in consolidation. In our consolidated balance sheets at December 31, 2019 and December 31, 2018, we have included approximately $100.3 million and $88.9 million, respectively, of accounts receivable and approximately $7.0 million and $5.6 million of accounts payable and accrued liabilities related to the Group, respectively.
 
The creditors of the Group do not have recourse to our general credit and there are no other arrangements that could expose us to losses on behalf of them. However, RadNet may be required to provide financial support to cover any operating expenses in excess of operating revenues.

We also own a 49% economic interest in ScriptSender, LLC, which provides secure data transmission services of medical information. Through a management agreement, RadNet provides management and accounting services and receives an agreed upon fee. ScriptSender LLC is dependent on the Company to finance its own activities, and as such we determined that it is a VIE but we are not a primary beneficiary since we do not have the power to direct the activities of the entity that most significantly impact the entity’s economic performance.

At all of our centers not serviced by the Group we have entered into long-term contracts (typically 40 years) with independent radiology groups to provide physician services at those centers. These radiology practices provide professional services, including supervision and interpretation of diagnostic imaging procedures, in our diagnostic imaging centers. The radiology practices maintain full control over the provision of professional services. Under these arrangements, in addition to obtaining technical fees for the use of our diagnostic imaging equipment and the provision of technical services, we provide management services and receive a fee based on the value of the services we provide. We own the diagnostic imaging equipment and, therefore, receive 100% of the technical reimbursements associated with imaging procedures. The radiology practice groups retain the professional reimbursements associated with imaging procedures after deducting management service fees paid to us and we have no economic controlling interest in these radiology practices as such, the financial results of these practices are not consolidated in our financial statements.
XML 84 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 85 R23.htm IDEA: XBRL DOCUMENT v3.20.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
PRINCIPLES OF CONSOLIDATION
PRINCIPLES OF CONSOLIDATION – The operating activities of subsidiaries are included in the accompanying consolidated financial statements (“financial statements”) from the date of acquisition. Investments in companies in which we have the ability to exercise significant influence, but not control, are accounted for by the equity method. All intercompany transactions and balances, with our consolidated entities and the unsettled amount of intercompany transactions with our equity method investees, have been eliminated in consolidation. As stated in Note 1 above, the Group consists of VIEs and we consolidate the operating activities and balance sheets of each. Additionally, we determined that our unconsolidated joint venture, ScriptSender, LLC, is also a VIE as it is dependent on our operational funding but we are not a primary beneficiary since RadNet does not have the power to direct the activities of the entity that most significantly impact the entity’s economic performance.
USE OF ESTIMATES
USE OF ESTIMATES - The financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP), which requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect various matters, including our reported amounts of assets and liabilities in our consolidated balance sheets at the dates of the financial statements; our disclosure of contingent assets and liabilities at the dates of the financial statements; and our reported amounts of revenues and expenses in our consolidated statements of operations during the reporting periods. These estimates involve judgments with respect to numerous factors that are difficult to predict and are beyond management’s control. As a result, actual amounts could materially differ from these estimates.
RECLASSIFICATION RECLASSIFICATION – For the year 2017, we have reclassified certain amounts within other income and expenses on the consolidated statement of operations and proceeds from issuance of debt on the consolidated statement of cash flows to conform to our 2018 and 2019 presentation. For the year 2018, we have reclassified certain amounts within other expenses on the consolidated statement of cash flows to conform to our 2019 presentation.
REVENUES
REVENUES – Our revenues generally relate to net patient fees received from various payors and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided
by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.
 
As it relates to the consolidated medical group, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by them as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to others centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.
 
Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual allowances under managed care and commercial insurance plans are based upon historical collection experience from such payors in accordance with the underlying contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have price concessions applied. We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect.

Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.

On January 1, 2018, we adopted the new revenue recognition accounting standard issued by the Financial Accounting Standards Board (“FASB”) and codified in the ASC as topic 606 (“ASC 606”). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding our revenue recognition policies and significant judgments employed in the determination of revenue.

We applied the modified retrospective approach to all contracts when adopting ASC 606. As a result, at the adoption of ASC 606 the majority of what was previously classified as the provision for bad debts in the statement of operations are now reflected as implicit price concessions and therefore included as a reduction to net operating revenues in 2018 and later. For changes in credit issues not assessed at the date of service, we will prospectively recognize those amounts in other operating expenses on the statement of operations. For periods prior to the adoption of ASC 606, the provision for bad debts has been presented consistent with the previous revenue recognition standards that required it to be presented separately as a component of net operating revenues. As part of the adoption of ASC 606 allowance for doubtful accounts was reclassified to be a component of net patient accounts receivable. Other than these changes in presentation on the consolidated statement of operations and consolidated balance sheet, the adoption of ASC 606 did not have a material impact on the consolidated financial statements. As part of the adoption of ASC 606, we elected two of the available practical expedients provided for in the standard. First, we did not adjust the transaction price for any financing components as those were deemed to be insignificant. Additionally, we expensed all incremental customer contract acquisition costs as incurred as such costs are not material and would be amortized over a period less than one year.

ACCOUNTS RECEIVABLE
ACCOUNTS RECEIVABLE – Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. We continuously monitor collections from our payors and record an estimated price concession based upon specific payor collection issues that we have identified and our historical experience.

In 2019 and 2018 we entered into factoring agreements with various institutions and sold certain accounts receivable under non-recourse agreements. These transactions are accounted for as a reduction in accounts receivable as the agreements transfer effective control over and risk related to the receivables to the buyers. The aggregate amounts factored under these facilities, net of discounts recorded to reflect market interest rates, was $9.0 million during the year ended December 31, 2019 and $20.5 million during the year ended December 31, 2018.

Proceeds on notes receivable are reflected as operating activities on our statement of cash flows and on our balance sheet as prepaid expenses and other current assets for the current portion and deposits and other for the long term portion. At December 31, 2019 we have $24.2 million remaining to be collected on these agreements. We do not utilize factoring arrangements as an integral part of our financing for working capital.
MEANINGFUL USE INCENTIVE MEANINGFUL USE INCENTIVE – Under the American Recovery and Reinvestment Act of 2009, a program was enacted that provides financial incentives for providers that successfully implement and utilize electronic health record technology to improve patient care. Our software development team in Canada developed a Radiology Information System (RIS) software platform that has been awarded meaningful use certification. We recorded the meaningful use incentive within non-operating income.
SOFTWARE REVENUE RECOGNITION
SOFTWARE REVENUE RECOGNITION – Our subsidiary, eRAD, Inc., sells Picture Archiving Communications Systems (“PACS”) and related services, primarily in the United States. The PACS systems sold by eRAD are primarily composed of certain elements: hardware, software, installation and training, and support. Sales are made primarily through eRAD’s sales force and generally include hardware, software, installation, training and first-year warranty support. Hardware, which is not unique or special purpose, is purchased from a third-party and resold to eRAD’s customers with a small mark-up.
 
We have determined that our core software products, such as PACS, are essential to most of our arrangements as hardware, software and related services are sold as an integrated package. Revenue is recognized when a performance obligation is satisfied by transferring a promised good or service to a customer.
  
For the years ended December 31, 2019, 2018 and 2017, we recorded approximately $10.1 million, $6.8 million, and $6.1 million, respectively, in revenue related to our eRAD business which is included in net service fee revenue in our consolidated statement of operations. At December 31, 2019 we had a deferred revenue liability of approximately $1.3 million associated with eRAD sales which we expect to recognize into revenue over the next 12 months.
SOFTWARE DEVELOPMENT COSTS
SOFTWARE DEVELOPMENT COSTS – When we develop our own software solutions through our eRad subsidiary, we capitalize and amortize those costs over their useful life. Costs related to the research and development of new software products
and enhancements to existing software products all for resale to our customers are expensed as incurred. If we enter into agreements where we license our software to outside customers, we have recorded the receipt of these funds against the capitalized software costs.

Our most major software development to date was the Radiology Information System, a front desk patient tracking software, which had total capitalized costs of approximately $6.4 million and was fully amortized as of December 31, 2018.

CONCENTRATION OF CREDIT RISKS CONCENTRATION OF CREDIT RISKS – Financial instruments that potentially subject us to credit risk are primarily cash equivalents and accounts receivable. We have placed our cash and cash equivalents with one major financial institution. At times, the cash in the financial institution is temporarily in excess of the amount insured by the Federal Deposit Insurance Corporation, or FDIC. Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. We continuously monitor collections and maintain an allowance for bad debts based upon our historical collection experience. In addition, we have notes receivable stemming from our factoring of accounts receivable as stated above. Companies with which we factor our receivables are well known established buyers of such instruments, have agreed to assume the full risk of their collection, and to date have made all payments due to us in a timely manner.
CASH AND CASH EQUIVALENTS
CASH AND CASH EQUIVALENTS – We consider all highly liquid investments that mature in three months or less when purchased to be cash equivalents. The carrying amount of cash and cash equivalents approximates the fair market value.
DEFERRED FINANCING COSTS DEFERRED FINANCING COSTS – Costs of financing are deferred and amortized using the effective interest rate method. Deferred financing costs are solely related to our Barclays Revolving Credit Facilities. Deferred financing costs, net of accumulated amortization, were $1.6 million and $1.4 million for the twelve months ended December 31, 2019 and 2018, respectively
INVENTORIES
INVENTORIES – Inventories, consisting mainly of medical supplies, are stated at the lower of cost or net realizable value with cost determined by the first-in, first-out method.
PROPERTY AND EQUIPMENT
PROPERTY AND EQUIPMENT – Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are provided using the straight-line method over the estimated useful lives, which range from 3 to 15 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 3 to 15 years. Maintenance and repairs are charged to expense as incurred.
BUSINESS COMBINATION
BUSINESS COMBINATION – When the qualifications for business combination accounting treatment are met, it requires us to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.
GOODWILL AND INDEFINITE LIVED INTANGIBLES GOODWILL AND INDEFINITE LIVED INTANGIBLES – Goodwill totaled $441.0 million and $418.1 million at December 31, 2019 and December 31, 2018, respectively. Indefinite lived intangible assets at December 31, 2019 were $11.3 million and $9.8 million at December 31, 2018 and are associated with the value of certain trade name intangibles. Goodwill and trade name intangibles are recorded as a result of business combinations. When we determine the carrying value of goodwill exceeds its fair value, an impairment charge would be recognized which should not exceed the total amount of goodwill allocated to that reporting unit. We determined fair values for each of the reporting units using the market approach, when available and appropriate, or the income approach, or a combination of both. We assess the valuation methodology based upon the relevance and availability of the data at the time we perform the valuation. If multiple valuation methodologies are used, the results are weighted appropriately.
LONG-LIVED ASSETS
LONG-LIVED ASSETS – We evaluate our long-lived assets (property and equipment) and intangibles, other than goodwill, for impairment when events or changes indicate the carrying amount of an asset may not be recoverable. Accounting standards requires that if the sum of the undiscounted expected future cash flows from a long-lived asset or definite-lived intangible is less than the carrying value of that asset, an asset impairment charge must be recognized. The amount of the impairment charge is calculated as the excess of the asset’s carrying value over its fair value, which generally represents the discounted future cash flows from that asset or in the case of assets we expect to sell, at fair value less costs to sell. We determined that there were no events or changes in circumstances that indicated our long-lived assets were impaired during any periods presented.
INCOME TAXES INCOME TAXES – Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income in determining whether our net deferred tax assets are more likely than not to be realized.
LEASES LEASES - We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liability, and long term operating lease liability in our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liability, and long-term finance lease liability in our consolidated balance sheets.  ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. We use the implicit rate when readily determinable. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We include options to extend a lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For a contract in which we are a lessee that contains fixed payments for both lease and non-lease components, we have elected to account for the components as a single lease component, as permitted. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term.
UNINSURED RISKS
UNINSURED RISKS – On November 1, 2008 we obtained a fully funded and insured workers’ compensation policy, thereby eliminating any uninsured risks for employee injuries occurring on or after that date. This fully funded policy remained in effect through November 1, 2013 and continues to cover any claims incurred through this date.
 
On November 1, 2013 we entered into a high-deductible workers’ compensation insurance policy. We have recorded liabilities of $3.8 million and $2.8 million for each of the years ending December 31, 2019 and December 31, 2018, respectively, for the estimated future cash obligations associated with the unpaid portion of the workers compensation claims incurred.
 
We and our affiliated physicians carry an annual medical malpractice insurance policy that protects us for claims that are filed during the policy year and that fall within policy limits. The policy has a deductible for which is $10,000 per incidence for the years ending December 31, 2019 and December 31, 2018, respectively.
 
In December 2008, in order to eliminate the exposure for claims not reported during the regular malpractice policy period, we purchased a medical malpractice claims made tail policy, which provides coverage for any claims reported in the event that our medical malpractice policy expires. As of December 31, 2019, this policy remains in effect.
 
We have entered into an arrangement with Blue Shield to administer and process claims under a self-insured plan that provides health insurance coverage for our employees and dependents. We have recorded liabilities as of December 31, 2019 and 2018 of $4.9 million and $4.8 million, respectively, for the estimated future cash obligations associated with the unpaid portion of the medical and dental claims incurred by our participants. Additionally, we entered into an agreement with Blue Shield for a stop loss policy that provides coverage for any claims that exceed $250,000 up to a maximum of $1.0 million in order for us to limit our exposure for unusual or catastrophic claims.
EMPLOYEE BENEFIT PLAN EMPLOYEE BENEFIT PLAN – We adopted a profit-sharing/savings plan pursuant to Section 401(k) of the Internal Revenue Code that covers substantially all non-professional employees. Eligible employees may contribute on a tax-deferred basis a percentage of compensation, up to the maximum allowable under tax law. Employee contributions vest immediately.
LOSS AND OTHER UNFAVORABLE CONTRACTS
LOSS AND OTHER UNFAVORABLE CONTRACTS – We assess the profitability of our contracts to provide management services to our contracted physician groups and identify those contracts where current operating results or forecasts indicate probable future losses. Anticipated future revenue is compared to anticipated costs and if the anticipated future cost exceeds the revenue, a loss contract accrual is recorded. In connection with the acquisition of Radiologix in November 2006, we acquired certain management service agreements which met this criterion and recorded to other non-current liabilities an $8.9 million loss contract accrual. Of the $4.6 million ending balance at December 31, 2018, approximately $4.0 million, ($2.8 million net of taxes), was settled against the purchase consideration of Hudson Valley Radiology Associates, P.L.L.C. (HVRA) by our VIE entity Lenox Hill Radiology and Medical Associates, P.C. and the remaining balance of approximately $558,000 was written off upon ending a contract with a physician group. See Note 4, Facility Acquisitions, Assets Held for Sale and Dispositions for further information on the purchase of HVRA.
 
Related to acquisition activity, we entered into certain operating lease commitments for facilities where the fair market rent differs from the lease contract rate. We recorded an unfavorable contract liability representing the difference between the total value of the fair market rent and the contract rent over the current term of the lease applicable from the date of acquisition.
EQUITY BASED COMPENSATION
EQUITY BASED COMPENSATION – We have one long-term incentive plan that we adopted in 2006 and which we first amended and restated as of April 20, 2015, and again on March 9, 2017 (the “Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. We have reserved for issuance under the Restated Plan 14,000,000 shares of common stock. We can issue options, stock awards, stock appreciation rights, stock units and cash awards under the Restated Plan. Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options and warrants generally vest over three to five years and expire five to ten years from date of grant. The compensation expense associated with option grants is calculated based on a valuation model, typically the Black–Scholes model, which requires certain management assumptions with respect to volatility. The compensation expense recognized for all equity-based awards is recognized over the awards’ service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees. See Note 11 Stock-Based Compensation for more information.
FOREIGN CURRENCY TRANSLATION
FOREIGN CURRENCY TRANSLATION – The functional currency of our foreign subsidiaries is the local currency. In accordance with ASC 830, Foreign Currency Matters, assets and liabilities denominated in foreign currencies are translated using the exchange rate at the balance sheet dates. Revenues and expenses are translated using average exchange rates prevailing during the reporting period. Any translation adjustments resulting from this process are shown separately as a component of accumulated other comprehensive income (loss). Foreign currency transaction gains and losses are included in the determination of net income.
COMPREHENSIVE (LOSS) INCOME
COMPREHENSIVE INCOME (LOSS) – Accounting guidance establishes rules for reporting and displaying comprehensive income (loss) and its components. Our unrealized gains or losses on foreign currency translation adjustments and our interest rate cap and swap agreements are included in comprehensive income (loss). The components of comprehensive income (loss) for the three years in the period ended December 31, 2019 are included in the consolidated statements of comprehensive income (loss).
CONTINGENCIES
CONTINGENCIES - We are party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business. With respect to these matters, we evaluate the developments on a regular basis and accrue a liability when we believe a loss is probable and the amount can be reasonably estimated. We believe that the amount or any estimable range of reasonably possible or probable loss will not, either individually or in the aggregate, have a material adverse effect on our business and consolidated financial statements. However, the outcome of these matters is inherently uncertain. Therefore, if one or more of these matters were resolved against us for amounts in excess of management's expectations, our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable, could be materially adversely affected.
DERIVATIVE INSTRUMENTS

DERIVATIVE INSTRUMENTS

2016 CAPS

In the fourth quarter of 2016, we entered into two forward interest rate cap agreements ("2016 Caps"). The 2016 Caps will mature in September and October 2020. The 2016 Caps had notional amounts of $150,000,000 and $350,000,000, respectively, which were designated at inception as cash flow hedges of future cash interest payments associated with portions of our variable rate bank debt. Under these arrangements, we purchased a cap on 3 month LIBOR at 2.0%. We are liable for a $5.3 million premium to enter into the caps which is being accrued to current liabilities on our balance sheet and paid over the life of the 2016 Caps.
 
At inception, we designated our 2016 Caps as cash flow hedges of floating-rate borrowings. In accordance with ASC Topic 815, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss of the hedge (i.e. change in fair value) is reported as a component of accumulated other comprehensive income in the consolidated statement of equity. See Fair Value Measurements section below for the fair value of the 2016 Caps at December 31, 2019.
 
A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive income (loss), net of taxes is as follows (amounts in thousands):

 
Interest Rate Contracts
 
 
 
 
For the twelve months ended
Amount of (Loss) Gain Recognized on Derivative, net of taxes
Location of Loss Recognized
in Income on Derivative
December 31, 2019
$(4,383)
Other Comprehensive Loss
December 31, 2018
2,876
Other Comprehensive Income
December 31, 2017
(880)
Other Comprehensive Loss
 
2019 SWAPS
In the second quarter of 2019, we entered into four forward interest rate agreements ("2019 swaps"). The 2019 swaps have total notional amounts of $500,000,000, consisting of two agreements of $50,000,000 each and two agreements of $200,000,000 each. The 2019 swaps will secure a constant interest rate associated with portions of our variable rate bank debt and have an effective date of October 13, 2020. They will mature in October 2023 for the two smaller notional and October 2025 for the two larger notional. Under these arrangements, we arranged the 2019 swaps with locked in 1 month LIBOR rates at 1.96% for the two $50,000,000 notional and at 2.05% for the two $200,000,000 notional.
At inception, we designated our 2019 swaps as cash flow hedges of floating-rate borrowings. In accordance with ASC Topic 815, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss of the hedge (i.e. change in fair value) is reported as a component of comprehensive loss in the consolidated statement of equity.  See Fair Value Measurements section below for the fair value of the 2019 swaps at December 31, 2019.

For the twelve months ended December 31, 2019
 
 
 
Effective Interest Rate Swap
Amount of Loss Recognized on Derivative, net of taxes
Location of Loss Recognized
in Income on Derivative
Interest rate contracts
$(5,870)
Other Comprehensive Loss

FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS – Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement:
 
Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
 
Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.
 
Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.

Derivatives:

The table below summarizes the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets in our consolidated balance sheets, as follows (in thousands):

 
As of December 31, 2019
 
Level 1
 
Level 2
 
Level 3
 
Total
Current and long term liabilities
 

 
 

 
 

 
 

2016 CAPS - Interest Rate Contracts
$

 
$
1,081

 
$

 
$
1,081

2019 SWAPS - Interest Rate Contracts
$

 
$
9,477

 
$

 
$
9,477

 
 
As of December 31, 2018
 
Level 1
 
Level 2
 
Level 3
 
Total
Current assets
 

 
 

 
 

 
 

2016 CAPS - Interest Rate Contracts
$

 
$
3,316

 
$

 
$
3,316



The estimated fair value of these contracts was determined using Level 2 inputs. More specifically, the fair value was determined by calculating the value of the difference between the fixed interest rate of the interest rate swaps and the counterparty’s forward LIBOR curve. The forward LIBOR curve is readily available in the public markets or can be derived from information available in the public markets.
 
Long Term Debt

The table below summarizes the estimated fair value and carrying amount of our SunTrust (Term Loan Agreement) and Barclays (First Lien Term Loans) long-term debt as follows (in thousands):
 
 
As of December 31, 2019
 
Level 1
 
Level 2
 
Level 3
 
Total Fair Value
 
Total Face Value
Term Loan Agreement and First Lien Term Loans
$

 
$
708,948

 
$

 
$
708,948

 
$
705,699

 
 
As of December 31, 2018
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Total Face Value
Term Loan Agreement and First Lien Term Loans
$

 
$
633,229

 
$

 
$
633,229

 
$
646,441


 
Our Barclays revolving credit facility had no aggregate principal amount outstanding as of December 31, 2019 and a $28.0 million principal amount outstanding as of December 31, 2018. Our SunTrust revolving credit facility had no aggregate principal amount outstanding for the periods ending December 31, 2019 and December 31, 2018, respectively.
 
The estimated fair values of our long-term debt, which is discussed in Note 8, was determined using Level 2 inputs for the Barclays and SunTrust term loans. Level 2 inputs primarily related to comparable market prices.
 
We consider the carrying amounts of cash and cash equivalents, receivables, other current assets, current liabilities and other notes payables to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment. Additionally, we consider the carrying amount of our capital lease obligations to approximate their fair value because the weighted average interest rate used to formulate the carrying amounts approximates current market rates.
EARNINGS PER SHARE
EARNINGS PER SHARE - Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):
 
 
Years Ended December 31,
 
2019
 
2018
 
2017
Net income attributable to RadNet, Inc. common stockholders
$
14,756

 
$
32,243

 
$
53

 
 
 
 
 
 
BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
 
 
 
 
 
Weighted average number of common shares outstanding during the period
49,674,858

 
48,114,275

 
46,880,775

Basic net income per share attributable to RadNet, Inc. common stockholders
$
0.30

 
$
0.67

 
$

DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
 
 
 
 
 
Weighted average number of common shares outstanding during the period
49,674,858

 
48,114,275

 
46,880,775

Add nonvested restricted stock subject only to service vesting
208,963

 
180,631

 
274,940

Add additional shares issuable upon exercise of stock options and warrants
360,185

 
384,093

 
246,206

Weighted average number of common shares used in calculating diluted net income per share
50,244,006

 
48,678,999

 
47,401,921

Diluted net income per share attributable to RadNet, Inc. common stockholders
$
0.29

 
$
0.66

 
$

 
 
 
 
 
 
Stock options excluded from the computation of diluted per share amounts:
 
 
 
 
 
Weighted average shares for which the exercise price exceeds average market price of common stock

 
6,250

 
175,037


INVESTMENT IN JOINT VENTURES
INVESTMENT IN JOINT VENTURES – We have 12 unconsolidated joint ventures with ownership interests ranging from 35% to 55%. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers.  Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture.  Our investment in these joint ventures is accounted for under the equity method, as we do not have a controlling financial interest in such ventures. We evaluate our investment in joint ventures, including cost in excess of book value (equity method goodwill) for impairment whenever indicators of impairment exist. No indicators of impairment existed as of December 31, 2019.
 
Sale of joint venture interest:
On April 1, 2017, we formed in conjuncture with Cedars Sinai Medical Center (“CSMC”) the Santa Monica Imaging Group, LLC (“SMIG”), consisting of two multi-modality imaging centers located in Santa Monica, CA with RadNet holding a 40% economic interest and CSMC holding a 60% economic interest. RadNet accounts for our share of the venture under the equity method. On January 1, 2019, CSMC purchased from the us an additional five percent economic interest in SMIG valued at $134,000. As a result of the transaction, our economic interest in SMIG has been reduced to 35%. We recorded a loss of $2,000 on the transaction.

Change in control of existing joint ventures

On October 6, 2014, we acquired a 49% equity interest in Garden State Radiology Network, LLC ("GSRN") for cash consideration of $2.2 million. The venture consisted of two imaging centers located in New Jersey. On August 1, 2019, the entity was dissolved by transferring ownership of the assets of the centers with each partner receiving full ownership of one center. See Note 4, Facility Acquisitions and Dispositions, for further information.

On April 12, 2018 we acquired 25% share capital in Nulogix, Inc. for cash consideration of $2.0 million. On August 1, 2019 we completed via the issuance of RadNet common stock valued at $1.5 million, the acquisition of the remaining 75% economic interest and we now consolidate the financial statements of Nulogix.  See Note 4, Facility Acquisitions and Dispositions, for further information.

On October 1, 2018, we obtained control over the operations of NJIN through an agreement with the other equity interest holder for no cash consideration. As such, we consolidated the financial statements of NJIN effective that date. The economic interest of each party remained the same after consolidation. See Note 4, Facility Acquisitions and Dispositions, to the consolidated financial statements contain herein for further information.

Joint venture investment and financial information
 
The following table is a summary of our investment in joint ventures during the years ended December 31, 2019 and December 31, 2018 (in thousands):
 
Balance as of December 31, 2017
$
52,435

Equity contributions in existing and purchase of interest in joint ventures
2,000

Equity in earnings in these joint ventures
11,377

Disposition of equity method interest upon acquisition of control in NJIN
(2,993
)
Distribution of earnings
(24,846
)
Balance as of December 31, 2018
$
37,973

Equity contributions in existing and purchase of interest in joint ventures
103

Equity in earnings in these joint ventures
8,350

Sale of ownership interest
(134
)
Dissolution of GSRN
(1,428
)
Nulogix return of capital
(792
)
Nulogix change in control
(1,004
)
Distribution of earnings
(8,598
)
Balance as of December 31, 2019
$
34,470



We charged management service fees from the centers underlying these joint ventures of approximately $11.4 million, $13.8 million and $13.1 million for the years ended December 31, 2019, 2018 and 2017, respectively . We eliminate any unrealized portion of our management service fees with our equity in earnings of joint ventures.
 
The following table is a summary of key unaudited financial data for these joint ventures as of December 31, 2019 and 2018, respectively, and for the years ended December 31, 2019, 2018 and 2017, respectively, (in thousands):

 
December 31,
Balance Sheet Data:
2019
 
2018
Current assets
$
27,427

 
$
28,317

Noncurrent assets
61,037

 
45,912

Current liabilities
(9,217
)
 
(4,300
)
Noncurrent liabilities
(18,872
)
 
(4,898
)
Total net assets
$
60,375

 
$
65,031

Book value of RadNet joint venture interests
$
28,001

 
$
30,030

Cost in excess of book value of acquired joint venture interests accounted for as equity method goodwill
6,469

 
7,943

Total value of RadNet joint venture interests
$
34,470

 
$
37,973

Total book value of other joint venture partner interests
$
32,374

 
$
35,001

  
 
2019
 
2018
 
2017
Net revenue
$
108,051

 
$
155,820

 
$
188,849

Net income
$
18,624

 
$
24,596

 
$
28,644


JSON 86 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "radnet10k2019document.htm": { "axisCustom": 1, "axisStandard": 38, "contextCount": 401, "dts": { "calculationLink": { "local": [ "rdnt-20191231_cal.xml" ] }, "definitionLink": { "local": [ "rdnt-20191231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "radnet10k2019document.htm" ] }, "labelLink": { "local": [ "rdnt-20191231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "rdnt-20191231_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml" ] }, "schema": { "local": [ "rdnt-20191231.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 872, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 48, "http://www.radnet.com/20191231": 11, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 64 }, "keyCustom": 89, "keyStandard": 522, "memberCustom": 97, "memberStandard": 48, "nsprefix": "rdnt", "nsuri": "http://www.radnet.com/20191231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.radnet.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - RECENT ACCOUNTING STANDARDS", "role": "http://www.radnet.com/role/RecentAccountingStandards", "shortName": "RECENT ACCOUNTING STANDARDS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS", "role": "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositions", "shortName": "FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS", "role": "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssets", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - PROPERTY AND EQUIPMENT", "role": "http://www.radnet.com/role/PropertyAndEquipment", "shortName": "PROPERTY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES", "role": "http://www.radnet.com/role/AccountsPayableAndAccruedExpenses", "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES", "role": "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeases", "shortName": "NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - LEASES (Notes)", "role": "http://www.radnet.com/role/LeasesNotes", "shortName": "LEASES (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - INCOME TAXES", "role": "http://www.radnet.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - STOCK-BASED COMPENSATION", "role": "http://www.radnet.com/role/StockBasedCompensation", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - QUARTERLY RESULTS OF OPERATIONS (unaudited)", "role": "http://www.radnet.com/role/QuarterlyResultsOfOperationsUnaudited", "shortName": "QUARTERLY RESULTS OF OPERATIONS (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.radnet.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117100 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://www.radnet.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118100 - Disclosure - SUBSEQUENT EVENTS", "role": "http://www.radnet.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119100 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS", "role": "http://www.radnet.com/role/ScheduleIiValuationAndQualifyingAccounts", "shortName": "SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfPrincipalTransactionsRevenueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfPrincipalTransactionsRevenueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - FACILITY ACQUISITIONS AND DISPOSITIONS (Tables)", "role": "http://www.radnet.com/role/FacilityAcquisitionsAndDispositionsTables", "shortName": "FACILITY ACQUISITIONS AND DISPOSITIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "role": "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsTables", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "role": "http://www.radnet.com/role/PropertyAndEquipmentTables", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)", "role": "http://www.radnet.com/role/AccountsPayableAndAccruedExpensesTables", "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Tables)", "role": "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesTables", "shortName": "NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.radnet.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - LEASES (Tables)", "role": "http://www.radnet.com/role/LeasesTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - INCOME TAXES (Tables)", "role": "http://www.radnet.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "role": "http://www.radnet.com/role/StockBasedCompensationTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316301 - Disclosure - QUARTERLY RESULTS OF OPERATIONS (Tables)", "role": "http://www.radnet.com/role/QuarterlyResultsOfOperationsTables", "shortName": "QUARTERLY RESULTS OF OPERATIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "INF", "first": true, "lang": null, "name": "rdnt:NumberOfCenters", "reportCount": 1, "unique": true, "unitRef": "Center", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401401 - Disclosure - NATURE OF BUSINESS (Details Narrative)", "role": "http://www.radnet.com/role/NatureOfBusinessDetailsNarrative", "shortName": "NATURE OF BUSINESS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "INF", "first": true, "lang": null, "name": "rdnt:NumberOfCenters", "reportCount": 1, "unique": true, "unitRef": "Center", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Summary of net revenue)", "role": "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummaryOfNetRevenue", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Summary of net revenue)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD_srt_ProductOrServiceAxis_rdnt_CommercialInsurance1Member", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:ReceivablesPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "rdnt:ContractsReceivableFactoredAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Narrative)", "role": "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:ReceivablesPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "rdnt:ContractsReceivableFactoredAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Derivatives)", "role": "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsDerivatives", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Derivatives)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:DerivativesPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateCapMember", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Fair Value Measurements)", "role": "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsFairValueMeasurements", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Fair Value Measurements)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Earnings Per Share)", "role": "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsEarningsPerShare", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Earnings Per Share)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "0", "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesRestrictedStock", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://www.radnet.com/role/ConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2017Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "rdnt:KeyFinancialDataInJointVenturesTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402408 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Investment in Joint Ventures)", "role": "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsInvestmentInJointVentures", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Investment in Joint Ventures)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "rdnt:EquityContributionsJointVentures", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "rdnt:KeyFinancialDataInJointVenturesTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402409 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Key Financial Data on Joint Ventures)", "role": "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsKeyFinancialDataOnJointVentures", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Key Financial Data on Joint Ventures)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "rdnt:KeyFinancialDataInJointVenturesTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS (Details - Narrative)", "role": "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "shortName": "FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS (Details - Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "I2018Q1Jan01", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS (Details - Assets held for sale)", "role": "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsAssetsHeldForSale", "shortName": "FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS (Details - Assets held for sale)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_rdnt_PropertyAndEquipmentMember", "decimals": "-3", "lang": null, "name": "us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Details - Schedule of Goodwill)", "role": "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Details - Schedule of Goodwill)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:GoodwillTransfers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "rdnt:GoodwillDeductibleForTaxPurposes", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Details - Narrative)", "role": "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Details - Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "rdnt:GoodwillDeductibleForTaxPurposes", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Details - Annual Amortization Schedule)", "role": "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsAnnualAmortizationSchedule", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Details - Annual Amortization Schedule)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - PROPERTY AND EQUIPMENT (Details)", "role": "http://www.radnet.com/role/PropertyAndEquipmentDetails", "shortName": "PROPERTY AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - PROPERTY AND EQUIPMENT (Details - Narrative)", "role": "http://www.radnet.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "PROPERTY AND EQUIPMENT (Details - Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)", "role": "http://www.radnet.com/role/AccountsPayableAndAccruedExpensesDetails", "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME", "role": "http://www.radnet.com/role/ConsolidatedStatementsOfComprehensiveLossIncome", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermLoansPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Schedule of Debt)", "role": "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt", "shortName": "NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Schedule of Debt)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermLoansPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtAndCapitalLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Annual Note Payable Maturities)", "role": "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsAnnualNotePayableMaturities", "shortName": "NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Annual Note Payable Maturities)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtAndCapitalLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "us-gaap:DeferredChargesPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Narrative)", "role": "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "shortName": "NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "D2018Q3Aug31_us-gaap_DebtInstrumentAxis_rdnt_RestatedAgreementMember", "decimals": "INF", "lang": null, "name": "us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4_us-gaap_LongtermDebtTypeAxis_rdnt_TermLoanMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Term Loans)", "role": "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsTermLoans", "shortName": "NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Term Loans)", "subGroupType": "details", "uniqueAnchor": null }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "D2016Q3Jul1_rdnt_LeverageRatioAxis_rdnt_LeverageRatioOneMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_rdnt_FirstLienCreditAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410406 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Margin Spread Based on Leverage Ratio)", "role": "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio", "shortName": "NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Margin Spread Based on Leverage Ratio)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "D2016Q3Jul1_rdnt_LeverageRatioAxis_rdnt_LeverageRatioOneMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_rdnt_FirstLienCreditAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R55": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "2410407 - Disclosure - NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Margin Spread Based on Leverage Ratio, Debt Instrument) (Details)", "role": "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails", "shortName": "NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Margin Spread Based on Leverage Ratio, Debt Instrument) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - LEASES (Details - Additional Information)", "role": "http://www.radnet.com/role/LeasesDetailsAdditionalInformation", "shortName": "LEASES (Details - Additional Information)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-5", "lang": null, "name": "rdnt:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411403 - Disclosure - LEASES (Details - Lease Cost)", "role": "http://www.radnet.com/role/LeasesDetailsLeaseCost", "shortName": "LEASES (Details - Lease Cost)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - LEASES (Details - Supplemental Cash Flows)", "role": "http://www.radnet.com/role/LeasesDetailsSupplementalCashFlows", "shortName": "LEASES (Details - Supplemental Cash Flows)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411405 - Disclosure - LEASES (Details - Supplemental Balance Sheet)", "role": "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet", "shortName": "LEASES (Details - Supplemental Balance Sheet)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "lang": null, "name": "rdnt:FinanceLeaseRightOfUseAssetGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - CONSOLIDATED STATEMENT OF EQUITY", "role": "http://www.radnet.com/role/ConsolidatedStatementOfEquity", "shortName": "CONSOLIDATED STATEMENT OF EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411406 - Disclosure - LEASES (Details - Maturities of Operating and Finance Lease)", "role": "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease", "shortName": "LEASES (Details - Maturities of Operating and Finance Lease)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - INCOME TAXES (Details - Income tax expense)", "role": "http://www.radnet.com/role/IncomeTaxesDetailsIncomeTaxExpense", "shortName": "INCOME TAXES (Details - Income tax expense)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413403 - Disclosure - INCOME TAXES (Details - Reconciliation of the statutory U.S. federal rate and effective rates)", "role": "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates", "shortName": "INCOME TAXES (Details - Reconciliation of the statutory U.S. federal rate and effective rates)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "rdnt:TaxCutsandJobsActChangeinTaxRateIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413404 - Disclosure - INCOME TAXES (Details - Narrative)", "role": "http://www.radnet.com/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details - Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "rdnt:TaxCutsandJobsActChangeinTaxRateIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413405 - Disclosure - NCOME TAXES (Details - Deferred tax assets and liabilities)", "role": "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities", "shortName": "NCOME TAXES (Details - Deferred tax assets and liabilities)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413406 - Disclosure - INCOME TAXES (Details - Unrecognized tax benefit)", "role": "http://www.radnet.com/role/IncomeTaxesDetailsUnrecognizedTaxBenefit", "shortName": "INCOME TAXES (Details - Unrecognized tax benefit)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - STOCK-BASED COMPENSATION (Details - Narrative)", "role": "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative", "shortName": "STOCK-BASED COMPENSATION (Details - Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414403 - Disclosure - STOCK-BASED COMPENSATION (Details-Outstanding options and warrants)", "role": "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants", "shortName": "STOCK-BASED COMPENSATION (Details-Outstanding options and warrants)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414404 - Disclosure - STOCK-BASED COMPENSATION (Details - RSU's)", "role": "http://www.radnet.com/role/StockBasedCompensationDetailsRsus", "shortName": "STOCK-BASED COMPENSATION (Details - RSU's)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416402 - Disclosure - QUARTERLY RESULTS OF OPERATIONS (unaudited) (Details - Statements of Operations)", "role": "http://www.radnet.com/role/QuarterlyResultsOfOperationsUnauditedDetailsStatementsOfOperations", "shortName": "QUARTERLY RESULTS OF OPERATIONS (unaudited) (Details - Statements of Operations)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "rdnt:OperatingLeaseRightofUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "D2019Q4Dec31-Dec31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_rdnt_WhiteRabbit.aiInc.Member", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsToFundLongtermLoansToRelatedParties", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417401 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "role": "http://www.radnet.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "D2020Q2Apr01-Apr01_us-gaap_BusinessAcquisitionAxis_rdnt_DeepHealthInc.Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418401 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "role": "http://www.radnet.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "D2020Q2Apr01-Apr01_us-gaap_BusinessAcquisitionAxis_rdnt_DeepHealthInc.Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForNotesReceivableMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419401 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)", "role": "http://www.radnet.com/role/ScheduleIiValuationAndQualifyingAccountsDetails", "shortName": "SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForNotesReceivableMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - NATURE OF BUSINESS", "role": "http://www.radnet.com/role/NatureOfBusiness", "shortName": "NATURE OF BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.radnet.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "D2017Q3Jul01-Jul31", "decimals": "-5", "first": true, "lang": null, "name": "rdnt:AssetsTransferredToAdvancedImagingAtTimoniumCrossingLlc", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - radnet10k2019document.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - radnet10k2019document.htm", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "div", "body", "html" ], "baseRef": "radnet10k2019document.htm", "contextRef": "D2017Q3Jul01-Jul31", "decimals": "-5", "first": true, "lang": null, "name": "rdnt:AssetsTransferredToAdvancedImagingAtTimoniumCrossingLlc", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 158, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r512" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r511" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r509" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r513" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity's Reporting Status Current" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/NatureOfBusinessDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r513" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r513" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r514" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r513" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r513" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r513" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r513" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity a Voluntary Filer" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity a Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/NatureOfBusinessDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r508" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r510" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "rdnt_A2019SWAPS1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2019 SWAPS1 [Member]", "label": "2019 SWAPS1 [Member]", "terseLabel": "2019 SWAPS1" } } }, "localname": "A2019SWAPS1Member", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_A2019SWAPSMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2019 SWAPS [Member]", "label": "2019 SWAPS [Member]", "terseLabel": "2019 SWAPS" } } }, "localname": "A2019SWAPSMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_AcquisitionOfDiagnosticImagingAssociatesCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "", "label": "Acquisition of Diagnostic Imaging Associates, cash", "terseLabel": "Acquisition of Diagnostic Imaging Associates, cash" } } }, "localname": "AcquisitionOfDiagnosticImagingAssociatesCash", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdnt_AcquisitionOfDiagnosticImagingAssociatesForRadnetCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "", "label": "Acquisition of Diagnostic Imaging Associates, for RadNet common stock", "terseLabel": "Acquisition of Diagnostic Imaging Associates, for RadNet common stock" } } }, "localname": "AcquisitionOfDiagnosticImagingAssociatesForRadnetCommonStock", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdnt_AcquisitionOfRadsiteLlcCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "", "label": "Acquisition of RadSite, LLC, cash", "terseLabel": "Acquisition of RadSite, LLC, cash" } } }, "localname": "AcquisitionOfRadsiteLlcCash", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdnt_AcquisitionOfRadsiteLlcForCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "", "label": "Acquisition of RadSite, LLC, for common stock", "terseLabel": "Acquisition of RadSite, LLC, for common stock" } } }, "localname": "AcquisitionOfRadsiteLlcForCommonStock", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdnt_AdditionalEquityInterestAcquired": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Additional equity interest acquired", "label": "Additional equity interest acquired", "terseLabel": "Additional equity interest acquired" } } }, "localname": "AdditionalEquityInterestAcquired", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "rdnt_AdvancedImagingAtTimoniumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Advanced Imaging at Timonium [Member]", "terseLabel": "Advanced Imaging at Timonium" } } }, "localname": "AdvancedImagingAtTimoniumMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_AggregateIntrinsicValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aggregate Intrinsic Value", "label": "Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "AggregateIntrinsicValue", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants" ], "xbrltype": "stringItemType" }, "rdnt_ArcadiaRadiologyImagingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arcadia Radiology Imaging [Member]", "label": "Arcadia Radiology Imaging [Member]", "terseLabel": "Arcadia Radiology Imaging" } } }, "localname": "ArcadiaRadiologyImagingMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill" ], "xbrltype": "domainItemType" }, "rdnt_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Table Text Block] for Assets And Liabilities Lessee [Table]", "label": "Assets And Liabilities Lessee [Table Text Block]", "terseLabel": "Assets and liabilities lessee" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "rdnt_AssetsTransferredToAdvancedImagingAtTimoniumCrossingLlc": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "", "label": "Assets transferred to Advanced Imaging at Timonium Crossing, LLC", "terseLabel": "Assets transferred to Advanced Imaging at Timonium Crossing, LLC" } } }, "localname": "AssetsTransferredToAdvancedImagingAtTimoniumCrossingLlc", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdnt_AssetsTransferredToSantaMonicaImagingGroupLlc": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "", "label": "Assets transferred to Santa Monica Imaging Group LLC", "terseLabel": "Assets transferred to Santa Monica Imaging Group LLC" } } }, "localname": "AssetsTransferredToSantaMonicaImagingGroupLlc", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdnt_AwardsIssuedToDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Awards issued to date", "label": "Awards issued to date", "terseLabel": "Awards issued to date" } } }, "localname": "AwardsIssuedToDate", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "rdnt_BarclaysMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Barclays [Member]", "label": "Barclays [Member]", "terseLabel": "Barclays" } } }, "localname": "BarclaysMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_BeachImagingGroupLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Beach Imaging Group, LLC [Member]", "terseLabel": "Beach Imaging Group, LLC" } } }, "localname": "BeachImagingGroupLLCMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_BeverlyRadiologyMedicalGroupIIIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Beverly Radiology Medical Group III [Member]", "label": "Beverly Radiology Medical Group III [Member]", "terseLabel": "Beverly Radiology Medical Group III" } } }, "localname": "BeverlyRadiologyMedicalGroupIIIMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NatureOfBusinessDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_BlueShieldMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Blue Shield [Member]", "label": "Blue Shield [Member]", "terseLabel": "Blue Shield" } } }, "localname": "BlueShieldMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_BoardMemberMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Board Member [Member]", "label": "Board Member [Member]", "terseLabel": "Board Member" } } }, "localname": "BoardMemberMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NatureOfBusinessDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_BreastlinkMedicalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Breastlink Medical [Member]", "terseLabel": "Breastlink Medical" } } }, "localname": "BreastlinkMedicalMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedBankDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Bank Debt", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Bank Debt", "terseLabel": "Bank debt assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedBankDebt", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedEquipmentDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment Debt", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment Debt", "terseLabel": "Equipment debt assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedEquipmentDebt", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFinanceLeaseLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Finance Lease Liabilities", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Finance Lease Liabilities", "terseLabel": "Finance lease liabilities acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFinanceLeaseLiabilities", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedNetWorkingCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Working Capital", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Working Capital", "terseLabel": "Net working capital acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedNetWorkingCapital", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating Lease Liabilities", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating Lease Liabilities", "terseLabel": "Operating lease liabilities acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRightOfUseAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Right Of Use Asset", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Right Of Use Asset", "terseLabel": "Right-of-use assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRightOfUseAsset", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedUnfavorableLeaseContracts": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Unfavorable Lease Contracts", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Unfavorable Lease Contracts", "terseLabel": "Unfavorable lease contracts acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedUnfavorableLeaseContracts", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedUnfavorableLeaseContractsGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Unfavorable Lease Contracts, Gross", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Unfavorable Lease Contracts, Gross", "terseLabel": "Unfavorable lease contracts acquired, gross" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedUnfavorableLeaseContractsGross", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_BusinessCombinationStepAcquisitionAdjustmentOfInvestmentBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Step Acquisition, Adjustment Of Investment Balance", "label": "Business Combination, Step Acquisition, Adjustment Of Investment Balance", "terseLabel": "Adjustment of New Jersey Imaging Network investment balance" } } }, "localname": "BusinessCombinationStepAcquisitionAdjustmentOfInvestmentBalance", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_BusinessCombinationStepAcquisitionCashAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Step Acquisition, Cash Acquired", "label": "Business Combination, Step Acquisition, Cash Acquired", "terseLabel": "Step acquisition, cash acquired" } } }, "localname": "BusinessCombinationStepAcquisitionCashAcquired", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdnt_CapitalLeaseDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "", "label": "Capital lease debt", "terseLabel": "Capital lease debt" } } }, "localname": "CapitalLeaseDebt", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdnt_CapitationArrangementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Capitation Arrangements [Member]", "label": "Capitation Arrangements [Member]", "terseLabel": "Revenue under capitation arrangements" } } }, "localname": "CapitationArrangementsMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummaryOfNetRevenue" ], "xbrltype": "domainItemType" }, "rdnt_Caps2016Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "2016 Caps [Member]", "terseLabel": "2016 Caps" } } }, "localname": "Caps2016Member", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_CashFlowLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash Flow Lessee [Abstract]", "label": "Cash Flow Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashFlowLesseeAbstract", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/LeasesDetailsSupplementalCashFlows" ], "xbrltype": "stringItemType" }, "rdnt_CedarsSinaiMedicalCenterMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cedars Sinai Medical Center [Member]", "label": "Cedars Sinai Medical Center [Member]", "terseLabel": "Cedars Sinai Medical Center" } } }, "localname": "CedarsSinaiMedicalCenterMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_CommercialInsurance1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commercial Insurance1 [Member]", "label": "Commercial Insurance1 [Member]", "terseLabel": "Commercial insurance" } } }, "localname": "CommercialInsurance1Member", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummaryOfNetRevenue" ], "xbrltype": "domainItemType" }, "rdnt_ComputerandOfficeEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Computer and Office Equipment [Member]", "label": "Computer and Office Equipment [Member]", "terseLabel": "Computer and Office Equipment" } } }, "localname": "ComputerandOfficeEquipmentMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_ContractLossAccrual": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contract loss accrual", "label": "Contract loss accrual", "terseLabel": "Contract loss accrual" } } }, "localname": "ContractLossAccrual", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_ContractLossAccrualWrittenOff": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contract Loss Accrual, Written Off", "label": "Contract Loss Accrual, Written Off", "terseLabel": "Contract loss accrual, written off" } } }, "localname": "ContractLossAccrualWrittenOff", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_ContractsReceivableFactoredAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contracts Receivable, Factored Amount", "label": "Contracts Receivable, Factored Amount", "terseLabel": "Factored accounts receivable" } } }, "localname": "ContractsReceivableFactoredAmount", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_ContractsReceivableFactoringReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Contracts Receivable, Factoring Receivable", "label": "Contracts Receivable, Factoring Receivable", "terseLabel": "Factoring receivable" } } }, "localname": "ContractsReceivableFactoringReceivable", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_ContributionsFromNoncontrollingInterests": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "", "label": "Contributions from noncontrolling interests", "terseLabel": "Contributions from noncontrolling interests" } } }, "localname": "ContributionsFromNoncontrollingInterests", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity" ], "xbrltype": "monetaryItemType" }, "rdnt_CovenantNotToCompeteMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Covenant Not To Compete [Member]", "terseLabel": "Covenant not to compete and other contracts" } } }, "localname": "CovenantNotToCompeteMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsAnnualAmortizationSchedule" ], "xbrltype": "domainItemType" }, "rdnt_DebtInstrumentCovenantLeverageRatioMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant, Leverage Ratio, Maximum", "label": "Debt Instrument, Covenant, Leverage Ratio, Maximum", "terseLabel": "Leverage ratio, less than" } } }, "localname": "DebtInstrumentCovenantLeverageRatioMaximum", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails" ], "xbrltype": "pureItemType" }, "rdnt_DebtInstrumentCovenantLiquidityRatioRequiredMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant, Liquidity Ratio Required, Minimum", "label": "Debt Instrument, Covenant, Liquidity Ratio Required, Minimum", "terseLabel": "Leverage ratio, greater than" } } }, "localname": "DebtInstrumentCovenantLiquidityRatioRequiredMinimum", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails" ], "xbrltype": "pureItemType" }, "rdnt_DebtInstrumentPeriodicPaymentPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Periodic Payment, Percent", "label": "Debt Instrument, Periodic Payment, Percent", "terseLabel": "Debt periodic payment, percent of total amount" } } }, "localname": "DebtInstrumentPeriodicPaymentPercent", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "percentItemType" }, "rdnt_DebtInstrumentPeriodicPaymentTermsAmortizationIncrease": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Periodic Payment Terms, Amortization Increase", "label": "Debt Instrument, Periodic Payment Terms, Amortization Increase", "terseLabel": "Debt periodic payment, amortization increase" } } }, "localname": "DebtInstrumentPeriodicPaymentTermsAmortizationIncrease", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_DeepHealthInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "DeepHealth, Inc. [Member]", "label": "DeepHealth, Inc. [Member]", "terseLabel": "DeepHealth, Inc." } } }, "localname": "DeepHealthInc.Member", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_DeferredTaxAssetsOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets, Operating Lease Liabilities", "label": "Deferred Tax Assets, Operating Lease Liabilities", "terseLabel": "Operating lease liability" } } }, "localname": "DeferredTaxAssetsOperatingLeaseLiabilities", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "rdnt_DeferredTaxAssetsTaxBenefitMayNotBeRealized": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets, Tax Benefit May Not Be Realized", "label": "Deferred Tax Assets, Tax Benefit May Not Be Realized", "terseLabel": "Deferred tax assets, tax benefit may not be realized" } } }, "localname": "DeferredTaxAssetsTaxBenefitMayNotBeRealized", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_DeferredTaxAssetsTaxDeferredExpenseStraightLinerentadjustment": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.", "label": "Deferred Tax Assets, Tax Deferred Expense, Straight-Line rent adjustment", "terseLabel": "Straight-Line rent adjustment" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseStraightLinerentadjustment", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "rdnt_DeferredTaxLiabilitiesOperatingRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Liabilities, Operating Right-Of-Use Assets", "label": "Deferred Tax Liabilities, Operating Right-Of-Use Assets", "negatedTerseLabel": "Operating lease right-of-use asset" } } }, "localname": "DeferredTaxLiabilitiesOperatingRightOfUseAssets", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "rdnt_DevelopedtechnologyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Developed technology [Member]", "label": "Developed technology [Member]", "terseLabel": "Developed Technology" } } }, "localname": "DevelopedtechnologyMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsAnnualAmortizationSchedule" ], "xbrltype": "domainItemType" }, "rdnt_DignityHealth.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Dignity Health. [Member]", "label": "Dignity Health. [Member]", "terseLabel": "Dignity Health." } } }, "localname": "DignityHealth.Member", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_DignityHealthMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Dignity Health [Member]", "terseLabel": "Dignity Health" } } }, "localname": "DignityHealthMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_ERADMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "eRAD [Member]", "terseLabel": "eRAD" } } }, "localname": "ERADMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_EffectiveIncomeTaxRateReconciliationGainonChangeinControlAmount": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Gain on Change in Control, Amount", "label": "Effective Income Tax Rate Reconciliation, Gain on Change in Control, Amount", "terseLabel": "Gain on change in control" } } }, "localname": "EffectiveIncomeTaxRateReconciliationGainonChangeinControlAmount", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates" ], "xbrltype": "monetaryItemType" }, "rdnt_EffectiveIncomeTaxRateReconciliationGainonChangeinControlPercent": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates": { "order": 7.0, "parentTag": "rdnt_IncomeTaxExpenseBenefitPercent", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Gain on Change in Control, Percent", "label": "Effective Income Tax Rate Reconciliation, Gain on Change in Control, Percent", "terseLabel": "Gain on change in control, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationGainonChangeinControlPercent", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates" ], "xbrltype": "percentItemType" }, "rdnt_EquipmentAcquiredAndLeaseholdImprovements": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "", "label": "Equipment acquired and leasehold improvements", "terseLabel": "Equipment acquired and leasehold improvements" } } }, "localname": "EquipmentAcquiredAndLeaseholdImprovements", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdnt_EquityContributionsJointVentures": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity contributions in existing joint ventures", "label": "Equity contributions in existing and purchase of interest in joint ventures", "terseLabel": "Equity contributions in existing and purchase of interest in joint ventures" } } }, "localname": "EquityContributionsJointVentures", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsInvestmentInJointVentures" ], "xbrltype": "monetaryItemType" }, "rdnt_EquityMethodInvestmentInitialOwnershipPercentageAfterDilution": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Method Investment, Initial Ownership Percentage After Dilution", "label": "Equity Method Investment, Initial Ownership Percentage After Dilution", "terseLabel": "Initial ownership percentage after dilution" } } }, "localname": "EquityMethodInvestmentInitialOwnershipPercentageAfterDilution", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "rdnt_EquityMethodInvestmentOwnershipPercentageInExchangeforAssetsContributed": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Method Investment Ownership Percentage In Exchange for Assets Contributed", "label": "Equity Method Investment Ownership Percentage In Exchange for Assets Contributed", "terseLabel": "Equity interest percentage in exchange for assets" } } }, "localname": "EquityMethodInvestmentOwnershipPercentageInExchangeforAssetsContributed", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "rdnt_EquityMethodInvestmentOwnershipPercentageInExchangeforCash": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Method Investment Ownership Percentage In Exchange for Cash", "label": "Equity Method Investment Ownership Percentage In Exchange for Cash", "terseLabel": "Equity interest percentage in exchange for cash" } } }, "localname": "EquityMethodInvestmentOwnershipPercentageInExchangeforCash", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "rdnt_EquityMethodInvestmentSharesPurchased": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Method Investment, Shares Purchased", "label": "Equity Method Investment, Shares Purchased", "terseLabel": "Shares purchased" } } }, "localname": "EquityMethodInvestmentSharesPurchased", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "rdnt_EquityMethodInvestmentsOptionToPurchaseAdditionalEquityMethodInvestment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity Method Investments, Option To Purchase Additional Equity Method Investment", "label": "Equity Method Investments, Option To Purchase Additional Equity Method Investment", "terseLabel": "Option to purchase additional equity method investment" } } }, "localname": "EquityMethodInvestmentsOptionToPurchaseAdditionalEquityMethodInvestment", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_EquityMethodInvestmentsOwnershipInterestPercentageAcquired": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Method Investments, Ownership Interest Percentage Acquired", "label": "Equity Method Investments, Ownership Interest Percentage Acquired", "terseLabel": "Ownership interest percentage acquired" } } }, "localname": "EquityMethodInvestmentsOwnershipInterestPercentageAcquired", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "rdnt_FacilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Facilities [Member]", "terseLabel": "Facilities" } } }, "localname": "FacilitiesMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "domainItemType" }, "rdnt_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finance Lease Assets And Liabilities Lessee [Abstract]", "label": "Finance Lease Assets And Liabilities Lessee [Abstract]", "terseLabel": "Finance Lease Assets And Liabilities Lessee [Abstract]" } } }, "localname": "FinanceLeaseAssetsAndLiabilitiesLesseeAbstract", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet" ], "xbrltype": "stringItemType" }, "rdnt_FinanceLeaseCost": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/LeasesDetailsLeaseCost": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Finance Lease Cost", "label": "Finance Lease Cost", "totalLabel": "Total finance lease cost" } } }, "localname": "FinanceLeaseCost", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/LeasesDetailsLeaseCost" ], "xbrltype": "monetaryItemType" }, "rdnt_FinanceLeaseRightOfUseAssetAccumulatedDepreciation": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Finance Lease Right Of Use Asset Accumulated Depreciation", "label": "Finance Lease Right Of Use Asset Accumulated Depreciation", "negatedTerseLabel": "Accumulated depreciation" } } }, "localname": "FinanceLeaseRightOfUseAssetAccumulatedDepreciation", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet" ], "xbrltype": "monetaryItemType" }, "rdnt_FinanceLeaseRightOfUseAssetGross": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Finance Lease Right Of Use Asset Gross", "label": "Finance Lease Right Of Use Asset Gross", "terseLabel": "Equipment at cost" } } }, "localname": "FinanceLeaseRightOfUseAssetGross", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet" ], "xbrltype": "monetaryItemType" }, "rdnt_FirstLienCreditAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "First Lien Credit Agreement [Member]", "terseLabel": "First Lien Credit Agreement" } } }, "localname": "FirstLienCreditAgreementMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_FirstLienCreditAgreementSeventhAmendmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First Lien Credit Agreement Seventh Amendment [Member]", "label": "First Lien Credit Agreement Seventh Amendment [Member]", "terseLabel": "Amendment No. 7 First Lien Credit Agreement" } } }, "localname": "FirstLienCreditAgreementSeventhAmendmentMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_FirstLienCreditAgreementSixthAmendmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First Lien Credit Agreement Sixth Amendment [Member]", "label": "First Lien Credit Agreement Sixth Amendment [Member]", "terseLabel": "Amendment No. 6 First Lien Credit Agreement" } } }, "localname": "FirstLienCreditAgreementSixthAmendmentMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_FirstLienTermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "First Lien Term Loan [Member]", "terseLabel": "First Lien Term Loans" } } }, "localname": "FirstLienTermLoanMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsTermLoans" ], "xbrltype": "domainItemType" }, "rdnt_FutureServiceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Future Services [Member]", "label": "Future Service [Member]", "terseLabel": "Future Service" } } }, "localname": "FutureServiceMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_GainLossonStepUpValuation": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.radnet.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Gain (Loss) on Step Up Valuation", "label": "Gain (Loss) on Step Up Valuation", "negatedLabel": "Gain on re-measurement of pre-existing interest", "negatedTerseLabel": "Gain on re-measurement of pre-existing interest", "terseLabel": "Gain on step up valuation" } } }, "localname": "GainLossonStepUpValuation", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/ConsolidatedStatementsOfOperations", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_GardenStateRadiologyNetworkLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Garden State Radiology Network LLC [Member]", "label": "Garden State Radiology Network LLC [Member]", "terseLabel": "Garden State Radiology Network LLC" } } }, "localname": "GardenStateRadiologyNetworkLLCMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_GlendaleAdvancedImagingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Glendale Advanced Imaging [Member]", "terseLabel": "Glendale Advanced Imaging" } } }, "localname": "GlendaleAdvancedImagingMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_GoodwillDeductibleForTaxPurposes": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Goodwill deductible for tax purposes", "label": "Goodwill deductible for tax purposes", "terseLabel": "Goodwill deductible for tax purposes" } } }, "localname": "GoodwillDeductibleForTaxPurposes", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_HealthCareManagementServiceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Health Care, Management Service [Member]", "label": "Health Care, Management Service [Member]", "terseLabel": "Management fee revenue" } } }, "localname": "HealthCareManagementServiceMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummaryOfNetRevenue" ], "xbrltype": "domainItemType" }, "rdnt_HealthCarePatientServiceOtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Health Care, Patient Service Other [Member]", "label": "Health Care, Patient Service Other [Member]", "terseLabel": "Other patient revenue" } } }, "localname": "HealthCarePatientServiceOtherMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummaryOfNetRevenue" ], "xbrltype": "domainItemType" }, "rdnt_HealthInsuranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Health Insurance [Member]", "terseLabel": "Health Insurance" } } }, "localname": "HealthInsuranceMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_HudsonValleyRadiologyAssociatesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Hudson Valley Radiology Associates [Member]", "label": "Hudson Valley Radiology Associates [Member]", "terseLabel": "Hudson Valley Radiology Associates" } } }, "localname": "HudsonValleyRadiologyAssociatesMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_ImagingOnCallMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Imaging On Call [Member]", "label": "Imaging On Call [Member]", "terseLabel": "Imaging On Call", "verboseLabel": "Imaging on call and software" } } }, "localname": "ImagingOnCallMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummaryOfNetRevenue" ], "xbrltype": "domainItemType" }, "rdnt_ImagingServicesCompanyofNewYorkMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Imaging Services Company of New York [Member]", "label": "Imaging Services Company of New York [Member]", "terseLabel": "Imaging Services Company of New York" } } }, "localname": "ImagingServicesCompanyofNewYorkMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill" ], "xbrltype": "domainItemType" }, "rdnt_IncomeTaxExpenseBenefitPercent": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "Income tax expense (benefit)", "label": "Income tax expense (benefit)", "totalLabel": "Income tax expense (benefit), percent" } } }, "localname": "IncomeTaxExpenseBenefitPercent", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates" ], "xbrltype": "percentItemType" }, "rdnt_IncreaseDecreaseInDeferredRent": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting rent yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.", "label": "Deferred rent", "terseLabel": "Deferred rent" } } }, "localname": "IncreaseDecreaseInDeferredRent", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdnt_IncreaseDecreaseInOtherNoncashItem": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase Decrease In Other Noncash Item", "label": "Increase Decrease In Other Noncash Item", "negatedTerseLabel": "Other non cash item in other expenses" } } }, "localname": "IncreaseDecreaseInOtherNoncashItem", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdnt_IncreaseDecreaseinOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase Decrease in Operating Lease Liability", "label": "Increase Decrease in Operating Lease Liability", "negatedTerseLabel": "Operating lease liability" } } }, "localname": "IncreaseDecreaseinOperatingLeaseLiability", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdnt_IncreaseInNoncontrollingInterestDueToStepAcquisition": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase In Noncontrolling Interest Due To Step Acquisition", "label": "Increase In Noncontrolling Interest Due To Step Acquisition", "terseLabel": "Re-measurement of noncontrolling interest upon change in control" } } }, "localname": "IncreaseInNoncontrollingInterestDueToStepAcquisition", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity" ], "xbrltype": "monetaryItemType" }, "rdnt_JeffersonHealthMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Jefferson Health [Member]", "label": "Jefferson Health [Member]", "terseLabel": "Jefferson Health" } } }, "localname": "JeffersonHealthMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_JointVentureMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Joint Venture [Member]", "terseLabel": "Joint Venture" } } }, "localname": "JointVentureMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_KernRadiologyImagingSystemsInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Kern Radiology Imaging Systems Inc. [Member]", "label": "Kern Radiology Imaging Systems Inc. [Member]", "terseLabel": "Kern Radiology Imaging Systems Inc." } } }, "localname": "KernRadiologyImagingSystemsInc.Member", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill" ], "xbrltype": "domainItemType" }, "rdnt_KeyFinancialDataForJointVenturesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Key financial data for joint ventures", "label": "Key financial data for joint ventures", "terseLabel": "Balance Sheet Data:" } } }, "localname": "KeyFinancialDataForJointVenturesAbstract", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsKeyFinancialDataOnJointVentures" ], "xbrltype": "stringItemType" }, "rdnt_KeyFinancialDataInJointVenturesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Joint venture investment and financial information [Table Text Block]", "label": "Joint venture investment and financial information", "terseLabel": "Joint venture investment and financial information" } } }, "localname": "KeyFinancialDataInJointVenturesTableTextBlock", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "rdnt_LeasesWeightedAverageDiscountRateAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Leases Weighted Average Discount Rate [Abstract]", "label": "Leases Weighted Average Discount Rate [Abstract]", "terseLabel": "Leases Weighted Average Discount Rate [Abstract]" } } }, "localname": "LeasesWeightedAverageDiscountRateAbstract", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet" ], "xbrltype": "stringItemType" }, "rdnt_LesseeLeaseTermofContract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee Lease Term of Contract", "label": "Lessee Lease Term of Contract", "terseLabel": "Lease term of contract" } } }, "localname": "LesseeLeaseTermofContract", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/LeasesDetailsAdditionalInformation" ], "xbrltype": "durationItemType" }, "rdnt_LesseeOperatingLeaseDeferredRent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee Operating Lease Deferred Rent", "label": "Lessee Operating Lease Deferred Rent", "terseLabel": "Deferred rent" } } }, "localname": "LesseeOperatingLeaseDeferredRent", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/LeasesDetailsAdditionalInformation" ], "xbrltype": "monetaryItemType" }, "rdnt_LesseeOperatingLeaseLeaseIncentives": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee Operating Lease Lease Incentives", "label": "Lessee Operating Lease Lease Incentives", "terseLabel": "Contract liabilities" } } }, "localname": "LesseeOperatingLeaseLeaseIncentives", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/LeasesDetailsAdditionalInformation" ], "xbrltype": "monetaryItemType" }, "rdnt_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee Operating Lease Lease Not Yet Commenced Undiscounted Amount", "label": "Lessee Operating Lease Lease Not Yet Commenced Undiscounted Amount", "terseLabel": "Operating lease not yet commenced" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/LeasesDetailsAdditionalInformation" ], "xbrltype": "monetaryItemType" }, "rdnt_LeverageRatioAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Leverage Ratio [Axis]", "label": "Leverage Ratio [Axis]", "terseLabel": "Leverage Ratio [Axis]" } } }, "localname": "LeverageRatioAxis", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "rdnt_LeverageRatioDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Leverage Ratio [Axis]", "label": "Leverage Ratio [Domain]", "terseLabel": "Leverage Ratio [Domain]" } } }, "localname": "LeverageRatioDomain", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_LeverageRatioFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Leverage Ratio Four [Member]", "label": "Leverage Ratio Four [Member]", "terseLabel": "\u2264 3.50x" } } }, "localname": "LeverageRatioFourMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio" ], "xbrltype": "domainItemType" }, "rdnt_LeverageRatioOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Leverage Ratio One [Member]", "label": "Leverage Ratio One [Member]", "terseLabel": "5.50x" } } }, "localname": "LeverageRatioOneMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio" ], "xbrltype": "domainItemType" }, "rdnt_LeverageRatioThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Leverage Ratio Three [Member]", "label": "Leverage Ratio Three [Member]", "terseLabel": "3.50x but \u2264 4.00x" } } }, "localname": "LeverageRatioThreeMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_LeverageRatioTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Leverage Ratio Two [Member]", "label": "Leverage Ratio Two [Member]", "terseLabel": "4.00x but \u2264 5.50x" } } }, "localname": "LeverageRatioTwoMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio" ], "xbrltype": "domainItemType" }, "rdnt_LineofCreditFacilityIncreaseBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Line of Credit Facility, Increase Borrowing Capacity", "label": "Line of Credit Facility, Increase Borrowing Capacity", "terseLabel": "Line of credit facility, increase borrowing capacity" } } }, "localname": "LineofCreditFacilityIncreaseBorrowingCapacity", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_LongtermDebtShorttermDebtandCapitalLeaseObligationsCurrentMaturities": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebtCalc2": { "order": 1.0, "parentTag": "rdnt_LongtermDebtShorttermDebtandCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Long-term Debt, Short-term Debt and Capital Lease Obligations, Current Maturities", "label": "Long-term Debt, Short-term Debt and Capital Lease Obligations, Current Maturities", "negatedLabel": "Less current portion" } } }, "localname": "LongtermDebtShorttermDebtandCapitalLeaseObligationsCurrentMaturities", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt" ], "xbrltype": "monetaryItemType" }, "rdnt_LongtermDebtShorttermDebtandCapitalLeaseObligationsExcludingCurrentMaturities": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebtCalc2": { "order": 2.0, "parentTag": "rdnt_LongtermDebtShorttermDebtandCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Long-term Debt, Short-term Debt and Capital Lease Obligations, Excluding Current Maturities", "label": "Long-term Debt, Short-term Debt and Capital Lease Obligations, Excluding Current Maturities", "terseLabel": "Long-term portion debt obligations" } } }, "localname": "LongtermDebtShorttermDebtandCapitalLeaseObligationsExcludingCurrentMaturities", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt" ], "xbrltype": "monetaryItemType" }, "rdnt_LongtermDebtShorttermDebtandCapitalLeaseObligationsIncludingCurrentMaturities": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebtCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Long-term Debt, Short-term Debt and Capital Lease Obligations, Including Current Maturities", "label": "Long-term Debt, Short-term Debt and Capital Lease Obligations, Including Current Maturities", "totalLabel": "Total debt obligations" } } }, "localname": "LongtermDebtShorttermDebtandCapitalLeaseObligationsIncludingCurrentMaturities", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt" ], "xbrltype": "monetaryItemType" }, "rdnt_LossandOtherUnfavorableContractsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss and Other Unfavorable Contracts [Policy Text Block]", "label": "Loss and Other Unfavorable Contracts [Policy Text Block]", "terseLabel": "LOSS AND OTHER UNFAVORABLE CONTRACTS" } } }, "localname": "LossandOtherUnfavorableContractsPolicyTextBlock", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rdnt_ManagementServiceContractsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Management Service Contracts [Member]", "terseLabel": "Management Service Contracts" } } }, "localname": "ManagementServiceContractsMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsAnnualAmortizationSchedule" ], "xbrltype": "domainItemType" }, "rdnt_MeaningfulUseIncentive": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Meaningful use incentive", "label": "Meaningful use incentive income", "terseLabel": "Meaningful use incentive income" } } }, "localname": "MeaningfulUseIncentive", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_MedicVisionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Medic Vision [Member]", "terseLabel": "Medic Vision" } } }, "localname": "MedicVisionMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_Medicaid1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicaid1 [Member]", "label": "Medicaid1 [Member]", "terseLabel": "Medicaid" } } }, "localname": "Medicaid1Member", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummaryOfNetRevenue" ], "xbrltype": "domainItemType" }, "rdnt_MedicalArtsRadiologicalGroupPCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical Arts Radiological Group, PC [Member]", "label": "Medical Arts Radiological Group, PC [Member]", "terseLabel": "Medical Arts Radiological Group, PC" } } }, "localname": "MedicalArtsRadiologicalGroupPCMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill" ], "xbrltype": "domainItemType" }, "rdnt_MedicalArtsRadiologyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical Arts Radiology [Member]", "label": "Medical Arts Radiology [Member]", "terseLabel": "Medical Arts Radiology" } } }, "localname": "MedicalArtsRadiologyMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_MedicalEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical Equipment [Member]", "label": "Medical Equipment [Member]", "terseLabel": "Medical Equipment" } } }, "localname": "MedicalEquipmentMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_MedicalInsuranceStopLossPolicyClaimAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Medical Insurance, Stop Loss Policy Claim Amount", "label": "Medical Insurance, Stop Loss Policy Claim Amount", "terseLabel": "Stop loss policy claim amount" } } }, "localname": "MedicalInsuranceStopLossPolicyClaimAmount", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_MedicalMalpracticeDeductiblePerIncidence": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Medical malpractice deductible per incidence", "label": "Medical malpractice deductible per incidence", "terseLabel": "Medical malpractice deductible per incidence" } } }, "localname": "MedicalMalpracticeDeductiblePerIncidence", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_Medicare1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicare1 [Member]", "label": "Medicare1 [Member]", "terseLabel": "Medicare" } } }, "localname": "Medicare1Member", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummaryOfNetRevenue" ], "xbrltype": "domainItemType" }, "rdnt_MemorialCareMedicalFoundationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "MemorialCare Medical Foundation [Member]", "terseLabel": "MemorialCare Medical Foundation" } } }, "localname": "MemorialCareMedicalFoundationMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill" ], "xbrltype": "domainItemType" }, "rdnt_NetIncomeFromJointVentures": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net Income From Joint Ventures", "label": "Net Income From Joint Ventures", "terseLabel": "Net Income From Joint Ventures" } } }, "localname": "NetIncomeFromJointVentures", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsKeyFinancialDataOnJointVentures" ], "xbrltype": "monetaryItemType" }, "rdnt_NetRevenueFromJointVentures": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net revenue from joint ventures", "label": "Net revenue", "terseLabel": "Net revenue" } } }, "localname": "NetRevenueFromJointVentures", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsKeyFinancialDataOnJointVentures" ], "xbrltype": "monetaryItemType" }, "rdnt_NewJerseyImagingNetworkLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "New Jersey Imaging Network, LLC [Member]", "label": "New Jersey Imaging Network, LLC [Member]", "terseLabel": "New Jersey Imaging Network, LLC" } } }, "localname": "NewJerseyImagingNetworkLLCMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill" ], "xbrltype": "domainItemType" }, "rdnt_NonCashSeverance": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Non cash severance.", "label": "Non cash severance", "terseLabel": "Non cash severance" } } }, "localname": "NonCashSeverance", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity", "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdnt_NonCashSeveranceShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Non Cash Severance Shares", "label": "Non Cash Severance Shares", "terseLabel": "Non-cash severance (in shares)" } } }, "localname": "NonCashSeveranceShares", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity" ], "xbrltype": "sharesItemType" }, "rdnt_NoncontrollingInterestDecreaseFromSpecialDistribution": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Noncontrolling Interest, Decrease From Special Distribution", "label": "Noncontrolling Interest, Decrease From Special Distribution", "negatedTerseLabel": "Special distribution from noncontrolling interest" } } }, "localname": "NoncontrollingInterestDecreaseFromSpecialDistribution", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity" ], "xbrltype": "monetaryItemType" }, "rdnt_NoncontrollingInterestSpecialDistribution": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Noncontrolling Interest, Special Distribution", "label": "Noncontrolling Interest, Special Distribution", "terseLabel": "Special distribution from noncontrolling interest" } } }, "localname": "NoncontrollingInterestSpecialDistribution", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdnt_NulogixInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nulogix,Inc. [Member]", "label": "Nulogix,Inc. [Member]", "terseLabel": "Nulogix,Inc." } } }, "localname": "NulogixInc.Member", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_NulogixMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Nulogix, Inc. [Member]", "terseLabel": "Nulogix, Inc." } } }, "localname": "NulogixMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_NumberOfCenters": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number Of Centers", "label": "Number Of Centers", "terseLabel": "Number of centers" } } }, "localname": "NumberOfCenters", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NatureOfBusinessDetailsNarrative" ], "xbrltype": "integerItemType" }, "rdnt_NumberofUnconsolidatedJointVentures": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Unconsolidated Joint Ventures", "label": "Number of Unconsolidated Joint Ventures", "terseLabel": "Number of unconsolidated joint ventures" } } }, "localname": "NumberofUnconsolidatedJointVentures", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "integerItemType" }, "rdnt_October2020CapMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "October 2020 [Member]", "terseLabel": "October 2020" } } }, "localname": "October2020CapMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_October2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "October 2023 [Member]", "label": "October 2023 [Member]", "terseLabel": "October 2023" } } }, "localname": "October2023Member", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_October2025Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "October 2025 [Member]", "label": "October 2025 [Member]", "terseLabel": "October 2025" } } }, "localname": "October2025Member", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_OncologyPracticesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Oncology practices [Member]", "terseLabel": "Oncology practices" } } }, "localname": "OncologyPracticesMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating Lease Assets And Liabilities Lessee [Abstract]", "label": "Operating Lease Assets And Liabilities Lessee [Abstract]", "terseLabel": "Operating Lease Assets And Liabilities Lessee [Abstract]" } } }, "localname": "OperatingLeaseAssetsAndLiabilitiesLesseeAbstract", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet" ], "xbrltype": "stringItemType" }, "rdnt_OperatingLeaseRightofUseAssetAmortization": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating Lease Right of Use Asset Amortization", "label": "Operating Lease Right of Use Asset Amortization", "terseLabel": "Amortization of operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightofUseAssetAmortization", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdnt_OrangeCountyDiagnosticsImagingCenterMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Orange County Diagnostics Imaging Center [Member]", "label": "Orange County Diagnostics Imaging Center [Member]", "terseLabel": "Orange County Diagnostics Imaging Center" } } }, "localname": "OrangeCountyDiagnosticsImagingCenterMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill" ], "xbrltype": "domainItemType" }, "rdnt_PatientServicesNetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Patient Services, Net [Member]", "label": "Patient Services, Net [Member]", "terseLabel": "Net service fee revenue", "verboseLabel": "Net service fee revenue" } } }, "localname": "PatientServicesNetMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummaryOfNetRevenue" ], "xbrltype": "domainItemType" }, "rdnt_PaymentstoAcquireEquityMethodInvestmentsAssetsContributed": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments to Acquire Equity Method Investments Assets Contributed", "label": "Payments to Acquire Equity Method Investments Assets Contributed", "terseLabel": "Payments to acquire equity method investments, Assets" } } }, "localname": "PaymentstoAcquireEquityMethodInvestmentsAssetsContributed", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_PaymentstoAcquireEquityMethodInvestmentsCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments to Acquire Equity Method Investments Cash", "label": "Payments to Acquire Equity Method Investments Cash", "terseLabel": "Payments to acquire equity method investments, cash" } } }, "localname": "PaymentstoAcquireEquityMethodInvestmentsCash", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_PricingLevelIIIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pricing Level III [Member]", "label": "Pricing Level III [Member]", "terseLabel": "Pricing Level III" } } }, "localname": "PricingLevelIIIMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails" ], "xbrltype": "domainItemType" }, "rdnt_PricingLevelIIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pricing Level II [Member]", "label": "Pricing Level II [Member]", "terseLabel": "Pricing Level II" } } }, "localname": "PricingLevelIIMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails" ], "xbrltype": "domainItemType" }, "rdnt_PricingLevelIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pricing Level I [Member]", "label": "Pricing Level I [Member]", "terseLabel": "Pricing Level I" } } }, "localname": "PricingLevelIMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails" ], "xbrltype": "domainItemType" }, "rdnt_PricingLevelIVMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pricing Level IV [Member]", "label": "Pricing Level IV [Member]", "terseLabel": "Pricing Level IV" } } }, "localname": "PricingLevelIVMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails" ], "xbrltype": "domainItemType" }, "rdnt_PricingLevelVMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pricing Level V [Member]", "label": "Pricing Level V [Member]", "terseLabel": "Pricing Level V" } } }, "localname": "PricingLevelVMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails" ], "xbrltype": "domainItemType" }, "rdnt_PrimedexHealthSystemsInc.andRadiologixMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primedex Health Systems Inc. and Radiologix [Member]", "label": "Primedex Health Systems Inc. and Radiologix [Member]", "terseLabel": "Primedex Health Systems Inc. and Radiologix" } } }, "localname": "PrimedexHealthSystemsInc.andRadiologixMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_ProceedsInExcessOfBookValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Proceeds in excess of book value", "label": "Proceeds in excess of book value", "terseLabel": "Proceeds in excess of book value" } } }, "localname": "ProceedsInExcessOfBookValue", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_PropertyAndEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Propery and equipment, net [Member]", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyAndEquipmentMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsAssetsHeldForSale", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_PropertyPlantandEquipmentNetIncludingRightofUseAssets": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Property Plant and Equipment Net Including Right of Use Assets", "label": "Property Plant and Equipment Net Including Right of Use Assets", "totalLabel": "Total property, equipment and right-of-use-assets" } } }, "localname": "PropertyPlantandEquipmentNetIncludingRightofUseAssets", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "rdnt_RadNetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "RadNet [Member]", "label": "RadNet [Member]", "terseLabel": "RadNet" } } }, "localname": "RadNetMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_RadiologixMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Radiologix [Member]", "terseLabel": "Radiologix" } } }, "localname": "RadiologixMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_RamicMahwahLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Ramic Mahwah LLC [Member]", "label": "Ramic Mahwah LLC [Member]", "terseLabel": "Ramic Mahwah LLC" } } }, "localname": "RamicMahwahLLCMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill" ], "xbrltype": "domainItemType" }, "rdnt_RavenHoldingsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Raven Holdings [Member]", "label": "Raven Holdings [Member]", "terseLabel": "Raven Holdings" } } }, "localname": "RavenHoldingsMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_RestatedAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restated Agreement [Member]", "label": "Restated Agreement [Member]", "terseLabel": "Restated Agreement", "verboseLabel": "Term Loan Agreement collateralized by NJIN's tangible and intangible assets" } } }, "localname": "RestatedAgreementMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsTermLoans" ], "xbrltype": "domainItemType" }, "rdnt_RestatedPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Restated Plan [Member]", "terseLabel": "Restated Plan" } } }, "localname": "RestatedPlanMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_RhodeIslandMedicalImagingIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Rhode Island Medical Imaging, Inc [Member]", "terseLabel": "Rhode Island Medical Imaging, Inc" } } }, "localname": "RhodeIslandMedicalImagingIncMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right Of Use Asset Obtained In Exchange For Lease Liability [Abstract]", "label": "Right Of Use Asset Obtained In Exchange For Lease Liability [Abstract]", "terseLabel": "Right-of-use & Equipment assets obtained in exchange for lease obligations:" } } }, "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/LeasesDetailsSupplementalCashFlows" ], "xbrltype": "stringItemType" }, "rdnt_SantaMonicaImagingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Santa Monica Imaging Group [Member]", "terseLabel": "Santa Monica Imaging Group" } } }, "localname": "SantaMonicaImagingMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_ScheduleOfLeverageRatioTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Leverage Ratio [Table Text Block]", "label": "Schedule Of Leverage Ratio [Table Text Block]", "terseLabel": "Schedule of leverage ratio" } } }, "localname": "ScheduleOfLeverageRatioTableTextBlock", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesTables" ], "xbrltype": "textBlockItemType" }, "rdnt_ScriptSenderMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "ScriptSender LLC [Member]", "terseLabel": "ScriptSender LLC" } } }, "localname": "ScriptSenderMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NatureOfBusinessDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_September2020CapMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "September 2020 [Member]", "terseLabel": "September 2020" } } }, "localname": "September2020CapMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodGrossValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Gross, Value", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Gross, Value", "terseLabel": "Issuance of stock upon exercise of options" } } }, "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodGrossValue", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity" ], "xbrltype": "monetaryItemType" }, "rdnt_SierraImagingAssociatesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Sierra Imaging Associates LLC [Member]", "terseLabel": "Sierra Imaging Associates" } } }, "localname": "SierraImagingAssociatesMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill" ], "xbrltype": "domainItemType" }, "rdnt_SouthernCaliforniaDiagnosticImagingIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Southern California Diagnostic Imaging, Inc [Member]", "label": "Southern California Diagnostic Imaging, Inc [Member]", "terseLabel": "Southern California Diagnostic Imaging, Inc" } } }, "localname": "SouthernCaliforniaDiagnosticImagingIncMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill" ], "xbrltype": "domainItemType" }, "rdnt_StockholdersEquityDeficitMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Total Radnet, Inc.'s Equity [Member]", "terseLabel": "Radnet, Inc. Stockholders' Equity" } } }, "localname": "StockholdersEquityDeficitMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity", "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "rdnt_SunTrustMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "SunTrust [Member]", "label": "SunTrust [Member]", "terseLabel": "SunTrust" } } }, "localname": "SunTrustMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_TaxCutsandJobsActChangeinTaxRateIncomeTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)", "label": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)", "terseLabel": "Tax cuts and jobs act, change in tax rate, income tax expense (benefit)" } } }, "localname": "TaxCutsandJobsActChangeinTaxRateIncomeTaxExpenseBenefit", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_TermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Term Loan [Member]", "terseLabel": "Term Loan" } } }, "localname": "TermLoanMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsTermLoans" ], "xbrltype": "domainItemType" }, "rdnt_TotalBookValueOfOtherJointVenturePartnerInterests": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total book value of other joint venture partner interests", "label": "Total book value of other joint venture partner interests", "terseLabel": "Total book value of other joint venture partner interests" } } }, "localname": "TotalBookValueOfOtherJointVenturePartnerInterests", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsKeyFinancialDataOnJointVentures" ], "xbrltype": "monetaryItemType" }, "rdnt_TotalOtherExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total other expenses", "label": "Total other expenses", "terseLabel": "Total other expenses" } } }, "localname": "TotalOtherExpenses", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/QuarterlyResultsOfOperationsUnauditedDetailsStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "rdnt_TradeNamesAmortizedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trade Names Amortized [Member]", "label": "Trade Names Amortized [Member]", "terseLabel": "Trade Names amortized" } } }, "localname": "TradeNamesAmortizedMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsAnnualAmortizationSchedule" ], "xbrltype": "domainItemType" }, "rdnt_TradeNamesIndefiniteLifeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trade Names Indefinite Life [Member]", "label": "Trade Names Indefinite Life [Member]", "terseLabel": "Trade Names indefinite life" } } }, "localname": "TradeNamesIndefiniteLifeMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsAnnualAmortizationSchedule" ], "xbrltype": "domainItemType" }, "rdnt_TurnerImagingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Turner Imaging [Member]", "terseLabel": "Turner Imaging" } } }, "localname": "TurnerImagingMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_TurnerImagingSystemsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Turner Imaging Systems [Member]", "label": "Turner Imaging Systems [Member]", "terseLabel": "Turner Imaging Systems" } } }, "localname": "TurnerImagingSystemsMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_USAttorneysOfficeForTheWesternDistrictofNewYorkMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "US Attorneys Office For The Western District of New York [Member]", "label": "US Attorneys Office For The Western District of New York [Member]", "terseLabel": "US Attorneys Office For The Western District of New York" } } }, "localname": "USAttorneysOfficeForTheWesternDistrictofNewYorkMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_UninsuredRisksPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Uninsured Risks [Policy Text Block]", "label": "Uninsured Risks [Policy Text Block]", "terseLabel": "UNINSURED RISKS" } } }, "localname": "UninsuredRisksPolicyTextBlock", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rdnt_UnrecognizedTaxBenefitsIncomeTaxPenaltiesandInterestAccruedDuringPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued During Period", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued During Period", "terseLabel": "Unrecognized tax benefits, income tax penalties and interest accrued during period" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesandInterestAccruedDuringPeriod", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_UnrecognizedTaxBenefitsIncreaseDecreaseChangeinEnactedTaxRate": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Unrecognized Tax Benefits, Increase (Decrease) Change in Enacted Tax Rate", "label": "Unrecognized Tax Benefits, Increase (Decrease) Change in Enacted Tax Rate", "terseLabel": "Increase (decrease) related to change in rate" } } }, "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseChangeinEnactedTaxRate", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsUnrecognizedTaxBenefit" ], "xbrltype": "monetaryItemType" }, "rdnt_UnrecognizedTaxBenefitsTaxImpactIfRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Unrecognized Tax Benefits, Tax Impact If Recognized", "label": "Unrecognized Tax Benefits, Tax Impact If Recognized", "terseLabel": "Unrecognized tax benefits, tax impact if recognized" } } }, "localname": "UnrecognizedTaxBenefitsTaxImpactIfRecognized", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_ValleyMetabolicImagingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Valley Metabolic Imaging LLC [Member]", "terseLabel": "Valley Metabolic Imaging" } } }, "localname": "ValleyMetabolicImagingMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill" ], "xbrltype": "domainItemType" }, "rdnt_VenturaCountyImagingGroupLLC.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Ventura County Imaging Group, LLC. [Member]", "label": "Ventura County Imaging Group, LLC. [Member]", "terseLabel": "Ventura County Imaging Group, LLC." } } }, "localname": "VenturaCountyImagingGroupLLC.Member", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_VenturaCountyImagingGroupLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Ventura County Imaging Group, LLC [Member]", "label": "Ventura County Imaging Group, LLC [Member]", "terseLabel": "Ventura County Imaging Group, LLC" } } }, "localname": "VenturaCountyImagingGroupLLCMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "rdnt_WashingtonHeightsMedicalManagementLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Washington Heights Medical Management, LLC [Member]", "label": "Washington Heights Medical Management, LLC [Member]", "terseLabel": "Washington Heights Medical Management, LLC" } } }, "localname": "WashingtonHeightsMedicalManagementLLCMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_WashingtonHeightsMedicalManagementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Washington Heights Medical Management [Member]", "terseLabel": "Washington Heights Medical Management" } } }, "localname": "WashingtonHeightsMedicalManagementMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill" ], "xbrltype": "domainItemType" }, "rdnt_WeightedAverageAmortizationPeriodRemainingInYears": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average amortization period remaining in years", "label": "Weighted average amortization period remaining in years", "terseLabel": "Weighted average amortization period remaining in years" } } }, "localname": "WeightedAverageAmortizationPeriodRemainingInYears", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsAnnualAmortizationSchedule" ], "xbrltype": "durationItemType" }, "rdnt_WeightedAverageRemainingContractualLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted Average Remaining Contractual Life abstract", "label": "Weighted Average Remaining Contractual Life", "terseLabel": "Weighted Average Remaining Contractual Life" } } }, "localname": "WeightedAverageRemainingContractualLife", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants" ], "xbrltype": "stringItemType" }, "rdnt_WeightedAverageRemainingLeaseTermAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted Average Remaining Lease Term [Abstract]", "label": "Weighted Average Remaining Lease Term [Abstract]", "terseLabel": "Weighted Average Remaining Lease Term [Abstract]" } } }, "localname": "WeightedAverageRemainingLeaseTermAbstract", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet" ], "xbrltype": "stringItemType" }, "rdnt_WestValleyImagingGroupLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "West Valley Imaging Group, LLC [Member]", "label": "West Valley Imaging Group, LLC [Member]", "terseLabel": "West Valley Imaging Group, LLC" } } }, "localname": "WestValleyImagingGroupLLCMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill" ], "xbrltype": "domainItemType" }, "rdnt_WhiteRabbit.aiInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "WhiteRabbit.ai Inc. [Member]", "label": "WhiteRabbit.ai Inc. [Member]", "terseLabel": "WhiteRabbit.ai Inc." } } }, "localname": "WhiteRabbit.aiInc.Member", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/RelatedPartyTransactionsDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_WomensImagingSpecialistsinHealthcareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Women's Imaging Specialists in Healthcare [Member]", "label": "Women's Imaging Specialists in Healthcare [Member]", "terseLabel": "Women's Imaging Specialists in Healthcare" } } }, "localname": "WomensImagingSpecialistsinHealthcareMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_WomensImagingSpecialistsyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Womens Imaging Specialists [Member]", "terseLabel": "Womens Imaging Specialists" } } }, "localname": "WomensImagingSpecialistsyMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill" ], "xbrltype": "domainItemType" }, "rdnt_WorkersCompensationPersonalInjury1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Workers' Compensation/Personal Injury1 [Member]", "label": "Workers' Compensation/Personal Injury1 [Member]", "terseLabel": "Workers' compensation/personal injury" } } }, "localname": "WorkersCompensationPersonalInjury1Member", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummaryOfNetRevenue" ], "xbrltype": "domainItemType" }, "rdnt_ZilkhaRadiologyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Zilkha Radiology [Member]", "label": "Zilkha Radiology [Member]", "terseLabel": "Zilkha Radiology" } } }, "localname": "ZilkhaRadiologyMember", "nsuri": "http://www.radnet.com/20191231", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill" ], "xbrltype": "domainItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r173" ], "lang": { "en-US": { "role": { "documentation": "Person with designation of chief executive officer.", "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/NatureOfBusinessDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r63", "r127", "r516" ], "lang": { "en-US": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of investment, including named security. Excludes consolidated entity.", "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/RelatedPartyTransactionsDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.", "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.", "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsAdditionalInformation", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt", "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsAdditionalInformation", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt", "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r172", "r256", "r258", "r496", "r497" ], "lang": { "en-US": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummaryOfNetRevenue" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummaryOfNetRevenue" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsAdditionalInformation", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt", "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsAdditionalInformation", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt", "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "Information by name of investment, including named security. Excludes consolidated entity.", "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/RelatedPartyTransactionsDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r135", "r515" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "terseLabel": "SCHEDULE II \u2013 VALUATION AND QUALIFYING ACCOUNTSRADNET, INC. AND SUBSIDIARIES" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/ScheduleIiValuationAndQualifyingAccounts" ], "xbrltype": "textBlockItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r173", "r457" ], "lang": { "en-US": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/NatureOfBusinessDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/NatureOfBusinessDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ValuationAndQualifyingAccountsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "localname": "ValuationAndQualifyingAccountsAbstract", "nsuri": "http://fasb.org/srt/2019-01-31", "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r135", "r515" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r433" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsAdditionalInformation" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/AccountsPayableAndAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.radnet.com/role/AccountsPayableAndAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable, accrued expenses and other", "totalLabel": "Total" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/AccountsPayableAndAccruedExpensesDetails", "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.radnet.com/role/AccountsPayableAndAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/AccountsPayableAndAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r8", "r28", "r174", "r175", "r257" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.radnet.com/role/AccountsPayableAndAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/AccountsPayableAndAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesFairValueDisclosure": { "auth_ref": [ "r49" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of accrued expenses.", "label": "Accrued Liabilities, Fair Value Disclosure", "terseLabel": "2016 CAPS - Interest Rate Contracts" } } }, "localname": "AccruedLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsFairValueMeasurements" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r12", "r13", "r49" ], "calculation": { "http://www.radnet.com/role/AccountsPayableAndAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/AccountsPayableAndAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedAmortizationOfOtherDeferredCosts": { "auth_ref": [ "r43" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amortization of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs, deferred acquisition costs of insurance companies, or deferred leasing costs for real estate operations.", "label": "Accumulated Amortization of Other Deferred Costs", "terseLabel": "Net of accumulated amortization" } } }, "localname": "AccumulatedAmortizationOfOtherDeferredCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r41", "r223" ], "calculation": { "http://www.radnet.com/role/PropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r67", "r68", "r69" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r66", "r69", "r70", "r377" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive (Loss) Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r204" ], "lang": { "en-US": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Amortization period" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r29" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in-capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r110", "r209" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "terseLabel": "Amortization expense" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsAdditionalInformation" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r266", "r290", "r295" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForNotesReceivableMember": { "auth_ref": [ "r134" ], "lang": { "en-US": { "role": { "documentation": "Allowance for portion expected to be uncollectible of receivable from written agreement to receive, at specified future date, money consisting of principal and accrued interest.", "label": "SEC Schedule, 12-09, Allowance, Notes Receivable [Member]", "terseLabel": "Accounts Receivable-Allowance for Bad Debts" } } }, "localname": "AllowanceForNotesReceivableMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AmortizationOfDeferredCharges": { "auth_ref": [ "r86" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of amortization of deferred charges applied against earnings during the period.", "label": "Amortization of Deferred Charges", "terseLabel": "Amortization of deferred charges" } } }, "localname": "AmortizationOfDeferredCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r82", "r110", "r422" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization and write off of deferred financing costs and loan discount" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r147" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Weighted average shares for which the exercise price exceeds average market price of common stock (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsEarningsPerShare" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r168", "r472", "r485" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r10", "r11", "r59" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup": { "auth_ref": [ "r219" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets held-for-sale that are not part of a disposal group.", "label": "Assets Held-for-sale, Not Part of Disposal Group", "terseLabel": "Assets held for sale", "verboseLabel": "Total assets held for sale" } } }, "localname": "AssetsHeldForSaleNotPartOfDisposalGroup", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsAssetsHeldForSale" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsHeldUnderCapitalLeasesMember": { "auth_ref": [ "r430" ], "lang": { "en-US": { "role": { "documentation": "Long lived property, plant or equipment assets held by a lessee through a capital lease arrangement.", "label": "Assets Held under Capital Leases [Member]", "terseLabel": "Equipment under financing/capital lease" } } }, "localname": "AssetsHeldUnderCapitalLeasesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r267", "r293" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative", "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants", "http://www.radnet.com/role/StockBasedCompensationDetailsRsus" ], "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill", "http://www.radnet.com/role/IncomeTaxesDetailsNarrative", "http://www.radnet.com/role/SubsequentEventsDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r342", "r343" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill", "http://www.radnet.com/role/IncomeTaxesDetailsNarrative", "http://www.radnet.com/role/SubsequentEventsDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": { "auth_ref": [ "r358" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned", "terseLabel": "Value of RadNet stock issued in acquisition", "verboseLabel": "Equity interest issued, value assigned" } } }, "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "RadNet stock issued in acquisition (shares)", "verboseLabel": "Shares issues (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r339" ], "lang": { "en-US": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Business acquisition, percentage of voting interests acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r352", "r353", "r355" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "verboseLabel": "Consideration transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r352", "r353" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Common stock issued as consideration" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r350", "r352", "r353", "r357" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "terseLabel": "Assumption of debt as consideration" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r109", "r360" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in value of contingent consideration", "verboseLabel": "Contingent consideration liability adjustment" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r351", "r354", "r359" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration to guarantee share value issued" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized": { "auth_ref": [ "r346" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount, measured at acquisition-date fair value, of all liabilities assumed that arise from contingencies and were recognized by the entity.", "label": "Business Combination, Liabilities Arising from Contingencies, Amount Recognized", "terseLabel": "Contingent consideration liability" } } }, "localname": "BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognizedOtherThanAtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount, measured at other than acquisition-date fair value, of all the liabilities assumed that arise from contingencies and were recognized by the entity, if the acquisition-date fair value cannot be determined and other criteria (as defined) related to the contingencies have been met.", "label": "Business Combination, Liabilities Arising from Contingencies, Amount Recognized, Other than at Fair Value", "terseLabel": "Business consideration liability adjustment recorded amount" } } }, "localname": "BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognizedOtherThanAtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": { "auth_ref": [ "r345" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lease obligation assumed in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation", "terseLabel": "Capital lease assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r345" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "verboseLabel": "Other current assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesCurrent": { "auth_ref": [ "r345" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary difference assumed at the acquisition date that are classified as current.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Current", "terseLabel": "Deferred tax liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment": { "auth_ref": [ "r345" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment", "terseLabel": "Equipment acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r344", "r345" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Intangible assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r345" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r344", "r345" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Fixed assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis": { "auth_ref": [ "r340" ], "lang": { "en-US": { "role": { "documentation": "Disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.", "label": "Business Combination, Separately Recognized Transactions [Axis]", "terseLabel": "Business Combination, Separately Recognized Transactions [Axis]" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain": { "auth_ref": [ "r340" ], "lang": { "en-US": { "role": { "documentation": "Type of transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in a business combination by transaction.", "label": "Business Combination, Separately Recognized Transactions [Domain]", "terseLabel": "Business Combination, Separately Recognized Transactions [Domain]" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": { "auth_ref": [ "r341" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain", "terseLabel": "Disposition of equity method interest upon acquisition of control in NJIN" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "In a business combination achieved in stages, this element represents the amount of loss recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss", "negatedTerseLabel": "Equity interest acquiree remeasurement loss" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsInvestmentInJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r119", "r338" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "BUSINESS COMBINATION" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r6", "r136", "r162" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "NATURE OF BUSINESS" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NatureOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalLeaseObligations": { "auth_ref": [ "r23", "r431", "r487" ], "calculation": { "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt": { "order": 5.0, "parentTag": "rdnt_LongtermDebtShorttermDebtandCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.", "label": "Capital Lease Obligations", "terseLabel": "Obligations under capital leases at interest rates ranging from 3.7% to 9.3%, due through 2022, collateralized by medical and office equipment (1)" } } }, "localname": "CapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeaseObligationsCurrent": { "auth_ref": [ "r21", "r429", "r431" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of capital lease obligation due within one year or the normal operating cycle, if longer.", "label": "Capital Lease Obligations, Current", "terseLabel": "Current portion of obligations under capital leases" } } }, "localname": "CapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeaseObligationsMember": { "auth_ref": [ "r431" ], "lang": { "en-US": { "role": { "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time.", "label": "Capital Lease Obligations [Member]", "terseLabel": "Capital Lease Obligations" } } }, "localname": "CapitalLeaseObligationsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalLeaseObligationsNoncurrent": { "auth_ref": [ "r53", "r429", "r431" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.", "label": "Capital Lease Obligations, Noncurrent", "terseLabel": "Obligations under capital lease, net of current portion" } } }, "localname": "CapitalLeaseObligationsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareGross": { "auth_ref": [ "r507" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.", "label": "Capitalized Computer Software, Gross", "terseLabel": "Capitalized software costs, gross" } } }, "localname": "CapitalizedComputerSoftwareGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r90" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash Acquired from Acquisition", "terseLabel": "Cash acquired from acquisition" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r37", "r112" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "CASH AND CASH EQUIVALENTS, end of period", "periodStartLabel": "CASH AND CASH EQUIVALENTS, beginning of period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets", "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "NET INCREASE (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r15", "r113", "r119" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "CASH AND CASH EQUIVALENTS" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassificationOfVariableInterestEntityDomain": { "auth_ref": [ "r379", "r380", "r382", "r384" ], "lang": { "en-US": { "role": { "documentation": "Categorization of Variable Interest Entities (VIE) for consolidation and (or) disclosure purposes, whether individually or in aggregate, by: (1) VIEs consolidated because the entity is the primary beneficiary, (2) VIEs not consolidated because the entity is not the primary beneficiary, and (3) VIEs or potential VIEs that are not consolidated because necessary information is not available. In general, a VIE is a corporation, partnership, trust, or any other legal structure used for business purposes that either (a) does not have equity investors with voting rights or (b) has equity investors that do not provide sufficient financial resources for the entity to support its activities. A VIE often holds financial assets, including loans or receivables, real estate or other property. A VIE may be essentially passive or it may engage in research and development or other activities on behalf of another company.", "label": "Variable Interest Entity, Classification [Domain]", "terseLabel": "Variable Interest Entity, Classification [Domain]" } } }, "localname": "ClassificationOfVariableInterestEntityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Promissory note" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r119", "r236", "r504", "r505" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r26" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock - par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r26" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock - authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r26" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock - issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r26", "r245" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock - outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r26" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock - $.0001 par value, 200,000,000 shares authorized; 50,314,328 and 48,977,485 shares issued and outstanding at December 31, 2019 and 2018 respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r118", "r272" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "EQUITY BASED COMPENSATION" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Components of Deferred Tax Assets [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "ComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r72", "r74", "r75" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfComprehensiveLossIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfComprehensiveLossIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r72", "r74", "r367", "r368", "r387" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfComprehensiveLossIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Less comprehensive income attributable to noncontrolling interests" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfComprehensiveLossIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r72", "r74", "r366", "r387" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfComprehensiveLossIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "COMPREHENSIVE INCOME" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfComprehensiveLossIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "COMPREHENSIVE (LOSS) INCOME" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r156", "r483" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "CONCENTRATION OF CREDIT RISKS" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r119", "r371", "r388", "r389" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "PRINCIPLES OF CONSOLIDATION" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r222" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress, Gross", "terseLabel": "Construction in progress, gross" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in Progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r253", "r254", "r257" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue liability" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r24", "r25", "r246", "r247" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Preferred stock issued upon conversion (in shares)" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r85" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of operations, excluding depreciation and amortization" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditDerivativesByContractTypeAxis": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "Information by major type of contract of credit derivatives.", "label": "Credit Derivatives Contract Type [Axis]", "terseLabel": "Credit Derivatives Contract Type [Axis]" } } }, "localname": "CreditDerivativesByContractTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CreditDerivativesContractTypeDomain": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "Represents major types of credit derivative contracts.", "label": "Credit Derivatives Contract Type [Domain]", "terseLabel": "Credit Derivatives Contract Type [Domain]" } } }, "localname": "CreditDerivativesContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r124", "r327", "r334" ], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsIncomeTaxExpense": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal current tax" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsIncomeTaxExpense" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock": { "auth_ref": [ "r244", "r432" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for debt and capital lease obligations can be reported. Information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. Also includes descriptions and amounts of capital leasing arrangements that consist of direct financing, sales type and leveraged leases. Disclosure may include the effect on the balance sheet and the income statement resulting from a change in lease classification for leases that at inception would have been classified differently had guidance been in effect at the inception of the original lease.", "label": "Debt and Capital Leases Disclosures [Text Block]", "terseLabel": "NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES" } } }, "localname": "DebtAndCapitalLeasesDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r21", "r22", "r23", "r473", "r474", "r484" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsTermLoans", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r23", "r240", "r474", "r484" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Total Carrying Value", "verboseLabel": "Total carrying value" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsTermLoans" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r421", "r424" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face Value", "verboseLabel": "Face value" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsTermLoans" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r412" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "First Lien Term Loans" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsFairValueMeasurements" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r51", "r242", "r421" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r51" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsTermLoans" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r52", "r408" ], "lang": { "en-US": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Debt instrument, maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r53" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsTermLoans", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r53", "r481" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment", "terseLabel": "Debt periodic payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r53" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Periodic payment, principal" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r53", "r128", "r246", "r248", "r249", "r250", "r420", "r421", "r424", "r482" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsTermLoans" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r420", "r424" ], "calculation": { "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt": { "order": 2.0, "parentTag": "rdnt_LongtermDebtShorttermDebtandCapitalLeaseObligationsIncludingCurrentMaturities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Discount on First Lien Term Loans" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r420", "r424" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Debt Instrument, Unamortized Discount, Current", "terseLabel": "Debt instrument, unamortized discount, current" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "auth_ref": [ "r420", "r421", "r422", "r423", "r424" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount (premium).", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "negatedLabel": "Discount", "terseLabel": "Debt, unamortized discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsTermLoans" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r43", "r119" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges, Policy [Policy Text Block]", "terseLabel": "DEFERRED FINANCING COSTS" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of common shares reserved for future issuance related to deferred compensation arrangements with individuals.", "label": "Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance", "terseLabel": "Shares available for future issuance, options, warrants, shares of restricted stock and other bonus awards" } } }, "localname": "DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r124", "r329", "r334" ], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsIncomeTaxExpense": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal deferred tax" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsIncomeTaxExpense" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r422" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Issuance costs" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r43", "r422" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Deferred financing costs, net of accumulated amortization" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "auth_ref": [ "r43", "r422" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Noncurrent, Net", "terseLabel": "Deferred financing costs" } } }, "localname": "DeferredFinanceCostsNoncurrentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentCreditCurrent": { "auth_ref": [ "r49", "r426" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.", "label": "Deferred Rent Credit, Current", "terseLabel": "Current portion of deferred rent" } } }, "localname": "DeferredRentCreditCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentCreditNoncurrent": { "auth_ref": [ "r55", "r426" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.", "label": "Deferred Rent Credit, Noncurrent", "terseLabel": "Deferred rent, net of current portion" } } }, "localname": "DeferredRentCreditNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r34" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "terseLabel": "Deferred revenue related to software sales" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r124", "r329", "r334" ], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsIncomeTaxExpense": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State deferred tax" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsIncomeTaxExpense" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r319" ], "calculation": { "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total Deferred Tax Assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossNoncurrent": { "auth_ref": [ "r305", "r306", "r319" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences and carryforwards, classified as noncurrent.", "label": "Deferred Tax Assets, Gross, Noncurrent", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsGrossNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r321" ], "calculation": { "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net Deferred Tax Asset" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r297", "r325", "r326" ], "calculation": { "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating losses" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "terseLabel": "Operating loss carryforwards, subject to expiration" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r299", "r325", "r326" ], "calculation": { "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "auth_ref": [ "r297", "r325", "r326" ], "calculation": { "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits", "terseLabel": "Equity compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "auth_ref": [ "r298", "r325", "r326" ], "calculation": { "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "verboseLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r297", "r325", "r326" ], "calculation": { "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "verboseLabel": "Unfavorable contract liability" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "auth_ref": [ "r297", "r325", "r326" ], "calculation": { "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r320" ], "calculation": { "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities": { "order": 9.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r306", "r321" ], "calculation": { "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Total Deferred Tax Liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts": { "auth_ref": [ "r298", "r325", "r326" ], "calculation": { "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs classified as other.", "label": "Deferred Tax Liabilities, Deferred Expense, Other Capitalized Costs", "negatedLabel": "Non accrual experience method reserve" } } }, "localname": "DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": { "auth_ref": [ "r299", "r325", "r326" ], "calculation": { "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets", "negatedLabel": "Intangibles" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill": { "auth_ref": [ "r299", "r325", "r326", "r361", "r362" ], "calculation": { "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from goodwill.", "label": "Deferred Tax Liabilities, Goodwill", "negatedLabel": "Goodwill", "terseLabel": "Deferred tax liabilities goodwill" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsNarrative", "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r299", "r325", "r326" ], "calculation": { "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "negatedLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r299", "r325", "r326" ], "calculation": { "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedLabel": "Property and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NcomeTaxesDetailsDeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r264" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Expected employee contribution" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Employee contribution, percent" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Employer matching contribution, percent" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DepositsAssets": { "auth_ref": [ "r43" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.", "label": "Deposits Assets", "terseLabel": "Deposits and other" } } }, "localname": "DepositsAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r110", "r221" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r110", "r165" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.radnet.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetNotionalAmount": { "auth_ref": [ "r391", "r392", "r394" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payments on the derivative asset.", "label": "Derivative Asset, Notional Amount", "terseLabel": "Notional amounts" } } }, "localname": "DerivativeAssetNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeBasisSpreadOnVariableRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The percentage points added to the reference rate to compute the variable rate on the interest rate derivative.", "label": "Derivative, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DerivativeBasisSpreadOnVariableRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsDerivatives", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsFairValueMeasurements", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r397", "r398", "r400", "r402" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsDerivatives", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsFairValueMeasurements", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r119", "r133", "r390", "r393", "r395", "r396", "r404" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "DERIVATIVE INSTRUMENTS" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r349" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Software developed for internal use" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).", "label": "Disclosure of Long Lived Assets Held-for-sale [Table Text Block]", "terseLabel": "Schedule of assets held for sale" } } }, "localname": "DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAndDispositionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsAssetsHeldForSale" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic Tax Authority" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DueFromRelatedPartiesCurrent": { "auth_ref": [ "r9", "r16", "r27", "r125", "r455" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).", "label": "Due from Related Parties, Current", "terseLabel": "Due from affiliates" } } }, "localname": "DueFromRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToAffiliateCurrent": { "auth_ref": [ "r19", "r126", "r455", "r499" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Affiliate, Current", "terseLabel": "Due to affiliates" } } }, "localname": "DueToAffiliateCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r80", "r138", "r143", "r144", "r145", "r146", "r150", "r480", "r494" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "netLabel": "Basic net income per share attributable to RadNet, inc. common stockholders (in dollars per share)", "terseLabel": "BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS (in dollars per share)", "verboseLabel": "Basic net (loss) income attributable to Radnet, Inc. common stockholders (loss) earnings per share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations", "http://www.radnet.com/role/QuarterlyResultsOfOperationsUnauditedDetailsStatementsOfOperations", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsEarningsPerShare" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "verboseLabel": "BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsEarningsPerShare" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r80", "r138", "r143", "r144", "r145", "r146", "r150", "r480", "r494" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "netLabel": "Diluted net income per share attributable to RadNet, Inc. common stockholders (in dollars per share)", "terseLabel": "DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS (in dollars per share)", "verboseLabel": "Diluted net (loss) income attributable to Radnet, Inc. common stockholders (loss) earnings per share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations", "http://www.radnet.com/role/QuarterlyResultsOfOperationsUnauditedDetailsStatementsOfOperations", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsEarningsPerShare" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "verboseLabel": "DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsEarningsPerShare" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Diluted, Other Disclosures [Abstract]", "terseLabel": "Stock options excluded from the computation of diluted per share amounts:" } } }, "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsEarningsPerShare" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r119", "r147", "r148", "r149" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "EARNINGS PER SHARE" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r417" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r308", "r309", "r332" ], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates": { "order": 1.0, "parentTag": "rdnt_IncomeTaxExpenseBenefitPercent", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "verboseLabel": "Federal tax, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r308", "r309", "r332" ], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates": { "order": 5.0, "parentTag": "rdnt_IncomeTaxExpenseBenefitPercent", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "verboseLabel": "Changes in valuation allowance, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r308", "r309", "r332" ], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates": { "order": 6.0, "parentTag": "rdnt_IncomeTaxExpenseBenefitPercent", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "verboseLabel": "Tax Cuts and Jobs Act, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense": { "auth_ref": [ "r308", "r309", "r332" ], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates": { "order": 4.0, "parentTag": "rdnt_IncomeTaxExpenseBenefitPercent", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.", "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent", "terseLabel": "Noncontrolling interests in partnerships, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r308", "r309", "r332" ], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates": { "order": 3.0, "parentTag": "rdnt_IncomeTaxExpenseBenefitPercent", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "verboseLabel": "Other Non deductible expenses, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r308", "r309", "r332" ], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates": { "order": 8.0, "parentTag": "rdnt_IncomeTaxExpenseBenefitPercent", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "verboseLabel": "Deferred true-ups and other, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates": { "order": 9.0, "parentTag": "rdnt_IncomeTaxExpenseBenefitPercent", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent", "verboseLabel": "Other reconciling items, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r308", "r309", "r332" ], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates": { "order": 2.0, "parentTag": "rdnt_IncomeTaxExpenseBenefitPercent", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "verboseLabel": "State franchise tax, net of federal benefit, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.radnet.com/role/AccountsPayableAndAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued salary and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/AccountsPayableAndAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized expense weighted average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r291" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummaryOfNetRevenue" ], "xbrltype": "stringItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Medical equipment", "verboseLabel": "Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease", "http://www.radnet.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity", "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentAggregateCost": { "auth_ref": [ "r38" ], "calculation": { "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsKeyFinancialDataOnJointVentures": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.", "label": "Equity Method Investment, Aggregate Cost", "terseLabel": "Total net assets", "totalLabel": "Total net assets" } } }, "localname": "EquityMethodInvestmentAggregateCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsKeyFinancialDataOnJointVentures", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "auth_ref": [ "r78", "r105", "r110", "r492" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.", "label": "Proceeds from Equity Method Investment, Distribution", "negatedLabel": "Distribution of earnings" } } }, "localname": "EquityMethodInvestmentDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsInvestmentInJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity interest percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/NatureOfBusinessDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": { "auth_ref": [ "r83", "r84", "r110" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment.", "label": "Equity Method Investment, Realized Gain (Loss) on Disposal", "negatedTerseLabel": "Loss on equity method investment", "terseLabel": "Sale of ownership interest", "verboseLabel": "Gain (loss) on equity method investment" } } }, "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsInvestmentInJointVentures", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets": { "auth_ref": [ "r4", "r122", "r182", "r187", "r415" ], "calculation": { "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsKeyFinancialDataOnJointVentures": { "order": 2.0, "parentTag": "us-gaap_EquityMethodInvestmentAggregateCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of assets reported by an equity method investment of the entity.", "label": "Equity Method Investment, Summarized Financial Information, Assets", "terseLabel": "Noncurrent assets" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsKeyFinancialDataOnJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets": { "auth_ref": [ "r4", "r122", "r182", "r187", "r415" ], "calculation": { "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsKeyFinancialDataOnJointVentures": { "order": 1.0, "parentTag": "us-gaap_EquityMethodInvestmentAggregateCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of current assets reported by an equity method investment of the entity.", "label": "Equity Method Investment, Summarized Financial Information, Current Assets", "terseLabel": "Current assets" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsKeyFinancialDataOnJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities": { "auth_ref": [ "r4", "r122", "r182", "r187", "r415" ], "calculation": { "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsKeyFinancialDataOnJointVentures": { "order": 3.0, "parentTag": "us-gaap_EquityMethodInvestmentAggregateCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of current liabilities reported by an equity method investment of the entity.", "label": "Equity Method Investment, Summarized Financial Information, Current Liabilities", "negatedLabel": "Current liabilities" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsKeyFinancialDataOnJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities": { "auth_ref": [ "r4", "r122", "r182", "r187", "r415" ], "calculation": { "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsKeyFinancialDataOnJointVentures": { "order": 4.0, "parentTag": "us-gaap_EquityMethodInvestmentAggregateCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of liabilities reported by an equity method investment of the entity.", "label": "Equity Method Investment, Summarized Financial Information, Liabilities", "negatedLabel": "Noncurrent liabilities" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsKeyFinancialDataOnJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets": { "auth_ref": [ "r185" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity.", "label": "Equity Method Investment, Underlying Equity in Net Assets", "terseLabel": "Cost in excess of book value of acquired joint venture interests accounted for as equity method goodwill" } } }, "localname": "EquityMethodInvestmentUnderlyingEquityInNetAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsKeyFinancialDataOnJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r38", "r169", "r181" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Book value of RadNet joint venture interests", "verboseLabel": "Fair value of investment" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsKeyFinancialDataOnJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r38", "r105", "r119", "r184", "r415" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Method Investments [Policy Text Block]", "terseLabel": "INVESTMENT IN JOINT VENTURES" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityMethodInvestmentsTextBlock": { "auth_ref": [ "r188" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.", "label": "Equity Method Investments [Table Text Block]", "terseLabel": "Schedule of investment in joint ventures" } } }, "localname": "EquityMethodInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r412" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Estimate of Fair Value Measurement" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsFairValueMeasurements" ], "xbrltype": "domainItemType" }, "us-gaap_EurodollarMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.", "label": "Eurodollar [Member]", "terseLabel": "Eurodollar" } } }, "localname": "EurodollarMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsFairValueMeasurements" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r406", "r413", "r414" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsFairValueMeasurements" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r406", "r413" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Schedule of fair value of assets and liabilities" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r261", "r262", "r263", "r407", "r465" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsFairValueMeasurements" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r406", "r410" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsFairValueMeasurements" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsFairValueMeasurements" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r409" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r261", "r262", "r263", "r407", "r466" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsFairValueMeasurements" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r261", "r262", "r263", "r407", "r467" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsFairValueMeasurements" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r261", "r262", "r263", "r407", "r468" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsFairValueMeasurements" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsFairValueMeasurements" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r436", "r444", "r452" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsLeaseCost": { "order": 2.0, "parentTag": "rdnt_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsLeaseCost" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r438", "r446" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Operating cash flows from financing leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsSupplementalCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finance Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Finance Lease, Liability, Payment, Due [Abstract]" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r435", "r451" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLeaseCalc2": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Total", "totalLabel": "Total finance lease liabilities", "verboseLabel": "Finance lease, liability" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsAdditionalInformation", "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease", "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r435" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Current portion of finance lease liability", "verboseLabel": "Current portion of finance lease" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets", "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r451" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Maturities of finance lease liability" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r435" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Long-term finance lease liability", "verboseLabel": "Finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets", "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r451" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLeaseCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total Lease Payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r451" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r451" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in next fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2020" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r451" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r451" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r451" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r451" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r451" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLeaseCalc2": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less imputed interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r437", "r446" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Financing cash flows from financing leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsSupplementalCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r434" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under finance lease.", "label": "Finance Lease, Right-of-Use Asset", "terseLabel": "Equipment, net", "totalLabel": "Equipment, net" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsAdditionalInformation", "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r436", "r444", "r452" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsLeaseCost": { "order": 1.0, "parentTag": "rdnt_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Depreciation of leased equipment" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsLeaseCost" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r449", "r452" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r448", "r452" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Finance leases - years" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialGuaranteeInsuranceContractsFutureExpectedPremiumRevenueToBeRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unearned premium revenue under contracts issued by an insurance entity that provide protection to the holder of a financial obligation from a financial loss in the event of a default.", "label": "Financial Guarantee Insurance Contracts, Unearned Premium Revenue", "terseLabel": "Interest rate caps premium liability" } } }, "localname": "FinancialGuaranteeInsuranceContractsFutureExpectedPremiumRevenueToBeRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five", "terseLabel": "Amortization year thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsAnnualAmortizationSchedule" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r210" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "Amortization year 2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsAnnualAmortizationSchedule" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r210" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "Amortization year 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsAnnualAmortizationSchedule" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r210" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "Amortization year 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsAnnualAmortizationSchedule" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r210" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "Amortization year 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsAnnualAmortizationSchedule" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r210" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "Amortization year 2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsAnnualAmortizationSchedule" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r203", "r205", "r208", "r212", "r470" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsAnnualAmortizationSchedule", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsAnnualAmortizationSchedule" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r203", "r207" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsAnnualAmortizationSchedule", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r208" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Amortiztion total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsAnnualAmortizationSchedule" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r119", "r416", "r419" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "FOREIGN CURRENCY TRANSLATION" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Computer and office equipment, furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r110", "r220", "r225" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.radnet.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "negatedLabel": "Loss (gain) on sale and disposal of equipment and other", "negatedTerseLabel": "Loss (gain) on sale and disposal of equipment and other" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r110" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.radnet.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedLabel": "Gain on sale of imaging centers and medical practice", "negatedTerseLabel": "Gain on sale of imaging centers" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee": { "auth_ref": [ "r83", "r84", "r110", "r478", "r495" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Stock in Subsidiary or Equity Method Investee", "terseLabel": "Dissolution of GSRN" } } }, "localname": "GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsInvestmentInJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r192", "r194" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, ending balance", "periodStartLabel": "Goodwill, beginning balance", "terseLabel": "Goodwill", "verboseLabel": "Goodwill acquired" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r195" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill acquired through acquisitions" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.radnet.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.", "label": "Goodwill and Intangible Asset Impairment", "terseLabel": "Loss on impairment", "verboseLabel": "Loss on impairment" } } }, "localname": "GoodwillAndIntangibleAssetImpairment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/ConsolidatedStatementsOfOperations", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r217" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy": { "auth_ref": [ "r119", "r211" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.", "label": "Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]", "terseLabel": "GOODWILL AND INDEFINITE LIVED INTANGIBLES" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r110", "r193", "r197", "r200" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "negatedTerseLabel": "Goodwill, impairment loss", "terseLabel": "Goodwill impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill [Member]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsAssetsHeldForSale" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillTransfers": { "auth_ref": [ "r198" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of transfers into (out of) an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Transfers", "terseLabel": "Goodwill transferred to other assets" } } }, "localname": "GoodwillTransfers", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "auth_ref": [ "r196" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Written off Related to Sale of Business Unit", "negatedTerseLabel": "Goodwill disposed of through sale or transfer" } } }, "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill" ], "xbrltype": "monetaryItemType" }, "us-gaap_HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of patient service revenue, net of contractual allowances and discounts, less the related provision for bad debts.", "label": "Health Care Organization, Patient Service Revenue Less Provision for Bad Debts", "terseLabel": "Service fee revenue" } } }, "localname": "HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_Revenues", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the provision for bad debts related to patient service revenue.", "label": "Health Care Organization, Patient Service Revenue Provision for Bad Debts", "negatedLabel": "Provision for bad debts" } } }, "localname": "HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummaryOfNetRevenue" ], "xbrltype": "monetaryItemType" }, "us-gaap_HealthCareOtherMember": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "Service provided for maintenance, diagnosis and treatment of physical and mental health, classified as other.", "label": "Health Care, Other [Member]", "terseLabel": "Other" } } }, "localname": "HealthCareOtherMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummaryOfNetRevenue" ], "xbrltype": "domainItemType" }, "us-gaap_HealthCarePatientServiceMember": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "Service provided to patient for maintenance, diagnosis and treatment of physical and mental health. Excludes service to resident in health care facility.", "label": "Health Care, Patient Service [Member]", "terseLabel": "Health Care, Patient Service" } } }, "localname": "HealthCarePatientServiceMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummaryOfNetRevenue" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r110", "r213" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "terseLabel": "Write off of the reporting unit trade name" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r119", "r218", "r228" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "LONG-LIVED ASSETS" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r130" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "terseLabel": "INCOME BEFORE INCOME TAXES" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r78", "r110", "r166", "r181", "r477", "r492" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedLabel": "Equity in earnings of joint ventures", "terseLabel": "Equity in earnings in these joint ventures" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations", "http://www.radnet.com/role/QuarterlyResultsOfOperationsUnauditedDetailsStatementsOfOperations", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsInvestmentInJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": { "auth_ref": [ "r110" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.", "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions", "negatedLabel": "Equity in earnings of joint ventures, net of dividends" } } }, "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsAssetsHeldForSale" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r337" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r124", "r167", "r335" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 }, "http://www.radnet.com/role/IncomeTaxesDetailsIncomeTaxExpense": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Provision for income taxes", "negatedTerseLabel": "Benefit from (provision for) income taxes", "totalLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations", "http://www.radnet.com/role/IncomeTaxesDetailsIncomeTaxExpense", "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates", "http://www.radnet.com/role/QuarterlyResultsOfOperationsUnauditedDetailsStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r76", "r119", "r303", "r304", "r317", "r318", "r322", "r336", "r506" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r302", "r308", "r309" ], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Changes in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r301", "r308", "r309" ], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "terseLabel": "Tax Cuts and Jobs Act" } } }, "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r123", "r308", "r309" ], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Federal tax" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense": { "auth_ref": [ "r308", "r309" ], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.", "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount", "negatedTerseLabel": "Noncontrolling interests in partnerships" } } }, "localname": "IncomeTaxReconciliationMinorityInterestIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": { "auth_ref": [ "r308", "r309" ], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount", "terseLabel": "Other Non deductible expenses" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r308" ], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Deferred true-ups and other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": { "auth_ref": [ "r308", "r309" ], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount", "terseLabel": "Other reconciling items" } } }, "localname": "IncomeTaxReconciliationOtherReconcilingItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r123", "r308", "r309" ], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "State franchise tax, net of federal benefit" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsReconciliationOfStatutoryUSFederalRateAndEffectiveRates" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r114" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid during the period for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r109" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable, accrued expenses and other" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r109" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r109" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Deferred taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r109" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r109" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r109" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]", "terseLabel": "Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "auth_ref": [ "r146" ], "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants", "terseLabel": "Add additional shares issuable upon exercise of stock options and warrants (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsEarningsPerShare" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r211" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite lived intangible assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r202", "r206" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Other intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r88", "r243" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r103", "r107", "r114" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid during the period for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCapMember": { "auth_ref": [ "r401" ], "lang": { "en-US": { "role": { "documentation": "Contract in which the cap writer, in return for a premium, agrees to limit, or cap, the cap holder's risk associated with an increase in interest rates. If rates go above a specified interest-rate-level (the strike price or the cap rate), the cap holder is entitled to receive cash payments equal to the excess of the market rate over the strike price multiplied by the notional principal amount.", "label": "Interest Rate Cap [Member]", "terseLabel": "Interest Rate Cap" } } }, "localname": "InterestRateCapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsDerivatives", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsFairValueMeasurements" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r401" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsDerivatives", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsFairValueMeasurements", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_InternalUseSoftwarePolicy": { "auth_ref": [ "r119", "r214", "r216" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.", "label": "Internal Use Software, Policy [Policy Text Block]", "terseLabel": "MEANINGFUL USE INCENTIVE" } } }, "localname": "InternalUseSoftwarePolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r14", "r58", "r119", "r151", "r190", "r191" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "INVENTORIES" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentAdvisoryManagementAndAdministrativeServiceMember": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "Investment advisory, asset management and administrative service. Includes, but is not limited to, distribution and shareholder service; and accounting, tax, legal, regulatory filing, share registration and shareholder correspondence activities.", "label": "Investment Advisory, Management and Administrative Service [Member]", "terseLabel": "Investment Advisory, Management and Administrative Service" } } }, "localname": "InvestmentAdvisoryManagementAndAdministrativeServiceMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentOwnedAtFairValue": { "auth_ref": [ "r498", "r500", "r501", "r502", "r503" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.", "label": "Investment Owned, at Fair Value", "terseLabel": "Investment owned, at fair value" } } }, "localname": "InvestmentOwnedAtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "auth_ref": [ "r38" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Investment in joint ventures", "verboseLabel": "Total value of RadNet joint venture interests" } } }, "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsInvestmentInJointVentures", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsKeyFinancialDataOnJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r450" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease, cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/PropertyAndEquipmentDetails", "http://www.radnet.com/role/PropertyAndEquipmentDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r453" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsAdditionalInformation", "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r443" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsAdditionalInformation", "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r440" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r442" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "terseLabel": "Operating lease, lease not yet commenced, term of contract" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsAdditionalInformation" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r451" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Maturities of operating lease liability" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r451" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLeaseCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r451" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r451" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r451" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r451" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r451" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r451" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r451" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLeaseCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r441" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Operating lease, renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsAdditionalInformation" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r441" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Operating lease, term of contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsAdditionalInformation" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r453" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of credit outstanding, amount" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r48" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r33", "r476", "r490" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r406" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "negatedTerseLabel": "2016 CAPS - Interest Rate Contracts" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsFairValueMeasurements" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "LONG-TERM LIABILITIES" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r23", "r474", "r484" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Total credit facilities outstanding" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r45", "r128" ], "lang": { "en-US": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Commitment fee percentage" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet": { "auth_ref": [ "r129" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) of the credit facility.", "label": "Line of Credit Facility, Increase (Decrease), Net", "terseLabel": "Credit facilities, increase (decrease)" } } }, "localname": "LineOfCreditFacilityIncreaseDecreaseForPeriodNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r45" ], "lang": { "en-US": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit facilities available" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Credit facility, borrowings available" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r45", "r128" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Unused capacity, commitment fee percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount awarded from other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded from Other Party", "terseLabel": "Litigation settlement" } } }, "localname": "LitigationSettlementAmountAwardedFromOtherParty", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LongLivedAssetsHeldForSaleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Long Lived Assets Held-for-sale [Line Items]", "terseLabel": "Long Lived Assets Held-for-sale [Line Items]" } } }, "localname": "LongLivedAssetsHeldForSaleLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsAssetsHeldForSale" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r23", "r241", "r474", "r487" ], "calculation": { "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt": { "order": 1.0, "parentTag": "rdnt_LongtermDebtShorttermDebtandCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r23" ], "calculation": { "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsAnnualNotePayableMaturities": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-term Debt and Lease Obligation", "totalLabel": "Total notes payable obligations" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsAnnualNotePayableMaturities" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsAnnualNotePayableMaturities": { "order": 4.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Principal amount of long-term debt and capital lease obligation maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Four", "terseLabel": "2023" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsAnnualNotePayableMaturities" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsAnnualNotePayableMaturities": { "order": 3.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Principal amount of long-term debt and capital lease obligation maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Three", "terseLabel": "2022" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsAnnualNotePayableMaturities" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsAnnualNotePayableMaturities": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Principal amount of long-term debt and capital lease obligation maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Two", "terseLabel": "2021" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsAnnualNotePayableMaturities" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsAnnualNotePayableMaturities": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Principal amount of long-term debt and capital lease obligation maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt and Capital Lease Obligations, Repayments of Principal in Next Twelve Months", "terseLabel": "2020" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsAnnualNotePayableMaturities" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermLoansPayable": { "auth_ref": [ "r53" ], "calculation": { "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt": { "order": 4.0, "parentTag": "rdnt_LongtermDebtShorttermDebtandCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Loans Payable, Noncurrent", "terseLabel": "Equipment notes payable at interest rates ranging from 4.4% to 5.6%, due through 2020, collateralized by medical equipment" } } }, "localname": "LongTermLoansPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r53" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes Payable, Noncurrent", "terseLabel": "Notes payable, net of current portion" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r53" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsTermLoans" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r53", "r239" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsTermLoans" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r235" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Loss contingency accrual liability" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maturities of Long-term Debt and Capital Lease Obligations [Abstract]", "terseLabel": "Maturities of Notes Payables [Abstract]" } } }, "localname": "MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsAnnualNotePayableMaturities" ], "xbrltype": "stringItemType" }, "us-gaap_MediumTermNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instruments with maturities ranging from five to ten years.", "label": "Medium-term Notes [Member]", "terseLabel": "Medium-term Notes" } } }, "localname": "MediumTermNotesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "auth_ref": [ "r5", "r363" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "terseLabel": "FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS" } } }, "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositions" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r57", "r475", "r489" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "auth_ref": [ "r251" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedLabel": "Distributions paid to noncontrolling interests" } } }, "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "auth_ref": [ "r251", "r369", "r370" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "negatedLabel": "Purchase of noncontrolling interests" } } }, "localname": "MinorityInterestDecreaseFromRedemptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Noncontrolling interest, ownership percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r106" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r106" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r106", "r108", "r111" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r71", "r73", "r79", "r111", "r148", "r479", "r493" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income attributable to RadNet, Inc. common stockholders", "totalLabel": "NET INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS", "verboseLabel": "Net (loss) income attributable to Radnet, Inc. common stockholders" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations", "http://www.radnet.com/role/QuarterlyResultsOfOperationsUnauditedDetailsStatementsOfOperations", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsEarningsPerShare" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r71", "r73", "r373", "r386" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Net income attributable to noncontrolling interests", "verboseLabel": "Net income (loss) attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations", "http://www.radnet.com/role/QuarterlyResultsOfOperationsUnauditedDetailsStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r139" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "New Accounting Pronouncements and Changes in Accounting Principles [Text Block]", "terseLabel": "RECENT ACCOUNTING STANDARDS" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/RecentAccountingStandards" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r348" ], "lang": { "en-US": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]", "terseLabel": "Noncompete Agreements" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest": { "auth_ref": [ "r252", "r369", "r375" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.", "label": "Noncontrolling Interest, Increase from Sale of Parent Equity Interest", "terseLabel": "Sale to noncontrolling interests, net of taxes" } } }, "localname": "NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r364" ], "lang": { "en-US": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity", "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r87" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total other expenses (income)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "terseLabel": "Current portion of notes payable" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable, Other Payables [Member]", "terseLabel": "Notes Payable, Other Payables" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt" ], "xbrltype": "domainItemType" }, "us-gaap_OffMarketLeaseUnfavorable": { "auth_ref": [ "r54" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents a liability associated with the acquisition of an off-market lease when the terms of the lease are unfavorable to the market terms for the lease at the date of acquisition.", "label": "Off-market Lease, Unfavorable", "terseLabel": "Unfavorable contract liability" } } }, "localname": "OffMarketLeaseUnfavorable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OffsettingAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Offsetting Assets [Line Items]", "terseLabel": "Offsetting Assets [Line Items]" } } }, "localname": "OffsettingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsDerivatives" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingAssetsTable": { "auth_ref": [ "r61", "r62" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.", "label": "Offsetting Assets [Table]", "terseLabel": "Offsetting Assets [Table]" } } }, "localname": "OffsettingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsDerivatives" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "terseLabel": "Total operating expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations", "http://www.radnet.com/role/QuarterlyResultsOfOperationsUnauditedDetailsStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "OPERATING EXPENSES" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "INCOME FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r445", "r452" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsLeaseCost" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r435" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLeaseCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total", "totalLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsAdditionalInformation", "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease", "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r435" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liability", "verboseLabel": "Current portion of operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets", "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r435" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term operating lease liability", "verboseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets", "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r439", "r446" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsSupplementalCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r434" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "rdnt_PropertyPlantandEquipmentNetIncludingRightofUseAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use-assets", "verboseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets", "http://www.radnet.com/role/LeasesDetailsAdditionalInformation", "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r449", "r452" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r448", "r452" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating leases - years" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsSupplementalBalanceSheet" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r425", "r427" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Total operating lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r425", "r427" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2019" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r425", "r427" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r425", "r427" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r425", "r427" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r425", "r427" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r425", "r427" ], "calculation": { "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease": { "order": 6.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r323" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforward" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsExpirationDate": { "auth_ref": [ "r323" ], "lang": { "en-US": { "role": { "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYY-MM-DD format.", "label": "Operating Loss Carryforwards, Expiration Date", "terseLabel": "Operating loss ending expiration date" } } }, "localname": "OperatingLossCarryforwardsExpirationDate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r324" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Assets [Abstract]", "terseLabel": "OTHER ASSETS" } } }, "localname": "OtherAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent": { "auth_ref": [ "r366", "r367", "r376" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent", "terseLabel": "Change in cumulative foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "auth_ref": [ "r65", "r67" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfComprehensiveLossIncome": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "terseLabel": "Change in fair value of cash flow hedge, net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfComprehensiveLossIncome", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsDerivatives" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r64", "r418" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfComprehensiveLossIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfComprehensiveLossIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r65", "r67", "r405" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfComprehensiveLossIncome": { "order": 4.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax", "negatedTerseLabel": "Change in fair value of cash flow hedge, net of taxes", "terseLabel": "Change in fair value of cash flow hedge, net of taxes" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity", "http://www.radnet.com/role/ConsolidatedStatementsOfComprehensiveLossIncome", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsDerivatives" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Expenses [Abstract]", "terseLabel": "OTHER INCOME AND EXPENSES" } } }, "localname": "OtherExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r54" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r89" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other expenses (income)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherTaxExpenseBenefit": { "auth_ref": [ "r131", "r307", "r330" ], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsIncomeTaxExpense": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other income tax expense (benefit).", "label": "Other Tax Expense (Benefit)", "terseLabel": "Other current tax" } } }, "localname": "OtherTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsIncomeTaxExpense" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": { "auth_ref": [ "r94" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.", "label": "Payments to Acquire Additional Interest in Subsidiaries", "negatedLabel": "Purchase of noncontrolling interests" } } }, "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r94", "r356" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Consideration transfered", "verboseLabel": "Payments to acquire business" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "auth_ref": [ "r94" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Payments to Acquire Equity Method Investments", "terseLabel": "Investment at cost", "verboseLabel": "Payments to acquire equity method investments" } } }, "localname": "PaymentsToAcquireEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInterestInJointVenture": { "auth_ref": [ "r94" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.", "label": "Payments to Acquire Interest in Joint Venture", "negatedLabel": "Equity contributions in existing and purchase of interest in joint ventures" } } }, "localname": "PaymentsToAcquireInterestInJointVenture", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r96" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Investment at cost" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r95" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "negatedLabel": "Purchase of imaging facilities" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r95" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": { "auth_ref": [ "r93", "r454" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.", "label": "Payments to Fund Long-term Loans to Related Parties", "terseLabel": "Equity investment loan to company outstanding", "verboseLabel": "Payments to fund loan to related parties" } } }, "localname": "PaymentsToFundLongtermLoansToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/RelatedPartyTransactionsDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToMinorityShareholders": { "auth_ref": [ "r102" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.", "label": "Payments to Noncontrolling Interests", "negatedLabel": "Distributions paid to noncontrolling interests" } } }, "localname": "PaymentsToMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r267", "r293" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r411" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsFairValueMeasurements" ], "xbrltype": "domainItemType" }, "us-gaap_PostemploymentBenefitPlansPolicy": { "auth_ref": [ "r119", "r260" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for postemployment benefits. Postemployment benefits are benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) special or contractual termination benefits, and d) stock compensation plans.", "label": "Postemployment Benefit Plans, Policy [Policy Text Block]", "terseLabel": "EMPLOYEE BENEFIT PLAN" } } }, "localname": "PostemploymentBenefitPlansPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r10", "r35", "r36" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.", "label": "Reclassification, Policy [Policy Text Block]", "terseLabel": "RECLASSIFICATION" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromContributedCapital": { "auth_ref": [ "r97" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period.", "label": "Proceeds from Contributed Capital", "terseLabel": "Contributions from noncontrolling partners" } } }, "localname": "ProceedsFromContributedCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromContributionsFromAffiliates": { "auth_ref": [ "r99" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.", "label": "Proceeds from Contributions from Affiliates", "terseLabel": "Cash contribution from partner in JV formation" } } }, "localname": "ProceedsFromContributionsFromAffiliates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfInterestInJointVenture": { "auth_ref": [ "r90" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of an investment interest in a joint venture that the reporting entity has not previously accounted for using consolidation or the equity method of accounting.", "label": "Proceeds from Divestiture of Interest in Joint Venture", "terseLabel": "Proceeds from the sale of equity interests in a joint venture", "verboseLabel": "Proceeds from sale of business" } } }, "localname": "ProceedsFromDivestitureOfInterestInJointVenture", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": { "auth_ref": [ "r90", "r105" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.", "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital", "negatedLabel": "Nulogix return of capital", "terseLabel": "Nulogix return of capital" } } }, "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsInvestmentInJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r97", "r294" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised", "terseLabel": "Proceeds from issuance of common stock upon exercise of options" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r98", "r129" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Proceeds from revolving credit facility" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfIntangibleAssets": { "auth_ref": [ "r91" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Proceeds from Sale of Intangible Assets", "terseLabel": "Proceeds from sale of internal use software" } } }, "localname": "ProceedsFromSaleOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": { "auth_ref": [ "r91" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from sale of machinery and equipment.", "label": "Proceeds from Sale of Machinery and Equipment", "terseLabel": "Proceeds from sale of imaging and medical practice assets" } } }, "localname": "ProceedsFromSaleOfMachineryAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r91" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": { "auth_ref": [ "r92" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.", "label": "Proceeds from Sales of Business, Affiliate and Productive Assets", "terseLabel": "Proceeds from sale of noncontrolling interest" } } }, "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromShortTermDebt": { "auth_ref": [ "r98" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from Short-term Debt", "terseLabel": "Proceeds from debt issuance, net of issuance costs" } } }, "localname": "ProceedsFromShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r71", "r73", "r104", "r168", "r171", "r366", "r372", "r374", "r386", "r387" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.radnet.com/role/ConsolidatedStatementsOfComprehensiveLossIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.radnet.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "netLabel": "Net income", "terseLabel": "NET INCOME", "totalLabel": "NET INCOME", "verboseLabel": "Net (loss) income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity", "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/ConsolidatedStatementsOfComprehensiveLossIncome", "http://www.radnet.com/role/ConsolidatedStatementsOfOperations", "http://www.radnet.com/role/QuarterlyResultsOfOperationsUnauditedDetailsStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r41", "r224" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease", "http://www.radnet.com/role/PropertyAndEquipmentDetails", "http://www.radnet.com/role/PropertyAndEquipmentDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r40", "r222" ], "calculation": { "http://www.radnet.com/role/PropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/PropertyAndEquipmentDetails", "http://www.radnet.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/PropertyAndEquipmentDetails", "http://www.radnet.com/role/PropertyAndEquipmentDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r17", "r18", "r224", "r491" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "rdnt_PropertyPlantandEquipmentNetIncludingRightofUseAssets", "weight": 1.0 }, "http://www.radnet.com/role/PropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets", "http://www.radnet.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNetIncludingAndExcludingCapitalLeasedAssetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment, Net, Including and Excluding Capital Leased Asset [Abstract]", "terseLabel": "PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS" } } }, "localname": "PropertyPlantAndEquipmentNetIncludingAndExcludingCapitalLeasedAssetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r39", "r119", "r224" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r17", "r224" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r17", "r222" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative", "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease", "http://www.radnet.com/role/PropertyAndEquipmentDetails", "http://www.radnet.com/role/PropertyAndEquipmentDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "PP&E useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": { "auth_ref": [ "r428" ], "lang": { "en-US": { "role": { "documentation": "Information by property that could be leased or is available for lease.", "label": "Property Subject to or Available for Operating Lease [Axis]", "terseLabel": "Property Subject to or Available for Operating Lease [Axis]" } } }, "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "stringItemType" }, "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": { "auth_ref": [ "r428" ], "lang": { "en-US": { "role": { "documentation": "A descriptive title of whether the property is subject to or available for operating lease.", "label": "Property Subject to or Available for Operating Lease [Domain]", "terseLabel": "Property Subject to or Available for Operating Lease [Domain]" } } }, "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsMaturitiesOfOperatingAndFinanceLease" ], "xbrltype": "domainItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r81", "r189" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision for bad debts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r153" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "QUARTERLY RESULTS OF OPERATIONS (unaudited)" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/QuarterlyResultsOfOperationsUnaudited" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r119", "r176", "r178", "r179", "r180" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "terseLabel": "ACCOUNTS RECEIVABLE" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsUnrecognizedTaxBenefit" ], "xbrltype": "stringItemType" }, "us-gaap_ReinsurancePolicyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Coverage retained or reinsured.", "label": "Reinsurance Policy [Domain]", "terseLabel": "Reinsurance Policy [Domain]" } } }, "localname": "ReinsurancePolicyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ReinsurancePolicyTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type, risk category or other classification of reinsurance coverage.", "label": "Reinsurance Policy, Type [Axis]", "terseLabel": "Reinsurance Policy, Type [Axis]" } } }, "localname": "ReinsurancePolicyTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r462" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r101" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedLabel": "Payments on term loan debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r101", "r129" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedLabel": "Payments on revolving credit facility" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities": { "auth_ref": [ "r100" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.", "label": "Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security", "negatedLabel": "Principal payments on notes and leases payable" } } }, "localname": "RepaymentsOfLongTermDebtAndCapitalSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "auth_ref": [ "r42", "r119", "r214", "r215", "r507" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.", "label": "Research, Development, and Computer Software, Policy [Policy Text Block]", "terseLabel": "SOFTWARE DEVELOPMENT COSTS" } } }, "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r147" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative", "http://www.radnet.com/role/StockBasedCompensationDetailsRsus" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r30", "r251", "r488" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r255", "r256" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 }, "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummaryOfNetRevenue": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Service fee revenue, net of contractual allowances and discounts" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummaryOfNetRevenue" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r120", "r259" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "SOFTWARE REVENUE RECOGNITION" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r120", "r121" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "REVENUES" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r77", "r163", "r164", "r170" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 }, "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummaryOfNetRevenue": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenue", "verboseLabel": "Net revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations", "http://www.radnet.com/role/QuarterlyResultsOfOperationsUnauditedDetailsStatementsOfOperations", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummaryOfNetRevenue" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "REVENUE" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r447", "r452" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Financing leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsSupplementalCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r447", "r452" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsSupplementalCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accounts payable and accrued expenses" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/AccountsPayableAndAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r342", "r343" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r330" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of components of income tax expense" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r53", "r128", "r246", "r248", "r249", "r250", "r420", "r421", "r424", "r482" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of term loans and financing activity" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of revolving credit facility, notes payable, and capital lease obligations" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r321" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of deferred tax assets and liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r399" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.", "label": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of effect of derivative instruments on comprehensive income" } } }, "localname": "ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r148" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of earnings per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r308" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of reconciliation of income tax expense" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]", "terseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummaryOfNetRevenue" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]", "terseLabel": "Schedule of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NatureOfBusinessDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r186" ], "lang": { "en-US": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]", "terseLabel": "Schedule of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NatureOfBusinessDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r203", "r207" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsAnnualAmortizationSchedule" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r199", "r201" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsScheduleOfGoodwill" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Schedule of goodwill and other intangible assets" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable": { "auth_ref": [ "r2", "r227" ], "lang": { "en-US": { "role": { "documentation": "Description and amounts of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).", "label": "Schedule of Long Lived Assets Held-for-sale [Table]", "terseLabel": "Schedule of Long Lived Assets Held-for-sale [Table]" } } }, "localname": "ScheduleOfLongLivedAssetsHeldForSaleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsAssetsHeldForSale" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of annual principal maturities of notes payable" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Schedule of RSA activity" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPrincipalTransactionsRevenueTextBlock": { "auth_ref": [ "r471" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of revenue by reporting categories or types of financial instruments, including derivatives but excluding dividends and interests, from trading for own account by broker dealers.", "label": "Schedule of Principal Transactions Revenue [Table Text Block]", "terseLabel": "Schedule of service fee revenue" } } }, "localname": "ScheduleOfPrincipalTransactionsRevenueTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r41", "r224" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/PropertyAndEquipmentDetails", "http://www.radnet.com/role/PropertyAndEquipmentDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r152" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Schedule of quarterly financial information" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/QuarterlyResultsOfOperationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r126", "r456", "r458", "r459", "r460", "r461" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r267", "r293" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative", "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants", "http://www.radnet.com/role/StockBasedCompensationDetailsRsus" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r273", "r286", "r287" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of options activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r316", "r331" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Schedule of unrecognized tax benefits" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of annual amortization expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuritiesFinancingTransactionAxis": { "auth_ref": [ "r60", "r132", "r469" ], "lang": { "en-US": { "role": { "documentation": "Information by type of securities financing transactions, including, but not limited to those measured at fair value or cost.", "label": "Securities Financing Transaction [Axis]", "terseLabel": "Securities Financing Transaction [Axis]" } } }, "localname": "SecuritiesFinancingTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SecuritiesFinancingTransactionTypeDomain": { "auth_ref": [ "r469" ], "lang": { "en-US": { "role": { "documentation": "Measurement of financing transaction securities held.", "label": "Securities Financing Transaction [Domain]", "terseLabel": "Securities Financing Transaction [Domain]" } } }, "localname": "SecuritiesFinancingTransactionTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SelfInsuranceReserve": { "auth_ref": [ "r54" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.", "label": "Self Insurance Reserve", "terseLabel": "Self-insurance accrual" } } }, "localname": "SelfInsuranceReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SettledLitigationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.", "label": "Settled Litigation [Member]", "terseLabel": "Settled Litigation" } } }, "localname": "SettledLitigationMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r110", "r230", "r232", "r233" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r109" ], "calculation": { "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r268" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Share-based payment award, award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "RSA's forfeited", "terseLabel": "RSA's forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative", "http://www.radnet.com/role/StockBasedCompensationDetailsRsus" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r285" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsRsus" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "RSA's granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsRsus" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average fair value, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsRsus" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "terseLabel": "RSA's unvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted-average fair value, ending balance", "periodStartLabel": "Weighted-average fair value, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsRsus" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsRsus" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r288" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted-Average Remaining Contractual Term (Years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsRsus" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "RSA's vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsRsus" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average fair value, vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsRsus" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative", "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants", "http://www.radnet.com/role/StockBasedCompensationDetailsRsus" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r274", "r276" ], "lang": { "en-US": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "RSA's outstanding, ending balance", "periodStartLabel": "RSA's outstanding, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsRsus" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsRsus" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r270" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Exercisable at the end (in shares)", "terseLabel": "Exercisable shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative", "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Exercisable at the end (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "terseLabel": "Options cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Canceled, forfeited or expired (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Canceled, forfeited or expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "netLabel": "Issuance of stock upon exercise of options (in shares)", "terseLabel": "Granted (in shares)", "verboseLabel": "Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity", "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative", "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r293" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate value outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r275", "r293" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Begining Balance (in shares)", "terseLabel": "Options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative", "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r274" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending Balance (in dollars per share)", "periodStartLabel": "Begining Balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r293" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period", "terseLabel": "Stock-based compensation (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity", "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r265", "r271" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative", "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants", "http://www.radnet.com/role/StockBasedCompensationDetailsRsus" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "verboseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r269" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Share-based payment award, expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r293" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate value exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r289" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable at the end" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r288" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Ending Balance" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r20", "r473", "r486" ], "calculation": { "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt": { "order": 3.0, "parentTag": "rdnt_LongtermDebtShorttermDebtandCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term Debt", "terseLabel": "Promissory note payable to the former owner of a practice acquired at an interest rate of 1.5% due through 2019", "verboseLabel": "Convertible promissory note" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r46" ], "lang": { "en-US": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r44" ], "lang": { "en-US": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsScheduleOfDebt", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Internally developed software for sale, licensing or long-term internal use.", "label": "Software Development [Member]", "terseLabel": "Software development costs", "verboseLabel": "Software in development" } } }, "localname": "SoftwareDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/GoodwillAndOtherIntangibleAssetsDetailsAnnualAmortizationSchedule", "http://www.radnet.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r131", "r328", "r333" ], "calculation": { "http://www.radnet.com/role/IncomeTaxesDetailsIncomeTaxExpense": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.", "label": "State and Local Income Tax Expense (Benefit), Continuing Operations", "terseLabel": "State current tax" } } }, "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsIncomeTaxExpense" ], "xbrltype": "monetaryItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r1", "r168", "r199", "r226", "r231", "r234", "r496" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r56", "r245" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity", "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity", "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity", "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows", "http://www.radnet.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r25", "r26", "r251" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Issuance of stock for acquisitions (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares (or other type of equity) forfeited during the period.", "label": "Shares Issued, Shares, Share-based Payment Arrangement, Forfeited", "negatedLabel": "Forfeiture of restricted stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r25", "r26", "r245", "r251", "r278" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r56", "r245", "r251" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Issuance of stock for acquisitions" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": { "auth_ref": [ "r292" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, Forfeited", "negatedTerseLabel": "Forfeiture of restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "terseLabel": "Equity Option" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/StockBasedCompensationDetailsNarrative", "http://www.radnet.com/role/StockBasedCompensationDetailsOutstandingOptionsAndWarrants" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r26", "r31", "r32", "r177" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total RadNet, Inc.'s stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r364", "r365", "r385" ], "calculation": { "http://www.radnet.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedBalanceSheets", "http://www.radnet.com/role/ConsolidatedStatementOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r463" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r463" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r463" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r464" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]", "terseLabel": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]", "terseLabel": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TaxYear2018Member": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "Identified as tax year 2018.", "label": "Tax Year 2018 [Member]", "terseLabel": "Tax Year 2018" } } }, "localname": "TaxYear2018Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r347" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade Names" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TransferOfInvestments": { "auth_ref": [ "r115", "r116", "r117" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of investments transferred from the entity's investments in noncash transactions.", "label": "Transfer from Investments", "terseLabel": "Transfer of fixed assets to new joint venture" } } }, "localname": "TransferOfInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FacilityAcquisitionsAssetsHeldForSaleAndDispositionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/LeasesDetailsAdditionalInformation" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r300", "r312" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized tax benefit, Balance at end of year", "periodStartLabel": "Unrecognized tax benefit, Balance at beginning of year", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsNarrative", "http://www.radnet.com/role/IncomeTaxesDetailsUnrecognizedTaxBenefit" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r313" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedTerseLabel": "Decrease related to prior year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsUnrecognizedTaxBenefit" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r310" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized tax benefits, income tax penalties and interest accrued" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r314" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Increases related to current year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsUnrecognizedTaxBenefit" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Increases related to prior year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsUnrecognizedTaxBenefit" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r315" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedLabel": "Expiration of the statute of limitations for the assessment of taxes" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/IncomeTaxesDetailsUnrecognizedTaxBenefit" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r154", "r155", "r157", "r158", "r159", "r160", "r161" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "USE OF ESTIMATES" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r135" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Balance at End of Year", "periodStartLabel": "Balance at Beginning of Year" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r135" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "Additional Charges Against Income" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r135" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedTerseLabel": "Deductions from Reserve" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r135" ], "lang": { "en-US": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis": { "auth_ref": [ "r379", "r380", "r384" ], "lang": { "en-US": { "role": { "documentation": "Information by category of Variable Interest Entity (VIE).", "label": "Variable Interest Entities [Axis]", "terseLabel": "Variable Interest Entities [Axis]" } } }, "localname": "VariableInterestEntitiesByClassificationOfEntityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityExpense": { "auth_ref": [ "r383" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense between the reporting entity and the Variable Interest Entity (VIE).", "label": "Variable Interest Entity, Measure of Activity, Expense", "terseLabel": "BRMG and NY Groups operating expenses" } } }, "localname": "VariableInterestEntityActivityBetweenVIEAndEntityExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NatureOfBusinessDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax": { "auth_ref": [ "r383" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Description of the amount of pre-tax income (loss) derived by the reporting entity from the Variable Interest Entity (VIE).", "label": "Variable Interest Entity, Measure of Activity, Income or Loss before Tax", "terseLabel": "Management services provided to BRMG and NY Groups" } } }, "localname": "VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NatureOfBusinessDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues": { "auth_ref": [ "r383" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of income between the reporting entity and the Variable Interest Entity (VIE).", "label": "Variable Interest Entity, Measure of Activity, Revenues", "terseLabel": "BRMG and NY Groups revenues" } } }, "localname": "VariableInterestEntityActivityBetweenVIEAndEntityRevenues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NatureOfBusinessDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets": { "auth_ref": [ "r378" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The carrying amount of the consolidated Variable Interest Entity's assets included in the reporting entity's statement of financial position.", "label": "Variable Interest Entity, Consolidated, Carrying Amount, Assets", "terseLabel": "BRMG and NY Groups accounts receivable" } } }, "localname": "VariableInterestEntityConsolidatedCarryingAmountAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NatureOfBusinessDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities": { "auth_ref": [ "r378" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount of the consolidated Variable Interest Entity's liabilities included in the reporting entity's statement of financial position.", "label": "Variable Interest Entity, Consolidated, Carrying Amount, Liabilities", "terseLabel": "BRMG and NY Groups accounts payable" } } }, "localname": "VariableInterestEntityConsolidatedCarryingAmountLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NatureOfBusinessDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity, Not Primary Beneficiary [Member]", "terseLabel": "Variable Interest Entity, Not Primary Beneficiary" } } }, "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "us-gaap_VariableInterestEntityOwnershipPercentage": { "auth_ref": [ "r381" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).", "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage", "terseLabel": "Economic interest" } } }, "localname": "VariableInterestEntityOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatio", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsMarginSpreadBasedOnLeverageRatioDebtInstrumentDetails", "http://www.radnet.com/role/NotesPayableRevolvingCreditFacilityAndCapitalLeasesDetailsNarrative", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r142", "r146" ], "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "netLabel": "Weighted average number of common shares used in calculating diluted net income per share (in shares)", "terseLabel": "Weighted average shares outstanding, diluted (in shares)", "verboseLabel": "Weighted average shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations", "http://www.radnet.com/role/QuarterlyResultsOfOperationsUnauditedDetailsStatementsOfOperations", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsEarningsPerShare" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r140", "r146" ], "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares outstanding, basic (in shares)", "verboseLabel": "Weighted average number of common shares outstanding during the period (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/ConsolidatedStatementsOfOperations", "http://www.radnet.com/role/QuarterlyResultsOfOperationsUnauditedDetailsStatementsOfOperations", "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsEarningsPerShare" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": { "auth_ref": [ "r141" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.", "label": "Weighted Average Number of Shares, Restricted Stock", "terseLabel": "Add nonvested restricted stock subject only to service vesting (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesRestrictedStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsEarningsPerShare" ], "xbrltype": "sharesItemType" }, "us-gaap_WorkersCompensationLiabilityCurrent": { "auth_ref": [ "r49" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Workers' Compensation Liability, Current", "terseLabel": "Workers' compensation liability, current" } } }, "localname": "WorkersCompensationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=SL94080555-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(m))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(ColumnA))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r139": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e2646-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33912-111571" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19379-109286" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=77912953&loc=d3e400-110220" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r229": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r259": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410195&loc=d3e80090-111668" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "c(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r296": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32059-109318" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r337": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "25", "SubTopic": "740", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=117412053&loc=d3e9972-128506" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "25", "SubTopic": "740", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=117412053&loc=d3e9979-128506" }, "r363": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5710-111685" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5710-111685" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5728-111685" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759159-111685" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759159-111685" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "d", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5747-111685" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5747-111685" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5708775-113959" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109978405&loc=d3e80720-113993" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28567-108399" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164653&loc=d3e41551-112718" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164758&loc=d3e45023-112735" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737" }, "r432": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r453": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r462": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r464": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=35711157&loc=d3e42567-110969" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(g))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996" }, "r5": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12.Column C.3,4)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C.Column C.7)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13.Column C.6)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14.Column E.2,3)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r508": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r509": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r510": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r511": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r512": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r513": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r514": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r515": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09" }, "r516": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.26(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=49176635&loc=d3e9760-107771" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" } }, "version": "2.1" } XML 87 R27.htm IDEA: XBRL DOCUMENT v3.20.1
PROPERTY AND EQUIPMENT (Tables)
12 Months Ended
Dec. 31, 2019
Property, Plant and Equipment [Abstract]  
Schedule of property and equipment
Property and equipment and accumulated depreciation and amortization are as follows (in thousands):
 
 
 
December 31,
 
2019
 
2018
Land
$
250

 
$
250

Medical equipment
425,892

 
449,776

Computer and office equipment, furniture and fixtures
120,490

 
102,798

Software development costs

 
6,391

Leasehold improvements
377,417

 
337,878

Equipment under financing/capital lease
14,105

 
12,119

Total property and equipment cost
938,154

 
909,212

Accumulated depreciation
(571,408
)
 
(563,483
)
Total property and equipment
$
366,746

 
$
345,729


XML 88 R19.htm IDEA: XBRL DOCUMENT v3.20.1
QUARTERLY RESULTS OF OPERATIONS (unaudited)
12 Months Ended
Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]  
QUARTERLY RESULTS OF OPERATIONS (unaudited) QUARTERLY RESULTS OF OPERATIONS (unaudited)
 
The following table sets forth a summary of our unaudited quarterly operating results for each of the last eight quarters in the years ended December 31, 2019 and 2018. This quarterly data has been derived from our unaudited consolidated interim financial statements which, in our opinion, have been prepared on substantially the same basis as the audited financial statements contained elsewhere in this report and include all normal recurring adjustments necessary for a fair presentation of the financial information for the periods presented. These unaudited quarterly results should be read in conjunction with our financial statements and notes thereto, included elsewhere in this report. The operating results in any quarter are not necessarily indicative of the results that may be expected for any future period (in thousands except per share data).
 
 
2019 Quarter Ended
 
2018 Quarter Ended
 
Mar 31
 
June 30
 
Sept 30
 
Dec 31
 
Mar 31
 
June 30
 
Sept 30
 
Dec 31
Statement of Operations Data:
 

 
 

 
 

 
 

 
 

 
 

 
 

 
 

Net  revenue
$
271,549

 
$
289,097

 
$
292,692

 
$
300,840

 
$
231,392

 
$
244,395

 
$
242,148

 
$
257,211

Total operating expenses
264,279

 
267,113

 
275,842

 
277,571

 
232,280

 
228,525

 
225,700

 
257,755

Total other expenses
12,295

 
13,668

 
11,897

 
10,194

 
10,040

 
10,646

 
10,670

 
(27,620
)
Equity in earnings of joint ventures
(1,873
)
 
(2,244
)
 
(1,955
)
 
(2,278
)
 
(2,977
)
 
(3,748
)
 
(2,822
)
 
(1,830
)
Benefit from (provision for) income taxes
1,230

 
(2,969
)
 
(1,816
)
 
(2,673
)
 
2,497

 
(2,505
)
 
(2,827
)
 
2,441

Net (loss) income
(1,922
)
 
7,591

 
5,092

 
12,680

 
(5,454
)
 
6,467

 
5,773

 
31,347

Net income (loss) attributable to noncontrolling interests
1,811

 
2,692

 
1,897

 
2,283

 
1,884

 
1,061

 
734

 
2,211

Net (loss) income attributable to Radnet, Inc. common stockholders
$
(3,733
)
 
$
4,899

 
$
3,195

 
$
10,397

 
$
(7,338
)
 
$
5,406

 
$
5,039

 
$
29,136

Basic net (loss) income attributable to Radnet, Inc. common stockholders (loss) earnings per share:
$
(0.08
)
 
$
0.10

 
$
0.06

 
$
0.21

 
$
(0.15
)
 
$
0.11

 
$
0.10

 
$
0.60

Diluted net (loss) income attributable to Radnet, Inc. common stockholders (loss) earnings per share:
$
(0.08
)
 
$
0.10

 
$
0.06

 
$
0.21

 
$
(0.15
)
 
$
0.11

 
$
0.10

 
$
0.59

Weighted average shares outstanding
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic
49,554

 
49,703

 
49,807

 
49,905

 
47,823

 
47,969

 
48,011

 
48,633

   Diluted
49,554

 
50,145

 
50,360

 
50,634

 
47,823

 
48,526

 
48,615

 
49,259


XML 89 R11.htm IDEA: XBRL DOCUMENT v3.20.1
FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS
12 Months Ended
Dec. 31, 2019
Business Combinations [Abstract]  
FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS FACILITY ACQUISITIONS, ASSETS HELD FOR SALE AND DISPOSITIONS
 
Acquisitions
 
On August 1, 2019 we completed a step-up acquisition upon the dissolution of our former 49% owned joint venture, Garden State Radiology LLC ("GSRN"). GSRN consisted of two multi-modality centers operating in New Jersey. GSRN became our wholly owned subsidiary with the withdrawal of the 51% majority partner for the full ownership of one center with no other consideration. We made a fair value determination of our original 49% interest which resulted in a step-up gain of  approximately $1.3 million. We determined a fair value of the remaining acquired imaging center of $3.1 million in assets and $426,000 in liabilities were recognized. We recorded $1,000 in other assets, $679,000 in fixed assets, $426,000 in right-of-use assets, $426,000 in operating lease liabilities, and $2.0 million in goodwill.

On August 1, 2019 we completed a step-up acquisition of our former 25% owned joint venture, Nulogix, via a stock issuance of RadNet common shares valued at $1.5 million to obtain the remaining 75% outstanding Nulogix shares. We made a fair value determination of the acquired assets and approximately $189,000 in fixed assets, $732,000 in intangible assets, $278,000 in deferred tax liability and goodwill of $1.3 million were recorded. We also made a fair value determination of our 25% pre-existing interest in the business and recognized a loss of $504,000 which is included in operating expenses within the consolidated statements of operations.
On April 1, 2019 we completed our acquisition of certain assets of Kern Radiology Imaging Systems Inc., consisting of four multi-modality imaging centers located in Bakersfield, California for purchase consideration of $19.3 million. We made a fair value determination of the acquired assets and assumed liabilities and approximately $10.1 million in property and equipment, $9.7 million in right-of-use assets, $36,000 in other assets, $3.4 million in intangible assets, $14.5 million in operating lease liabilities, and $10.5 million in goodwill were recorded.
On April 1, 2019 we completed our acquisition of certain assets of Zilkha Radiology Inc. consisting of two multi-modality centers located in Islip, New York for purchase consideration of $4.5 million. We made a fair value determination of the acquired assets and assumed liabilities and approximately $2.2 million in property and equipment, $5.1 million in right-of-use assets, $100,000 in intangible assets, $5.1 million in operating lease liabilities, $332,000 in finance lease liabilities and $2.6 million in goodwill were recorded.
On February 28, 2019, one of VIE entities, Lenox Hill Radiology and Medical Imaging Associates, P.C. ("LHR"), purchased the membership interest of Hudson Valley Radiology Associates, P.L.L.C. ("HVRA") for $6.0 million of RadNet common stock and contingent consideration valued at $680,000 to guarantee the share value issued for a period of six months post acquisition date. LHR has performed a fair value purchase price allocation and recorded equipment of $10,000, a covenant not to compete of $50,000, trade name of $380,000, other intangible assets of $340,000 and goodwill of $3.1 million from the transaction. In connection with the acquisition, RadNet also settled against the purchase consideration, $2.8 million, net of taxes, of an unfavorable vendor contract with HVRA stemming from the previous acquisition of Radiologix, Inc. in November 2006.
On February 1, 2019 our majority owned subsidiary, West Valley Imaging Group, LLC ("WVIG") completed its acquisition of certain assets of West Valley Imaging Center, LLC ("West Valley"), consisting of a single multi-modality imaging center located in West Hills, CA for purchase consideration of $3.0 million all of which was initially funded by the Company. We have made a fair value determination of the acquired assets and approximately $300,000 in equipment and fixed assets, $7,000 in other assets, $200,000 in intangible assets and $2.5 million in goodwill were recorded. Subsequent to the transaction, our partner in WVIG, Cedars Sinai Medical Center, contributed $750,000 in cash to maintain its 25% economic interest in the venture.

On December 3, 2018 we completed our acquisition of certain assets of Orange County Diagnostics Imaging Center consisting of five multi-modality imaging centers located in Orange County, California for purchase consideration of $6.6 million. We have made a fair valuation determination of the acquired assets and approximately $23,000 of current assets, $69,000 of other assets, $2.8 million of leaseholds and equipment, a $50,000 of covenant not to compete, and $3.6 million of goodwill were recorded.

On November 5, 2018 we completed our acquisition of certain assets of Arcadia Radiology Imaging consisting of one multi-modality imaging center and one women’s center located in Arcadia, California for purchase consideration of $3.8 million. We have made a fair value determination of the acquired assets and approximately $20,000 of other assets, $819,000 of leaseholds, $80,000 equipment, $300,000 in covenants not to compete, and $2.6 million of goodwill were recorded.

On November 1, 2018 we completed our acquisition of certain assets of Southern California Diagnostic Imaging consisting of a multi-modality imaging center located in Santa Ana, California for purchase consideration of $1.4 million. We have made a fair value determination of the acquired assets and approximately $18,000 of other assets, $1.2 million of leasehold improvements, $110,000 of equipment, $50,000 of covenants not to compete, and $41,000 of goodwill were recorded.

On October 1, 2018 we obtained control over the operations of New Jersey Imaging Network (NJIN), formerly a joint venture, consisting of eighteen multi-modality imaging centers located throughout the state of New Jersey for no consideration through an agreement with the other equity interest holder. The change in control was effective upon the execution of an Irrevocable Proxy Agreement with the joint venture partner and third amendment of the operating agreement, which provided RadNet with the ability to make unilateral operating decisions. We have made a fair value determination of the acquired net assets and approximately $11.6 million of net working capital, $235,000 of other assets, $34.4 million of property and equipment, $582,000 of trade name. $106.1 million of goodwill, $1.0 million in net unfavorable lease contracts, $5.2 million of assumed equipment debt, and $60.0 million of assumed bank debt were recorded. We also made a fair value determination of our 49% pre existing interest in the business of approximately $42.5 million and we recognized fair value of non controlling interest of $44.3 million on the date of the transaction. The re-measurement in valuation from an existing equity investment in joint venture resulted in a gain of $39.5 million which is included in Other Income within the consolidated statements of operations.

On October 1, 2018 we acquired certain assets of Medical Arts Radiology consisting of a 10 multi-modality imaging centers located in Long Island, New York. Total purchase consideration of $59.6 million consisted of cash in the amount of $50.9 million, issuance of 531,560 RadNet common shares valued at $8.0 million on the acquisition date and contingent consideration valued at $739,000 to guarantee the share value issued for a period of twelve months post acquisition date. We also assumed $2.7 million in equipment debt. We have made a value determination of the acquired assets and approximately $2.7 million of net working capital, $224,000 of other assets,$16.0 million of property and equipment, $24,000 in a covenant not to compete, $1.4 million for its trade name, unfavorable lease contracts of $130,000 and $40.7 million of goodwill were recorded.

On September 1, 2018 we completed our acquisition of certain assets of Washington Heights Medical Management, LLC, consisting of a multi-modality imaging center located in New York, New York, for $3.3 million in cash. We have made a fair value determination of the acquired assets and approximately $43,000 other assets, $904,000 of leaseholds and equipment, $50,000 in a covenant not to compete, and $2.3 million of goodwill were recorded.

On April 1, 2018 we completed our acquisition of certain assets of Women’s Imaging Specialists in Healthcare, consisting of a single multi-modality center located in the city of Fresno California, for purchase consideration of $5.1 million in cash. We have made a fair value determination of the acquired assets and approximately $636,000 of fixed assets and equipment, $143,000 in intangible covenants not to compete, $53,000 in intangible trade name, and $4.3 million in goodwill were recorded.

On April 1, 2018 we completed our acquisition of certain assets of Valley Metabolic Imaging LLC, consisting of a single multi-modality center located in Fresno, California, for purchase consideration of $1.7 million in cash. We have made a fair value determination of the acquired assets and approximately $22,000 of fixed assets and equipment, $183,000 in intangible covenants not to compete, and $1.5 million in goodwill were recorded.

On April 1, 2018 we completed our acquisition of certain assets of Sierra Imaging Associates LLC, consisting of a single multi-modality center located in Clovis, California, for purchase consideration of $1.5 million in cash. We have made a fair value determination of the acquired assets and approximately $270,000 of fixed assets and equipment, $83,000 in intangible covenants not to compete, and $1.1 million in goodwill were recorded.

On February 22, 2018 we completed our acquisition of certain assets of Imaging Services Company of New York, LLC, consisting of a single multi-modality center located in New York, New York, for purchase consideration of $5.8 million. We have made a fair value determination of the acquired assets and approximately $3.0 million in fixed asset and equipment, a $100,000 covenant not to compete, and $2.7 million in goodwill were recorded.

On January 1, 2018 we formed Beach Imaging Group, LLC (“Beach Imaging”) and contributed the operations of 24 imaging facilities spread across southern Los Angeles and Orange Counties. On the same day, MemorialCare Medical Foundation contributed $22.3 million in cash, $7.6 million in fixed assets, $7.4 million in equipment, and $545,000 in goodwill. As part of the formation, the Beach Imaging assumed $4.0 million in capital lease debt. As a result of the transaction, the Company will retain a 60% controlling interest in Beach Imaging and MemorialCare Medical Foundation will retain a 40% noncontrolling interest in Beach Imaging.

Joint venture formations
On February 13, 2019 we formed a wholly owned subsidiary, Ventura County Imaging Group, LLC ("VCIG"). On March 1, 2019, Dignity Health joined as a venture partner. Total agreed contribution of both parties was $10.4 million of cash and assets with RadNet contributing net assets with a book value of $4.3 million for a 60% economic interest and Dignity Health contributing $6.1 million in cash and assets for a 40% economic interest. For its contribution, RadNet transferred net assets of three wholly owned multi-modality imaging centers. Dignity Health contributed approximately $800,000 in assets to acquire 5% economic interest and paid RadNet $5.3 million for an additional 35% economic interest. We maintain controlling economic interest in VCIG and fully consolidate the results into our financial statements.

Assets held for sale
Effective January 1, 2018 we agreed to sell certain assets of four women’s imaging centers to MemorialCare Medical Foundation. The sale was initially anticipated within 12 months of the effective date. We are currently in discussions with the buyer and expect to complete the sale in 2020. The following table summarizes the major categories of assets which remain classified as held for sale in the accompanying consolidated balance sheets at December 31, 2019 (in thousands):
Property and equipment, net
$1,049
Goodwill
992

Total assets held for sale
$2,041


Dispositions
On April 1, 2017, we formed in conjunction with Cedars Sinai Medical Center (“CSMC”) the Santa Monica Imaging Group, LLC (“SMIG”), consisting of two multi-modality imaging centers located in Santa Monica, CA. Upon formation, RadNet held a 40% economic interest and CSMC held a 60% economic interest. RadNet accounts for our share of the venture under the equity method. On January 1, 2019, CSMC purchased from us an additional five percent economic interest in SMIG valued at $134,000. As a result of the transaction, our economic interest in SMIG has been reduced to 35%. We recorded a loss of $2,000 on the transaction.

On September 1, 2017 we completed the equity sale of a wholly owned breast oncology practice, Breastlink Medical Group, Inc., to Verity Medical Foundation for approximately $2.8 million. We recorded a gain of approximately $845,000 and incurred severance expense of approximately $1.2 million on this transaction.
 
On July 1, 2017 we formed a majority owned subsidiary, Advanced Imaging at Timonium Crossing, LLC, in conjunction with the University of Maryland St. Joseph Medical Center. As part of that transaction, we sold a 25% noncontrolling interest in an imaging center of our wholly owned subsidiary, Advanced Imaging Partners, Inc., to the University of Maryland St. Joseph Medical Center for $3.9 million. On the date of sale, the net book value of the 25% interest was $1.1 million and the proceeds in excess of net book value amounting to $2.8 million were recorded to equity.
 
On April 28, 2017 we completed the sale of five imaging centers operating in Rhode Island to Rhode Island Medical Imaging, Inc. for approximately $4.5 million. We recorded a gain of approximately $1.9 million in the second quarter with regard to this transaction and have no remaining imaging centers in the state.
 
On April 1, 2017 we received from Cedars Sinai Medical Center $5.9 million in exchange for a 25% noncontrolling interest in the West Valley Imaging Group, LLC (“WVI”). The determined net book value of the 25% interest was approximately $3.0 million. The proceeds in excess of the net book value, amounting to $1.8 million net of taxes, were recorded to equity.
 
On April 1, 2017 we completed the sale of 2 wholly owned oncology practices to Cedars Sinai Medical Center in connection with the sale of non-controlling interest of the WVI subsidiary described above for approximately $1.2 million. We recorded a gain of approximately $361,000 on this transaction.
XML 90 R15.htm IDEA: XBRL DOCUMENT v3.20.1
NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES
12 Months Ended
Dec. 31, 2019
Debt Disclosure [Abstract]  
NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES
  
Revolving credit facility, notes payable, and capital lease obligations:
 
 
December 31, 2019
 
December 31, 2018
First Lien Term Loans collateralized by RadNet's tangible and intangible assets
$
649,824

 
$
587,191

Discount on First Lien Term Loans
(13,579
)
 
(15,112
)
Term Loan Agreement collateralized by NJIN's tangible and intangible assets
55,875

 
59,250

Revolving Credit Facility

 
28,000

Promissory note payable to the former owner of a practice acquired at an interest rate of 1.5% due through 2019

 
199

Equipment notes payable at interest rates ranging from 4.4% to 5.6%, due through 2020, collateralized by medical equipment
275

 
632

Obligations under capital leases at interest rates ranging from 3.7% to 9.3%, due through 2022, collateralized by medical and office equipment (1)

 
12,119

Total debt obligations
692,395

 
672,279

Less current portion
(39,691
)
 
(39,267
)
Long-term portion debt obligations
$
652,704

 
$
633,012


(1)Obligations under capital leases were transferred to Finance Lease Liability at January 1, 2019 in accordance with the adoption of Accounting Standards Update No 2016-02, Leases (Topic 842). See Note 9, Leases, for more information.

The following is a listing of annual principal maturities of notes payable exclusive of all related discounts and repayments on our revolving credit facilities for years ending December 31 (in thousands):

2020
$
43,571

2021
43,670

2022
44,795

2023
573,938

Total notes payable obligations
$
705,974




Senior Credit Facilities:

At December 31, 2019, our Barclays credit facilities were comprised of one tranche of term loans (“First Lien Term Loans”) and a revolving credit facility of $137.5 million (the “Barclays Revolving Credit Facility”), both of which are provided pursuant to the Amended and Restated First Lien Credit and Guaranty Agreement dated July 1, 2016 (as amended, the "First Lien Credit Agreement").

At December 31, 2019, our SunTrust credit facilities, which relate to our consolidated subsidiary NJIN, were comprised of one term loan (the "SunTrust Term Loan") and a revolving credit facility of $30.0 million (the "SunTrust Revolving Credit Facility") both of which are provided pursuant to the SunTrust Restated Credit Agreement.

As of December 31, 2019, we were in compliance with all covenants under our credit facilities.

Deferred financing costs at December 31, 2019, net of accumulated amortization, was $1.6 million and is specifically related to our Barclays Revolving Credit Facility.
 
Included in our consolidated balance sheets at December 31, 2019 are $636.2 million of First Lien Term Loans and $55.9 million of SunTrust Term Loan debt for a combined total of $692.1 million (net of unamortized discounts of $13.6 million) in thousands:

 
Face Value
 
Discount
 
Total Carrying
Value
First Lien Term Loans
$
649,824

 
$
(13,579
)
 
$
636,245

Term Loan Agreement
55,875

 

 
55,875

Total Term Loans
$
705,699

 
$
(13,579
)
 
$
692,120



We had no outstanding balance under our $137.5 million Barclays Revolving Credit Facility at December 31, 2019 and had reserved an additional $5.9 million for certain letters of credit. The remaining $131.7 million of our Barclays Revolving Credit Facility was available to draw upon as of December 31, 2019. We also had no balance under our $30.0 million SunTrust Revolving Credit Facility related to our consolidated subsidiary NJIN at December 31, 2019.

The following relates to our Barclays financing activities:

2019 Amendments to the First Lien Credit Agreement:

On April 18, 2019 we entered into the following two new amendments to the First Lien Credit Agreement: (i) Amendment No. 6, Consent and Incremental Joinder Agreement to Credit and Guaranty Agreement dated as of April 18, 2019 (the “Sixth Amendment”); and (ii) Amendment No. 7 to Credit and Guaranty Agreement dated as of April 18, 2019 (the “Seventh Amendment”). The Sixth Amendment amended the First Lien Credit Agreement to issue $100.0 million in incremental First Lien Term Loans and to add an additional $20.0 million of revolving commitments to the Barclay's Revolving Credit Facility. The Seventh Amendment amends the First Lien Credit Agreement to extend the maturity date of the Barclays Revolving Credit Facility by an additional two years to July 1, 2023, unless sooner terminated in accordance with the terms of the First Lien Credit Agreement. Total issue costs added in relation to the amendments in 2019 amounted to approximately $4.4 million. Of this amount, $2.1 million was identified and capitalized as discount on debt, $683,000 was capitalized as deferred financing costs, and $1.6 million was expensed. Amounts capitalized will be amortized over the remaining term of the agreement.

Terms of Barclays Credit Facilites:

First Lien Term Loans:
  
Interest: First Lien Term Loans bear interest at either an Adjusted Eurodollar Rate or a Base Rate plus an applicable margin. Rates of the applicable margin for borrowing under the First Lien Credit Agreement will alter depending on our leverage ratio, according to the following schedule:
First Lien Leverage Ratio
Eurodollar Rate Spread
Base Rate Spread
> 5.50x
4.50%
3.50%
> 4.00x but ≤ 5.50x
3.75%
2.75%
>3.50x but ≤ 4.00x
3.50%
2.50%
≤ 3.50x
3.25%
2.25%


At December 31, 2019 the effective Adjusted Eurodollar Rate and the Base Rate for the First Lien Term Loans was 2.01% and 4.75%, respectively and the applicable margin for Adjusted Eurodollar Rate and Base Rate borrowings was 3.50% and 2.50%, respectively.

Payments. The First Lien Credit Agreement provides for quarterly payments of principal under the First Lien Term Loans in the amount of approximately $9.7 million.

Maturity Date. The maturity date for the First Lien Term Loans shall be on the earliest to occur of (i) July 1, 2023, and (ii) the date on which all First Lien Term Loans shall become due and payable in full under the First Lien Credit Agreement, whether by acceleration or otherwise.

Additional Borrowing. Under the First Lien Credit Agreement, we can elect to request (i) an increase to the existing Barclays Revolving Credit Facility and/or (ii) issue additional First Lien Term Loans, provided that the aggregate amount of such increases and additions does not exceed (a) $100.0 million and (b) as long as the First Lien Leverage Ratio (as defined in the First Lien Credit Agreement) would not exceed 4.00:1.00 after giving effect to such incremental facilities, an uncapped amount of incremental facilities, in each case subject to the conditions and limitations set forth in the First Lien Credit Agreement. Each
lender approached to provide all or a portion of any incremental facility may elect or decline, in its sole discretion, to provide an incremental commitment or loan.
Barclays Revolving Credit Facility:

Interest: Revolving loans borrowed under the Revolving Credit Facility bear interest at either an Adjusted Eurodollar Rate or a Base Rate plus an applicable margin. Rates of the applicable margin for borrowing under the Revolving Credit Facility also change depending on our leverage ratio and are the same rates as noted in the schedule above for First Lien Term Loans. As of December 31, 2019, the effective interest rate payable on revolving loans was 7.25%.
 
Letters of Credit: For letters of credit issued under the Revolving Credit Facility, letter of credit fees accrue at the applicable margin of Adjusted Eurodollar Rate, currently 3.50% , and fronting fees accrue at 0.25% per annum, in each case on the average aggregate daily maximum amount available to be drawn under all letters of credit issued under the First Lien Credit Agreement. In addition a commitment fee of 0.50% per annum accrues on the unused revolver commitments under the Revolving Credit Facility.
 
Maturity Date: The Revolving Credit Facility will terminate on the earliest to occur of (i) July 1, 2023, (ii) the date we voluntarily agree to permanently reduce the Revolving Credit Facility to zero pursuant to section 2.13(b) of the First Lien Credit Agreement, and (iii) the date the Revolving Credit Facility is terminated due to specific events of default pursuant to section 8.01 of the First Lien Credit Agreement.

 
The following relates to our SunTrust financing activities:

Amended and Restated Revolving Credit and Term Loan Agreement

On August 31, 2018, our subsidiary, NJIN, entered into the Amended and Restated Revolving Credit and Term Loan Agreement (as amended, the "SunTrust Restated Credit Agreement") as borrower with SunTrust Bank and other financial institutions as lenders and to provide NJIN aggregate credit facilities of $90.0 million as categorized below:

SunTrust Term Loan: Pursuant to the SunTrust Restated Credit Agreement, the lenders thereunder made a term loan to NJIN in the amount of $60.0 million. The SunTrust Term Loan is repayable in scheduled quarterly amounts (as described below) and has a maturity date of the earlier of (i) August 31, 2023 and (ii) the date on which the principal amount of the SunTrust Term Loan has been declared or automatically has become due and payable (whether by acceleration or otherwise).

SunTrust Revolving Credit Facility: The SunTrust Restated Credit Agreement establishes a $30.0 million revolving credit facility available to NJIN for funding requirements. The SunTrust Revolving Credit Facility terminates on the earliest of (i) August 31, 2023, (ii) the voluntary termination thereof by NJIN pursuant to Section 2.8 of the SunTrust Restated Credit Agreement, or (iii) the date on which all amounts outstanding under the SunTrust Restated Credit Agreement have been declared or have automatically become due and payable (whether by acceleration or otherwise). NJIN has not borrowed against the revolving credit line.

Interest: Interest rates and fees of the applicable margin for borrowing under the SunTrust Restated Credit Agreement adjust depending on our leverage ratio, according to the following table:

Pricing Level
Leverage Ratio
Applicable Margin for Eurodollar Loans
Applicable Margin for Base Rate Loans
Applicable Margin for Letter of Credit Fees
Applicable Percentage for Commitment Fee
I
Greater than or equal to 3.00:1.00
2.75%
per annum
1.75%
per annum
2.75%
per annum
0.45%
per annum
II
Less than 3.00:1.00 but greater than or equal to 2.50:1.00
2.25%
per annum
1.25%
per annum
2.25%
per annum
0.40%
per annum
III
Less than 2.50:1.00 but greater than or equal to
2.00:1.00
2.00%
per annum
1.00%
per annum
2.00%
per annum
0.35%
per annum
IV
Less than 2.00:1.00 but greater than or equal to 1.50:1.00
1.75%
per annum
0.75%
per annum
1.75%
per annum
0.30%
per annum
V
Less than 1.50:1.00
1.50%
per annum
0.50%
per annum
1.50%
per annum
0.30%
per annum



The loans and other obligations outstanding under the SunTrust Restated Credit Agreement currently bear applicable margin and fees based on Pricing Level III described above.The loans outstanding under the SunTrust Restated Credit Agreement currently bear interest based on a three month Eurodollar election, plus the applicable margin.

Payments: The scheduled amortization of the SunTrust Term Loan began December 31, 2018 with quarterly payments of $750,000, representing annual amortization equal to 5.0% of the original principal amount of the SunTrust Term Loan. At scheduled intervals, the quarterly amortization increases by $375,000, with the remaining balance to be paid at maturity.
XML 91 R36.htm IDEA: XBRL DOCUMENT v3.20.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Narrative)
1 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2019
USD ($)
joint_venture
shares
Nov. 05, 2019
USD ($)
Aug. 01, 2019
USD ($)
Jan. 01, 2019
USD ($)
Apr. 12, 2018
USD ($)
Mar. 01, 2018
USD ($)
Feb. 01, 2018
USD ($)
shares
Mar. 24, 2017
USD ($)
Sep. 30, 2019
USD ($)
Nov. 06, 2014
USD ($)
Sep. 30, 2019
Dec. 31, 2019
USD ($)
joint_venture
shares
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Oct. 11, 2019
shares
Jun. 30, 2019
USD ($)
Feb. 28, 2019
USD ($)
Aug. 01, 2017
Apr. 01, 2017
Nov. 30, 2006
USD ($)
Property, Plant and Equipment [Line Items]                                        
Factored accounts receivable                       $ 9,000,000.0 $ 20,500,000              
Factoring receivable $ 24,200,000                     24,200,000                
Meaningful use incentive income                           $ 250,000            
Service fee revenue, net of contractual allowances and discounts                       1,028,236,000 868,741,000              
Deferred revenue liability 1,300,000                     1,300,000                
Deferred financing costs, net of accumulated amortization 1,600,000                     1,600,000 1,400,000              
Goodwill 440,981,000                     440,981,000 418,093,000 256,776,000            
Indefinite lived intangible assets 11,300,000                     11,300,000 9,800,000              
Loss on impairment                       0 3,937,000 0            
Goodwill impairment                         3,800,000              
Workers' compensation liability, current 3,800,000                     3,800,000 2,800,000              
Medical malpractice deductible per incidence 10,000                     $ 10,000 10,000              
Employer matching contribution, percent                       1.00%                
Employee contribution, percent                       4.00%                
Expected employee contribution                       $ 3,000,000.0 2,600,000              
Contract loss accrual                         4,600,000              
Contract loss accrual, written off                         558,000              
Unfavorable contract liability 2,200,000                     2,200,000                
Total net assets $ 60,375,000                     $ 60,375,000 65,031,000              
Number of unconsolidated joint ventures | joint_venture 12                     12                
Loss on equity method investment                       $ 134,000                
Medic Vision                                        
Property, Plant and Equipment [Line Items]                                        
Equity interest percentage 14.21%             12.50%       14.21%                
Investment at cost           $ 200,000   $ 1,000,000.0                        
Option to purchase additional equity method investment               $ 1,400,000                        
Ownership interest percentage acquired           1.96%                            
Initial ownership percentage after dilution           12.25%                            
Total net assets $ 1,200,000                     $ 1,200,000                
Turner Imaging Systems                                        
Property, Plant and Equipment [Line Items]                                        
Investment at cost             $ 2,000,000.0                          
Shares purchased | shares             2,100,000                          
Turner Imaging                                        
Property, Plant and Equipment [Line Items]                                        
Preferred stock issued upon conversion (in shares) | shares                             80,000          
WhiteRabbit.ai Inc.                                        
Property, Plant and Equipment [Line Items]                                        
Investment at cost   $ 1,000,000.0                                    
Payments to fund loan to related parties $ 2,500,000 $ 2,500,000                                    
Santa Monica Imaging Group | RadNet                                        
Property, Plant and Equipment [Line Items]                                        
Equity interest percentage       35.00%                           40.00% 40.00%  
Loss on equity method investment       $ 2,000                                
Santa Monica Imaging Group | Cedars Sinai Medical Center                                        
Property, Plant and Equipment [Line Items]                                        
Equity interest percentage                                   60.00% 60.00%  
Additional equity interest acquired       5.00%                                
Investment owned, at fair value       $ 134,000                                
2016 Caps | LIBOR                                        
Property, Plant and Equipment [Line Items]                                        
Basis spread on variable rate 2.00%                     2.00%                
September 2020                                        
Property, Plant and Equipment [Line Items]                                        
Notional amounts $ 150,000,000                     $ 150,000,000                
October 2020                                        
Property, Plant and Equipment [Line Items]                                        
Notional amounts 350,000,000                     350,000,000                
Radiologix                                        
Property, Plant and Equipment [Line Items]                                        
Contract loss accrual                                       $ 8,900,000
Hudson Valley Radiology Associates                                        
Property, Plant and Equipment [Line Items]                                        
Goodwill                                 $ 3,100,000      
Hudson Valley Radiology Associates | Primedex Health Systems Inc. and Radiologix                                        
Property, Plant and Equipment [Line Items]                                        
Unfavorable lease contracts acquired, gross                                 4,000,000.0      
Unfavorable lease contracts acquired                                 $ 2,800,000      
Garden State Radiology Network LLC                                        
Property, Plant and Equipment [Line Items]                                        
Goodwill     $ 2,000,000.0                                  
Equity interest percentage     49.00%                                  
Investment at cost                   $ 2,200,000                    
Loss on equity method investment     $ (1,300,000)                                  
Nulogix, Inc.                                        
Property, Plant and Equipment [Line Items]                                        
Equity interest percentage     75.00%   25.00%                              
Investment at cost     $ 1,500,000   $ 2,000,000.0                              
Loss on equity method investment     $ 504,000                                  
Health Insurance                                        
Property, Plant and Equipment [Line Items]                                        
Self-insurance accrual 4,900,000                     $ 4,900,000 4,800,000              
Minimum                                        
Property, Plant and Equipment [Line Items]                                        
Share-based payment award, award vesting period                       3 years                
Share-based payment award, expiration period                       5 years                
Minimum | Blue Shield                                        
Property, Plant and Equipment [Line Items]                                        
Stop loss policy claim amount 250,000                     $ 250,000                
Minimum | Dignity Health | Glendale Advanced Imaging | Joint Venture                                        
Property, Plant and Equipment [Line Items]                                        
Economic interest                       35.00%                
Minimum | Property and equipment, net                                        
Property, Plant and Equipment [Line Items]                                        
PP&E useful life                       3 years                
Minimum | Leasehold improvements                                        
Property, Plant and Equipment [Line Items]                                        
PP&E useful life                       3 years                
Maximum                                        
Property, Plant and Equipment [Line Items]                                        
Share-based payment award, award vesting period                       5 years                
Share-based payment award, expiration period                       10 years                
Maximum | Blue Shield                                        
Property, Plant and Equipment [Line Items]                                        
Stop loss policy claim amount 1,000,000.0                     $ 1,000,000.0                
Maximum | Dignity Health | Glendale Advanced Imaging | Joint Venture                                        
Property, Plant and Equipment [Line Items]                                        
Economic interest                       55.00%                
Maximum | Property and equipment, net                                        
Property, Plant and Equipment [Line Items]                                        
PP&E useful life                       15 years                
Maximum | Leasehold improvements                                        
Property, Plant and Equipment [Line Items]                                        
PP&E useful life                       15 years                
Barclays                                        
Property, Plant and Equipment [Line Items]                                        
Total credit facilities outstanding 0                     $ 0 28,000,000.0              
SunTrust                                        
Property, Plant and Equipment [Line Items]                                        
Total credit facilities outstanding 0                     0 0              
Software developed for internal use                                        
Property, Plant and Equipment [Line Items]                                        
Capitalized software costs, gross $ 6,400,000                     6,400,000                
Imaging On Call                                        
Property, Plant and Equipment [Line Items]                                        
Loss on impairment                         3,900,000              
Goodwill impairment                         3,800,000              
Write off of the reporting unit trade name                         100,000              
Net service fee revenue                                        
Property, Plant and Equipment [Line Items]                                        
Service fee revenue, net of contractual allowances and discounts                       1,028,236,000 868,741,000 810,623,000            
Net service fee revenue | eRAD                                        
Property, Plant and Equipment [Line Items]                                        
Service fee revenue, net of contractual allowances and discounts                       10,100,000 6,800,000 6,100,000            
Investment Advisory, Management and Administrative Service                                        
Property, Plant and Equipment [Line Items]                                        
Service fee revenue, net of contractual allowances and discounts                       $ 11,400,000 13,800,000 $ 13,100,000            
Investment Advisory, Management and Administrative Service | Minimum | Property and equipment, net                                        
Property, Plant and Equipment [Line Items]                                        
PP&E useful life                     3 years                  
Investment Advisory, Management and Administrative Service | Minimum | Leasehold improvements                                        
Property, Plant and Equipment [Line Items]                                        
PP&E useful life                     3 years                  
Restated Plan                                        
Property, Plant and Equipment [Line Items]                                        
Shares authorized | shares 14,000,000                     14,000,000                
Restated Plan | Minimum                                        
Property, Plant and Equipment [Line Items]                                        
Share-based payment award, award vesting period                       3 years                
Share-based payment award, expiration period                       5 years                
Restated Plan | Maximum                                        
Property, Plant and Equipment [Line Items]                                        
Share-based payment award, award vesting period                       5 years                
Share-based payment award, expiration period                       10 years                
US Attorneys Office For The Western District of New York                                        
Property, Plant and Equipment [Line Items]                                        
Loss contingency accrual liability                               $ 2,300,000        
Settled Litigation | US Attorneys Office For The Western District of New York                                        
Property, Plant and Equipment [Line Items]                                        
Litigation settlement                 $ 2,200,000                      
2016 Caps                                        
Property, Plant and Equipment [Line Items]                                        
Interest rate caps premium liability $ 5,300,000                     $ 5,300,000                
2019 SWAPS                                        
Property, Plant and Equipment [Line Items]                                        
Notional amounts                               500,000,000        
2019 SWAPS | Interest Rate Swap                                        
Property, Plant and Equipment [Line Items]                                        
Notional amounts                               $ 50,000,000        
2019 SWAPS | Interest Rate Swap | LIBOR                                        
Property, Plant and Equipment [Line Items]                                        
Basis spread on variable rate                               1.96%        
2019 SWAPS | October 2023                                        
Property, Plant and Equipment [Line Items]                                        
Notional amounts                               $ 50,000,000        
2019 SWAPS | October 2025                                        
Property, Plant and Equipment [Line Items]                                        
Notional amounts                               200,000,000        
2019 SWAPS1 | Interest Rate Swap                                        
Property, Plant and Equipment [Line Items]                                        
Notional amounts                               $ 200,000,000        
2019 SWAPS1 | Interest Rate Swap | LIBOR                                        
Property, Plant and Equipment [Line Items]                                        
Basis spread on variable rate                               2.05%        
Promissory note                                        
Property, Plant and Equipment [Line Items]                                        
Convertible promissory note $ 0                     $ 0 $ 199,000              
Promissory note | Turner Imaging                                        
Property, Plant and Equipment [Line Items]                                        
Convertible promissory note       $ 143,000                                
XML 92 R32.htm IDEA: XBRL DOCUMENT v3.20.1
STOCK-BASED COMPENSATION (Tables)
12 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]  
Schedule of options activity The following summarizes all of our option transactions for the twelve months ended December 31, 2019:
Outstanding Options
Under the 2006 Plan
 
Shares
 
Weighted Average
Exercise price
Per Common Share
 
Weighted Average
Remaining
Contractual
Life(in years)
 
Aggregate
Intrinsic
Value
Balance, December 31, 2018
 
513,282

 
$
7.44

 
 
 
 
Granted
 
89,200

 
10.93

 
 
 
 
Exercised
 
(12,500
)
 
6.00

 
 
 
 
Canceled, forfeited or expired
 
(111,031
)
 
0.79

 
 
 
 
Balance, December 31, 2019
 
478,951

 
8.21

 
7.33
 
$
5,790,763

Exercisable at December 31, 2019
 
148,456

 
7.29

 
6.42
 
1,931,633


Schedule of RSA activity The following summarizes all unvested RSA’s activities during the twelve months ended December 31, 2019:
 
 
RSA's
 
Weighted-Average
Remaining
Contractual
Term (Years)
 
Weighted-Average
Fair Value
RSA's unvested at December 31, 2018
277,504

 
 
 
$
9.77

Changes during the period
 
 
 
 
 
Granted
636,656

 
 
 
$
11.78

Vested
(524,726
)
 
 
 
$
11.03

Forfeited
(1,500
)
 
 
 
$
12.76

RSA's unvested at December 31, 2019
387,934

 
1.13
 
$
11.61


XML 93 R53.htm IDEA: XBRL DOCUMENT v3.20.1
NOTES PAYABLE, REVOLVING CREDIT FACILITY AND CAPITAL LEASES (Details - Term Loans) - Term Loan
$ in Thousands
Dec. 31, 2019
USD ($)
Debt Instrument [Line Items]  
Face Value $ 705,699
Discount (13,579)
Total Carrying Value 692,120
First Lien Term Loans  
Debt Instrument [Line Items]  
Face Value 649,824
Discount (13,579)
Total Carrying Value 636,245
Restated Agreement  
Debt Instrument [Line Items]  
Face Value 55,875
Discount 0
Total Carrying Value $ 55,875
XML 94 R57.htm IDEA: XBRL DOCUMENT v3.20.1
LEASES (Details - Lease Cost)
$ in Thousands
12 Months Ended
Dec. 31, 2019
USD ($)
Leases [Abstract]  
Operating lease cost $ 95,348
Depreciation of leased equipment 3,135
Interest on lease liabilities 395
Total finance lease cost $ 3,530
XML 95 R70.htm IDEA: XBRL DOCUMENT v3.20.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
$ in Millions
Dec. 31, 2019
Nov. 05, 2019
WhiteRabbit.ai Inc.    
Related Party Transaction [Line Items]    
Equity investment loan to company outstanding $ 2.5 $ 2.5